(lp0
(dp1
S'line'
p2
S'In this review the authors summarise the most important cell-surface bound pathogenical factors such as fibrinogen, fibronectin, thrombin, collagen, laminin and vitronectin-binding proteins and extracellular virulence enzymes of Candida albicans and some microbiological aspects of oral candidiasis (candidosis).\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I161
sS'uniprot'
p8
VP04004
p9
sS'lengthInChars'
p10
I28
sS'name'
p11
Vvitronectin-binding proteins
p12
sS'lengthInWords'
p13
I2
sa(dp14
g7
I149
sg8
S''
p15
sg10
I7
sg11
Vlaminin
p16
sg13
I1
sa(dp17
g7
I104
sg8
VP22087
p18
sg10
I10
sg11
Vfibrinogen
p19
sg13
I1
sa(dp20
g7
I129
sg8
VP00734
p21
sg10
I8
sg11
Vthrombin
p22
sg13
I1
sasS'diseases'
p23
(lp24
(dp25
g7
I300
sS'cui'
p26
VC0006840
p27
sg10
I10
sg11
Vcandidosis
p28
sg13
I1
sa(dp29
g7
I229
sg26
VC0006840
p30
sg10
I69
sg11
VCandida albicans and some microbiological aspects of oral candidiasis
p31
sg13
I9
sasa(dp32
g2
S'Predicted pathogenic CHD7 variants have been identified in individuals with isolated features of CHARGE including autism and hypogonadotropic hypogonadism.\n'
p33
sg4
(lp34
(dp35
g7
I10
sg8
g15
sg10
I24
sg11
Vpathogenic CHD7 variants
p36
sg13
I3
sasg23
(lp37
(dp38
g7
I125
sg26
VC0022735
p39
sg10
I29
sg11
Vhypogonadotropic hypogonadism
p40
sg13
I2
sa(dp41
g7
I114
sg26
VC0004352
p42
sg10
I6
sg11
Vautism
p43
sg13
I1
sasa(dp44
g2
S'We previously demonstrated that a part of human CHD7 interacts with a part of human CHD8, another chromodomain helicase DNA binding protein presumably being involved in the pathogenesis of neurodevelopmental (NDD) and autism spectrum disorders (ASD).\n'
p45
sg4
(lp46
(dp47
g7
I111
sg8
g15
sg10
I28
sg11
Vhelicase DNA binding protein
p48
sg13
I4
sa(dp49
g7
I42
sg8
g15
sg10
I10
sg11
Vhuman CHD7
p50
sg13
I2
sasg23
(lp51
(dp52
g7
I245
sg26
VC1510586
p53
sg10
I3
sg11
VASD
p54
sg13
I1
sa(dp55
g7
I173
sg26
VC0699748
p56
sg10
I12
sg11
Vpathogenesis
p57
sg13
I1
sa(dp58
g7
I218
sg26
VC1510586
p59
sg10
I25
sg11
Vautism spectrum disorders
p60
sg13
I3
sasa(dp61
g2
S'Focal or weak expression was seen in malignant fibrous histiocytoma (2/27), synovial sarcoma (1/11), Ewing sarcoma (1/5), and epithelioid sarcoma (3/5), whereas one epithelioid sarcoma displayed strong expression for Arpp.\n'
p62
sg4
(lp63
(dp64
g7
I217
sg8
g15
sg10
I4
sg11
VArpp
p65
sg13
I1
sasg23
(lp66
(dp67
g7
I126
sg26
VC0205944
p68
sg10
I19
sg11
Vepithelioid sarcoma
p69
sg13
I2
sa(dp70
g7
I37
sg26
VC0334463
p71
sg10
I30
sg11
Vmalignant fibrous histiocytoma
p72
sg13
I3
sa(dp73
g7
I101
sg26
VC0553580
p74
sg10
I13
sg11
VEwing sarcoma
p75
sg13
I2
sa(dp76
g7
I126
sg26
VC0205944
p77
sg10
I19
sg11
Vepithelioid sarcoma
p78
sg13
I2
sa(dp79
g7
I76
sg26
VC0039101
p80
sg10
I16
sg11
Vsynovial sarcoma
p81
sg13
I2
sasa(dp82
g2
S'IL-21, a Tfh cell-derived cytokine, provides instructional cues for GC B cell maturation, with disruption of IL-21 signaling representing a potential therapeutic strategy for autoantibody-driven diseases such as systemic lupus erythematosus.\n'
p83
sg4
(lp84
(dp85
g7
I0
sg8
g15
sg10
I5
sg11
VIL-21
p86
sg13
I1
sasg23
(lp87
(dp88
g7
I212
sg26
VC0024141
p89
sg10
I28
sg11
Vsystemic lupus erythematosus
p90
sg13
I3
sasa(dp91
g2
S'Anti-IL-21 treatment also led to a reduction in GC B cells, CD138hi plasmablasts, IFN-Gamma-dependent IgG2c production, and autoantibodies, indicating that Tfh cell-derived IL-21 is critical for pathological B cell cues in lupus.\n'
p92
sg4
(lp93
(dp94
g7
I82
sg8
VP01579
p95
sg10
I25
sg11
VIFN-Gamma-dependent IgG2c
p96
sg13
I2
sa(dp97
g7
I5
sg8
g15
sg10
I5
sg11
VIL-21
p98
sg13
I1
sasg23
(lp99
(dp100
g7
I223
sg26
VC0024131
p101
sg10
I5
sg11
Vlupus
p102
sg13
I1
sasa(dp103
g2
S'In spite of convincing evidence for the use of mycophenolate mofetil (MMF) in lupus nephritis, the German "Gemeinsame Bundesausschuss" (GBA) has not yet decided on its reimbursement.\n'
p104
sg4
(lp105
sg23
(lp106
(dp107
g7
I78
sg26
VC0024143
p108
sg10
I15
sg11
Vlupus nephritis
p109
sg13
I2
sasa(dp110
g2
S'Applying this information to other autoimmune diseases, IIM patients displayed positive GC-A/GC-B log-ratios, indicating predominant IFNAlfa activity.\n'
p111
sg4
(lp112
sg23
(lp113
(dp114
g7
I56
sg26
VC2931785
p115
sg10
I3
sg11
VIIM
p116
sg13
I1
sa(dp117
g7
I35
sg26
VC0004364
p118
sg10
I19
sg11
Vautoimmune diseases
p119
sg13
I2
sasa(dp120
g2
S'We now find that EBV-encoded latent membrane protein 2A (LMP2A) mimics B-cell antigen receptor (BCR) signaling in murine GC B cells, causing altered humoral immune responses and autoimmune diseases.\n'
p121
sg4
(lp122
(dp123
g7
I17
sg8
VP35968
p124
sg10
I38
sg11
VEBV-encoded latent membrane protein 2A
p125
sg13
I5
sa(dp126
g7
I96
sg8
VP11274
p127
sg10
I3
sg11
VBCR
p128
sg13
I1
sa(dp129
g7
I71
sg8
VP14209
p130
sg10
I23
sg11
VB-cell antigen receptor
p131
sg13
I3
sasg23
(lp132
(dp133
g7
I178
sg26
VC0004364
p134
sg10
I19
sg11
Vautoimmune diseases
p135
sg13
I2
sasa(dp136
g2
S'GC B-cell-specific LMP2A expression led to systemic lupus erythematosus-like autoimmune phenotypes in an age-dependent manner.\n'
p137
sg4
(lp138
sg23
(lp139
(dp140
g7
I43
sg26
VC0024141
p141
sg10
I28
sg11
Vsystemic lupus erythematosus
p142
sg13
I3
sa(dp143
g7
I77
sg26
VC0443146
p144
sg10
I10
sg11
Vautoimmune
p145
sg13
I1
sasa(dp146
g2
S'We propose that these previously unidentified cells, designated "rogue GC B cells," are a major driver of autoantibody production and provide a mechanistic explanation for the linked production of IgE and autoantibodies in autoimmune disease.\n'
p147
sg4
(lp148
(dp149
g7
I197
sg8
VP01854
p150
sg10
I3
sg11
VIgE
p151
sg13
I1
sasg23
(lp152
(dp153
g7
I223
sg26
VC0004364
p154
sg10
I18
sg11
Vautoimmune disease
p155
sg13
I2
sa(dp156
g7
I197
sg26
VC0270850
p157
sg10
I3
sg11
VIgE
p158
sg13
I1
sasa(dp159
g2
S'This is the first report implicating RXRA in CHD with 9q duplication, providing additional data in understanding the genetic etiology of tetralogy of Fallot, CHD, and disorders linked to 9q microduplication syndrome.\n'
p160
sg4
(lp161
(dp162
g7
I37
sg8
VP19793
p163
sg10
I4
sg11
VRXRA
p164
sg13
I1
sasg23
(lp165
(dp166
g7
I207
sg26
VC0039082
p167
sg10
I8
sg11
Vsyndrome
p168
sg13
I1
sa(dp169
g7
I57
sg26
VC1705960
p170
sg10
I11
sg11
Vduplication
p171
sg13
I1
sa(dp172
g7
I137
sg26
VC0039685
p173
sg10
I19
sg11
Vtetralogy of Fallot
p174
sg13
I3
sasa(dp175
g2
S'To investigate the effects of carnitine on cardiac function, collagen contents, peroxisome proliferator-activated receptor alpha (PPARalpha) and retinoid X receptor alpha (RXRct) expressions in a rat alcoholic cardiomyopathy modeL.\n'
p176
sg4
(lp177
(dp178
g7
I130
sg8
g15
sg10
I9
sg11
VPPARalpha
p179
sg13
I1
sa(dp180
g7
I80
sg8
g15
sg10
I48
sg11
Vperoxisome proliferator-activated receptor alpha
p181
sg13
I4
sa(dp182
g7
I172
sg8
VP19793
p183
sg10
I5
sg11
VRXRct
p184
sg13
I1
sa(dp185
g7
I145
sg8
VP19793
p186
sg10
I25
sg11
Vretinoid X receptor alpha
p187
sg13
I4
sasg23
(lp188
(dp189
g7
I200
sg26
VC0007192
p190
sg10
I24
sg11
Valcoholic cardiomyopathy
p191
sg13
I2
sasa(dp192
g2
S'In this study, we show that an established model of congenital heart disease, the retinoid X receptor alpha knockout (RXRalpha-/-) embryo, displays a malformed epicardium.\n'
p193
sg4
(lp194
(dp195
g7
I82
sg8
VP19793
p196
sg10
I25
sg11
Vretinoid X receptor alpha
p197
sg13
I4
sasg23
(lp198
(dp199
g7
I52
sg26
VC0152021
p200
sg10
I24
sg11
Vcongenital heart disease
p201
sg13
I3
sasa(dp202
g2
S"The immunomodulatory receptor Siglec-3/CD33 influences risk for late-onset Alzheimer's disease (LOAD), an apparently human-specific post-reproductive disease.\n"
p203
sg4
(lp204
(dp205
g7
I30
sg8
VP20138
p206
sg10
I8
sg11
VSiglec-3
p207
sg13
I1
sa(dp208
g7
I39
sg8
VP20138
p209
sg10
I4
sg11
VCD33
p210
sg13
I1
sasg23
(lp211
(dp212
g7
I75
sg26
VC1521724
p213
sg10
I19
sg11
VAlzheimer's disease
p214
sg13
I2
sasa(dp215
g2
S"Genome-wide association studies and meta-analyses implicated that increased risk of developing Alzheimer's diseases (AD) has been associated with the ABCA7, APOE, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, CR1, DSG2, EPHA1, FERMT2, HLA-DRB1, HLA-DRB4, INPP5D, MEF2C, MS4A4A, MS4A4E, MS4A6E, NME8, PICALM, PLD3, PTK2B, RIN3, SLC24A4, SORL1, and ZCWPW1 genes.\n"
p216
sg4
(lp217
(dp218
g7
I292
sg8
g15
sg10
I6
sg11
VPICALM
p219
sg13
I1
sa(dp220
g7
I176
sg8
g15
sg10
I5
sg11
VCD2AP
p221
sg13
I1
sa(dp222
g7
I270
sg8
g15
sg10
I6
sg11
VMS4A4E
p223
sg13
I1
sa(dp224
g7
I255
sg8
g15
sg10
I5
sg11
VMEF2C
p225
sg13
I1
sa(dp226
g7
I227
sg8
VP30486
p227
sg10
I3
sg11
VHLA
p228
sg13
I1
sa(dp229
g7
I206
sg8
g15
sg10
I4
sg11
VDSG2
p230
sg13
I1
sa(dp231
g7
I189
sg8
g15
sg10
I5
sg11
VCELF1
p232
sg13
I1
sa(dp233
g7
I157
sg8
VP02649
p234
sg10
I4
sg11
VAPOE
p235
sg13
I1
sa(dp236
g7
I150
sg8
g15
sg10
I5
sg11
VABCA7
p237
sg13
I1
sa(dp238
g7
I313
sg8
g15
sg10
I4
sg11
VRIN3
p239
sg13
I1
sa(dp240
g7
I328
sg8
g15
sg10
I5
sg11
VSORL1
p241
sg13
I1
sa(dp242
g7
I319
sg8
g15
sg10
I7
sg11
VSLC24A4
p243
sg13
I1
sa(dp244
g7
I247
sg8
g15
sg10
I6
sg11
VINPP5D
p245
sg13
I1
sa(dp246
g7
I262
sg8
g15
sg10
I6
sg11
VMS4A4A
p247
sg13
I1
sa(dp248
g7
I183
sg8
VP20138
p249
sg10
I4
sg11
VCD33
p250
sg13
I1
sa(dp251
g7
I300
sg8
g15
sg10
I4
sg11
VPLD3
p252
sg13
I1
sa(dp253
g7
I219
sg8
g15
sg10
I6
sg11
VFERMT2
p254
sg13
I1
sa(dp255
g7
I169
sg8
g15
sg10
I5
sg11
VCASS4
p256
sg13
I1
sa(dp257
g7
I196
sg8
VP10909
p258
sg10
I3
sg11
VCLU
p259
sg13
I1
sa(dp260
g7
I306
sg8
g15
sg10
I5
sg11
VPTK2B
p261
sg13
I1
sa(dp262
g7
I212
sg8
VP21709
p263
sg10
I5
sg11
VEPHA1
p264
sg13
I1
sa(dp265
g7
I278
sg8
g15
sg10
I6
sg11
VMS4A6E
p266
sg13
I1
sa(dp267
g7
I227
sg8
VP30486
p268
sg10
I3
sg11
VHLA
p269
sg13
I1
sa(dp270
g7
I201
sg8
VP17927
p271
sg10
I3
sg11
VCR1
p272
sg13
I1
sa(dp273
g7
I339
sg8
g15
sg10
I12
sg11
VZCWPW1 genes
p274
sg13
I2
sa(dp275
g7
I286
sg8
g15
sg10
I4
sg11
VNME8
p276
sg13
I1
sa(dp277
g7
I231
sg8
g15
sg10
I4
sg11
VDRB1
p278
sg13
I1
sasg23
(lp279
(dp280
g7
I95
sg26
VC0002395
p281
sg10
I20
sg11
VAlzheimer's diseases
p282
sg13
I2
sa(dp283
g7
I117
sg26
VC0002395
p284
sg10
I2
sg11
VAD
p285
sg13
I1
sasa(dp286
g2
S"The association of variants in CLU, CR1, PICALM, BIN1, ABCA7, and CD33 genes with late-onset Alzheimer's disease (LOAD) was evaluated and confirmed through genome-wide association study.\n"
p287
sg4
(lp288
(dp289
g7
I31
sg8
VP10909
p290
sg10
I3
sg11
VCLU
p291
sg13
I1
sa(dp292
g7
I41
sg8
g15
sg10
I6
sg11
VPICALM
p293
sg13
I1
sa(dp294
g7
I55
sg8
g15
sg10
I5
sg11
VABCA7
p295
sg13
I1
sa(dp296
g7
I66
sg8
VP20138
p297
sg10
I10
sg11
VCD33 genes
p298
sg13
I2
sa(dp299
g7
I36
sg8
VP17927
p300
sg10
I3
sg11
VCR1
p301
sg13
I1
sasg23
(lp302
(dp303
g7
I93
sg26
VC1521724
p304
sg10
I19
sg11
VAlzheimer's disease
p305
sg13
I2
sasa(dp306
g2
S"This study therefore examined whether the functionally relevant PTPN22 polymorphism is associated with Wegener's granulomatosis (WG).\n"
p307
sg4
(lp308
(dp309
g7
I64
sg8
g15
sg10
I6
sg11
VPTPN22
p310
sg13
I1
sasg23
(lp311
(dp312
g7
I129
sg26
VC0043092
p313
sg10
I2
sg11
VWG
p314
sg13
I1
sa(dp315
g7
I103
sg26
VC0043092
p316
sg10
I24
sg11
VWegener's granulomatosis
p317
sg13
I2
sasa(dp318
g2
S'The results showed that in vivo, the expression of osteopontin (OPN) vascular cell adhesion molecule (VCAM-1), and levels of integrin AlfavBeta3 in the aortic tissue in SCH and Hypothyroidism (CH) groups was higher than in the control group.\n'
p319
sg4
(lp320
(dp321
g7
I69
sg8
g15
sg10
I31
sg11
Vvascular cell adhesion molecule
p322
sg13
I4
sa(dp323
g7
I102
sg8
VP19320
p324
sg10
I6
sg11
VVCAM-1
p325
sg13
I1
sa(dp326
g7
I64
sg8
VP10451
p327
sg10
I3
sg11
VOPN
p328
sg13
I1
sa(dp329
g7
I51
sg8
VP10451
p330
sg10
I11
sg11
Vosteopontin
p331
sg13
I1
sasg23
(lp332
(dp333
g7
I177
sg26
VC0020676
p334
sg10
I14
sg11
VHypothyroidism
p335
sg13
I1
sa(dp336
g7
I83
sg26
VC0001511
p337
sg10
I8
sg11
Vadhesion
p338
sg13
I1
sasa(dp339
g2
S'We analyzed concentrations of osteopontin (OPN) in patients with pancreatic ductal adenocarcinoma (PDAC) in order to determine firstly whether it is useful to distinguish between PDAC patients and those with chronic non-hereditary pancreatitis (CP) and type 2 diabetes mellitus (T2DM), and secondly whether OPN concentrations depend on the PDAC stage.\n'
p340
sg4
(lp341
(dp342
g7
I30
sg8
VP10451
p343
sg10
I11
sg11
Vosteopontin
p344
sg13
I1
sa(dp345
g7
I43
sg8
VP10451
p346
sg10
I3
sg11
VOPN
p347
sg13
I1
sa(dp348
g7
I43
sg8
VP10451
p349
sg10
I3
sg11
VOPN
p350
sg13
I1
sasg23
(lp351
(dp352
g7
I253
sg26
VC0011860
p353
sg10
I24
sg11
Vtype 2 diabetes mellitus
p354
sg13
I4
sa(dp355
g7
I65
sg26
VC1335302
p356
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p357
sg13
I3
sa(dp358
g7
I220
sg26
VC0238339
p359
sg10
I23
sg11
Vhereditary pancreatitis
p360
sg13
I2
sa(dp361
g7
I279
sg26
VC0011860
p362
sg10
I4
sg11
VT2DM
p363
sg13
I1
sa(dp364
g7
I99
sg26
VC1335302
p365
sg10
I4
sg11
VPDAC
p366
sg13
I1
sa(dp367
g7
I99
sg26
VC1335302
p368
sg10
I4
sg11
VPDAC
p369
sg13
I1
sa(dp370
g7
I99
sg26
VC1335302
p371
sg10
I4
sg11
VPDAC
p372
sg13
I1
sasa(dp373
g2
S'Our pilot study demonstrates the usefulness of estimating OPN levels to differentiate between pancreatic cancer and chronic pancreatitis.\n'
p374
sg4
(lp375
sg23
(lp376
(dp377
g7
I116
sg26
VC0149521
p378
sg10
I20
sg11
Vchronic pancreatitis
p379
sg13
I2
sa(dp380
g7
I94
sg26
VC0235974
p381
sg10
I17
sg11
Vpancreatic cancer
p382
sg13
I2
sasa(dp383
g2
S"We aimed to test IRX3's roles in the browning program and to evaluate the association between the genetic variants in IRX3 and human obesity.\n"
p384
sg4
(lp385
(dp386
g7
I17
sg8
VP78415
p387
sg10
I4
sg11
VIRX3
p388
sg13
I1
sa(dp389
g7
I17
sg8
VP78415
p390
sg10
I4
sg11
VIRX3
p391
sg13
I1
sasg23
(lp392
(dp393
g7
I133
sg26
VC0028754
p394
sg10
I7
sg11
Vobesity
p395
sg13
I1
sasa(dp396
g2
S'Rare variants of IRX3 were associated with human obesity.\n'
p397
sg4
(lp398
(dp399
g7
I17
sg8
VP78415
p400
sg10
I4
sg11
VIRX3
p401
sg13
I1
sasg23
(lp402
(dp403
g7
I49
sg26
VC0028754
p404
sg10
I7
sg11
Vobesity
p405
sg13
I1
sasa(dp406
g2
S'Recent prevalent research topic concentrated in the three neighboring genes of FTO: RPGRIP1L, IRX3 and IRX5, as having a functional link between obesity-associated common variants within FTO and the observed human phenotypes.\n'
p407
sg4
(lp408
(dp409
g7
I84
sg8
g15
sg10
I8
sg11
VRPGRIP1L
p410
sg13
I1
sa(dp411
g7
I103
sg8
VP78411
p412
sg10
I4
sg11
VIRX5
p413
sg13
I1
sa(dp414
g7
I79
sg8
g15
sg10
I3
sg11
VFTO
p415
sg13
I1
sa(dp416
g7
I94
sg8
VP78415
p417
sg10
I4
sg11
VIRX3
p418
sg13
I1
sasg23
(lp419
(dp420
g7
I145
sg26
VC0028754
p421
sg10
I7
sg11
Vobesity
p422
sg13
I1
sasa(dp423
g2
S'IRX3 expression has been functionally associated in obesity-associated long-distance susceptibility loci, but the effect of the IRX3 genetic variants on human obesity and obesity-related metabolism remains uncertain.\n'
p424
sg4
(lp425
(dp426
g7
I0
sg8
VP78415
p427
sg10
I4
sg11
VIRX3
p428
sg13
I1
sa(dp429
g7
I128
sg8
VP78415
p430
sg10
I21
sg11
VIRX3 genetic variants
p431
sg13
I3
sasg23
(lp432
(dp433
g7
I52
sg26
VC0028754
p434
sg10
I7
sg11
Vobesity
p435
sg13
I1
sa(dp436
g7
I52
sg26
VC0028754
p437
sg10
I7
sg11
Vobesity
p438
sg13
I1
sa(dp439
g7
I52
sg26
VC0028754
p440
sg10
I7
sg11
Vobesity
p441
sg13
I1
sasa(dp442
g2
S'IRX3 genetic variants associate with birth weight, BMI and AST/ALT-related transaminase metabolism, supporting the role of IRX3 as an obesity-associated susceptibility gene.\n'
p443
sg4
(lp444
(dp445
g7
I0
sg8
VP78415
p446
sg10
I4
sg11
VIRX3
p447
sg13
I1
sa(dp448
g7
I59
sg8
VP51689
p449
sg10
I3
sg11
VAST
p450
sg13
I1
sa(dp451
g7
I63
sg8
VP13716
p452
sg10
I3
sg11
VALT
p453
sg13
I1
sa(dp454
g7
I0
sg8
VP78415
p455
sg10
I4
sg11
VIRX3
p456
sg13
I1
sasg23
(lp457
(dp458
g7
I134
sg26
VC0028754
p459
sg10
I7
sg11
Vobesity
p460
sg13
I1
sasa(dp461
g2
S'The fat mass and obesity associated (Fto) and iroquois homeobox 3 (Irx3) genes have been recognised as important obesity-related genes.\n'
p462
sg4
(lp463
(dp464
g7
I67
sg8
VP78415
p465
sg10
I4
sg11
VIrx3
p466
sg13
I1
sa(dp467
g7
I4
sg8
g15
sg10
I31
sg11
Vfat mass and obesity associated
p468
sg13
I5
sa(dp469
g7
I46
sg8
VP78415
p470
sg10
I19
sg11
Viroquois homeobox 3
p471
sg13
I3
sa(dp472
g7
I37
sg8
g15
sg10
I3
sg11
VFto
p473
sg13
I1
sasg23
(lp474
(dp475
g7
I17
sg26
VC0028754
p476
sg10
I7
sg11
Vobesity
p477
sg13
I1
sa(dp478
g7
I17
sg26
VC0028754
p479
sg10
I7
sg11
Vobesity
p480
sg13
I1
sasa(dp481
g2
S'The analysis of the FTO-IRX3 locus revealed high LD and high order gene-gene interactions for BMI linked obesity.\n'
p482
sg4
(lp483
(dp484
g7
I20
sg8
g15
sg10
I14
sg11
VFTO-IRX3 locus
p485
sg13
I2
sasg23
(lp486
(dp487
g7
I105
sg26
VC0028754
p488
sg10
I7
sg11
Vobesity
p489
sg13
I1
sasa(dp490
g2
S'In this multi-analytical approach, FTO rs9939609 and IRX3 rs3751723, along with TCF7L2 rs7903146 and TMEM18 rs6548238, emerged as the major SNPs contributing to BMI linked obesity risk in the North Indian population.\n'
p491
sg4
(lp492
(dp493
g7
I101
sg8
g15
sg10
I16
sg11
VTMEM18 rs6548238
p494
sg13
I2
sa(dp495
g7
I35
sg8
g15
sg10
I13
sg11
VFTO rs9939609
p496
sg13
I2
sa(dp497
g7
I53
sg8
VP78415
p498
sg10
I4
sg11
VIRX3
p499
sg13
I1
sasg23
(lp500
(dp501
g7
I172
sg26
VC0028754
p502
sg10
I7
sg11
Vobesity
p503
sg13
I1
sasa(dp504
g2
S'Obesity-associated cis-acting elements in non-coding region of FTO regulate the expression of IRX3 gene, thus activating obesity networks.\n'
p505
sg4
(lp506
(dp507
g7
I63
sg8
g15
sg10
I3
sg11
VFTO
p508
sg13
I1
sa(dp509
g7
I94
sg8
VP78415
p510
sg10
I9
sg11
VIRX3 gene
p511
sg13
I2
sasg23
(lp512
(dp513
g7
I0
sg26
VC0028754
p514
sg10
I7
sg11
VObesity
p515
sg13
I1
sa(dp516
g7
I121
sg26
VC0028754
p517
sg10
I7
sg11
Vobesity
p518
sg13
I1
sa(dp519
g7
I19
sg26
VC0007099
p520
sg10
I3
sg11
Vcis
p521
sg13
I1
sasa(dp522
g2
S'Considering the properties of the substructure and their biological functions, we identified the putative diagnostic biomarker microRNAs, some of which have been reported on the PubMed citations while the rest, that is, miR-204-5p, miR-567, miR-454-3p, miR-338-3p, and miR-139-5p, were predicted as the putative novel microRNA biomarker for the diagnosis of NSCLC adenocarcinoma.\n'
p523
sg4
(lp524
(dp525
g7
I232
sg8
g15
sg10
I7
sg11
VmiR-567
p526
sg13
I1
sa(dp527
g7
I241
sg8
g15
sg10
I10
sg11
VmiR-454-3p
p528
sg13
I1
sa(dp529
g7
I253
sg8
g15
sg10
I10
sg11
VmiR-338-3p
p530
sg13
I1
sa(dp531
g7
I269
sg8
g15
sg10
I10
sg11
VmiR-139-5p
p532
sg13
I1
sa(dp533
g7
I220
sg8
g15
sg10
I10
sg11
VmiR-204-5p
p534
sg13
I1
sasg23
(lp535
(dp536
g7
I364
sg26
VC0001418
p537
sg10
I14
sg11
Vadenocarcinoma
p538
sg13
I1
sa(dp539
g7
I358
sg26
VC0007131
p540
sg10
I5
sg11
VNSCLC
p541
sg13
I1
sasa(dp542
g2
S'We demonstrated that Hsa-miR-567 expression is significantly downregulated in poor prognosis breast cancer, compared to better prognosis breast cancer, having a role in the control of cell proliferation and migration by regulating KPNA4 gene.\n'
p543
sg4
(lp544
(dp545
g7
I21
sg8
g15
sg10
I11
sg11
VHsa-miR-567
p546
sg13
I1
sa(dp547
g7
I231
sg8
g15
sg10
I10
sg11
VKPNA4 gene
p548
sg13
I2
sasg23
(lp549
(dp550
g7
I93
sg26
VC0678222
p551
sg10
I13
sg11
Vbreast cancer
p552
sg13
I2
sa(dp553
g7
I189
sg26
VC0334094
p554
sg10
I13
sg11
Vproliferation
p555
sg13
I1
sa(dp556
g7
I21
sg26
VC0393754
p557
sg10
I3
sg11
VHsa
p558
sg13
I1
sa(dp559
g7
I93
sg26
VC0678222
p560
sg10
I13
sg11
Vbreast cancer
p561
sg13
I2
sasa(dp562
g2
S'In this study, based on our previously published in silico results, we proved both in vitro (cell line studies) and ex vivo (clinical studies), that Hsa-miR-567 expression is significantly downregulated in breast cancer with poor prognosis when compared to breast cancer with better prognosis.\n'
p563
sg4
(lp564
(dp565
g7
I149
sg8
g15
sg10
I11
sg11
VHsa-miR-567
p566
sg13
I1
sasg23
(lp567
(dp568
g7
I206
sg26
VC0678222
p569
sg10
I13
sg11
Vbreast cancer
p570
sg13
I2
sa(dp571
g7
I206
sg26
VC0678222
p572
sg10
I13
sg11
Vbreast cancer
p573
sg13
I2
sa(dp574
g7
I149
sg26
VC0393754
p575
sg10
I3
sg11
VHsa
p576
sg13
I1
sasa(dp577
g2
S'More intriguingly, we demonstrated that the ectopic expression of Hsa-miR-567 in poor prognosis breast cancer cell line strongly inhibits in vitro cell proliferation and migration.\n'
p578
sg4
(lp579
(dp580
g7
I66
sg8
g15
sg10
I11
sg11
VHsa-miR-567
p581
sg13
I1
sasg23
(lp582
(dp583
g7
I96
sg26
VC0678222
p584
sg10
I13
sg11
Vbreast cancer
p585
sg13
I2
sa(dp586
g7
I66
sg26
VC0393754
p587
sg10
I3
sg11
VHsa
p588
sg13
I1
sa(dp589
g7
I152
sg26
VC0334094
p590
sg10
I13
sg11
Vproliferation
p591
sg13
I1
sasa(dp592
g2
S'Furthermore, we showed in vivo that breast cancer cells, stably expressing Hsa-miR-567, xenografted in mouse, reduce tumor growth ability.\n'
p593
sg4
(lp594
(dp595
g7
I75
sg8
g15
sg10
I11
sg11
VHsa-miR-567
p596
sg13
I1
sasg23
(lp597
(dp598
g7
I75
sg26
VC0393754
p599
sg10
I3
sg11
VHsa
p600
sg13
I1
sa(dp601
g7
I117
sg26
VC0598934
p602
sg10
I12
sg11
Vtumor growth
p603
sg13
I2
sa(dp604
g7
I36
sg26
VC0678222
p605
sg10
I13
sg11
Vbreast cancer
p606
sg13
I2
sasa(dp607
g2
S'Consistently, we found that karyopherin 4 (KPNA4), predicted target gene of Hsa-miR-567 as identified by our in silico analysis, is upregulated in highly aggressive MDA-MB-231 breast cancer cell line and patient tissues with poor prognosis with respect to good prognosis.\n'
p608
sg4
(lp609
(dp610
g7
I43
sg8
g15
sg10
I5
sg11
VKPNA4
p611
sg13
I1
sa(dp612
g7
I76
sg8
g15
sg10
I11
sg11
VHsa-miR-567
p613
sg13
I1
sasg23
(lp614
(dp615
g7
I76
sg26
VC0393754
p616
sg10
I3
sg11
VHsa
p617
sg13
I1
sa(dp618
g7
I154
sg26
VC0001807
p619
sg10
I10
sg11
Vaggressive
p620
sg13
I1
sa(dp621
g7
I176
sg26
VC0678222
p622
sg10
I13
sg11
Vbreast cancer
p623
sg13
I2
sasa(dp624
g2
S'The three-MUC diagnostic model (MUC3, MUC5AC, and MUC6) showed an excellent ability to discriminate pancreatic cancer from non-malignant tissues, and yielded information that may prove useful for the development of clinical applications.\n'
p625
sg4
(lp626
(dp627
g7
I32
sg8
g15
sg10
I4
sg11
VMUC3
p628
sg13
I1
sa(dp629
g7
I50
sg8
g15
sg10
I4
sg11
VMUC6
p630
sg13
I1
sasg23
(lp631
(dp632
g7
I100
sg26
VC0235974
p633
sg10
I17
sg11
Vpancreatic cancer
p634
sg13
I2
sasa(dp635
g2
S'Recent studies of cancer have identified novel functions of the low-density lipoprotein receptor-related protein 4-muscle-specific kinase (LRP4-MuSK) pathway.\n'
p636
sg4
(lp637
(dp638
g7
I144
sg8
g15
sg10
I4
sg11
VMuSK
p639
sg13
I1
sa(dp640
g7
I139
sg8
g15
sg10
I4
sg11
VLRP4
p641
sg13
I1
sa(dp642
g7
I64
sg8
g15
sg10
I73
sg11
Vlow-density lipoprotein receptor-related protein 4-muscle-specific kinase
p643
sg13
I6
sasg23
(lp644
(dp645
g7
I18
sg26
VC0006826
p646
sg10
I6
sg11
Vcancer
p647
sg13
I1
sasa(dp648
g2
S'Genes potentially associated with deregulation of the extracellular matrix organization pathway (CTSB, TNXB, COL4A3, COL16A1, COL24A1, COL5A2, NID1, LOXL2, MMP11, TRIM24 and MUSK) and DNA repair function (NBN and MSH2) were detected by WES, suggesting that other cancer-associated genes have pathogenic effects in the risk of familial PTC development.\n'
p649
sg4
(lp650
(dp651
g7
I174
sg8
g15
sg10
I4
sg11
VMUSK
p652
sg13
I1
sa(dp653
g7
I97
sg8
VP07858
p654
sg10
I4
sg11
VCTSB
p655
sg13
I1
sa(dp656
g7
I143
sg8
VP14543
p657
sg10
I4
sg11
VNID1
p658
sg13
I1
sa(dp659
g7
I205
sg8
g15
sg10
I3
sg11
VNBN
p660
sg13
I1
sa(dp661
g7
I126
sg8
g15
sg10
I7
sg11
VCOL24A1
p662
sg13
I1
sa(dp663
g7
I149
sg8
g15
sg10
I5
sg11
VLOXL2
p664
sg13
I1
sa(dp665
g7
I156
sg8
VP24347
p666
sg10
I5
sg11
VMMP11
p667
sg13
I1
sa(dp668
g7
I163
sg8
g15
sg10
I6
sg11
VTRIM24
p669
sg13
I1
sa(dp670
g7
I103
sg8
g15
sg10
I4
sg11
VTNXB
p671
sg13
I1
sa(dp672
g7
I213
sg8
VP43246
p673
sg10
I4
sg11
VMSH2
p674
sg13
I1
sa(dp675
g7
I117
sg8
g15
sg10
I7
sg11
VCOL16A1
p676
sg13
I1
sasg23
(lp677
(dp678
g7
I335
sg26
VC0238463
p679
sg10
I3
sg11
VPTC
p680
sg13
I1
sa(dp681
g7
I263
sg26
VC0006826
p682
sg10
I6
sg11
Vcancer
p683
sg13
I1
sasa(dp684
g2
S'Using SVM analysis and five gene expression profile data confirmation, a 15-gene signature (HES5, ZNF417, GLRA2, OR8D2, HOXA7, FABP6, MUSK, HTR6, GRIP2, KLRK1, VEGFA, AKAP12, RHEB, NCRNA00152 and PMEPA1) were identified as a predictor of recurrence risk and prognosis for colon cancer patients.\n'
p685
sg4
(lp686
(dp687
g7
I92
sg8
g15
sg10
I4
sg11
VHES5
p688
sg13
I1
sa(dp689
g7
I153
sg8
VP26718
p690
sg10
I5
sg11
VKLRK1
p691
sg13
I1
sa(dp692
g7
I146
sg8
g15
sg10
I5
sg11
VGRIP2
p693
sg13
I1
sa(dp694
g7
I167
sg8
g15
sg10
I6
sg11
VAKAP12
p695
sg13
I1
sa(dp696
g7
I134
sg8
g15
sg10
I4
sg11
VMUSK
p697
sg13
I1
sa(dp698
g7
I140
sg8
VP50406
p699
sg10
I4
sg11
VHTR6
p700
sg13
I1
sa(dp701
g7
I106
sg8
VP23416
p702
sg10
I5
sg11
VGLRA2
p703
sg13
I1
sa(dp704
g7
I98
sg8
g15
sg10
I6
sg11
VZNF417
p705
sg13
I1
sa(dp706
g7
I196
sg8
g15
sg10
I6
sg11
VPMEPA1
p707
sg13
I1
sa(dp708
g7
I120
sg8
VP31268
p709
sg10
I5
sg11
VHOXA7
p710
sg13
I1
sa(dp711
g7
I113
sg8
g15
sg10
I5
sg11
VOR8D2
p712
sg13
I1
sa(dp713
g7
I175
sg8
g15
sg10
I4
sg11
VRHEB
p714
sg13
I1
sa(dp715
g7
I127
sg8
VP51161
p716
sg10
I5
sg11
VFABP6
p717
sg13
I1
sasg23
(lp718
(dp719
g7
I272
sg26
VC0699790
p720
sg10
I12
sg11
Vcolon cancer
p721
sg13
I2
sa(dp722
g7
I238
sg26
VC1458156
p723
sg10
I10
sg11
Vrecurrence
p724
sg13
I1
sasa(dp725
g2
S'In addition, the tumor cells were positive for Calretinin, Creatine Kinase (CK)5/6, CK7, CKAEI 1/3, Wilms Tumor protein (WT-1), and Vimentin, but were negative for Alpha Feto protein (AFP), Thrombotic Thrombocytopenic Purpura (TTP-1), Anti-Hepatocyte Specific Antigen (HSA), Synaptophysin, CK20, and Homeobox protein (CDx-2).\n'
p726
sg4
(lp727
(dp728
g7
I164
sg8
VP02771
p729
sg10
I18
sg11
VAlpha Feto protein
p730
sg13
I3
sa(dp731
g7
I300
sg8
VP54821
p732
sg10
I16
sg11
VHomeobox protein
p733
sg13
I2
sa(dp734
g7
I318
sg8
g15
sg10
I5
sg11
VCDx-2
p735
sg13
I1
sa(dp736
g7
I47
sg8
VP22676
p737
sg10
I10
sg11
VCalretinin
p738
sg13
I1
sa(dp739
g7
I59
sg8
VP12532
p740
sg10
I15
sg11
VCreatine Kinase
p741
sg13
I2
sa(dp742
g7
I84
sg8
VP08729
p743
sg10
I3
sg11
VCK7
p744
sg13
I1
sa(dp745
g7
I100
sg8
g15
sg10
I19
sg11
VWilms Tumor protein
p746
sg13
I3
sa(dp747
g7
I275
sg8
VP08247
p748
sg10
I13
sg11
VSynaptophysin
p749
sg13
I1
sa(dp750
g7
I227
sg8
g15
sg10
I5
sg11
VTTP-1
p751
sg13
I1
sa(dp752
g7
I269
sg8
g15
sg10
I3
sg11
VHSA
p753
sg13
I1
sa(dp754
g7
I76
sg8
VP12532
p755
sg10
I2
sg11
VCK
p756
sg13
I1
sa(dp757
g7
I184
sg8
VP02771
p758
sg10
I3
sg11
VAFP
p759
sg13
I1
sa(dp760
g7
I290
sg8
VP35900
p761
sg10
I4
sg11
VCK20
p762
sg13
I1
sa(dp763
g7
I235
sg8
VP14209
p764
sg10
I32
sg11
VAnti-Hepatocyte Specific Antigen
p765
sg13
I3
sasg23
(lp766
(dp767
g7
I235
sg26
VC0393754
p768
sg10
I32
sg11
VAnti-Hepatocyte Specific Antigen
p769
sg13
I3
sa(dp770
g7
I227
sg26
VC0034155
p771
sg10
I3
sg11
VTTP
p772
sg13
I1
sa(dp773
g7
I190
sg26
VC0034155
p774
sg10
I35
sg11
VThrombotic Thrombocytopenic Purpura
p775
sg13
I3
sa(dp776
g7
I269
sg26
VC0393754
p777
sg10
I3
sg11
VHSA
p778
sg13
I1
sa(dp779
g7
I100
sg26
VC0027708
p780
sg10
I11
sg11
VWilms Tumor
p781
sg13
I2
sa(dp782
g7
I17
sg26
VC0027651
p783
sg10
I5
sg11
Vtumor
p784
sg13
I1
sasa(dp785
g2
S'Furthermore WT1 is a good marker of response to JAK2 inhibitors especially for patients without blasts and for patients who develop anemia or thrombocytopenia not for progression but as therapy related toxicity.\n'
p786
sg4
(lp787
(dp788
g7
I12
sg8
g15
sg10
I3
sg11
VWT1
p789
sg13
I1
sa(dp790
g7
I48
sg8
g15
sg10
I4
sg11
VJAK2
p791
sg13
I1
sasg23
(lp792
(dp793
g7
I12
sg26
VC0027708
p794
sg10
I3
sg11
VWT1
p795
sg13
I1
sa(dp796
g7
I132
sg26
VC0002871
p797
sg10
I6
sg11
Vanemia
p798
sg13
I1
sasa(dp799
g2
S'Furthermore, we detect functionally defective LRFN2 missense mutations in autism and schizophrenia patients.\n'
p800
sg4
(lp801
(dp802
g7
I46
sg8
g15
sg10
I5
sg11
VLRFN2
p803
sg13
I1
sasg23
(lp804
(dp805
g7
I85
sg26
VC0036341
p806
sg10
I13
sg11
Vschizophrenia
p807
sg13
I1
sa(dp808
g7
I74
sg26
VC0004352
p809
sg10
I6
sg11
Vautism
p810
sg13
I1
sasa(dp811
g2
S'Gain-of-function (GOF) mutations in RHBDF2 cause tylosis.\n'
p812
sg4
(lp813
sg23
(lp814
(dp815
g7
I49
sg26
VC0022584
p816
sg10
I7
sg11
Vtylosis
p817
sg13
I1
sasa(dp818
g2
S'The curly bare mouse model of tylosis, carrying a GOF mutation in the Rhbdf2 gene (Rhbdf2 cub ), presents with epidermal hyperplasia and shows accelerated cutaneous wound-healing phenotype through enhanced secretion of the epidermal growth factor receptor family ligand amphiregulin.\n'
p819
sg4
(lp820
(dp821
g7
I223
sg8
VP01133
p822
sg10
I32
sg11
Vepidermal growth factor receptor
p823
sg13
I4
sa(dp824
g7
I83
sg8
g15
sg10
I10
sg11
VRhbdf2 cub
p825
sg13
I2
sa(dp826
g7
I270
sg8
VP15514
p827
sg10
I12
sg11
Vamphiregulin
p828
sg13
I1
sa(dp829
g7
I70
sg8
g15
sg10
I11
sg11
VRhbdf2 gene
p830
sg13
I2
sasg23
(lp831
(dp832
g7
I30
sg26
VC0022584
p833
sg10
I7
sg11
Vtylosis
p834
sg13
I1
sa(dp835
g7
I111
sg26
VC1707929
p836
sg10
I21
sg11
Vepidermal hyperplasia
p837
sg13
I2
sasa(dp838
g2
S'iRhom2, a member of the rhomboid-like pseudoprotease superfamily, regulates the maturation and trafficking of ADAM17 and is associated with inflammatory arthritis.\n'
p839
sg4
(lp840
(dp841
g7
I110
sg8
VP78536
p842
sg10
I6
sg11
VADAM17
p843
sg13
I1
sa(dp844
g7
I24
sg8
VP63125
p845
sg10
I40
sg11
Vrhomboid-like pseudoprotease superfamily
p846
sg13
I3
sasg23
(lp847
(dp848
g7
I140
sg26
VC0003864
p849
sg10
I22
sg11
Vinflammatory arthritis
p850
sg13
I2
sasa(dp851
g2
S'In humans, gain-of-function (GOF) mutations in RHBDF2 cause the skin disease tylosis.\n'
p852
sg4
(lp853
(dp854
g7
I47
sg8
g15
sg10
I6
sg11
VRHBDF2
p855
sg13
I1
sasg23
(lp856
(dp857
g7
I64
sg26
VC0037274
p858
sg10
I12
sg11
Vskin disease
p859
sg13
I2
sa(dp860
g7
I77
sg26
VC0022584
p861
sg10
I7
sg11
Vtylosis
p862
sg13
I1
sasa(dp863
g2
S'We generated a mouse model of human tylosis and show that GOF mutations in RHBDF2 cause tylosis by enhancing the amount of amphiregulin (AREG) secretion.\n'
p864
sg4
(lp865
(dp866
g7
I75
sg8
g15
sg10
I6
sg11
VRHBDF2
p867
sg13
I1
sa(dp868
g7
I123
sg8
VP15514
p869
sg10
I12
sg11
Vamphiregulin
p870
sg13
I1
sa(dp871
g7
I137
sg8
VP15514
p872
sg10
I4
sg11
VAREG
p873
sg13
I1
sasg23
(lp874
(dp875
g7
I36
sg26
VC0022584
p876
sg10
I7
sg11
Vtylosis
p877
sg13
I1
sa(dp878
g7
I36
sg26
VC0022584
p879
sg10
I7
sg11
Vtylosis
p880
sg13
I1
sasa(dp881
g2
S'Collectively, our data suggest that RHBDF2 plays a critical role in regulating EGFR signaling and its downstream events, including development of tylosis, by facilitating enhanced secretion of AREG.\n'
p882
sg4
(lp883
(dp884
g7
I36
sg8
g15
sg10
I6
sg11
VRHBDF2
p885
sg13
I1
sasg23
(lp886
(dp887
g7
I146
sg26
VC0022584
p888
sg10
I7
sg11
Vtylosis
p889
sg13
I1
sasa(dp890
g2
S'Mutations in RHBDF2 cause tylosis, a very rare disorder characterized by high life-time risk of ESCC, but no other well-established predisposition genes have been identified.\n'
p891
sg4
(lp892
sg23
(lp893
(dp894
g7
I26
sg26
VC0022584
p895
sg10
I7
sg11
Vtylosis
p896
sg13
I1
sa(dp897
g7
I42
sg26
VC0678236
p898
sg10
I13
sg11
Vrare disorder
p899
sg13
I2
sasa(dp900
g2
S'Gain-of-function mutations in iRHOM2 underlie Tylosis with oesophageal cancer (TOC), characterized by palmoplantar thickening, upregulate K16 with robust downregulation of its type II keratin binding partner, K6.\n'
p901
sg4
(lp902
(dp903
g7
I176
sg8
g15
sg10
I31
sg11
Vtype II keratin binding partner
p904
sg13
I5
sasg23
(lp905
(dp906
g7
I79
sg26
VC1835664
p907
sg10
I3
sg11
VTOC
p908
sg13
I1
sa(dp909
g7
I46
sg26
VC1835664
p910
sg10
I31
sg11
VTylosis with oesophageal cancer
p911
sg13
I4
sasa(dp912
g2
S'A short-lived membrane protein IRHOM2 pedals a cascade of events by regulating Epidermal Growth Factor Receptor (EGFR) signalling in parallel with metalloproteases which results their involvement in cancer as well as in rheumatoid arthritis.\n'
p913
sg4
(lp914
(dp915
g7
I147
sg8
g15
sg10
I16
sg11
Vmetalloproteases
p916
sg13
I1
sa(dp917
g7
I113
sg8
VP01133
p918
sg10
I4
sg11
VEGFR
p919
sg13
I1
sa(dp920
g7
I79
sg8
VP01133
p921
sg10
I32
sg11
VEpidermal Growth Factor Receptor
p922
sg13
I4
sasg23
(lp923
(dp924
g7
I199
sg26
VC0006826
p925
sg10
I6
sg11
Vcancer
p926
sg13
I1
sa(dp927
g7
I220
sg26
VC0003873
p928
sg10
I20
sg11
Vrheumatoid arthritis
p929
sg13
I2
sasa(dp930
g2
S'Cells from patients with a dominantly inherited cancer susceptibility syndrome called tylosis with esophageal cancer (TOC) have amino-terminal mutations in iRhom2.\n'
p931
sg4
(lp932
sg23
(lp933
(dp934
g7
I48
sg26
VC0006826
p935
sg10
I6
sg11
Vcancer
p936
sg13
I1
sa(dp937
g7
I118
sg26
VC1835664
p938
sg10
I3
sg11
VTOC
p939
sg13
I1
sa(dp940
g7
I86
sg26
VC1835664
p941
sg10
I30
sg11
Vtylosis with esophageal cancer
p942
sg13
I4
sa(dp943
g7
I70
sg26
VC0039082
p944
sg10
I8
sg11
Vsyndrome
p945
sg13
I1
sasa(dp946
g2
S'A diagnosis of tylosis with oesophageal cancer is made on the basis of a positive family history, characteristic clinical features, including cutaneous and oesophageal lesions, and genetic analysis for mutations in RHBDF2.\n'
p947
sg4
(lp948
(dp949
g7
I215
sg8
g15
sg10
I6
sg11
VRHBDF2
p950
sg13
I1
sasg23
(lp951
(dp952
g7
I28
sg26
VC0546837
p953
sg10
I18
sg11
Voesophageal cancer
p954
sg13
I2
sa(dp955
g7
I15
sg26
VC0022584
p956
sg10
I7
sg11
Vtylosis
p957
sg13
I1
sasa(dp958
g2
S'To investigate the content of serum microRNA-126 (miR-126) and its role in screening retinal endothelial injury and early diagnosis of proliferative diabetic retinopathy.\n'
p959
sg4
(lp960
sg23
(lp961
(dp962
g7
I135
sg26
VC0154830
p963
sg10
I34
sg11
Vproliferative diabetic retinopathy
p964
sg13
I3
sasa(dp965
g2
S'Let-7d, miR-21, miR-107, miR-126, miR-145, miR-146a, miR-182, and miR-192 significantly increased at the Rp-60 (control versus sham P &lt; .001).\n'
p966
sg4
(lp967
(dp968
g7
I53
sg8
g15
sg10
I7
sg11
VmiR-182
p969
sg13
I1
sa(dp970
g7
I34
sg8
g15
sg10
I7
sg11
VmiR-145
p971
sg13
I1
sa(dp972
g7
I43
sg8
g15
sg10
I8
sg11
VmiR-146a
p973
sg13
I1
sa(dp974
g7
I16
sg8
g15
sg10
I7
sg11
VmiR-107
p975
sg13
I1
sa(dp976
g7
I8
sg8
g15
sg10
I6
sg11
VmiR-21
p977
sg13
I1
sa(dp978
g7
I25
sg8
g15
sg10
I7
sg11
VmiR-126
p979
sg13
I1
sasg23
(lp980
sa(dp981
g2
S'We characterized the retinal vascular phenotype of miR-126-/- mice, and tested the function of miR-126 strands (miR-126-3p and -5p) using in vitro angiogenesis models and a mouse model of neovascular age-related macular degeneration.\n'
p982
sg4
(lp983
(dp984
g7
I112
sg8
g15
sg10
I18
sg11
VmiR-126-3p and -5p
p985
sg13
I3
sasg23
(lp986
(dp987
g7
I188
sg26
VC0271084
p988
sg10
I44
sg11
Vneovascular age-related macular degeneration
p989
sg13
I4
sa(dp990
g7
I21
sg26
VC0549652
p991
sg10
I16
sg11
Vretinal vascular
p992
sg13
I2
sasa(dp993
g2
S'Mutations in Eyes shut homolog (EYS) are one of the most common causes of autosomal recessive (ar) retinitis pigmentosa (RP), a progressive blinding disorder.\n'
p994
sg4
(lp995
sg23
(lp996
(dp997
g7
I121
sg26
VC0035334
p998
sg10
I2
sg11
VRP
p999
sg13
I1
sa(dp1000
g7
I99
sg26
VC0035334
p1001
sg10
I20
sg11
Vretinitis pigmentosa
p1002
sg13
I2
sasa(dp1003
g2
S'We compare the choroidal vascular area between Bietti crystalline dystrophy (BCD) patients with CYP4V2 mutations, retinitis pigmentosa (RP) patients with EYS mutations, and normal controls, and investigate the correlation between choroidal vascular area and associated parameters.\n'
p1004
sg4
(lp1005
(dp1006
g7
I96
sg8
g15
sg10
I16
sg11
VCYP4V2 mutations
p1007
sg13
I2
sasg23
(lp1008
(dp1009
g7
I47
sg26
VC1859486
p1010
sg10
I28
sg11
VBietti crystalline dystrophy
p1011
sg13
I3
sa(dp1012
g7
I114
sg26
VC0035334
p1013
sg10
I20
sg11
Vretinitis pigmentosa
p1014
sg13
I2
sa(dp1015
g7
I136
sg26
VC0035334
p1016
sg10
I2
sg11
VRP
p1017
sg13
I1
sa(dp1018
g7
I77
sg26
VC1859486
p1019
sg10
I3
sg11
VBCD
p1020
sg13
I1
sasa(dp1021
g2
S'Mutations in the EYS (eyes shut homolog) gene are a common cause of autosomal recessive (ar) retinitis pigmentosa (RP).\n'
p1022
sg4
(lp1023
sg23
(lp1024
(dp1025
g7
I115
sg26
VC0035334
p1026
sg10
I2
sg11
VRP
p1027
sg13
I1
sa(dp1028
g7
I93
sg26
VC0035334
p1029
sg10
I20
sg11
Vretinitis pigmentosa
p1030
sg13
I2
sasa(dp1031
g2
S'Without a mammalian model of human EYS disease, there is limited understanding of details of disease expression and rates of progression of the retinal degeneration.\n'
p1032
sg4
(lp1033
sg23
(lp1034
(dp1035
g7
I144
sg26
VC0035304
p1036
sg10
I20
sg11
Vretinal degeneration
p1037
sg13
I2
sasa(dp1038
g2
S'EYS and USH2A are the most common causative genes for retinitis pigmentosa (RP) in Japan.\n'
p1039
sg4
(lp1040
(dp1041
g7
I8
sg8
g15
sg10
I5
sg11
VUSH2A
p1042
sg13
I1
sasg23
(lp1043
(dp1044
g7
I8
sg26
VC1848634
p1045
sg10
I5
sg11
VUSH2A
p1046
sg13
I1
sa(dp1047
g7
I76
sg26
VC0035334
p1048
sg10
I2
sg11
VRP
p1049
sg13
I1
sa(dp1050
g7
I54
sg26
VC0035334
p1051
sg10
I20
sg11
Vretinitis pigmentosa
p1052
sg13
I2
sasa(dp1053
g2
S'Mutations in EYS are associated with autosomal recessive retinitis pigmentosa (arRP) and autosomal recessive cone-rod dystrophy (arCRD) however, the function of EYS and the molecular mechanisms of how these mutations cause retinal degeneration are still unclear.\n'
p1054
sg4
(lp1055
sg23
(lp1056
(dp1057
g7
I37
sg26
VC0339526
p1058
sg10
I40
sg11
Vautosomal recessive retinitis pigmentosa
p1059
sg13
I4
sa(dp1060
g7
I109
sg26
VC0035334
p1061
sg10
I18
sg11
Vcone-rod dystrophy
p1062
sg13
I2
sa(dp1063
g7
I79
sg26
VC0339526
p1064
sg10
I4
sg11
VarRP
p1065
sg13
I1
sa(dp1066
g7
I223
sg26
VC0035304
p1067
sg10
I20
sg11
Vretinal degeneration
p1068
sg13
I2
sasa(dp1069
g2
S'We constructed an EYS-knockout zebrafish-line by TALEN technology which showed visual impairment at an early age, while the histological and immunofluorescence assays indicated the presence of progressive retinal degeneration with a cone predominately affected pattern.\n'
p1070
sg4
(lp1071
sg23
(lp1072
(dp1073
g7
I205
sg26
VC0035304
p1074
sg10
I20
sg11
Vretinal degeneration
p1075
sg13
I2
sa(dp1076
g7
I79
sg26
VC3489703
p1077
sg10
I17
sg11
Vvisual impairment
p1078
sg13
I2
sasa(dp1079
g2
S'Mutations in the extracellular matrix protein eyes shut homolog (EYS) cause photoreceptor degeneration in patients with retinitis pigmentosa 25 (RP25).\n'
p1080
sg4
(lp1081
sg23
(lp1082
(dp1083
g7
I120
sg26
VC1864446
p1084
sg10
I23
sg11
Vretinitis pigmentosa 25
p1085
sg13
I3
sa(dp1086
g7
I76
sg26
VC1998028
p1087
sg10
I26
sg11
Vphotoreceptor degeneration
p1088
sg13
I2
sa(dp1089
g7
I145
sg26
VC1864446
p1090
sg10
I4
sg11
VRP25
p1091
sg13
I1
sasa(dp1092
g2
S'Idiopathic myelofibrosis is a chronic myeloproliferative disorder in which the characteristic fibroblast proliferation is thought to be a secondary phenomenon resulting from the inappropriate release of megakaryocyte- and/or monocyte-derived growth factors, including PDGF, TGF-beta, bFGF and calmodulin.\n'
p1093
sg4
(lp1094
(dp1095
g7
I284
sg8
VP53370
p1096
sg10
I4
sg11
VbFGF
p1097
sg13
I1
sa(dp1098
g7
I293
sg8
g15
sg10
I10
sg11
Vcalmodulin
p1099
sg13
I1
sa(dp1100
g7
I268
sg8
VP04085
p1101
sg10
I14
sg11
VPDGF, TGF-beta
p1102
sg13
I2
sasg23
(lp1103
(dp1104
g7
I0
sg26
VC0001815
p1105
sg10
I24
sg11
VIdiopathic myelofibrosis
p1106
sg13
I2
sa(dp1107
g7
I30
sg26
VC1292778
p1108
sg10
I35
sg11
Vchronic myeloproliferative disorder
p1109
sg13
I3
sa(dp1110
g7
I105
sg26
VC0334094
p1111
sg10
I13
sg11
Vproliferation
p1112
sg13
I1
sasa(dp1113
g2
S'The urinary concentration of calmodulin and basic fibroblast growth factor (bFGF) was determined in a total of 53 patients with various chronic myeloproliferative disorders (CMPD), including 22 patients with idiopathic myelofibrosis (IMF).\n'
p1114
sg4
(lp1115
(dp1116
g7
I76
sg8
VP53370
p1117
sg10
I4
sg11
VbFGF
p1118
sg13
I1
sa(dp1119
g7
I29
sg8
g15
sg10
I10
sg11
Vcalmodulin
p1120
sg13
I1
sa(dp1121
g7
I44
sg8
VP53370
p1122
sg10
I30
sg11
Vbasic fibroblast growth factor
p1123
sg13
I4
sasg23
(lp1124
(dp1125
g7
I234
sg26
VC0001815
p1126
sg10
I3
sg11
VIMF
p1127
sg13
I1
sa(dp1128
g7
I174
sg26
VC1861922
p1129
sg10
I4
sg11
VCMPD
p1130
sg13
I1
sa(dp1131
g7
I136
sg26
VC1861922
p1132
sg10
I36
sg11
Vchronic myeloproliferative disorders
p1133
sg13
I3
sa(dp1134
g7
I208
sg26
VC0001815
p1135
sg10
I24
sg11
Vidiopathic myelofibrosis
p1136
sg13
I2
sasa(dp1137
g2
S'Calmodulin excretion was significantly elevated in IMF (0.29 +/- 0.04 microgram/mmol creatinine) (P &lt; 0.001), when compared to polycythaemia vera (PV) (0.14 +/- 0.02), essential thrombocythaemia (ET) (0.13 +/- 0.04), chronic myeloid leukaemia (CML) (0.16 +/- 0.02), unclassified myeloproliferative disorders (UMPD) (0.11 +/- 0.02) and age-matched controls (0.1 +/- 0.02) (P &lt; 0.001).\n'
p1138
sg4
(lp1139
(dp1140
g7
I0
sg8
g15
sg10
I10
sg11
VCalmodulin
p1141
sg13
I1
sasg23
(lp1142
(dp1143
g7
I199
sg26
VC0040028
p1144
sg10
I2
sg11
VET
p1145
sg13
I1
sa(dp1146
g7
I220
sg26
VC0023473
p1147
sg10
I25
sg11
Vchronic myeloid leukaemia
p1148
sg13
I3
sa(dp1149
g7
I247
sg26
VC0023473
p1150
sg10
I3
sg11
VCML
p1151
sg13
I1
sa(dp1152
g7
I282
sg26
VC0027022
p1153
sg10
I28
sg11
Vmyeloproliferative disorders
p1154
sg13
I2
sa(dp1155
g7
I130
sg26
VC0032463
p1156
sg10
I18
sg11
Vpolycythaemia vera
p1157
sg13
I2
sa(dp1158
g7
I171
sg26
VC0040028
p1159
sg10
I26
sg11
Vessential thrombocythaemia
p1160
sg13
I2
sa(dp1161
g7
I150
sg26
VC0032463
p1162
sg10
I2
sg11
VPV
p1163
sg13
I1
sasa(dp1164
g2
S'The proteins are 1) aM, a mutant CaM in which domain I has been deleted; 2) TaM, first domain of cTnC, last three domains of CaM; 3) TaM-BMI, same as TaM, except the nonfunctional first Ca2(+)-binding domain has been restored by mutagenesis; 4) CaT, first domain of CaM, last three domains of cTnC.\n'
p1165
sg4
(lp1166
(dp1167
g7
I186
sg8
VP00918
p1168
sg10
I21
sg11
VCa2(+)-binding domain
p1169
sg13
I2
sa(dp1170
g7
I97
sg8
VP63316
p1171
sg10
I4
sg11
VcTnC
p1172
sg13
I1
sa(dp1173
g7
I33
sg8
VP01768
p1174
sg10
I3
sg11
VCaM
p1175
sg13
I1
sa(dp1176
g7
I97
sg8
VP63316
p1177
sg10
I4
sg11
VcTnC
p1178
sg13
I1
sasg23
(lp1179
(dp1180
g7
I33
sg26
VC1861821
p1181
sg10
I3
sg11
VCaM
p1182
sg13
I1
sa(dp1183
g7
I76
sg26
VC1834582
p1184
sg10
I3
sg11
VTaM
p1185
sg13
I1
sa(dp1186
g7
I76
sg26
VC1834582
p1187
sg10
I3
sg11
VTaM
p1188
sg13
I1
sa(dp1189
g7
I76
sg26
VC1834582
p1190
sg10
I3
sg11
VTaM
p1191
sg13
I1
sa(dp1192
g7
I33
sg26
VC1861821
p1193
sg10
I3
sg11
VCaM
p1194
sg13
I1
sa(dp1195
g7
I33
sg26
VC1861821
p1196
sg10
I3
sg11
VCaM
p1197
sg13
I1
sa(dp1198
g7
I26
sg26
VC0596988
p1199
sg10
I6
sg11
Vmutant
p1200
sg13
I1
sasa(dp1201
g2
S'The kinetics of activation of PDE by CaM, TaM, and TaM-BMI were identical.\n'
p1202
sg4
(lp1203
(dp1204
g7
I30
sg8
VP49419
p1205
sg10
I3
sg11
VPDE
p1206
sg13
I1
sa(dp1207
g7
I37
sg8
VP01768
p1208
sg10
I3
sg11
VCaM
p1209
sg13
I1
sasg23
(lp1210
(dp1211
g7
I42
sg26
VC1834582
p1212
sg10
I3
sg11
VTaM
p1213
sg13
I1
sa(dp1214
g7
I30
sg26
VC1849508
p1215
sg10
I3
sg11
VPDE
p1216
sg13
I1
sa(dp1217
g7
I42
sg26
VC1834582
p1218
sg10
I3
sg11
VTaM
p1219
sg13
I1
sa(dp1220
g7
I37
sg26
VC1861821
p1221
sg10
I3
sg11
VCaM
p1222
sg13
I1
sasa(dp1223
g2
S'In addition, TaM-BMI was a potent competitive inhibitor of MLCK activation by CaM (Ki = 66 nM).\n'
p1224
sg4
(lp1225
(dp1226
g7
I59
sg8
VP56539
p1227
sg10
I4
sg11
VMLCK
p1228
sg13
I1
sa(dp1229
g7
I78
sg8
VP01768
p1230
sg10
I3
sg11
VCaM
p1231
sg13
I1
sasg23
(lp1232
(dp1233
g7
I13
sg26
VC1834582
p1234
sg10
I3
sg11
VTaM
p1235
sg13
I1
sa(dp1236
g7
I78
sg26
VC1861821
p1237
sg10
I3
sg11
VCaM
p1238
sg13
I1
sasa(dp1239
g2
S'We conclude 1) a domain I is necessary to activate these target enzymes, and the substitution of the corresponding region of cTnC into CaM leads to differential effects; 2) an active first Ca2(+)-binding site is not essential for activation of PDE and the primary sequence of the first domain of CaM need not be highly conserved; 3) for CaM kinase II, determinants in the first domain are critical whereas more flexibility exists for the remaining three domains; 4) since TaM-BMI acts as a potent competitive inhibitor of MLCK binding of CaM to a target enzyme and activation can be dissociable events.\n'
p1240
sg4
(lp1241
(dp1242
g7
I189
sg8
VP00918
p1243
sg10
I19
sg11
VCa2(+)-binding site
p1244
sg13
I2
sa(dp1245
g7
I244
sg8
VP49419
p1246
sg10
I3
sg11
VPDE
p1247
sg13
I1
sa(dp1248
g7
I135
sg8
VP01768
p1249
sg10
I3
sg11
VCaM
p1250
sg13
I1
sa(dp1251
g7
I135
sg8
VP01768
p1252
sg10
I3
sg11
VCaM
p1253
sg13
I1
sa(dp1254
g7
I135
sg8
VP01768
p1255
sg10
I3
sg11
VCaM
p1256
sg13
I1
sa(dp1257
g7
I125
sg8
VP63316
p1258
sg10
I4
sg11
VcTnC
p1259
sg13
I1
sa(dp1260
g7
I337
sg8
g15
sg10
I13
sg11
VCaM kinase II
p1261
sg13
I3
sa(dp1262
g7
I522
sg8
VP56539
p1263
sg10
I4
sg11
VMLCK
p1264
sg13
I1
sasg23
(lp1265
(dp1266
g7
I244
sg26
VC1849508
p1267
sg10
I3
sg11
VPDE
p1268
sg13
I1
sa(dp1269
g7
I135
sg26
VC1861821
p1270
sg10
I3
sg11
VCaM
p1271
sg13
I1
sa(dp1272
g7
I472
sg26
VC1834582
p1273
sg10
I3
sg11
VTaM
p1274
sg13
I1
sa(dp1275
g7
I135
sg26
VC1861821
p1276
sg10
I3
sg11
VCaM
p1277
sg13
I1
sa(dp1278
g7
I135
sg26
VC1861821
p1279
sg10
I3
sg11
VCaM
p1280
sg13
I1
sa(dp1281
g7
I135
sg26
VC1861821
p1282
sg10
I3
sg11
VCaM
p1283
sg13
I1
sasa(dp1284
g2
S'However, a specific electrostatic interaction between R812 of MLCK and CaM is suggested by the complete failure in MLCK activation if this residue is changed to an A. Electrostatic interactions between MLCK and CaM are also indicated by the TaM-BM1 mutant.\n'
p1285
sg4
(lp1286
(dp1287
g7
I62
sg8
VP56539
p1288
sg10
I4
sg11
VMLCK
p1289
sg13
I1
sa(dp1290
g7
I71
sg8
VP01768
p1291
sg10
I3
sg11
VCaM
p1292
sg13
I1
sa(dp1293
g7
I62
sg8
VP56539
p1294
sg10
I4
sg11
VMLCK
p1295
sg13
I1
sa(dp1296
g7
I241
sg8
g15
sg10
I14
sg11
VTaM-BM1 mutant
p1297
sg13
I2
sa(dp1298
g7
I62
sg8
VP56539
p1299
sg10
I4
sg11
VMLCK
p1300
sg13
I1
sa(dp1301
g7
I71
sg8
VP01768
p1302
sg10
I3
sg11
VCaM
p1303
sg13
I1
sasg23
(lp1304
(dp1305
g7
I249
sg26
VC0596988
p1306
sg10
I6
sg11
Vmutant
p1307
sg13
I1
sa(dp1308
g7
I241
sg26
VC1834582
p1309
sg10
I3
sg11
VTaM
p1310
sg13
I1
sa(dp1311
g7
I71
sg26
VC1861821
p1312
sg10
I3
sg11
VCaM
p1313
sg13
I1
sa(dp1314
g7
I71
sg26
VC1861821
p1315
sg10
I3
sg11
VCaM
p1316
sg13
I1
sasa(dp1317
g2
S'The resulting MLCK-CaM complex is therefore, inactive but can bind TaM-BM1.\n'
p1318
sg4
(lp1319
(dp1320
g7
I14
sg8
VP56539
p1321
sg10
I16
sg11
VMLCK-CaM complex
p1322
sg13
I2
sasg23
(lp1323
(dp1324
g7
I67
sg26
VC1834582
p1325
sg10
I3
sg11
VTaM
p1326
sg13
I1
sa(dp1327
g7
I19
sg26
VC1861821
p1328
sg10
I3
sg11
VCaM
p1329
sg13
I1
sasa(dp1330
g2
S'TaM-BMI is a genetically engineered chimeric protein consisting of the first 55 amino acids of cardiac troponin C (but with the normally inactive first Ca2+ binding domain reactivated by site- directed mutagenesis) ligated to the last three domains of chicken calmodulin (George, S.E., VanBerkum, M.F., Ono, T., Cook, R., Hanley, R.M., Putkey, J.A., and Means, A. R. (1990) J. Biol.\n'
p1331
sg4
(lp1332
(dp1333
g7
I95
sg8
VP63316
p1334
sg10
I18
sg11
Vcardiac troponin C
p1335
sg13
I3
sasg23
(lp1336
(dp1337
g7
I0
sg26
VC1834582
p1338
sg10
I3
sg11
VTaM
p1339
sg13
I1
sasa(dp1340
g2
S'Alterations of three amino acids predicted to lie on the external surface of calmodulin (E14A, T34K, S38M) recapitulated the phenotype of TaM-BMI and exhibited a Ki of 38 nM.\n'
p1341
sg4
(lp1342
(dp1343
g7
I77
sg8
g15
sg10
I10
sg11
Vcalmodulin
p1344
sg13
I1
sasg23
(lp1345
(dp1346
g7
I138
sg26
VC1834582
p1347
sg10
I3
sg11
VTaM
p1348
sg13
I1
sasa(dp1349
g2
S'Both the triple mutant and TaM-BMI activated phosphodiesterase and bound a synthetic peptide analog of the calmodulin binding region of smMLCK with an affinity similar to that of native calmodulin (Kact and Kd values of approximately 2 and 3 nM respectively).\n'
p1350
sg4
(lp1351
(dp1352
g7
I107
sg8
g15
sg10
I10
sg11
Vcalmodulin
p1353
sg13
I1
sa(dp1354
g7
I107
sg8
VP63244
p1355
sg10
I25
sg11
Vcalmodulin binding region
p1356
sg13
I3
sasg23
(lp1357
(dp1358
g7
I27
sg26
VC1834582
p1359
sg10
I3
sg11
VTaM
p1360
sg13
I1
sa(dp1361
g7
I16
sg26
VC0596988
p1362
sg10
I6
sg11
Vmutant
p1363
sg13
I1
sasa(dp1364
g2
S'When a synthetic peptide analog of the myosin light chain phosphorylation site was used as substrate rather than the 20-kDa light chains, TaM-BMI and the triple mutant were partial agonists: the Km for peptide substrate was increased 100- and 60-fold, and catalytic activity was 45 and 60%, respectively, relative to calmodulin.\n'
p1365
sg4
(lp1366
(dp1367
g7
I39
sg8
VP08590
p1368
sg10
I39
sg11
Vmyosin light chain phosphorylation site
p1369
sg13
I5
sa(dp1370
g7
I117
sg8
g15
sg10
I19
sg11
V20-kDa light chains
p1371
sg13
I3
sa(dp1372
g7
I317
sg8
g15
sg10
I10
sg11
Vcalmodulin
p1373
sg13
I1
sasg23
(lp1374
(dp1375
g7
I161
sg26
VC0596988
p1376
sg10
I6
sg11
Vmutant
p1377
sg13
I1
sa(dp1378
g7
I138
sg26
VC1834582
p1379
sg10
I3
sg11
VTaM
p1380
sg13
I1
sasa(dp1381
g2
S'These data suggest TaM-BMI and E14A/T34K/S38M may interact with the calmodulin binding domain of smMLCK in a manner similar to calmodulin.\n'
p1382
sg4
(lp1383
(dp1384
g7
I68
sg8
g15
sg10
I10
sg11
Vcalmodulin
p1385
sg13
I1
sa(dp1386
g7
I68
sg8
g15
sg10
I10
sg11
Vcalmodulin
p1387
sg13
I1
sasg23
(lp1388
(dp1389
g7
I19
sg26
VC1834582
p1390
sg10
I3
sg11
VTaM
p1391
sg13
I1
sasa(dp1392
g2
S'Recently mitoNEET has been shown to be a major role player in the mitochondrial function associated with metabolic type diseases such as obesity and cancers.\n'
p1393
sg4
(lp1394
sg23
(lp1395
(dp1396
g7
I149
sg26
VC0006826
p1397
sg10
I7
sg11
Vcancers
p1398
sg13
I1
sa(dp1399
g7
I137
sg26
VC0028754
p1400
sg10
I7
sg11
Vobesity
p1401
sg13
I1
sasa(dp1402
g2
S'To investigate CISD1 mRNA and protein in human adipose tissue in association with obesity and adipogenesis.\n'
p1403
sg4
(lp1404
(dp1405
g7
I15
sg8
g15
sg10
I10
sg11
VCISD1 mRNA
p1406
sg13
I2
sasg23
(lp1407
(dp1408
g7
I82
sg26
VC0028754
p1409
sg10
I7
sg11
Vobesity
p1410
sg13
I1
sasa(dp1411
g2
S'SAT and VAT CISD1 mRNA and protein levels were significantly decreased in subjects with obesity and negatively correlated with BMI after controlling for age and sex.\n'
p1412
sg4
(lp1413
(dp1414
g7
I8
sg8
g15
sg10
I14
sg11
VVAT CISD1 mRNA
p1415
sg13
I3
sa(dp1416
g7
I0
sg8
VP21673
p1417
sg10
I3
sg11
VSAT
p1418
sg13
I1
sasg23
(lp1419
(dp1420
g7
I88
sg26
VC0028754
p1421
sg10
I7
sg11
Vobesity
p1422
sg13
I1
sasa(dp1423
g2
S'In participants with morbid obesity, VAT CISD1 gene expression was positively correlated with insulin sensitivity (r = 0.47, P = 0.01), and bariatric surgery-induced weight loss led to increased SAT CISD1 mRNA levels.\n'
p1424
sg4
(lp1425
(dp1426
g7
I94
sg8
VP01308
p1427
sg10
I7
sg11
Vinsulin
p1428
sg13
I1
sa(dp1429
g7
I37
sg8
g15
sg10
I14
sg11
VVAT CISD1 gene
p1430
sg13
I3
sa(dp1431
g7
I195
sg8
VP21673
p1432
sg10
I14
sg11
VSAT CISD1 mRNA
p1433
sg13
I3
sasg23
(lp1434
(dp1435
g7
I21
sg26
VC0028756
p1436
sg10
I14
sg11
Vmorbid obesity
p1437
sg13
I2
sa(dp1438
g7
I94
sg26
VC0920563
p1439
sg10
I19
sg11
Vinsulin sensitivity
p1440
sg13
I2
sasa(dp1441
g2
S'These data suggest a possible role of CISD1 in obesity-associated dysfunctional adipogenesis in human VAT.\n'
p1442
sg4
(lp1443
(dp1444
g7
I38
sg8
g15
sg10
I5
sg11
VCISD1
p1445
sg13
I1
sasg23
(lp1446
(dp1447
g7
I47
sg26
VC0028754
p1448
sg10
I7
sg11
Vobesity
p1449
sg13
I1
sasa(dp1450
g2
S'DNA = deoxyribonucleic acid; CRC = colorectal cancer; EU = European Union; WHO = World Health Organization; FOBT = fecal occult blood test; CBMN = cytokinesis-blocked micronucleus assay; MN = micronuclei; NPB = nucleoplasmic bridges; NDI = Nuclear Division Index; FAP = familial adenomatous polyposis; HNPCC = hereditary non-polypoid colorectal cancer; IBD = inflammatory bowel diseases; ROC = receiver operating characteristics; AUROC = area under the receiver operating characteristics curve.\n'
p1451
sg4
(lp1452
sg23
(lp1453
(dp1454
g7
I359
sg26
VC0021390
p1455
sg10
I27
sg11
Vinflammatory bowel diseases
p1456
sg13
I3
sa(dp1457
g7
I302
sg26
VC1333990
p1458
sg10
I5
sg11
VHNPCC
p1459
sg13
I1
sa(dp1460
g7
I353
sg26
VC0021390
p1461
sg10
I3
sg11
VIBD
p1462
sg13
I1
sa(dp1463
g7
I234
sg26
VC1563705
p1464
sg10
I3
sg11
VNDI
p1465
sg13
I1
sa(dp1466
g7
I270
sg26
VC0032580
p1467
sg10
I30
sg11
Vfamilial adenomatous polyposis
p1468
sg13
I3
sa(dp1469
g7
I35
sg26
VC1527249
p1470
sg10
I17
sg11
Vcolorectal cancer
p1471
sg13
I2
sa(dp1472
g7
I264
sg26
VC0032580
p1473
sg10
I3
sg11
VFAP
p1474
sg13
I1
sa(dp1475
g7
I29
sg26
VC1527249
p1476
sg10
I3
sg11
VCRC
p1477
sg13
I1
sa(dp1478
g7
I35
sg26
VC1527249
p1479
sg10
I17
sg11
Vcolorectal cancer
p1480
sg13
I2
sasa(dp1481
g2
S'Clinical comparison of our patient with those previously reported with overlapping 11q duplications allows us to define the minimal duplicated region associated with craniosynostosis and strongly supports the hypothesis that the constitutional increased dosage of the FGF3 and FGF4 genes is a risk factor for craniosynostosis in humans.\n'
p1482
sg4
(lp1483
(dp1484
g7
I268
sg8
VP11487
p1485
sg10
I4
sg11
VFGF3
p1486
sg13
I1
sa(dp1487
g7
I277
sg8
VP08620
p1488
sg10
I10
sg11
VFGF4 genes
p1489
sg13
I2
sasg23
(lp1490
(dp1491
g7
I166
sg26
VC0010278
p1492
sg10
I16
sg11
Vcraniosynostosis
p1493
sg13
I1
sa(dp1494
g7
I166
sg26
VC0010278
p1495
sg10
I16
sg11
Vcraniosynostosis
p1496
sg13
I1
sasa(dp1497
g2
S'Excitatory GABA actions, induced by altered expression of chloride transporters (KCC2/NKCC1), can contribute to seizure generation in temporal lobe epilepsy.\n'
p1498
sg4
(lp1499
(dp1500
g7
I58
sg8
g15
sg10
I21
sg11
Vchloride transporters
p1501
sg13
I2
sa(dp1502
g7
I86
sg8
VP55011
p1503
sg10
I5
sg11
VNKCC1
p1504
sg13
I1
sa(dp1505
g7
I81
sg8
g15
sg10
I4
sg11
VKCC2
p1506
sg13
I1
sasg23
(lp1507
(dp1508
g7
I112
sg26
VC0036572
p1509
sg10
I7
sg11
Vseizure
p1510
sg13
I1
sa(dp1511
g7
I134
sg26
VC0014556
p1512
sg10
I22
sg11
Vtemporal lobe epilepsy
p1513
sg13
I3
sasa(dp1514
g2
S'Alterations in the balance of K-Na-2Cl cotransporter (NKCC1) and Na-Cl cotransporter (KCC2) activity may cause depolarizing effect of Gamma-aminobutyric Acid (GABA), and contribute to epileptogenesis in human temporal lobe epilepsy.\n'
p1515
sg4
(lp1516
(dp1517
g7
I30
sg8
g15
sg10
I22
sg11
VK-Na-2Cl cotransporter
p1518
sg13
I2
sa(dp1519
g7
I86
sg8
g15
sg10
I4
sg11
VKCC2
p1520
sg13
I1
sa(dp1521
g7
I65
sg8
g15
sg10
I19
sg11
VNa-Cl cotransporter
p1522
sg13
I2
sa(dp1523
g7
I54
sg8
VP55011
p1524
sg10
I5
sg11
VNKCC1
p1525
sg13
I1
sasg23
(lp1526
(dp1527
g7
I209
sg26
VC0014556
p1528
sg10
I22
sg11
Vtemporal lobe epilepsy
p1529
sg13
I3
sasa(dp1530
g2
S'In the current pilot study we provide the first documented look at efficacy of bumetanide, a specific NKCC1 antagonist, on reduction of seizure frequency in adult patients with temporal lobe epilepsy.\n'
p1531
sg4
(lp1532
(dp1533
g7
I102
sg8
VP55011
p1534
sg10
I5
sg11
VNKCC1
p1535
sg13
I1
sasg23
(lp1536
(dp1537
g7
I136
sg26
VC0036572
p1538
sg10
I7
sg11
Vseizure
p1539
sg13
I1
sa(dp1540
g7
I177
sg26
VC0014556
p1541
sg10
I22
sg11
Vtemporal lobe epilepsy
p1542
sg13
I3
sasa(dp1543
g2
S'Aim of the present research work was to study the relationship between the degree of dementia and the serum levels of homocysteine(Hcy), high-sensitive C-reactive protein(hs-CRP), D-Dimer and vascular dementia(VaD) of patients, and to investigate the mechanism of Hcy, hs-CRP and D-Dimer in the vascular dementia.\n'
p1544
sg4
(lp1545
(dp1546
g7
I152
sg8
VP02741
p1547
sg10
I18
sg11
VC-reactive protein
p1548
sg13
I2
sa(dp1549
g7
I171
sg8
VP02741
p1550
sg10
I6
sg11
Vhs-CRP
p1551
sg13
I1
sa(dp1552
g7
I171
sg8
VP02741
p1553
sg10
I6
sg11
Vhs-CRP
p1554
sg13
I1
sa(dp1555
g7
I180
sg8
g15
sg10
I7
sg11
VD-Dimer
p1556
sg13
I1
sasg23
(lp1557
(dp1558
g7
I85
sg26
VC0497327
p1559
sg10
I8
sg11
Vdementia
p1560
sg13
I1
sa(dp1561
g7
I192
sg26
VC0011269
p1562
sg10
I17
sg11
Vvascular dementia
p1563
sg13
I2
sa(dp1564
g7
I192
sg26
VC0011269
p1565
sg10
I17
sg11
Vvascular dementia
p1566
sg13
I2
sasa(dp1567
g2
S'Hcy, hs-CRP and D-Dimer are involved in the pathogenesis of vascular dementia (VAD), There is a significant correlation between the severity of vascular dementia and Hcy and Hs-CRP.\n'
p1568
sg4
(lp1569
(dp1570
g7
I174
sg8
VP02741
p1571
sg10
I6
sg11
VHs-CRP
p1572
sg13
I1
sa(dp1573
g7
I16
sg8
g15
sg10
I7
sg11
VD-Dimer
p1574
sg13
I1
sa(dp1575
g7
I5
sg8
VP02741
p1576
sg10
I6
sg11
Vhs-CRP
p1577
sg13
I1
sasg23
(lp1578
(dp1579
g7
I60
sg26
VC0011269
p1580
sg10
I17
sg11
Vvascular dementia
p1581
sg13
I2
sa(dp1582
g7
I60
sg26
VC0011269
p1583
sg10
I17
sg11
Vvascular dementia
p1584
sg13
I2
sa(dp1585
g7
I44
sg26
VC0699748
p1586
sg10
I12
sg11
Vpathogenesis
p1587
sg13
I1
sa(dp1588
g7
I79
sg26
VC0011269
p1589
sg10
I3
sg11
VVAD
p1590
sg13
I1
sasa(dp1591
g2
S"In 205 patients with dementia [89 with Alzheimer's disease (AD), 47 with vascular dementia (VaD), 69 with mixed dementia (MD)], 113 persons with mild cognitive impairment and in 107 controls serum adiponectin, leptin and resistin levels, pro-inflammatory [interleukin-6 (IL-6), C-reactive protein (hsCRP) and chitotriosidase] and anti-inflammatory (25-OH vitamin D, HDL-cholesterol and paraoxonase 1) markers, as well as glucose metabolism parameters (glucose, insulin and HOMA-IR) were determined.\n"
p1592
sg4
(lp1593
(dp1594
g7
I278
sg8
VP02741
p1595
sg10
I18
sg11
VC-reactive protein
p1596
sg13
I2
sa(dp1597
g7
I461
sg8
VP01308
p1598
sg10
I7
sg11
Vinsulin
p1599
sg13
I1
sa(dp1600
g7
I366
sg8
VP28845
p1601
sg10
I15
sg11
VHDL-cholesterol
p1602
sg13
I1
sa(dp1603
g7
I271
sg8
VP05231
p1604
sg10
I4
sg11
VIL-6
p1605
sg13
I1
sa(dp1606
g7
I309
sg8
g15
sg10
I15
sg11
Vchitotriosidase
p1607
sg13
I1
sa(dp1608
g7
I255
sg8
VP05231
p1609
sg10
I14
sg11
V[interleukin-6
p1610
sg13
I1
sa(dp1611
g7
I197
sg8
g15
sg10
I11
sg11
Vadiponectin
p1612
sg13
I1
sa(dp1613
g7
I386
sg8
VP14222
p1614
sg10
I13
sg11
Vparaoxonase 1
p1615
sg13
I2
sa(dp1616
g7
I473
sg8
VP06213
p1617
sg10
I7
sg11
VHOMA-IR
p1618
sg13
I1
sa(dp1619
g7
I210
sg8
VP41159
p1620
sg10
I6
sg11
Vleptin
p1621
sg13
I1
sasg23
(lp1622
(dp1623
g7
I145
sg26
VC1270972
p1624
sg10
I25
sg11
Vmild cognitive impairment
p1625
sg13
I3
sa(dp1626
g7
I39
sg26
VC1521724
p1627
sg10
I19
sg11
VAlzheimer's disease
p1628
sg13
I2
sa(dp1629
g7
I73
sg26
VC0011269
p1630
sg10
I17
sg11
Vvascular dementia
p1631
sg13
I2
sa(dp1632
g7
I21
sg26
VC0497327
p1633
sg10
I8
sg11
Vdementia
p1634
sg13
I1
sa(dp1635
g7
I60
sg26
VC1521724
p1636
sg10
I2
sg11
VAD
p1637
sg13
I1
sa(dp1638
g7
I92
sg26
VC0011269
p1639
sg10
I3
sg11
VVaD
p1640
sg13
I1
sa(dp1641
g7
I21
sg26
VC0497327
p1642
sg10
I8
sg11
Vdementia
p1643
sg13
I1
sasa(dp1644
g2
S'After adjusting for possible confounding cardiovascular risk factors, high CRP was independently associated with vascular dementia but not Alzheimer disease.\n'
p1645
sg4
(lp1646
(dp1647
g7
I75
sg8
VP02741
p1648
sg10
I3
sg11
VCRP
p1649
sg13
I1
sasg23
(lp1650
(dp1651
g7
I113
sg26
VC0011269
p1652
sg10
I17
sg11
Vvascular dementia
p1653
sg13
I2
sa(dp1654
g7
I139
sg26
VC0002395
p1655
sg10
I17
sg11
VAlzheimer disease
p1656
sg13
I2
sasa(dp1657
g2
S'In this prospective study of an elderly Asian community cohort with more than 10 years of follow-up, the baseline serum CRP level was associated with future development of vascular dementia, but not Alzheimer disease after adjusting for common cardiovascular risk factors, stroke, and competing risk of death.\n'
p1658
sg4
(lp1659
(dp1660
g7
I114
sg8
VP02741
p1661
sg10
I9
sg11
Vserum CRP
p1662
sg13
I2
sasg23
(lp1663
(dp1664
g7
I172
sg26
VC0011269
p1665
sg10
I17
sg11
Vvascular dementia
p1666
sg13
I2
sa(dp1667
g7
I273
sg26
VC0038454
p1668
sg10
I6
sg11
Vstroke
p1669
sg13
I1
sa(dp1670
g7
I199
sg26
VC0002395
p1671
sg10
I17
sg11
VAlzheimer disease
p1672
sg13
I2
sasa(dp1673
g2
S"Hypersensitive C-reaction protein (hsCRP) may be a risk factor for cognitive impairment resulting from Alzheimer's disease (AD), stroke, and vascular dementia.\n"
p1674
sg4
(lp1675
(dp1676
g7
I15
sg8
g15
sg10
I18
sg11
VC-reaction protein
p1677
sg13
I2
sasg23
(lp1678
(dp1679
g7
I67
sg26
VC0338656
p1680
sg10
I20
sg11
Vcognitive impairment
p1681
sg13
I2
sa(dp1682
g7
I129
sg26
VC0038454
p1683
sg10
I6
sg11
Vstroke
p1684
sg13
I1
sa(dp1685
g7
I103
sg26
VC1521724
p1686
sg10
I19
sg11
VAlzheimer's disease
p1687
sg13
I2
sa(dp1688
g7
I124
sg26
VC1521724
p1689
sg10
I2
sg11
VAD
p1690
sg13
I1
sa(dp1691
g7
I141
sg26
VC0011269
p1692
sg10
I17
sg11
Vvascular dementia
p1693
sg13
I2
sasa(dp1694
g2
S"The following markers of inflammation: enzymatic activity of leukocyte elastase (LE), functional activity of alpha-1-proteinase inhibitor (Alfa1-PI), levels of C-reactive protein (CRP) and interleukin-6 (IL-6) were measured in the blood plasma of patients with Alzheimer's disease (AD) and vascular dementia (VD).\n"
p1695
sg4
(lp1696
(dp1697
g7
I180
sg8
VP02741
p1698
sg10
I3
sg11
VCRP
p1699
sg13
I1
sa(dp1700
g7
I189
sg8
VP05231
p1701
sg10
I13
sg11
Vinterleukin-6
p1702
sg13
I1
sa(dp1703
g7
I61
sg8
VP08246
p1704
sg10
I18
sg11
Vleukocyte elastase
p1705
sg13
I2
sa(dp1706
g7
I109
sg8
VP63123
p1707
sg10
I28
sg11
Valpha-1-proteinase inhibitor
p1708
sg13
I2
sa(dp1709
g7
I160
sg8
VP02741
p1710
sg10
I18
sg11
VC-reactive protein
p1711
sg13
I2
sa(dp1712
g7
I81
sg8
VP08246
p1713
sg10
I2
sg11
VLE
p1714
sg13
I1
sa(dp1715
g7
I204
sg8
VP05231
p1716
sg10
I4
sg11
VIL-6
p1717
sg13
I1
sasg23
(lp1718
(dp1719
g7
I290
sg26
VC0011269
p1720
sg10
I17
sg11
Vvascular dementia
p1721
sg13
I2
sa(dp1722
g7
I261
sg26
VC1521724
p1723
sg10
I19
sg11
VAlzheimer's disease
p1724
sg13
I2
sa(dp1725
g7
I282
sg26
VC1521724
p1726
sg10
I2
sg11
VAD
p1727
sg13
I1
sa(dp1728
g7
I309
sg26
VC0011269
p1729
sg10
I2
sg11
VVD
p1730
sg13
I1
sa(dp1731
g7
I25
sg26
VC0021368
p1732
sg10
I12
sg11
Vinflammation
p1733
sg13
I1
sasa(dp1734
g2
S'Lichenoid dermatitis and bullous pemphigoid appear to be DT more associated with anti-PD-1/PD-L1 antibody.\n'
p1735
sg4
(lp1736
(dp1737
g7
I81
sg8
VP18621
p1738
sg10
I9
sg11
Vanti-PD-1
p1739
sg13
I1
sasg23
(lp1740
(dp1741
g7
I0
sg26
VC0162848
p1742
sg10
I20
sg11
VLichenoid dermatitis
p1743
sg13
I2
sa(dp1744
g7
I25
sg26
VC0030805
p1745
sg10
I18
sg11
Vbullous pemphigoid
p1746
sg13
I2
sasa(dp1747
g2
S'We have previously demonstrated that Bmi1 is upregulated in HCC with bile duct tumor thrombi, a subtype of HCC characterized by profuse expression of hepatic stem cell markers.\n'
p1748
sg4
(lp1749
(dp1750
g7
I37
sg8
VP35226
p1751
sg10
I4
sg11
VBmi1
p1752
sg13
I1
sasg23
(lp1753
(dp1754
g7
I85
sg26
VC0087086
p1755
sg10
I7
sg11
Vthrombi
p1756
sg13
I1
sa(dp1757
g7
I69
sg26
VC0005396
p1758
sg10
I15
sg11
Vbile duct tumor
p1759
sg13
I3
sa(dp1760
g7
I60
sg26
VC2239176
p1761
sg10
I3
sg11
VHCC
p1762
sg13
I1
sa(dp1763
g7
I60
sg26
VC2239176
p1764
sg10
I3
sg11
VHCC
p1765
sg13
I1
sasa(dp1766
g2
S'BMI1 is a core component of the polycomb repressive complex 1 (PRC1) and is up-regulated in biliary tract cancer (BTC), contributing to aggressive clinical features.\n'
p1767
sg4
(lp1768
(dp1769
g7
I63
sg8
g15
sg10
I4
sg11
VPRC1
p1770
sg13
I1
sa(dp1771
g7
I0
sg8
VP35226
p1772
sg10
I4
sg11
VBMI1
p1773
sg13
I1
sa(dp1774
g7
I32
sg8
g15
sg10
I29
sg11
Vpolycomb repressive complex 1
p1775
sg13
I4
sasg23
(lp1776
(dp1777
g7
I92
sg26
VC0750952
p1778
sg10
I20
sg11
Vbiliary tract cancer
p1779
sg13
I3
sa(dp1780
g7
I114
sg26
VC0750952
p1781
sg10
I3
sg11
VBTC
p1782
sg13
I1
sa(dp1783
g7
I136
sg26
VC0001807
p1784
sg10
I10
sg11
Vaggressive
p1785
sg13
I1
sasa(dp1786
g2
S'In this study we investigated the cytotoxic effects of PTC-209, a recently developed inhibitor of BMI1, in BTC cells.\n'
p1787
sg4
(lp1788
(dp1789
g7
I85
sg8
VP35226
p1790
sg10
I17
sg11
Vinhibitor of BMI1
p1791
sg13
I3
sasg23
(lp1792
(dp1793
g7
I55
sg26
VC0238463
p1794
sg10
I3
sg11
VPTC
p1795
sg13
I1
sasa(dp1796
g2
S'The expression of Bmi1 was examined immunohistochemically in HCC patients with BDTT (B+ group), HCC patients with vascular invasion (V+ group) and combined hepatocellular carcinoma and cholangiocarcinoma (C+ group), respectively.\n'
p1797
sg4
(lp1798
(dp1799
g7
I18
sg8
VP35226
p1800
sg10
I4
sg11
VBmi1
p1801
sg13
I1
sasg23
(lp1802
(dp1803
g7
I123
sg26
VC2699153
p1804
sg10
I8
sg11
Vinvasion
p1805
sg13
I1
sa(dp1806
g7
I147
sg26
VC0221287
p1807
sg10
I56
sg11
Vcombined hepatocellular carcinoma and cholangiocarcinoma
p1808
sg13
I5
sa(dp1809
g7
I61
sg26
VC2239176
p1810
sg10
I3
sg11
VHCC
p1811
sg13
I1
sa(dp1812
g7
I61
sg26
VC2239176
p1813
sg10
I3
sg11
VHCC
p1814
sg13
I1
sasa(dp1815
g2
S'Relative risk of gallbladder cancer per unit increment of z-score adjusted for age, smoking status and BMI (except for BMI itself) and stratified by birth year, sex and sub-cohorts, was for BMI 1.31 (95% confidence interval 1.11, 1.57) and blood glucose 1.76 (1.10, 2.85).\n'
p1816
sg4
(lp1817
sg23
(lp1818
(dp1819
g7
I17
sg26
VC0153452
p1820
sg10
I18
sg11
Vgallbladder cancer
p1821
sg13
I2
sasa(dp1822
g2
S'Normal, prostatitis, and prostate cancer specimens were retrospectively selected and examined by immunohistochemistry for PEDF expression and infiltration of immune CD68 + macrophagic cells.\n'
p1823
sg4
(lp1824
(dp1825
g7
I122
sg8
VP36955
p1826
sg10
I4
sg11
VPEDF
p1827
sg13
I1
sasg23
(lp1828
(dp1829
g7
I142
sg26
VC0332448
p1830
sg10
I12
sg11
Vinfiltration
p1831
sg13
I1
sa(dp1832
g7
I25
sg26
VC0600139
p1833
sg10
I15
sg11
Vprostate cancer
p1834
sg13
I2
sa(dp1835
g7
I8
sg26
VC0033581
p1836
sg10
I11
sg11
Vprostatitis
p1837
sg13
I1
sasa(dp1838
g2
S'Mice deficient in RORbeta develop retinal degeneration that results in blindness.\n'
p1839
sg4
(lp1840
sg23
(lp1841
(dp1842
g7
I71
sg26
VC0456909
p1843
sg10
I9
sg11
Vblindness
p1844
sg13
I1
sa(dp1845
g7
I34
sg26
VC0035304
p1846
sg10
I20
sg11
Vretinal degeneration
p1847
sg13
I2
sasa(dp1848
g2
S'To compare the prevalence of dental caries in children with cleft lip/palate with national data at the same age.\n'
p1849
sg4
(lp1850
sg23
(lp1851
(dp1852
g7
I60
sg26
VC0158646
p1853
sg10
I16
sg11
Vcleft lip/palate
p1854
sg13
I2
sa(dp1855
g7
I29
sg26
VC0333519
p1856
sg10
I13
sg11
Vdental caries
p1857
sg13
I2
sasa(dp1858
g2
S'Children with a cleft lip/palate have higher levels of dental caries compared to those with a cleft lip alone; 2.\n'
p1859
sg4
(lp1860
sg23
(lp1861
(dp1862
g7
I16
sg26
VC0008924
p1863
sg10
I9
sg11
Vcleft lip
p1864
sg13
I2
sa(dp1865
g7
I55
sg26
VC0333519
p1866
sg10
I13
sg11
Vdental caries
p1867
sg13
I2
sa(dp1868
g7
I16
sg26
VC0158646
p1869
sg10
I16
sg11
Vcleft lip/palate
p1870
sg13
I2
sasa(dp1871
g2
S'We investigate the following key questions: (1) Does laboratory induced exposure to thin ideals (waiting room design) relate to impairments in terms of body image, affect and eating behavior and biological stress response (salivary alpha-amylase, salivary cortisol, heart rate and heart rate variability) in 18 to 35 year old female suffering from anorexia and bulimia nervosa (AN, BN) compared to female healthy controls and to a sample of females suffering from mixed mental disorders (depression, anxiety and somatic symptom disorder (SSD) disorders)?\n'
p1872
sg4
(lp1873
(dp1874
g7
I223
sg8
VP04745
p1875
sg10
I22
sg11
Vsalivary alpha-amylase
p1876
sg13
I2
sasg23
(lp1877
(dp1878
g7
I348
sg26
VC0003123
p1879
sg10
I8
sg11
Vanorexia
p1880
sg13
I1
sa(dp1881
g7
I361
sg26
VC2267227
p1882
sg10
I15
sg11
Vbulimia nervosa
p1883
sg13
I2
sa(dp1884
g7
I470
sg26
VC0004936
p1885
sg10
I16
sg11
Vmental disorders
p1886
sg13
I2
sa(dp1887
g7
I333
sg26
VC0683278
p1888
sg10
I9
sg11
Vsuffering
p1889
sg13
I1
sa(dp1890
g7
I538
sg26
VC1838022
p1891
sg10
I3
sg11
VSSD
p1892
sg13
I1
sa(dp1893
g7
I333
sg26
VC0683278
p1894
sg10
I9
sg11
Vsuffering
p1895
sg13
I1
sa(dp1896
g7
I488
sg26
VC0011581
p1897
sg10
I10
sg11
Vdepression
p1898
sg13
I1
sa(dp1899
g7
I520
sg26
VC1457887
p1900
sg10
I7
sg11
Vsymptom
p1901
sg13
I1
sasa(dp1902
g2
S'Mutations in OCRL1 cause the X-linked Dent disease type 2 (DD2; OMIM# 300555), characterized by low-molecular weight proteinuria, hypercalciuria, and the variable presence of cataracts, glaucoma and intellectual disability without structural brain anomalies.\n'
p1903
sg4
(lp1904
sg23
(lp1905
(dp1906
g7
I199
sg26
VC0025362
p1907
sg10
I23
sg11
Vintellectual disability
p1908
sg13
I2
sa(dp1909
g7
I38
sg26
VC0878681
p1910
sg10
I12
sg11
VDent disease
p1911
sg13
I2
sa(dp1912
g7
I13
sg26
VC0028860
p1913
sg10
I5
sg11
VOCRL1
p1914
sg13
I1
sa(dp1915
g7
I186
sg26
VC0017601
p1916
sg10
I8
sg11
Vglaucoma
p1917
sg13
I1
sa(dp1918
g7
I175
sg26
VC0521707
p1919
sg10
I9
sg11
Vcataracts
p1920
sg13
I1
sa(dp1921
g7
I130
sg26
VC0020438
p1922
sg10
I14
sg11
Vhypercalciuria
p1923
sg13
I1
sasa(dp1924
g2
S'Oculocerebrorenal syndrome of Lowe (OCRL, OMIM 309000), also known as Lowe syndrome, is a rare X-linked multisystem disorder characterized by congenital cataracts, mental retardation, and Fanconi syndrome of the kidney proximal tubules.\n'
p1925
sg4
(lp1926
sg23
(lp1927
(dp1928
g7
I70
sg26
VC0028860
p1929
sg10
I13
sg11
VLowe syndrome
p1930
sg13
I2
sa(dp1931
g7
I188
sg26
VC0015624
p1932
sg10
I16
sg11
VFanconi syndrome
p1933
sg13
I2
sa(dp1934
g7
I142
sg26
VC0009691
p1935
sg10
I20
sg11
Vcongenital cataracts
p1936
sg13
I2
sa(dp1937
g7
I104
sg26
VC0559758
p1938
sg10
I20
sg11
Vmultisystem disorder
p1939
sg13
I2
sa(dp1940
g7
I0
sg26
VC0028860
p1941
sg10
I34
sg11
VOculocerebrorenal syndrome of Lowe
p1942
sg13
I4
sa(dp1943
g7
I36
sg26
VC0028860
p1944
sg10
I4
sg11
VOCRL
p1945
sg13
I1
sa(dp1946
g7
I164
sg26
VC0025362
p1947
sg10
I18
sg11
Vmental retardation
p1948
sg13
I2
sasa(dp1949
g2
S'Mutations in OCRL, an inositol polyphosphate 5-phosphatase, result in Oculocerebrorenal syndrome of Lowe, an X-linked recessive disorder that presents with congenital cataracts, glaucoma, renal dysfunction and mental retardation.\n'
p1950
sg4
(lp1951
(dp1952
g7
I22
sg8
VP32019
p1953
sg10
I36
sg11
Vinositol polyphosphate 5-phosphatase
p1954
sg13
I3
sasg23
(lp1955
(dp1956
g7
I156
sg26
VC0009691
p1957
sg10
I20
sg11
Vcongenital cataracts
p1958
sg13
I2
sa(dp1959
g7
I70
sg26
VC0028860
p1960
sg10
I34
sg11
VOculocerebrorenal syndrome of Lowe
p1961
sg13
I4
sa(dp1962
g7
I210
sg26
VC0025362
p1963
sg10
I18
sg11
Vmental retardation
p1964
sg13
I2
sa(dp1965
g7
I178
sg26
VC0017601
p1966
sg10
I8
sg11
Vglaucoma
p1967
sg13
I1
sa(dp1968
g7
I13
sg26
VC0028860
p1969
sg10
I4
sg11
VOCRL
p1970
sg13
I1
sasa(dp1971
g2
S'One patient had chronic alcoholism, the other porphyria variegata; both initially presented with water-and-electrolyte disorders, notably hyponatraemia.\n'
p1972
sg4
(lp1973
sg23
(lp1974
(dp1975
g7
I46
sg26
VC0162532
p1976
sg10
I19
sg11
Vporphyria variegata
p1977
sg13
I2
sa(dp1978
g7
I16
sg26
VC0001973
p1979
sg10
I18
sg11
Vchronic alcoholism
p1980
sg13
I2
sasa(dp1981
g2
S'We investigated the associations of Delta-6-desaturase (D6D) and Delta-5-desaturase (D5D) activities with stroke risk factors and risk of stroke among 1842 men from the prospective, population-based Kuopio Ischaemic Heart Disease Risk Factor Study, aged 42-60 years and free of CVD at baseline in 1984-1989.\n'
p1982
sg4
(lp1983
(dp1984
g7
I65
sg8
g15
sg10
I18
sg11
VDelta-5-desaturase
p1985
sg13
I1
sa(dp1986
g7
I56
sg8
g15
sg10
I3
sg11
VD6D
p1987
sg13
I1
sa(dp1988
g7
I85
sg8
g15
sg10
I3
sg11
VD5D
p1989
sg13
I1
sa(dp1990
g7
I36
sg8
g15
sg10
I18
sg11
VDelta-6-desaturase
p1991
sg13
I1
sasg23
(lp1992
(dp1993
g7
I206
sg26
VC0151744
p1994
sg10
I23
sg11
VIschaemic Heart Disease
p1995
sg13
I3
sa(dp1996
g7
I106
sg26
VC0038454
p1997
sg10
I6
sg11
Vstroke
p1998
sg13
I1
sa(dp1999
g7
I106
sg26
VC0038454
p2000
sg10
I6
sg11
Vstroke
p2001
sg13
I1
sa(dp2002
g7
I278
sg26
VC0007222
p2003
sg10
I3
sg11
VCVD
p2004
sg13
I1
sasa(dp2005
g2
S'Neither D6D activity (multivariable-adjusted extreme-quartile hazard ratios (HR) 1*18; 95 % CI 0*80, 1*74) nor D5D activity (HR 1*06; 95 % CI 0*70, 1*60) were associated with stroke risk.\n'
p2006
sg4
(lp2007
(dp2008
g7
I8
sg8
g15
sg10
I3
sg11
VD6D
p2009
sg13
I1
sasg23
(lp2010
(dp2011
g7
I175
sg26
VC0038454
p2012
sg10
I6
sg11
Vstroke
p2013
sg13
I1
sasa(dp2014
g2
S'In conclusion, higher D5D activity was favourably associated and higher D6D activity unfavourably associated with several stroke risk factors, but not with the risk of incident stroke.\n'
p2015
sg4
(lp2016
(dp2017
g7
I72
sg8
g15
sg10
I3
sg11
VD6D
p2018
sg13
I1
sasg23
(lp2019
(dp2020
g7
I122
sg26
VC0038454
p2021
sg10
I6
sg11
Vstroke
p2022
sg13
I1
sa(dp2023
g7
I122
sg26
VC0038454
p2024
sg10
I6
sg11
Vstroke
p2025
sg13
I1
sasa(dp2026
g2
S'Present findings suggested that high serum 22:6n-3 and D5D as well as low 16:0, 16:1n-7 and D6D were associated with a low prevalence of hypertension in this Chinese population.\n'
p2027
sg4
(lp2028
(dp2029
g7
I37
sg8
g15
sg10
I13
sg11
Vserum 22:6n-3
p2030
sg13
I2
sa(dp2031
g7
I92
sg8
g15
sg10
I3
sg11
VD6D
p2032
sg13
I1
sasg23
(lp2033
(dp2034
g7
I137
sg26
VC0020538
p2035
sg10
I12
sg11
Vhypertension
p2036
sg13
I1
sasa(dp2037
g2
S'Pancreatic adenocarcinoma tissues obtained from 104 patients were subjected to cytokeratin 19 and CD31 double immunostaining to identify cancer cells and endothelial cells simultaneously.\n'
p2038
sg4
(lp2039
(dp2040
g7
I79
sg8
g15
sg10
I14
sg11
Vcytokeratin 19
p2041
sg13
I2
sa(dp2042
g7
I98
sg8
VP69905
p2043
sg10
I4
sg11
VCD31
p2044
sg13
I1
sasg23
(lp2045
(dp2046
g7
I137
sg26
VC0006826
p2047
sg10
I6
sg11
Vcancer
p2048
sg13
I1
sa(dp2049
g7
I0
sg26
VC0281361
p2050
sg10
I25
sg11
VPancreatic adenocarcinoma
p2051
sg13
I2
sasa(dp2052
g2
S'Using BM chimera, we found that serpinB1 deficiency in BM cells was necessary and sufficient to reproduce the BM neutropenia of sB1(-/-) mice.\n'
p2053
sg4
(lp2054
(dp2055
g7
I32
sg8
VP30740
p2056
sg10
I8
sg11
VserpinB1
p2057
sg13
I1
sasg23
(lp2058
(dp2059
g7
I9
sg26
VC1318484
p2060
sg10
I7
sg11
Vchimera
p2061
sg13
I1
sasa(dp2062
g2
S'Moreover, we showed that genetic deletion of CG, but not NE, fully rescued the BM neutropenia in sB1(-/-) mice.\n'
p2063
sg4
(lp2064
sg23
(lp2065
sa(dp2066
g2
S'In fact, depletion of the endoplasmic reticulum from calcium induces metabolic changes resembling, in many respects, those produced by transient cerebral ischemia: it causes an inhibition of the activity of the eucaryotic initiation factor elF-2 alpha (by phosphorylation), a disaggregation of polyribosomes and thus an inhibition of global protein synthesis, and an increased expression of certain genes such as transcription factors (c-fos and c-jun) and the glucose-related protein grp78.\n'
p2067
sg4
(lp2068
(dp2069
g7
I446
sg8
VP05412
p2070
sg10
I5
sg11
Vc-jun
p2071
sg13
I1
sa(dp2072
g7
I240
sg8
g15
sg10
I11
sg11
VelF-2 alpha
p2073
sg13
I2
sa(dp2074
g7
I485
sg8
VP11021
p2075
sg10
I5
sg11
Vgrp78
p2076
sg13
I1
sa(dp2077
g7
I436
sg8
VP01100
p2078
sg10
I5
sg11
Vc-fos
p2079
sg13
I1
sasg23
(lp2080
(dp2081
g7
I135
sg26
VC0917805
p2082
sg10
I27
sg11
Vtransient cerebral ischemia
p2083
sg13
I3
sasa(dp2084
g2
S'TGH rabbits showed advanced aortic atherosclerosis, accompanied by intimal thickening of coronary and renal arteries, fatty liver changes, and xanthoma.\n'
p2085
sg4
(lp2086
(dp2087
g7
I0
sg8
g15
sg10
I3
sg11
VTGH
p2088
sg13
I1
sasg23
(lp2089
(dp2090
g7
I28
sg26
VC0155733
p2091
sg10
I22
sg11
Vaortic atherosclerosis
p2092
sg13
I2
sa(dp2093
g7
I143
sg26
VC0302314
p2094
sg10
I8
sg11
Vxanthoma
p2095
sg13
I1
sa(dp2096
g7
I118
sg26
VC0015695
p2097
sg10
I11
sg11
Vfatty liver
p2098
sg13
I2
sasa(dp2099
g2
S'The study group comprised 39 men and 3 women (42 and 3 CAS procedures, respectively) with severe carotid stenosis (average age 70.0 +/- 6.6 years).\n'
p2100
sg4
(lp2101
sg23
(lp2102
(dp2103
g7
I97
sg26
VC0007282
p2104
sg10
I16
sg11
Vcarotid stenosis
p2105
sg13
I2
sa(dp2106
g7
I55
sg26
VC0750927
p2107
sg10
I3
sg11
VCAS
p2108
sg13
I1
sasa(dp2109
g2
S'Evidence has indicated that the protein and mRNA levels of serine-arginine protein kinase-1 (SRPK-1) are upregulated in NSCLC tissues.\n'
p2110
sg4
(lp2111
(dp2112
g7
I93
sg8
g15
sg10
I6
sg11
VSRPK-1
p2113
sg13
I1
sa(dp2114
g7
I59
sg8
VP30740
p2115
sg10
I32
sg11
Vserine-arginine protein kinase-1
p2116
sg13
I3
sasg23
(lp2117
(dp2118
g7
I120
sg26
VC0007131
p2119
sg10
I5
sg11
VNSCLC
p2120
sg13
I1
sasa(dp2121
g2
S'However, the functions of SRPK1 and targeted therapy for SRPK1 in the progression and treatment of NSCLC remain to be fully elucidated.\n'
p2122
sg4
(lp2123
(dp2124
g7
I26
sg8
g15
sg10
I5
sg11
VSRPK1
p2125
sg13
I1
sa(dp2126
g7
I26
sg8
g15
sg10
I5
sg11
VSRPK1
p2127
sg13
I1
sasg23
(lp2128
(dp2129
g7
I99
sg26
VC0007131
p2130
sg10
I5
sg11
VNSCLC
p2131
sg13
I1
sasa(dp2132
g2
S'In the present study, the mRNA and protein expression levels of SRPK-1 in NSCLC cells and tissues were analyzed using reverse transcription-quantitative polymerase chain reaction analysis and SDS-PAGE, and the role of SRPK1 in the progression of NSCLC was investigated.\n'
p2133
sg4
(lp2134
(dp2135
g7
I64
sg8
g15
sg10
I6
sg11
VSRPK-1
p2136
sg13
I1
sa(dp2137
g7
I218
sg8
g15
sg10
I5
sg11
VSRPK1
p2138
sg13
I1
sasg23
(lp2139
(dp2140
g7
I74
sg26
VC0007131
p2141
sg10
I5
sg11
VNSCLC
p2142
sg13
I1
sa(dp2143
g7
I74
sg26
VC0007131
p2144
sg10
I5
sg11
VNSCLC
p2145
sg13
I1
sa(dp2146
g7
I192
sg26
VC0272170
p2147
sg10
I3
sg11
VSDS
p2148
sg13
I1
sasa(dp2149
g2
S'The curative effects of ChanSRPK-1 on the inhibition of growth, migration and invasion of NSCLC were also examined in vitro and in vivo.\n'
p2150
sg4
(lp2151
sg23
(lp2152
(dp2153
g7
I78
sg26
VC2699153
p2154
sg10
I8
sg11
Vinvasion
p2155
sg13
I1
sa(dp2156
g7
I90
sg26
VC0007131
p2157
sg10
I5
sg11
VNSCLC
p2158
sg13
I1
sasa(dp2159
g2
S'The results revealed that the mRNA and protein levels of SRPK-1 were upregulated in NSCLC cells and tumor tissues.\n'
p2160
sg4
(lp2161
(dp2162
g7
I57
sg8
g15
sg10
I6
sg11
VSRPK-1
p2163
sg13
I1
sasg23
(lp2164
(dp2165
g7
I100
sg26
VC0027651
p2166
sg10
I5
sg11
Vtumor
p2167
sg13
I1
sa(dp2168
g7
I84
sg26
VC0007131
p2169
sg10
I5
sg11
VNSCLC
p2170
sg13
I1
sasa(dp2171
g2
S'Higher expression of SRPK1 promoted NSCLC cell growth, migration and invasion, whereas lower expression of SRPK-1 suppressed growth, migration and invasion of the NSCLC cells.\n'
p2172
sg4
(lp2173
(dp2174
g7
I21
sg8
g15
sg10
I5
sg11
VSRPK1
p2175
sg13
I1
sa(dp2176
g7
I107
sg8
g15
sg10
I6
sg11
VSRPK-1
p2177
sg13
I1
sasg23
(lp2178
(dp2179
g7
I69
sg26
VC2699153
p2180
sg10
I8
sg11
Vinvasion
p2181
sg13
I1
sa(dp2182
g7
I36
sg26
VC0007131
p2183
sg10
I5
sg11
VNSCLC
p2184
sg13
I1
sa(dp2185
g7
I69
sg26
VC2699153
p2186
sg10
I8
sg11
Vinvasion
p2187
sg13
I1
sa(dp2188
g7
I36
sg26
VC0007131
p2189
sg10
I5
sg11
VNSCLC
p2190
sg13
I1
sasa(dp2191
g2
S'Taken together, SRPK-1 may offer potential as a therapeutic target oncogenic molecular in NSCLC, and ChanSRPK-1 may be a therapeutic agent with functions as a target and for oncolytic therapy in the treatment of NSCLC.\n'
p2192
sg4
(lp2193
(dp2194
g7
I16
sg8
g15
sg10
I6
sg11
VSRPK-1
p2195
sg13
I1
sasg23
(lp2196
(dp2197
g7
I90
sg26
VC0007131
p2198
sg10
I5
sg11
VNSCLC
p2199
sg13
I1
sa(dp2200
g7
I90
sg26
VC0007131
p2201
sg10
I5
sg11
VNSCLC
p2202
sg13
I1
sasa(dp2203
g2
S'A recent report adds to this puzzle, showing that the main effect of SRPK1 overexpression in non-small-cell lung carcinoma is to stimulate a stem cell-like phenotype.\n'
p2204
sg4
(lp2205
(dp2206
g7
I69
sg8
g15
sg10
I5
sg11
VSRPK1
p2207
sg13
I1
sasg23
(lp2208
(dp2209
g7
I93
sg26
VC0007131
p2210
sg10
I29
sg11
Vnon-small-cell lung carcinoma
p2211
sg13
I3
sasa(dp2212
g2
S'SRPK1 was associated with the clinical features of human NSCLC, including clinical stage (p &lt; 0.001) and T (p = 0.001), N (p = 0.007), and M (p = 0.001) classifications.\n'
p2213
sg4
(lp2214
(dp2215
g7
I0
sg8
g15
sg10
I5
sg11
VSRPK1
p2216
sg13
I1
sasg23
(lp2217
(dp2218
g7
I57
sg26
VC0007131
p2219
sg10
I5
sg11
VNSCLC
p2220
sg13
I1
sasa(dp2221
g2
S'Ectopic overexpression of SRPK1 promoted the acquisition of a stem cell-like phenotype in human NSCLC cell lines cultured in vitro.\n'
p2222
sg4
(lp2223
(dp2224
g7
I26
sg8
g15
sg10
I5
sg11
VSRPK1
p2225
sg13
I1
sasg23
(lp2226
(dp2227
g7
I96
sg26
VC0007131
p2228
sg10
I5
sg11
VNSCLC
p2229
sg13
I1
sasa(dp2230
g2
S'Mouse studies indicated that SRPK1 promoted NSCLC cell line tumour growth and SRPK1 overexpression reduced the number of tumour cells required to initiate tumourigenesis in vivo.\n'
p2231
sg4
(lp2232
(dp2233
g7
I29
sg8
g15
sg10
I5
sg11
VSRPK1
p2234
sg13
I1
sa(dp2235
g7
I29
sg8
g15
sg10
I5
sg11
VSRPK1
p2236
sg13
I1
sasg23
(lp2237
(dp2238
g7
I60
sg26
VC0027651
p2239
sg10
I6
sg11
Vtumour
p2240
sg13
I1
sa(dp2241
g7
I44
sg26
VC0007131
p2242
sg10
I5
sg11
VNSCLC
p2243
sg13
I1
sa(dp2244
g7
I60
sg26
VC0027651
p2245
sg10
I6
sg11
Vtumour
p2246
sg13
I1
sasa(dp2247
g2
S'Mechanistically, gene set enrichment analysis showed that Wnt/Beta-catenin signalling correlated with SRPK1 mRNA levels and this signalling pathway was hyperactivated by ectopic SRPK1 expression in NSCLC cell lines.\n'
p2248
sg4
(lp2249
(dp2250
g7
I62
sg8
VP35222
p2251
sg10
I12
sg11
VBeta-catenin
p2252
sg13
I1
sa(dp2253
g7
I102
sg8
g15
sg10
I5
sg11
VSRPK1
p2254
sg13
I1
sa(dp2255
g7
I102
sg8
g15
sg10
I10
sg11
VSRPK1 mRNA
p2256
sg13
I2
sasg23
(lp2257
(dp2258
g7
I198
sg26
VC0007131
p2259
sg10
I5
sg11
VNSCLC
p2260
sg13
I1
sasa(dp2261
g2
S'Immunofluorescence demonstrated that SRPK1 enhanced Beta-catenin accumulation in the nuclei of NSCLC cell lines, and inhibition of Beta-catenin signalling abrogated the SRPK1-induced stem cell-like phenotype.\n'
p2262
sg4
(lp2263
(dp2264
g7
I52
sg8
VP35222
p2265
sg10
I12
sg11
VBeta-catenin
p2266
sg13
I1
sa(dp2267
g7
I52
sg8
VP35222
p2268
sg10
I12
sg11
VBeta-catenin
p2269
sg13
I1
sa(dp2270
g7
I37
sg8
g15
sg10
I5
sg11
VSRPK1
p2271
sg13
I1
sa(dp2272
g7
I37
sg8
g15
sg10
I5
sg11
VSRPK1
p2273
sg13
I1
sasg23
(lp2274
(dp2275
g7
I95
sg26
VC0007131
p2276
sg10
I5
sg11
VNSCLC
p2277
sg13
I1
sasa(dp2278
g2
S'Together, our findings suggest that SRPK1 promotes a stem cell-like phenotype in NSCLC via Wnt/Beta-catenin signalling.\n'
p2279
sg4
(lp2280
(dp2281
g7
I95
sg8
VP35222
p2282
sg10
I12
sg11
VBeta-catenin
p2283
sg13
I1
sa(dp2284
g7
I36
sg8
g15
sg10
I5
sg11
VSRPK1
p2285
sg13
I1
sasg23
(lp2286
(dp2287
g7
I81
sg26
VC0007131
p2288
sg10
I5
sg11
VNSCLC
p2289
sg13
I1
sasa(dp2290
g2
S'Moreover, SRPK1 may represent a novel target for human NSCLC diagnosis and therapy.\n'
p2291
sg4
(lp2292
(dp2293
g7
I10
sg8
g15
sg10
I5
sg11
VSRPK1
p2294
sg13
I1
sasg23
(lp2295
(dp2296
g7
I55
sg26
VC0007131
p2297
sg10
I5
sg11
VNSCLC
p2298
sg13
I1
sasa(dp2299
g2
S'Dys-regulation of serine-arginine protein kinase 1 (SRPK1) has been reported in non-small cell lung cancer (NSCLC).\n'
p2300
sg4
(lp2301
(dp2302
g7
I52
sg8
g15
sg10
I5
sg11
VSRPK1
p2303
sg13
I1
sa(dp2304
g7
I18
sg8
VP30740
p2305
sg10
I32
sg11
Vserine-arginine protein kinase 1
p2306
sg13
I4
sasg23
(lp2307
(dp2308
g7
I80
sg26
VC0007131
p2309
sg10
I26
sg11
Vnon-small cell lung cancer
p2310
sg13
I4
sa(dp2311
g7
I108
sg26
VC0007131
p2312
sg10
I5
sg11
VNSCLC
p2313
sg13
I1
sa(dp2314
g7
I0
sg26
VC0013364
p2315
sg10
I3
sg11
VDys
p2316
sg13
I1
sasa(dp2317
g2
S'In this study, the expression of SRPK1 in NSCLC tissues was determined using real-time PCR, and the roles of SRPK1 in the progression of NSCLC were investigated.\n'
p2318
sg4
(lp2319
(dp2320
g7
I33
sg8
g15
sg10
I5
sg11
VSRPK1
p2321
sg13
I1
sa(dp2322
g7
I33
sg8
g15
sg10
I5
sg11
VSRPK1
p2323
sg13
I1
sasg23
(lp2324
(dp2325
g7
I42
sg26
VC0007131
p2326
sg10
I5
sg11
VNSCLC
p2327
sg13
I1
sa(dp2328
g7
I42
sg26
VC0007131
p2329
sg10
I5
sg11
VNSCLC
p2330
sg13
I1
sasa(dp2331
g2
S'It was found that both the mRNA level and the protein level of SRPK1 were up-regulated in NSCLC tissues.\n'
p2332
sg4
(lp2333
(dp2334
g7
I63
sg8
g15
sg10
I5
sg11
VSRPK1
p2335
sg13
I1
sasg23
(lp2336
(dp2337
g7
I90
sg26
VC0007131
p2338
sg10
I5
sg11
VNSCLC
p2339
sg13
I1
sasa(dp2340
g2
S'Forced expression of SRPK1 promoted the growth and migration of NSCLC cells, while knocking down the expression of SRPK1 inhibited the growth, migration, and tumorigenicity of NSCLC cells.\n'
p2341
sg4
(lp2342
(dp2343
g7
I21
sg8
g15
sg10
I5
sg11
VSRPK1
p2344
sg13
I1
sa(dp2345
g7
I21
sg8
g15
sg10
I5
sg11
VSRPK1
p2346
sg13
I1
sasg23
(lp2347
(dp2348
g7
I158
sg26
VC1519697
p2349
sg10
I14
sg11
Vtumorigenicity
p2350
sg13
I1
sa(dp2351
g7
I64
sg26
VC0007131
p2352
sg10
I5
sg11
VNSCLC
p2353
sg13
I1
sa(dp2354
g7
I64
sg26
VC0007131
p2355
sg10
I5
sg11
VNSCLC
p2356
sg13
I1
sasa(dp2357
g2
S'Taken together, SRPK1 might play an oncogenic role in NSCLC, and SRPK1 might be a therapeutic target for NSCLC.\n'
p2358
sg4
(lp2359
(dp2360
g7
I16
sg8
g15
sg10
I5
sg11
VSRPK1
p2361
sg13
I1
sa(dp2362
g7
I16
sg8
g15
sg10
I5
sg11
VSRPK1
p2363
sg13
I1
sasg23
(lp2364
(dp2365
g7
I54
sg26
VC0007131
p2366
sg10
I5
sg11
VNSCLC
p2367
sg13
I1
sa(dp2368
g7
I54
sg26
VC0007131
p2369
sg10
I5
sg11
VNSCLC
p2370
sg13
I1
sasa(dp2371
g2
S'We report the case of a woman with an early-onset endometrial adenocarcinoma who was suspected to be affected with Lynch syndrome based on tumor dMMR phenotype (MSI associated with loss of expression of MSH2 and MSH6 proteins).\n'
p2372
sg4
(lp2373
(dp2374
g7
I203
sg8
VP43246
p2375
sg10
I4
sg11
VMSH2
p2376
sg13
I1
sa(dp2377
g7
I212
sg8
VP52701
p2378
sg10
I13
sg11
VMSH6 proteins
p2379
sg13
I2
sasg23
(lp2380
(dp2381
g7
I115
sg26
VC1333990
p2382
sg10
I14
sg11
VLynch syndrome
p2383
sg13
I2
sa(dp2384
g7
I161
sg26
VC0920269
p2385
sg10
I3
sg11
VMSI
p2386
sg13
I1
sa(dp2387
g7
I50
sg26
VC1153706
p2388
sg10
I26
sg11
Vendometrial adenocarcinoma
p2389
sg13
I2
sa(dp2390
g7
I139
sg26
VC0027651
p2391
sg10
I5
sg11
Vtumor
p2392
sg13
I1
sasa(dp2393
g2
S'The patient had intellectual disability and presented with a prostatic adenocarcinoma with an incidentally identified synchronous sigmoid adenocarcinoma that exhibited deficient MMR with an absence of MSH2 and MSH6 protein expression.\n'
p2394
sg4
(lp2395
(dp2396
g7
I201
sg8
VP43246
p2397
sg10
I4
sg11
VMSH2
p2398
sg13
I1
sa(dp2399
g7
I210
sg8
VP52701
p2400
sg10
I12
sg11
VMSH6 protein
p2401
sg13
I2
sasg23
(lp2402
(dp2403
g7
I71
sg26
VC0001418
p2404
sg10
I14
sg11
Vadenocarcinoma
p2405
sg13
I1
sa(dp2406
g7
I61
sg26
VC0007112
p2407
sg10
I24
sg11
Vprostatic adenocarcinoma
p2408
sg13
I2
sa(dp2409
g7
I16
sg26
VC0025362
p2410
sg10
I23
sg11
Vintellectual disability
p2411
sg13
I2
sasa(dp2412
g2
S'Relative to YAs, OAs were characterised by smaller muscle volume, greater IMAT volume, lower muscle strength, and higher levels of myeloperoxidase, P-selectin, soluble intercellular adhesion molecule 1, and vascular cell adhesion molecule 1.\n'
p2413
sg4
(lp2414
(dp2415
g7
I131
sg8
VP05164
p2416
sg10
I15
sg11
Vmyeloperoxidase
p2417
sg13
I1
sa(dp2418
g7
I148
sg8
VP16109
p2419
sg10
I10
sg11
VP-selectin
p2420
sg13
I1
sa(dp2421
g7
I160
sg8
VP05362
p2422
sg10
I41
sg11
Vsoluble intercellular adhesion molecule 1
p2423
sg13
I5
sa(dp2424
g7
I207
sg8
g15
sg10
I33
sg11
Vvascular cell adhesion molecule 1
p2425
sg13
I5
sasg23
(lp2426
(dp2427
g7
I182
sg26
VC0001511
p2428
sg10
I8
sg11
Vadhesion
p2429
sg13
I1
sa(dp2430
g7
I182
sg26
VC0001511
p2431
sg10
I8
sg11
Vadhesion
p2432
sg13
I1
sa(dp2433
g7
I17
sg26
VC0599973
p2434
sg10
I3
sg11
VOAs
p2435
sg13
I1
sasa(dp2436
g2
S'Cloning and characterization of ADMP has made it feasible to determine its prospective role in the absence of androgens in prostate cancer.\n'
p2437
sg4
(lp2438
(dp2439
g7
I32
sg8
g15
sg10
I4
sg11
VADMP
p2440
sg13
I1
sasg23
(lp2441
(dp2442
g7
I123
sg26
VC0600139
p2443
sg10
I15
sg11
Vprostate cancer
p2444
sg13
I2
sasa(dp2445
g2
S'47, XXY Klinefelter syndrome; (2) more frequently postzygotic mosaicism for IKBKG mutation.2 Detection of postzygotic mosaicism is dependant of tissue sampling localization and percentage of mutated cells in the sample.\n'
p2446
sg4
(lp2447
(dp2448
g7
I76
sg8
g15
sg10
I5
sg11
VIKBKG
p2449
sg13
I1
sasg23
(lp2450
(dp2451
g7
I8
sg26
VC0022735
p2452
sg10
I20
sg11
VKlinefelter syndrome
p2453
sg13
I2
sa(dp2454
g7
I62
sg26
VC0392053
p2455
sg10
I9
sg11
Vmosaicism
p2456
sg13
I1
sa(dp2457
g7
I62
sg26
VC0392053
p2458
sg10
I9
sg11
Vmosaicism
p2459
sg13
I1
sasa(dp2460
g2
S'A higher M-protein level was evidenced at 10w and 4 mice developed paraplegia at 8/9w in low-Ca-MM group only.\n'
p2461
sg4
(lp2462
sg23
(lp2463
(dp2464
g7
I67
sg26
VC0030486
p2465
sg10
I10
sg11
Vparaplegia
p2466
sg13
I1
sasa(dp2467
g2
S'In contrast, the expression level of the proteins did not show a significant change at 9 weeks, but this increased to 3-fold at 30 weeks for carbonic anhydrase VII, ras related protein Rab 6, Annexin A2, neurofibromatosis type 2 and aldehyde dehydrogenase.\n'
p2468
sg4
(lp2469
(dp2470
g7
I165
sg8
VP11233
p2471
sg10
I25
sg11
Vras related protein Rab 6
p2472
sg13
I5
sa(dp2473
g7
I192
sg8
VP07355
p2474
sg10
I63
sg11
VAnnexin A2, neurofibromatosis type 2 and aldehyde dehydrogenase
p2475
sg13
I8
sa(dp2476
g7
I141
sg8
VP43166
p2477
sg10
I22
sg11
Vcarbonic anhydrase VII
p2478
sg13
I3
sasg23
(lp2479
(dp2480
g7
I204
sg26
VC0027832
p2481
sg10
I24
sg11
Vneurofibromatosis type 2
p2482
sg13
I3
sasa(dp2483
g2
S'Clinical data were collected and analyzed from 71 cases of primary nephrotic syndrome with glucocorticoid-induced ocular hypertension, glaucoma or cataract from Jun.\n'
p2484
sg4
(lp2485
(dp2486
g7
I161
sg8
VP05412
p2487
sg10
I3
sg11
VJun
p2488
sg13
I1
sasg23
(lp2489
(dp2490
g7
I147
sg26
VC0086543
p2491
sg10
I8
sg11
Vcataract
p2492
sg13
I1
sa(dp2493
g7
I135
sg26
VC0017601
p2494
sg10
I8
sg11
Vglaucoma
p2495
sg13
I1
sa(dp2496
g7
I67
sg26
VC0027726
p2497
sg10
I18
sg11
Vnephrotic syndrome
p2498
sg13
I2
sa(dp2499
g7
I114
sg26
VC0028840
p2500
sg10
I19
sg11
Vocular hypertension
p2501
sg13
I2
sasa(dp2502
g2
S'c-Jun, c-Jun N-terminal kinase(JNK) and endothelin B (ETB) receptor have been shown to contribute to the pathogenesis of glaucoma.\n'
p2503
sg4
(lp2504
(dp2505
g7
I0
sg8
VP05412
p2506
sg10
I5
sg11
Vc-Jun
p2507
sg13
I1
sa(dp2508
g7
I31
sg8
VP53779
p2509
sg10
I3
sg11
VJNK
p2510
sg13
I1
sa(dp2511
g7
I40
sg8
g15
sg10
I27
sg11
Vendothelin B (ETB) receptor
p2512
sg13
I4
sa(dp2513
g7
I7
sg8
VP53779
p2514
sg10
I23
sg11
Vc-Jun N-terminal kinase
p2515
sg13
I3
sasg23
(lp2516
(dp2517
g7
I105
sg26
VC0699748
p2518
sg10
I12
sg11
Vpathogenesis
p2519
sg13
I1
sa(dp2520
g7
I121
sg26
VC0017601
p2521
sg10
I8
sg11
Vglaucoma
p2522
sg13
I1
sasa(dp2523
g2
S'JUN is expressed after glaucoma-relevant injuries and Jun deficiency protects RGCs after mechanical injury to the optic nerve.\n'
p2524
sg4
(lp2525
(dp2526
g7
I54
sg8
VP05412
p2527
sg10
I3
sg11
VJun
p2528
sg13
I1
sa(dp2529
g7
I0
sg8
VP05412
p2530
sg10
I3
sg11
VJUN
p2531
sg13
I1
sasg23
(lp2532
(dp2533
g7
I23
sg26
VC0017601
p2534
sg10
I8
sg11
Vglaucoma
p2535
sg13
I1
sasa(dp2536
g2
S'JUN was expressed in a temporal and spatial pattern consistent with a role in glaucomatous injury.\n'
p2537
sg4
(lp2538
(dp2539
g7
I0
sg8
VP05412
p2540
sg10
I3
sg11
VJUN
p2541
sg13
I1
sasg23
(lp2542
sa(dp2543
g2
S'Jun deficiency protected RGC somas from ocular hypertensive injury, but did not protect RGC axons from glaucomatous neurodegeneration.\n'
p2544
sg4
(lp2545
(dp2546
g7
I0
sg8
VP05412
p2547
sg10
I3
sg11
VJun
p2548
sg13
I1
sasg23
(lp2549
(dp2550
g7
I116
sg26
VC0027746
p2551
sg10
I17
sg11
Vneurodegeneration
p2552
sg13
I1
sasa(dp2553
g2
S'Jun is a major regulator of RGC somal degeneration after glaucomatous ocular hypertensive injury.\n'
p2554
sg4
(lp2555
(dp2556
g7
I0
sg8
VP05412
p2557
sg10
I3
sg11
VJun
p2558
sg13
I1
sasg23
(lp2559
(dp2560
g7
I38
sg26
VC0011164
p2561
sg10
I12
sg11
Vdegeneration
p2562
sg13
I1
sasa(dp2563
g2
S'These results suggest in glaucomatous neurodegeneration, JNK-JUN signaling has a major role as a pro-death signaling pathway between axonal injury and somal degeneration.\n'
p2564
sg4
(lp2565
(dp2566
g7
I61
sg8
VP05412
p2567
sg10
I3
sg11
VJUN
p2568
sg13
I1
sa(dp2569
g7
I57
sg8
VP53779
p2570
sg10
I3
sg11
VJNK
p2571
sg13
I1
sasg23
(lp2572
(dp2573
g7
I43
sg26
VC0011164
p2574
sg10
I12
sg11
Vdegeneration
p2575
sg13
I1
sa(dp2576
g7
I38
sg26
VC0027746
p2577
sg10
I17
sg11
Vneurodegeneration
p2578
sg13
I1
sasa(dp2579
g2
S'To test performance, computer-derived outputs were compared to previously published features of several well-characterized mouse models of ophthalmic disease and their controls: normal C57BL/6J mice; Jun-sufficient and Jun-deficient mice subjected to controlled optic nerve crush (CONC); and DBA/2J mice with naturally occurring glaucoma.\n'
p2580
sg4
(lp2581
(dp2582
g7
I200
sg8
VP05412
p2583
sg10
I3
sg11
VJun
p2584
sg13
I1
sa(dp2585
g7
I200
sg8
VP05412
p2586
sg10
I3
sg11
VJun
p2587
sg13
I1
sasg23
(lp2588
(dp2589
g7
I329
sg26
VC0017601
p2590
sg10
I8
sg11
Vglaucoma
p2591
sg13
I1
sa(dp2592
g7
I292
sg26
VC0398550
p2593
sg10
I3
sg11
VDBA
p2594
sg13
I1
sasa(dp2595
g2
S'Automated characterization of C57BL/6J retinas predicted 54,642 RGCs per normal retina, and identified a 48.3% Jun-dependent loss of cells at 35 days post CONC and a 71.2% loss of RGCs among 16-month-old DBA/2J mice with glaucoma.\n'
p2596
sg4
(lp2597
(dp2598
g7
I111
sg8
VP05412
p2599
sg10
I3
sg11
VJun
p2600
sg13
I1
sasg23
(lp2601
(dp2602
g7
I221
sg26
VC0017601
p2603
sg10
I8
sg11
Vglaucoma
p2604
sg13
I1
sa(dp2605
g7
I204
sg26
VC0398550
p2606
sg10
I3
sg11
VDBA
p2607
sg13
I1
sasa(dp2608
g2
S'This study evaluates, for we believe the first time, polymorphisms on the SNARE complex-related genes STX1A (rs2228607), VAMP2 (26bp Ins/Del) and SYT1 (rs1880867 and rs2251214) on the response to immediate-release methylphenidate (IR-MPH) in a naturalistic sample of adults with ADHD.\n'
p2609
sg4
(lp2610
(dp2611
g7
I146
sg8
VP21579
p2612
sg10
I4
sg11
VSYT1
p2613
sg13
I1
sa(dp2614
g7
I74
sg8
g15
sg10
I33
sg11
VSNARE complex-related genes STX1A
p2615
sg13
I4
sa(dp2616
g7
I137
sg8
VP01719
p2617
sg10
I3
sg11
VDel
p2618
sg13
I1
sasg23
(lp2619
(dp2620
g7
I279
sg26
VC1263846
p2621
sg10
I4
sg11
VADHD
p2622
sg13
I1
sa(dp2623
g7
I133
sg26
VC1533172
p2624
sg10
I3
sg11
VIns
p2625
sg13
I1
sasa(dp2626
g2
S'We tested the association between ADHD and polymorphisms on the SNARE genes STX1A (rs2228607), SYT1 (rs1880867 and rs2251214), VAMP2 (26bp Ins/Del) and SNAP25 (rs6108461 and rs8636) on a sample comprised of 548 adults with ADHD and 644 non-affected controls.\n'
p2627
sg4
(lp2628
(dp2629
g7
I95
sg8
VP21579
p2630
sg10
I4
sg11
VSYT1
p2631
sg13
I1
sa(dp2632
g7
I143
sg8
VP01719
p2633
sg10
I3
sg11
VDel
p2634
sg13
I1
sa(dp2635
g7
I64
sg8
g15
sg10
I17
sg11
VSNARE genes STX1A
p2636
sg13
I3
sa(dp2637
g7
I34
sg8
g15
sg10
I4
sg11
VADHD
p2638
sg13
I1
sasg23
(lp2639
(dp2640
g7
I34
sg26
VC1263846
p2641
sg10
I4
sg11
VADHD
p2642
sg13
I1
sa(dp2643
g7
I139
sg26
VC1533172
p2644
sg10
I3
sg11
VIns
p2645
sg13
I1
sa(dp2646
g7
I34
sg26
VC1263846
p2647
sg10
I4
sg11
VADHD
p2648
sg13
I1
sasa(dp2649
g2
S'We genotyped eight single nucleotide polymorphisms (SNP) of Syntaxin 1A (STX1A), vesicle-associated membrane protein 2 (VAMP2) and synaptosomal-associated protein 25 kDa (SNAP25) and conducted case-control studies in 1404 male ADHD and 617 male controls.\n'
p2650
sg4
(lp2651
(dp2652
g7
I73
sg8
g15
sg10
I5
sg11
VSTX1A
p2653
sg13
I1
sa(dp2654
g7
I109
sg8
VP63027
p2655
sg10
I56
sg11
Vprotein 2 (VAMP2) and synaptosomal-associated protein 25
p2656
sg13
I7
sa(dp2657
g7
I60
sg8
g15
sg10
I11
sg11
VSyntaxin 1A
p2658
sg13
I2
sasg23
(lp2659
(dp2660
g7
I227
sg26
VC1263846
p2661
sg10
I4
sg11
VADHD
p2662
sg13
I1
sa(dp2663
g7
I81
sg26
VC0333262
p2664
sg10
I7
sg11
Vvesicle
p2665
sg13
I1
sasa(dp2666
g2
S'In this study; it was aimed to investigate the association of the synaptobrevin-2 (VAMP-2) gene Ins/Del polymorphism and syntaxin 1A gene intron 7 polymorphism, which take place in encoding presynaptic protein, with adult ADHD.\n'
p2667
sg4
(lp2668
(dp2669
g7
I66
sg8
VP63027
p2670
sg10
I15
sg11
Vsynaptobrevin-2
p2671
sg13
I1
sa(dp2672
g7
I83
sg8
VP63027
p2673
sg10
I6
sg11
VVAMP-2
p2674
sg13
I1
sa(dp2675
g7
I121
sg8
g15
sg10
I16
sg11
Vsyntaxin 1A gene
p2676
sg13
I3
sa(dp2677
g7
I100
sg8
VP01719
p2678
sg10
I3
sg11
VDel
p2679
sg13
I1
sasg23
(lp2680
(dp2681
g7
I96
sg26
VC1533172
p2682
sg10
I3
sg11
VIns
p2683
sg13
I1
sa(dp2684
g7
I222
sg26
VC1263846
p2685
sg10
I4
sg11
VADHD
p2686
sg13
I1
sasa(dp2687
g2
S'A significant difference was determined between ADHD and VAMP-2 Ins/Del polymorphism and syntaxin 1A intron 7 polymorphism according to the control group.\n'
p2688
sg4
(lp2689
(dp2690
g7
I68
sg8
VP01719
p2691
sg10
I3
sg11
VDel
p2692
sg13
I1
sa(dp2693
g7
I57
sg8
VP63027
p2694
sg10
I10
sg11
VVAMP-2 Ins
p2695
sg13
I2
sa(dp2696
g7
I89
sg8
g15
sg10
I11
sg11
Vsyntaxin 1A
p2697
sg13
I2
sa(dp2698
g7
I48
sg8
g15
sg10
I4
sg11
VADHD
p2699
sg13
I1
sasg23
(lp2700
(dp2701
g7
I64
sg26
VC1533172
p2702
sg10
I3
sg11
VIns
p2703
sg13
I1
sa(dp2704
g7
I48
sg26
VC1263846
p2705
sg10
I4
sg11
VADHD
p2706
sg13
I1
sasa(dp2707
g2
S'We sequenced genes coding for components of the SNARE complex (STX1A, VAMP2, SNAP25) and their regulatory proteins (STXBP1/Munc18-1, SYT1), which are essential for neurotransmission, in 95 patients with idiopathic mental retardation.\n'
p2708
sg4
(lp2709
(dp2710
g7
I133
sg8
VP21579
p2711
sg10
I4
sg11
VSYT1
p2712
sg13
I1
sa(dp2713
g7
I116
sg8
VP61764
p2714
sg10
I6
sg11
VSTXBP1
p2715
sg13
I1
sa(dp2716
g7
I70
sg8
VP63027
p2717
sg10
I5
sg11
VVAMP2
p2718
sg13
I1
sa(dp2719
g7
I63
sg8
g15
sg10
I5
sg11
VSTX1A
p2720
sg13
I1
sa(dp2721
g7
I48
sg8
g15
sg10
I13
sg11
VSNARE complex
p2722
sg13
I2
sa(dp2723
g7
I123
sg8
VP61764
p2724
sg10
I8
sg11
VMunc18-1
p2725
sg13
I1
sasg23
(lp2726
(dp2727
g7
I214
sg26
VC0025362
p2728
sg10
I18
sg11
Vmental retardation
p2729
sg13
I2
sasa(dp2730
g2
S'This was substantiated by the cellular co-localization of B1R with NOX1 and NOX2 and opens the possibility that B1R-enhanced oxidative stress is derived from vascular and infiltrating immune cells in diabetes.\n'
p2731
sg4
(lp2732
(dp2733
g7
I67
sg8
g15
sg10
I4
sg11
VNOX1
p2734
sg13
I1
sa(dp2735
g7
I76
sg8
VP04839
p2736
sg10
I4
sg11
VNOX2
p2737
sg13
I1
sasg23
(lp2738
(dp2739
g7
I125
sg26
VC0242606
p2740
sg10
I16
sg11
Voxidative stress
p2741
sg13
I2
sa(dp2742
g7
I171
sg26
VC0332448
p2743
sg10
I12
sg11
Vinfiltrating
p2744
sg13
I1
sa(dp2745
g7
I200
sg26
VC0011849
p2746
sg10
I8
sg11
Vdiabetes
p2747
sg13
I1
sasa(dp2748
g2
S'The degree of adiposity, insulin resistance, and dyslipidemia in KW mice was not influenced by Nox1 deletion as determined by nuclear magnetic resonance spectroscopy, glucose tolerance tests, and plasma analyses.\n'
p2749
sg4
(lp2750
(dp2751
g7
I95
sg8
g15
sg10
I4
sg11
VNox1
p2752
sg13
I1
sa(dp2753
g7
I25
sg8
VP01308
p2754
sg10
I7
sg11
Vinsulin
p2755
sg13
I1
sasg23
(lp2756
(dp2757
g7
I175
sg26
VC0020963
p2758
sg10
I9
sg11
Vtolerance
p2759
sg13
I1
sa(dp2760
g7
I14
sg26
VC0028754
p2761
sg10
I9
sg11
Vadiposity
p2762
sg13
I1
sa(dp2763
g7
I49
sg26
VC0242339
p2764
sg10
I12
sg11
Vdyslipidemia
p2765
sg13
I1
sa(dp2766
g7
I25
sg26
VC0021655
p2767
sg10
I18
sg11
Vinsulin resistance
p2768
sg13
I2
sasa(dp2769
g2
S'Foram avaliados 25 pacientes com diagnostico de DPOC, classificados de acordo com criterios da Global Initiative for Chronic Obstructive Lung Disease, e 25 individuos saudaveis.\n'
p2770
sg4
(lp2771
sg23
(lp2772
(dp2773
g7
I117
sg26
VC0024117
p2774
sg10
I32
sg11
VChronic Obstructive Lung Disease
p2775
sg13
I4
sasa(dp2776
g2
S'The present study examined the involvement of Shh signaling on the disruption of hippocampal neurogenesis in rats with hypothyroidism.\n'
p2777
sg4
(lp2778
(dp2779
g7
I46
sg8
g15
sg10
I3
sg11
VShh
p2780
sg13
I1
sasg23
(lp2781
(dp2782
g7
I119
sg26
VC0020676
p2783
sg10
I14
sg11
Vhypothyroidism
p2784
sg13
I1
sasa(dp2785
g2
S'Developmental hypothyroidism increased Shh(+) neurons bilaterally and abolished the asymmetric distribution pattern on PND 21.\n'
p2786
sg4
(lp2787
sg23
(lp2788
(dp2789
g7
I14
sg26
VC0020676
p2790
sg10
I14
sg11
Vhypothyroidism
p2791
sg13
I1
sa(dp2792
g7
I119
sg26
VC0013405
p2793
sg10
I3
sg11
VPND
p2794
sg13
I1
sasa(dp2795
g2
S'Adult hypothyroidism also disrupted the asymmetric distribution of Mid1(+) cells but did not affect the distribution of Shh(+) hilar neurons.\n'
p2796
sg4
(lp2797
(dp2798
g7
I67
sg8
g15
sg10
I4
sg11
VMid1
p2799
sg13
I1
sa(dp2800
g7
I120
sg8
g15
sg10
I3
sg11
VShh
p2801
sg13
I1
sasg23
(lp2802
(dp2803
g7
I0
sg26
VC0271787
p2804
sg10
I20
sg11
VAdult hypothyroidism
p2805
sg13
I2
sasa(dp2806
g2
S'The results suggest that the hippocampal neurogenesis disruption seen in hypothyroidism involves changes in asymmetric Shh(+) neuron distribution in developmental hypothyroidism and altered Mid1 expression in both developmental and adult-stage hypothyroidism.\n'
p2807
sg4
(lp2808
(dp2809
g7
I190
sg8
g15
sg10
I4
sg11
VMid1
p2810
sg13
I1
sasg23
(lp2811
(dp2812
g7
I73
sg26
VC0020676
p2813
sg10
I14
sg11
Vhypothyroidism
p2814
sg13
I1
sa(dp2815
g7
I73
sg26
VC0020676
p2816
sg10
I14
sg11
Vhypothyroidism
p2817
sg13
I1
sa(dp2818
g7
I73
sg26
VC0020676
p2819
sg10
I14
sg11
Vhypothyroidism
p2820
sg13
I1
sasa(dp2821
g2
S'Moreover, maternal hypothyroxinemia and hypothyroidism reduced expression of the Shh signaling pathway on PN7, PN14, and PN21.\n'
p2822
sg4
(lp2823
(dp2824
g7
I81
sg8
g15
sg10
I3
sg11
VShh
p2825
sg13
I1
sasg23
(lp2826
(dp2827
g7
I40
sg26
VC0020676
p2828
sg10
I14
sg11
Vhypothyroidism
p2829
sg13
I1
sasa(dp2830
g2
S'Our study supports the hypothesis that developmental hypothyroxinemia induced by mild ID, and hypothyroidism induced by severe ID or MMZ, reduce the proliferation of CGNPs, which may be ascribed to the downregulation of the Shh signaling pathway.\n'
p2831
sg4
(lp2832
(dp2833
g7
I224
sg8
g15
sg10
I3
sg11
VShh
p2834
sg13
I1
sasg23
(lp2835
(dp2836
g7
I94
sg26
VC0020676
p2837
sg10
I14
sg11
Vhypothyroidism
p2838
sg13
I1
sa(dp2839
g7
I149
sg26
VC0334094
p2840
sg10
I13
sg11
Vproliferation
p2841
sg13
I1
sasa(dp2842
g2
S'Taken together, these results suggest that Shh expression is related to the morphological cerebellar changes in experimental hypothyroidism and that sustained signaling by Shh may play a key role in normal development, particularly lobulation, in the cerebellum.\n'
p2843
sg4
(lp2844
(dp2845
g7
I43
sg8
g15
sg10
I3
sg11
VShh
p2846
sg13
I1
sa(dp2847
g7
I43
sg8
g15
sg10
I3
sg11
VShh
p2848
sg13
I1
sasg23
(lp2849
(dp2850
g7
I125
sg26
VC0020676
p2851
sg10
I14
sg11
Vhypothyroidism
p2852
sg13
I1
sasa(dp2853
g2
S'Common congenital anomalies associated with SMMCI are: severe to mild intellectual disability, congenital heart disease, cleft lip and/or palate and less frequently, microcephaly, hypopituitarism, hypotelorism, convergent strabismus, oesophageal and duodenal atresia, cervical hemivertebrae, cervical dermoid, hypothyroidism, scoliosis, absent kidney, micropenis and ambiguous genitalia.\n'
p2854
sg4
(lp2855
sg23
(lp2856
(dp2857
g7
I180
sg26
VC0020635
p2858
sg10
I15
sg11
Vhypopituitarism
p2859
sg13
I1
sa(dp2860
g7
I70
sg26
VC0025362
p2861
sg10
I23
sg11
Vintellectual disability
p2862
sg13
I2
sa(dp2863
g7
I166
sg26
VC0025958
p2864
sg10
I12
sg11
Vmicrocephaly
p2865
sg13
I1
sa(dp2866
g7
I250
sg26
VC0266174
p2867
sg10
I16
sg11
Vduodenal atresia
p2868
sg13
I2
sa(dp2869
g7
I121
sg26
VC0008924
p2870
sg10
I9
sg11
Vcleft lip
p2871
sg13
I2
sa(dp2872
g7
I95
sg26
VC0152021
p2873
sg10
I24
sg11
Vcongenital heart disease
p2874
sg13
I3
sa(dp2875
g7
I197
sg26
VC0424711
p2876
sg10
I12
sg11
Vhypotelorism
p2877
sg13
I1
sa(dp2878
g7
I44
sg26
VC1840235
p2879
sg10
I5
sg11
VSMMCI
p2880
sg13
I1
sa(dp2881
g7
I326
sg26
VC0700208
p2882
sg10
I9
sg11
Vscoliosis
p2883
sg13
I1
sa(dp2884
g7
I310
sg26
VC0020676
p2885
sg10
I14
sg11
Vhypothyroidism
p2886
sg13
I1
sa(dp2887
g7
I301
sg26
VC0011649
p2888
sg10
I7
sg11
Vdermoid
p2889
sg13
I1
sa(dp2890
g7
I367
sg26
VC0266362
p2891
sg10
I19
sg11
Vambiguous genitalia
p2892
sg13
I2
sa(dp2893
g7
I7
sg26
VC0000768
p2894
sg10
I20
sg11
Vcongenital anomalies
p2895
sg13
I2
sa(dp2896
g7
I352
sg26
VC0266435
p2897
sg10
I10
sg11
Vmicropenis
p2898
sg13
I1
sa(dp2899
g7
I337
sg26
VC0542519
p2900
sg10
I13
sg11
Vabsent kidney
p2901
sg13
I2
sa(dp2902
g7
I211
sg26
VC0014877
p2903
sg10
I21
sg11
Vconvergent strabismus
p2904
sg13
I2
sasa(dp2905
g2
S'In comparison with normal DNA, tumour DNA of a total of eight patients (seven with germ cell neoplasm and one with testicular lymphoma) showed increased dosages of KRAS2, PDGFA, EGFR, MET and PDGFB.\n'
p2906
sg4
(lp2907
(dp2908
g7
I164
sg8
VP01116
p2909
sg10
I5
sg11
VKRAS2
p2910
sg13
I1
sa(dp2911
g7
I171
sg8
VP04085
p2912
sg10
I5
sg11
VPDGFA
p2913
sg13
I1
sa(dp2914
g7
I192
sg8
VP01127
p2915
sg10
I5
sg11
VPDGFB
p2916
sg13
I1
sasg23
(lp2917
(dp2918
g7
I31
sg26
VC0027651
p2919
sg10
I6
sg11
Vtumour
p2920
sg13
I1
sa(dp2921
g7
I83
sg26
VC0205851
p2922
sg10
I18
sg11
Vgerm cell neoplasm
p2923
sg13
I3
sa(dp2924
g7
I115
sg26
VC0349644
p2925
sg10
I19
sg11
Vtesticular lymphoma
p2926
sg13
I2
sasa(dp2927
g2
S'We have in previous studies found higher CSF concentrations of interleukin-8 (IL-8), monocyte chemoattractant protein 1 (MCP-1/CCL-2), chitinase-3-like protein 1 (CHI3L1/YKL-40), and neurofilament light chain (NF-L) in euthymic patients with bipolar disorder compared with controls.\n'
p2928
sg4
(lp2929
(dp2930
g7
I163
sg8
VP36222
p2931
sg10
I6
sg11
VCHI3L1
p2932
sg13
I1
sa(dp2933
g7
I78
sg8
VP60568
p2934
sg10
I4
sg11
VIL-8
p2935
sg13
I1
sa(dp2936
g7
I135
sg8
VP36222
p2937
sg10
I26
sg11
Vchitinase-3-like protein 1
p2938
sg13
I3
sa(dp2939
g7
I183
sg8
VP07196
p2940
sg10
I25
sg11
Vneurofilament light chain
p2941
sg13
I3
sa(dp2942
g7
I121
sg8
VP41597
p2943
sg10
I5
sg11
VMCP-1
p2944
sg13
I1
sa(dp2945
g7
I210
sg8
VP07196
p2946
sg10
I4
sg11
VNF-L
p2947
sg13
I1
sa(dp2948
g7
I127
sg8
VP43320
p2949
sg10
I5
sg11
VCCL-2
p2950
sg13
I1
sa(dp2951
g7
I63
sg8
VP60568
p2952
sg10
I13
sg11
Vinterleukin-8
p2953
sg13
I1
sasg23
(lp2954
(dp2955
g7
I127
sg26
VC1852438
p2956
sg10
I3
sg11
VCCL
p2957
sg13
I1
sa(dp2958
g7
I242
sg26
VC0005586
p2959
sg10
I16
sg11
Vbipolar disorder
p2960
sg13
I2
sasa(dp2961
g2
S'CSF levels of tryptophan (TRP), KYNA, quinolinic acid (QUIN), interleukin (IL)-6, IL-8 and tumor necrosis factor-alpha (TNF-Alfa) were analyzed in 23 twins with schizophrenia or bipolar disorder, and in their not affected co-twins.\n'
p2962
sg4
(lp2963
(dp2964
g7
I120
sg8
VP01375
p2965
sg10
I8
sg11
VTNF-Alfa
p2966
sg13
I1
sa(dp2967
g7
I91
sg8
VP01375
p2968
sg10
I27
sg11
Vtumor necrosis factor-alpha
p2969
sg13
I3
sa(dp2970
g7
I62
sg8
VP60568
p2971
sg10
I18
sg11
Vinterleukin (IL)-6
p2972
sg13
I2
sasg23
(lp2973
(dp2974
g7
I161
sg26
VC0036341
p2975
sg10
I13
sg11
Vschizophrenia
p2976
sg13
I1
sa(dp2977
g7
I178
sg26
VC0005586
p2978
sg10
I16
sg11
Vbipolar disorder
p2979
sg13
I2
sa(dp2980
g7
I91
sg26
VC0333516
p2981
sg10
I14
sg11
Vtumor necrosis
p2982
sg13
I2
sasa(dp2983
g2
S'However, the functional role of CTHRC1 and its related mechanism in breast cancer still remains unclear.\n'
p2984
sg4
(lp2985
(dp2986
g7
I32
sg8
g15
sg10
I6
sg11
VCTHRC1
p2987
sg13
I1
sasg23
(lp2988
(dp2989
g7
I68
sg26
VC0678222
p2990
sg10
I13
sg11
Vbreast cancer
p2991
sg13
I2
sasa(dp2992
g2
S'CTHRC1 expressions in breast cancer tissues and cells were assessed by qRT-PCR, western blot and immunohistochemistry.\n'
p2993
sg4
(lp2994
(dp2995
g7
I0
sg8
g15
sg10
I6
sg11
VCTHRC1
p2996
sg13
I1
sasg23
(lp2997
(dp2998
g7
I22
sg26
VC0678222
p2999
sg10
I13
sg11
Vbreast cancer
p3000
sg13
I2
sasa(dp3001
g2
S'We found CTHRC1 was frequently up-regulated in human breast cancer cells and tissues.\n'
p3002
sg4
(lp3003
(dp3004
g7
I9
sg8
g15
sg10
I6
sg11
VCTHRC1
p3005
sg13
I1
sasg23
(lp3006
(dp3007
g7
I53
sg26
VC0678222
p3008
sg10
I13
sg11
Vbreast cancer
p3009
sg13
I2
sasa(dp3010
g2
S'Then our cohort study and further meta-analysis validated high expression of CTHRC1 was associated with aggressive clinicopathological features and poor clinical outcome of breast cancer patients.\n'
p3011
sg4
(lp3012
(dp3013
g7
I77
sg8
g15
sg10
I6
sg11
VCTHRC1
p3014
sg13
I1
sasg23
(lp3015
(dp3016
g7
I173
sg26
VC0678222
p3017
sg10
I13
sg11
Vbreast cancer
p3018
sg13
I2
sa(dp3019
g7
I104
sg26
VC0001807
p3020
sg10
I10
sg11
Vaggressive
p3021
sg13
I1
sasa(dp3022
g2
S'In addition, CTHRC1 promoted cell proliferation, invasion and migration and suppressed cell apoptosis in breast cancer, which might be by activating GSK-3Beta/Beta-catenin signaling and inhibiting Bax/Caspase-9/Caspase-3 signaling respectively; and these biological functions of CTHRC1 could be directly negatively regulated by miR-30c.\n'
p3023
sg4
(lp3024
(dp3025
g7
I328
sg8
g15
sg10
I7
sg11
VmiR-30c
p3026
sg13
I1
sa(dp3027
g7
I13
sg8
g15
sg10
I6
sg11
VCTHRC1
p3028
sg13
I1
sa(dp3029
g7
I149
sg8
VP49841
p3030
sg10
I9
sg11
VGSK-3Beta
p3031
sg13
I1
sa(dp3032
g7
I13
sg8
g15
sg10
I6
sg11
VCTHRC1
p3033
sg13
I1
sa(dp3034
g7
I201
sg8
VP55211
p3035
sg10
I9
sg11
VCaspase-9
p3036
sg13
I1
sa(dp3037
g7
I211
sg8
VP42574
p3038
sg10
I9
sg11
VCaspase-3
p3039
sg13
I1
sa(dp3040
g7
I159
sg8
VP35222
p3041
sg10
I12
sg11
VBeta-catenin
p3042
sg13
I1
sasg23
(lp3043
(dp3044
g7
I105
sg26
VC0678222
p3045
sg10
I13
sg11
Vbreast cancer
p3046
sg13
I2
sa(dp3047
g7
I49
sg26
VC2699153
p3048
sg10
I8
sg11
Vinvasion
p3049
sg13
I1
sa(dp3050
g7
I34
sg26
VC0334094
p3051
sg10
I13
sg11
Vproliferation
p3052
sg13
I1
sasa(dp3053
g2
S'Taken together, we identified the role of miR-30c/CTHRC1 axis in breast cancer progression and demonstrated CTHRC1 may serve as a prognostic biomarker and therapeutic target for breast cancer.\n'
p3054
sg4
(lp3055
(dp3056
g7
I50
sg8
g15
sg10
I6
sg11
VCTHRC1
p3057
sg13
I1
sa(dp3058
g7
I42
sg8
g15
sg10
I7
sg11
VmiR-30c
p3059
sg13
I1
sa(dp3060
g7
I50
sg8
g15
sg10
I6
sg11
VCTHRC1
p3061
sg13
I1
sasg23
(lp3062
(dp3063
g7
I65
sg26
VC0678222
p3064
sg10
I13
sg11
Vbreast cancer
p3065
sg13
I2
sa(dp3066
g7
I72
sg26
VC0178874
p3067
sg10
I18
sg11
Vcancer progression
p3068
sg13
I2
sasa(dp3069
g2
S'Collagen triple helix repeat containing 1 (CTHRC1) was identified as a novel gene expressed in the adventitia and neointima on arterial injury and was found to be overexpressed in several malignant tumors, such as breast cancer and malignant melanoma.\n'
p3070
sg4
(lp3071
(dp3072
g7
I43
sg8
g15
sg10
I6
sg11
VCTHRC1
p3073
sg13
I1
sa(dp3074
g7
I0
sg8
g15
sg10
I41
sg11
VCollagen triple helix repeat containing 1
p3075
sg13
I6
sasg23
(lp3076
(dp3077
g7
I188
sg26
VC0006826
p3078
sg10
I16
sg11
Vmalignant tumors
p3079
sg13
I2
sa(dp3080
g7
I214
sg26
VC0678222
p3081
sg10
I13
sg11
Vbreast cancer
p3082
sg13
I2
sa(dp3083
g7
I232
sg26
VC0025202
p3084
sg10
I18
sg11
Vmalignant melanoma
p3085
sg13
I2
sa(dp3086
g7
I114
sg26
VC2936380
p3087
sg10
I9
sg11
Vneointima
p3088
sg13
I1
sasa(dp3089
g2
S'The aim of this research was to clarify the clinicopathologic significance of CTHRC1 expression in human breast cancer.\n'
p3090
sg4
(lp3091
(dp3092
g7
I78
sg8
g15
sg10
I6
sg11
VCTHRC1
p3093
sg13
I1
sasg23
(lp3094
(dp3095
g7
I105
sg26
VC0678222
p3096
sg10
I13
sg11
Vbreast cancer
p3097
sg13
I2
sasa(dp3098
g2
S'22 cases of breast cancer tissues, randomly selected from clinically diagnosed patients, showed a significant increase of CTHRC1 mRNA expression compared to the normal tissue from the same patients using RT-PCR and real-time PCR.\n'
p3099
sg4
(lp3100
(dp3101
g7
I122
sg8
g15
sg10
I11
sg11
VCTHRC1 mRNA
p3102
sg13
I2
sasg23
(lp3103
(dp3104
g7
I12
sg26
VC0678222
p3105
sg10
I13
sg11
Vbreast cancer
p3106
sg13
I2
sasa(dp3107
g2
S'A high level of CTHRC1 expression was observed in 111 (58.7 %) out of 189 breast cancer patients and the expression was significantly correlated with histologic grade (P = 0.026), nodal status (P &lt; 0.001), and TNM pathologic stage (P = 0.002).\n'
p3108
sg4
(lp3109
(dp3110
g7
I16
sg8
g15
sg10
I6
sg11
VCTHRC1
p3111
sg13
I1
sasg23
(lp3112
(dp3113
g7
I74
sg26
VC0678222
p3114
sg10
I13
sg11
Vbreast cancer
p3115
sg13
I2
sasa(dp3116
g2
S'Taken together, the results showed that CTHRC1 over-expression was significantly associated with clinicopathological factors of poor prognosis in invasive ductal carcinoma.\n'
p3117
sg4
(lp3118
(dp3119
g7
I40
sg8
g15
sg10
I6
sg11
VCTHRC1
p3120
sg13
I1
sasg23
(lp3121
(dp3122
g7
I146
sg26
VC1134719
p3123
sg10
I25
sg11
Vinvasive ductal carcinoma
p3124
sg13
I3
sasa(dp3125
g2
S'CTHRC1 could be used as a supplementary prognostic biomarker and a potential therapeutic target in breast cancer.\n'
p3126
sg4
(lp3127
(dp3128
g7
I0
sg8
g15
sg10
I6
sg11
VCTHRC1
p3129
sg13
I1
sasg23
(lp3130
(dp3131
g7
I99
sg26
VC0678222
p3132
sg10
I13
sg11
Vbreast cancer
p3133
sg13
I2
sasa(dp3134
g2
S'CTHRC1 has recently been shown to be expressed in human cancers such as breast cancer and melanoma.\n'
p3135
sg4
(lp3136
(dp3137
g7
I0
sg8
g15
sg10
I6
sg11
VCTHRC1
p3138
sg13
I1
sasg23
(lp3139
(dp3140
g7
I90
sg26
VC0025202
p3141
sg10
I8
sg11
Vmelanoma
p3142
sg13
I1
sa(dp3143
g7
I56
sg26
VC0006826
p3144
sg10
I7
sg11
Vcancers
p3145
sg13
I1
sa(dp3146
g7
I72
sg26
VC0678222
p3147
sg10
I13
sg11
Vbreast cancer
p3148
sg13
I2
sasa(dp3149
g2
S'CTHRC1 has not been studied in breast cancer by immunohistochemistry.\n'
p3150
sg4
(lp3151
(dp3152
g7
I0
sg8
g15
sg10
I6
sg11
VCTHRC1
p3153
sg13
I1
sasg23
(lp3154
(dp3155
g7
I31
sg26
VC0678222
p3156
sg10
I13
sg11
Vbreast cancer
p3157
sg13
I2
sasa(dp3158
g2
S'To examine expression of CTHRC1 together with periostin and versican in breast cancer patients and investigate its association with clinicopathological characteristics.\n'
p3159
sg4
(lp3160
(dp3161
g7
I25
sg8
g15
sg10
I6
sg11
VCTHRC1
p3162
sg13
I1
sasg23
(lp3163
(dp3164
g7
I72
sg26
VC0678222
p3165
sg10
I13
sg11
Vbreast cancer
p3166
sg13
I2
sasa(dp3167
g2
S'Expression of CTHRC1, versican and periostin was significantly higher in breast cancer than in normal tissue or precursor lesions.\n'
p3168
sg4
(lp3169
(dp3170
g7
I14
sg8
g15
sg10
I6
sg11
VCTHRC1
p3171
sg13
I1
sasg23
(lp3172
(dp3173
g7
I73
sg26
VC0678222
p3174
sg10
I13
sg11
Vbreast cancer
p3175
sg13
I2
sasa(dp3176
g2
S'CTHRC1 and periostin play important roles in breast cancer progression.\n'
p3177
sg4
(lp3178
(dp3179
g7
I11
sg8
g15
sg10
I9
sg11
Vperiostin
p3180
sg13
I1
sa(dp3181
g7
I0
sg8
g15
sg10
I6
sg11
VCTHRC1
p3182
sg13
I1
sasg23
(lp3183
(dp3184
g7
I52
sg26
VC0178874
p3185
sg10
I18
sg11
Vcancer progression
p3186
sg13
I2
sasa(dp3187
g2
S'These preliminary results show that combined evaluation of CTHRC1 and periostin could serve as a potential marker for breast cancer bone metastasis; the other observations contribute to the description of the tumour microenvironment, with implications for lymph node and bone metastasis.\n'
p3188
sg4
(lp3189
(dp3190
g7
I70
sg8
g15
sg10
I9
sg11
Vperiostin
p3191
sg13
I1
sa(dp3192
g7
I59
sg8
g15
sg10
I6
sg11
VCTHRC1
p3193
sg13
I1
sasg23
(lp3194
(dp3195
g7
I209
sg26
VC0027651
p3196
sg10
I6
sg11
Vtumour
p3197
sg13
I1
sa(dp3198
g7
I132
sg26
VC0153690
p3199
sg10
I15
sg11
Vbone metastasis
p3200
sg13
I2
sa(dp3201
g7
I118
sg26
VC0678222
p3202
sg10
I13
sg11
Vbreast cancer
p3203
sg13
I2
sa(dp3204
g7
I132
sg26
VC0153690
p3205
sg10
I15
sg11
Vbone metastasis
p3206
sg13
I2
sasa(dp3207
g2
S'Cthrc1 has also been shown to be highly active and potent in degrading extracellular matrix proteins and was found to be overexpressed in several malignant tumours, such as breast cancer and malignant melanoma.\n'
p3208
sg4
(lp3209
(dp3210
g7
I0
sg8
g15
sg10
I6
sg11
VCthrc1
p3211
sg13
I1
sasg23
(lp3212
(dp3213
g7
I146
sg26
VC0006826
p3214
sg10
I17
sg11
Vmalignant tumours
p3215
sg13
I2
sa(dp3216
g7
I173
sg26
VC0678222
p3217
sg10
I13
sg11
Vbreast cancer
p3218
sg13
I2
sa(dp3219
g7
I191
sg26
VC0025202
p3220
sg10
I18
sg11
Vmalignant melanoma
p3221
sg13
I2
sasa(dp3222
g2
S'Replication extended to the following polymorphisms: PKN2 (rs305217), GTF2B (rs7538427), EPHA4 (rs1517440), YTHDF3 (rs12115114), ANKFN1 (rs17758761) and PTPRM (rs4798571), which did not reach the threshold of significance in a follow-up of the first genome-wide association study (GWAS) conducted in multiple sclerosis; TMEM39A (rs1132200), which appeared as a newly identified susceptibility gene in the same study; a gene previously reaching GWAS significance in Italy, CBLB (rs9657904); IL12B (rs6887695, rs10045431), a susceptibility gene shared by diverse autoimmune diseases and, finally, another gene showing inconclusive association with multiple sclerosis, CNR1 (rs1049353).\n'
p3223
sg4
(lp3224
(dp3225
g7
I70
sg8
g15
sg10
I5
sg11
VGTF2B
p3226
sg13
I1
sa(dp3227
g7
I53
sg8
g15
sg10
I4
sg11
VPKN2
p3228
sg13
I1
sa(dp3229
g7
I129
sg8
g15
sg10
I6
sg11
VANKFN1
p3230
sg13
I1
sa(dp3231
g7
I490
sg8
VP29460
p3232
sg10
I5
sg11
VIL12B
p3233
sg13
I1
sa(dp3234
g7
I666
sg8
g15
sg10
I4
sg11
VCNR1
p3235
sg13
I1
sa(dp3236
g7
I153
sg8
VP28827
p3237
sg10
I5
sg11
VPTPRM
p3238
sg13
I1
sa(dp3239
g7
I108
sg8
g15
sg10
I19
sg11
VYTHDF3 (rs12115114)
p3240
sg13
I2
sa(dp3241
g7
I89
sg8
VP54764
p3242
sg10
I5
sg11
VEPHA4
p3243
sg13
I1
sasg23
(lp3244
(dp3245
g7
I300
sg26
VC0026769
p3246
sg10
I18
sg11
Vmultiple sclerosis
p3247
sg13
I2
sa(dp3248
g7
I561
sg26
VC0004364
p3249
sg10
I19
sg11
Vautoimmune diseases
p3250
sg13
I2
sa(dp3251
g7
I300
sg26
VC0026769
p3252
sg10
I18
sg11
Vmultiple sclerosis
p3253
sg13
I2
sasa(dp3254
g2
S'In conclusion, our present study showed that MAGE-C1/CT7, SSX1, SSX2 and SSX4 were co-expressed in MM cell lines and the primary myeloma cells in MM patients, but not expressed in BM cells of healthy subjects.\n'
p3255
sg4
(lp3256
(dp3257
g7
I58
sg8
g15
sg10
I4
sg11
VSSX1
p3258
sg13
I1
sa(dp3259
g7
I73
sg8
g15
sg10
I4
sg11
VSSX4
p3260
sg13
I1
sa(dp3261
g7
I45
sg8
VP43355
p3262
sg10
I4
sg11
VMAGE
p3263
sg13
I1
sa(dp3264
g7
I64
sg8
g15
sg10
I4
sg11
VSSX2
p3265
sg13
I1
sa(dp3266
g7
I53
sg8
g15
sg10
I3
sg11
VCT7
p3267
sg13
I1
sasg23
(lp3268
(dp3269
g7
I129
sg26
VC0026764
p3270
sg10
I7
sg11
Vmyeloma
p3271
sg13
I1
sasa(dp3272
g2
S'Using the current tissue collection and 5-fold cross validation, the four most significant loci (CDKN2A EX2, CDX2, HOXA1 and OPCML) individually distinguish lung adenocarcinoma from non-cancer lung with a sensitivity of 67-86% and specificity of 74-82%.\n'
p3273
sg4
(lp3274
(dp3275
g7
I125
sg8
g15
sg10
I5
sg11
VOPCML
p3276
sg13
I1
sa(dp3277
g7
I109
sg8
g15
sg10
I4
sg11
VCDX2
p3278
sg13
I1
sa(dp3279
g7
I115
sg8
VP49639
p3280
sg10
I5
sg11
VHOXA1
p3281
sg13
I1
sa(dp3282
g7
I97
sg8
VP42771
p3283
sg10
I10
sg11
VCDKN2A EX2
p3284
sg13
I2
sasg23
(lp3285
(dp3286
g7
I157
sg26
VC0152013
p3287
sg10
I19
sg11
Vlung adenocarcinoma
p3288
sg13
I2
sa(dp3289
g7
I186
sg26
VC0006826
p3290
sg10
I6
sg11
Vcancer
p3291
sg13
I1
sasa(dp3292
g2
S'The four most highly ranked loci, CDKN2A EX2, CDX2, HOXA1 and OPCML, which show significant DNA methylation even in stage IA tumor samples, merit further investigation as some of the most promising lung adenocarcinoma markers identified to date.\n'
p3293
sg4
(lp3294
(dp3295
g7
I52
sg8
VP49639
p3296
sg10
I5
sg11
VHOXA1
p3297
sg13
I1
sa(dp3298
g7
I46
sg8
g15
sg10
I4
sg11
VCDX2
p3299
sg13
I1
sa(dp3300
g7
I62
sg8
g15
sg10
I5
sg11
VOPCML
p3301
sg13
I1
sa(dp3302
g7
I34
sg8
VP42771
p3303
sg10
I10
sg11
VCDKN2A EX2
p3304
sg13
I2
sasg23
(lp3305
(dp3306
g7
I125
sg26
VC0027651
p3307
sg10
I5
sg11
Vtumor
p3308
sg13
I1
sa(dp3309
g7
I198
sg26
VC0152013
p3310
sg10
I19
sg11
Vlung adenocarcinoma
p3311
sg13
I2
sasa(dp3312
g2
S'We used a range of approaches for the treatment of 123 patients with chronic cholecystitis and concomitant gallbladder dysfunction plus opisthorchiasis including extremely high-frequency electromagnetic irradiation (EHF therapy) in the combination with the oral intake of the choleretic herbal remedies followed by the transverse galvanization of the epigastric region with due regard for the phase of the rhythm of the functional activity of the gallbladder.\n'
p3313
sg4
(lp3314
sg23
(lp3315
(dp3316
g7
I69
sg26
VC0085694
p3317
sg10
I21
sg11
Vchronic cholecystitis
p3318
sg13
I2
sa(dp3319
g7
I107
sg26
VC0232769
p3320
sg10
I23
sg11
Vgallbladder dysfunction
p3321
sg13
I2
sa(dp3322
g7
I136
sg26
VC0029106
p3323
sg10
I15
sg11
Vopisthorchiasis
p3324
sg13
I1
sasa(dp3325
g2
S'It guarantees (is a predictor) receiving of high therapeutic effect (Percent Concordant of = 86.4%; the standardized coefficient = 2.54; r = 0.001) of the complex treatment including EHF-therapy with use of chronobiological approach to treatment of patients with chronic cholecystitis in combination with a chronic opisthorchiasis.\n'
p3326
sg4
(lp3327
sg23
(lp3328
(dp3329
g7
I263
sg26
VC0085694
p3330
sg10
I21
sg11
Vchronic cholecystitis
p3331
sg13
I2
sa(dp3332
g7
I315
sg26
VC0029106
p3333
sg10
I15
sg11
Vopisthorchiasis
p3334
sg13
I1
sasa(dp3335
g2
S"Abbreviations used: ACN: Acetonitrile, ANOVA: One-way analysis of variance, BrdU: Bromodeoxyuridine, 13C-NMR: Carbon-13 Nuclear magnetic resonance, CAD: Caspase-activated endonuclease, CCD-18Co: Human colon normal, DLD1: Human Duke's type C colorectal adenocarcinoma, DMRT: Duncan's multiple range test, DMSO: Dimethyl sulfoxide, DNA: Deoxyribonucleic acid, DR4/5: Death receptor 4/5 protein, EMEM: Eagle's minimum essential media, FBS: Fetal bovine serum, FITC Annexin V: Annexin V conjugated with fluorescein isothiocyanate, FITC-DEVD-FMK: Fluorescein isothiocyanate conjugate of caspase inhibitor Asp-Glu-Val-Asp-fluoromethyl ketone, FITC-IETD-FMK: Fluorescein isothiocyanate conjugate of caspase inhibitor Ile-Glu-Thr-Asp-fluoromethyl ketone, FITC-LEHD-FMK: Fluorescein isothiocyanate conjugate of caspase inhibitor Leu-Glu-His-Asp-fluoromethyl ketone, G0: Quiescent phase of cell cycle, G1: Gap 1 phase of cell cycle, G2: Gap 2 phase of cell cycle, GC-MS: Gas chromatography-mass spectrometry, HeLa: Human cervical adenocarcinoma, HPLC: High performance liquid chromatography, HT29: Human colon adenocarcinoma, Huh7.5: Human hepatocellular carcinoma, IC50: Half maximal inhibitory concentration, KSHV: Kaposi's sarcoma-associated herpesvirus, M phase: Mitotic phase of cell cycle, MCF7: Human breast adenocarcinoma, NMR: Nuclear magnetic resonance, PBS: Phosphate-buffered saline, PI: Propidium iodide, RNase: Ribonuclease, rt: Retention time, S phase: Synthesis phase of cell cycle, SD: Standard deviation, SRB: Sulforhodamine B, TCA: Trichloroacetic acid, TLC: Thin layer chromatography, TNF-R1: Tumor necrosis factor receptor 1 protein, TUNEL: Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling, UV: Ultraviolet.\n"
p3336
sg4
(lp3337
(dp3338
g7
I1518
sg8
g15
sg10
I16
sg11
VSulforhodamine B
p3339
sg13
I2
sa(dp3340
g7
I582
sg8
VP39880
p3341
sg10
I7
sg11
Vcaspase
p3342
sg13
I1
sa(dp3343
g7
I1652
sg8
VP04053
p3344
sg10
I37
sg11
VTerminal deoxynucleotidyl transferase
p3345
sg13
I3
sa(dp3346
g7
I1408
sg8
VP07998
p3347
sg10
I5
sg11
VRNase
p3348
sg13
I1
sa(dp3349
g7
I582
sg8
VP39880
p3350
sg10
I7
sg11
Vcaspase
p3351
sg13
I1
sa(dp3352
g7
I1088
sg8
g15
sg10
I34
sg11
VHuman colon adenocarcinoma, Huh7.5
p3353
sg13
I4
sa(dp3354
g7
I185
sg8
VP21817
p3355
sg10
I8
sg11
VCCD-18Co
p3356
sg13
I1
sa(dp3357
g7
I195
sg8
g15
sg10
I24
sg11
VHuman colon normal, DLD1
p3358
sg13
I4
sa(dp3359
g7
I1603
sg8
VP01375
p3360
sg10
I40
sg11
VTumor necrosis factor receptor 1 protein
p3361
sg13
I6
sa(dp3362
g7
I148
sg8
g15
sg10
I3
sg11
VCAD
p3363
sg13
I1
sa(dp3364
g7
I1691
sg8
VP04053
p3365
sg10
I3
sg11
VTdT
p3366
sg13
I1
sa(dp3367
g7
I457
sg8
VP08758
p3368
sg10
I25
sg11
VFITC Annexin V: Annexin V
p3369
sg13
I5
sa(dp3370
g7
I1595
sg8
VP01375
p3371
sg10
I6
sg11
VTNF-R1
p3372
sg13
I1
sa(dp3373
g7
I365
sg8
g15
sg10
I26
sg11
VDeath receptor 4/5 protein
p3374
sg13
I4
sa(dp3375
g7
I582
sg8
VP39880
p3376
sg10
I7
sg11
Vcaspase
p3377
sg13
I1
sa(dp3378
g7
I1513
sg8
VP50991
p3379
sg10
I3
sg11
VSRB
p3380
sg13
I1
sa(dp3381
g7
I153
sg8
VP39748
p3382
sg10
I30
sg11
VCaspase-activated endonuclease
p3383
sg13
I2
sa(dp3384
g7
I358
sg8
g15
sg10
I5
sg11
VDR4/5
p3385
sg13
I1
sasg23
(lp3386
(dp3387
g7
I1354
sg26
VC1720830
p3388
sg10
I3
sg11
VPBS
p3389
sg13
I1
sa(dp3390
g7
I432
sg26
VC0015624
p3391
sg10
I3
sg11
VFBS
p3392
sg13
I1
sa(dp3393
g7
I1011
sg26
VC0279672
p3394
sg10
I23
sg11
Vcervical adenocarcinoma
p3395
sg13
I2
sa(dp3396
g7
I1207
sg26
VC0036220
p3397
sg10
I16
sg11
VKaposi's sarcoma
p3398
sg13
I2
sa(dp3399
g7
I20
sg26
VC1136042
p3400
sg10
I3
sg11
VACN
p3401
sg13
I1
sa(dp3402
g7
I1603
sg26
VC0333516
p3403
sg10
I14
sg11
VTumor necrosis
p3404
sg13
I2
sa(dp3405
g7
I148
sg26
VC0010054
p3406
sg10
I3
sg11
VCAD
p3407
sg13
I1
sa(dp3408
g7
I185
sg26
VC0008928
p3409
sg10
I3
sg11
VCCD
p3410
sg13
I1
sa(dp3411
g7
I241
sg26
VC1319315
p3412
sg10
I25
sg11
Vcolorectal adenocarcinoma
p3413
sg13
I2
sa(dp3414
g7
I1130
sg26
VC1512411
p3415
sg10
I24
sg11
Vhepatocellular carcinoma
p3416
sg13
I2
sa(dp3417
g7
I1298
sg26
VC0858252
p3418
sg10
I21
sg11
Vbreast adenocarcinoma
p3419
sg13
I2
sa(dp3420
g7
I1094
sg26
VC0338106
p3421
sg10
I20
sg11
Vcolon adenocarcinoma
p3422
sg13
I2
sasa(dp3423
g2
S'The compounds preferentially inhibited the proliferation of T-lymphoma CEM and Molt/4, prostate PC-3, kidney Caki-1 and hepatoma Huh-7 tumor cells, but were virtually inactive against other tumor cell lines including B-lymphoma Raji and cervix carcinoma HeLa cells.\n'
p3424
sg4
(lp3425
(dp3426
g7
I87
sg8
VP49221
p3427
sg10
I13
sg11
Vprostate PC-3
p3428
sg13
I2
sa(dp3429
g7
I79
sg8
g15
sg10
I6
sg11
VMolt/4
p3430
sg13
I1
sasg23
(lp3431
(dp3432
g7
I43
sg26
VC0334094
p3433
sg10
I13
sg11
Vproliferation
p3434
sg13
I1
sa(dp3435
g7
I62
sg26
VC0024299
p3436
sg10
I8
sg11
Vlymphoma
p3437
sg13
I1
sa(dp3438
g7
I135
sg26
VC0027651
p3439
sg10
I5
sg11
Vtumor
p3440
sg13
I1
sa(dp3441
g7
I135
sg26
VC0027651
p3442
sg10
I5
sg11
Vtumor
p3443
sg13
I1
sa(dp3444
g7
I71
sg26
VC0276037
p3445
sg10
I3
sg11
VCEM
p3446
sg13
I1
sa(dp3447
g7
I62
sg26
VC0024299
p3448
sg10
I8
sg11
Vlymphoma
p3449
sg13
I1
sa(dp3450
g7
I120
sg26
VC0023903
p3451
sg10
I8
sg11
Vhepatoma
p3452
sg13
I1
sa(dp3453
g7
I237
sg26
VC0302592
p3454
sg10
I16
sg11
Vcervix carcinoma
p3455
sg13
I2
sasa(dp3456
g2
S'MAN2A1-FER was also overexpressed in PC3 or DU145 (prostate cancer), NIH3T3 (fibroblast), H23 (lung cancer), and A-172 (glioblastoma multiforme) cell lines and knocked out in HUH7 (liver cancer) cells.\n'
p3457
sg4
(lp3458
(dp3459
g7
I7
sg8
VP10109
p3460
sg10
I3
sg11
VFER
p3461
sg13
I1
sa(dp3462
g7
I0
sg8
g15
sg10
I6
sg11
VMAN2A1
p3463
sg13
I1
sasg23
(lp3464
(dp3465
g7
I120
sg26
VC1621958
p3466
sg10
I23
sg11
Vglioblastoma multiforme
p3467
sg13
I2
sa(dp3468
g7
I95
sg26
VC0684249
p3469
sg10
I11
sg11
Vlung cancer
p3470
sg13
I2
sa(dp3471
g7
I181
sg26
VC0345904
p3472
sg10
I12
sg11
Vliver cancer
p3473
sg13
I2
sa(dp3474
g7
I51
sg26
VC0600139
p3475
sg10
I15
sg11
Vprostate cancer
p3476
sg13
I2
sasa(dp3477
g2
S'Embelin strongly inhibited cell growth especially in human prostate cancer cell lines, including PC3, DU145, LNCaP-LN3 and normal prostate epithelial cell, RWPE-1 compared to breast cancer (MDA-MB-231, MCF-7, and T47D), hepatoma (HepG2, Hep3B, and HuH-7), or choriocarcinoma (JEG-3).\n'
p3478
sg4
(lp3479
(dp3480
g7
I97
sg8
VP42025
p3481
sg10
I3
sg11
VPC3
p3482
sg13
I1
sasg23
(lp3483
(dp3484
g7
I259
sg26
VC0008497
p3485
sg10
I15
sg11
Vchoriocarcinoma
p3486
sg13
I1
sa(dp3487
g7
I220
sg26
VC0023903
p3488
sg10
I8
sg11
Vhepatoma
p3489
sg13
I1
sa(dp3490
g7
I59
sg26
VC0600139
p3491
sg10
I15
sg11
Vprostate cancer
p3492
sg13
I2
sa(dp3493
g7
I175
sg26
VC0678222
p3494
sg10
I13
sg11
Vbreast cancer
p3495
sg13
I2
sasa(dp3496
g2
S'Objective  To study the phenotype and overview the clinical management on Cleft Lip and/or Palate (CL/P) with Nevoid Basal Cell Carcinoma Syndrome (NBCCS) patients in Peking University School and Hospital of Stomatology.\n'
p3497
sg4
(lp3498
sg23
(lp3499
(dp3500
g7
I74
sg26
VC0008924
p3501
sg10
I9
sg11
VCleft Lip
p3502
sg13
I2
sa(dp3503
g7
I110
sg26
VC0004779
p3504
sg10
I36
sg11
VNevoid Basal Cell Carcinoma Syndrome
p3505
sg13
I5
sa(dp3506
g7
I148
sg26
VC0004779
p3507
sg10
I5
sg11
VNBCCS
p3508
sg13
I1
sasa(dp3509
g2
S'Mice carrying compound mutations in hedgehog acyltransferase (Hhat) and patched1 (Ptch1) exhibited perturbations in the SHH gradient during frontonasal development, which led to hypoplastic nasal process outgrowth, epithelial seam persistence, and cleft lip.\n'
p3510
sg4
(lp3511
(dp3512
g7
I36
sg8
g15
sg10
I24
sg11
Vhedgehog acyltransferase
p3513
sg13
I2
sa(dp3514
g7
I62
sg8
g15
sg10
I4
sg11
VHhat
p3515
sg13
I1
sa(dp3516
g7
I82
sg8
g15
sg10
I5
sg11
VPtch1
p3517
sg13
I1
sa(dp3518
g7
I72
sg8
g15
sg10
I8
sg11
Vpatched1
p3519
sg13
I1
sasg23
(lp3520
(dp3521
g7
I248
sg26
VC0008924
p3522
sg10
I9
sg11
Vcleft lip
p3523
sg13
I2
sasa(dp3524
g2
S'Nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant or spontaneous disorder characterized by multiple cutaneous basal cell carcinomas, odontogenic keratocysts, skeletal anomalies and facial dysmorphology, including cleft lip and palate.\n'
p3525
sg4
(lp3526
sg23
(lp3527
(dp3528
g7
I0
sg26
VC0004779
p3529
sg10
I36
sg11
VNevoid basal cell carcinoma syndrome
p3530
sg13
I5
sa(dp3531
g7
I130
sg26
VC0007117
p3532
sg10
I21
sg11
Vbasal cell carcinomas
p3533
sg13
I3
sa(dp3534
g7
I165
sg26
VC0341038
p3535
sg10
I11
sg11
Vkeratocysts
p3536
sg13
I1
sa(dp3537
g7
I38
sg26
VC0004779
p3538
sg10
I5
sg11
VNBCCS
p3539
sg13
I1
sa(dp3540
g7
I233
sg26
VC0158646
p3541
sg10
I20
sg11
Vcleft lip and palate
p3542
sg13
I4
sasa(dp3543
g2
S'Holoprosencephaly is addressed under the following headings: alobar, semilobar, and lobar holoprosencephaly; arrhinencephaly; agenesis of the corpus callosum; pituitary abnormalities; hindbrain abnormalities; syntelencephaly; aprosencephaly/atelencephaly; neural tube defects; facial anomalies; median cleft lip; minor facial anomalies; single maxillary central incisor; holoprosencephaly-like phenotype; epidemiology; genetic causes of holoprosencephaly; teratogenic causes of holoprosencephaly; SHH mutations; ZIC2 mutations; SIX3 mutations; TGIF mutations; PTCH mutations; GLI2 mutations; FAST1 mutations; TDGF1 mutations; and DHCR7 mutations.\n'
p3544
sg4
(lp3545
(dp3546
g7
I560
sg8
g15
sg10
I14
sg11
VPTCH mutations
p3547
sg13
I2
sa(dp3548
g7
I630
sg8
g15
sg10
I5
sg11
VDHCR7
p3549
sg13
I1
sa(dp3550
g7
I512
sg8
g15
sg10
I14
sg11
VZIC2 mutations
p3551
sg13
I2
sa(dp3552
g7
I497
sg8
g15
sg10
I13
sg11
VSHH mutations
p3553
sg13
I2
sa(dp3554
g7
I576
sg8
VP10070
p3555
sg10
I14
sg11
VGLI2 mutations
p3556
sg13
I2
sa(dp3557
g7
I544
sg8
VP22301
p3558
sg10
I14
sg11
VTGIF mutations
p3559
sg13
I2
sa(dp3560
g7
I592
sg8
g15
sg10
I15
sg11
VFAST1 mutations
p3561
sg13
I2
sa(dp3562
g7
I609
sg8
VP13385
p3563
sg10
I15
sg11
VTDGF1 mutations
p3564
sg13
I2
sa(dp3565
g7
I528
sg8
g15
sg10
I14
sg11
VSIX3 mutations
p3566
sg13
I2
sasg23
(lp3567
(dp3568
g7
I109
sg26
VC0078982
p3569
sg10
I15
sg11
Varrhinencephaly
p3570
sg13
I1
sa(dp3571
g7
I0
sg26
VC0079541
p3572
sg10
I17
sg11
VHoloprosencephaly
p3573
sg13
I1
sa(dp3574
g7
I126
sg26
VC0175754
p3575
sg10
I31
sg11
Vagenesis of the corpus callosum
p3576
sg13
I5
sa(dp3577
g7
I90
sg26
VC0079541
p3578
sg10
I17
sg11
Vholoprosencephaly
p3579
sg13
I1
sa(dp3580
g7
I90
sg26
VC0079541
p3581
sg10
I17
sg11
Vholoprosencephaly
p3582
sg13
I1
sa(dp3583
g7
I241
sg26
VC0431348
p3584
sg10
I13
sg11
Vatelencephaly
p3585
sg13
I1
sa(dp3586
g7
I90
sg26
VC0079541
p3587
sg10
I17
sg11
Vholoprosencephaly
p3588
sg13
I1
sa(dp3589
g7
I226
sg26
VC0431349
p3590
sg10
I14
sg11
Vaprosencephaly
p3591
sg13
I1
sa(dp3592
g7
I295
sg26
VC1850256
p3593
sg10
I16
sg11
Vmedian cleft lip
p3594
sg13
I3
sa(dp3595
g7
I337
sg26
VC1840235
p3596
sg10
I32
sg11
Vsingle maxillary central incisor
p3597
sg13
I4
sa(dp3598
g7
I84
sg26
VC0431362
p3599
sg10
I23
sg11
Vlobar holoprosencephaly
p3600
sg13
I2
sasa(dp3601
g2
S'Markers of the different classes obtained were found associated with the two resistance loci, PcA and R-284B-2, mapped on Asw, and with five out of eight QTLs for partial resistance in the MN map.\n'
p3602
sg4
(lp3603
(dp3604
g7
I94
sg8
g15
sg10
I3
sg11
VPcA
p3605
sg13
I1
sasg23
(lp3606
(dp3607
g7
I94
sg26
VC0268398
p3608
sg10
I3
sg11
VPcA
p3609
sg13
I1
sasa(dp3610
g2
S'In this study, the RGAs were mapped in two recombinant inbred line (RIL) populations that segregate for crown rust resistance: the diploid Avena strigosa x Avena wiestii RIL population (Asw), which has been used for mapping the complex locus PcA, and the hexaploid MN841801-1 x Noble-2 RIL population (MN), in which QTLs have been located.\n'
p3611
sg4
(lp3612
(dp3613
g7
I242
sg8
g15
sg10
I3
sg11
VPcA
p3614
sg13
I1
sasg23
(lp3615
(dp3616
g7
I110
sg26
VC1321554
p3617
sg10
I4
sg11
Vrust
p3618
sg13
I1
sa(dp3619
g7
I242
sg26
VC0268398
p3620
sg10
I3
sg11
VPcA
p3621
sg13
I1
sasa(dp3622
g2
S'Markers based on RGA L7M2 co-localized with markers defining the QTL Prq1a in linkage group MN3, and were located 15.2 cM from PcA in linkage group AswAC.\n'
p3623
sg4
(lp3624
(dp3625
g7
I127
sg8
g15
sg10
I3
sg11
VPcA
p3626
sg13
I1
sasg23
(lp3627
(dp3628
g7
I127
sg26
VC0268398
p3629
sg10
I3
sg11
VPcA
p3630
sg13
I1
sasa(dp3631
g2
S'The SCAR marker for Pc94 was also located in the QTL Prq1a but at 39.5 cM from PcA in AswAC, indicating that the NBS-LRR sequence represented by this marker is not related to PcA.\n'
p3632
sg4
(lp3633
(dp3634
g7
I4
sg8
VP62701
p3635
sg10
I4
sg11
VSCAR
p3636
sg13
I1
sa(dp3637
g7
I79
sg8
g15
sg10
I3
sg11
VPcA
p3638
sg13
I1
sa(dp3639
g7
I79
sg8
g15
sg10
I12
sg11
VPcA in AswAC
p3640
sg13
I3
sasg23
(lp3641
(dp3642
g7
I4
sg26
VC2004491
p3643
sg10
I4
sg11
VSCAR
p3644
sg13
I1
sa(dp3645
g7
I79
sg26
VC0268398
p3646
sg10
I3
sg11
VPcA
p3647
sg13
I1
sa(dp3648
g7
I113
sg26
VC0398791
p3649
sg10
I3
sg11
VNBS
p3650
sg13
I1
sa(dp3651
g7
I79
sg26
VC0268398
p3652
sg10
I3
sg11
VPcA
p3653
sg13
I1
sasa(dp3654
g2
S'The dissociation of the approximately 3500-kDa hexagonal bilayer (HBL) hemoglobin (Hb) of Lumbricus terrestris upon exposure to Gdm salts, urea and the heteropolytungstates [SiW11O39]8- (SiW), [NaSb9W21O86]18- (SbW) and [BaAs4W40O140]27- (AsW) at neutral pH was followed by gel filtration, SDS-polyacrylamide gel electrophoresis, and scanning transmission electron microscopy.\n'
p3655
sg4
(lp3656
(dp3657
g7
I47
sg8
VP09382
p3658
sg10
I17
sg11
Vhexagonal bilayer
p3659
sg13
I2
sa(dp3660
g7
I66
sg8
VP09382
p3661
sg10
I3
sg11
VHBL
p3662
sg13
I1
sa(dp3663
g7
I83
sg8
g15
sg10
I2
sg11
VHb
p3664
sg13
I1
sa(dp3665
g7
I71
sg8
g15
sg10
I10
sg11
Vhemoglobin
p3666
sg13
I1
sasg23
(lp3667
(dp3668
g7
I290
sg26
VC0272170
p3669
sg10
I3
sg11
VSDS
p3670
sg13
I1
sa(dp3671
g7
I128
sg26
VC0085207
p3672
sg10
I3
sg11
VGdm
p3673
sg13
I1
sa(dp3674
g7
I4
sg26
VC0086168
p3675
sg10
I12
sg11
Vdissociation
p3676
sg13
I1
sasa(dp3677
g2
S'OxyHb dissociation decreased in the order Gdm*SCN &gt; Gdm.Cl &gt; urea &gt; Gdm.OAc and AsW &gt; SbW &gt; SiW.\n'
p3678
sg4
(lp3679
sg23
(lp3680
(dp3681
g7
I42
sg26
VC0085207
p3682
sg10
I3
sg11
VGdm
p3683
sg13
I1
sa(dp3684
g7
I42
sg26
VC0085207
p3685
sg10
I3
sg11
VGdm
p3686
sg13
I1
sa(dp3687
g7
I6
sg26
VC0086168
p3688
sg10
I12
sg11
Vdissociation
p3689
sg13
I1
sasa(dp3690
g2
S'However, whether melatonin could exert its neuroprotective function against soluble ABeta1-42-induced neurotoxicity during AD development through regulating Reelin-Dab1 signaling remains poorly understood.\n'
p3691
sg4
(lp3692
(dp3693
g7
I164
sg8
g15
sg10
I4
sg11
VDab1
p3694
sg13
I1
sa(dp3695
g7
I157
sg8
VP78509
p3696
sg10
I6
sg11
VReelin
p3697
sg13
I1
sasg23
(lp3698
sa(dp3699
g2
S'Using in vitro study, Reelin inactivation completely abolished the protective effect of melatonin against ABeta1-42-induced neurotoxicity.\n'
p3700
sg4
(lp3701
sg23
(lp3702
(dp3703
g7
I29
sg26
VC0544461
p3704
sg10
I12
sg11
Vinactivation
p3705
sg13
I1
sasa(dp3706
g2
S'Although RELN is associated with neurodevelopment and neurological diseases, it represents a previously uncharacterized target for developmental Pb neurotoxicity.\n'
p3707
sg4
(lp3708
sg23
(lp3709
sa(dp3710
g2
S'The increased risk of DCI in people with migraine with aura is because migraine with aura is also associated with right-to-left shunts and this increased risk of DCI appears to be confi ned to those with a large PFO or other large shunt.\n'
p3711
sg4
(lp3712
sg23
(lp3713
(dp3714
g7
I22
sg26
VC0007124
p3715
sg10
I3
sg11
VDCI
p3716
sg13
I1
sa(dp3717
g7
I22
sg26
VC0007124
p3718
sg10
I3
sg11
VDCI
p3719
sg13
I1
sa(dp3720
g7
I41
sg26
VC0154723
p3721
sg10
I18
sg11
Vmigraine with aura
p3722
sg13
I3
sa(dp3723
g7
I41
sg26
VC0154723
p3724
sg10
I18
sg11
Vmigraine with aura
p3725
sg13
I3
sasa(dp3726
g2
S'As opposed to patients with thrombotic disease and migraine, divers can choose to reduce DCI risk.\n'
p3727
sg4
(lp3728
sg23
(lp3729
(dp3730
g7
I51
sg26
VC0149931
p3731
sg10
I8
sg11
Vmigraine
p3732
sg13
I1
sa(dp3733
g7
I89
sg26
VC0007124
p3734
sg10
I3
sg11
VDCI
p3735
sg13
I1
sasa(dp3736
g2
S"We conducted a multicenter randomized, placebo-controlled double-blind parallel-group study in Japanese Parkinson's disease (PD) patients with wearing-off motor fluctuations to determine the clinical efficacy and safety of entacapone as an adjunct to concomitant treatment with levodopa and a dopa decarboxylase inhibitor (DCI).\n"
p3737
sg4
(lp3738
(dp3739
g7
I323
sg8
VP42126
p3740
sg10
I3
sg11
VDCI
p3741
sg13
I1
sa(dp3742
g7
I293
sg8
VP20711
p3743
sg10
I28
sg11
Vdopa decarboxylase inhibitor
p3744
sg13
I3
sasg23
(lp3745
(dp3746
g7
I104
sg26
VC0030567
p3747
sg10
I19
sg11
VParkinson's disease
p3748
sg13
I2
sa(dp3749
g7
I323
sg26
VC0007124
p3750
sg10
I3
sg11
VDCI
p3751
sg13
I1
sa(dp3752
g7
I65
sg26
VC0456909
p3753
sg10
I5
sg11
Vblind
p3754
sg13
I1
sa(dp3755
g7
I298
sg26
VC0007124
p3756
sg10
I23
sg11
Vdecarboxylase inhibitor
p3757
sg13
I2
sa(dp3758
g7
I161
sg26
VC0231239
p3759
sg10
I12
sg11
Vfluctuations
p3760
sg13
I1
sa(dp3761
g7
I125
sg26
VC0030567
p3762
sg10
I2
sg11
VPD
p3763
sg13
I1
sasa(dp3764
g2
S"In the treatment of Parkinson's disease, levodopa, DCI, MAO-B inhibitor, COMT inhibitors, dopamine receptor agonists, amantadine, anticholinergics have been applied and new drugs are being developed.\n"
p3765
sg4
(lp3766
(dp3767
g7
I51
sg8
VP42126
p3768
sg10
I3
sg11
VDCI
p3769
sg13
I1
sa(dp3770
g7
I56
sg8
VP27338
p3771
sg10
I5
sg11
VMAO-B
p3772
sg13
I1
sa(dp3773
g7
I73
sg8
VP21964
p3774
sg10
I4
sg11
VCOMT
p3775
sg13
I1
sa(dp3776
g7
I90
sg8
g15
sg10
I17
sg11
Vdopamine receptor
p3777
sg13
I2
sasg23
(lp3778
(dp3779
g7
I51
sg26
VC0007124
p3780
sg10
I3
sg11
VDCI
p3781
sg13
I1
sa(dp3782
g7
I20
sg26
VC0030567
p3783
sg10
I19
sg11
VParkinson's disease
p3784
sg13
I2
sasa(dp3785
g2
S'High ADAMTS-7 levels are associated with acute myocardial infarction (AMI), although its involvement in ventricular remodeling is unclear.\n'
p3786
sg4
(lp3787
sg23
(lp3788
(dp3789
g7
I70
sg26
VC0155626
p3790
sg10
I3
sg11
VAMI
p3791
sg13
I1
sa(dp3792
g7
I41
sg26
VC0155626
p3793
sg10
I27
sg11
Vacute myocardial infarction
p3794
sg13
I3
sasa(dp3795
g2
S'The study aimed to examine plasma ADAMTS-7 levels in patients with acute myocardial infarction (AMI) and the relationship between plasma ADAMTS-7 levels and heart function.\n'
p3796
sg4
(lp3797
sg23
(lp3798
(dp3799
g7
I96
sg26
VC0155626
p3800
sg10
I3
sg11
VAMI
p3801
sg13
I1
sa(dp3802
g7
I67
sg26
VC0155626
p3803
sg10
I27
sg11
Vacute myocardial infarction
p3804
sg13
I3
sasa(dp3805
g2
S'In order to investigate the interaction between the cytokines and keratinocyte and determine the role of cytokines in hyperproliferative of chronic otitis media with cholesteatoma, we observe the expression of matrix metalloproteinase 9 (MMP9), vascular endothelial growth factor (VEGF), keratinocyte growth factor (KGF) and its receptor (KGFR) in middle ear cholesteatoma.\n'
p3806
sg4
(lp3807
(dp3808
g7
I288
sg8
VP21781
p3809
sg10
I26
sg11
Vkeratinocyte growth factor
p3810
sg13
I3
sa(dp3811
g7
I245
sg8
g15
sg10
I34
sg11
Vvascular endothelial growth factor
p3812
sg13
I4
sa(dp3813
g7
I210
sg8
VP14780
p3814
sg10
I33
sg11
Vmatrix metalloproteinase 9 (MMP9)
p3815
sg13
I4
sa(dp3816
g7
I316
sg8
VP21781
p3817
sg10
I3
sg11
VKGF
p3818
sg13
I1
sa(dp3819
g7
I281
sg8
g15
sg10
I4
sg11
VVEGF
p3820
sg13
I1
sasg23
(lp3821
(dp3822
g7
I348
sg26
VC0155490
p3823
sg10
I24
sg11
Vmiddle ear cholesteatoma
p3824
sg13
I3
sa(dp3825
g7
I140
sg26
VC0271441
p3826
sg10
I20
sg11
Vchronic otitis media
p3827
sg13
I3
sa(dp3828
g7
I166
sg26
VC0008373
p3829
sg10
I13
sg11
Vcholesteatoma
p3830
sg13
I1
sasa(dp3831
g2
S'We examined the expression of MMP9, VEGF, KGF, KGFR and Ki-67 by immunohistochemistry in 50 specimens from chronic otitis media with cholesteatoma and 15 specimens from the normal skin of external auditory meatus.\n'
p3832
sg4
(lp3833
(dp3834
g7
I42
sg8
VP21781
p3835
sg10
I3
sg11
VKGF
p3836
sg13
I1
sa(dp3837
g7
I56
sg8
VP46013
p3838
sg10
I5
sg11
VKi-67
p3839
sg13
I1
sa(dp3840
g7
I30
sg8
VP14780
p3841
sg10
I4
sg11
VMMP9
p3842
sg13
I1
sasg23
(lp3843
(dp3844
g7
I133
sg26
VC0008373
p3845
sg10
I13
sg11
Vcholesteatoma
p3846
sg13
I1
sa(dp3847
g7
I107
sg26
VC0271441
p3848
sg10
I20
sg11
Vchronic otitis media
p3849
sg13
I3
sasa(dp3850
g2
S'The present study was performed to investigate the expressions of transforming growth factor Beta1 (TGF-Beta1) and matrix metalloproteinase-9 (MMP-9) in an experimental model of tympanosclerosis and their possible roles in the formation of this disorder.\n'
p3851
sg4
(lp3852
(dp3853
g7
I66
sg8
VP01137
p3854
sg10
I32
sg11
Vtransforming growth factor Beta1
p3855
sg13
I4
sa(dp3856
g7
I100
sg8
VP01137
p3857
sg10
I9
sg11
VTGF-Beta1
p3858
sg13
I1
sa(dp3859
g7
I115
sg8
VP14780
p3860
sg10
I26
sg11
Vmatrix metalloproteinase-9
p3861
sg13
I2
sa(dp3862
g7
I143
sg8
VP14780
p3863
sg10
I5
sg11
VMMP-9
p3864
sg13
I1
sasg23
(lp3865
(dp3866
g7
I178
sg26
VC0395887
p3867
sg10
I16
sg11
Vtympanosclerosis
p3868
sg13
I1
sasa(dp3869
g2
S'Our data indicate that, for the first time, the alteration in expressions of TGF-Beta1 and MMP-9 were involved in the formation of tympanosclerosis, which may represent an important mechanism underlying the pathogenesis of tympanosclerosis.\n'
p3870
sg4
(lp3871
(dp3872
g7
I91
sg8
VP14780
p3873
sg10
I5
sg11
VMMP-9
p3874
sg13
I1
sa(dp3875
g7
I77
sg8
VP01137
p3876
sg10
I9
sg11
VTGF-Beta1
p3877
sg13
I1
sasg23
(lp3878
(dp3879
g7
I131
sg26
VC0395887
p3880
sg10
I16
sg11
Vtympanosclerosis
p3881
sg13
I1
sa(dp3882
g7
I207
sg26
VC0699748
p3883
sg10
I12
sg11
Vpathogenesis
p3884
sg13
I1
sa(dp3885
g7
I131
sg26
VC0395887
p3886
sg10
I16
sg11
Vtympanosclerosis
p3887
sg13
I1
sasa(dp3888
g2
S'LTA increased the activity of MMP-9, not TIMPs in middle ear epithelia, suggesting that disturbed balance between MMP-9 and TIMPs could play an active role in LTA-induced otitis media.\n'
p3889
sg4
(lp3890
(dp3891
g7
I30
sg8
VP14780
p3892
sg10
I5
sg11
VMMP-9
p3893
sg13
I1
sa(dp3894
g7
I41
sg8
VP01033
p3895
sg10
I5
sg11
VTIMPs
p3896
sg13
I1
sa(dp3897
g7
I30
sg8
VP14780
p3898
sg10
I5
sg11
VMMP-9
p3899
sg13
I1
sa(dp3900
g7
I41
sg8
VP01033
p3901
sg10
I5
sg11
VTIMPs
p3902
sg13
I1
sasg23
(lp3903
(dp3904
g7
I171
sg26
VC0029882
p3905
sg10
I12
sg11
Votitis media
p3906
sg13
I2
sasa(dp3907
g2
S'To evaluate the role of MMP-9 and MMP-2 in pediatric patients with middle ear effusion (MEE) and determine the pathogenesis of otitis media with effusion (OME) and allergy.\n'
p3908
sg4
(lp3909
(dp3910
g7
I24
sg8
VP14780
p3911
sg10
I5
sg11
VMMP-9
p3912
sg13
I1
sa(dp3913
g7
I34
sg8
VP08253
p3914
sg10
I5
sg11
VMMP-2
p3915
sg13
I1
sasg23
(lp3916
(dp3917
g7
I67
sg26
VC0029883
p3918
sg10
I19
sg11
Vmiddle ear effusion
p3919
sg13
I3
sa(dp3920
g7
I111
sg26
VC0699748
p3921
sg10
I12
sg11
Vpathogenesis
p3922
sg13
I1
sa(dp3923
g7
I164
sg26
VC0020517
p3924
sg10
I7
sg11
Vallergy
p3925
sg13
I1
sa(dp3926
g7
I127
sg26
VC0029883
p3927
sg10
I26
sg11
Votitis media with effusion
p3928
sg13
I4
sa(dp3929
g7
I88
sg26
VC0029883
p3930
sg10
I3
sg11
VMEE
p3931
sg13
I1
sa(dp3932
g7
I155
sg26
VC0029883
p3933
sg10
I3
sg11
VOME
p3934
sg13
I1
sasa(dp3935
g2
S'A new study reports that loss of solute carrier family 13 member 5, which transports citrate across cell membranes, halts liver cancer cell growth by altering both energy production and mammalian target of rapamycin signaling in human liver cancer cell lines and in both an in vitro and in vivo model of liver tumors, suggesting a new target for liver cancer chemoprevention and/or chemotherapy.\n'
p3936
sg4
(lp3937
(dp3938
g7
I33
sg8
g15
sg10
I31
sg11
Vsolute carrier family 13 member
p3939
sg13
I5
sasg23
(lp3940
(dp3941
g7
I128
sg26
VC1516170
p3942
sg10
I18
sg11
Vcancer cell growth
p3943
sg13
I3
sa(dp3944
g7
I122
sg26
VC0345904
p3945
sg10
I12
sg11
Vliver cancer
p3946
sg13
I2
sa(dp3947
g7
I122
sg26
VC0345904
p3948
sg10
I12
sg11
Vliver cancer
p3949
sg13
I2
sa(dp3950
g7
I304
sg26
VC0023903
p3951
sg10
I12
sg11
Vliver tumors
p3952
sg13
I2
sasa(dp3953
g2
S'However, despite the emerging importance of SLC13A5 in energy homeostasis, whether perturbation of SLC13A5 affects the metabolism and malignancy of hepatocellular carcinoma is unknown.\n'
p3954
sg4
(lp3955
(dp3956
g7
I44
sg8
g15
sg10
I7
sg11
VSLC13A5
p3957
sg13
I1
sa(dp3958
g7
I44
sg8
g15
sg10
I7
sg11
VSLC13A5
p3959
sg13
I1
sasg23
(lp3960
(dp3961
g7
I148
sg26
VC1512411
p3962
sg10
I24
sg11
Vhepatocellular carcinoma
p3963
sg13
I2
sa(dp3964
g7
I134
sg26
VC0006826
p3965
sg10
I10
sg11
Vmalignancy
p3966
sg13
I1
sasa(dp3967
g2
S'Together, our findings expand the role of SLC13A5 from facilitating hepatic energy homeostasis to influencing hepatoma cell proliferation and suggest a potential role of SLC13A5 in the progression of human hepatocellular carcinoma.\n'
p3968
sg4
(lp3969
(dp3970
g7
I42
sg8
g15
sg10
I7
sg11
VSLC13A5
p3971
sg13
I1
sa(dp3972
g7
I42
sg8
g15
sg10
I7
sg11
VSLC13A5
p3973
sg13
I1
sasg23
(lp3974
(dp3975
g7
I206
sg26
VC1512411
p3976
sg10
I24
sg11
Vhepatocellular carcinoma
p3977
sg13
I2
sa(dp3978
g7
I110
sg26
VC0023903
p3979
sg10
I8
sg11
Vhepatoma
p3980
sg13
I1
sa(dp3981
g7
I124
sg26
VC0334094
p3982
sg10
I13
sg11
Vproliferation
p3983
sg13
I1
sasa(dp3984
g2
S'We applied the MINDy (Modulator Inference by Network Dynamics) algorithm to four TFs (ESR1, FOXA1, GATA3 and SPDEF) that are key drivers of estrogen receptor-positive (ER+) breast cancer risk, as well as cancer progression.\n'
p3985
sg4
(lp3986
(dp3987
g7
I92
sg8
VP55317
p3988
sg10
I5
sg11
VFOXA1
p3989
sg13
I1
sa(dp3990
g7
I109
sg8
g15
sg10
I5
sg11
VSPDEF
p3991
sg13
I1
sa(dp3992
g7
I86
sg8
VP03372
p3993
sg10
I4
sg11
VESR1
p3994
sg13
I1
sa(dp3995
g7
I140
sg8
VP03372
p3996
sg10
I17
sg11
Vestrogen receptor
p3997
sg13
I2
sa(dp3998
g7
I99
sg8
VP23771
p3999
sg10
I5
sg11
VGATA3
p4000
sg13
I1
sasg23
(lp4001
(dp4002
g7
I204
sg26
VC0178874
p4003
sg10
I18
sg11
Vcancer progression
p4004
sg13
I2
sa(dp4005
g7
I173
sg26
VC0678222
p4006
sg10
I13
sg11
Vbreast cancer
p4007
sg13
I2
sasa(dp4008
g2
S'In female patients with locally advanced breast cancer (labc) and good response to neoadjuvant chemotherapy (nact), including endocrine therapy, what is the role of breast-conserving surgery (bcs) compared with mastectomy?In female patients with labc, is radiotherapy (rt) indicated for those who have undergone mastectomy?does locoregional rt, compared with breast or chest wall rt alone, result in a higher survival rate and lower recurrence rates?is rt indicated for those achieving a pathologic complete response (pcr) to nact?In female patients with labc who receive nact, is the most appropriate axillary staging procedure sentinel lymph node biopsy (slnb) or axillary dissection?\n'
p4009
sg4
(lp4010
sg23
(lp4011
(dp4012
g7
I629
sg26
VC0677944
p4013
sg10
I19
sg11
Vsentinel lymph node
p4014
sg13
I3
sa(dp4015
g7
I41
sg26
VC0678222
p4016
sg10
I13
sg11
Vbreast cancer
p4017
sg13
I2
sa(dp4018
g7
I433
sg26
VC1458156
p4019
sg10
I10
sg11
Vrecurrence
p4020
sg13
I1
sasa(dp4021
g2
S'y 1 namyNeHTKN c BKN, BblRBneHHblM Ha cpoKe bepeMeHHocTN 11 HeA, B cBR3N c HapacTaHNeM myNToneHNN npoBeAeHa TepanNR NHTepoepoHoM-Alfa co II TpNMecTpa bepeMeHHocTN, c nocneAyhweN TepanNeN KnaApNbNHoM nocne poAoB.\n'
p4022
sg4
(lp4023
(dp4024
g7
I0
sg8
g15
sg10
I20
sg11
Vy 1 namyNeHTKN c BKN
p4025
sg13
I5
sasg23
(lp4026
sa(dp4027
g2
S'There also is evidence of altered expression of peptides associated with inflammation in mood disorder patients, encouraging experimental treatment with anti-inflammatory agents; of these, the COX-II inhibitor celecoxib has shown some evidence of benefit.\n'
p4028
sg4
(lp4029
(dp4030
g7
I193
sg8
VP00403
p4031
sg10
I6
sg11
VCOX-II
p4032
sg13
I1
sasg23
(lp4033
(dp4034
g7
I89
sg26
VC0525045
p4035
sg10
I13
sg11
Vmood disorder
p4036
sg13
I2
sa(dp4037
g7
I73
sg26
VC0021368
p4038
sg10
I12
sg11
Vinflammation
p4039
sg13
I1
sasa(dp4040
g2
S"After serological and medical examinations, individuals were separated into the following groups: Chagas' disease patients without manifest cardiac involvement (CDP-0), CDP with suspected or borderline cardiac disease (CDP-1), CDP with moderate myocardial dysfunction (CDP-2), CDP with overt cardiac dysfunction (CDP-3) and controls including healthy subjects (HS) and patients with idiopathic myocarditis (IMP).\n"
p4041
sg4
(lp4042
(dp4043
g7
I161
sg8
VP39880
p4044
sg10
I5
sg11
VCDP-0
p4045
sg13
I1
sa(dp4046
g7
I161
sg8
VP39880
p4047
sg10
I3
sg11
VCDP
p4048
sg13
I1
sa(dp4049
g7
I313
sg8
VP39880
p4050
sg10
I5
sg11
VCDP-3
p4051
sg13
I1
sa(dp4052
g7
I269
sg8
VP39880
p4053
sg10
I5
sg11
VCDP-2
p4054
sg13
I1
sa(dp4055
g7
I161
sg8
VP39880
p4056
sg10
I3
sg11
VCDP
p4057
sg13
I1
sa(dp4058
g7
I161
sg8
VP39880
p4059
sg10
I3
sg11
VCDP
p4060
sg13
I1
sa(dp4061
g7
I219
sg8
VP39880
p4062
sg10
I5
sg11
VCDP-1
p4063
sg13
I1
sasg23
(lp4064
(dp4065
g7
I383
sg26
VC0155689
p4066
sg10
I22
sg11
Vidiopathic myocarditis
p4067
sg13
I2
sa(dp4068
g7
I245
sg26
VC0340515
p4069
sg10
I22
sg11
Vmyocardial dysfunction
p4070
sg13
I2
sa(dp4071
g7
I202
sg26
VC0018799
p4072
sg10
I15
sg11
Vcardiac disease
p4073
sg13
I2
sa(dp4074
g7
I98
sg26
VC0041234
p4075
sg10
I15
sg11
VChagas' disease
p4076
sg13
I2
sasa(dp4077
g2
S'In the present study, immunohistochemical staining revealed that the expression of TRIM16 was decreased in prostate adenocarcinoma compared with that in normal prostate tissues.\n'
p4078
sg4
(lp4079
(dp4080
g7
I83
sg8
g15
sg10
I6
sg11
VTRIM16
p4081
sg13
I1
sasg23
(lp4082
(dp4083
g7
I107
sg26
VC0007112
p4084
sg10
I23
sg11
Vprostate adenocarcinoma
p4085
sg13
I2
sasa(dp4086
g2
S'Western blot analysis showed that TRIM16 was downregulated in distant metastatic cancer tissues compared with that in non-distant metastatic cancer tissues.\n'
p4087
sg4
(lp4088
(dp4089
g7
I34
sg8
g15
sg10
I6
sg11
VTRIM16
p4090
sg13
I1
sasg23
(lp4091
(dp4092
g7
I70
sg26
VC0027627
p4093
sg10
I17
sg11
Vmetastatic cancer
p4094
sg13
I2
sa(dp4095
g7
I70
sg26
VC0027627
p4096
sg10
I17
sg11
Vmetastatic cancer
p4097
sg13
I2
sasa(dp4098
g2
S'The overexpression of TRIM16 inhibited the migration and invasion of prostate cancer cells as well as inhibiting the epithelial-to-mesenchymal transition process, whereas TRIM16 depletion enhanced these processes.\n'
p4099
sg4
(lp4100
(dp4101
g7
I22
sg8
g15
sg10
I6
sg11
VTRIM16
p4102
sg13
I1
sa(dp4103
g7
I22
sg8
g15
sg10
I6
sg11
VTRIM16
p4104
sg13
I1
sasg23
(lp4105
(dp4106
g7
I69
sg26
VC0600139
p4107
sg10
I15
sg11
Vprostate cancer
p4108
sg13
I2
sa(dp4109
g7
I57
sg26
VC2699153
p4110
sg10
I8
sg11
Vinvasion
p4111
sg13
I1
sa(dp4112
g7
I143
sg26
VC0599156
p4113
sg10
I10
sg11
Vtransition
p4114
sg13
I1
sasa(dp4115
g2
S'Taken together, these findings suggest that TRIM16 may be an important molecular target which may aid in the design of novel therapeutic agents for prostate cancer.\n'
p4116
sg4
(lp4117
(dp4118
g7
I44
sg8
g15
sg10
I6
sg11
VTRIM16
p4119
sg13
I1
sasg23
(lp4120
(dp4121
g7
I148
sg26
VC0600139
p4122
sg10
I15
sg11
Vprostate cancer
p4123
sg13
I2
sasa(dp4124
g2
S'However, the role of TRIM16 in ovarian cancer has never been revealed.\n'
p4125
sg4
(lp4126
(dp4127
g7
I21
sg8
g15
sg10
I6
sg11
VTRIM16
p4128
sg13
I1
sasg23
(lp4129
(dp4130
g7
I31
sg26
VC1140680
p4131
sg10
I14
sg11
Vovarian cancer
p4132
sg13
I2
sasa(dp4133
g2
S'Thus, in this study, we investigated the roles and mechanisms of TRIM16 in ovarian cancer.\n'
p4134
sg4
(lp4135
(dp4136
g7
I65
sg8
g15
sg10
I6
sg11
VTRIM16
p4137
sg13
I1
sasg23
(lp4138
(dp4139
g7
I75
sg26
VC1140680
p4140
sg10
I14
sg11
Vovarian cancer
p4141
sg13
I2
sasa(dp4142
g2
S'Our results demonstrated that TRIM16 expression was low in ovarian cancer cell lines.\n'
p4143
sg4
(lp4144
(dp4145
g7
I30
sg8
g15
sg10
I6
sg11
VTRIM16
p4146
sg13
I1
sasg23
(lp4147
(dp4148
g7
I59
sg26
VC1140680
p4149
sg10
I14
sg11
Vovarian cancer
p4150
sg13
I2
sasa(dp4151
g2
S'In addition, overexpression of TRIM16 significantly inhibited the migration and invasion in vitro, as well as suppressed the epithelial-mesenchymal transition (EMT) phenotype in ovarian cancer cells.\n'
p4152
sg4
(lp4153
(dp4154
g7
I31
sg8
g15
sg10
I6
sg11
VTRIM16
p4155
sg13
I1
sa(dp4156
g7
I160
sg8
g15
sg10
I3
sg11
VEMT
p4157
sg13
I1
sa(dp4158
g7
I125
sg8
g15
sg10
I33
sg11
Vepithelial-mesenchymal transition
p4159
sg13
I2
sasg23
(lp4160
(dp4161
g7
I178
sg26
VC1140680
p4162
sg10
I14
sg11
Vovarian cancer
p4163
sg13
I2
sa(dp4164
g7
I80
sg26
VC2699153
p4165
sg10
I8
sg11
Vinvasion
p4166
sg13
I1
sa(dp4167
g7
I148
sg26
VC0599156
p4168
sg10
I10
sg11
Vtransition
p4169
sg13
I1
sasa(dp4170
g2
S'Furthermore, overexpression of TRIM16 greatly inhibited the protein expression levels of Shh, Smo, Ptc, Gli-1, MMP2, and MMP9 in ovarian cancer cells.\n'
p4171
sg4
(lp4172
(dp4173
g7
I99
sg8
g15
sg10
I3
sg11
VPtc
p4174
sg13
I1
sa(dp4175
g7
I89
sg8
g15
sg10
I3
sg11
VShh
p4176
sg13
I1
sa(dp4177
g7
I104
sg8
VP08151
p4178
sg10
I5
sg11
VGli-1
p4179
sg13
I1
sa(dp4180
g7
I121
sg8
VP14780
p4181
sg10
I4
sg11
VMMP9
p4182
sg13
I1
sa(dp4183
g7
I94
sg8
g15
sg10
I3
sg11
VSmo
p4184
sg13
I1
sa(dp4185
g7
I31
sg8
g15
sg10
I6
sg11
VTRIM16
p4186
sg13
I1
sa(dp4187
g7
I111
sg8
VP08253
p4188
sg10
I4
sg11
VMMP2
p4189
sg13
I1
sasg23
(lp4190
(dp4191
g7
I99
sg26
VC0238463
p4192
sg10
I3
sg11
VPtc
p4193
sg13
I1
sa(dp4194
g7
I129
sg26
VC1140680
p4195
sg10
I14
sg11
Vovarian cancer
p4196
sg13
I2
sasa(dp4197
g2
S'Taken together, these results strongly suggest that TRIM16 inhibits the migration and invasion via suppressing the Sonic hedgehog signaling pathway in ovarian cancer cells.\n'
p4198
sg4
(lp4199
(dp4200
g7
I52
sg8
g15
sg10
I6
sg11
VTRIM16
p4201
sg13
I1
sa(dp4202
g7
I115
sg8
g15
sg10
I14
sg11
VSonic hedgehog
p4203
sg13
I2
sasg23
(lp4204
(dp4205
g7
I86
sg26
VC2699153
p4206
sg10
I8
sg11
Vinvasion
p4207
sg13
I1
sa(dp4208
g7
I151
sg26
VC1140680
p4209
sg10
I14
sg11
Vovarian cancer
p4210
sg13
I2
sasa(dp4211
g2
S'Thus, TRIM16 may be a novel potential therapeutic target for ovarian cancer.\n'
p4212
sg4
(lp4213
(dp4214
g7
I6
sg8
g15
sg10
I6
sg11
VTRIM16
p4215
sg13
I1
sasg23
(lp4216
(dp4217
g7
I61
sg26
VC1140680
p4218
sg10
I14
sg11
Vovarian cancer
p4219
sg13
I2
sasa(dp4220
g2
S'In melanoma cells, loss of TRIM16 expression is a marker of cell migration and metastasis, while the BRAF inhibitor, vemurafenib, induces melanoma cell growth arrest in a TRIM16-dependent manner.\n'
p4221
sg4
(lp4222
(dp4223
g7
I27
sg8
g15
sg10
I6
sg11
VTRIM16
p4224
sg13
I1
sa(dp4225
g7
I27
sg8
g15
sg10
I6
sg11
VTRIM16
p4226
sg13
I1
sa(dp4227
g7
I101
sg8
VP15056
p4228
sg10
I4
sg11
VBRAF
p4229
sg13
I1
sasg23
(lp4230
(dp4231
g7
I3
sg26
VC0025202
p4232
sg10
I8
sg11
Vmelanoma
p4233
sg13
I1
sa(dp4234
g7
I79
sg26
VC0027627
p4235
sg10
I10
sg11
Vmetastasis
p4236
sg13
I1
sa(dp4237
g7
I3
sg26
VC0025202
p4238
sg10
I8
sg11
Vmelanoma
p4239
sg13
I1
sa(dp4240
g7
I152
sg26
VC0333951
p4241
sg10
I13
sg11
Vgrowth arrest
p4242
sg13
I2
sasa(dp4243
g2
S'These findings suggest that the combination of C012 and vemurafenib may have therapeutic potential for the treatment of melanoma, and, that reactivation of TRIM16 may be an effective strategy for patients with this disease.\n'
p4244
sg4
(lp4245
(dp4246
g7
I156
sg8
g15
sg10
I6
sg11
VTRIM16
p4247
sg13
I1
sasg23
(lp4248
(dp4249
g7
I120
sg26
VC0025202
p4250
sg10
I8
sg11
Vmelanoma
p4251
sg13
I1
sasa(dp4252
g2
S'Tripartite Motif-containing protein 16 (TRIM16) is a member of a large family of tripartite motif (TRIM) proteins, that has been implicated in the pathogenesis of multiple cancers.\n'
p4253
sg4
(lp4254
(dp4255
g7
I0
sg8
g15
sg10
I38
sg11
VTripartite Motif-containing protein 16
p4256
sg13
I4
sa(dp4257
g7
I40
sg8
g15
sg10
I6
sg11
VTRIM16
p4258
sg13
I1
sa(dp4259
g7
I81
sg8
g15
sg10
I16
sg11
Vtripartite motif
p4260
sg13
I2
sa(dp4261
g7
I40
sg8
g15
sg10
I4
sg11
VTRIM
p4262
sg13
I1
sasg23
(lp4263
(dp4264
g7
I147
sg26
VC0699748
p4265
sg10
I12
sg11
Vpathogenesis
p4266
sg13
I1
sa(dp4267
g7
I172
sg26
VC0006826
p4268
sg10
I7
sg11
Vcancers
p4269
sg13
I1
sasa(dp4270
g2
S'Co-immunoprecipitation assay demonstrated that TDP43 bound TRIM16 in neuroblastoma and breast cancer cells.\n'
p4271
sg4
(lp4272
(dp4273
g7
I59
sg8
g15
sg10
I6
sg11
VTRIM16
p4274
sg13
I1
sa(dp4275
g7
I47
sg8
g15
sg10
I5
sg11
VTDP43
p4276
sg13
I1
sasg23
(lp4277
(dp4278
g7
I87
sg26
VC0678222
p4279
sg10
I13
sg11
Vbreast cancer
p4280
sg13
I2
sa(dp4281
g7
I69
sg26
VC0027819
p4282
sg10
I13
sg11
Vneuroblastoma
p4283
sg13
I1
sasa(dp4284
g2
S'High levels of TRIM16 and TDP43 are associated with good prognosis in both human neuroblastoma and breast cancer tissues.\n'
p4285
sg4
(lp4286
(dp4287
g7
I15
sg8
g15
sg10
I6
sg11
VTRIM16
p4288
sg13
I1
sa(dp4289
g7
I26
sg8
g15
sg10
I5
sg11
VTDP43
p4290
sg13
I1
sasg23
(lp4291
(dp4292
g7
I81
sg26
VC0027819
p4293
sg10
I13
sg11
Vneuroblastoma
p4294
sg13
I1
sa(dp4295
g7
I99
sg26
VC0678222
p4296
sg10
I13
sg11
Vbreast cancer
p4297
sg13
I2
sasa(dp4298
g2
S'Importantly, we found TDP43 expression was required for TRIM16-induced inhibition of neuroblastoma and breast cancer cell growth and the repressive effect of TRIM16 on cell cycle regulatory proteins, E2F1 and pRb.\n'
p4299
sg4
(lp4300
(dp4301
g7
I56
sg8
g15
sg10
I6
sg11
VTRIM16
p4302
sg13
I1
sa(dp4303
g7
I22
sg8
g15
sg10
I5
sg11
VTDP43
p4304
sg13
I1
sa(dp4305
g7
I209
sg8
g15
sg10
I3
sg11
VpRb
p4306
sg13
I1
sa(dp4307
g7
I200
sg8
g15
sg10
I4
sg11
VE2F1
p4308
sg13
I1
sa(dp4309
g7
I56
sg8
g15
sg10
I6
sg11
VTRIM16
p4310
sg13
I1
sasg23
(lp4311
(dp4312
g7
I110
sg26
VC1516170
p4313
sg10
I18
sg11
Vcancer cell growth
p4314
sg13
I3
sa(dp4315
g7
I85
sg26
VC0027819
p4316
sg10
I13
sg11
Vneuroblastoma
p4317
sg13
I1
sasa(dp4318
g2
S'Taken together, our data suggest that TRIM16 and TDP43 are both good prognosis indicators; also we showed that TRIM16 inhibits cancer cell viability by a novel mechanism involving interaction and stabilisation of TDP43 with consequent effects on E2F1 and pRb proteins.\n'
p4319
sg4
(lp4320
(dp4321
g7
I38
sg8
g15
sg10
I6
sg11
VTRIM16
p4322
sg13
I1
sa(dp4323
g7
I255
sg8
g15
sg10
I12
sg11
VpRb proteins
p4324
sg13
I2
sa(dp4325
g7
I49
sg8
g15
sg10
I5
sg11
VTDP43
p4326
sg13
I1
sa(dp4327
g7
I38
sg8
g15
sg10
I6
sg11
VTRIM16
p4328
sg13
I1
sa(dp4329
g7
I49
sg8
g15
sg10
I5
sg11
VTDP43
p4330
sg13
I1
sa(dp4331
g7
I246
sg8
g15
sg10
I4
sg11
VE2F1
p4332
sg13
I1
sasg23
(lp4333
(dp4334
g7
I127
sg26
VC0006826
p4335
sg10
I6
sg11
Vcancer
p4336
sg13
I1
sasa(dp4337
g2
S'Tripartite motif 16 (TRIM16), a member of the RING B-box coiled-coil (RBCC)/tripartite totif (TRIM) protein family, has been demonstrated to have significant effects on tumor migration by previous studies, but its specific contribution to hepatocellular carcinoma (HCC) is currently unknown.\n'
p4338
sg4
(lp4339
(dp4340
g7
I21
sg8
g15
sg10
I4
sg11
VTRIM
p4341
sg13
I1
sa(dp4342
g7
I21
sg8
g15
sg10
I6
sg11
VTRIM16
p4343
sg13
I1
sa(dp4344
g7
I0
sg8
g15
sg10
I19
sg11
VTripartite motif 16
p4345
sg13
I3
sasg23
(lp4346
(dp4347
g7
I169
sg26
VC0027651
p4348
sg10
I5
sg11
Vtumor
p4349
sg13
I1
sa(dp4350
g7
I265
sg26
VC2239176
p4351
sg10
I3
sg11
VHCC
p4352
sg13
I1
sa(dp4353
g7
I239
sg26
VC2239176
p4354
sg10
I24
sg11
Vhepatocellular carcinoma
p4355
sg13
I2
sasa(dp4356
g2
S'Compared with paired normal liver tissues in clinical cancer samples, we found that the expression of TRIM16 was significantly downregulated in HCC lesions.\n'
p4357
sg4
(lp4358
(dp4359
g7
I102
sg8
g15
sg10
I6
sg11
VTRIM16
p4360
sg13
I1
sasg23
(lp4361
(dp4362
g7
I144
sg26
VC2239176
p4363
sg10
I3
sg11
VHCC
p4364
sg13
I1
sa(dp4365
g7
I54
sg26
VC0006826
p4366
sg10
I6
sg11
Vcancer
p4367
sg13
I1
sasa(dp4368
g2
S'In a previous study, we demonstrated that TRIM16 suppressed cancer malignancy and that TRIM16 expression levels were associated with favorable prognostic parameters of patients with cancer.\n'
p4369
sg4
(lp4370
(dp4371
g7
I42
sg8
g15
sg10
I6
sg11
VTRIM16
p4372
sg13
I1
sa(dp4373
g7
I42
sg8
g15
sg10
I6
sg11
VTRIM16
p4374
sg13
I1
sasg23
(lp4375
(dp4376
g7
I67
sg26
VC0006826
p4377
sg10
I10
sg11
Vmalignancy
p4378
sg13
I1
sa(dp4379
g7
I60
sg26
VC0006826
p4380
sg10
I6
sg11
Vcancer
p4381
sg13
I1
sa(dp4382
g7
I60
sg26
VC0006826
p4383
sg10
I6
sg11
Vcancer
p4384
sg13
I1
sasa(dp4385
g2
S'In the present study, we examined 29 human breast cancer specimens, and found that TRIM16 was lowly expressed in breast cancers; thus, TRIM16 expression is negatively correlated with metastasis in breast cancer patients.\n'
p4386
sg4
(lp4387
(dp4388
g7
I83
sg8
g15
sg10
I6
sg11
VTRIM16
p4389
sg13
I1
sa(dp4390
g7
I83
sg8
g15
sg10
I6
sg11
VTRIM16
p4391
sg13
I1
sasg23
(lp4392
(dp4393
g7
I43
sg26
VC0006142
p4394
sg10
I13
sg11
Vbreast cancer
p4395
sg13
I2
sa(dp4396
g7
I43
sg26
VC0006142
p4397
sg10
I13
sg11
Vbreast cancer
p4398
sg13
I2
sa(dp4399
g7
I113
sg26
VC0006142
p4400
sg10
I14
sg11
Vbreast cancers
p4401
sg13
I2
sa(dp4402
g7
I183
sg26
VC0027627
p4403
sg10
I10
sg11
Vmetastasis
p4404
sg13
I1
sasa(dp4405
g2
S'Moreover, we showed that TRIM16 suppressed CSC properties in a population of breast cancer cells.\n'
p4406
sg4
(lp4407
(dp4408
g7
I25
sg8
g15
sg10
I6
sg11
VTRIM16
p4409
sg13
I1
sasg23
(lp4410
(dp4411
g7
I77
sg26
VC0678222
p4412
sg10
I13
sg11
Vbreast cancer
p4413
sg13
I2
sasa(dp4414
g2
S'TRIM16 depletion resulted in an increased proportion of CSCs relative to breast cancer cells when several assays were used to assess CSC properties.\n'
p4415
sg4
(lp4416
(dp4417
g7
I0
sg8
g15
sg10
I6
sg11
VTRIM16
p4418
sg13
I1
sasg23
(lp4419
(dp4420
g7
I73
sg26
VC0678222
p4421
sg10
I13
sg11
Vbreast cancer
p4422
sg13
I2
sasa(dp4423
g2
S'In conclusion, we propose that inhibition of CSC properties may be one of the functions of TRIM16 as a suppressor of breast cancer progression.\n'
p4424
sg4
(lp4425
(dp4426
g7
I91
sg8
g15
sg10
I6
sg11
VTRIM16
p4427
sg13
I1
sasg23
(lp4428
(dp4429
g7
I124
sg26
VC0178874
p4430
sg10
I18
sg11
Vcancer progression
p4431
sg13
I2
sasa(dp4432
g2
S'In an effort to profile the expression patterns of TRIM superfamily in several non-small cell lung cancer (NSCLC) cell lines, we found that the expression of 10 TRIM genes including TRIM3, TRIM7, TRIM14, TRIM16, TRIM21, TRIM22, TRIM29, TRIM59, TRIM66 and TRIM70 was significantly upregulated in NSCLC cell lines compared with the normal human bronchial epithelial (HBE) cell line, whereas the expression of 7 other TRIM genes including TRIM4, TRIM9, TRIM36, TRIM46, TRIM54, TRIM67 and TRIM76 was significantly down-regulated in NSCLC cell lines compared with that in HBE cells.\n'
p4433
sg4
(lp4434
(dp4435
g7
I212
sg8
VP19474
p4436
sg10
I6
sg11
VTRIM21
p4437
sg13
I1
sa(dp4438
g7
I244
sg8
g15
sg10
I6
sg11
VTRIM66
p4439
sg13
I1
sa(dp4440
g7
I196
sg8
g15
sg10
I6
sg11
VTRIM14
p4441
sg13
I1
sa(dp4442
g7
I161
sg8
g15
sg10
I10
sg11
VTRIM genes
p4443
sg13
I2
sa(dp4444
g7
I458
sg8
g15
sg10
I6
sg11
VTRIM46
p4445
sg13
I1
sa(dp4446
g7
I204
sg8
g15
sg10
I6
sg11
VTRIM16
p4447
sg13
I1
sa(dp4448
g7
I220
sg8
g15
sg10
I6
sg11
VTRIM22
p4449
sg13
I1
sa(dp4450
g7
I450
sg8
g15
sg10
I6
sg11
VTRIM36
p4451
sg13
I1
sa(dp4452
g7
I228
sg8
g15
sg10
I6
sg11
VTRIM29
p4453
sg13
I1
sa(dp4454
g7
I182
sg8
g15
sg10
I5
sg11
VTRIM3
p4455
sg13
I1
sa(dp4456
g7
I474
sg8
g15
sg10
I6
sg11
VTRIM67
p4457
sg13
I1
sa(dp4458
g7
I443
sg8
g15
sg10
I5
sg11
VTRIM9
p4459
sg13
I1
sa(dp4460
g7
I436
sg8
g15
sg10
I5
sg11
VTRIM4
p4461
sg13
I1
sa(dp4462
g7
I51
sg8
g15
sg10
I16
sg11
VTRIM superfamily
p4463
sg13
I2
sa(dp4464
g7
I255
sg8
g15
sg10
I6
sg11
VTRIM70
p4465
sg13
I1
sa(dp4466
g7
I236
sg8
g15
sg10
I6
sg11
VTRIM59
p4467
sg13
I1
sa(dp4468
g7
I189
sg8
g15
sg10
I5
sg11
VTRIM7
p4469
sg13
I1
sa(dp4470
g7
I466
sg8
g15
sg10
I6
sg11
VTRIM54
p4471
sg13
I1
sasg23
(lp4472
(dp4473
g7
I107
sg26
VC0007131
p4474
sg10
I5
sg11
VNSCLC
p4475
sg13
I1
sa(dp4476
g7
I79
sg26
VC0007131
p4477
sg10
I26
sg11
Vnon-small cell lung cancer
p4478
sg13
I4
sa(dp4479
g7
I107
sg26
VC0007131
p4480
sg10
I5
sg11
VNSCLC
p4481
sg13
I1
sa(dp4482
g7
I107
sg26
VC0007131
p4483
sg10
I5
sg11
VNSCLC
p4484
sg13
I1
sasa(dp4485
g2
S'The present study was to examine the effect of Tripartite motif 16 (TRIM16) on epithelial-mesenchymal transition (EMT) and metastasis in non-small cell lung cancer (NSCLC) cells, and its clinical significance in NSCLC.\n'
p4486
sg4
(lp4487
(dp4488
g7
I68
sg8
g15
sg10
I6
sg11
VTRIM16
p4489
sg13
I1
sa(dp4490
g7
I47
sg8
g15
sg10
I19
sg11
VTripartite motif 16
p4491
sg13
I3
sasg23
(lp4492
(dp4493
g7
I102
sg26
VC0599156
p4494
sg10
I10
sg11
Vtransition
p4495
sg13
I1
sa(dp4496
g7
I137
sg26
VC0007131
p4497
sg10
I26
sg11
Vnon-small cell lung cancer
p4498
sg13
I4
sa(dp4499
g7
I165
sg26
VC0007131
p4500
sg10
I5
sg11
VNSCLC
p4501
sg13
I1
sa(dp4502
g7
I123
sg26
VC0027627
p4503
sg10
I10
sg11
Vmetastasis
p4504
sg13
I1
sa(dp4505
g7
I165
sg26
VC0007131
p4506
sg10
I5
sg11
VNSCLC
p4507
sg13
I1
sasa(dp4508
g2
S'The correlation of TRIM16 expression and clinical features of NSCLC was analyzed in paraffin-embedded archived normal lung tissues and NSCLC tissues by immunohistochemical analysis.\n'
p4509
sg4
(lp4510
(dp4511
g7
I19
sg8
g15
sg10
I6
sg11
VTRIM16
p4512
sg13
I1
sasg23
(lp4513
(dp4514
g7
I62
sg26
VC0007131
p4515
sg10
I5
sg11
VNSCLC
p4516
sg13
I1
sa(dp4517
g7
I62
sg26
VC0007131
p4518
sg10
I5
sg11
VNSCLC
p4519
sg13
I1
sasa(dp4520
g2
S'The expression of TRIM16 was markedly decreased in NSCLC and correlated with tumor metastasis.\n'
p4521
sg4
(lp4522
(dp4523
g7
I18
sg8
g15
sg10
I6
sg11
VTRIM16
p4524
sg13
I1
sasg23
(lp4525
(dp4526
g7
I51
sg26
VC0007131
p4527
sg10
I5
sg11
VNSCLC
p4528
sg13
I1
sa(dp4529
g7
I77
sg26
VC0027627
p4530
sg10
I16
sg11
Vtumor metastasis
p4531
sg13
I2
sasa(dp4532
g2
S'Upregulation of TRIM16 significantly inhibited EMT and metastasis of NSCLC cells.\n'
p4533
sg4
(lp4534
(dp4535
g7
I16
sg8
g15
sg10
I6
sg11
VTRIM16
p4536
sg13
I1
sasg23
(lp4537
(dp4538
g7
I55
sg26
VC0027627
p4539
sg10
I10
sg11
Vmetastasis
p4540
sg13
I1
sa(dp4541
g7
I69
sg26
VC0007131
p4542
sg10
I5
sg11
VNSCLC
p4543
sg13
I1
sasa(dp4544
g2
S'In contrast, silencing TRIM16 expression significantly promoted the EMT and metastasis of NSCLC cells both in vitro and in vivo.\n'
p4545
sg4
(lp4546
(dp4547
g7
I23
sg8
g15
sg10
I6
sg11
VTRIM16
p4548
sg13
I1
sasg23
(lp4549
(dp4550
g7
I76
sg26
VC0027627
p4551
sg10
I10
sg11
Vmetastasis
p4552
sg13
I1
sa(dp4553
g7
I90
sg26
VC0007131
p4554
sg10
I5
sg11
VNSCLC
p4555
sg13
I1
sasa(dp4556
g2
S'Moreover, we demonstrated that downregulation of TRIM16 activated the sonic hedgehog pathway, and that inhibition of the sonic hedgehog pathway by cyclopamine abrogated the effect of TRIM16-downregulation induced EMT and metastasis on NSCLC cells.\n'
p4557
sg4
(lp4558
(dp4559
g7
I213
sg8
g15
sg10
I3
sg11
VEMT
p4560
sg13
I1
sa(dp4561
g7
I49
sg8
g15
sg10
I6
sg11
VTRIM16
p4562
sg13
I1
sa(dp4563
g7
I49
sg8
g15
sg10
I6
sg11
VTRIM16
p4564
sg13
I1
sasg23
(lp4565
(dp4566
g7
I221
sg26
VC0027627
p4567
sg10
I10
sg11
Vmetastasis
p4568
sg13
I1
sa(dp4569
g7
I235
sg26
VC0007131
p4570
sg10
I5
sg11
VNSCLC
p4571
sg13
I1
sasa(dp4572
g2
S'Our results suggest that TRIM16 is a potential pharmacologic target for the treatment of NSCLC and promotion TRIM16 expression might represent a novel strategy to NSCLC metastasis.\n'
p4573
sg4
(lp4574
(dp4575
g7
I25
sg8
g15
sg10
I6
sg11
VTRIM16
p4576
sg13
I1
sa(dp4577
g7
I25
sg8
g15
sg10
I6
sg11
VTRIM16
p4578
sg13
I1
sasg23
(lp4579
(dp4580
g7
I89
sg26
VC0007131
p4581
sg10
I5
sg11
VNSCLC
p4582
sg13
I1
sa(dp4583
g7
I89
sg26
VC0007131
p4584
sg10
I5
sg11
VNSCLC
p4585
sg13
I1
sa(dp4586
g7
I169
sg26
VC0027627
p4587
sg10
I10
sg11
Vmetastasis
p4588
sg13
I1
sasa(dp4589
g2
S'High basal or induced expression of the tripartite motif protein, TRIM16, leads to reduce cell growth and migration of neuroblastoma and skin squamous cell carcinoma cells.\n'
p4590
sg4
(lp4591
(dp4592
g7
I66
sg8
g15
sg10
I6
sg11
VTRIM16
p4593
sg13
I1
sasg23
(lp4594
(dp4595
g7
I137
sg26
VC0553723
p4596
sg10
I28
sg11
Vskin squamous cell carcinoma
p4597
sg13
I4
sa(dp4598
g7
I119
sg26
VC0027819
p4599
sg10
I13
sg11
Vneuroblastoma
p4600
sg13
I1
sasa(dp4601
g2
S'However, the role of TRIM16 in melanoma is currently unknown.\n'
p4602
sg4
(lp4603
(dp4604
g7
I21
sg8
g15
sg10
I6
sg11
VTRIM16
p4605
sg13
I1
sasg23
(lp4606
(dp4607
g7
I31
sg26
VC0025202
p4608
sg10
I8
sg11
Vmelanoma
p4609
sg13
I1
sasa(dp4610
g2
S'TRIM16 protein levels were markedly reduced in human melanoma cell lines, compared with normal human epidermal melanocytes due to both DNA methylation and reduced protein stability.\n'
p4611
sg4
(lp4612
(dp4613
g7
I0
sg8
g15
sg10
I14
sg11
VTRIM16 protein
p4614
sg13
I2
sasg23
(lp4615
(dp4616
g7
I53
sg26
VC0025202
p4617
sg10
I8
sg11
Vmelanoma
p4618
sg13
I1
sasa(dp4619
g2
S'TRIM16 knockdown strongly increased cell migration in normal human epidermal melanocytes, while TRIM16 overexpression reduced cell migration and proliferation of melanoma cells in an interferon beta 1 (IFNBeta1)-dependent manner.\n'
p4620
sg4
(lp4621
(dp4622
g7
I202
sg8
VP01574
p4623
sg10
I8
sg11
VIFNBeta1
p4624
sg13
I1
sa(dp4625
g7
I183
sg8
VP01574
p4626
sg10
I17
sg11
Vinterferon beta 1
p4627
sg13
I3
sa(dp4628
g7
I0
sg8
g15
sg10
I6
sg11
VTRIM16
p4629
sg13
I1
sa(dp4630
g7
I0
sg8
g15
sg10
I6
sg11
VTRIM16
p4631
sg13
I1
sasg23
(lp4632
(dp4633
g7
I162
sg26
VC0025202
p4634
sg10
I8
sg11
Vmelanoma
p4635
sg13
I1
sa(dp4636
g7
I145
sg26
VC0334094
p4637
sg10
I13
sg11
Vproliferation
p4638
sg13
I1
sasa(dp4639
g2
S'Low level TRIM16 expression in 91 melanoma patient samples, strongly correlated with lymph node metastasis, and, predicted poor patient prognosis in a separate cohort of 170 melanoma patients with lymph node metastasis.\n'
p4640
sg4
(lp4641
(dp4642
g7
I10
sg8
g15
sg10
I6
sg11
VTRIM16
p4643
sg13
I1
sasg23
(lp4644
(dp4645
g7
I85
sg26
VC0686619
p4646
sg10
I21
sg11
Vlymph node metastasis
p4647
sg13
I3
sa(dp4648
g7
I34
sg26
VC0025202
p4649
sg10
I8
sg11
Vmelanoma
p4650
sg13
I1
sa(dp4651
g7
I85
sg26
VC0686619
p4652
sg10
I21
sg11
Vlymph node metastasis
p4653
sg13
I3
sa(dp4654
g7
I34
sg26
VC0025202
p4655
sg10
I8
sg11
Vmelanoma
p4656
sg13
I1
sasa(dp4657
g2
S'The BRAF inhibitor, vemurafenib, increased TRIM16 protein levels in melanoma cells in vitro, and induced growth arrest in BRAF-mutant melanoma cells in a TRIM16-dependent manner.\n'
p4658
sg4
(lp4659
(dp4660
g7
I4
sg8
VP15056
p4661
sg10
I4
sg11
VBRAF
p4662
sg13
I1
sa(dp4663
g7
I43
sg8
g15
sg10
I6
sg11
VTRIM16
p4664
sg13
I1
sa(dp4665
g7
I43
sg8
g15
sg10
I14
sg11
VTRIM16 protein
p4666
sg13
I2
sa(dp4667
g7
I4
sg8
VP15056
p4668
sg10
I4
sg11
VBRAF
p4669
sg13
I1
sasg23
(lp4670
(dp4671
g7
I68
sg26
VC0025202
p4672
sg10
I8
sg11
Vmelanoma
p4673
sg13
I1
sa(dp4674
g7
I68
sg26
VC0025202
p4675
sg10
I8
sg11
Vmelanoma
p4676
sg13
I1
sa(dp4677
g7
I127
sg26
VC0596988
p4678
sg10
I6
sg11
Vmutant
p4679
sg13
I1
sa(dp4680
g7
I105
sg26
VC0333951
p4681
sg10
I13
sg11
Vgrowth arrest
p4682
sg13
I2
sasa(dp4683
g2
S'High levels of TRIM16 in melanoma tissues from patients treated with Vemurafenib correlated with clinical response.\n'
p4684
sg4
(lp4685
(dp4686
g7
I15
sg8
g15
sg10
I6
sg11
VTRIM16
p4687
sg13
I1
sasg23
(lp4688
(dp4689
g7
I25
sg26
VC0025202
p4690
sg10
I8
sg11
Vmelanoma
p4691
sg13
I1
sasa(dp4692
g2
S'Our data, for the first time, demonstrates TRIM16 is a marker of cell migration and metastasis, and a novel treatment target in melanoma.\n'
p4693
sg4
(lp4694
(dp4695
g7
I43
sg8
g15
sg10
I6
sg11
VTRIM16
p4696
sg13
I1
sasg23
(lp4697
(dp4698
g7
I128
sg26
VC0025202
p4699
sg10
I8
sg11
Vmelanoma
p4700
sg13
I1
sa(dp4701
g7
I84
sg26
VC0027627
p4702
sg10
I10
sg11
Vmetastasis
p4703
sg13
I1
sasa(dp4704
g2
S'Recently it has been reported that Shosaiko-to (SHO), a traditional Chinese medicine used for treating gastritis and hepatitis, also has been found useful for treating gastric ulcers, although no pharmacological study has yet investigated the precise antiulcer properties of SHO.\n'
p4705
sg4
(lp4706
(dp4707
g7
I48
sg8
g15
sg10
I3
sg11
VSHO
p4708
sg13
I1
sa(dp4709
g7
I48
sg8
g15
sg10
I3
sg11
VSHO
p4710
sg13
I1
sa(dp4711
g7
I35
sg8
g15
sg10
I11
sg11
VShosaiko-to
p4712
sg13
I1
sasg23
(lp4713
(dp4714
g7
I168
sg26
VC0038358
p4715
sg10
I14
sg11
Vgastric ulcers
p4716
sg13
I2
sa(dp4717
g7
I103
sg26
VC0017152
p4718
sg10
I9
sg11
Vgastritis
p4719
sg13
I1
sa(dp4720
g7
I117
sg26
VC0019159
p4721
sg10
I9
sg11
Vhepatitis
p4722
sg13
I1
sasa(dp4723
g2
S'Shosaiko-to (Xiao-chai-hu-tang, SHO), which is a Kampo medicine prepared by decocting a prescription of 7 kinds of medical plants, has been used mainly to treat chronic hepatitis in Japan.\n'
p4724
sg4
(lp4725
sg23
(lp4726
(dp4727
g7
I161
sg26
VC0019189
p4728
sg10
I17
sg11
Vchronic hepatitis
p4729
sg13
I2
sasa(dp4730
g2
S'The ability of FEX to enhance CC10 production may account, at least in part, for the clinical efficacy of the agent in allergic disorders, including allergic rhinitis.\n'
p4731
sg4
(lp4732
(dp4733
g7
I15
sg8
g15
sg10
I3
sg11
VFEX
p4734
sg13
I1
sasg23
(lp4735
(dp4736
g7
I149
sg26
VC2607914
p4737
sg10
I17
sg11
Vallergic rhinitis
p4738
sg13
I2
sa(dp4739
g7
I119
sg26
VC0020517
p4740
sg10
I18
sg11
Vallergic disorders
p4741
sg13
I2
sasa(dp4742
g2
S'Fexofenadine HCl (FEX) has previously been shown to have anti-inflammatory properties in relieving nasal congestion in allergic rhinitis.\n'
p4743
sg4
(lp4744
sg23
(lp4745
(dp4746
g7
I119
sg26
VC2607914
p4747
sg10
I17
sg11
Vallergic rhinitis
p4748
sg13
I2
sa(dp4749
g7
I99
sg26
VC0027424
p4750
sg10
I16
sg11
Vnasal congestion
p4751
sg13
I2
sasa(dp4752
g2
S'This selective COX-2 inhibitor activity by FEX may contribute to its anti-inflammatory properties in relieving nasal congestion in allergic rhinitis.\n'
p4753
sg4
(lp4754
(dp4755
g7
I43
sg8
g15
sg10
I3
sg11
VFEX
p4756
sg13
I1
sa(dp4757
g7
I15
sg8
VP35354
p4758
sg10
I5
sg11
VCOX-2
p4759
sg13
I1
sasg23
(lp4760
(dp4761
g7
I111
sg26
VC0027424
p4762
sg10
I16
sg11
Vnasal congestion
p4763
sg13
I2
sa(dp4764
g7
I131
sg26
VC2607914
p4765
sg10
I17
sg11
Vallergic rhinitis
p4766
sg13
I2
sasa(dp4767
g2
S'A 24-h extended-release formulation of fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg (FEX 180 mg/PSE 240 mg) has recently been approved by the US Food and Drug Administration for symptom relief of seasonal allergic rhinitis, including nasal congestion.\n'
p4768
sg4
(lp4769
sg23
(lp4770
(dp4771
g7
I184
sg26
VC1457887
p4772
sg10
I7
sg11
Vsymptom
p4773
sg13
I1
sa(dp4774
g7
I240
sg26
VC0027424
p4775
sg10
I16
sg11
Vnasal congestion
p4776
sg13
I2
sa(dp4777
g7
I202
sg26
VC0018621
p4778
sg10
I26
sg11
Vseasonal allergic rhinitis
p4779
sg13
I3
sasa(dp4780
g2
S'We elected to study the effects of usual clinically recommended doses of fexofenadine (FEX), montelukast (ML) and FEX + ML combination, compared with placebo (PL), on nasal AMP challenge in patients with persistent allergic rhinitis.\n'
p4781
sg4
(lp4782
sg23
(lp4783
(dp4784
g7
I215
sg26
VC2607914
p4785
sg10
I17
sg11
Vallergic rhinitis
p4786
sg13
I2
sasa(dp4787
g2
S'Twelve patients with persistent allergic rhinitis (all skin prick positive to house dust mite) were randomized in a double-blind cross-over fashion to receive for 1 week either FEX 180 mg, ML 10 mg, FEX 180 mg + ML 10 mg combination, or PL, with nasal AMP challenge performed 12 h after dosing.\n'
p4788
sg4
(lp4789
sg23
(lp4790
(dp4791
g7
I32
sg26
VC2607914
p4792
sg10
I17
sg11
Vallergic rhinitis
p4793
sg13
I2
sa(dp4794
g7
I55
sg26
VC0476227
p4795
sg10
I10
sg11
Vskin prick
p4796
sg13
I2
sa(dp4797
g7
I123
sg26
VC0456909
p4798
sg10
I5
sg11
Vblind
p4799
sg13
I1
sasa(dp4800
g2
S'Objective We elected to study the comparative effectiveness of usual clinically recommended doses of desloratadine (DES), fexofenadine (FEX), and levocetirizine (LEV), on nasal adenosine monophosphate (AMP) challenge in patients with perennial allergic rhinitis (PAR).\n'
p4801
sg4
(lp4802
sg23
(lp4803
(dp4804
g7
I234
sg26
VC0035457
p4805
sg10
I27
sg11
Vperennial allergic rhinitis
p4806
sg13
I3
sa(dp4807
g7
I101
sg26
VC0394006
p4808
sg10
I13
sg11
Vdesloratadine
p4809
sg13
I1
sa(dp4810
g7
I116
sg26
VC0394006
p4811
sg10
I3
sg11
VDES
p4812
sg13
I1
sa(dp4813
g7
I263
sg26
VC0035457
p4814
sg10
I3
sg11
VPAR
p4815
sg13
I1
sasa(dp4816
g2
S'We performed a placebo-controlled evaluation of the effects of BB and fexofenadine (FEX) on subjective and objective outcomes in patients with perennial allergic rhinitis.\n'
p4817
sg4
(lp4818
sg23
(lp4819
(dp4820
g7
I143
sg26
VC0035457
p4821
sg10
I27
sg11
Vperennial allergic rhinitis
p4822
sg13
I3
sasa(dp4823
g2
S'Sixteen patients with perennial allergic rhinitis and house dust mite sensitization were randomized in double-blind cross-over fashion to receive for 1 week either BB 50 mg twice daily, FEX 180 mg once daily and placebo (PL) once daily, or PL twice daily.\n'
p4824
sg4
(lp4825
sg23
(lp4826
(dp4827
g7
I22
sg26
VC0035457
p4828
sg10
I27
sg11
Vperennial allergic rhinitis
p4829
sg13
I3
sa(dp4830
g7
I110
sg26
VC0456909
p4831
sg10
I5
sg11
Vblind
p4832
sg13
I1
sasa(dp4833
g2
S'BB and FEX, in comparison to PL, were equally effective in attenuating the nasal response to AMP and in improving nasal symptoms, highlighting a potential role for BB in the treatment of allergic rhinitis.\n'
p4834
sg4
(lp4835
sg23
(lp4836
(dp4837
g7
I187
sg26
VC2607914
p4838
sg10
I17
sg11
Vallergic rhinitis
p4839
sg13
I2
sa(dp4840
g7
I114
sg26
VC0231918
p4841
sg10
I14
sg11
Vnasal symptoms
p4842
sg13
I2
sasa(dp4843
g2
S'In vitro studies have shown much higher H1-receptor antagonist potency with desloratadine (DL) compared to fexofenadine (FEX), although it is unclear whether this has any clinical relevance on disease control parameters in seasonal allergic rhinitis (SAR), especially for nasal congestion.\n'
p4844
sg4
(lp4845
(dp4846
g7
I40
sg8
g15
sg10
I11
sg11
VH1-receptor
p4847
sg13
I1
sasg23
(lp4848
(dp4849
g7
I223
sg26
VC0018621
p4850
sg10
I26
sg11
Vseasonal allergic rhinitis
p4851
sg13
I3
sa(dp4852
g7
I251
sg26
VC0018621
p4853
sg10
I3
sg11
VSAR
p4854
sg13
I1
sa(dp4855
g7
I272
sg26
VC0027424
p4856
sg10
I16
sg11
Vnasal congestion
p4857
sg13
I2
sasa(dp4858
g2
S'Protein disulfide isomerase a4 (PDIA4) is implicated in the growth and death of tumor cells; however, its molecular mechanism and therapeutic potential in cancer are unclear.\n'
p4859
sg4
(lp4860
(dp4861
g7
I32
sg8
VP13667
p4862
sg10
I5
sg11
VPDIA4
p4863
sg13
I1
sa(dp4864
g7
I0
sg8
VP13667
p4865
sg10
I30
sg11
VProtein disulfide isomerase a4
p4866
sg13
I4
sasg23
(lp4867
(dp4868
g7
I155
sg26
VC0006826
p4869
sg10
I6
sg11
Vcancer
p4870
sg13
I1
sa(dp4871
g7
I80
sg26
VC0027651
p4872
sg10
I5
sg11
Vtumor
p4873
sg13
I1
sasa(dp4874
g2
S'Here, we found that PDIA4 expression was upregulated in a variety of tumor cell lines and human lung adenocarcinoma tissues.\n'
p4875
sg4
(lp4876
(dp4877
g7
I20
sg8
VP13667
p4878
sg10
I5
sg11
VPDIA4
p4879
sg13
I1
sasg23
(lp4880
(dp4881
g7
I69
sg26
VC0027651
p4882
sg10
I5
sg11
Vtumor
p4883
sg13
I1
sa(dp4884
g7
I96
sg26
VC0152013
p4885
sg10
I19
sg11
Vlung adenocarcinoma
p4886
sg13
I2
sasa(dp4887
g2
S'Consistently, Lewis lung carcinoma cells overexpressing PDIA4 grew faster than did parental cells in tumor-bearing mice, as shown by a reduced survival rate, increased tumor size and metastasis, and decreased cell death and caspases 3 and 7 activity.\n'
p4888
sg4
(lp4889
(dp4890
g7
I56
sg8
VP13667
p4891
sg10
I5
sg11
VPDIA4
p4892
sg13
I1
sa(dp4893
g7
I224
sg8
VP39880
p4894
sg10
I10
sg11
Vcaspases 3
p4895
sg13
I2
sasg23
(lp4896
(dp4897
g7
I101
sg26
VC0027651
p4898
sg10
I5
sg11
Vtumor
p4899
sg13
I1
sa(dp4900
g7
I101
sg26
VC0027651
p4901
sg10
I5
sg11
Vtumor
p4902
sg13
I1
sa(dp4903
g7
I183
sg26
VC0027627
p4904
sg10
I10
sg11
Vmetastasis
p4905
sg13
I1
sa(dp4906
g7
I14
sg26
VC0243038
p4907
sg10
I20
sg11
VLewis lung carcinoma
p4908
sg13
I3
sasa(dp4909
g2
S'Moreover, results obtained in mice with spontaneous hepatoma indicated that PDIA4 deficiency significantly reduced hepatic tumorigenesis and cyst formation and increased mouse survival, tumor death, and caspases 3 and 7 activity.\n'
p4910
sg4
(lp4911
(dp4912
g7
I76
sg8
VP13667
p4913
sg10
I5
sg11
VPDIA4
p4914
sg13
I1
sa(dp4915
g7
I203
sg8
VP39880
p4916
sg10
I10
sg11
Vcaspases 3
p4917
sg13
I2
sasg23
(lp4918
(dp4919
g7
I52
sg26
VC0023903
p4920
sg10
I8
sg11
Vhepatoma
p4921
sg13
I1
sa(dp4922
g7
I123
sg26
VC0027651
p4923
sg10
I5
sg11
Vtumor
p4924
sg13
I1
sa(dp4925
g7
I141
sg26
VC0010709
p4926
sg10
I4
sg11
Vcyst
p4927
sg13
I1
sa(dp4928
g7
I123
sg26
VC0007621
p4929
sg10
I13
sg11
Vtumorigenesis
p4930
sg13
I1
sasa(dp4931
g2
S'These findings characterize PDIA4 as a negative regulator of cancer cell apoptosis and suggest that PDIA4 is a potential therapeutic target for cancer.\n'
p4932
sg4
(lp4933
(dp4934
g7
I28
sg8
VP13667
p4935
sg10
I5
sg11
VPDIA4
p4936
sg13
I1
sa(dp4937
g7
I28
sg8
VP13667
p4938
sg10
I5
sg11
VPDIA4
p4939
sg13
I1
sasg23
(lp4940
(dp4941
g7
I61
sg26
VC0006826
p4942
sg10
I6
sg11
Vcancer
p4943
sg13
I1
sa(dp4944
g7
I61
sg26
VC0006826
p4945
sg10
I6
sg11
Vcancer
p4946
sg13
I1
sasa(dp4947
g2
S'Top cancer-associated protein alterations were characterized by: (1) elevations in APEX1, HYOU1 and PDIA4, indicative of increased DNA repair machinery and heightened anti-oxidant defense mechanisms; (2) increased LRPPRC, STOML2, COPG1 and EPRS, suggesting altered tumor metabolism and inflammation; (3) reductions in SPTB, SPTA1 and ANK1 implying dysregulation of membrane integrity; and (4) decreased SLCA41 suggesting altered pH regulation.\n'
p4948
sg4
(lp4949
(dp4950
g7
I100
sg8
VP13667
p4951
sg10
I5
sg11
VPDIA4
p4952
sg13
I1
sa(dp4953
g7
I318
sg8
g15
sg10
I4
sg11
VSPTB
p4954
sg13
I1
sa(dp4955
g7
I240
sg8
VP19235
p4956
sg10
I4
sg11
VEPRS
p4957
sg13
I1
sa(dp4958
g7
I83
sg8
VP27695
p4959
sg10
I5
sg11
VAPEX1
p4960
sg13
I1
sa(dp4961
g7
I214
sg8
VP42704
p4962
sg10
I6
sg11
VLRPPRC
p4963
sg13
I1
sa(dp4964
g7
I334
sg8
VP16157
p4965
sg10
I4
sg11
VANK1
p4966
sg13
I1
sa(dp4967
g7
I222
sg8
g15
sg10
I6
sg11
VSTOML2
p4968
sg13
I1
sa(dp4969
g7
I324
sg8
VP02549
p4970
sg10
I5
sg11
VSPTA1
p4971
sg13
I1
sa(dp4972
g7
I230
sg8
g15
sg10
I5
sg11
VCOPG1
p4973
sg13
I1
sa(dp4974
g7
I90
sg8
g15
sg10
I5
sg11
VHYOU1
p4975
sg13
I1
sasg23
(lp4976
(dp4977
g7
I4
sg26
VC0006826
p4978
sg10
I6
sg11
Vcancer
p4979
sg13
I1
sa(dp4980
g7
I265
sg26
VC0027651
p4981
sg10
I5
sg11
Vtumor
p4982
sg13
I1
sa(dp4983
g7
I286
sg26
VC0021368
p4984
sg10
I12
sg11
Vinflammation
p4985
sg13
I1
sasa(dp4986
g2
S'Here, we demonstrate that CDDP-resistant non-small lung cancer cells undergo profound remodeling of their endoplasmic reticulum (ER) proteome (&gt;80 proteins identified by proteomics) and exhibit a dramatic overexpression of two protein disulfide isomerases, PDIA4 and PDIA6, without any alteration in ER-cytosol Ca(2+) fluxes.\n'
p4987
sg4
(lp4988
(dp4989
g7
I260
sg8
VP13667
p4990
sg10
I5
sg11
VPDIA4
p4991
sg13
I1
sa(dp4992
g7
I270
sg8
g15
sg10
I5
sg11
VPDIA6
p4993
sg13
I1
sasg23
(lp4994
(dp4995
g7
I51
sg26
VC0684249
p4996
sg10
I11
sg11
Vlung cancer
p4997
sg13
I2
sasa(dp4998
g2
S'Ten heat-shock-protein- (HSP-) associated protein complexes were separated and identified, and the differentially expressed proteins related to cancers were also found, such as HSP60, protein disulfide-isomerase A4 (ERp72), and transitional endoplasmic reticulum ATPase (TER ATPase).\n'
p4999
sg4
(lp5000
(dp5001
g7
I4
sg8
g15
sg10
I55
sg11
Vheat-shock-protein- (HSP-) associated protein complexes
p5002
sg13
I5
sa(dp5003
g7
I216
sg8
VP13667
p5004
sg10
I5
sg11
VERp72
p5005
sg13
I1
sa(dp5006
g7
I228
sg8
g15
sg10
I41
sg11
Vtransitional endoplasmic reticulum ATPase
p5007
sg13
I4
sa(dp5008
g7
I177
sg8
VP10809
p5009
sg10
I5
sg11
VHSP60
p5010
sg13
I1
sa(dp5011
g7
I271
sg8
g15
sg10
I10
sg11
VTER ATPase
p5012
sg13
I2
sasg23
(lp5013
(dp5014
g7
I144
sg26
VC0006826
p5015
sg10
I7
sg11
Vcancers
p5016
sg13
I1
sa(dp5017
g7
I25
sg26
VC0034152
p5018
sg10
I3
sg11
VHSP
p5019
sg13
I1
sasa(dp5020
g2
S'Anti-CENPB was associated with joint pain [odds ratio (OR) 0.17], interstitial lung disease (OR 0.24) and telangiectasia (OR 4.00) (P &lt; 0.05).\n'
p5021
sg4
(lp5022
(dp5023
g7
I0
sg8
VP07199
p5024
sg10
I10
sg11
VAnti-CENPB
p5025
sg13
I1
sasg23
(lp5026
(dp5027
g7
I106
sg26
VC0039446
p5028
sg10
I14
sg11
Vtelangiectasia
p5029
sg13
I1
sa(dp5030
g7
I66
sg26
VC0206062
p5031
sg10
I25
sg11
Vinterstitial lung disease
p5032
sg13
I3
sa(dp5033
g7
I31
sg26
VC0003862
p5034
sg10
I10
sg11
Vjoint pain
p5035
sg13
I2
sasa(dp5036
g2
S'Congenital anonychia is an inherited autosomal recessive disorder characterized by complete absence of fingernails or toenails, or both.\n'
p5037
sg4
(lp5038
sg23
(lp5039
(dp5040
g7
I11
sg26
VC0265998
p5041
sg10
I9
sg11
Vanonychia
p5042
sg13
I1
sasa(dp5043
g2
S'Previous studies have identified mutations in the RSPO4 and LMX1B components of the Wnt pathway in patients with the hypoplastic nail disorders anonychia and nail-patella syndrome, respectively.\n'
p5044
sg4
(lp5045
(dp5046
g7
I60
sg8
g15
sg10
I5
sg11
VLMX1B
p5047
sg13
I1
sa(dp5048
g7
I50
sg8
g15
sg10
I5
sg11
VRSPO4
p5049
sg13
I1
sasg23
(lp5050
(dp5051
g7
I144
sg26
VC0265998
p5052
sg10
I9
sg11
Vanonychia
p5053
sg13
I1
sa(dp5054
g7
I129
sg26
VC0027339
p5055
sg10
I14
sg11
Vnail disorders
p5056
sg13
I2
sa(dp5057
g7
I158
sg26
VC0027341
p5058
sg10
I21
sg11
Vnail-patella syndrome
p5059
sg13
I2
sasa(dp5060
g2
S'Congenital anonychia is a rare autosomal-recessive disorder characterized by the absence of finger- and toenails.\n'
p5061
sg4
(lp5062
sg23
(lp5063
(dp5064
g7
I11
sg26
VC0265998
p5065
sg10
I9
sg11
Vanonychia
p5066
sg13
I1
sasa(dp5067
g2
S'The results suggest that consumption of a white corn/bean snack (70%/30% blend) attenuates weight gain, fat mass accumulation, adipocyte size and nonalcoholic fatty liver disease in HFD-fed mice by inhibiting PPARGamma and SREBF2.\n'
p5068
sg4
(lp5069
(dp5070
g7
I223
sg8
g15
sg10
I6
sg11
VSREBF2
p5071
sg13
I1
sasg23
(lp5072
(dp5073
g7
I146
sg26
VC0400966
p5074
sg10
I32
sg11
Vnonalcoholic fatty liver disease
p5075
sg13
I4
sa(dp5076
g7
I48
sg26
VC0010046
p5077
sg10
I4
sg11
Vcorn
p5078
sg13
I1
sasa(dp5079
g2
S'These results demonstrated that the gene polymorphism of SREBP2 not only significantly associated with the clinical phenotypes of ONFH but also closely related to lipid metabolism disorder.\n'
p5080
sg4
(lp5081
(dp5082
g7
I57
sg8
g15
sg10
I6
sg11
VSREBP2
p5083
sg13
I1
sasg23
(lp5084
(dp5085
g7
I163
sg26
VC0154251
p5086
sg10
I25
sg11
Vlipid metabolism disorder
p5087
sg13
I3
sasa(dp5088
g2
S'Farnesoid X receptor (FXR, NR1H4) plays an important role in the regulation of bile acid homeostasis in liver and intestine and may exert protective effects against certain forms of cancer such as colon carcinoma.\n'
p5089
sg4
(lp5090
(dp5091
g7
I22
sg8
VP23945
p5092
sg10
I3
sg11
VFXR
p5093
sg13
I1
sa(dp5094
g7
I0
sg8
g15
sg10
I20
sg11
VFarnesoid X receptor
p5095
sg13
I3
sa(dp5096
g7
I27
sg8
g15
sg10
I5
sg11
VNR1H4
p5097
sg13
I1
sasg23
(lp5098
(dp5099
g7
I182
sg26
VC0006826
p5100
sg10
I6
sg11
Vcancer
p5101
sg13
I1
sa(dp5102
g7
I197
sg26
VC0699790
p5103
sg10
I15
sg11
Vcolon carcinoma
p5104
sg13
I2
sasa(dp5105
g2
S'Similar to FXR, microRNA-192 (miR-192) is mainly expressed in the liver and colon and plays an important role in the pathogenesis of colon carcinoma.\n'
p5106
sg4
(lp5107
(dp5108
g7
I11
sg8
VP23945
p5109
sg10
I3
sg11
VFXR
p5110
sg13
I1
sasg23
(lp5111
(dp5112
g7
I117
sg26
VC0699748
p5113
sg10
I12
sg11
Vpathogenesis
p5114
sg13
I1
sa(dp5115
g7
I133
sg26
VC0699790
p5116
sg10
I15
sg11
Vcolon carcinoma
p5117
sg13
I2
sasa(dp5118
g2
S'In addition, the correlation between FXR and miR-192 expression was studied by linear regression analyses in colonic adenocarcinoma tissue from 27 patients.\n'
p5119
sg4
(lp5120
(dp5121
g7
I37
sg8
VP23945
p5122
sg10
I3
sg11
VFXR
p5123
sg13
I1
sa(dp5124
g7
I45
sg8
g15
sg10
I7
sg11
VmiR-192
p5125
sg13
I1
sasg23
(lp5126
(dp5127
g7
I109
sg26
VC0338106
p5128
sg10
I22
sg11
Vcolonic adenocarcinoma
p5129
sg13
I2
sasa(dp5130
g2
S'Significant inverse correlations were detected in colonic adenocarcinoma between NR1H4 mRNA and miR-192-3p expression.\n'
p5131
sg4
(lp5132
(dp5133
g7
I96
sg8
g15
sg10
I10
sg11
VmiR-192-3p
p5134
sg13
I1
sa(dp5135
g7
I81
sg8
g15
sg10
I10
sg11
VNR1H4 mRNA
p5136
sg13
I2
sasg23
(lp5137
(dp5138
g7
I50
sg26
VC0338106
p5139
sg10
I22
sg11
Vcolonic adenocarcinoma
p5140
sg13
I2
sasa(dp5141
g2
S'In vitro, we measured the impact of APC inactivation and deoxycholic acid (DCA) treatment on FXR expression in human colon cancer HCT-116 cells transfected with silencing RNA for APC and HT-29 cells carrying inactivated APC.\n'
p5142
sg4
(lp5143
(dp5144
g7
I36
sg8
VP25054
p5145
sg10
I3
sg11
VAPC
p5146
sg13
I1
sa(dp5147
g7
I93
sg8
VP23945
p5148
sg10
I3
sg11
VFXR
p5149
sg13
I1
sa(dp5150
g7
I36
sg8
VP25054
p5151
sg10
I3
sg11
VAPC
p5152
sg13
I1
sasg23
(lp5153
(dp5154
g7
I40
sg26
VC0544461
p5155
sg10
I12
sg11
Vinactivation
p5156
sg13
I1
sa(dp5157
g7
I36
sg26
VC0033036
p5158
sg10
I3
sg11
VAPC
p5159
sg13
I1
sa(dp5160
g7
I36
sg26
VC0033036
p5161
sg10
I3
sg11
VAPC
p5162
sg13
I1
sa(dp5163
g7
I117
sg26
VC0699790
p5164
sg10
I12
sg11
Vcolon cancer
p5165
sg13
I2
sa(dp5166
g7
I36
sg26
VC0033036
p5167
sg10
I3
sg11
VAPC
p5168
sg13
I1
sasa(dp5169
g2
S'In human HCT-116 but not HT-29 colon cancer cells, DCA induced FXR expression and lowered CpG methylation of FXR.\n'
p5170
sg4
(lp5171
(dp5172
g7
I63
sg8
VP23945
p5173
sg10
I3
sg11
VFXR
p5174
sg13
I1
sa(dp5175
g7
I63
sg8
VP23945
p5176
sg10
I3
sg11
VFXR
p5177
sg13
I1
sasg23
(lp5178
(dp5179
g7
I31
sg26
VC0699790
p5180
sg10
I12
sg11
Vcolon cancer
p5181
sg13
I2
sasa(dp5182
g2
S'We conclude that the loss of APC function favors the silencing of FXR expression through CpG hypermethylation in mouse colonic mucosa and human colon cells, leading to reduced expression of downstream targets (SHP, IBABP) involved in BA homeostasis while increasing the expression of factors (COX-2, c-MYC) that contribute to inflammation and colon cancer.\n'
p5183
sg4
(lp5184
(dp5185
g7
I66
sg8
VP23945
p5186
sg10
I3
sg11
VFXR
p5187
sg13
I1
sa(dp5188
g7
I29
sg8
VP25054
p5189
sg10
I3
sg11
VAPC
p5190
sg13
I1
sa(dp5191
g7
I210
sg8
g15
sg10
I3
sg11
VSHP
p5192
sg13
I1
sa(dp5193
g7
I293
sg8
VP35354
p5194
sg10
I5
sg11
VCOX-2
p5195
sg13
I1
sa(dp5196
g7
I215
sg8
VP51161
p5197
sg10
I5
sg11
VIBABP
p5198
sg13
I1
sa(dp5199
g7
I300
sg8
VP12524
p5200
sg10
I5
sg11
Vc-MYC
p5201
sg13
I1
sasg23
(lp5202
(dp5203
g7
I343
sg26
VC0699790
p5204
sg10
I12
sg11
Vcolon cancer
p5205
sg13
I2
sa(dp5206
g7
I29
sg26
VC0033036
p5207
sg10
I3
sg11
VAPC
p5208
sg13
I1
sa(dp5209
g7
I326
sg26
VC0021368
p5210
sg10
I12
sg11
Vinflammation
p5211
sg13
I1
sasa(dp5212
g2
S'This study investigates the regulation of FXR in the development of human colon cancer.\n'
p5213
sg4
(lp5214
(dp5215
g7
I42
sg8
VP23945
p5216
sg10
I3
sg11
VFXR
p5217
sg13
I1
sasg23
(lp5218
(dp5219
g7
I74
sg26
VC0699790
p5220
sg10
I12
sg11
Vcolon cancer
p5221
sg13
I2
sasa(dp5222
g2
S'We used immunohistochemistry of FXR in normal tissue (n = 238), polyps (n = 32), and adenocarcinomas, staged I-IV (n = 43, 39, 68, and 9), of the colon; RT-quantitative PCR, reverse-phase protein array, and Western blot analysis in 15 colon cancer cell lines; NR1H4 promoter methylation and mRNA expression in colon cancer samples from The Cancer Genome Atlas; DNA methyltransferase inhibition; methyl-DNA immunoprecipitation (MeDIP); bisulfite sequencing; and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) knockdown assessment to investigate FXR regulation in colon cancer development.\n'
p5223
sg4
(lp5224
(dp5225
g7
I515
sg8
VP01116
p5226
sg10
I4
sg11
VKRAS
p5227
sg13
I1
sa(dp5228
g7
I260
sg8
g15
sg10
I14
sg11
VNR1H4 promoter
p5229
sg13
I2
sa(dp5230
g7
I461
sg8
VP01116
p5231
sg10
I52
sg11
VV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
p5232
sg13
I7
sa(dp5233
g7
I32
sg8
VP23945
p5234
sg10
I3
sg11
VFXR
p5235
sg13
I1
sasg23
(lp5236
(dp5237
g7
I64
sg26
VC0032584
p5238
sg10
I6
sg11
Vpolyps
p5239
sg13
I1
sa(dp5240
g7
I85
sg26
VC0001418
p5241
sg10
I15
sg11
Vadenocarcinomas
p5242
sg13
I1
sa(dp5243
g7
I235
sg26
VC0699790
p5244
sg10
I12
sg11
Vcolon cancer
p5245
sg13
I2
sa(dp5246
g7
I479
sg26
VC1882848
p5247
sg10
I11
sg11
Vrat sarcoma
p5248
sg13
I2
sa(dp5249
g7
I340
sg26
VC0006826
p5250
sg10
I6
sg11
VCancer
p5251
sg13
I1
sa(dp5252
g7
I235
sg26
VC0699790
p5253
sg10
I12
sg11
Vcolon cancer
p5254
sg13
I2
sa(dp5255
g7
I235
sg26
VC0699790
p5256
sg10
I12
sg11
Vcolon cancer
p5257
sg13
I2
sasa(dp5258
g2
S'The NR1H4 promoter is methylated in ~12% colon cancer The Cancer Genome Atlas samples, and methylation patterns segregate with tumor subtypes.\n'
p5259
sg4
(lp5260
(dp5261
g7
I4
sg8
g15
sg10
I14
sg11
VNR1H4 promoter
p5262
sg13
I2
sasg23
(lp5263
(dp5264
g7
I127
sg26
VC0027651
p5265
sg10
I5
sg11
Vtumor
p5266
sg13
I1
sa(dp5267
g7
I58
sg26
VC0006826
p5268
sg10
I6
sg11
VCancer
p5269
sg13
I1
sa(dp5270
g7
I41
sg26
VC0699790
p5271
sg10
I12
sg11
Vcolon cancer
p5272
sg13
I2
sasa(dp5273
g2
S'FXR expression is decreased early in human colon cancer progression, and both DNA methylation and KRAS signaling may be contributing factors to FXR silencing.\n'
p5274
sg4
(lp5275
(dp5276
g7
I0
sg8
VP23945
p5277
sg10
I3
sg11
VFXR
p5278
sg13
I1
sa(dp5279
g7
I0
sg8
VP23945
p5280
sg10
I3
sg11
VFXR
p5281
sg13
I1
sa(dp5282
g7
I98
sg8
VP01116
p5283
sg10
I4
sg11
VKRAS
p5284
sg13
I1
sasg23
(lp5285
(dp5286
g7
I49
sg26
VC0178874
p5287
sg10
I18
sg11
Vcancer progression
p5288
sg13
I2
sasa(dp5289
g2
S'FXR potentially suppresses epithelial-to-mesenchymal transition and other oncogenic signaling cascades, and restoration of FXR activity, by blocking silencing mechanisms or increasing residual FXR activity, represents promising therapeutic options for the treatment of colon cancer.\n'
p5290
sg4
(lp5291
(dp5292
g7
I0
sg8
VP23945
p5293
sg10
I3
sg11
VFXR
p5294
sg13
I1
sa(dp5295
g7
I0
sg8
VP23945
p5296
sg10
I3
sg11
VFXR
p5297
sg13
I1
sa(dp5298
g7
I0
sg8
VP23945
p5299
sg10
I3
sg11
VFXR
p5300
sg13
I1
sasg23
(lp5301
(dp5302
g7
I140
sg26
VC0233660
p5303
sg10
I8
sg11
Vblocking
p5304
sg13
I1
sa(dp5305
g7
I269
sg26
VC0699790
p5306
sg10
I12
sg11
Vcolon cancer
p5307
sg13
I2
sa(dp5308
g7
I53
sg26
VC0599156
p5309
sg10
I10
sg11
Vtransition
p5310
sg13
I1
sasa(dp5311
g2
S'Aim of this study was to analyze FXR expression in human normal intestinal mucosa and colon carcinoma.\n'
p5312
sg4
(lp5313
(dp5314
g7
I33
sg8
VP23945
p5315
sg10
I3
sg11
VFXR
p5316
sg13
I1
sasg23
(lp5317
(dp5318
g7
I86
sg26
VC0699790
p5319
sg10
I15
sg11
Vcolon carcinoma
p5320
sg13
I2
sasa(dp5321
g2
S'We achieved systematic mapping of FXR expression of human intestinal mucosa and analysis of 75 human colon carcinomas using FXR immunohistochemistry on formalin-fixed, paraffin-embedded tissue.\n'
p5322
sg4
(lp5323
(dp5324
g7
I34
sg8
VP23945
p5325
sg10
I3
sg11
VFXR
p5326
sg13
I1
sa(dp5327
g7
I124
sg8
VP23945
p5328
sg10
I24
sg11
VFXR immunohistochemistry
p5329
sg13
I2
sasg23
(lp5330
(dp5331
g7
I107
sg26
VC0007097
p5332
sg10
I10
sg11
Vcarcinomas
p5333
sg13
I1
sasa(dp5334
g2
S'Development of colon carcinoma in humans is associated with reduced FXR expression independent of site and may reflect an impaired defense against potentially carcinogenic bile acids along their intestinal gradient.\n'
p5335
sg4
(lp5336
(dp5337
g7
I68
sg8
VP23945
p5338
sg10
I3
sg11
VFXR
p5339
sg13
I1
sasg23
(lp5340
(dp5341
g7
I15
sg26
VC0699790
p5342
sg10
I15
sg11
Vcolon carcinoma
p5343
sg13
I2
sa(dp5344
g7
I122
sg26
VC0684336
p5345
sg10
I8
sg11
Vimpaired
p5346
sg13
I1
sasa(dp5347
g2
S'When FXR is activated in the intestine and in colon cancer cells, there is an induction of apoptosis and removal of genetically altered cells, which may otherwise progress to complete transformation.\n'
p5348
sg4
(lp5349
(dp5350
g7
I5
sg8
VP23945
p5351
sg10
I3
sg11
VFXR
p5352
sg13
I1
sasg23
(lp5353
(dp5354
g7
I46
sg26
VC0699790
p5355
sg10
I12
sg11
Vcolon cancer
p5356
sg13
I2
sa(dp5357
g7
I184
sg26
VC1510411
p5358
sg10
I14
sg11
Vtransformation
p5359
sg13
I1
sasa(dp5360
g2
S'Thus, from a therapeutic standpoint, strategies aimed at reactivating FXR expression in colon tumors might be useful in treatment of colon cancer.\n'
p5361
sg4
(lp5362
(dp5363
g7
I70
sg8
VP23945
p5364
sg10
I3
sg11
VFXR
p5365
sg13
I1
sasg23
(lp5366
(dp5367
g7
I133
sg26
VC0699790
p5368
sg10
I12
sg11
Vcolon cancer
p5369
sg13
I2
sa(dp5370
g7
I88
sg26
VC0009375
p5371
sg10
I12
sg11
Vcolon tumors
p5372
sg13
I2
sasa(dp5373
g2
S'G-CSF administration has neuroprotective effects in CNS and the potential to be a therapeutic agent in multiple sclerosis.\n'
p5374
sg4
(lp5375
(dp5376
g7
I0
sg8
VP09919
p5377
sg10
I5
sg11
VG-CSF
p5378
sg13
I1
sasg23
(lp5379
(dp5380
g7
I103
sg26
VC0026769
p5381
sg10
I18
sg11
Vmultiple sclerosis
p5382
sg13
I2
sasa(dp5383
g2
S'The conclusions of G-CSF treatment in EAE mice suggest that G-CSF is clinically applicable and may be considered for future use in therapeutic measures for multiple sclerosis treatment.\n'
p5384
sg4
(lp5385
(dp5386
g7
I19
sg8
VP09919
p5387
sg10
I5
sg11
VG-CSF
p5388
sg13
I1
sa(dp5389
g7
I19
sg8
VP09919
p5390
sg10
I5
sg11
VG-CSF
p5391
sg13
I1
sasg23
(lp5392
(dp5393
g7
I156
sg26
VC0026769
p5394
sg10
I18
sg11
Vmultiple sclerosis
p5395
sg13
I2
sasa(dp5396
g2
S'In a group of 19 consecutive patients with multiple sclerosis given autografts, we employed granulocyte colony-stimulating factors to mobilize stem cells from the bone marrow to the peripheral blood, either the original granulocyte colony-stimulating factor (n = 10) or a Mexican granulocyte colony-stimulating factor biosimilar (n = 9).\n'
p5397
sg4
(lp5398
(dp5399
g7
I92
sg8
VP09919
p5400
sg10
I37
sg11
Vgranulocyte colony-stimulating factor
p5401
sg13
I3
sa(dp5402
g7
I92
sg8
VP09919
p5403
sg10
I38
sg11
Vgranulocyte colony-stimulating factors
p5404
sg13
I3
sa(dp5405
g7
I92
sg8
VP09919
p5406
sg10
I37
sg11
Vgranulocyte colony-stimulating factor
p5407
sg13
I3
sasg23
(lp5408
(dp5409
g7
I43
sg26
VC0026769
p5410
sg10
I18
sg11
Vmultiple sclerosis
p5411
sg13
I2
sasa(dp5412
g2
S'Moreover, FoxC1 was recruited to the ZEB2 promoter by its interaction with the pioneer transcription factor pre-B-cell leukemia homeobox 1 (PBX1).\n'
p5413
sg4
(lp5414
(dp5415
g7
I108
sg8
VP40424
p5416
sg10
I30
sg11
Vpre-B-cell leukemia homeobox 1
p5417
sg13
I4
sa(dp5418
g7
I10
sg8
g15
sg10
I5
sg11
VFoxC1
p5419
sg13
I1
sa(dp5420
g7
I37
sg8
g15
sg10
I13
sg11
VZEB2 promoter
p5421
sg13
I2
sa(dp5422
g7
I140
sg8
VP40424
p5423
sg10
I4
sg11
VPBX1
p5424
sg13
I1
sasg23
(lp5425
(dp5426
g7
I108
sg26
VC0023485
p5427
sg10
I19
sg11
Vpre-B-cell leukemia
p5428
sg13
I2
sasa(dp5429
g2
S'Enforced overexpression or RNAi-mediated knockdown of PBX1 contributed to the diminished or restored Cx32 expression in GES-1 and the gastric carcinoma cell line BGC823, respectively.\n'
p5430
sg4
(lp5431
(dp5432
g7
I54
sg8
VP40424
p5433
sg10
I4
sg11
VPBX1
p5434
sg13
I1
sa(dp5435
g7
I101
sg8
VP08034
p5436
sg10
I4
sg11
VCx32
p5437
sg13
I1
sa(dp5438
g7
I120
sg8
g15
sg10
I5
sg11
VGES-1
p5439
sg13
I1
sasg23
(lp5440
(dp5441
g7
I134
sg26
VC0699791
p5442
sg10
I17
sg11
Vgastric carcinoma
p5443
sg13
I2
sasa(dp5444
g2
S'Chimeric transcription factor E2A-PBX1 induces the development of acute lymphoblastic B-cell leukemia in children.\n'
p5445
sg4
(lp5446
(dp5447
g7
I30
sg8
VP15923
p5448
sg10
I3
sg11
VE2A
p5449
sg13
I1
sa(dp5450
g7
I34
sg8
VP40424
p5451
sg10
I4
sg11
VPBX1
p5452
sg13
I1
sasg23
(lp5453
(dp5454
g7
I86
sg26
VC0023434
p5455
sg10
I15
sg11
VB-cell leukemia
p5456
sg13
I2
sasa(dp5457
g2
S'Using a transgenic mouse model, we previously demonstrated that homeobox (HOX) gene HOXA9 genetically interact with E2A-PBX1 gene in the development of B-cell leukemia in mice.\n'
p5458
sg4
(lp5459
(dp5460
g7
I74
sg8
VP52954
p5461
sg10
I3
sg11
VHOX
p5462
sg13
I1
sa(dp5463
g7
I84
sg8
VP31269
p5464
sg10
I5
sg11
VHOXA9
p5465
sg13
I1
sa(dp5466
g7
I64
sg8
VP52954
p5467
sg10
I8
sg11
Vhomeobox
p5468
sg13
I1
sa(dp5469
g7
I120
sg8
VP40424
p5470
sg10
I4
sg11
VPBX1
p5471
sg13
I1
sa(dp5472
g7
I116
sg8
VP15923
p5473
sg10
I3
sg11
VE2A
p5474
sg13
I1
sasg23
(lp5475
(dp5476
g7
I152
sg26
VC0023434
p5477
sg10
I15
sg11
VB-cell leukemia
p5478
sg13
I2
sasa(dp5479
g2
S'Pre-B-cell leukemia homeobox 1 (PBX1) was originally identified as a proto-oncogene in human leukemia.\n'
p5480
sg4
(lp5481
(dp5482
g7
I32
sg8
VP40424
p5483
sg10
I4
sg11
VPBX1
p5484
sg13
I1
sa(dp5485
g7
I0
sg8
VP40424
p5486
sg10
I30
sg11
VPre-B-cell leukemia homeobox 1
p5487
sg13
I4
sasg23
(lp5488
(dp5489
g7
I11
sg26
VC0023418
p5490
sg10
I8
sg11
Vleukemia
p5491
sg13
I1
sa(dp5492
g7
I0
sg26
VC0023485
p5493
sg10
I19
sg11
VPre-B-cell leukemia
p5494
sg13
I2
sasa(dp5495
g2
S'Although this protein has been shown to contribute to cellular development and tumorigenesis, the role of PBX1 in gastric carcinoma (GC) remains unclear.\n'
p5496
sg4
(lp5497
(dp5498
g7
I106
sg8
VP40424
p5499
sg10
I4
sg11
VPBX1
p5500
sg13
I1
sasg23
(lp5501
(dp5502
g7
I133
sg26
VC0699791
p5503
sg10
I2
sg11
VGC
p5504
sg13
I1
sa(dp5505
g7
I79
sg26
VC0007621
p5506
sg10
I13
sg11
Vtumorigenesis
p5507
sg13
I1
sa(dp5508
g7
I114
sg26
VC0699791
p5509
sg10
I17
sg11
Vgastric carcinoma
p5510
sg13
I2
sasa(dp5511
g2
S'In childhood acute lymphoblastic leukemia (ALL), t(1;19)(q23;p13.3) with TCF3-PBX1 fusion is one of the most frequent translocations.\n'
p5512
sg4
(lp5513
(dp5514
g7
I61
sg8
g15
sg10
I5
sg11
Vp13.3
p5515
sg13
I1
sa(dp5516
g7
I78
sg8
VP40424
p5517
sg10
I4
sg11
VPBX1
p5518
sg13
I1
sa(dp5519
g7
I73
sg8
VP0C1Z6
p5520
sg10
I4
sg11
VTCF3
p5521
sg13
I1
sasg23
(lp5522
(dp5523
g7
I3
sg26
VC0023452
p5524
sg10
I38
sg11
Vchildhood acute lymphoblastic leukemia
p5525
sg13
I4
sasa(dp5526
g2
S'Here we report that Dact1-deficient mice have multiple physiological defects that resemble the human neonate disease congenital caudal regression syndrome, including caudal vertebrae agenesis, anorectal malformation, renal agenesis/dysplasia, fused kidneys, and loss of bladder.\n'
p5527
sg4
(lp5528
(dp5529
g7
I20
sg8
g15
sg10
I5
sg11
VDact1
p5530
sg13
I1
sasg23
(lp5531
(dp5532
g7
I232
sg26
VC0334044
p5533
sg10
I9
sg11
Vdysplasia
p5534
sg13
I1
sa(dp5535
g7
I193
sg26
VC2974527
p5536
sg10
I22
sg11
Vanorectal malformation
p5537
sg13
I2
sa(dp5538
g7
I243
sg26
VC0266305
p5539
sg10
I13
sg11
Vfused kidneys
p5540
sg13
I2
sa(dp5541
g7
I109
sg26
VC0242354
p5542
sg10
I18
sg11
Vdisease congenital
p5543
sg13
I2
sa(dp5544
g7
I128
sg26
VC0300948
p5545
sg10
I26
sg11
Vcaudal regression syndrome
p5546
sg13
I3
sa(dp5547
g7
I183
sg26
VC0332907
p5548
sg10
I8
sg11
Vagenesis
p5549
sg13
I1
sa(dp5550
g7
I217
sg26
VC0542519
p5551
sg10
I14
sg11
Vrenal agenesis
p5552
sg13
I2
sasa(dp5553
g2
S'Calretinin-immunopositive immature Sertoli cells revealed by co-localization of both markers, calretinin and CK-18, were identified in the mixed atrophy group in seminiferous tubules demonstrating spermatogenic failure.\n'
p5554
sg4
(lp5555
(dp5556
g7
I94
sg8
VP22676
p5557
sg10
I10
sg11
Vcalretinin
p5558
sg13
I1
sa(dp5559
g7
I0
sg8
VP22676
p5560
sg10
I10
sg11
VCalretinin
p5561
sg13
I1
sa(dp5562
g7
I109
sg8
VP05783
p5563
sg10
I5
sg11
VCK-18
p5564
sg13
I1
sasg23
(lp5565
(dp5566
g7
I145
sg26
VC0333641
p5567
sg10
I7
sg11
Vatrophy
p5568
sg13
I1
sasa(dp5569
g2
S'Disorders of Sertoli cell differentiation as indicated by calretinin and/or CK-18 expression contribute to the multifactorial mechanisms underlying spermatogenic failure.\n'
p5570
sg4
(lp5571
(dp5572
g7
I58
sg8
VP22676
p5573
sg10
I10
sg11
Vcalretinin
p5574
sg13
I1
sasg23
(lp5575
sa(dp5576
g2
S'In the group representing normal spermatogenesis (obstructive azoospermia, 6 men) and in the group characterized by spermatocyte maturation arrest (6 men), the areas occupied by anti-Mullerian hormone- and CK-18-positive cells were minimal.\n'
p5577
sg4
(lp5578
(dp5579
g7
I178
sg8
VP03971
p5580
sg10
I22
sg11
Vanti-Mullerian hormone
p5581
sg13
I2
sasg23
(lp5582
(dp5583
g7
I62
sg26
VC1321542
p5584
sg10
I11
sg11
Vazoospermia
p5585
sg13
I1
sa(dp5586
g7
I129
sg26
VC0333951
p5587
sg10
I17
sg11
Vmaturation arrest
p5588
sg13
I2
sasa(dp5589
g2
S'Quantitative measurements on testicular biopsies revealed the highest CK-18 expression in the mixed atrophy biopsies (22 men), a lower expression in the Sertoli cell-only (SCO) biopsies (12 men), and minimal residual staining in the group considered as representing normal spermatogenesis (six obstructive azoospermia patients).\n'
p5590
sg4
(lp5591
(dp5592
g7
I70
sg8
VP05783
p5593
sg10
I5
sg11
VCK-18
p5594
sg13
I1
sasg23
(lp5595
(dp5596
g7
I100
sg26
VC0333641
p5597
sg10
I7
sg11
Vatrophy
p5598
sg13
I1
sa(dp5599
g7
I306
sg26
VC1321542
p5600
sg10
I11
sg11
Vazoospermia
p5601
sg13
I1
sasa(dp5602
g2
S'The cause that determined the spermatogenic defect in the other cases of male infertility with high CK-18 expression may have damaged both the Sertoli and the germ cells.\n'
p5603
sg4
(lp5604
(dp5605
g7
I100
sg8
VP05783
p5606
sg10
I5
sg11
VCK-18
p5607
sg13
I1
sasg23
(lp5608
(dp5609
g7
I73
sg26
VC0021364
p5610
sg10
I16
sg11
Vmale infertility
p5611
sg13
I2
sasa(dp5612
g2
S'Kidney function and proteinuria were more severe in patients with PAX2 mutations than in those without the mutation.\n'
p5613
sg4
(lp5614
(dp5615
g7
I66
sg8
g15
sg10
I4
sg11
VPAX2
p5616
sg13
I1
sasg23
(lp5617
sa(dp5618
g2
S'These were associated with enhanced expression of beta-catenin, Oct3/4, WT1, Pax2 and nephrin, an essential transmembrane protein required for the formation of the scaffoldings of the podocyte slit-diaphragm, permitting the filtration of small ions, but not massive excretion of proteins, hence proteinuria.\n'
p5619
sg4
(lp5620
(dp5621
g7
I77
sg8
g15
sg10
I4
sg11
VPax2
p5622
sg13
I1
sa(dp5623
g7
I64
sg8
g15
sg10
I6
sg11
VOct3/4
p5624
sg13
I1
sa(dp5625
g7
I50
sg8
VP35222
p5626
sg10
I12
sg11
Vbeta-catenin
p5627
sg13
I1
sa(dp5628
g7
I86
sg8
g15
sg10
I7
sg11
Vnephrin
p5629
sg13
I1
sa(dp5630
g7
I72
sg8
g15
sg10
I3
sg11
VWT1
p5631
sg13
I1
sasg23
(lp5632
(dp5633
g7
I72
sg26
VC0027708
p5634
sg10
I3
sg11
VWT1
p5635
sg13
I1
sasa(dp5636
g2
S'ENH1 interacts with various Protein Kinase C (PKC) isozymes and Protein Kinase D1 (PKD1).\n'
p5637
sg4
(lp5638
(dp5639
g7
I83
sg8
VP98161
p5640
sg10
I4
sg11
VPKD1
p5641
sg13
I1
sa(dp5642
g7
I0
sg8
g15
sg10
I4
sg11
VENH1
p5643
sg13
I1
sa(dp5644
g7
I28
sg8
VP17252
p5645
sg10
I16
sg11
VProtein Kinase C
p5646
sg13
I3
sa(dp5647
g7
I64
sg8
g15
sg10
I17
sg11
VProtein Kinase D1
p5648
sg13
I3
sa(dp5649
g7
I46
sg8
VP17252
p5650
sg10
I3
sg11
VPKC
p5651
sg13
I1
sasg23
(lp5652
(dp5653
g7
I83
sg26
VC3149841
p5654
sg10
I4
sg11
VPKD1
p5655
sg13
I1
sa(dp5656
g7
I28
sg26
VC1868682
p5657
sg10
I16
sg11
VProtein Kinase C
p5658
sg13
I3
sa(dp5659
g7
I64
sg26
VC3149841
p5660
sg10
I17
sg11
VProtein Kinase D1
p5661
sg13
I3
sa(dp5662
g7
I46
sg26
VC1868682
p5663
sg10
I3
sg11
VPKC
p5664
sg13
I1
sasa(dp5665
g2
S'The downstream events of the ENH1-PKC/PKD1 complex remain unknown.\n'
p5666
sg4
(lp5667
(dp5668
g7
I38
sg8
VP98161
p5669
sg10
I4
sg11
VPKD1
p5670
sg13
I1
sa(dp5671
g7
I29
sg8
g15
sg10
I4
sg11
VENH1
p5672
sg13
I1
sa(dp5673
g7
I34
sg8
VP17252
p5674
sg10
I3
sg11
VPKC
p5675
sg13
I1
sasg23
(lp5676
(dp5677
g7
I38
sg26
VC3149841
p5678
sg10
I4
sg11
VPKD1
p5679
sg13
I1
sa(dp5680
g7
I34
sg26
VC1868682
p5681
sg10
I3
sg11
VPKC
p5682
sg13
I1
sasa(dp5683
g2
S'From a yeast two-hybrid assay, we have identified Enigma Homolog 1 (ENH1) as a new binding partner of PKD1.\n'
p5684
sg4
(lp5685
(dp5686
g7
I68
sg8
g15
sg10
I4
sg11
VENH1
p5687
sg13
I1
sa(dp5688
g7
I102
sg8
VP98161
p5689
sg10
I4
sg11
VPKD1
p5690
sg13
I1
sa(dp5691
g7
I50
sg8
VP50479
p5692
sg10
I16
sg11
VEnigma Homolog 1
p5693
sg13
I3
sasg23
(lp5694
(dp5695
g7
I102
sg26
VC3149841
p5696
sg10
I4
sg11
VPKD1
p5697
sg13
I1
sasa(dp5698
g2
S'Since in neurons, ENH1, associated with protein kinase Cepsilon, was shown to modulate the activity of N-type calcium channels, and the pore-forming subunit of the cardiac L-type voltage-gated calcium channel, alpha1C, possesses a potential phosphorylation site for PKD1, we studied here a possible role of ENH1 and PKD1 in the regulation of the cardiac L-type voltage-gated calcium channel.\n'
p5699
sg4
(lp5700
(dp5701
g7
I18
sg8
g15
sg10
I4
sg11
VENH1
p5702
sg13
I1
sa(dp5703
g7
I18
sg8
g15
sg10
I4
sg11
VENH1
p5704
sg13
I1
sa(dp5705
g7
I40
sg8
VP33981
p5706
sg10
I23
sg11
Vprotein kinase Cepsilon
p5707
sg13
I3
sa(dp5708
g7
I266
sg8
VP98161
p5709
sg10
I4
sg11
VPKD1
p5710
sg13
I1
sa(dp5711
g7
I266
sg8
VP98161
p5712
sg10
I4
sg11
VPKD1
p5713
sg13
I1
sasg23
(lp5714
(dp5715
g7
I266
sg26
VC3149841
p5716
sg10
I4
sg11
VPKD1
p5717
sg13
I1
sa(dp5718
g7
I219
sg26
VC0850310
p5719
sg10
I9
sg11
Vpossesses
p5720
sg13
I1
sa(dp5721
g7
I266
sg26
VC3149841
p5722
sg10
I4
sg11
VPKD1
p5723
sg13
I1
sasa(dp5724
g2
S'Both ENH1 and PKD1 interact with alpha1C in cardiomyocytes.\n'
p5725
sg4
(lp5726
(dp5727
g7
I14
sg8
VP98161
p5728
sg10
I4
sg11
VPKD1
p5729
sg13
I1
sa(dp5730
g7
I5
sg8
g15
sg10
I4
sg11
VENH1
p5731
sg13
I1
sasg23
(lp5732
(dp5733
g7
I14
sg26
VC3149841
p5734
sg10
I4
sg11
VPKD1
p5735
sg13
I1
sasa(dp5736
g2
S'Silencing of ENH1 prevented the binding of PKD1 to alpha1C.\n'
p5737
sg4
(lp5738
(dp5739
g7
I13
sg8
g15
sg10
I4
sg11
VENH1
p5740
sg13
I1
sa(dp5741
g7
I43
sg8
VP98161
p5742
sg10
I4
sg11
VPKD1
p5743
sg13
I1
sasg23
(lp5744
(dp5745
g7
I43
sg26
VC3149841
p5746
sg10
I4
sg11
VPKD1
p5747
sg13
I1
sasa(dp5748
g2
S'Moreover, a dominant negative mutant of PKD1 or the silencing of ENH1 inhibited the alpha-adrenergic-induced increase of L-type calcium currents.\n'
p5749
sg4
(lp5750
(dp5751
g7
I65
sg8
g15
sg10
I4
sg11
VENH1
p5752
sg13
I1
sa(dp5753
g7
I40
sg8
VP98161
p5754
sg10
I4
sg11
VPKD1
p5755
sg13
I1
sasg23
(lp5756
(dp5757
g7
I12
sg26
VC1512032
p5758
sg10
I17
sg11
Vdominant negative
p5759
sg13
I2
sa(dp5760
g7
I40
sg26
VC3149841
p5761
sg10
I4
sg11
VPKD1
p5762
sg13
I1
sa(dp5763
g7
I30
sg26
VC0596988
p5764
sg10
I6
sg11
Vmutant
p5765
sg13
I1
sasa(dp5766
g2
S'We found a new binding partner, ENH1, and a new target, alpha1C, for PKD1 in neonatal rat cardiomyocytes.\n'
p5767
sg4
(lp5768
(dp5769
g7
I32
sg8
g15
sg10
I4
sg11
VENH1
p5770
sg13
I1
sa(dp5771
g7
I69
sg8
VP98161
p5772
sg10
I4
sg11
VPKD1
p5773
sg13
I1
sasg23
(lp5774
(dp5775
g7
I69
sg26
VC3149841
p5776
sg10
I4
sg11
VPKD1
p5777
sg13
I1
sasa(dp5778
g2
S'We propose a model where ENH1 scaffolds PKD1 to alpha1C in order to form a signalling complex that regulates the activity of cardiac L-type voltage-gated Ca(2+) channels.\n'
p5779
sg4
(lp5780
(dp5781
g7
I25
sg8
g15
sg10
I4
sg11
VENH1
p5782
sg13
I1
sa(dp5783
g7
I40
sg8
VP98161
p5784
sg10
I4
sg11
VPKD1
p5785
sg13
I1
sasg23
(lp5786
(dp5787
g7
I40
sg26
VC3149841
p5788
sg10
I4
sg11
VPKD1
p5789
sg13
I1
sasa(dp5790
g2
S'Seven putative candidate genes located in 4q22, DAPP1, BMPR1B, PKD2, HERC3, SMARCAD1, CEB1 and ENH were screened for mutations but no somatic alterations were identified.\n'
p5791
sg4
(lp5792
(dp5793
g7
I63
sg8
g15
sg10
I4
sg11
VPKD2
p5794
sg13
I1
sa(dp5795
g7
I55
sg8
g15
sg10
I6
sg11
VBMPR1B
p5796
sg13
I1
sa(dp5797
g7
I76
sg8
g15
sg10
I8
sg11
VSMARCAD1
p5798
sg13
I1
sa(dp5799
g7
I69
sg8
g15
sg10
I5
sg11
VHERC3
p5800
sg13
I1
sa(dp5801
g7
I48
sg8
g15
sg10
I5
sg11
VDAPP1
p5802
sg13
I1
sa(dp5803
g7
I95
sg8
g15
sg10
I3
sg11
VENH
p5804
sg13
I1
sa(dp5805
g7
I86
sg8
g15
sg10
I4
sg11
VCEB1
p5806
sg13
I1
sasg23
(lp5807
(dp5808
g7
I63
sg26
VC2751306
p5809
sg10
I4
sg11
VPKD2
p5810
sg13
I1
sasa(dp5811
g2
S'There is growing evidence for extramotor dysfunction (EMd) in amyotrophic lateral sclerosis (ALS), with a reported prevalence of up to 52%.\n'
p5812
sg4
(lp5813
sg23
(lp5814
(dp5815
g7
I54
sg26
VC0340861
p5816
sg10
I3
sg11
VEMd
p5817
sg13
I1
sa(dp5818
g7
I93
sg26
VC0002736
p5819
sg10
I3
sg11
VALS
p5820
sg13
I1
sa(dp5821
g7
I62
sg26
VC0002736
p5822
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p5823
sg13
I3
sa(dp5824
g7
I30
sg26
VC0340861
p5825
sg10
I22
sg11
Vextramotor dysfunction
p5826
sg13
I2
sasa(dp5827
g2
S"Moreover, StA conferred significant protection against MPTP-induced loss of TH-positive dopaminergic neurons in a Parkinson's disease (PD) mice model.\n"
p5828
sg4
(lp5829
(dp5830
g7
I10
sg8
VP50402
p5831
sg10
I3
sg11
VStA
p5832
sg13
I1
sasg23
(lp5833
(dp5834
g7
I135
sg26
VC0030567
p5835
sg10
I2
sg11
VPD
p5836
sg13
I1
sa(dp5837
g7
I114
sg26
VC0030567
p5838
sg10
I19
sg11
VParkinson's disease
p5839
sg13
I2
sasa(dp5840
g2
S'The aim of this study was to compare the mRNA expression patterns of Interleukin (IL)-4, interferon (IFN)-Gamma and Acyl Co A long chain 3 (ACSL3) in peripheral blood leukocytes of children with and without asthma.\n'
p5841
sg4
(lp5842
(dp5843
g7
I140
sg8
g15
sg10
I5
sg11
VACSL3
p5844
sg13
I1
sa(dp5845
g7
I116
sg8
g15
sg10
I22
sg11
VAcyl Co A long chain 3
p5846
sg13
I6
sa(dp5847
g7
I89
sg8
VP01563
p5848
sg10
I22
sg11
Vinterferon (IFN)-Gamma
p5849
sg13
I2
sa(dp5850
g7
I69
sg8
VP60568
p5851
sg10
I18
sg11
VInterleukin (IL)-4
p5852
sg13
I2
sasg23
(lp5853
(dp5854
g7
I207
sg26
VC0004096
p5855
sg10
I6
sg11
Vasthma
p5856
sg13
I1
sasa(dp5857
g2
S'IL-4 mRNA expression was significantly increased (P &lt; 0.05) in children with asthma compared to healthy control group whereas no differences were observed for either IFN-Gamma or ACSL3 mRNA.\n'
p5858
sg4
(lp5859
(dp5860
g7
I0
sg8
VP05112
p5861
sg10
I9
sg11
VIL-4 mRNA
p5862
sg13
I2
sa(dp5863
g7
I169
sg8
VP01579
p5864
sg10
I9
sg11
VIFN-Gamma
p5865
sg13
I1
sa(dp5866
g7
I182
sg8
g15
sg10
I10
sg11
VACSL3 mRNA
p5867
sg13
I2
sasg23
(lp5868
(dp5869
g7
I80
sg26
VC0004096
p5870
sg10
I6
sg11
Vasthma
p5871
sg13
I1
sasa(dp5872
g2
S"Methylation of the ACSL3 5'-CGI was found to be significantly associated with maternal airborne PAH exposure exceeding 2.41 ng/m(3) (OR = 13.8; p&lt;0.001; sensitivity = 75%; specificity = 82%) and with a parental report of asthma symptoms in children prior to age 5 (OR = 3.9; p&lt;0.05).\n"
p5873
sg4
(lp5874
(dp5875
g7
I19
sg8
g15
sg10
I12
sg11
VACSL3 5'-CGI
p5876
sg13
I2
sasg23
(lp5877
(dp5878
g7
I224
sg26
VC0004096
p5879
sg10
I6
sg11
Vasthma
p5880
sg13
I1
sa(dp5881
g7
I96
sg26
VC0152171
p5882
sg10
I3
sg11
VPAH
p5883
sg13
I1
sasa(dp5884
g2
S"Thus, if validated, methylated ACSL3 5'CGI in UCWBC DNA may be a surrogate endpoint for transplacental PAH exposure and/or a potential biomarker for environmentally-related asthma.\n"
p5885
sg4
(lp5886
(dp5887
g7
I31
sg8
g15
sg10
I11
sg11
VACSL3 5'CGI
p5888
sg13
I2
sasg23
(lp5889
(dp5890
g7
I103
sg26
VC0152171
p5891
sg10
I3
sg11
VPAH
p5892
sg13
I1
sa(dp5893
g7
I173
sg26
VC0004096
p5894
sg10
I6
sg11
Vasthma
p5895
sg13
I1
sasa(dp5896
g2
S'The aim of the study was to investigate the expression of selected genes encoding enzymes involved in the antioxidant defense system (superoxide dismutase 2, SOD2; aldehyde dehydrogenase 1, ALDH1A1; microsomal glutathione S-transferase 1, MGST1) in fragments of anterior lens capsules of patients with pseudoexfoliation syndrome (PEX).\n'
p5897
sg4
(lp5898
(dp5899
g7
I199
sg8
VP10620
p5900
sg10
I38
sg11
Vmicrosomal glutathione S-transferase 1
p5901
sg13
I4
sa(dp5902
g7
I134
sg8
VP04179
p5903
sg10
I22
sg11
Vsuperoxide dismutase 2
p5904
sg13
I3
sa(dp5905
g7
I239
sg8
VP10620
p5906
sg10
I5
sg11
VMGST1
p5907
sg13
I1
sa(dp5908
g7
I164
sg8
VP49366
p5909
sg10
I24
sg11
Valdehyde dehydrogenase 1
p5910
sg13
I3
sa(dp5911
g7
I158
sg8
VP04179
p5912
sg10
I4
sg11
VSOD2
p5913
sg13
I1
sa(dp5914
g7
I190
sg8
VP00352
p5915
sg10
I7
sg11
VALDH1A1
p5916
sg13
I1
sasg23
(lp5917
(dp5918
g7
I302
sg26
VC0206368
p5919
sg10
I26
sg11
Vpseudoexfoliation syndrome
p5920
sg13
I2
sa(dp5921
g7
I330
sg26
VC0206368
p5922
sg10
I3
sg11
VPEX
p5923
sg13
I1
sasa(dp5924
g2
S'Twenty-four eyes of 24 patients with refractory diffuse diabetic macular edema scheduled to undergo phacoemulsification cataract surgery were randomly assigned to receive either a 4-mg IVT (n = 12) or a 40-mg STI (n = 12) of triamcinolone acetonide during cataract surgery.\n'
p5925
sg4
(lp5926
sg23
(lp5927
(dp5928
g7
I120
sg26
VC0086543
p5929
sg10
I8
sg11
Vcataract
p5930
sg13
I1
sa(dp5931
g7
I120
sg26
VC0086543
p5932
sg10
I8
sg11
Vcataract
p5933
sg13
I1
sa(dp5934
g7
I56
sg26
VC0730285
p5935
sg10
I22
sg11
Vdiabetic macular edema
p5936
sg13
I3
sasa(dp5937
g2
S'FANCJ belongs to a conserved iron-sulfur (Fe S) cluster family of helicases important for genomic stability including XPD (nucleotide excision repair), DDX11 (sister chromatid cohesion), and RTEL (telomere metabolism), genetically linked to xeroderma pigmentosum/Cockayne syndrome, Warsaw breakage syndrome, and dyskeratosis congenita, respectively.\n'
p5938
sg4
(lp5939
(dp5940
g7
I118
sg8
VP18074
p5941
sg10
I3
sg11
VXPD
p5942
sg13
I1
sa(dp5943
g7
I0
sg8
g15
sg10
I5
sg11
VFANCJ
p5944
sg13
I1
sa(dp5945
g7
I66
sg8
g15
sg10
I9
sg11
Vhelicases
p5946
sg13
I1
sa(dp5947
g7
I152
sg8
g15
sg10
I5
sg11
VDDX11
p5948
sg13
I1
sasg23
(lp5949
(dp5950
g7
I241
sg26
VC0043346
p5951
sg10
I21
sg11
Vxeroderma pigmentosum
p5952
sg13
I2
sa(dp5953
g7
I0
sg26
VC1836860
p5954
sg10
I5
sg11
VFANCJ
p5955
sg13
I1
sa(dp5956
g7
I282
sg26
VC3150658
p5957
sg10
I24
sg11
VWarsaw breakage syndrome
p5958
sg13
I3
sa(dp5959
g7
I118
sg26
VC0268138
p5960
sg10
I3
sg11
VXPD
p5961
sg13
I1
sa(dp5962
g7
I312
sg26
VC0265965
p5963
sg10
I22
sg11
Vdyskeratosis congenita
p5964
sg13
I2
sa(dp5965
g7
I263
sg26
VC0009207
p5966
sg10
I17
sg11
VCockayne syndrome
p5967
sg13
I2
sasa(dp5968
g2
S'NUAK1 and NUAK2 double mutants exhibited exencephaly, facial clefting, and spina bifida.\n'
p5969
sg4
(lp5970
(dp5971
g7
I10
sg8
g15
sg10
I20
sg11
VNUAK2 double mutants
p5972
sg13
I3
sa(dp5973
g7
I0
sg8
g15
sg10
I5
sg11
VNUAK1
p5974
sg13
I1
sasg23
(lp5975
(dp5976
g7
I41
sg26
VC0266453
p5977
sg10
I11
sg11
Vexencephaly
p5978
sg13
I1
sa(dp5979
g7
I75
sg26
VC0080178
p5980
sg10
I12
sg11
Vspina bifida
p5981
sg13
I2
sasa(dp5982
g2
S'Interstitial pneumonia with autoimmune features (IPAF) is a newly described entity that encompasses interstitial lung disease in patients with clinical, serologic, or morphologic features suggestive of but not diagnostic of collagen vascular disease; these patients are thought to have better outcomes than idiopathic interstitial pneumonias.\n'
p5983
sg4
(lp5984
sg23
(lp5985
(dp5986
g7
I100
sg26
VC0206062
p5987
sg10
I25
sg11
Vinterstitial lung disease
p5988
sg13
I3
sa(dp5989
g7
I307
sg26
VC2350236
p5990
sg10
I34
sg11
Vidiopathic interstitial pneumonias
p5991
sg13
I3
sa(dp5992
g7
I0
sg26
VC0206061
p5993
sg10
I22
sg11
VInterstitial pneumonia
p5994
sg13
I2
sa(dp5995
g7
I28
sg26
VC0443146
p5996
sg10
I10
sg11
Vautoimmune
p5997
sg13
I1
sa(dp5998
g7
I224
sg26
VC0262428
p5999
sg10
I25
sg11
Vcollagen vascular disease
p6000
sg13
I3
sasa(dp6001
g2
S'IPAF is a new term to label patients with possible collagen vascular disease-related interstitial lung disease.\n'
p6002
sg4
(lp6003
(dp6004
g7
I0
sg8
g15
sg10
I4
sg11
VIPAF
p6005
sg13
I1
sasg23
(lp6006
(dp6007
g7
I51
sg26
VC0262428
p6008
sg10
I25
sg11
Vcollagen vascular disease
p6009
sg13
I3
sa(dp6010
g7
I85
sg26
VC0206062
p6011
sg10
I25
sg11
Vinterstitial lung disease
p6012
sg13
I3
sasa(dp6013
g2
S'Interstitial pneumonia with autoimmune features (IPAF) identifies a recently recognized autoimmune syndrome characterized by interstitial lung disease and autoantibodies positivity, but absence of a specific connective tissue disease diagnosis or alternative etiology.\n'
p6014
sg4
(lp6015
sg23
(lp6016
(dp6017
g7
I0
sg26
VC0206061
p6018
sg10
I22
sg11
VInterstitial pneumonia
p6019
sg13
I2
sa(dp6020
g7
I28
sg26
VC0443146
p6021
sg10
I10
sg11
Vautoimmune
p6022
sg13
I1
sa(dp6023
g7
I99
sg26
VC0039082
p6024
sg10
I8
sg11
Vsyndrome
p6025
sg13
I1
sa(dp6026
g7
I208
sg26
VC0009782
p6027
sg10
I25
sg11
Vconnective tissue disease
p6028
sg13
I3
sa(dp6029
g7
I28
sg26
VC0443146
p6030
sg10
I10
sg11
Vautoimmune
p6031
sg13
I1
sa(dp6032
g7
I125
sg26
VC0206062
p6033
sg10
I25
sg11
Vinterstitial lung disease
p6034
sg13
I3
sasa(dp6035
g2
S'To identify the prognostic factors for survival in patients with interstitial pneumonia with autoimmune features (IPAF) who meet the serological domain of the IPAF criteria.\n'
p6036
sg4
(lp6037
sg23
(lp6038
(dp6039
g7
I65
sg26
VC0206061
p6040
sg10
I22
sg11
Vinterstitial pneumonia
p6041
sg13
I2
sa(dp6042
g7
I93
sg26
VC0443146
p6043
sg10
I10
sg11
Vautoimmune
p6044
sg13
I1
sasa(dp6045
g2
S'Univariate Cox analysis revealed systemic sclerosis (SSc)-specific and SSc-associated antibodies (ANA nucleolar pattern, ANA centromere pattern, anti-ribonucleoprotein and anti-Scl-70) positive IPAF, radiological NSIP pattern, bronchoalveolar lavage fluid lymphocytes &gt;15%, and age as significant prognostic factors for survival.\n'
p6046
sg4
(lp6047
(dp6048
g7
I145
sg8
VP52272
p6049
sg10
I22
sg11
Vanti-ribonucleoprotein
p6050
sg13
I1
sa(dp6051
g7
I172
sg8
VP17542
p6052
sg10
I11
sg11
Vanti-Scl-70
p6053
sg13
I1
sasg23
(lp6054
(dp6055
g7
I53
sg26
VC0036429
p6056
sg10
I3
sg11
VSSc
p6057
sg13
I1
sa(dp6058
g7
I33
sg26
VC0036421
p6059
sg10
I18
sg11
Vsystemic sclerosis
p6060
sg13
I2
sa(dp6061
g7
I53
sg26
VC0036429
p6062
sg10
I3
sg11
VSSc
p6063
sg13
I1
sasa(dp6064
g2
S'We confirmed that radiological NSIP pattern and age are poor prognostic factors for the survival of IPAF patients.\n'
p6065
sg4
(lp6066
sg23
(lp6067
sa(dp6068
g2
S'To marshal these ununiform classification criteria, the "European Respiratory Society/American Thoracic Society Task Force on Undifferentiated Forms of Connective Tissue Disease-associated Interstitial Lung Disease" proposed a consensus regarding the nomenclature and classification criteria for patients with IIP and features of autoimmunity with the term "interstitial pneumonia with autoimmune features" (IPAF).\n'
p6069
sg4
(lp6070
sg23
(lp6071
(dp6072
g7
I189
sg26
VC0206062
p6073
sg10
I25
sg11
VInterstitial Lung Disease
p6074
sg13
I3
sa(dp6075
g7
I95
sg26
VC0729233
p6076
sg10
I8
sg11
VThoracic
p6077
sg13
I1
sa(dp6078
g7
I330
sg26
VC0004368
p6079
sg10
I12
sg11
Vautoimmunity
p6080
sg13
I1
sa(dp6081
g7
I358
sg26
VC0206061
p6082
sg10
I22
sg11
Vinterstitial pneumonia
p6083
sg13
I2
sa(dp6084
g7
I386
sg26
VC0443146
p6085
sg10
I10
sg11
Vautoimmune
p6086
sg13
I1
sa(dp6087
g7
I152
sg26
VC0009782
p6088
sg10
I25
sg11
VConnective Tissue Disease
p6089
sg13
I3
sasa(dp6090
g2
S'It was reported that patients with IPAF accounted for 7.3%~34.1% of patients with interstitial lung disease (ILD).\n'
p6091
sg4
(lp6092
sg23
(lp6093
(dp6094
g7
I82
sg26
VC0206062
p6095
sg10
I25
sg11
Vinterstitial lung disease
p6096
sg13
I3
sa(dp6097
g7
I109
sg26
VC0206062
p6098
sg10
I3
sg11
VILD
p6099
sg13
I1
sasa(dp6100
g2
S'Furthermore, it is not determined whether IPAF is a distinct category of ILD or simply a part of IIP.\n'
p6101
sg4
(lp6102
(dp6103
g7
I42
sg8
g15
sg10
I4
sg11
VIPAF
p6104
sg13
I1
sasg23
(lp6105
sa(dp6106
g2
S'Interstitial pneumonia with autoimmune features (IPAF) describes the subset of patients with interstitial pneumonia who have features suggesting underlying autoimmunity, but whose features fall short of a clear diagnosis of CTD.\n'
p6107
sg4
(lp6108
sg23
(lp6109
(dp6110
g7
I0
sg26
VC0206061
p6111
sg10
I22
sg11
VInterstitial pneumonia
p6112
sg13
I2
sa(dp6113
g7
I93
sg26
VC0206061
p6114
sg10
I22
sg11
Vinterstitial pneumonia
p6115
sg13
I2
sa(dp6116
g7
I28
sg26
VC0443146
p6117
sg10
I10
sg11
Vautoimmune
p6118
sg13
I1
sa(dp6119
g7
I156
sg26
VC0004368
p6120
sg10
I12
sg11
Vautoimmunity
p6121
sg13
I1
sasa(dp6122
g2
S'CTD associated ILD (CTD-ILD) occurs most commonly in the context of an established CTD, but can be the first and/or only manifestation of an occult CTD or occur in patients who have features suggestive of an autoimmune process, but not meeting diagnostic criteria for a defined CTD-recently defined as "interstitial pneumonia with autoimmune features" (IPAF).\n'
p6123
sg4
(lp6124
sg23
(lp6125
(dp6126
g7
I303
sg26
VC0206061
p6127
sg10
I22
sg11
Vinterstitial pneumonia
p6128
sg13
I2
sa(dp6129
g7
I208
sg26
VC0443146
p6130
sg10
I18
sg11
Vautoimmune process
p6131
sg13
I2
sa(dp6132
g7
I208
sg26
VC0443146
p6133
sg10
I10
sg11
Vautoimmune
p6134
sg13
I1
sasa(dp6135
g2
S'A recent European Respiratory Society/American Thoracic Society statement proposed research criteria for interstitial pneumonia with autoimmune features (IPAF), which includes findings from the clinical, serologic, and morphologic domains.\n'
p6136
sg4
(lp6137
sg23
(lp6138
(dp6139
g7
I133
sg26
VC0443146
p6140
sg10
I10
sg11
Vautoimmune
p6141
sg13
I1
sa(dp6142
g7
I105
sg26
VC0206061
p6143
sg10
I22
sg11
Vinterstitial pneumonia
p6144
sg13
I2
sa(dp6145
g7
I47
sg26
VC0729233
p6146
sg10
I8
sg11
VThoracic
p6147
sg13
I1
sasa(dp6148
g2
S'- Patients with idiopathic interstitial pneumonia at the University of Chicago who underwent surgical lung biopsy or lung transplantation were assessed for IPAF histopathologic features, using the initial pathology interpretation in the electronic records.\n'
p6149
sg4
(lp6150
sg23
(lp6151
(dp6152
g7
I16
sg26
VC0085786
p6153
sg10
I33
sg11
Vidiopathic interstitial pneumonia
p6154
sg13
I3
sa(dp6155
g7
I205
sg26
VC0677042
p6156
sg10
I9
sg11
Vpathology
p6157
sg13
I1
sasa(dp6158
g2
S'This rereview demonstrated nonspecific interstitial pneumonia in 8 of 36 patients (22.2%) and lymphoplasmacytic infiltrates in 6 of 36 patients (16.7%), resulting in an additional 7 of 36 patients (19.4%) with idiopathic interstitial pneumonia that met the IPAF criteria.\n'
p6159
sg4
(lp6160
sg23
(lp6161
(dp6162
g7
I112
sg26
VC0332448
p6163
sg10
I11
sg11
Vinfiltrates
p6164
sg13
I1
sa(dp6165
g7
I210
sg26
VC0085786
p6166
sg10
I33
sg11
Vidiopathic interstitial pneumonia
p6167
sg13
I3
sa(dp6168
g7
I27
sg26
VC1290344
p6169
sg10
I34
sg11
Vnonspecific interstitial pneumonia
p6170
sg13
I3
sasa(dp6171
g2
S'The objective of this study is to determine the CT findings and patterns of interstitial pneumonia with autoimmune features (IPAF) and to assess whether imaging can predict survival for patients with IPAF.\n'
p6172
sg4
(lp6173
sg23
(lp6174
(dp6175
g7
I76
sg26
VC0206061
p6176
sg10
I22
sg11
Vinterstitial pneumonia
p6177
sg13
I2
sa(dp6178
g7
I104
sg26
VC0443146
p6179
sg10
I10
sg11
Vautoimmune
p6180
sg13
I1
sasa(dp6181
g2
S'Subjects with high baseline levels of SCF had lower cardiovascular (n = 340) and all-cause mortality (n = 1159) as well as a lower risk of heart failure (n = 177), stroke (n = 318) and myocardial infarction (n = 452).\n'
p6182
sg4
(lp6183
(dp6184
g7
I38
sg8
VP21583
p6185
sg10
I3
sg11
VSCF
p6186
sg13
I1
sasg23
(lp6187
(dp6188
g7
I164
sg26
VC0038454
p6189
sg10
I6
sg11
Vstroke
p6190
sg13
I1
sa(dp6191
g7
I139
sg26
VC0018802
p6192
sg10
I13
sg11
Vheart failure
p6193
sg13
I2
sa(dp6194
g7
I185
sg26
VC0027051
p6195
sg10
I21
sg11
Vmyocardial infarction
p6196
sg13
I2
sasa(dp6197
g2
S'The highest SCF quartile remained independently associated with a lower risk of a lower risk of cardiovascular [hazard ratio and 95% confidence interval 0.59 (0.43-0.81)] and all-cause mortality [0.68 (0.57-0.81)], heart failure [0.50 (0.31-0.80)] and stroke [0.66 (0.47-0.92)], but not with MI [0.96 (0.72-1.27)] as compared with the lowest quartile when adjusting for traditional cardiovascular risk factors in Cox proportional hazard regression models.\n'
p6198
sg4
(lp6199
(dp6200
g7
I12
sg8
VP21583
p6201
sg10
I3
sg11
VSCF
p6202
sg13
I1
sasg23
(lp6203
(dp6204
g7
I252
sg26
VC0038454
p6205
sg10
I6
sg11
Vstroke
p6206
sg13
I1
sa(dp6207
g7
I215
sg26
VC0018802
p6208
sg10
I13
sg11
Vheart failure
p6209
sg13
I2
sasa(dp6210
g2
S'These data suggest that a stroke-damaged brain is repairable by SCF + G-CSF even 6 months after the lesion occurs.\n'
p6211
sg4
(lp6212
(dp6213
g7
I70
sg8
VP09919
p6214
sg10
I5
sg11
VG-CSF
p6215
sg13
I1
sa(dp6216
g7
I64
sg8
VP21583
p6217
sg10
I3
sg11
VSCF
p6218
sg13
I1
sasg23
(lp6219
(dp6220
g7
I26
sg26
VC0038454
p6221
sg10
I6
sg11
Vstroke
p6222
sg13
I1
sasa(dp6223
g2
S'Preload-recruitable stroke work was significantly higher in pigs after SCF treatment (Ad.SCF, 55.5+/-11.6 mm Hg versus Ad.Beta-gal, 31.6+/-12.6 mm Hg, P=0.005), indicating enhanced cardiac function.\n'
p6224
sg4
(lp6225
(dp6226
g7
I122
sg8
VP16278
p6227
sg10
I8
sg11
VBeta-gal
p6228
sg13
I1
sasg23
(lp6229
(dp6230
g7
I20
sg26
VC0038454
p6231
sg10
I6
sg11
Vstroke
p6232
sg13
I1
sasa(dp6233
g2
S'After stroke, a condition associated with brain aging where oxidative injury affects peri-infarcted regions, a simultaneous increase in SCF and IGF-I expression was found in the cortex, suggesting that a similar cooperative response takes place in vivo.\n'
p6234
sg4
(lp6235
(dp6236
g7
I144
sg8
VP01343
p6237
sg10
I5
sg11
VIGF-I
p6238
sg13
I1
sa(dp6239
g7
I136
sg8
VP21583
p6240
sg10
I3
sg11
VSCF
p6241
sg13
I1
sasg23
(lp6242
(dp6243
g7
I16
sg26
VC0012634
p6244
sg10
I9
sg11
Vcondition
p6245
sg13
I1
sa(dp6246
g7
I6
sg26
VC0038454
p6247
sg10
I6
sg11
Vstroke
p6248
sg13
I1
sasa(dp6249
g2
S'We have demonstrated the therapeutic effects of the combination of stem cell factor (SCF) and granulocyte-colony stimulating factor (G-CSF) (SCF+G-CSF) on chronic stroke.\n'
p6250
sg4
(lp6251
(dp6252
g7
I141
sg8
VP09919
p6253
sg10
I9
sg11
VSCF+G-CSF
p6254
sg13
I1
sa(dp6255
g7
I94
sg8
VP09919
p6256
sg10
I37
sg11
Vgranulocyte-colony stimulating factor
p6257
sg13
I3
sa(dp6258
g7
I67
sg8
VP21583
p6259
sg10
I16
sg11
Vstem cell factor
p6260
sg13
I3
sa(dp6261
g7
I133
sg8
VP09919
p6262
sg10
I5
sg11
VG-CSF
p6263
sg13
I1
sa(dp6264
g7
I85
sg8
VP21583
p6265
sg10
I3
sg11
VSCF
p6266
sg13
I1
sasg23
(lp6267
(dp6268
g7
I163
sg26
VC0038454
p6269
sg10
I6
sg11
Vstroke
p6270
sg13
I1
sasa(dp6271
g2
S'However, it remains unclear how SCF+G-CSF repairs the brain in chronic stroke.\n'
p6272
sg4
(lp6273
(dp6274
g7
I32
sg8
VP09919
p6275
sg10
I9
sg11
VSCF+G-CSF
p6276
sg13
I1
sasg23
(lp6277
(dp6278
g7
I71
sg26
VC0038454
p6279
sg10
I6
sg11
Vstroke
p6280
sg13
I1
sasa(dp6281
g2
S'In this study, we determined the effects of SCF+G-CSF on neuronal network remodeling in the aged brain of chronic stroke.\n'
p6282
sg4
(lp6283
(dp6284
g7
I44
sg8
VP09919
p6285
sg10
I9
sg11
VSCF+G-CSF
p6286
sg13
I1
sasg23
(lp6287
(dp6288
g7
I114
sg26
VC0038454
p6289
sg10
I6
sg11
Vstroke
p6290
sg13
I1
sasa(dp6291
g2
S'These data suggest that SCF+G-CSF treatment in chronic stroke remodels neural circuits in the aged brain.\n'
p6292
sg4
(lp6293
(dp6294
g7
I24
sg8
VP09919
p6295
sg10
I9
sg11
VSCF+G-CSF
p6296
sg13
I1
sasg23
(lp6297
(dp6298
g7
I55
sg26
VC0038454
p6299
sg10
I6
sg11
Vstroke
p6300
sg13
I1
sasa(dp6301
g2
S'The growth inhibition under combination treatment and single agent was explored by the MTT cell viability assay and the Annexin V/propidium iodide (PI) apoptosis assay in different CTCL cell lines and tumor cells derived from Sezary syndrome patients.\n'
p6302
sg4
(lp6303
(dp6304
g7
I120
sg8
VP08758
p6305
sg10
I31
sg11
VAnnexin V/propidium iodide (PI)
p6306
sg13
I4
sasg23
(lp6307
(dp6308
g7
I201
sg26
VC0027651
p6309
sg10
I5
sg11
Vtumor
p6310
sg13
I1
sa(dp6311
g7
I226
sg26
VC0036920
p6312
sg10
I15
sg11
VSezary syndrome
p6313
sg13
I2
sasa(dp6314
g2
S'The patients presented with the characteristic symptoms of Jacobsen syndrome (JBS), including: mental retardation, short stature, and craniofacial dysmorphism in all 3 cases; cardiac defects in 2 cases; and thrombocytopenia, brain abnormality, eye coloboma, recurrent infections, cryptorchidism and toe anomalies in single cases.\n'
p6315
sg4
(lp6316
sg23
(lp6317
(dp6318
g7
I231
sg26
VC0015393
p6319
sg10
I16
sg11
Vabnormality, eye
p6320
sg13
I2
sa(dp6321
g7
I59
sg26
VC0795841
p6322
sg10
I17
sg11
VJacobsen syndrome
p6323
sg13
I2
sa(dp6324
g7
I147
sg26
VC1737329
p6325
sg10
I11
sg11
Vdysmorphism
p6326
sg13
I1
sa(dp6327
g7
I268
sg26
VC0021311
p6328
sg10
I10
sg11
Vinfections
p6329
sg13
I1
sa(dp6330
g7
I175
sg26
VC0741916
p6331
sg10
I15
sg11
Vcardiac defects
p6332
sg13
I2
sa(dp6333
g7
I248
sg26
VC0009363
p6334
sg10
I8
sg11
Vcoloboma
p6335
sg13
I1
sa(dp6336
g7
I78
sg26
VC0795841
p6337
sg10
I3
sg11
VJBS
p6338
sg13
I1
sa(dp6339
g7
I95
sg26
VC0025362
p6340
sg10
I18
sg11
Vmental retardation
p6341
sg13
I2
sa(dp6342
g7
I115
sg26
VC0013336
p6343
sg10
I13
sg11
Vshort stature
p6344
sg13
I2
sa(dp6345
g7
I280
sg26
VC0010417
p6346
sg10
I14
sg11
Vcryptorchidism
p6347
sg13
I1
sasa(dp6348
g2
S'Two brothers showed hypotonia, mental retardation, ocular abnormalities with impaired vision and colobomas and a breathing pattern compatible with JBS.\n'
p6349
sg4
(lp6350
sg23
(lp6351
(dp6352
g7
I77
sg26
VC0042798
p6353
sg10
I15
sg11
Vimpaired vision
p6354
sg13
I2
sa(dp6355
g7
I97
sg26
VC0009363
p6356
sg10
I9
sg11
Vcolobomas
p6357
sg13
I1
sa(dp6358
g7
I31
sg26
VC0025362
p6359
sg10
I18
sg11
Vmental retardation
p6360
sg13
I2
sa(dp6361
g7
I147
sg26
VC0795841
p6362
sg10
I3
sg11
VJBS
p6363
sg13
I1
sa(dp6364
g7
I20
sg26
VC0026827
p6365
sg10
I9
sg11
Vhypotonia
p6366
sg13
I1
sasa(dp6367
g2
S'The expression of EPH receptor A8 (EPHA8), synovial sarcoma translocation chromosome 18 (SS18), interactor of little elongation complex ELL subunit 1 (ICE1), patched 1 (PTCH1), mutS homolog 3 (MSH3) and caspase recruitment domain family member 11 (CARD11) were also shown to be altered in GC cells in the cBioPortal for Cancer Genomics analysis.\n'
p6368
sg4
(lp6369
(dp6370
g7
I177
sg8
VP20585
p6371
sg10
I14
sg11
VmutS homolog 3
p6372
sg13
I3
sa(dp6373
g7
I193
sg8
VP20585
p6374
sg10
I4
sg11
VMSH3
p6375
sg13
I1
sa(dp6376
g7
I35
sg8
VP29322
p6377
sg10
I5
sg11
VEPHA8
p6378
sg13
I1
sa(dp6379
g7
I169
sg8
g15
sg10
I5
sg11
VPTCH1
p6380
sg13
I1
sa(dp6381
g7
I158
sg8
g15
sg10
I9
sg11
Vpatched 1
p6382
sg13
I2
sa(dp6383
g7
I110
sg8
VP55199
p6384
sg10
I39
sg11
Vlittle elongation complex ELL subunit 1
p6385
sg13
I6
sa(dp6386
g7
I203
sg8
g15
sg10
I52
sg11
Vcaspase recruitment domain family member 11 (CARD11)
p6387
sg13
I7
sa(dp6388
g7
I18
sg8
VP29322
p6389
sg10
I15
sg11
VEPH receptor A8
p6390
sg13
I3
sasg23
(lp6391
(dp6392
g7
I211
sg26
VC0271510
p6393
sg10
I11
sg11
Vrecruitment
p6394
sg13
I1
sa(dp6395
g7
I60
sg26
VC0040715
p6396
sg10
I13
sg11
Vtranslocation
p6397
sg13
I1
sa(dp6398
g7
I43
sg26
VC0039101
p6399
sg10
I16
sg11
Vsynovial sarcoma
p6400
sg13
I2
sa(dp6401
g7
I320
sg26
VC0006826
p6402
sg10
I6
sg11
VCancer
p6403
sg13
I1
sasa(dp6404
g2
S'Moreover, lncRNA RP11-838N2.4 acts as an endogenous sponge, suppressing the function of miR-10a through conserved sequences and increasing the expression of EphA8 that enhanced the rate of cell apoptosis, thereby intensified sensitivity of GBM cells to TMZ.\n'
p6405
sg4
(lp6406
(dp6407
g7
I88
sg8
g15
sg10
I7
sg11
VmiR-10a
p6408
sg13
I1
sa(dp6409
g7
I157
sg8
VP29322
p6410
sg10
I5
sg11
VEphA8
p6411
sg13
I1
sa(dp6412
g7
I10
sg8
g15
sg10
I19
sg11
VlncRNA RP11-838N2.4
p6413
sg13
I2
sasg23
(lp6414
(dp6415
g7
I240
sg26
VC0017636
p6416
sg10
I3
sg11
VGBM
p6417
sg13
I1
sa(dp6418
g7
I17
sg26
VC1838601
p6419
sg10
I4
sg11
VRP11
p6420
sg13
I1
sasa(dp6421
g2
S'In this study, we determined the mRNA and protein expression levels of EphA8 in cancerous and normal ovarian tissue samples by quantitative reverse transcription PCR (qRT-PCR) (N = 60) and tissue microarray immunohistochemistry analysis (TMA-IHC) (N = 223) respectively.\n'
p6422
sg4
(lp6423
(dp6424
g7
I71
sg8
VP29322
p6425
sg10
I5
sg11
VEphA8
p6426
sg13
I1
sasg23
(lp6427
sa(dp6428
g2
S"EphA8 protein levels in cancer tissues were correlated with epithelial ovarian cancer (EOC) patients' clinical characteristics and overall survival.\n"
p6429
sg4
(lp6430
(dp6431
g7
I0
sg8
VP29322
p6432
sg10
I13
sg11
VEphA8 protein
p6433
sg13
I2
sasg23
(lp6434
(dp6435
g7
I60
sg26
VC0677886
p6436
sg10
I25
sg11
Vepithelial ovarian cancer
p6437
sg13
I3
sa(dp6438
g7
I87
sg26
VC0677886
p6439
sg10
I3
sg11
VEOC
p6440
sg13
I1
sa(dp6441
g7
I24
sg26
VC0006826
p6442
sg10
I6
sg11
Vcancer
p6443
sg13
I1
sasa(dp6444
g2
S'Collectively, we unveil a branch of the miR-10a/EphA8 pathway that regulates the progression of glioma.\n'
p6445
sg4
(lp6446
(dp6447
g7
I48
sg8
VP29322
p6448
sg10
I5
sg11
VEphA8
p6449
sg13
I1
sa(dp6450
g7
I40
sg8
g15
sg10
I7
sg11
VmiR-10a
p6451
sg13
I1
sasg23
(lp6452
(dp6453
g7
I96
sg26
VC0017638
p6454
sg10
I6
sg11
Vglioma
p6455
sg13
I1
sasa(dp6456
g2
S'To further explore these mutations, we examined all reported mutations of NTRK3, FES, KDR, EPHA3, NTRK2, JAK1, PDGFRA, EPHA7, EPHA8, ERBB4, FGFR1, MLK4 and GUCY2F genes in the 24 colorectal cancer cell lines.\n'
p6457
sg4
(lp6458
(dp6459
g7
I156
sg8
VP51841
p6460
sg10
I12
sg11
VGUCY2F genes
p6461
sg13
I2
sa(dp6462
g7
I105
sg8
VP23458
p6463
sg10
I4
sg11
VJAK1
p6464
sg13
I1
sa(dp6465
g7
I133
sg8
g15
sg10
I5
sg11
VERBB4
p6466
sg13
I1
sa(dp6467
g7
I147
sg8
g15
sg10
I4
sg11
VMLK4
p6468
sg13
I1
sa(dp6469
g7
I111
sg8
VP16234
p6470
sg10
I6
sg11
VPDGFRA
p6471
sg13
I1
sa(dp6472
g7
I74
sg8
g15
sg10
I5
sg11
VNTRK3
p6473
sg13
I1
sa(dp6474
g7
I81
sg8
VP07332
p6475
sg10
I3
sg11
VFES
p6476
sg13
I1
sa(dp6477
g7
I126
sg8
VP29322
p6478
sg10
I5
sg11
VEPHA8
p6479
sg13
I1
sa(dp6480
g7
I119
sg8
g15
sg10
I5
sg11
VEPHA7
p6481
sg13
I1
sa(dp6482
g7
I140
sg8
VP20930
p6483
sg10
I5
sg11
VFGFR1
p6484
sg13
I1
sa(dp6485
g7
I98
sg8
g15
sg10
I5
sg11
VNTRK2
p6486
sg13
I1
sa(dp6487
g7
I86
sg8
VP35968
p6488
sg10
I3
sg11
VKDR
p6489
sg13
I1
sa(dp6490
g7
I91
sg8
VP29320
p6491
sg10
I5
sg11
VEPHA3
p6492
sg13
I1
sasg23
(lp6493
(dp6494
g7
I179
sg26
VC1527249
p6495
sg10
I17
sg11
Vcolorectal cancer
p6496
sg13
I2
sasa(dp6497
g2
S'The serum tryptase level was normal, cysteine-rich hydrophobic domain 2 (CHIC2) deletion analysis of bone marrow cells was negative and no evidence of mastocytosis or other hematological disorder was found in the bone marrow.\n'
p6498
sg4
(lp6499
(dp6500
g7
I4
sg8
g15
sg10
I14
sg11
Vserum tryptase
p6501
sg13
I2
sa(dp6502
g7
I73
sg8
g15
sg10
I5
sg11
VCHIC2
p6503
sg13
I1
sa(dp6504
g7
I37
sg8
g15
sg10
I34
sg11
Vcysteine-rich hydrophobic domain 2
p6505
sg13
I4
sasg23
(lp6506
(dp6507
g7
I151
sg26
VC0042111
p6508
sg10
I12
sg11
Vmastocytosis
p6509
sg13
I1
sa(dp6510
g7
I173
sg26
VC0018939
p6511
sg10
I22
sg11
Vhematological disorder
p6512
sg13
I2
sasa(dp6513
g2
S'Integrin AlfavBeta3 (vitronectin receptor) plays a prominent role in angiogenesis, a key pathogenic feature of rheumatoid arthritis (RA).\n'
p6514
sg4
(lp6515
(dp6516
g7
I21
sg8
VP04004
p6517
sg10
I20
sg11
Vvitronectin receptor
p6518
sg13
I2
sasg23
(lp6519
(dp6520
g7
I133
sg26
VC0003873
p6521
sg10
I2
sg11
VRA
p6522
sg13
I1
sa(dp6523
g7
I111
sg26
VC0003873
p6524
sg10
I20
sg11
Vrheumatoid arthritis
p6525
sg13
I2
sasa(dp6526
g2
S'In experimental autoimmune encephalomyelitis (EAE), we found that inflammatory cytokine-producing Th17 cells showed increased CD73 expression as disease progressed.\n'
p6527
sg4
(lp6528
(dp6529
g7
I126
sg8
VP21589
p6530
sg10
I4
sg11
VCD73
p6531
sg13
I1
sasg23
(lp6532
(dp6533
g7
I16
sg26
VC0443146
p6534
sg10
I10
sg11
Vautoimmune
p6535
sg13
I1
sa(dp6536
g7
I27
sg26
VC0014070
p6537
sg10
I17
sg11
Vencephalomyelitis
p6538
sg13
I1
sa(dp6539
g7
I46
sg26
VC0014070
p6540
sg10
I3
sg11
VEAE
p6541
sg13
I1
sasa(dp6542
g2
S"The aim of the present study was to analyze the activities of extracellular purine metabolizing enzymes, CD39 (apyrase, EC 3.6.1.5) and CD73 (ecto-5' nucleotidase, EC 3.1.3.5) in experimental autoimmune encephalomyelitis (EAE).\n"
p6543
sg4
(lp6544
(dp6545
g7
I164
sg8
g15
sg10
I10
sg11
VEC 3.1.3.5
p6546
sg13
I2
sa(dp6547
g7
I136
sg8
VP21589
p6548
sg10
I26
sg11
VCD73 (ecto-5' nucleotidase
p6549
sg13
I3
sa(dp6550
g7
I105
sg8
VP49961
p6551
sg10
I4
sg11
VCD39
p6552
sg13
I1
sa(dp6553
g7
I111
sg8
VP49961
p6554
sg10
I7
sg11
Vapyrase
p6555
sg13
I1
sasg23
(lp6556
(dp6557
g7
I203
sg26
VC0014070
p6558
sg10
I17
sg11
Vencephalomyelitis
p6559
sg13
I1
sa(dp6560
g7
I192
sg26
VC0443146
p6561
sg10
I10
sg11
Vautoimmune
p6562
sg13
I1
sa(dp6563
g7
I222
sg26
VC0014070
p6564
sg10
I3
sg11
VEAE
p6565
sg13
I1
sasa(dp6566
g2
S'Secondly, CD73 promotes the migration of pathogenic T cells into the central nervous system during experimental autoimmune encephalomyelitis.\n'
p6567
sg4
(lp6568
(dp6569
g7
I10
sg8
VP21589
p6570
sg10
I4
sg11
VCD73
p6571
sg13
I1
sasg23
(lp6572
(dp6573
g7
I77
sg26
VC0027769
p6574
sg10
I7
sg11
Vnervous
p6575
sg13
I1
sa(dp6576
g7
I112
sg26
VC0443146
p6577
sg10
I10
sg11
Vautoimmune
p6578
sg13
I1
sa(dp6579
g7
I123
sg26
VC0014070
p6580
sg10
I17
sg11
Vencephalomyelitis
p6581
sg13
I1
sasa(dp6582
g2
S'Because of the strong immunosuppressive and antiinflammatory properties of adenosine, we predicted that cd73(-/-) mice would develop severe experimental autoimmune encephalomyelitis (EAE), an animal model for the central nervous system (CNS) inflammatory disease, multiple sclerosis.\n'
p6583
sg4
(lp6584
(dp6585
g7
I104
sg8
VP21589
p6586
sg10
I9
sg11
Vcd73(-/-)
p6587
sg13
I1
sasg23
(lp6588
(dp6589
g7
I242
sg26
VC1290884
p6590
sg10
I20
sg11
Vinflammatory disease
p6591
sg13
I2
sa(dp6592
g7
I164
sg26
VC0014070
p6593
sg10
I17
sg11
Vencephalomyelitis
p6594
sg13
I1
sa(dp6595
g7
I264
sg26
VC0026769
p6596
sg10
I18
sg11
Vmultiple sclerosis
p6597
sg13
I2
sa(dp6598
g7
I183
sg26
VC0014070
p6599
sg10
I3
sg11
VEAE
p6600
sg13
I1
sa(dp6601
g7
I153
sg26
VC0443146
p6602
sg10
I10
sg11
Vautoimmune
p6603
sg13
I1
sa(dp6604
g7
I221
sg26
VC0027769
p6605
sg10
I7
sg11
Vnervous
p6606
sg13
I1
sasa(dp6607
g2
S'To determine the molecular background of the development of hypopharyngeal squamous cell carcinomas (HPSCCs) and double esophageal squamous cell carcinomas (DESCCs), the present study immunohistochemically assessed tumor-related protein expression [p53, Fhit (fragile histidine triad), E-cadherin and activation-induced cytidine deaminase (AID)], and subsequently determined the correlation between protein expression and clinicopathological data.\n'
p6608
sg4
(lp6609
(dp6610
g7
I249
sg8
VP42771
p6611
sg10
I3
sg11
Vp53
p6612
sg13
I1
sa(dp6613
g7
I340
sg8
g15
sg10
I3
sg11
VAID
p6614
sg13
I1
sa(dp6615
g7
I286
sg8
VP12830
p6616
sg10
I10
sg11
VE-cadherin
p6617
sg13
I1
sa(dp6618
g7
I254
sg8
VP49789
p6619
sg10
I4
sg11
VFhit
p6620
sg13
I1
sa(dp6621
g7
I260
sg8
VP49789
p6622
sg10
I23
sg11
Vfragile histidine triad
p6623
sg13
I3
sa(dp6624
g7
I301
sg8
g15
sg10
I37
sg11
Vactivation-induced cytidine deaminase
p6625
sg13
I3
sasg23
(lp6626
(dp6627
g7
I75
sg26
VC0007137
p6628
sg10
I24
sg11
Vsquamous cell carcinomas
p6629
sg13
I3
sa(dp6630
g7
I75
sg26
VC0007137
p6631
sg10
I24
sg11
Vsquamous cell carcinomas
p6632
sg13
I3
sa(dp6633
g7
I215
sg26
VC0027651
p6634
sg10
I5
sg11
Vtumor
p6635
sg13
I1
sasa(dp6636
g2
S'We identified 27 mutated genes, of which 19 genes are reported in COSMIC database (ZNF208, CRNN, ATXN3, DCTN1, RP1L1, PRB4, PRB1, MUC4, HS6ST3, MUC17, JAM2, ITGAD, IREB2, IQUB, CORO1B, CCDC121, AKAP2, ACAN and ACADL), and eight genes have not previously been described in gastric cancer (CCDC178, ARMC4, TUBB6, PLIN4, PKLR, PDZD2, DMBT1and DAB1).Additionally,GPX4 and MPND in 19q13.3-13.4 region, is characterized as a novel fusion-gene.\n'
p6637
sg4
(lp6638
(dp6639
g7
I194
sg8
g15
sg10
I5
sg11
VAKAP2
p6640
sg13
I1
sa(dp6641
g7
I331
sg8
g15
sg10
I13
sg11
VDMBT1and DAB1
p6642
sg13
I2
sa(dp6643
g7
I144
sg8
g15
sg10
I5
sg11
VMUC17
p6644
sg13
I1
sa(dp6645
g7
I118
sg8
VP10163
p6646
sg10
I4
sg11
VPRB4
p6647
sg13
I1
sa(dp6648
g7
I91
sg8
g15
sg10
I4
sg11
VCRNN
p6649
sg13
I1
sa(dp6650
g7
I124
sg8
VP02812
p6651
sg10
I4
sg11
VPRB1
p6652
sg13
I1
sa(dp6653
g7
I210
sg8
VP28330
p6654
sg10
I5
sg11
VACADL
p6655
sg13
I1
sa(dp6656
g7
I171
sg8
g15
sg10
I4
sg11
VIQUB
p6657
sg13
I1
sa(dp6658
g7
I111
sg8
g15
sg10
I5
sg11
VRP1L1
p6659
sg13
I1
sa(dp6660
g7
I201
sg8
VP16112
p6661
sg10
I4
sg11
VACAN
p6662
sg13
I1
sa(dp6663
g7
I311
sg8
g15
sg10
I5
sg11
VPLIN4
p6664
sg13
I1
sa(dp6665
g7
I177
sg8
g15
sg10
I6
sg11
VCORO1B
p6666
sg13
I1
sa(dp6667
g7
I151
sg8
VP57087
p6668
sg10
I4
sg11
VJAM2
p6669
sg13
I1
sa(dp6670
g7
I157
sg8
g15
sg10
I5
sg11
VITGAD
p6671
sg13
I1
sa(dp6672
g7
I83
sg8
g15
sg10
I6
sg11
VZNF208
p6673
sg13
I1
sa(dp6674
g7
I185
sg8
g15
sg10
I7
sg11
VCCDC121
p6675
sg13
I1
sa(dp6676
g7
I104
sg8
g15
sg10
I5
sg11
VDCTN1
p6677
sg13
I1
sa(dp6678
g7
I359
sg8
VP36969
p6679
sg10
I4
sg11
VGPX4
p6680
sg13
I1
sa(dp6681
g7
I297
sg8
g15
sg10
I5
sg11
VARMC4
p6682
sg13
I1
sa(dp6683
g7
I136
sg8
g15
sg10
I6
sg11
VHS6ST3
p6684
sg13
I1
sa(dp6685
g7
I97
sg8
g15
sg10
I5
sg11
VATXN3
p6686
sg13
I1
sa(dp6687
g7
I324
sg8
g15
sg10
I5
sg11
VPDZD2
p6688
sg13
I1
sa(dp6689
g7
I164
sg8
VP48200
p6690
sg10
I5
sg11
VIREB2
p6691
sg13
I1
sa(dp6692
g7
I318
sg8
VP30613
p6693
sg10
I4
sg11
VPKLR
p6694
sg13
I1
sa(dp6695
g7
I304
sg8
g15
sg10
I5
sg11
VTUBB6
p6696
sg13
I1
sasg23
(lp6697
(dp6698
g7
I272
sg26
VC0024623
p6699
sg10
I14
sg11
Vgastric cancer
p6700
sg13
I2
sasa(dp6701
g2
S'To investigate the association between gastric cardia adenocarcinoma (GCA) and ten functional single nucleotide polymorphisms (SNPs), including TP53BP1 rs560191 G&gt;C, CASP8 rs1035142 G&gt;T, CASP7 rs3127075 G&gt;C, CASP7 rs7907519 C&gt;A, and six C1orf10/CRNN variants.\n'
p6702
sg4
(lp6703
(dp6704
g7
I217
sg8
VP55210
p6705
sg10
I17
sg11
VCASP7 rs7907519 C
p6706
sg13
I3
sa(dp6707
g7
I-1
sg8
VP55210
p6708
sg10
I19
sg11
VCASP7 rs3127075 G>C
p6709
sg13
I3
sa(dp6710
g7
I257
sg8
g15
sg10
I4
sg11
VCRNN
p6711
sg13
I1
sa(dp6712
g7
I-1
sg8
g15
sg10
I20
sg11
VTP53BP1 rs560191 G>C
p6713
sg13
I3
sa(dp6714
g7
I249
sg8
g15
sg10
I7
sg11
VC1orf10
p6715
sg13
I1
sasg23
(lp6716
(dp6717
g7
I39
sg26
VC1333762
p6718
sg10
I29
sg11
Vgastric cardia adenocarcinoma
p6719
sg13
I3
sa(dp6720
g7
I70
sg26
VC0039483
p6721
sg10
I3
sg11
VGCA
p6722
sg13
I1
sasa(dp6723
g2
S'They were synthesized from substituted anthranilic acids and trimellitic anhydride chloride, followed by reaction with primary amines and were tested for the inhibition of five physiologically relevant CA isoforms, the human (h) hCA I, II, IV, VII and XII, some of which are involved in serious pathologies (CA II, IV and XII in glaucoma; CA VII in epilepsy; CA XII in some solid tumors).\n'
p6724
sg4
(lp6725
(dp6726
g7
I339
sg8
VP43166
p6727
sg10
I6
sg11
VCA VII
p6728
sg13
I2
sa(dp6729
g7
I359
sg8
g15
sg10
I6
sg11
VCA XII
p6730
sg13
I2
sa(dp6731
g7
I202
sg8
VP38606
p6732
sg10
I11
sg11
VCA isoforms
p6733
sg13
I2
sasg23
(lp6734
(dp6735
g7
I374
sg26
VC0280100
p6736
sg10
I12
sg11
Vsolid tumors
p6737
sg13
I2
sa(dp6738
g7
I349
sg26
VC0014544
p6739
sg10
I8
sg11
Vepilepsy
p6740
sg13
I1
sa(dp6741
g7
I329
sg26
VC0017601
p6742
sg10
I8
sg11
Vglaucoma
p6743
sg13
I1
sasa(dp6744
g2
S'More intense StarD6 immunolocalization was seen in the strata radiatum and lacunosum-moleculare, particularly in CA1-2 areas until 12 h after pilocarpine-induced epilepsy.\n'
p6745
sg4
(lp6746
(dp6747
g7
I13
sg8
VP59095
p6748
sg10
I6
sg11
VStarD6
p6749
sg13
I1
sasg23
(lp6750
(dp6751
g7
I162
sg26
VC0014544
p6752
sg10
I8
sg11
Vepilepsy
p6753
sg13
I1
sasa(dp6754
g2
S'Regulation of these steps requires successive binding of MED26 N-terminal domain (NTD) to TATA-binding protein-associated factor 7 (TAF7) and Eleven-nineteen lysine-rich in leukemia-Associated Factor 1 (EAF1).\n'
p6755
sg4
(lp6756
(dp6757
g7
I203
sg8
g15
sg10
I4
sg11
VEAF1
p6758
sg13
I1
sa(dp6759
g7
I90
sg8
VP20226
p6760
sg10
I40
sg11
VTATA-binding protein-associated factor 7
p6761
sg13
I4
sa(dp6762
g7
I57
sg8
g15
sg10
I23
sg11
VMED26 N-terminal domain
p6763
sg13
I3
sa(dp6764
g7
I132
sg8
g15
sg10
I4
sg11
VTAF7
p6765
sg13
I1
sa(dp6766
g7
I193
sg8
g15
sg10
I8
sg11
VFactor 1
p6767
sg13
I2
sasg23
(lp6768
(dp6769
g7
I173
sg26
VC0023418
p6770
sg10
I8
sg11
Vleukemia
p6771
sg13
I1
sasa(dp6772
g2
S'Sperm-specific histone variants Sp H1 and Sp H2B are maintained as phosphorylated derivatives N and O/P throughout spermatogenesis and early embryogenesis and egg specific histone variants CS H1 and CS H2A are phosphorylated during early embryogenesis.\n'
p6773
sg4
(lp6774
(dp6775
g7
I42
sg8
VP62807
p6776
sg10
I6
sg11
VSp H2B
p6777
sg13
I2
sa(dp6778
g7
I199
sg8
VP04908
p6779
sg10
I6
sg11
VCS H2A
p6780
sg13
I2
sa(dp6781
g7
I159
sg8
VP62805
p6782
sg10
I35
sg11
Vegg specific histone variants CS H1
p6783
sg13
I6
sa(dp6784
g7
I0
sg8
VP62805
p6785
sg10
I37
sg11
VSperm-specific histone variants Sp H1
p6786
sg13
I5
sasg23
(lp6787
sa(dp6788
g2
S'Then, in parallel with chromatin decondensation, nearly all phosphorylated Sp H1 is lost from the pronuclear chromatin, with the concurrent assimilation of the egg phosphoprotein CS H1.\n'
p6789
sg4
(lp6790
(dp6791
g7
I160
sg8
g15
sg10
I24
sg11
Vegg phosphoprotein CS H1
p6792
sg13
I4
sasg23
(lp6793
sa(dp6794
g2
S'The anaemia and thrombocytopenia of hypophysectomized (Hypox) rats could be corrected readily by daily treatment with human placental lactogen.\n'
p6795
sg4
(lp6796
sg23
(lp6797
(dp6798
g7
I4
sg26
VC0002871
p6799
sg10
I7
sg11
Vanaemia
p6800
sg13
I1
sasa(dp6801
g2
S'HA-nIR women have markedly elevated LH, often have minimally elevated serum prolactin, and have polycystic ovaries.\n'
p6802
sg4
(lp6803
(dp6804
g7
I3
sg8
g15
sg10
I3
sg11
VnIR
p6805
sg13
I1
sa(dp6806
g7
I70
sg8
VP01236
p6807
sg10
I15
sg11
Vserum prolactin
p6808
sg13
I2
sasg23
(lp6809
(dp6810
g7
I96
sg26
VC0032460
p6811
sg10
I18
sg11
Vpolycystic ovaries
p6812
sg13
I2
sasa(dp6813
g2
S'Therefore, it was hypothesized that SIRT1 might be important in the development of myocardial infarction.\n'
p6814
sg4
(lp6815
(dp6816
g7
I36
sg8
g15
sg10
I5
sg11
VSIRT1
p6817
sg13
I1
sasg23
(lp6818
(dp6819
g7
I83
sg26
VC0027051
p6820
sg10
I21
sg11
Vmyocardial infarction
p6821
sg13
I2
sasa(dp6822
g2
S'These findings provide direct evidence that the SIRT1/UCP-2 axis might be important in myocardial infarction, and suggest that this axis may be a novel therapeutic target for the treatment of cardiovascular disease.\n'
p6823
sg4
(lp6824
(dp6825
g7
I54
sg8
VP55851
p6826
sg10
I10
sg11
VUCP-2 axis
p6827
sg13
I2
sa(dp6828
g7
I48
sg8
g15
sg10
I5
sg11
VSIRT1
p6829
sg13
I1
sasg23
(lp6830
(dp6831
g7
I192
sg26
VC0007222
p6832
sg10
I22
sg11
Vcardiovascular disease
p6833
sg13
I2
sa(dp6834
g7
I87
sg26
VC0027051
p6835
sg10
I21
sg11
Vmyocardial infarction
p6836
sg13
I2
sasa(dp6837
g2
S'Inclusion criteria were non-small-cell lung cancer patients with bone metastases confirmed by pathology or cytology; available imaging data of pelvic metastatic lesions; aged 18 to 75 years old; expected survival at least 3 months; not receiving taxane, bevacizumab, thalidomide, rh-endostatin, or bisphosphonate; not having radiation therapy within 3 months of enrollment into study; normal results of routine blood tests, liver and kidney function, and electrocardiogram; absence of cardiovascular disease, autoimmune disease, vasculitis, severe infection, diabetes, and other concomitant disease; and signed informed consent.\n'
p6838
sg4
(lp6839
sg23
(lp6840
(dp6841
g7
I579
sg26
VC0243087
p6842
sg10
I19
sg11
Vconcomitant disease
p6843
sg13
I2
sa(dp6844
g7
I485
sg26
VC0007222
p6845
sg10
I22
sg11
Vcardiovascular disease
p6846
sg13
I2
sa(dp6847
g7
I65
sg26
VC0153690
p6848
sg10
I15
sg11
Vbone metastases
p6849
sg13
I2
sa(dp6850
g7
I529
sg26
VC0042384
p6851
sg10
I10
sg11
Vvasculitis
p6852
sg13
I1
sa(dp6853
g7
I509
sg26
VC0004364
p6854
sg10
I18
sg11
Vautoimmune disease
p6855
sg13
I2
sa(dp6856
g7
I548
sg26
VC0009450
p6857
sg10
I9
sg11
Vinfection
p6858
sg13
I1
sa(dp6859
g7
I39
sg26
VC0684249
p6860
sg10
I11
sg11
Vlung cancer
p6861
sg13
I2
sa(dp6862
g7
I559
sg26
VC0011849
p6863
sg10
I8
sg11
Vdiabetes
p6864
sg13
I1
sa(dp6865
g7
I94
sg26
VC0677042
p6866
sg10
I9
sg11
Vpathology
p6867
sg13
I1
sasa(dp6868
g2
S'Further study is needed to confirm survival benefit of platinum-based chemotherapy for elderly non-small-cell lung cancer [UMIN-CTR (www.umin.ac.jp/ctr/) ID: C000000146].\n'
p6869
sg4
(lp6870
sg23
(lp6871
(dp6872
g7
I110
sg26
VC0684249
p6873
sg10
I11
sg11
Vlung cancer
p6874
sg13
I2
sasa(dp6875
g2
S'ObcneAoBanN 40 namyNeHToB c aKc-CnA (KpNTepNN ASAS, 2009; Bo3pacT 38,5+/-12,1 roAa; 29 (72,5%) MyX4NH; AnNTenbHocTb aKc-CnA 6,67+/-5,8 roAa; NHAeKc BASDAI &gt;=4,0), KoTopble B cny4aNHoM nopRAKe pa3AeneHbl Ha rpynnbl: 20 bonbHblx npNHNManN myeneKoKcNb no 400 Mr/cyT B Te4eHNe 30 AHeN, 20 namyNeHToB - B Te4eHNe 7 AHeN myeneKoKcNb no 600 Mr/cyT, 3aTeM npoAonXNnN npNeM npenapaTa no 200 Mr/cyT Ao 1 Mec.\n'
p6876
sg4
(lp6877
(dp6878
g7
I12
sg8
g15
sg10
I23
sg11
V40 namyNeHToB c aKc-CnA
p6879
sg13
I4
sa(dp6880
g7
I388
sg8
g15
sg10
I12
sg11
VcyT Ao 1 Mec
p6881
sg13
I4
sa(dp6882
g7
I262
sg8
g15
sg10
I21
sg11
VcyT B Te4eHNe 30 AHeN
p6883
sg13
I5
sa(dp6884
g7
I103
sg8
g15
sg10
I36
sg11
VAnNTenbHocTb aKc-CnA 6,67+/-5,8 roAa
p6885
sg13
I4
sa(dp6886
g7
I37
sg8
g15
sg10
I13
sg11
VKpNTepNN ASAS
p6887
sg13
I2
sa(dp6888
g7
I262
sg8
g15
sg10
I3
sg11
VcyT
p6889
sg13
I1
sasg23
(lp6890
sa(dp6891
g2
S'NamyNeHTbl HapRAy co cTaHAapTHoN cxeMoN ne4eHNR nony4anN MenaKceH 3 Mr/cyT B Te4eHNe 3 Mec.\n'
p6892
sg4
(lp6893
(dp6894
g7
I11
sg8
VP08235
p6895
sg10
I59
sg11
VHapRAy co cTaHAapTHoN cxeMoN ne4eHNR nony4anN MenaKceH 3 Mr
p6896
sg13
I9
sa(dp6897
g7
I71
sg8
g15
sg10
I19
sg11
VcyT B Te4eHNe 3 Mec
p6898
sg13
I5
sasg23
(lp6899
sa(dp6900
g2
S'NonoBNHa ETNx namyNeHToB bblnN onepNpoBaHbl cpa3y, a ApyrNe - nocne oapMaKonorN4ecKoro npeKoHANmyNoHNpoBaHNR aKToBerNHoM B Ao3e 1200 Mr/cyT B Te4eHNe 1,5 Mec.\n'
p6901
sg4
(lp6902
(dp6903
g7
I136
sg8
g15
sg10
I21
sg11
VcyT B Te4eHNe 1,5 Mec
p6904
sg13
I5
sa(dp6905
g7
I133
sg8
VP08235
p6906
sg10
I2
sg11
VMr
p6907
sg13
I1
sasg23
(lp6908
sa(dp6909
g2
S'NamyNeHTbl npNHNManN MarHepoT B cpeAHeM no 1878+/-823 Mr/cyT B Te4eHNe 4,2+/-29 Mec.\n'
p6910
sg4
(lp6911
(dp6912
g7
I57
sg8
g15
sg10
I15
sg11
VcyT B Te4eHNe 4
p6913
sg13
I4
sasg23
(lp6914
sa(dp6915
g2
S'To determine the effects of laser photocoagulation on serum levels of angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), soluble angiopoietin receptor Tie-2 (Tie-2), Ang-1/Ang-2 ratio and vascular endothelial growth factor (VEGF) in patients with type 2 diabetes mellitus (T2DM) and proliferative diabetic retinopathy (PDR).\n'
p6916
sg4
(lp6917
(dp6918
g7
I94
sg8
g15
sg10
I14
sg11
Vangiopoietin-2
p6919
sg13
I1
sa(dp6920
g7
I185
sg8
g15
sg10
I34
sg11
Vvascular endothelial growth factor
p6921
sg13
I4
sa(dp6922
g7
I126
sg8
g15
sg10
I27
sg11
Vangiopoietin receptor Tie-2
p6923
sg13
I3
sa(dp6924
g7
I221
sg8
g15
sg10
I4
sg11
VVEGF
p6925
sg13
I1
sa(dp6926
g7
I110
sg8
VP03950
p6927
sg10
I5
sg11
VAng-2
p6928
sg13
I1
sa(dp6929
g7
I110
sg8
VP03950
p6930
sg10
I5
sg11
VAng-2
p6931
sg13
I1
sa(dp6932
g7
I70
sg8
g15
sg10
I14
sg11
Vangiopoietin-1
p6933
sg13
I1
sa(dp6934
g7
I86
sg8
VP03950
p6935
sg10
I5
sg11
VAng-1
p6936
sg13
I1
sa(dp6937
g7
I148
sg8
g15
sg10
I5
sg11
VTie-2
p6938
sg13
I1
sa(dp6939
g7
I86
sg8
VP03950
p6940
sg10
I5
sg11
VAng-1
p6941
sg13
I1
sasg23
(lp6942
(dp6943
g7
I270
sg26
VC0011860
p6944
sg10
I4
sg11
VT2DM
p6945
sg13
I1
sa(dp6946
g7
I280
sg26
VC0154830
p6947
sg10
I34
sg11
Vproliferative diabetic retinopathy
p6948
sg13
I3
sa(dp6949
g7
I244
sg26
VC0011860
p6950
sg10
I24
sg11
Vtype 2 diabetes mellitus
p6951
sg13
I4
sa(dp6952
g7
I316
sg26
VC0154830
p6953
sg10
I3
sg11
VPDR
p6954
sg13
I1
sasa(dp6955
g2
S'Certain mutations in the COL1A1 and COL1A2 genes produce clinical symptoms of both osteogenesis imperfecta (OI) and Ehlers-Danlos syndrome (EDS) that include abnormal craniofacial growth, dental malocclusion, and dentinogenesis imperfecta.\n'
p6956
sg4
(lp6957
(dp6958
g7
I36
sg8
VP01893
p6959
sg10
I12
sg11
VCOL1A2 genes
p6960
sg13
I2
sasg23
(lp6961
(dp6962
g7
I108
sg26
VC0029434
p6963
sg10
I2
sg11
VOI
p6964
sg13
I1
sa(dp6965
g7
I116
sg26
VC0013720
p6966
sg10
I22
sg11
VEhlers-Danlos syndrome
p6967
sg13
I2
sa(dp6968
g7
I213
sg26
VC0011436
p6969
sg10
I25
sg11
Vdentinogenesis imperfecta
p6970
sg13
I2
sa(dp6971
g7
I83
sg26
VC0029434
p6972
sg10
I23
sg11
Vosteogenesis imperfecta
p6973
sg13
I2
sa(dp6974
g7
I188
sg26
VC0024636
p6975
sg10
I19
sg11
Vdental malocclusion
p6976
sg13
I2
sa(dp6977
g7
I140
sg26
VC0013720
p6978
sg10
I3
sg11
VEDS
p6979
sg13
I1
sasa(dp6980
g2
S'RBP1, TFRC, SPP1, SAA1, ARHGAP8, and NDRG1, which were upregulated, and GATA3, PLAGL1, APOD, DUSP1, and CYR61, which were downregulated, were considered as candidate genes associated with invasion of cervical cancer.\n'
p6981
sg4
(lp6982
(dp6983
g7
I104
sg8
g15
sg10
I5
sg11
VCYR61
p6984
sg13
I1
sa(dp6985
g7
I6
sg8
VP02786
p6986
sg10
I4
sg11
VTFRC
p6987
sg13
I1
sa(dp6988
g7
I87
sg8
VP05090
p6989
sg10
I4
sg11
VAPOD
p6990
sg13
I1
sa(dp6991
g7
I12
sg8
VP10451
p6992
sg10
I4
sg11
VSPP1
p6993
sg13
I1
sa(dp6994
g7
I93
sg8
VP28562
p6995
sg10
I5
sg11
VDUSP1
p6996
sg13
I1
sa(dp6997
g7
I79
sg8
g15
sg10
I6
sg11
VPLAGL1
p6998
sg13
I1
sa(dp6999
g7
I72
sg8
VP23771
p7000
sg10
I5
sg11
VGATA3
p7001
sg13
I1
sa(dp7002
g7
I37
sg8
g15
sg10
I5
sg11
VNDRG1
p7003
sg13
I1
sa(dp7004
g7
I0
sg8
VP29374
p7005
sg10
I4
sg11
VRBP1
p7006
sg13
I1
sasg23
(lp7007
(dp7008
g7
I188
sg26
VC2699153
p7009
sg10
I8
sg11
Vinvasion
p7010
sg13
I1
sa(dp7011
g7
I200
sg26
VC0302592
p7012
sg10
I15
sg11
Vcervical cancer
p7013
sg13
I2
sasa(dp7014
g2
S'In addition, RGS18-/- mice presented a mild thrombocytopenia, accompanied with a marked deficit in MK number in the bone marrow.\n'
p7015
sg4
(lp7016
(dp7017
g7
I13
sg8
g15
sg10
I5
sg11
VRGS18
p7018
sg13
I1
sasg23
(lp7019
(dp7020
g7
I88
sg26
VC0162429
p7021
sg10
I7
sg11
Vdeficit
p7022
sg13
I1
sasa(dp7023
g2
S'Finally, RGS18 deficiency was correlated to a defect of platelet recovery in vivo under acute conditions of thrombocytopenia.\n'
p7024
sg4
(lp7025
(dp7026
g7
I9
sg8
g15
sg10
I5
sg11
VRGS18
p7027
sg13
I1
sasg23
(lp7028
sa(dp7029
g2
S'RGS18 depletion in zebrafish results in thrombocytopenia, as 66 to 88% of the embryos lack thrombocytes after injection of an ATG or splice-blocking morpholino, respectively.\n'
p7030
sg4
(lp7031
(dp7032
g7
I0
sg8
g15
sg10
I5
sg11
VRGS18
p7033
sg13
I1
sasg23
(lp7034
(dp7035
g7
I140
sg26
VC0233660
p7036
sg10
I8
sg11
Vblocking
p7037
sg13
I1
sasa(dp7038
g2
S'Nuts, when eaten alongside other nutritionally rich foods, may decrease obesity and related chronic disease risks, which are high among African American women in the rural South.\n'
p7039
sg4
(lp7040
sg23
(lp7041
(dp7042
g7
I72
sg26
VC0028754
p7043
sg10
I7
sg11
Vobesity
p7044
sg13
I1
sa(dp7045
g7
I92
sg26
VC0008679
p7046
sg10
I15
sg11
Vchronic disease
p7047
sg13
I2
sasa(dp7048
g2
S'Nut consumption decreases risk for obesity and chronic diseases, which are prevalent among African-American women in the rural southeastern United States.\n'
p7049
sg4
(lp7050
(dp7051
g7
I0
sg8
g15
sg10
I3
sg11
VNut
p7052
sg13
I1
sasg23
(lp7053
(dp7054
g7
I35
sg26
VC0028754
p7055
sg10
I7
sg11
Vobesity
p7056
sg13
I1
sa(dp7057
g7
I47
sg26
VC0008679
p7058
sg10
I16
sg11
Vchronic diseases
p7059
sg13
I2
sasa(dp7060
g2
S'Recently, UCH-L1 has been found to increase cancer cell migration and invasion by modulating hydrogen peroxide generated by NADPH oxidase 4 (NOX4).\n'
p7061
sg4
(lp7062
(dp7063
g7
I141
sg8
g15
sg10
I4
sg11
VNOX4
p7064
sg13
I1
sa(dp7065
g7
I10
sg8
VP09936
p7066
sg10
I6
sg11
VUCH-L1
p7067
sg13
I1
sa(dp7068
g7
I124
sg8
g15
sg10
I15
sg11
VNADPH oxidase 4
p7069
sg13
I3
sasg23
(lp7070
(dp7071
g7
I44
sg26
VC0006826
p7072
sg10
I6
sg11
Vcancer
p7073
sg13
I1
sa(dp7074
g7
I70
sg26
VC2699153
p7075
sg10
I8
sg11
Vinvasion
p7076
sg13
I1
sasa(dp7077
g2
S'This study also showed that UCH-L1 promotes angiogenesis of HUVECs, as well as invasion in cancer cells, by up-regulating ROS by deubiquitination of NOX4, suggesting that UCH-L1 plays a key role in angiogenesis of HUVECS by regulating ROS levels by deubiquitination of NOX4.\n'
p7078
sg4
(lp7079
(dp7080
g7
I149
sg8
g15
sg10
I4
sg11
VNOX4
p7081
sg13
I1
sa(dp7082
g7
I149
sg8
g15
sg10
I4
sg11
VNOX4
p7083
sg13
I1
sa(dp7084
g7
I28
sg8
VP09936
p7085
sg10
I6
sg11
VUCH-L1
p7086
sg13
I1
sa(dp7087
g7
I28
sg8
VP09936
p7088
sg10
I6
sg11
VUCH-L1
p7089
sg13
I1
sasg23
(lp7090
(dp7091
g7
I79
sg26
VC2699153
p7092
sg10
I8
sg11
Vinvasion
p7093
sg13
I1
sa(dp7094
g7
I91
sg26
VC0006826
p7095
sg10
I6
sg11
Vcancer
p7096
sg13
I1
sasa(dp7097
g2
S'NADPH oxidase 4 (NOX4) is a member of the NADPH oxidase (NOX) family of enzymes and has been found abnormally expressed in human cancers.\n'
p7098
sg4
(lp7099
(dp7100
g7
I42
sg8
VP30043
p7101
sg10
I26
sg11
VNADPH oxidase (NOX) family
p7102
sg13
I4
sa(dp7103
g7
I17
sg8
g15
sg10
I4
sg11
VNOX4
p7104
sg13
I1
sa(dp7105
g7
I0
sg8
g15
sg10
I15
sg11
VNADPH oxidase 4
p7106
sg13
I3
sasg23
(lp7107
(dp7108
g7
I129
sg26
VC0006826
p7109
sg10
I7
sg11
Vcancers
p7110
sg13
I1
sasa(dp7111
g2
S'Among NADPH oxidase isoforms, NADPH oxidase4 (Nox4) is highly expressed in the kidney and has an important role in kidney diseases, such as diabetic nephropathy and renal carcinoma.\n'
p7112
sg4
(lp7113
(dp7114
g7
I30
sg8
VP30043
p7115
sg10
I14
sg11
VNADPH oxidase4
p7116
sg13
I2
sa(dp7117
g7
I6
sg8
VP30043
p7118
sg10
I22
sg11
VNADPH oxidase isoforms
p7119
sg13
I3
sa(dp7120
g7
I46
sg8
g15
sg10
I4
sg11
VNox4
p7121
sg13
I1
sasg23
(lp7122
(dp7123
g7
I140
sg26
VC0011881
p7124
sg10
I20
sg11
Vdiabetic nephropathy
p7125
sg13
I2
sa(dp7126
g7
I165
sg26
VC0007134
p7127
sg10
I15
sg11
Vrenal carcinoma
p7128
sg13
I2
sa(dp7129
g7
I115
sg26
VC0022658
p7130
sg10
I15
sg11
Vkidney diseases
p7131
sg13
I2
sasa(dp7132
g2
S'Finally, we show that NOX4 silencing, through PKM2, sensitizes cultured and ex vivo freshly isolated human-renal carcinoma cells to drug-induced cell death in xenograft models and ex vivo cultures.\n'
p7133
sg4
(lp7134
(dp7135
g7
I22
sg8
g15
sg10
I4
sg11
VNOX4
p7136
sg13
I1
sasg23
(lp7137
(dp7138
g7
I107
sg26
VC0007134
p7139
sg10
I15
sg11
Vrenal carcinoma
p7140
sg13
I2
sasa(dp7141
g2
S'Although the NOX isoforms NOX2, 4, 5, 6, and RAC1 were readily detectable by RT-PCR in pancreatic ductal adenocarcinoma (PDAC)-derived Panc1 and Colo357 cells, only NOX4 and RAC1 were expressed at higher levels comparable to those in peripheral blood monocytes.\n'
p7142
sg4
(lp7143
(dp7144
g7
I45
sg8
VP63000
p7145
sg10
I4
sg11
VRAC1
p7146
sg13
I1
sa(dp7147
g7
I45
sg8
VP63000
p7148
sg10
I4
sg11
VRAC1
p7149
sg13
I1
sa(dp7150
g7
I165
sg8
g15
sg10
I4
sg11
VNOX4
p7151
sg13
I1
sasg23
(lp7152
(dp7153
g7
I121
sg26
VC1335302
p7154
sg10
I4
sg11
VPDAC
p7155
sg13
I1
sa(dp7156
g7
I87
sg26
VC1335302
p7157
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p7158
sg13
I3
sasa(dp7159
g2
S'In the case-pediatric control and case-adult control analyses, five polymorphisms were associated with increased likelihood of pediatric-onset type 2 diabetes; only one of these polymorphisms (CADM2/rs1307880) also showed a consistent effect in the case-sibling analysis.\n'
p7160
sg4
(lp7161
(dp7162
g7
I193
sg8
g15
sg10
I5
sg11
VCADM2
p7163
sg13
I1
sasg23
(lp7164
(dp7165
g7
I143
sg26
VC0011860
p7166
sg10
I15
sg11
Vtype 2 diabetes
p7167
sg13
I3
sasa(dp7168
g2
S'ADORA/rs903361, CADM2/rs13078807, GNPDA2/rs10938397, VEGFA/rs6905288 and FTO/rs9939609 are associated with an increased risk of pediatric-onset type 2 diabetes in the Mexican population.\n'
p7169
sg4
(lp7170
(dp7171
g7
I16
sg8
g15
sg10
I5
sg11
VCADM2
p7172
sg13
I1
sa(dp7173
g7
I34
sg8
g15
sg10
I6
sg11
VGNPDA2
p7174
sg13
I1
sa(dp7175
g7
I73
sg8
g15
sg10
I3
sg11
VFTO
p7176
sg13
I1
sasg23
(lp7177
(dp7178
g7
I144
sg26
VC0011860
p7179
sg10
I15
sg11
Vtype 2 diabetes
p7180
sg13
I3
sasa(dp7181
g2
S'Finally, we did not identify any rare mutations co-segregating with obesity in common obesity susceptibility genes, except for CADM2 and QPCTL, where we found two novel variants (p.Arg81His and p.Leu98Pro, respectively) in three obese individuals.\n'
p7182
sg4
(lp7183
(dp7184
g7
I137
sg8
g15
sg10
I5
sg11
VQPCTL
p7185
sg13
I1
sa(dp7186
g7
I127
sg8
g15
sg10
I5
sg11
VCADM2
p7187
sg13
I1
sasg23
(lp7188
(dp7189
g7
I68
sg26
VC0028754
p7190
sg10
I7
sg11
Vobesity
p7191
sg13
I1
sa(dp7192
g7
I229
sg26
VC0028754
p7193
sg10
I5
sg11
Vobese
p7194
sg13
I1
sa(dp7195
g7
I68
sg26
VC0028754
p7196
sg10
I7
sg11
Vobesity
p7197
sg13
I1
sasa(dp7198
g2
S'Eight obesity-related SNPs in the FTO, MAP2K5, NEGR1, FLJ35779, ETV5, CADM2, and NUDT3 genes were nominally significantly associated with hair color among 5,876 individuals of European ancestry.\n'
p7199
sg4
(lp7200
(dp7201
g7
I54
sg8
g15
sg10
I8
sg11
VFLJ35779
p7202
sg13
I1
sa(dp7203
g7
I81
sg8
g15
sg10
I11
sg11
VNUDT3 genes
p7204
sg13
I2
sa(dp7205
g7
I34
sg8
g15
sg10
I3
sg11
VFTO
p7206
sg13
I1
sa(dp7207
g7
I47
sg8
g15
sg10
I5
sg11
VNEGR1
p7208
sg13
I1
sa(dp7209
g7
I70
sg8
g15
sg10
I5
sg11
VCADM2
p7210
sg13
I1
sa(dp7211
g7
I39
sg8
g15
sg10
I6
sg11
VMAP2K5
p7212
sg13
I1
sa(dp7213
g7
I64
sg8
VP41161
p7214
sg10
I4
sg11
VETV5
p7215
sg13
I1
sasg23
(lp7216
(dp7217
g7
I6
sg26
VC0028754
p7218
sg10
I7
sg11
Vobesity
p7219
sg13
I1
sasa(dp7220
g2
S'Here, we searched biological databases and discovered 33 additional genes associated with human obesity (CADM2, GIPR, GPCR5B, LRP1B, NEGR1, NRXN3, SH2B1, FANCL, GNPDA2, HMGCR, MAP2K5, NUDT3, PRKD1, QPCTL, TNNI3K, MTCH2, DNAJC27, SLC39A8, MTIF3, RPL27A, SEC16B, ETV5, HMGA1, TFAP2B, TUB, ZNF608, FAIM2, KCTD15, LINGO2, POC5, PTBP2, TMEM18, TMEM160).\n'
p7221
sg4
(lp7222
(dp7223
g7
I274
sg8
g15
sg10
I6
sg11
VTFAP2B
p7224
sg13
I1
sa(dp7225
g7
I112
sg8
VP48546
p7226
sg10
I4
sg11
VGIPR
p7227
sg13
I1
sa(dp7228
g7
I169
sg8
VP04035
p7229
sg10
I5
sg11
VHMGCR
p7230
sg13
I1
sa(dp7231
g7
I147
sg8
g15
sg10
I5
sg11
VSH2B1
p7232
sg13
I1
sa(dp7233
g7
I229
sg8
g15
sg10
I7
sg11
VSLC39A8
p7234
sg13
I1
sa(dp7235
g7
I331
sg8
g15
sg10
I6
sg11
VTMEM18
p7236
sg13
I1
sa(dp7237
g7
I184
sg8
g15
sg10
I5
sg11
VNUDT3
p7238
sg13
I1
sa(dp7239
g7
I287
sg8
g15
sg10
I6
sg11
VZNF608
p7240
sg13
I1
sa(dp7241
g7
I191
sg8
g15
sg10
I5
sg11
VPRKD1
p7242
sg13
I1
sa(dp7243
g7
I318
sg8
g15
sg10
I4
sg11
VPOC5
p7244
sg13
I1
sa(dp7245
g7
I176
sg8
g15
sg10
I6
sg11
VMAP2K5
p7246
sg13
I1
sa(dp7247
g7
I140
sg8
g15
sg10
I5
sg11
VNRXN3
p7248
sg13
I1
sa(dp7249
g7
I154
sg8
g15
sg10
I5
sg11
VFANCL
p7250
sg13
I1
sa(dp7251
g7
I133
sg8
g15
sg10
I5
sg11
VNEGR1
p7252
sg13
I1
sa(dp7253
g7
I213
sg8
g15
sg10
I5
sg11
VMTCH2
p7254
sg13
I1
sa(dp7255
g7
I161
sg8
g15
sg10
I6
sg11
VGNPDA2
p7256
sg13
I1
sa(dp7257
g7
I253
sg8
g15
sg10
I6
sg11
VSEC16B
p7258
sg13
I1
sa(dp7259
g7
I310
sg8
g15
sg10
I6
sg11
VLINGO2
p7260
sg13
I1
sa(dp7261
g7
I339
sg8
g15
sg10
I7
sg11
VTMEM160
p7262
sg13
I1
sa(dp7263
g7
I198
sg8
g15
sg10
I5
sg11
VQPCTL
p7264
sg13
I1
sa(dp7265
g7
I105
sg8
g15
sg10
I5
sg11
VCADM2
p7266
sg13
I1
sa(dp7267
g7
I267
sg8
VP17096
p7268
sg10
I5
sg11
VHMGA1
p7269
sg13
I1
sa(dp7270
g7
I324
sg8
g15
sg10
I5
sg11
VPTBP2
p7271
sg13
I1
sa(dp7272
g7
I282
sg8
VP50607
p7273
sg10
I3
sg11
VTUB
p7274
sg13
I1
sa(dp7275
g7
I220
sg8
g15
sg10
I7
sg11
VDNAJC27
p7276
sg13
I1
sa(dp7277
g7
I126
sg8
g15
sg10
I5
sg11
VLRP1B
p7278
sg13
I1
sa(dp7279
g7
I245
sg8
VP46776
p7280
sg10
I6
sg11
VRPL27A
p7281
sg13
I1
sa(dp7282
g7
I205
sg8
g15
sg10
I6
sg11
VTNNI3K
p7283
sg13
I1
sa(dp7284
g7
I295
sg8
g15
sg10
I5
sg11
VFAIM2
p7285
sg13
I1
sa(dp7286
g7
I261
sg8
VP41161
p7287
sg10
I4
sg11
VETV5
p7288
sg13
I1
sa(dp7289
g7
I302
sg8
g15
sg10
I6
sg11
VKCTD15
p7290
sg13
I1
sa(dp7291
g7
I238
sg8
g15
sg10
I5
sg11
VMTIF3
p7292
sg13
I1
sasg23
(lp7293
(dp7294
g7
I96
sg26
VC0028754
p7295
sg10
I7
sg11
Vobesity
p7296
sg13
I1
sasa(dp7297
g2
S'Connections among specific proteins (Bax, Bcl-2, bFGF, COX-1, COX-2, E-cad, p15, p53, PCNA, TGFbeta3, TUNEL, vWF) in control of cell proliferation, apoptosis, cell adhesion, tumor vascularity and PGE2 content were evaluated in colon cancer as related to disease progression and survival.\n'
p7298
sg4
(lp7299
(dp7300
g7
I42
sg8
VP10415
p7301
sg10
I5
sg11
VBcl-2
p7302
sg13
I1
sa(dp7303
g7
I86
sg8
VP12004
p7304
sg10
I4
sg11
VPCNA
p7305
sg13
I1
sa(dp7306
g7
I81
sg8
VP42771
p7307
sg10
I3
sg11
Vp53
p7308
sg13
I1
sa(dp7309
g7
I69
sg8
g15
sg10
I5
sg11
VE-cad
p7310
sg13
I1
sa(dp7311
g7
I49
sg8
VP53370
p7312
sg10
I4
sg11
VbFGF
p7313
sg13
I1
sa(dp7314
g7
I55
sg8
VP00395
p7315
sg10
I5
sg11
VCOX-1
p7316
sg13
I1
sa(dp7317
g7
I76
sg8
VP53999
p7318
sg10
I3
sg11
Vp15
p7319
sg13
I1
sa(dp7320
g7
I62
sg8
VP35354
p7321
sg10
I5
sg11
VCOX-2
p7322
sg13
I1
sa(dp7323
g7
I109
sg8
VP04275
p7324
sg10
I3
sg11
VvWF
p7325
sg13
I1
sasg23
(lp7326
(dp7327
g7
I174
sg26
VC0027651
p7328
sg10
I5
sg11
Vtumor
p7329
sg13
I1
sa(dp7330
g7
I164
sg26
VC0001511
p7331
sg10
I8
sg11
Vadhesion
p7332
sg13
I1
sa(dp7333
g7
I254
sg26
VC0242656
p7334
sg10
I19
sg11
Vdisease progression
p7335
sg13
I2
sa(dp7336
g7
I227
sg26
VC0699790
p7337
sg10
I12
sg11
Vcolon cancer
p7338
sg13
I2
sa(dp7339
g7
I71
sg26
VC0010054
p7340
sg10
I3
sg11
Vcad
p7341
sg13
I1
sa(dp7342
g7
I133
sg26
VC0334094
p7343
sg10
I13
sg11
Vproliferation
p7344
sg13
I1
sasa(dp7345
g2
S'In conclusion, this study demonstrates that MVD quantified using a Mab to CD105 is an independent prognostic parameter for survival of patients with colorectal cancer, and that plasma levels of CD105, TGFbeta1, TGFbeta3 and CD105/TGFbeta complexes may be useful markers for assessing disease progression.\n'
p7346
sg4
(lp7347
(dp7348
g7
I74
sg8
VP17813
p7349
sg10
I5
sg11
VCD105
p7350
sg13
I1
sa(dp7351
g7
I74
sg8
VP17813
p7352
sg10
I5
sg11
VCD105
p7353
sg13
I1
sa(dp7354
g7
I74
sg8
VP17813
p7355
sg10
I5
sg11
VCD105
p7356
sg13
I1
sa(dp7357
g7
I201
sg8
VP01137
p7358
sg10
I8
sg11
VTGFbeta1
p7359
sg13
I1
sa(dp7360
g7
I201
sg8
VP01137
p7361
sg10
I7
sg11
VTGFbeta
p7362
sg13
I1
sasg23
(lp7363
(dp7364
g7
I149
sg26
VC1527249
p7365
sg10
I17
sg11
Vcolorectal cancer
p7366
sg13
I2
sa(dp7367
g7
I284
sg26
VC0242656
p7368
sg10
I19
sg11
Vdisease progression
p7369
sg13
I2
sasa(dp7370
g2
S'We developed a mouse model for colon cancer that identifies an early role for TGF-beta1 in tumor suppression and implicates TGF-beta2 or TGF-beta3 in the prevention of metastasis.\n'
p7371
sg4
(lp7372
(dp7373
g7
I78
sg8
VP01137
p7374
sg10
I9
sg11
VTGF-beta1
p7375
sg13
I1
sa(dp7376
g7
I124
sg8
VP61812
p7377
sg10
I9
sg11
VTGF-beta2
p7378
sg13
I1
sa(dp7379
g7
I137
sg8
VP10600
p7380
sg10
I9
sg11
VTGF-beta3
p7381
sg13
I1
sasg23
(lp7382
(dp7383
g7
I91
sg26
VC0027651
p7384
sg10
I5
sg11
Vtumor
p7385
sg13
I1
sa(dp7386
g7
I31
sg26
VC0699790
p7387
sg10
I12
sg11
Vcolon cancer
p7388
sg13
I2
sa(dp7389
g7
I168
sg26
VC0027627
p7390
sg10
I10
sg11
Vmetastasis
p7391
sg13
I1
sa(dp7392
g7
I97
sg26
VC0221103
p7393
sg10
I11
sg11
Vsuppression
p7394
sg13
I1
sasa(dp7395
g2
S'We have developed a gene-environment interaction model of holoprosencephaly in mice, in which mutation of the Sonic hedgehog coreceptor, Cdon, synergizes with transient in utero exposure to ethanol.\n'
p7396
sg4
(lp7397
(dp7398
g7
I110
sg8
g15
sg10
I25
sg11
VSonic hedgehog coreceptor
p7399
sg13
I3
sa(dp7400
g7
I137
sg8
g15
sg10
I4
sg11
VCdon
p7401
sg13
I1
sasg23
(lp7402
(dp7403
g7
I58
sg26
VC0079541
p7404
sg10
I17
sg11
Vholoprosencephaly
p7405
sg13
I1
sasa(dp7406
g2
S'We report here that t-butyl alcohol, which is neither a substrate nor an inhibitor of alcohol dehydrogenases or Cyp2E1, is a potent inducer of holoprosencephaly in Cdon mutant mice.\n'
p7407
sg4
(lp7408
(dp7409
g7
I112
sg8
VP05181
p7410
sg10
I6
sg11
VCyp2E1
p7411
sg13
I1
sa(dp7412
g7
I73
sg8
VP49366
p7413
sg10
I35
sg11
Vinhibitor of alcohol dehydrogenases
p7414
sg13
I4
sa(dp7415
g7
I164
sg8
g15
sg10
I11
sg11
VCdon mutant
p7416
sg13
I2
sasg23
(lp7417
(dp7418
g7
I143
sg26
VC0079541
p7419
sg10
I17
sg11
Vholoprosencephaly
p7420
sg13
I1
sa(dp7421
g7
I169
sg26
VC0596988
p7422
sg10
I6
sg11
Vmutant
p7423
sg13
I1
sasa(dp7424
g2
S'In addition, Boc, but not Cdon, mediates axon guidance information provided by Hh in specific neuronal populations, whereas mutations in the CDON cause holoprosencephaly, a human congenital anomaly defined by forebrain midline defects prominently associated with diminished Hh pathway activity.\n'
p7425
sg4
(lp7426
(dp7427
g7
I26
sg8
g15
sg10
I4
sg11
VCdon
p7428
sg13
I1
sa(dp7429
g7
I13
sg8
g15
sg10
I3
sg11
VBoc
p7430
sg13
I1
sasg23
(lp7431
(dp7432
g7
I179
sg26
VC0000768
p7433
sg10
I18
sg11
Vcongenital anomaly
p7434
sg13
I2
sa(dp7435
g7
I152
sg26
VC0079541
p7436
sg10
I17
sg11
Vholoprosencephaly
p7437
sg13
I1
sasa(dp7438
g2
S'Sequencing of the CDON, SHH, ZIC2, SIX3, and TGIF genes (associated with holoprosencephaly) did not disclose pathogenic alterations.\n'
p7439
sg4
(lp7440
(dp7441
g7
I45
sg8
VP22301
p7442
sg10
I10
sg11
VTGIF genes
p7443
sg13
I2
sa(dp7444
g7
I29
sg8
g15
sg10
I4
sg11
VZIC2
p7445
sg13
I1
sa(dp7446
g7
I24
sg8
g15
sg10
I3
sg11
VSHH
p7447
sg13
I1
sa(dp7448
g7
I18
sg8
g15
sg10
I4
sg11
VCDON
p7449
sg13
I1
sa(dp7450
g7
I35
sg8
g15
sg10
I4
sg11
VSIX3
p7451
sg13
I1
sasg23
(lp7452
(dp7453
g7
I73
sg26
VC0079541
p7454
sg10
I17
sg11
Vholoprosencephaly
p7455
sg13
I1
sasa(dp7456
g2
S'Serum levels of HMGB-1 are increased in patients with AAA than those in normal controls because the ALs in AAAs secrete HMGB-1.\n'
p7457
sg4
(lp7458
(dp7459
g7
I16
sg8
VP09429
p7460
sg10
I6
sg11
VHMGB-1
p7461
sg13
I1
sa(dp7462
g7
I107
sg8
g15
sg10
I4
sg11
VAAAs
p7463
sg13
I1
sa(dp7464
g7
I16
sg8
VP09429
p7465
sg10
I6
sg11
VHMGB-1
p7466
sg13
I1
sasg23
(lp7467
(dp7468
g7
I54
sg26
VC0162871
p7469
sg10
I3
sg11
VAAA
p7470
sg13
I1
sa(dp7471
g7
I107
sg26
VC0271742
p7472
sg10
I4
sg11
VAAAs
p7473
sg13
I1
sa(dp7474
g7
I100
sg26
VC0002736
p7475
sg10
I3
sg11
VALs
p7476
sg13
I1
sasa(dp7477
g2
S'Triple A syndrome (alacrima, achalasia, adrenal failure, progressive neurodegenerative disease) is caused by mutations in the AAAS gene which encodes the protein alacrima achalasia adrenal insufficiency neurologic disorder (ALADIN).\n'
p7478
sg4
(lp7479
(dp7480
g7
I126
sg8
g15
sg10
I9
sg11
VAAAS gene
p7481
sg13
I2
sasg23
(lp7482
(dp7483
g7
I69
sg26
VC0524851
p7484
sg10
I25
sg11
Vneurodegenerative disease
p7485
sg13
I2
sa(dp7486
g7
I19
sg26
VC0344505
p7487
sg10
I8
sg11
Valacrima
p7488
sg13
I1
sa(dp7489
g7
I19
sg26
VC0344505
p7490
sg10
I8
sg11
Valacrima
p7491
sg13
I1
sa(dp7492
g7
I181
sg26
VC0001623
p7493
sg10
I21
sg11
Vadrenal insufficiency
p7494
sg13
I2
sa(dp7495
g7
I203
sg26
VC0027765
p7496
sg10
I19
sg11
Vneurologic disorder
p7497
sg13
I2
sa(dp7498
g7
I0
sg26
VC0271742
p7499
sg10
I17
sg11
VTriple A syndrome
p7500
sg13
I3
sa(dp7501
g7
I126
sg26
VC0271742
p7502
sg10
I4
sg11
VAAAS
p7503
sg13
I1
sa(dp7504
g7
I29
sg26
VC0014848
p7505
sg10
I9
sg11
Vachalasia
p7506
sg13
I1
sa(dp7507
g7
I40
sg26
VC0001623
p7508
sg10
I15
sg11
Vadrenal failure
p7509
sg13
I2
sa(dp7510
g7
I29
sg26
VC0014848
p7511
sg10
I9
sg11
Vachalasia
p7512
sg13
I1
sasa(dp7513
g2
S'The prevalence and progression of anterior atlantoaxial subluxations (aAASs), vertical subluxations (VSs), subaxial subluxations (SASs), and associated cervical myelopathy in RA over the past 50 years were determined.\n'
p7514
sg4
(lp7515
sg23
(lp7516
(dp7517
g7
I152
sg26
VC0149645
p7518
sg10
I19
sg11
Vcervical myelopathy
p7519
sg13
I2
sasa(dp7520
g2
S'The results further proved that overexpression of NKG2A in NK cells was important for inhibiting the recruitment and activity of neutrophils to alleviate DSS-induced colitis.\n'
p7521
sg4
(lp7522
(dp7523
g7
I50
sg8
VP26715
p7524
sg10
I5
sg11
VNKG2A
p7525
sg13
I1
sasg23
(lp7526
(dp7527
g7
I101
sg26
VC0271510
p7528
sg10
I11
sg11
Vrecruitment
p7529
sg13
I1
sa(dp7530
g7
I166
sg26
VC0009319
p7531
sg10
I7
sg11
Vcolitis
p7532
sg13
I1
sa(dp7533
g7
I154
sg26
VC0011195
p7534
sg10
I3
sg11
VDSS
p7535
sg13
I1
sasa(dp7536
g2
S'Here, we provide a new anti-inflammation mechanism about ANXA1 secreted from injured IECs, where ANXA1 can stimulate the expression of NKG2A in NK cells that affect the recruitment and activity of neutrophils necessary for pathology of colitis.\n'
p7537
sg4
(lp7538
(dp7539
g7
I57
sg8
VP04083
p7540
sg10
I5
sg11
VANXA1
p7541
sg13
I1
sa(dp7542
g7
I135
sg8
VP26715
p7543
sg10
I5
sg11
VNKG2A
p7544
sg13
I1
sa(dp7545
g7
I57
sg8
VP04083
p7546
sg10
I5
sg11
VANXA1
p7547
sg13
I1
sasg23
(lp7548
(dp7549
g7
I223
sg26
VC0677042
p7550
sg10
I9
sg11
Vpathology
p7551
sg13
I1
sa(dp7552
g7
I28
sg26
VC0021368
p7553
sg10
I12
sg11
Vinflammation
p7554
sg13
I1
sa(dp7555
g7
I236
sg26
VC0009319
p7556
sg10
I7
sg11
Vcolitis
p7557
sg13
I1
sa(dp7558
g7
I169
sg26
VC0271510
p7559
sg10
I11
sg11
Vrecruitment
p7560
sg13
I1
sasa(dp7561
g2
S'Elevated levels of inflammatory cytokines (IL-8 and CCL2) were observed in the aqueous humor samples obtained from atopic glaucoma patients compared with those from senile cataract patients.\n'
p7562
sg4
(lp7563
(dp7564
g7
I52
sg8
VP13500
p7565
sg10
I4
sg11
VCCL2
p7566
sg13
I1
sasg23
(lp7567
(dp7568
g7
I79
sg26
VC0595936
p7569
sg10
I13
sg11
Vaqueous humor
p7570
sg13
I2
sa(dp7571
g7
I115
sg26
VC0392707
p7572
sg10
I6
sg11
Vatopic
p7573
sg13
I1
sa(dp7574
g7
I165
sg26
VC0036646
p7575
sg10
I15
sg11
Vsenile cataract
p7576
sg13
I2
sa(dp7577
g7
I122
sg26
VC0017601
p7578
sg10
I8
sg11
Vglaucoma
p7579
sg13
I1
sasa(dp7580
g2
S'Morphologic studies revealed a diffuse glomerulonephritis characterized by the presence of numerous subendothelial deposits containing IgG, IgA, C3, Clq, C4, and properdin, and an acute dermal vasculitis associated with similar immune complex deposits.\n'
p7581
sg4
(lp7582
(dp7583
g7
I140
sg8
VP11912
p7584
sg10
I3
sg11
VIgA
p7585
sg13
I1
sa(dp7586
g7
I162
sg8
VP27918
p7587
sg10
I9
sg11
Vproperdin
p7588
sg13
I1
sasg23
(lp7589
(dp7590
g7
I31
sg26
VC0859036
p7591
sg10
I26
sg11
Vdiffuse glomerulonephritis
p7592
sg13
I2
sa(dp7593
g7
I193
sg26
VC0042384
p7594
sg10
I10
sg11
Vvasculitis
p7595
sg13
I1
sasa(dp7596
g2
S'Sixth (abducens) nerve palsy (ANP) is far less frequent in children and has not been reported as a sign of acute disseminated encephalomyelitis (ADEM).\n'
p7597
sg4
(lp7598
sg23
(lp7599
(dp7600
g7
I145
sg26
VC0014059
p7601
sg10
I4
sg11
VADEM
p7602
sg13
I1
sa(dp7603
g7
I107
sg26
VC0014059
p7604
sg10
I36
sg11
Vacute disseminated encephalomyelitis
p7605
sg13
I3
sa(dp7606
g7
I17
sg26
VC0262576
p7607
sg10
I11
sg11
Vnerve palsy
p7608
sg13
I2
sasa(dp7609
g2
S'We present an infant case of ADEM with bilateral abducens nerve palsy (BANP).\n'
p7610
sg4
(lp7611
sg23
(lp7612
(dp7613
g7
I49
sg26
VC0271355
p7614
sg10
I20
sg11
Vabducens nerve palsy
p7615
sg13
I3
sasa(dp7616
g2
S'We report one case of BANP in a 15-month-old boy of fulminant ADEM.\n'
p7617
sg4
(lp7618
sg23
(lp7619
sa(dp7620
g2
S'BANP can be a symptom of ADEM.\n'
p7621
sg4
(lp7622
(dp7623
g7
I0
sg8
g15
sg10
I4
sg11
VBANP
p7624
sg13
I1
sasg23
(lp7625
(dp7626
g7
I14
sg26
VC1457887
p7627
sg10
I7
sg11
Vsymptom
p7628
sg13
I1
sasa(dp7629
g2
S'Therefore, we investigated the possible mechanisms of the beneficial effect of LCZ696, in which the inhibition of neprilysin enhances atrial natriuretic peptide (NP) or brain NP (ANP or BNP)-evoked signals that can block Ang II/AT1 receptor-induced aldosterone (Ald) synthesis in human adrenocortical cells.\n'
p7630
sg4
(lp7631
(dp7632
g7
I228
sg8
VP30556
p7633
sg10
I12
sg11
VAT1 receptor
p7634
sg13
I2
sa(dp7635
g7
I114
sg8
VP08473
p7636
sg10
I10
sg11
Vneprilysin
p7637
sg13
I1
sa(dp7638
g7
I262
sg8
VP33897
p7639
sg10
I3
sg11
VAld
p7640
sg13
I1
sa(dp7641
g7
I249
sg8
VP33897
p7642
sg10
I11
sg11
Valdosterone
p7643
sg13
I1
sa(dp7644
g7
I179
sg8
VP16066
p7645
sg10
I3
sg11
VANP
p7646
sg13
I1
sa(dp7647
g7
I221
sg8
VP01019
p7648
sg10
I6
sg11
VAng II
p7649
sg13
I2
sa(dp7650
g7
I134
sg8
VP16066
p7651
sg10
I43
sg11
Vatrial natriuretic peptide (NP) or brain NP
p7652
sg13
I7
sa(dp7653
g7
I186
sg8
VP16860
p7654
sg10
I3
sg11
VBNP
p7655
sg13
I1
sasg23
(lp7656
(dp7657
g7
I249
sg26
VC0162309
p7658
sg10
I11
sg11
Valdosterone
p7659
sg13
I1
sa(dp7660
g7
I228
sg26
VC0004135
p7661
sg10
I3
sg11
VAT1
p7662
sg13
I1
sa(dp7663
g7
I262
sg26
VC0162309
p7664
sg10
I3
sg11
VAld
p7665
sg13
I1
sasa(dp7666
g2
S'In Ang II-sensitized human adrenocortical cells, ANP or BNP alone, but not LBQ657 or valsartan alone, significantly decreased Ald synthesis.\n'
p7667
sg4
(lp7668
(dp7669
g7
I49
sg8
VP16066
p7670
sg10
I3
sg11
VANP
p7671
sg13
I1
sa(dp7672
g7
I56
sg8
VP16860
p7673
sg10
I3
sg11
VBNP
p7674
sg13
I1
sa(dp7675
g7
I3
sg8
VP01019
p7676
sg10
I6
sg11
VAng II
p7677
sg13
I2
sa(dp7678
g7
I126
sg8
VP33897
p7679
sg10
I3
sg11
VAld
p7680
sg13
I1
sasg23
(lp7681
(dp7682
g7
I126
sg26
VC0162309
p7683
sg10
I3
sg11
VAld
p7684
sg13
I1
sasa(dp7685
g2
S'The level of suppression of Ald synthesis by ANP or BNP with LBQ657 was greater than that by ANP or BNP without LBQ657.\n'
p7686
sg4
(lp7687
(dp7688
g7
I45
sg8
VP16066
p7689
sg10
I3
sg11
VANP
p7690
sg13
I1
sa(dp7691
g7
I28
sg8
VP33897
p7692
sg10
I3
sg11
VAld
p7693
sg13
I1
sa(dp7694
g7
I45
sg8
VP16066
p7695
sg10
I3
sg11
VANP
p7696
sg13
I1
sa(dp7697
g7
I52
sg8
VP16860
p7698
sg10
I3
sg11
VBNP
p7699
sg13
I1
sasg23
(lp7700
(dp7701
g7
I28
sg26
VC0162309
p7702
sg10
I3
sg11
VAld
p7703
sg13
I1
sa(dp7704
g7
I13
sg26
VC0221103
p7705
sg10
I11
sg11
Vsuppression
p7706
sg13
I1
sasa(dp7707
g2
S"In recent years, researchers have found that adiponectin (ANP) plays an important role in the pathogenesis of Alzheimer's disease (AD), and low serum concentrations of ANP are associated with AD.\n"
p7708
sg4
(lp7709
(dp7710
g7
I58
sg8
VP16066
p7711
sg10
I3
sg11
VANP
p7712
sg13
I1
sa(dp7713
g7
I58
sg8
VP16066
p7714
sg10
I3
sg11
VANP
p7715
sg13
I1
sa(dp7716
g7
I45
sg8
g15
sg10
I11
sg11
Vadiponectin
p7717
sg13
I1
sasg23
(lp7718
(dp7719
g7
I131
sg26
VC1521724
p7720
sg10
I2
sg11
VAD
p7721
sg13
I1
sa(dp7722
g7
I131
sg26
VC1521724
p7723
sg10
I2
sg11
VAD
p7724
sg13
I1
sa(dp7725
g7
I110
sg26
VC1521724
p7726
sg10
I19
sg11
VAlzheimer's disease
p7727
sg13
I2
sa(dp7728
g7
I94
sg26
VC0699748
p7729
sg10
I12
sg11
Vpathogenesis
p7730
sg13
I1
sasa(dp7731
g2
S"The MAPT H1c haplotype is a risk factor for the neurodegenerative tauopathies progressive supranuclear palsy (PSP) and Alzheimer's disease.\n"
p7732
sg4
(lp7733
(dp7734
g7
I4
sg8
VP16403
p7735
sg10
I18
sg11
VMAPT H1c haplotype
p7736
sg13
I3
sasg23
(lp7737
(dp7738
g7
I110
sg26
VC0038868
p7739
sg10
I3
sg11
VPSP
p7740
sg13
I1
sa(dp7741
g7
I119
sg26
VC1521724
p7742
sg10
I19
sg11
VAlzheimer's disease
p7743
sg13
I2
sa(dp7744
g7
I66
sg26
VC0949664
p7745
sg10
I11
sg11
Vtauopathies
p7746
sg13
I1
sa(dp7747
g7
I78
sg26
VC0038868
p7748
sg10
I30
sg11
Vprogressive supranuclear palsy
p7749
sg13
I3
sasa(dp7750
g2
S"In addition, the MAPT H1-clade specific sub-haplotype, H1c, has been strongly associated with the tauopathies, progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) and, to a lesser extent, with Alzheimer's disease (AD).\n"
p7751
sg4
(lp7752
(dp7753
g7
I55
sg8
VP16403
p7754
sg10
I3
sg11
VH1c
p7755
sg13
I1
sasg23
(lp7756
(dp7757
g7
I235
sg26
VC1521724
p7758
sg10
I2
sg11
VAD
p7759
sg13
I1
sa(dp7760
g7
I111
sg26
VC0038868
p7761
sg10
I30
sg11
Vprogressive supranuclear palsy
p7762
sg13
I3
sa(dp7763
g7
I214
sg26
VC1521724
p7764
sg10
I19
sg11
VAlzheimer's disease
p7765
sg13
I2
sa(dp7766
g7
I143
sg26
VC0038868
p7767
sg10
I3
sg11
VPSP
p7768
sg13
I1
sa(dp7769
g7
I179
sg26
VC0393570
p7770
sg10
I3
sg11
VCBD
p7771
sg13
I1
sa(dp7772
g7
I152
sg26
VC0393570
p7773
sg10
I25
sg11
Vcorticobasal degeneration
p7774
sg13
I2
sa(dp7775
g7
I98
sg26
VC0949664
p7776
sg10
I11
sg11
Vtauopathies
p7777
sg13
I1
sasa(dp7778
g2
S"Previously we have shown that the H1c haplotype on the background of the H1 clade of haplotypes at the MAPT locus is associated with increased risk for progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and Alzheimer's disease (AD).\n"
p7779
sg4
(lp7780
(dp7781
g7
I34
sg8
VP16403
p7782
sg10
I13
sg11
VH1c haplotype
p7783
sg13
I2
sasg23
(lp7784
(dp7785
g7
I217
sg26
VC0393570
p7786
sg10
I3
sg11
VCBD
p7787
sg13
I1
sa(dp7788
g7
I226
sg26
VC1521724
p7789
sg10
I19
sg11
VAlzheimer's disease
p7790
sg13
I2
sa(dp7791
g7
I190
sg26
VC0393570
p7792
sg10
I25
sg11
Vcorticobasal degeneration
p7793
sg13
I2
sa(dp7794
g7
I152
sg26
VC0038868
p7795
sg10
I30
sg11
Vprogressive supranuclear palsy
p7796
sg13
I3
sa(dp7797
g7
I247
sg26
VC1521724
p7798
sg10
I2
sg11
VAD
p7799
sg13
I1
sa(dp7800
g7
I184
sg26
VC0038868
p7801
sg10
I3
sg11
VPSP
p7802
sg13
I1
sasa(dp7803
g2
S'By comparing the interstitial fluid profile of the leiomyoma with that of the normal myometrium, the levels of seven proteins were found to be significantly different: four structural organization proteins (desmin, prelamin-A/C, transgelin and Alfa-actinin-1), an inflammatory response (Alfa1-antitrypsin), a response to oxidative stress (peroxiredoxin-2), and a folding protein (heat shock 70 kDa protein 1A/1B).\n'
p7804
sg4
(lp7805
(dp7806
g7
I229
sg8
g15
sg10
I10
sg11
Vtransgelin
p7807
sg13
I1
sa(dp7808
g7
I339
sg8
VP32119
p7809
sg10
I15
sg11
Vperoxiredoxin-2
p7810
sg13
I1
sa(dp7811
g7
I287
sg8
g15
sg10
I17
sg11
VAlfa1-antitrypsin
p7812
sg13
I1
sa(dp7813
g7
I215
sg8
VP49815
p7814
sg10
I12
sg11
Vprelamin-A/C
p7815
sg13
I1
sa(dp7816
g7
I207
sg8
VP98155
p7817
sg10
I6
sg11
Vdesmin
p7818
sg13
I1
sasg23
(lp7819
(dp7820
g7
I51
sg26
VC0023267
p7821
sg10
I9
sg11
Vleiomyoma
p7822
sg13
I1
sa(dp7823
g7
I264
sg26
VC1155266
p7824
sg10
I21
sg11
Vinflammatory response
p7825
sg13
I2
sa(dp7826
g7
I321
sg26
VC0242606
p7827
sg10
I16
sg11
Voxidative stress
p7828
sg13
I2
sasa(dp7829
g2
S'Desmin, Alfa1-antitrypsin and peroxiredoxin-2 were upregulated in the leiomyoma, whereas heat shock 70 kDa protein 1A/1B, Alfa-actinin-1, prelamin-A/C and transgelin were downregulated.\n'
p7830
sg4
(lp7831
(dp7832
g7
I0
sg8
VP98155
p7833
sg10
I6
sg11
VDesmin
p7834
sg13
I1
sa(dp7835
g7
I8
sg8
g15
sg10
I17
sg11
VAlfa1-antitrypsin
p7836
sg13
I1
sa(dp7837
g7
I30
sg8
VP32119
p7838
sg10
I15
sg11
Vperoxiredoxin-2
p7839
sg13
I1
sasg23
(lp7840
(dp7841
g7
I70
sg26
VC0023267
p7842
sg10
I9
sg11
Vleiomyoma
p7843
sg13
I1
sasa(dp7844
g2
S"Our data suggest that LL-37, in addition to its established roles, may play a role in the chronic neuroinflammation which is observed in neurodegenerative diseases such as Alzheimer's and Parkinson's disease.\n"
p7845
sg4
(lp7846
sg23
(lp7847
(dp7848
g7
I188
sg26
VC0030567
p7849
sg10
I19
sg11
VParkinson's disease
p7850
sg13
I2
sa(dp7851
g7
I137
sg26
VC0524851
p7852
sg10
I26
sg11
Vneurodegenerative diseases
p7853
sg13
I2
sasa(dp7854
g2
S"Muscle cramps may be a symptom of any of several conditions, including radiculopathies, Parkinson's disease, hypothyroidism, diabetes mellitus, vascular problems, electrolyte disorders, and metabolic myopathies.\n"
p7855
sg4
(lp7856
sg23
(lp7857
(dp7858
g7
I190
sg26
VC0270984
p7859
sg10
I20
sg11
Vmetabolic myopathies
p7860
sg13
I2
sa(dp7861
g7
I109
sg26
VC0020676
p7862
sg10
I14
sg11
Vhypothyroidism
p7863
sg13
I1
sa(dp7864
g7
I125
sg26
VC0011849
p7865
sg10
I17
sg11
Vdiabetes mellitus
p7866
sg13
I2
sa(dp7867
g7
I71
sg26
VC0700594
p7868
sg10
I15
sg11
Vradiculopathies
p7869
sg13
I1
sa(dp7870
g7
I88
sg26
VC0030567
p7871
sg10
I19
sg11
VParkinson's disease
p7872
sg13
I2
sa(dp7873
g7
I23
sg26
VC1457887
p7874
sg10
I7
sg11
Vsymptom
p7875
sg13
I1
sa(dp7876
g7
I0
sg26
VC0026821
p7877
sg10
I13
sg11
VMuscle cramps
p7878
sg13
I2
sasa(dp7879
g2
S"Dystonia unrelated to treatment can be typical (blepharospasm, torticollis), atypical (parkinsonian writer's cramp, camptocormia, anismus), or occurring in earlyonset Parkinson disease (the so-called kinesigenic foot dystonia, considered a hallmark of early-onset Parkinson's disease).\n"
p7880
sg4
(lp7881
sg23
(lp7882
(dp7883
g7
I116
sg26
VC0264162
p7884
sg10
I12
sg11
Vcamptocormia
p7885
sg13
I1
sa(dp7886
g7
I63
sg26
VC0040485
p7887
sg10
I11
sg11
Vtorticollis
p7888
sg13
I1
sa(dp7889
g7
I167
sg26
VC0030567
p7890
sg10
I17
sg11
VParkinson disease
p7891
sg13
I2
sa(dp7892
g7
I0
sg26
VC0393593
p7893
sg10
I8
sg11
VDystonia
p7894
sg13
I1
sa(dp7895
g7
I100
sg26
VC0338902
p7896
sg10
I14
sg11
Vwriter's cramp
p7897
sg13
I2
sa(dp7898
g7
I264
sg26
VC0030567
p7899
sg10
I19
sg11
VParkinson's disease
p7900
sg13
I2
sa(dp7901
g7
I130
sg26
VC0267601
p7902
sg10
I7
sg11
Vanismus
p7903
sg13
I1
sa(dp7904
g7
I217
sg26
VC0393593
p7905
sg10
I8
sg11
Vdystonia
p7906
sg13
I1
sa(dp7907
g7
I48
sg26
VC0005747
p7908
sg10
I13
sg11
Vblepharospasm
p7909
sg13
I1
sasa(dp7910
g2
S"Topics discussed include writer's cramp, multiple sclerosis, Parkinson's disease, schizophrenia, drug-induced parkinsonism, dopamine depletion, dysgraphia, motor development, developmental coordination disorder, caffeine, alertness, arousal, sleep deprivation, visual feedback transformation and suppression, eye-hand coordination, pen grip, pen pressure, movement fluency, bimanual interference, dominant versus non-dominant hand, tracing, freehand drawing, spiral drawing, reading, typewriting, and automatic segmentation.\n"
p7911
sg4
(lp7912
sg23
(lp7913
(dp7914
g7
I175
sg26
VC0011757
p7915
sg10
I35
sg11
Vdevelopmental coordination disorder
p7916
sg13
I3
sa(dp7917
g7
I144
sg26
VC0234144
p7918
sg10
I10
sg11
Vdysgraphia
p7919
sg13
I1
sa(dp7920
g7
I61
sg26
VC0030567
p7921
sg10
I19
sg11
VParkinson's disease
p7922
sg13
I2
sa(dp7923
g7
I41
sg26
VC0026769
p7924
sg10
I18
sg11
Vmultiple sclerosis
p7925
sg13
I2
sa(dp7926
g7
I212
sg26
VC2919093
p7927
sg10
I8
sg11
Vcaffeine
p7928
sg13
I1
sa(dp7929
g7
I97
sg26
VC0270729
p7930
sg10
I25
sg11
Vdrug-induced parkinsonism
p7931
sg13
I2
sa(dp7932
g7
I82
sg26
VC0036341
p7933
sg10
I13
sg11
Vschizophrenia
p7934
sg13
I1
sa(dp7935
g7
I25
sg26
VC0338902
p7936
sg10
I14
sg11
Vwriter's cramp
p7937
sg13
I2
sa(dp7938
g7
I296
sg26
VC0221103
p7939
sg10
I11
sg11
Vsuppression
p7940
sg13
I1
sa(dp7941
g7
I277
sg26
VC1510411
p7942
sg10
I14
sg11
Vtransformation
p7943
sg13
I1
sasa(dp7944
g2
S"We comparatively investigated predictive and reactive grip force behaviour in 12 subjects with basal ganglia dysfunction (six subjects with Parkinson's disease, six subjects with writer's cramp), two subjects chronically lacking all tactile and proprioceptive sensory feedback and 16 sex- and age-matched control subjects.\n"
p7945
sg4
(lp7946
sg23
(lp7947
(dp7948
g7
I140
sg26
VC0030567
p7949
sg10
I19
sg11
VParkinson's disease
p7950
sg13
I2
sa(dp7951
g7
I179
sg26
VC0338902
p7952
sg10
I14
sg11
Vwriter's cramp
p7953
sg13
I2
sasa(dp7954
g2
S'Thus the proliferative synovitis in this CACP syndrome can be more accurately thought of as hypercellularity by infiltrating macrophages with a contribution by proliferating fibroblastic synoviocytes.\n'
p7955
sg4
(lp7956
sg23
(lp7957
(dp7958
g7
I112
sg26
VC0332448
p7959
sg10
I12
sg11
Vinfiltrating
p7960
sg13
I1
sa(dp7961
g7
I46
sg26
VC0039082
p7962
sg10
I8
sg11
Vsyndrome
p7963
sg13
I1
sa(dp7964
g7
I9
sg26
VC0263949
p7965
sg10
I23
sg11
Vproliferative synovitis
p7966
sg13
I2
sa(dp7967
g7
I41
sg26
VC1859690
p7968
sg10
I4
sg11
VCACP
p7969
sg13
I1
sa(dp7970
g7
I92
sg26
VC0020507
p7971
sg10
I16
sg11
Vhypercellularity
p7972
sg13
I1
sasa(dp7973
g2
S'A 263 Kb homozygous deletion of FMN1 was associated with oligosyndactyly, radioulnar synostosis, hearing loss and renal defects, features identical to ld mice.\n'
p7974
sg4
(lp7975
(dp7976
g7
I32
sg8
g15
sg10
I4
sg11
VFMN1
p7977
sg13
I1
sasg23
(lp7978
(dp7979
g7
I97
sg26
VC0011053
p7980
sg10
I12
sg11
Vhearing loss
p7981
sg13
I2
sa(dp7982
g7
I74
sg26
VC0158761
p7983
sg10
I21
sg11
Vradioulnar synostosis
p7984
sg13
I2
sasa(dp7985
g2
S'A 1.7 Mb duplication encompassing both the GREM1 and FMN1 genes was detected in a patient with isolated Cenani-Lenz-like oligosyndactyly of the hands, resembling the transgenic chick wings in which Grem1 was over-expressed.\n'
p7986
sg4
(lp7987
(dp7988
g7
I43
sg8
g15
sg10
I5
sg11
VGREM1
p7989
sg13
I1
sa(dp7990
g7
I53
sg8
g15
sg10
I10
sg11
VFMN1 genes
p7991
sg13
I2
sa(dp7992
g7
I198
sg8
g15
sg10
I5
sg11
VGrem1
p7993
sg13
I1
sasg23
(lp7994
(dp7995
g7
I9
sg26
VC1705960
p7996
sg10
I11
sg11
Vduplication
p7997
sg13
I1
sasa(dp7998
g2
S'Typical image of Crouzon syndrome has been found in the woman and three children and its abortive form--in the man.\n'
p7999
sg4
(lp8000
sg23
(lp8001
(dp8002
g7
I17
sg26
VC0010273
p8003
sg10
I16
sg11
VCrouzon syndrome
p8004
sg13
I2
sasa(dp8005
g2
S'In acute fatty liver of pregnancy, profound hemostatic changes occur, which may be caused by a combination of liver failure and disseminated intravascular coagulation.\n'
p8006
sg4
(lp8007
sg23
(lp8008
(dp8009
g7
I110
sg26
VC0085605
p8010
sg10
I13
sg11
Vliver failure
p8011
sg13
I2
sa(dp8012
g7
I128
sg26
VC0012739
p8013
sg10
I38
sg11
Vdisseminated intravascular coagulation
p8014
sg13
I3
sa(dp8015
g7
I3
sg26
VC1455728
p8016
sg10
I30
sg11
Vacute fatty liver of pregnancy
p8017
sg13
I5
sasa(dp8018
g2
S'To estimate the frequency of disseminated intravascular coagulation (DIC); elucidate the genesis of hemostatic dysfunction; and characterize associated hemolysis in women with acute fatty liver of pregnancy.\n'
p8019
sg4
(lp8020
sg23
(lp8021
(dp8022
g7
I176
sg26
VC1455728
p8023
sg10
I30
sg11
Vacute fatty liver of pregnancy
p8024
sg13
I5
sa(dp8025
g7
I69
sg26
VC0012739
p8026
sg10
I3
sg11
VDIC
p8027
sg13
I1
sa(dp8028
g7
I152
sg26
VC0019054
p8029
sg10
I9
sg11
Vhemolysis
p8030
sg13
I1
sa(dp8031
g7
I29
sg26
VC0012739
p8032
sg10
I38
sg11
Vdisseminated intravascular coagulation
p8033
sg13
I3
sasa(dp8034
g2
S'The most common obstetric causes of admission were massive postpartum haemorrhage (n=42, 20.29%) and pregnancy associated hypertension (n=36, 17.39%), followed by acute fatty liver of pregnancy (AFLP, n=27, 13.04%), obstetric disseminated intravascular coagulation (DIC, n=23, 11.11%).\n'
p8035
sg4
(lp8036
sg23
(lp8037
(dp8038
g7
I101
sg26
VC0340274
p8039
sg10
I33
sg11
Vpregnancy associated hypertension
p8040
sg13
I3
sa(dp8041
g7
I59
sg26
VC0032797
p8042
sg10
I22
sg11
Vpostpartum haemorrhage
p8043
sg13
I2
sa(dp8044
g7
I226
sg26
VC0012739
p8045
sg10
I38
sg11
Vdisseminated intravascular coagulation
p8046
sg13
I3
sa(dp8047
g7
I195
sg26
VC1455728
p8048
sg10
I4
sg11
VAFLP
p8049
sg13
I1
sa(dp8050
g7
I163
sg26
VC1455728
p8051
sg10
I30
sg11
Vacute fatty liver of pregnancy
p8052
sg13
I5
sa(dp8053
g7
I266
sg26
VC0012739
p8054
sg10
I3
sg11
VDIC
p8055
sg13
I1
sasa(dp8056
g2
S'In this study, we detected the expression of HOXA7 gene in human acute promyelocytic leukemia cell line NB4.\n'
p8057
sg4
(lp8058
(dp8059
g7
I45
sg8
VP31268
p8060
sg10
I10
sg11
VHOXA7 gene
p8061
sg13
I2
sasg23
(lp8062
(dp8063
g7
I65
sg26
VC0023487
p8064
sg10
I28
sg11
Vacute promyelocytic leukemia
p8065
sg13
I3
sasa(dp8066
g2
S'The study suggested that HOXA7 might be a new gene candidate that influences the maturation of acute myeloid leukemia, and provided the molecular basis for the treatment for acute promyelocyticleukemia.\n'
p8067
sg4
(lp8068
(dp8069
g7
I25
sg8
VP31268
p8070
sg10
I5
sg11
VHOXA7
p8071
sg13
I1
sasg23
(lp8072
(dp8073
g7
I95
sg26
VC0023467
p8074
sg10
I22
sg11
Vacute myeloid leukemia
p8075
sg13
I3
sasa(dp8076
g2
S'Although PBX proteins are known to increase DNA-binding/transcriptional activity of HOX proteins through their direct binding, the functional importance of their interaction in leukemogenesis is unclear.We recently reported that overexpression of a 4-homeobox-gene signature (ie, PBX3/HOXA7/HOXA9/HOXA11) is an independent predictor of poor survival in patients with cytogenetically abnormal acute myeloid leukemia (CA-AML).\n'
p8077
sg4
(lp8078
(dp8079
g7
I285
sg8
VP31268
p8080
sg10
I5
sg11
VHOXA7
p8081
sg13
I1
sa(dp8082
g7
I291
sg8
VP31269
p8083
sg10
I5
sg11
VHOXA9
p8084
sg13
I1
sa(dp8085
g7
I84
sg8
g15
sg10
I12
sg11
VHOX proteins
p8086
sg13
I2
sa(dp8087
g7
I280
sg8
VP40424
p8088
sg10
I4
sg11
VPBX3
p8089
sg13
I1
sa(dp8090
g7
I297
sg8
VP31270
p8091
sg10
I6
sg11
VHOXA11
p8092
sg13
I1
sa(dp8093
g7
I9
sg8
VP02649
p8094
sg10
I12
sg11
VPBX proteins
p8095
sg13
I2
sasg23
(lp8096
(dp8097
g7
I392
sg26
VC0023467
p8098
sg10
I22
sg11
Vacute myeloid leukemia
p8099
sg13
I3
sa(dp8100
g7
I177
sg26
VC0598766
p8101
sg10
I14
sg11
Vleukemogenesis
p8102
sg13
I1
sa(dp8103
g7
I419
sg26
VC0023467
p8104
sg10
I3
sg11
VAML
p8105
sg13
I1
sasa(dp8106
g2
S'In this study, we investigated the cytotoxic activity of Antp-TPR peptide toward acute myeloid leukemia (AML) cells.\n'
p8107
sg4
(lp8108
(dp8109
g7
I57
sg8
VP31268
p8110
sg10
I16
sg11
VAntp-TPR peptide
p8111
sg13
I2
sasg23
(lp8112
(dp8113
g7
I81
sg26
VC0023467
p8114
sg10
I22
sg11
Vacute myeloid leukemia
p8115
sg13
I3
sa(dp8116
g7
I105
sg26
VC0023467
p8117
sg10
I3
sg11
VAML
p8118
sg13
I1
sasa(dp8119
g2
S'By investigations of muscle tissue from patients with polymyositis, inclusion-body myositis (IBM), and dermatomyositis a predominance of the cytokines interleukin-1 alpha and -1 beta and transforming growth factor beta was observed.\n'
p8120
sg4
(lp8121
(dp8122
g7
I187
sg8
VP18075
p8123
sg10
I31
sg11
Vtransforming growth factor beta
p8124
sg13
I4
sa(dp8125
g7
I151
sg8
VP01583
p8126
sg10
I31
sg11
Vinterleukin-1 alpha and -1 beta
p8127
sg13
I5
sasg23
(lp8128
(dp8129
g7
I68
sg26
VC0238190
p8130
sg10
I23
sg11
Vinclusion-body myositis
p8131
sg13
I2
sa(dp8132
g7
I54
sg26
VC0085655
p8133
sg10
I12
sg11
Vpolymyositis
p8134
sg13
I1
sa(dp8135
g7
I93
sg26
VC0238190
p8136
sg10
I3
sg11
VIBM
p8137
sg13
I1
sa(dp8138
g7
I103
sg26
VC0221056
p8139
sg10
I15
sg11
Vdermatomyositis
p8140
sg13
I1
sasa(dp8141
g2
S'Tuberous sclerosis is associated with three central nervous system pathologies: cortical/subcortical tubers, subependymal nodules (SENs), and subependymal giant cell astrocytomas (SEGAs).\n'
p8142
sg4
(lp8143
sg23
(lp8144
(dp8145
g7
I166
sg26
VC0004114
p8146
sg10
I12
sg11
Vastrocytomas
p8147
sg13
I1
sa(dp8148
g7
I122
sg26
VC0028259
p8149
sg10
I7
sg11
Vnodules
p8150
sg13
I1
sa(dp8151
g7
I52
sg26
VC0027769
p8152
sg10
I7
sg11
Vnervous
p8153
sg13
I1
sa(dp8154
g7
I0
sg26
VC0041341
p8155
sg10
I18
sg11
VTuberous sclerosis
p8156
sg13
I2
sa(dp8157
g7
I155
sg26
VC0017547
p8158
sg10
I5
sg11
Vgiant
p8159
sg13
I1
sasa(dp8160
g2
S'As about 10-15% of SENs enlarge and transform into SEGAs, we examined here the possible mechanism of the phenomenon.\n'
p8161
sg4
(lp8162
sg23
(lp8163
sa(dp8164
g2
S'Subependymal nodules (SENs) and subependymal giant cell astrocytomas (SEGAs) are common brain lesions found in patients with tuberous sclerosis complex (TSC).\n'
p8165
sg4
(lp8166
sg23
(lp8167
(dp8168
g7
I153
sg26
VC0041341
p8169
sg10
I3
sg11
VTSC
p8170
sg13
I1
sa(dp8171
g7
I56
sg26
VC0004114
p8172
sg10
I12
sg11
Vastrocytomas
p8173
sg13
I1
sa(dp8174
g7
I125
sg26
VC0041341
p8175
sg10
I26
sg11
Vtuberous sclerosis complex
p8176
sg13
I3
sa(dp8177
g7
I88
sg26
VC0221505
p8178
sg10
I13
sg11
Vbrain lesions
p8179
sg13
I2
sa(dp8180
g7
I45
sg26
VC0017547
p8181
sg10
I5
sg11
Vgiant
p8182
sg13
I1
sa(dp8183
g7
I13
sg26
VC0028259
p8184
sg10
I7
sg11
Vnodules
p8185
sg13
I1
sasa(dp8186
g2
S'Nine SENs had measured MTR below 20.72% and six nodules among these were located in the region of the foramen of Monro, which is the characteristic location of SGCA.\n'
p8187
sg4
(lp8188
(dp8189
g7
I160
sg8
g15
sg10
I4
sg11
VSGCA
p8190
sg13
I1
sasg23
(lp8191
(dp8192
g7
I48
sg26
VC0028259
p8193
sg10
I7
sg11
Vnodules
p8194
sg13
I1
sasa(dp8195
g2
S'In ulcerative colitis (UC), PNAd-expressing HEV-like vessels are induced, preferentially in the active phase, and T cells, particularly CD4(+) T cells, are closely associated with these vessels, suggesting that T cell recruitment via PNAd-expressing HEV-like vessels plays at least a partial role in UC pathogenesis.\n'
p8196
sg4
(lp8197
(dp8198
g7
I136
sg8
VP01730
p8199
sg10
I3
sg11
VCD4
p8200
sg13
I1
sa(dp8201
g7
I28
sg8
g15
sg10
I4
sg11
VPNAd
p8202
sg13
I1
sa(dp8203
g7
I28
sg8
g15
sg10
I4
sg11
VPNAd
p8204
sg13
I1
sasg23
(lp8205
(dp8206
g7
I3
sg26
VC0009324
p8207
sg10
I18
sg11
Vulcerative colitis
p8208
sg13
I2
sa(dp8209
g7
I23
sg26
VC0009324
p8210
sg10
I2
sg11
VUC
p8211
sg13
I1
sa(dp8212
g7
I218
sg26
VC0271510
p8213
sg10
I11
sg11
Vrecruitment
p8214
sg13
I1
sa(dp8215
g7
I23
sg26
VC0009324
p8216
sg10
I2
sg11
VUC
p8217
sg13
I1
sa(dp8218
g7
I303
sg26
VC0699748
p8219
sg10
I12
sg11
Vpathogenesis
p8220
sg13
I1
sasa(dp8221
g2
S'In the colonic mucosa with ulcerative colitis (UC), it has been suggested that L-selectin-peripheral lymph node addressin (PNAd) interaction plays a role in lymphocyte recruitment, which requires PNAd induction on high endothelial venule (HEV)-like vessels.\n'
p8222
sg4
(lp8223
(dp8224
g7
I123
sg8
g15
sg10
I4
sg11
VPNAd
p8225
sg13
I1
sa(dp8226
g7
I79
sg8
g15
sg10
I42
sg11
VL-selectin-peripheral lymph node addressin
p8227
sg13
I4
sa(dp8228
g7
I123
sg8
g15
sg10
I4
sg11
VPNAd
p8229
sg13
I1
sasg23
(lp8230
(dp8231
g7
I168
sg26
VC0271510
p8232
sg10
I11
sg11
Vrecruitment
p8233
sg13
I1
sa(dp8234
g7
I27
sg26
VC0009324
p8235
sg10
I18
sg11
Vulcerative colitis
p8236
sg13
I2
sa(dp8237
g7
I47
sg26
VC0009324
p8238
sg10
I2
sg11
VUC
p8239
sg13
I1
sasa(dp8240
g2
S'Positive lod scores were found for marker loci at the proximal part of the short arm of the X chromosome, DXS255 and TIMP (Zmax = 3.93 and 3.18 at theta = 0.0), suggesting an assignment of the locus for AIED to this part of the X chromosome.\n'
p8241
sg4
(lp8242
(dp8243
g7
I117
sg8
VP16035
p8244
sg10
I4
sg11
VTIMP
p8245
sg13
I1
sasg23
(lp8246
(dp8247
g7
I203
sg26
VC0268505
p8248
sg10
I4
sg11
VAIED
p8249
sg13
I1
sasa(dp8250
g2
S'As a CXC subtype member of the chemokine superfamily, CXCL13 is considered to be involved in systemic lupus erythematosus (SLE), especially in lupus nephritis (LN).\n'
p8251
sg4
(lp8252
(dp8253
g7
I54
sg8
g15
sg10
I6
sg11
VCXCL13
p8254
sg13
I1
sasg23
(lp8255
(dp8256
g7
I123
sg26
VC0024141
p8257
sg10
I3
sg11
VSLE
p8258
sg13
I1
sa(dp8259
g7
I93
sg26
VC0024141
p8260
sg10
I28
sg11
Vsystemic lupus erythematosus
p8261
sg13
I3
sa(dp8262
g7
I143
sg26
VC0024143
p8263
sg10
I15
sg11
Vlupus nephritis
p8264
sg13
I2
sa(dp8265
g7
I160
sg26
VC0024143
p8266
sg10
I2
sg11
VLN
p8267
sg13
I1
sasa(dp8268
g2
S'Among these, the CXCL13/CXCR5 axis is thought to be involved critically in systemic lupus erythematosus (SLE) and lupus nephritis pathogenesis.\n'
p8269
sg4
(lp8270
(dp8271
g7
I24
sg8
VP32302
p8272
sg10
I5
sg11
VCXCR5
p8273
sg13
I1
sa(dp8274
g7
I17
sg8
g15
sg10
I6
sg11
VCXCL13
p8275
sg13
I1
sasg23
(lp8276
(dp8277
g7
I75
sg26
VC0024141
p8278
sg10
I28
sg11
Vsystemic lupus erythematosus
p8279
sg13
I3
sa(dp8280
g7
I114
sg26
VC0024143
p8281
sg10
I15
sg11
Vlupus nephritis
p8282
sg13
I2
sa(dp8283
g7
I105
sg26
VC0024141
p8284
sg10
I3
sg11
VSLE
p8285
sg13
I1
sa(dp8286
g7
I130
sg26
VC0699748
p8287
sg10
I12
sg11
Vpathogenesis
p8288
sg13
I1
sasa(dp8289
g2
S'We propose that CXCR5 is involved critically in B cell trafficking and germinal cell (GC) formation in murine lupus and in guiding pathogenic DN T cells into lymphoid organs and kidneys, and we therefore describe new pathomechanisms for the CXCL13/CXCR5 axis in SLE.\n'
p8290
sg4
(lp8291
(dp8292
g7
I16
sg8
VP32302
p8293
sg10
I5
sg11
VCXCR5
p8294
sg13
I1
sa(dp8295
g7
I16
sg8
VP32302
p8296
sg10
I5
sg11
VCXCR5
p8297
sg13
I1
sa(dp8298
g7
I241
sg8
g15
sg10
I6
sg11
VCXCL13
p8299
sg13
I1
sasg23
(lp8300
(dp8301
g7
I262
sg26
VC0014060
p8302
sg10
I3
sg11
VSLE
p8303
sg13
I1
sa(dp8304
g7
I110
sg26
VC0024131
p8305
sg10
I5
sg11
Vlupus
p8306
sg13
I1
sasa(dp8307
g2
S'Abnormal overexpression of CXCL13 is observed in many inflamed tissues and in particular in autoimmune diseases.\n'
p8308
sg4
(lp8309
(dp8310
g7
I27
sg8
g15
sg10
I6
sg11
VCXCL13
p8311
sg13
I1
sasg23
(lp8312
(dp8313
g7
I92
sg26
VC0004364
p8314
sg10
I19
sg11
Vautoimmune diseases
p8315
sg13
I2
sasa(dp8316
g2
S'The chemokine CXC ligand 13 protein (CXCL13) is reported to closely related to the disease activity and severity of systemic lupus erythematosus (SLE), moreover, the level of CXCL13 was markedly raised in kidney tissues of lupus nephritis (LN) patients.\n'
p8317
sg4
(lp8318
(dp8319
g7
I37
sg8
g15
sg10
I6
sg11
VCXCL13
p8320
sg13
I1
sa(dp8321
g7
I4
sg8
VP55773
p8322
sg10
I31
sg11
Vchemokine CXC ligand 13 protein
p8323
sg13
I5
sa(dp8324
g7
I37
sg8
g15
sg10
I6
sg11
VCXCL13
p8325
sg13
I1
sasg23
(lp8326
(dp8327
g7
I146
sg26
VC0024141
p8328
sg10
I3
sg11
VSLE
p8329
sg13
I1
sa(dp8330
g7
I223
sg26
VC0024143
p8331
sg10
I15
sg11
Vlupus nephritis
p8332
sg13
I2
sa(dp8333
g7
I116
sg26
VC0024141
p8334
sg10
I28
sg11
Vsystemic lupus erythematosus
p8335
sg13
I3
sa(dp8336
g7
I240
sg26
VC0024143
p8337
sg10
I2
sg11
VLN
p8338
sg13
I1
sasa(dp8339
g2
S'Mutations in ADAMTS13, ADAMTS2, ADAMTS10, ADAMTS17, ADAMTSL2 and ADAMTSL4 have been identified in distinct human genetic disorders ranging from thrombotic thrombocytopenic purpura to acromelic dysplasia.\n'
p8340
sg4
(lp8341
(dp8342
g7
I65
sg8
g15
sg10
I8
sg11
VADAMTSL4
p8343
sg13
I1
sa(dp8344
g7
I23
sg8
g15
sg10
I7
sg11
VADAMTS2
p8345
sg13
I1
sa(dp8346
g7
I42
sg8
g15
sg10
I8
sg11
VADAMTS17
p8347
sg13
I1
sa(dp8348
g7
I13
sg8
g15
sg10
I8
sg11
VADAMTS13
p8349
sg13
I1
sa(dp8350
g7
I52
sg8
g15
sg10
I8
sg11
VADAMTSL2
p8351
sg13
I1
sa(dp8352
g7
I32
sg8
g15
sg10
I8
sg11
VADAMTS10
p8353
sg13
I1
sasg23
(lp8354
(dp8355
g7
I113
sg26
VC0019247
p8356
sg10
I17
sg11
Vgenetic disorders
p8357
sg13
I2
sa(dp8358
g7
I193
sg26
VC0334044
p8359
sg10
I9
sg11
Vdysplasia
p8360
sg13
I1
sa(dp8361
g7
I144
sg26
VC0034155
p8362
sg10
I35
sg11
Vthrombotic thrombocytopenic purpura
p8363
sg13
I3
sasa(dp8364
g2
S'Treatment with Ponatinib resulted in an amelioration of the BLM-induced pulmonary fibrosis in rats with reductions of the pathological score, collagen deposition, p-Smad3, Alfa-SMA, PDGF-BB and FGF-2 expression.\n'
p8365
sg4
(lp8366
(dp8367
g7
I182
sg8
VP04085
p8368
sg10
I7
sg11
VPDGF-BB
p8369
sg13
I1
sa(dp8370
g7
I177
sg8
g15
sg10
I3
sg11
VSMA
p8371
sg13
I1
sa(dp8372
g7
I194
sg8
VP53370
p8373
sg10
I5
sg11
VFGF-2
p8374
sg13
I1
sasg23
(lp8375
(dp8376
g7
I60
sg26
VC0005859
p8377
sg10
I3
sg11
VBLM
p8378
sg13
I1
sa(dp8379
g7
I72
sg26
VC0034069
p8380
sg10
I18
sg11
Vpulmonary fibrosis
p8381
sg13
I2
sa(dp8382
g7
I177
sg26
VC0026847
p8383
sg10
I3
sg11
VSMA
p8384
sg13
I1
sasa(dp8385
g2
S'This study intends to explore the effects of microRNA-126 (miR-126) on cell proliferation, apoptosis, and tumor angiogenesis in hepatocellular carcinoma (HCC) by regulating epidermal growth factor-like domain 7 (EGFL7) through extracellular signal-regulated kinase (ERK) signaling.\n'
p8386
sg4
(lp8387
(dp8388
g7
I227
sg8
VP53779
p8389
sg10
I37
sg11
Vextracellular signal-regulated kinase
p8390
sg13
I3
sa(dp8391
g7
I266
sg8
VP29323
p8392
sg10
I3
sg11
VERK
p8393
sg13
I1
sa(dp8394
g7
I212
sg8
g15
sg10
I5
sg11
VEGFL7
p8395
sg13
I1
sa(dp8396
g7
I173
sg8
VP01133
p8397
sg10
I37
sg11
Vepidermal growth factor-like domain 7
p8398
sg13
I5
sasg23
(lp8399
(dp8400
g7
I76
sg26
VC0334094
p8401
sg10
I13
sg11
Vproliferation
p8402
sg13
I1
sa(dp8403
g7
I154
sg26
VC2239176
p8404
sg10
I3
sg11
VHCC
p8405
sg13
I1
sa(dp8406
g7
I106
sg26
VC1519670
p8407
sg10
I18
sg11
Vtumor angiogenesis
p8408
sg13
I2
sa(dp8409
g7
I128
sg26
VC2239176
p8410
sg10
I24
sg11
Vhepatocellular carcinoma
p8411
sg13
I2
sasa(dp8412
g2
S'This study aims to explore the effects of microRNA-126 (miR-126) on tumor proliferation and angiogenesis of hepatocellular carcinoma (HCC) by targeting EGFL7.\n'
p8413
sg4
(lp8414
(dp8415
g7
I152
sg8
g15
sg10
I5
sg11
VEGFL7
p8416
sg13
I1
sasg23
(lp8417
(dp8418
g7
I134
sg26
VC2239176
p8419
sg10
I3
sg11
VHCC
p8420
sg13
I1
sa(dp8421
g7
I74
sg26
VC0334094
p8422
sg10
I13
sg11
Vproliferation
p8423
sg13
I1
sa(dp8424
g7
I68
sg26
VC0027651
p8425
sg10
I5
sg11
Vtumor
p8426
sg13
I1
sa(dp8427
g7
I108
sg26
VC2239176
p8428
sg10
I24
sg11
Vhepatocellular carcinoma
p8429
sg13
I2
sasa(dp8430
g2
S'Lately, another angiogenic factor, epidermal growth factor-like domain multiple 7 (EGFL7), has attracted interest due to its possible relationship with hepatocellular carcinoma metastasis.\n'
p8431
sg4
(lp8432
(dp8433
g7
I16
sg8
g15
sg10
I17
sg11
Vangiogenic factor
p8434
sg13
I2
sa(dp8435
g7
I83
sg8
g15
sg10
I5
sg11
VEGFL7
p8436
sg13
I1
sa(dp8437
g7
I35
sg8
VP01133
p8438
sg10
I46
sg11
Vepidermal growth factor-like domain multiple 7
p8439
sg13
I6
sasg23
(lp8440
(dp8441
g7
I177
sg26
VC0027627
p8442
sg10
I10
sg11
Vmetastasis
p8443
sg13
I1
sa(dp8444
g7
I152
sg26
VC1512411
p8445
sg10
I24
sg11
Vhepatocellular carcinoma
p8446
sg13
I2
sasa(dp8447
g2
S'To evaluate expression of VEGF and EGFL7 in human hepatocellular carcinoma, compared to corresponding cirrhotic surrounding tissue.\n'
p8448
sg4
(lp8449
(dp8450
g7
I35
sg8
g15
sg10
I5
sg11
VEGFL7
p8451
sg13
I1
sasg23
(lp8452
(dp8453
g7
I50
sg26
VC1512411
p8454
sg10
I24
sg11
Vhepatocellular carcinoma
p8455
sg13
I2
sasa(dp8456
g2
S'While VEGF expression was constant, regardless of tumour differentiation stage and unchanged compared to surrounding cirrhotic tissue, EGFL7 expression increased in less differentiated hepatocellular carcinoma.\n'
p8457
sg4
(lp8458
(dp8459
g7
I135
sg8
g15
sg10
I5
sg11
VEGFL7
p8460
sg13
I1
sasg23
(lp8461
(dp8462
g7
I185
sg26
VC1512411
p8463
sg10
I24
sg11
Vhepatocellular carcinoma
p8464
sg13
I2
sa(dp8465
g7
I50
sg26
VC0027651
p8466
sg10
I6
sg11
Vtumour
p8467
sg13
I1
sasa(dp8468
g2
S'The preferential expression of EGFL7 in less differentiated hepatocellular carcinoma compared to VEGF, suggests a possible important role of this angiogenic factor in a later oncogenic and infiltrative/metastatic phase.\n'
p8469
sg4
(lp8470
(dp8471
g7
I146
sg8
g15
sg10
I17
sg11
Vangiogenic factor
p8472
sg13
I2
sa(dp8473
g7
I31
sg8
g15
sg10
I5
sg11
VEGFL7
p8474
sg13
I1
sasg23
(lp8475
(dp8476
g7
I60
sg26
VC1512411
p8477
sg10
I24
sg11
Vhepatocellular carcinoma
p8478
sg13
I2
sasa(dp8479
g2
S'Epidermal growth factor-like domain multiple 7 (EGFL7), recently identified as a secreted protein regulated by oxygen exposure, plays a critical role in promoting metastasis of hepatocellular carcinoma (HCC).\n'
p8480
sg4
(lp8481
(dp8482
g7
I0
sg8
VP01133
p8483
sg10
I46
sg11
VEpidermal growth factor-like domain multiple 7
p8484
sg13
I6
sa(dp8485
g7
I48
sg8
g15
sg10
I5
sg11
VEGFL7
p8486
sg13
I1
sasg23
(lp8487
(dp8488
g7
I163
sg26
VC0027627
p8489
sg10
I10
sg11
Vmetastasis
p8490
sg13
I1
sa(dp8491
g7
I203
sg26
VC2239176
p8492
sg10
I3
sg11
VHCC
p8493
sg13
I1
sa(dp8494
g7
I177
sg26
VC2239176
p8495
sg10
I24
sg11
Vhepatocellular carcinoma
p8496
sg13
I2
sasa(dp8497
g2
S'This assay detected EGFL7 in lysates of non-small-cell lung cancer and hepatocellular carcinoma cell lines and also hepatocellular carcinoma, breast cancer, and ovarian cancer tissues.\n'
p8498
sg4
(lp8499
(dp8500
g7
I20
sg8
g15
sg10
I5
sg11
VEGFL7
p8501
sg13
I1
sasg23
(lp8502
(dp8503
g7
I55
sg26
VC0684249
p8504
sg10
I11
sg11
Vlung cancer
p8505
sg13
I2
sa(dp8506
g7
I142
sg26
VC0678222
p8507
sg10
I13
sg11
Vbreast cancer
p8508
sg13
I2
sa(dp8509
g7
I71
sg26
VC1512411
p8510
sg10
I24
sg11
Vhepatocellular carcinoma
p8511
sg13
I2
sa(dp8512
g7
I161
sg26
VC1140680
p8513
sg10
I14
sg11
Vovarian cancer
p8514
sg13
I2
sa(dp8515
g7
I71
sg26
VC1512411
p8516
sg10
I24
sg11
Vhepatocellular carcinoma
p8517
sg13
I2
sasa(dp8518
g2
S'Recent studies have suggested that epidermal growth factor-like domain multiple 7 (EGFL7) is overexpressed by many tumors, such as colorectal cancer and hepatocellular carcinoma; it is also correlated with progression, metastasis, and a poor prognosis.\n'
p8519
sg4
(lp8520
(dp8521
g7
I83
sg8
g15
sg10
I5
sg11
VEGFL7
p8522
sg13
I1
sa(dp8523
g7
I35
sg8
VP01133
p8524
sg10
I46
sg11
Vepidermal growth factor-like domain multiple 7
p8525
sg13
I6
sasg23
(lp8526
(dp8527
g7
I115
sg26
VC0027651
p8528
sg10
I6
sg11
Vtumors
p8529
sg13
I1
sa(dp8530
g7
I219
sg26
VC0027627
p8531
sg10
I10
sg11
Vmetastasis
p8532
sg13
I1
sa(dp8533
g7
I131
sg26
VC1527249
p8534
sg10
I17
sg11
Vcolorectal cancer
p8535
sg13
I2
sa(dp8536
g7
I153
sg26
VC1512411
p8537
sg10
I24
sg11
Vhepatocellular carcinoma
p8538
sg13
I2
sasa(dp8539
g2
S'RT-PCR and Western blot were employed to detect Egfl7 expression in normal adult human tissues and 10 human epithelial tumors including hepatocellular carcinoma (HCC), lung cancer, breast cancer, prostate cancer, colorectal cancer, gastric cancer, esophageal cancer, malignant glioma, ovarian cancer and renal cancer.\n'
p8540
sg4
(lp8541
(dp8542
g7
I48
sg8
g15
sg10
I5
sg11
VEgfl7
p8543
sg13
I1
sasg23
(lp8544
(dp8545
g7
I188
sg26
VC0376358
p8546
sg10
I16
sg11
Vcancer, prostate
p8547
sg13
I2
sa(dp8548
g7
I136
sg26
VC2239176
p8549
sg10
I24
sg11
Vhepatocellular carcinoma
p8550
sg13
I2
sa(dp8551
g7
I304
sg26
VC0740457
p8552
sg10
I12
sg11
Vrenal cancer
p8553
sg13
I2
sa(dp8554
g7
I162
sg26
VC2239176
p8555
sg10
I3
sg11
VHCC
p8556
sg13
I1
sa(dp8557
g7
I173
sg26
VC0006826
p8558
sg10
I6
sg11
Vcancer
p8559
sg13
I1
sa(dp8560
g7
I173
sg26
VC0006142
p8561
sg10
I14
sg11
Vcancer, breast
p8562
sg13
I2
sa(dp8563
g7
I285
sg26
VC1140680
p8564
sg10
I14
sg11
Vovarian cancer
p8565
sg13
I2
sa(dp8566
g7
I267
sg26
VC0555198
p8567
sg10
I16
sg11
Vmalignant glioma
p8568
sg13
I2
sa(dp8569
g7
I205
sg26
VC1527249
p8570
sg10
I18
sg11
Vcancer, colorectal
p8571
sg13
I2
sa(dp8572
g7
I240
sg26
VC0546837
p8573
sg10
I18
sg11
Vcancer, esophageal
p8574
sg13
I2
sa(dp8575
g7
I108
sg26
VC1368683
p8576
sg10
I17
sg11
Vepithelial tumors
p8577
sg13
I2
sa(dp8578
g7
I224
sg26
VC0024623
p8579
sg10
I15
sg11
Vcancer, gastric
p8580
sg13
I2
sasa(dp8581
g2
S'We describe here the isolation of an EGFL7-specific antibody from a mammalian cell-based full-length antibody display library generated from peripheral blood mononuclear cells of patients with hepatocellular carcinoma.\n'
p8582
sg4
(lp8583
(dp8584
g7
I37
sg8
g15
sg10
I23
sg11
VEGFL7-specific antibody
p8585
sg13
I2
sasg23
(lp8586
(dp8587
g7
I193
sg26
VC1512411
p8588
sg10
I24
sg11
Vhepatocellular carcinoma
p8589
sg13
I2
sasa(dp8590
g2
S'In a previous study, we reported a critical role of epidermal growth factor-like domain 7 (EGFL7) in the metastasis of hepatocellular carcinoma (HCC) and documented it to be a prognostic biomarker as well as a potential therapeutic target for HCC.\n'
p8591
sg4
(lp8592
(dp8593
g7
I91
sg8
g15
sg10
I5
sg11
VEGFL7
p8594
sg13
I1
sa(dp8595
g7
I52
sg8
VP01133
p8596
sg10
I37
sg11
Vepidermal growth factor-like domain 7
p8597
sg13
I5
sasg23
(lp8598
(dp8599
g7
I105
sg26
VC0027627
p8600
sg10
I10
sg11
Vmetastasis
p8601
sg13
I1
sa(dp8602
g7
I145
sg26
VC2239176
p8603
sg10
I3
sg11
VHCC
p8604
sg13
I1
sa(dp8605
g7
I119
sg26
VC2239176
p8606
sg10
I24
sg11
Vhepatocellular carcinoma
p8607
sg13
I2
sa(dp8608
g7
I145
sg26
VC2239176
p8609
sg10
I3
sg11
VHCC
p8610
sg13
I1
sasa(dp8611
g2
S'Collectively, our results provide evidence that loss of expression of miR-4516 in psoriatic skin might be contributing to accelerated migration, resistance to apoptosis and differentiation as seen in psoriasis lesional keratinocytes and also highlight its potential as a novel small molecule for therapeutic intervention in psoriasis.\n'
p8612
sg4
(lp8613
(dp8614
g7
I70
sg8
g15
sg10
I8
sg11
VmiR-4516
p8615
sg13
I1
sasg23
(lp8616
(dp8617
g7
I200
sg26
VC0033860
p8618
sg10
I9
sg11
Vpsoriasis
p8619
sg13
I1
sa(dp8620
g7
I200
sg26
VC0033860
p8621
sg10
I9
sg11
Vpsoriasis
p8622
sg13
I1
sasa(dp8623
g2
S'High expression levels of miR-146-5p, miR-199a-5p, miR-199b-5p, miR-1285-5p, miR-1915-3p, and miR-4516, and low miR-148b-3p expression were associated with infiltrative growth of follicular variant of papillary thyroid carcinomas.\n'
p8624
sg4
(lp8625
(dp8626
g7
I38
sg8
g15
sg10
I11
sg11
VmiR-199a-5p
p8627
sg13
I1
sa(dp8628
g7
I64
sg8
g15
sg10
I11
sg11
VmiR-1285-5p
p8629
sg13
I1
sa(dp8630
g7
I26
sg8
g15
sg10
I10
sg11
VmiR-146-5p
p8631
sg13
I1
sa(dp8632
g7
I94
sg8
g15
sg10
I8
sg11
VmiR-4516
p8633
sg13
I1
sa(dp8634
g7
I112
sg8
g15
sg10
I11
sg11
VmiR-148b-3p
p8635
sg13
I1
sa(dp8636
g7
I51
sg8
g15
sg10
I11
sg11
VmiR-199b-5p
p8637
sg13
I1
sa(dp8638
g7
I77
sg8
g15
sg10
I11
sg11
VmiR-1915-3p
p8639
sg13
I1
sasg23
(lp8640
(dp8641
g7
I219
sg26
VC0007097
p8642
sg10
I10
sg11
Vcarcinomas
p8643
sg13
I1
sasa(dp8644
g2
S'We further show that overexpression of hsa-miR-4516 downregulates STAT3, p-STAT3, CDK6, and UBE2N proteins that are consistently upregulated in psoriasis and induces apoptosis in HaCaT cells.\n'
p8645
sg4
(lp8646
(dp8647
g7
I39
sg8
g15
sg10
I12
sg11
Vhsa-miR-4516
p8648
sg13
I1
sa(dp8649
g7
I82
sg8
g15
sg10
I4
sg11
VCDK6
p8650
sg13
I1
sa(dp8651
g7
I92
sg8
VP61088
p8652
sg10
I14
sg11
VUBE2N proteins
p8653
sg13
I2
sa(dp8654
g7
I73
sg8
VP40763
p8655
sg10
I7
sg11
Vp-STAT3
p8656
sg13
I1
sa(dp8657
g7
I66
sg8
VP40763
p8658
sg10
I5
sg11
VSTAT3
p8659
sg13
I1
sasg23
(lp8660
(dp8661
g7
I144
sg26
VC0033860
p8662
sg10
I9
sg11
Vpsoriasis
p8663
sg13
I1
sa(dp8664
g7
I39
sg26
VC0393754
p8665
sg10
I3
sg11
Vhsa
p8666
sg13
I1
sasa(dp8667
g2
S'A general defect in napsin A or cathepsin H expression or activity was not the specific cause for abnormal surfactant accumulation in juvenile pulmonary alveolar proteinosis.\n'
p8668
sg4
(lp8669
(dp8670
g7
I32
sg8
VP09668
p8671
sg10
I11
sg11
Vcathepsin H
p8672
sg13
I2
sa(dp8673
g7
I20
sg8
g15
sg10
I8
sg11
Vnapsin A
p8674
sg13
I2
sasg23
(lp8675
(dp8676
g7
I143
sg26
VC0034050
p8677
sg10
I30
sg11
Vpulmonary alveolar proteinosis
p8678
sg13
I3
sasa(dp8679
g2
S'Significantly increased activities of cathepsin H and aminopeptidase were detected in BAL fluid from patients with idiopathic pulmonary fibrosis (IPF), cryptogenic organizing pneumonia (COP), chronic eosinophilic pneumonia (CEP) and hypersensitivity pneumonitis (HP).\n'
p8680
sg4
(lp8681
(dp8682
g7
I38
sg8
VP09668
p8683
sg10
I30
sg11
Vcathepsin H and aminopeptidase
p8684
sg13
I4
sasg23
(lp8685
(dp8686
g7
I152
sg26
VC0242770
p8687
sg10
I32
sg11
Vcryptogenic organizing pneumonia
p8688
sg13
I3
sa(dp8689
g7
I233
sg26
VC0002390
p8690
sg10
I28
sg11
Vhypersensitivity pneumonitis
p8691
sg13
I2
sa(dp8692
g7
I146
sg26
VC3161101
p8693
sg10
I3
sg11
VIPF
p8694
sg13
I1
sa(dp8695
g7
I115
sg26
VC3161101
p8696
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p8697
sg13
I3
sa(dp8698
g7
I263
sg26
VC0002390
p8699
sg10
I2
sg11
VHP
p8700
sg13
I1
sa(dp8701
g7
I192
sg26
VC0008680
p8702
sg10
I30
sg11
Vchronic eosinophilic pneumonia
p8703
sg13
I3
sa(dp8704
g7
I186
sg26
VC0242770
p8705
sg10
I3
sg11
VCOP
p8706
sg13
I1
sa(dp8707
g7
I224
sg26
VC0162530
p8708
sg10
I3
sg11
VCEP
p8709
sg13
I1
sasa(dp8710
g2
S'The function of CpsB, a PHP family protein tyrosine phosphatase from Streptococcus pneumonia, is to regulate biosynthesis of capsular polysaccharide, an important virulence determinant.\n'
p8711
sg4
(lp8712
(dp8713
g7
I24
sg8
VP41225
p8714
sg10
I39
sg11
VPHP family protein tyrosine phosphatase
p8715
sg13
I5
sa(dp8716
g7
I16
sg8
VP09668
p8717
sg10
I4
sg11
VCpsB
p8718
sg13
I1
sasg23
(lp8719
(dp8720
g7
I83
sg26
VC0032285
p8721
sg10
I9
sg11
Vpneumonia
p8722
sg13
I1
sasa(dp8723
g2
S'Vitreous samples from individuals with exogenous endophthalmitis (n = 18) were analyzed via Luminex assay and enzyme-linked immunosorbent assay for the cytokines VEGF-A, tumor necrosis factor (TNF), interleukin 6 (IL-6), IL-8 (chemokine [CXCL]-8), IL-1Beta, IL-10, IL-12p70, IL-33, interferon (IFN)-Gamma, IFN-Alfa, IFN-Beta, chemokine ligand (CCL)-3, IL-2, IL-5, IL-15, CXCL-10, CCL-2, IL-1Ra, CCL-5, IL-17, and CCL-11.\n'
p8724
sg4
(lp8725
(dp8726
g7
I170
sg8
VP01375
p8727
sg10
I21
sg11
Vtumor necrosis factor
p8728
sg13
I3
sa(dp8729
g7
I352
sg8
VP60568
p8730
sg10
I4
sg11
VIL-2
p8731
sg13
I1
sa(dp8732
g7
I193
sg8
VP01375
p8733
sg10
I3
sg11
VTNF
p8734
sg13
I1
sa(dp8735
g7
I294
sg8
VP01562
p8736
sg10
I3
sg11
VIFN
p8737
sg13
I1
sa(dp8738
g7
I358
sg8
VP05113
p8739
sg10
I4
sg11
VIL-5
p8740
sg13
I1
sa(dp8741
g7
I413
sg8
VP43320
p8742
sg10
I6
sg11
VCCL-11
p8743
sg13
I1
sa(dp8744
g7
I395
sg8
VP43320
p8745
sg10
I5
sg11
VCCL-5
p8746
sg13
I1
sa(dp8747
g7
I380
sg8
VP43320
p8748
sg10
I5
sg11
VCCL-2
p8749
sg13
I1
sa(dp8750
g7
I282
sg8
VP01563
p8751
sg10
I10
sg11
Vinterferon
p8752
sg13
I1
sa(dp8753
g7
I364
sg8
VP40933
p8754
sg10
I5
sg11
VIL-15
p8755
sg13
I1
sa(dp8756
g7
I152
sg8
VP01374
p8757
sg10
I16
sg11
Vcytokines VEGF-A
p8758
sg13
I2
sa(dp8759
g7
I248
sg8
VP01584
p8760
sg10
I8
sg11
VIL-1Beta
p8761
sg13
I1
sa(dp8762
g7
I306
sg8
VP01562
p8763
sg10
I8
sg11
VIFN-Alfa
p8764
sg13
I1
sa(dp8765
g7
I387
sg8
VP18510
p8766
sg10
I6
sg11
VIL-1Ra
p8767
sg13
I1
sa(dp8768
g7
I199
sg8
VP05231
p8769
sg10
I13
sg11
Vinterleukin 6
p8770
sg13
I2
sa(dp8771
g7
I316
sg8
VP01574
p8772
sg10
I34
sg11
VIFN-Beta, chemokine ligand (CCL)-3
p8773
sg13
I4
sa(dp8774
g7
I214
sg8
VP05231
p8775
sg10
I4
sg11
VIL-6
p8776
sg13
I1
sasg23
(lp8777
(dp8778
g7
I170
sg26
VC0333516
p8779
sg10
I14
sg11
Vtumor necrosis
p8780
sg13
I2
sa(dp8781
g7
I344
sg26
VC1852438
p8782
sg10
I3
sg11
VCCL
p8783
sg13
I1
sa(dp8784
g7
I344
sg26
VC1852438
p8785
sg10
I3
sg11
VCCL
p8786
sg13
I1
sa(dp8787
g7
I49
sg26
VC0014236
p8788
sg10
I15
sg11
Vendophthalmitis
p8789
sg13
I1
sa(dp8790
g7
I344
sg26
VC1852438
p8791
sg10
I3
sg11
VCCL
p8792
sg13
I1
sa(dp8793
g7
I344
sg26
VC1852438
p8794
sg10
I3
sg11
VCCL
p8795
sg13
I1
sasa(dp8796
g2
S'Among four patients with KS carrying a CHD7 mutation, one had perceptive deafness and two had a cleft lip/palate.\n'
p8797
sg4
(lp8798
(dp8799
g7
I39
sg8
g15
sg10
I4
sg11
VCHD7
p8800
sg13
I1
sasg23
(lp8801
(dp8802
g7
I62
sg26
VC0018784
p8803
sg10
I19
sg11
Vperceptive deafness
p8804
sg13
I2
sa(dp8805
g7
I96
sg26
VC0158646
p8806
sg10
I16
sg11
Vcleft lip/palate
p8807
sg13
I2
sasa(dp8808
g2
S'We report two brothers of Chinese origin who have an apparently unique syndrome of cleft lip/palate, profound sensorineural deafness, and a sacral lipoma.\n'
p8809
sg4
(lp8810
sg23
(lp8811
(dp8812
g7
I71
sg26
VC0039082
p8813
sg10
I8
sg11
Vsyndrome
p8814
sg13
I1
sa(dp8815
g7
I147
sg26
VC3489413
p8816
sg10
I6
sg11
Vlipoma
p8817
sg13
I1
sa(dp8818
g7
I83
sg26
VC0158646
p8819
sg10
I16
sg11
Vcleft lip/palate
p8820
sg13
I2
sa(dp8821
g7
I110
sg26
VC0018784
p8822
sg10
I22
sg11
Vsensorineural deafness
p8823
sg13
I2
sasa(dp8824
g2
S'Immunofluorescent staining showed that there were cell nuclei stained for c-Fos, c-Myc, and p53, and cytoplasm positive for c-Raf, in the glomeruli of patients with proliferative types of glomerulonephritis, including IgA nephritis and lupus nephritis, and in patients with focal glomerular sclerosis.\n'
p8825
sg4
(lp8826
(dp8827
g7
I124
sg8
VP04049
p8828
sg10
I5
sg11
Vc-Raf
p8829
sg13
I1
sa(dp8830
g7
I81
sg8
VP12524
p8831
sg10
I5
sg11
Vc-Myc
p8832
sg13
I1
sa(dp8833
g7
I218
sg8
VP11912
p8834
sg10
I3
sg11
VIgA
p8835
sg13
I1
sa(dp8836
g7
I74
sg8
VP01100
p8837
sg10
I5
sg11
Vc-Fos
p8838
sg13
I1
sa(dp8839
g7
I92
sg8
VP42771
p8840
sg10
I3
sg11
Vp53
p8841
sg13
I1
sasg23
(lp8842
(dp8843
g7
I165
sg26
VC0334094
p8844
sg10
I13
sg11
Vproliferative
p8845
sg13
I1
sa(dp8846
g7
I274
sg26
VC0017668
p8847
sg10
I26
sg11
Vfocal glomerular sclerosis
p8848
sg13
I3
sa(dp8849
g7
I188
sg26
VC0017658
p8850
sg10
I18
sg11
Vglomerulonephritis
p8851
sg13
I1
sa(dp8852
g7
I236
sg26
VC0024143
p8853
sg10
I15
sg11
Vlupus nephritis
p8854
sg13
I2
sa(dp8855
g7
I197
sg26
VC0027697
p8856
sg10
I9
sg11
Vnephritis
p8857
sg13
I1
sasa(dp8858
g2
S'The objective of the study was to compare the diagnostic yield of home-made ELISA tests based on synthetic chimeric fibrin/filaggrin citrullinated peptides (CFFCPs) with CCP3 and CCP3.1 commercial tests to detect anti-citrullinated protein/peptide antibodies (ACPAs) in rheumatoid arthritis (RA) patients.\n'
p8859
sg4
(lp8860
(dp8861
g7
I179
sg8
g15
sg10
I6
sg11
VCCP3.1
p8862
sg13
I1
sa(dp8863
g7
I170
sg8
g15
sg10
I4
sg11
VCCP3
p8864
sg13
I1
sa(dp8865
g7
I116
sg8
VP22087
p8866
sg10
I6
sg11
Vfibrin
p8867
sg13
I1
sa(dp8868
g7
I123
sg8
VP20930
p8869
sg10
I9
sg11
Vfilaggrin
p8870
sg13
I1
sa(dp8871
g7
I147
sg8
g15
sg10
I17
sg11
Vpeptides (CFFCPs)
p8872
sg13
I2
sasg23
(lp8873
(dp8874
g7
I292
sg26
VC0003873
p8875
sg10
I2
sg11
VRA
p8876
sg13
I1
sa(dp8877
g7
I270
sg26
VC0003873
p8878
sg10
I20
sg11
Vrheumatoid arthritis
p8879
sg13
I2
sasa(dp8880
g2
S'In the present study, we aimed to estimate the concentrations of cytokines (interleukin 6, IL-6, tumor necrosis factor-Alfa, TNF-Alfa) and auto-antibodies (rheumatoid factor IgM isotype, IgM-RF, antinuclear auto-antibodies, ANA, anti-cyclic citrullinated peptide antibodies IgG isotype, IgG anti-CCP3.1, anti-cardiolipin IgG isotype, IgG anti-aCL) in serum of patients with eRA (early rheumatoid arthritis) and HCVrA (hepatitis C virus-related arthropathy) and to assess the utility of IL-6, TNF-Alfa together with IgG anti-CCP and IgM-RF in distinguishing between patients with true eRA and HCVrA, in the idea of using them as differential immunomarkers.\n'
p8881
sg4
(lp8882
(dp8883
g7
I334
sg8
VP53396
p8884
sg10
I12
sg11
VIgG anti-aCL
p8885
sg13
I2
sa(dp8886
g7
I229
sg8
g15
sg10
I56
sg11
Vanti-cyclic citrullinated peptide antibodies IgG isotype
p8887
sg13
I6
sa(dp8888
g7
I125
sg8
VP01375
p8889
sg10
I8
sg11
VTNF-Alfa
p8890
sg13
I1
sa(dp8891
g7
I91
sg8
VP05231
p8892
sg10
I4
sg11
VIL-6
p8893
sg13
I1
sa(dp8894
g7
I374
sg8
VP03372
p8895
sg10
I3
sg11
VeRA
p8896
sg13
I1
sa(dp8897
g7
I287
sg8
VP07320
p8898
sg10
I12
sg11
VIgG anti-CCP
p8899
sg13
I2
sa(dp8900
g7
I91
sg8
VP05231
p8901
sg10
I4
sg11
VIL-6
p8902
sg13
I1
sa(dp8903
g7
I287
sg8
g15
sg10
I15
sg11
VIgG anti-CCP3.1
p8904
sg13
I2
sa(dp8905
g7
I379
sg8
VP01116
p8906
sg10
I26
sg11
Vearly rheumatoid arthritis
p8907
sg13
I3
sa(dp8908
g7
I374
sg8
VP03372
p8909
sg10
I3
sg11
VeRA
p8910
sg13
I1
sa(dp8911
g7
I97
sg8
VP01375
p8912
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p8913
sg13
I3
sa(dp8914
g7
I125
sg8
VP01375
p8915
sg10
I8
sg11
VTNF-Alfa
p8916
sg13
I1
sa(dp8917
g7
I156
sg8
VP04207
p8918
sg10
I37
sg11
Vrheumatoid factor IgM isotype, IgM-RF
p8919
sg13
I5
sa(dp8920
g7
I174
sg8
VP29965
p8921
sg10
I3
sg11
VIgM
p8922
sg13
I1
sa(dp8923
g7
I224
sg8
g15
sg10
I3
sg11
VANA
p8924
sg13
I1
sa(dp8925
g7
I76
sg8
VP05231
p8926
sg10
I13
sg11
Vinterleukin 6
p8927
sg13
I2
sasg23
(lp8928
(dp8929
g7
I418
sg26
VC0019196
p8930
sg10
I11
sg11
Vhepatitis C
p8931
sg13
I2
sa(dp8932
g7
I444
sg26
VC0022408
p8933
sg10
I11
sg11
Varthropathy
p8934
sg13
I1
sa(dp8935
g7
I97
sg26
VC0333516
p8936
sg10
I14
sg11
Vtumor necrosis
p8937
sg13
I2
sa(dp8938
g7
I296
sg26
VC1832526
p8939
sg10
I3
sg11
VCCP
p8940
sg13
I1
sa(dp8941
g7
I385
sg26
VC0003873
p8942
sg10
I20
sg11
Vrheumatoid arthritis
p8943
sg13
I2
sasa(dp8944
g2
S'Logistic regressions were used to investigate whether using both tests (anti-CCP2 and anti-CCP3) gives a better prediction of rheumatoid arthritis.\n'
p8945
sg4
(lp8946
(dp8947
g7
I86
sg8
g15
sg10
I9
sg11
Vanti-CCP3
p8948
sg13
I1
sa(dp8949
g7
I72
sg8
g15
sg10
I9
sg11
Vanti-CCP2
p8950
sg13
I1
sasg23
(lp8951
(dp8952
g7
I126
sg26
VC0003873
p8953
sg10
I20
sg11
Vrheumatoid arthritis
p8954
sg13
I2
sa(dp8955
g7
I9
sg26
VC0684320
p8956
sg10
I11
sg11
Vregressions
p8957
sg13
I1
sasa(dp8958
g2
S'Binary logistic regressions indicated that the likelihood of having rheumatoid arthritis (RA) is significantly higher when testing positive on both CCP2 and CCP3 compared to CCP2 or CCP3 alone.\n'
p8959
sg4
(lp8960
(dp8961
g7
I148
sg8
g15
sg10
I4
sg11
VCCP2
p8962
sg13
I1
sa(dp8963
g7
I157
sg8
g15
sg10
I4
sg11
VCCP3
p8964
sg13
I1
sa(dp8965
g7
I148
sg8
g15
sg10
I4
sg11
VCCP2
p8966
sg13
I1
sa(dp8967
g7
I157
sg8
g15
sg10
I4
sg11
VCCP3
p8968
sg13
I1
sasg23
(lp8969
(dp8970
g7
I16
sg26
VC0684320
p8971
sg10
I11
sg11
Vregressions
p8972
sg13
I1
sa(dp8973
g7
I90
sg26
VC0003873
p8974
sg10
I2
sg11
VRA
p8975
sg13
I1
sa(dp8976
g7
I68
sg26
VC0003873
p8977
sg10
I20
sg11
Vrheumatoid arthritis
p8978
sg13
I2
sasa(dp8979
g2
S'The presence of ACPA was determined by the visually read, qualitative rapid CCPoint(R) test (Euro-Diagnostica, Malmoe, Sweden) compared to routinely used ELISA assays (Immunoscan CCPlus(R)-Euro-Diagnostica, Sweden, and QuantLite(R) CCP3-INOVA Diagnostics Inc., USA), in the sera of 184 patients: early RA(n = 38), established RA (n = 84), inflammatory arthritis(n = 34) and systemic lupus erythematosus (SLE) (n = 28).\n'
p8980
sg4
(lp8981
sg23
(lp8982
(dp8983
g7
I339
sg26
VC0003864
p8984
sg10
I22
sg11
Vinflammatory arthritis
p8985
sg13
I2
sa(dp8986
g7
I404
sg26
VC0024141
p8987
sg10
I3
sg11
VSLE
p8988
sg13
I1
sa(dp8989
g7
I374
sg26
VC0024141
p8990
sg10
I28
sg11
Vsystemic lupus erythematosus
p8991
sg13
I3
sasa(dp8992
g2
S'Here we report that oncogenic activation of ERK plays an important role in transcriptional activation of CD47 through nuclear respiratory factor 1 (NRF-1) in melanoma cells.\n'
p8993
sg4
(lp8994
(dp8995
g7
I118
sg8
g15
sg10
I28
sg11
Vnuclear respiratory factor 1
p8996
sg13
I4
sa(dp8997
g7
I148
sg8
g15
sg10
I5
sg11
VNRF-1
p8998
sg13
I1
sa(dp8999
g7
I105
sg8
g15
sg10
I4
sg11
VCD47
p9000
sg13
I1
sa(dp9001
g7
I44
sg8
VP29323
p9002
sg10
I3
sg11
VERK
p9003
sg13
I1
sasg23
(lp9004
(dp9005
g7
I158
sg26
VC0025202
p9006
sg10
I8
sg11
Vmelanoma
p9007
sg13
I1
sasa(dp9008
g2
S'So these results suggest that NRF-1-mediated regulation of CD47 expression is a novel mechanism by which ERK signalling promotes the pathogenesis of melanoma, and that the combination of CD47 blockade and BRAF/MEK inhibitors may be a useful approach for improving their therapeutic efficacy.\n'
p9009
sg4
(lp9010
(dp9011
g7
I187
sg8
g15
sg10
I13
sg11
VCD47 blockade
p9012
sg13
I2
sa(dp9013
g7
I30
sg8
g15
sg10
I5
sg11
VNRF-1
p9014
sg13
I1
sa(dp9015
g7
I105
sg8
VP29323
p9016
sg10
I3
sg11
VERK
p9017
sg13
I1
sa(dp9018
g7
I205
sg8
VP15056
p9019
sg10
I4
sg11
VBRAF
p9020
sg13
I1
sa(dp9021
g7
I59
sg8
g15
sg10
I4
sg11
VCD47
p9022
sg13
I1
sa(dp9023
g7
I210
sg8
VP45985
p9024
sg10
I3
sg11
VMEK
p9025
sg13
I1
sasg23
(lp9026
(dp9027
g7
I149
sg26
VC0025202
p9028
sg10
I8
sg11
Vmelanoma
p9029
sg13
I1
sa(dp9030
g7
I133
sg26
VC0699748
p9031
sg10
I12
sg11
Vpathogenesis
p9032
sg13
I1
sasa(dp9033
g2
S'We reported that ERAlfa increases nuclear respiratory factor-1 (NRF-1), which regulates nuclear-encoded mitochondrial gene transcription, in MCF-7 breast cancer cells and NRF-1 knockdown stimulates apoptosis.\n'
p9034
sg4
(lp9035
(dp9036
g7
I34
sg8
g15
sg10
I28
sg11
Vnuclear respiratory factor-1
p9037
sg13
I3
sa(dp9038
g7
I64
sg8
g15
sg10
I5
sg11
VNRF-1
p9039
sg13
I1
sa(dp9040
g7
I64
sg8
g15
sg10
I5
sg11
VNRF-1
p9041
sg13
I1
sasg23
(lp9042
(dp9043
g7
I147
sg26
VC0678222
p9044
sg10
I13
sg11
Vbreast cancer
p9045
sg13
I2
sasa(dp9046
g2
S'Whether NRF-1 and target gene expression is altered in endocrine resistant breast cancer cells is unknown.\n'
p9047
sg4
(lp9048
(dp9049
g7
I8
sg8
g15
sg10
I5
sg11
VNRF-1
p9050
sg13
I1
sasg23
(lp9051
(dp9052
g7
I75
sg26
VC0678222
p9053
sg10
I13
sg11
Vbreast cancer
p9054
sg13
I2
sasa(dp9055
g2
S'Mechanistically, nutritional deficiencies could reduce hypoxia-inducible factor Alfa (HIF-1Alfa) protein expression to increase C-MYC protein level, which in turn increased nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM) transcription to enhance the activity of OXPHOS, suggesting that metabolic reprogramming by the changes of microenvironment during the carcinogenesis can provide some novel therapeutic clues to traditional cancer treatments.\n'
p9056
sg4
(lp9057
(dp9058
g7
I173
sg8
g15
sg10
I28
sg11
Vnuclear respiratory factor 1
p9059
sg13
I4
sa(dp9060
g7
I251
sg8
g15
sg10
I4
sg11
VTFAM
p9061
sg13
I1
sa(dp9062
g7
I55
sg8
g15
sg10
I29
sg11
Vhypoxia-inducible factor Alfa
p9063
sg13
I3
sa(dp9064
g7
I203
sg8
g15
sg10
I4
sg11
VNRF1
p9065
sg13
I1
sa(dp9066
g7
I298
sg8
VP12235
p9067
sg10
I6
sg11
VOXPHOS
p9068
sg13
I1
sa(dp9069
g7
I213
sg8
g15
sg10
I36
sg11
Vmitochondrial transcription factor A
p9070
sg13
I4
sa(dp9071
g7
I128
sg8
VP01106
p9072
sg10
I13
sg11
VC-MYC protein
p9073
sg13
I2
sasg23
(lp9074
(dp9075
g7
I55
sg26
VC0242184
p9076
sg10
I7
sg11
Vhypoxia
p9077
sg13
I1
sa(dp9078
g7
I463
sg26
VC0006826
p9079
sg10
I6
sg11
Vcancer
p9080
sg13
I1
sa(dp9081
g7
I392
sg26
VC0596263
p9082
sg10
I14
sg11
Vcarcinogenesis
p9083
sg13
I1
sa(dp9084
g7
I17
sg26
VC0162429
p9085
sg10
I24
sg11
Vnutritional deficiencies
p9086
sg13
I2
sasa(dp9087
g2
S'Here we show how ROS through a novel redox signalling pathway involving nuclear respiratory factor-1 (NRF-1) and p27 contribute to E2-induced growth of MCF-7 breast cancer cells.\n'
p9088
sg4
(lp9089
(dp9090
g7
I102
sg8
g15
sg10
I5
sg11
VNRF-1
p9091
sg13
I1
sa(dp9092
g7
I72
sg8
g15
sg10
I28
sg11
Vnuclear respiratory factor-1
p9093
sg13
I3
sa(dp9094
g7
I113
sg8
VP40305
p9095
sg10
I3
sg11
Vp27
p9096
sg13
I1
sasg23
(lp9097
(dp9098
g7
I158
sg26
VC0678222
p9099
sg10
I13
sg11
Vbreast cancer
p9100
sg13
I2
sasa(dp9101
g2
S'We identified a missense mutation arginine 33 to glutamine (R33Q) in CD300f by direct sequencing of exon 2 in peripheral blood samples from 50 patients with multiple sclerosis (MS).\n'
p9102
sg4
(lp9103
sg23
(lp9104
(dp9105
g7
I157
sg26
VC0026769
p9106
sg10
I18
sg11
Vmultiple sclerosis
p9107
sg13
I2
sa(dp9108
g7
I177
sg26
VC0026769
p9109
sg10
I2
sg11
VMS
p9110
sg13
I1
sasa(dp9111
g2
S'CD300f -/- mice were protected from death after cecal ligation and puncture (CLP), a murine model of septic peritonitis.\n'
p9112
sg4
(lp9113
sg23
(lp9114
(dp9115
g7
I108
sg26
VC0031154
p9116
sg10
I11
sg11
Vperitonitis
p9117
sg13
I1
sasa(dp9118
g2
S'Here we identify the critical role of CD300f in inhibiting LPS-induced skin inflammation.\n'
p9119
sg4
(lp9120
sg23
(lp9121
(dp9122
g7
I71
sg26
VC0011603
p9123
sg10
I17
sg11
Vskin inflammation
p9124
sg13
I2
sa(dp9125
g7
I59
sg26
VC0175697
p9126
sg10
I3
sg11
VLPS
p9127
sg13
I1
sasa(dp9128
g2
S'Thus, ceramide-CD300f binding inhibits LPS-induced skin inflammation, implicating CD300f as a negative regulator of Toll-like receptor 4 (TLR4) signaling in vivo.\n'
p9129
sg4
(lp9130
(dp9131
g7
I138
sg8
g15
sg10
I4
sg11
VTLR4
p9132
sg13
I1
sa(dp9133
g7
I116
sg8
g15
sg10
I20
sg11
VToll-like receptor 4
p9134
sg13
I3
sasg23
(lp9135
(dp9136
g7
I51
sg26
VC0011603
p9137
sg10
I17
sg11
Vskin inflammation
p9138
sg13
I2
sa(dp9139
g7
I39
sg26
VC0175697
p9140
sg10
I3
sg11
VLPS
p9141
sg13
I1
sasa(dp9142
g2
S'The aim of the present auto-commentary is to highlight recent findings regarding the Cd300lf and Cd300lb receptors and their emerging roles in the development of autoimmune disease.\n'
p9143
sg4
(lp9144
(dp9145
g7
I97
sg8
g15
sg10
I17
sg11
VCd300lb receptors
p9146
sg13
I2
sasg23
(lp9147
(dp9148
g7
I162
sg26
VC0004364
p9149
sg10
I18
sg11
Vautoimmune disease
p9150
sg13
I2
sasa(dp9151
g2
S'CD300f (CLM-1) is a phosphatidylserine receptor known to positively regulate efferocytosis by macrophages, and CD300f gene-deficient mice are predisposed to develop a lupus-like disease.\n'
p9152
sg4
(lp9153
(dp9154
g7
I8
sg8
VP07942
p9155
sg10
I5
sg11
VCLM-1
p9156
sg13
I1
sa(dp9157
g7
I20
sg8
g15
sg10
I27
sg11
Vphosphatidylserine receptor
p9158
sg13
I2
sasg23
(lp9159
(dp9160
g7
I167
sg26
VC0024131
p9161
sg10
I5
sg11
Vlupus
p9162
sg13
I1
sasa(dp9163
g2
S'The consequences are the expansion of memory T cells and increased ANA levels in aged CD300f-deficient mice, which predispose CD300f-deficient mice to develop an overt autoimmune disease when exposed to an overload of apoptotic cells, or an exacerbated autoimmunity when combined with FcGammaRIIB deficiency.\n'
p9164
sg4
(lp9165
(dp9166
g7
I285
sg8
VP31994
p9167
sg10
I11
sg11
VFcGammaRIIB
p9168
sg13
I1
sa(dp9169
g7
I67
sg8
g15
sg10
I3
sg11
VANA
p9170
sg13
I1
sasg23
(lp9171
(dp9172
g7
I253
sg26
VC0004368
p9173
sg10
I12
sg11
Vautoimmunity
p9174
sg13
I1
sa(dp9175
g7
I168
sg26
VC0004364
p9176
sg10
I18
sg11
Vautoimmune disease
p9177
sg13
I2
sasa(dp9178
g2
S'Anaemia was categorized as severe (Hb &lt;7 g/dL), moderate (Hb 7-9.9 g/dL) or mild (Hb 10-10.9 g/dL).\n'
p9179
sg4
(lp9180
sg23
(lp9181
(dp9182
g7
I0
sg26
VC0002871
p9183
sg10
I7
sg11
VAnaemia
p9184
sg13
I1
sasa(dp9185
g2
S'Thrombocytopenia is a common adverse event in cancer patients treated with antibody-drug conjugates (ADC), including AGS-16C3F, an ADC targeting ENPP3 (ectonucleotide pyrophosphatase/phosphodiesterase-3) and trastuzumab emtansine (T-DM1).\n'
p9186
sg4
(lp9187
(dp9188
g7
I101
sg8
VP20711
p9189
sg10
I3
sg11
VADC
p9190
sg13
I1
sa(dp9191
g7
I152
sg8
g15
sg10
I50
sg11
Vectonucleotide pyrophosphatase/phosphodiesterase-3
p9192
sg13
I2
sa(dp9193
g7
I75
sg8
VP20711
p9194
sg10
I24
sg11
Vantibody-drug conjugates
p9195
sg13
I2
sa(dp9196
g7
I117
sg8
VP78504
p9197
sg10
I9
sg11
VAGS-16C3F
p9198
sg13
I1
sa(dp9199
g7
I145
sg8
g15
sg10
I5
sg11
VENPP3
p9200
sg13
I1
sasg23
(lp9201
(dp9202
g7
I233
sg26
VC2931688
p9203
sg10
I3
sg11
VDM1
p9204
sg13
I1
sa(dp9205
g7
I117
sg26
VC0796126
p9206
sg10
I3
sg11
VAGS
p9207
sg13
I1
sa(dp9208
g7
I46
sg26
VC0006826
p9209
sg10
I6
sg11
Vcancer
p9210
sg13
I1
sasa(dp9211
g2
S"In this study, we investigated induction of B 10 cell's IL-10 competency in vitro and its effect on ligature-induced experimental periodontitis in vivo.\n"
p9212
sg4
(lp9213
sg23
(lp9214
(dp9215
g7
I130
sg26
VC0031099
p9216
sg10
I13
sg11
Vperiodontitis
p9217
sg13
I1
sasa(dp9218
g2
S'Although both luminal-like subtypes were associated with increased androgen receptor expression and signaling, only luminal B prostate cancers were significantly associated with postoperative response to androgen deprivation therapy (ADT) in a subset analysis in our retrospective cohorts (n = 315) matching patients based on clinicopathologic variables (luminal B 10-year metastasis: treated, 33% vs untreated, 55%; nonluminal B 10-year metastasis: treated, 37% vs untreated, 21%; P = .006 for interaction).\n'
p9219
sg4
(lp9220
(dp9221
g7
I67
sg8
VP10275
p9222
sg10
I17
sg11
Vandrogen receptor
p9223
sg13
I2
sasg23
(lp9224
(dp9225
g7
I373
sg26
VC0027627
p9226
sg10
I10
sg11
Vmetastasis
p9227
sg13
I1
sa(dp9228
g7
I373
sg26
VC0027627
p9229
sg10
I10
sg11
Vmetastasis
p9230
sg13
I1
sa(dp9231
g7
I126
sg26
VC0376358
p9232
sg10
I16
sg11
Vprostate cancers
p9233
sg13
I2
sasa(dp9234
g2
S'We investigated the function and possible mechanisms of KPNA2 involved in rheumatoid arthritis (RA).\n'
p9235
sg4
(lp9236
(dp9237
g7
I56
sg8
VP52292
p9238
sg10
I5
sg11
VKPNA2
p9239
sg13
I1
sasg23
(lp9240
(dp9241
g7
I96
sg26
VC0003873
p9242
sg10
I2
sg11
VRA
p9243
sg13
I1
sa(dp9244
g7
I74
sg26
VC0003873
p9245
sg10
I20
sg11
Vrheumatoid arthritis
p9246
sg13
I2
sasa(dp9247
g2
S"Analysis of expression profiling experiments of peripheral blood mononuclear cells (PBMC) demonstrates statistically significant KPNA1-, NLRP1- and NLRP3-gene expression phenotypes associated with human genotypes of Crohn's disease (CD), Huntington's disease (HD) and rheumatoid arthritis (RA) populations.\n"
p9248
sg4
(lp9249
(dp9250
g7
I238
sg8
g15
sg10
I20
sg11
VHuntington's disease
p9251
sg13
I2
sa(dp9252
g7
I137
sg8
g15
sg10
I5
sg11
VNLRP1
p9253
sg13
I1
sa(dp9254
g7
I260
sg8
g15
sg10
I2
sg11
VHD
p9255
sg13
I1
sasg23
(lp9256
(dp9257
g7
I290
sg26
VC0003873
p9258
sg10
I2
sg11
VRA
p9259
sg13
I1
sa(dp9260
g7
I216
sg26
VC0010346
p9261
sg10
I15
sg11
VCrohn's disease
p9262
sg13
I2
sa(dp9263
g7
I260
sg26
VC0020179
p9264
sg10
I2
sg11
VHD
p9265
sg13
I1
sa(dp9266
g7
I238
sg26
VC0020179
p9267
sg10
I20
sg11
VHuntington's disease
p9268
sg13
I2
sa(dp9269
g7
I268
sg26
VC0003873
p9270
sg10
I20
sg11
Vrheumatoid arthritis
p9271
sg13
I2
sa(dp9272
g7
I233
sg26
VC0010346
p9273
sg10
I2
sg11
VCD
p9274
sg13
I1
sasa(dp9275
g2
S'In Astrocytoma, IDH-mutant, PIK3R1 mutations (P = 0.0014) and altered retinoblastoma pathway genes (RB1, CDKN2A, and CDK4) (P = 0.013) were independent predictors of poor survival.\n'
p9276
sg4
(lp9277
(dp9278
g7
I105
sg8
VP42771
p9279
sg10
I6
sg11
VCDKN2A
p9280
sg13
I1
sa(dp9281
g7
I70
sg8
g15
sg10
I28
sg11
Vretinoblastoma pathway genes
p9282
sg13
I3
sa(dp9283
g7
I28
sg8
VP27986
p9284
sg10
I6
sg11
VPIK3R1
p9285
sg13
I1
sa(dp9286
g7
I117
sg8
VP11802
p9287
sg10
I4
sg11
VCDK4
p9288
sg13
I1
sa(dp9289
g7
I100
sg8
VP27986
p9290
sg10
I3
sg11
VRB1
p9291
sg13
I1
sasg23
(lp9292
(dp9293
g7
I20
sg26
VC0596988
p9294
sg10
I6
sg11
Vmutant
p9295
sg13
I1
sa(dp9296
g7
I70
sg26
VC0035335
p9297
sg10
I14
sg11
Vretinoblastoma
p9298
sg13
I1
sa(dp9299
g7
I3
sg26
VC0004114
p9300
sg10
I11
sg11
VAstrocytoma
p9301
sg13
I1
sasa(dp9302
g2
S'We evaluated immunohistochemical expression of CDKN1B, CDKN1A, CDKN2A, CDK2, CDK4, CDK6, cyclin D1, cyclin E1, and phosphorylated retinoblastoma protein (phospho-RB1) in a cohort of 267 patients with NETs.\n'
p9303
sg4
(lp9304
(dp9305
g7
I100
sg8
VP24864
p9306
sg10
I9
sg11
Vcyclin E1
p9307
sg13
I2
sa(dp9308
g7
I47
sg8
VP46527
p9309
sg10
I6
sg11
VCDKN1B
p9310
sg13
I1
sa(dp9311
g7
I83
sg8
g15
sg10
I4
sg11
VCDK6
p9312
sg13
I1
sa(dp9313
g7
I77
sg8
VP11802
p9314
sg10
I4
sg11
VCDK4
p9315
sg13
I1
sa(dp9316
g7
I55
sg8
VP38936
p9317
sg10
I6
sg11
VCDKN1A
p9318
sg13
I1
sa(dp9319
g7
I71
sg8
VP24941
p9320
sg10
I4
sg11
VCDK2
p9321
sg13
I1
sa(dp9322
g7
I89
sg8
VP24385
p9323
sg10
I9
sg11
Vcyclin D1
p9324
sg13
I2
sa(dp9325
g7
I63
sg8
VP42771
p9326
sg10
I6
sg11
VCDKN2A
p9327
sg13
I1
sasg23
(lp9328
(dp9329
g7
I130
sg26
VC0035335
p9330
sg10
I14
sg11
Vretinoblastoma
p9331
sg13
I1
sasa(dp9332
g2
S'The cyclin D-cyclin dependent kinase (CDK) 4/6-inhibitor of CDK4 (INK4)-retinoblastoma (Rb) pathway plays a crucial role in cell cycle progression and its dysregulation is an important contributor to endocrine therapy resistance.\n'
p9333
sg4
(lp9334
(dp9335
g7
I43
sg8
VP42771
p9336
sg10
I21
sg11
V4/6-inhibitor of CDK4
p9337
sg13
I3
sa(dp9338
g7
I72
sg8
g15
sg10
I14
sg11
Vretinoblastoma
p9339
sg13
I1
sa(dp9340
g7
I4
sg8
VP24385
p9341
sg10
I52
sg11
Vcyclin D-cyclin dependent kinase (CDK) 4/6-inhibitor
p9342
sg13
I6
sa(dp9343
g7
I66
sg8
VP42771
p9344
sg10
I4
sg11
VINK4
p9345
sg13
I1
sasg23
(lp9346
(dp9347
g7
I72
sg26
VC0035335
p9348
sg10
I14
sg11
Vretinoblastoma
p9349
sg13
I1
sasa(dp9350
g2
S'The pathways for the proteins p53/p21 and p16Ink4a/retinoblastoma protein are important for irreversible growth arrest and senescent cells.\n'
p9351
sg4
(lp9352
(dp9353
g7
I34
sg8
VP42857
p9354
sg10
I3
sg11
Vp21
p9355
sg13
I1
sa(dp9356
g7
I42
sg8
VP42771
p9357
sg10
I8
sg11
Vp16Ink4a
p9358
sg13
I1
sa(dp9359
g7
I51
sg8
g15
sg10
I22
sg11
Vretinoblastoma protein
p9360
sg13
I2
sa(dp9361
g7
I30
sg8
VP42771
p9362
sg10
I3
sg11
Vp53
p9363
sg13
I1
sasg23
(lp9364
(dp9365
g7
I105
sg26
VC0333951
p9366
sg10
I13
sg11
Vgrowth arrest
p9367
sg13
I2
sa(dp9368
g7
I51
sg26
VC0035335
p9369
sg10
I14
sg11
Vretinoblastoma
p9370
sg13
I1
sasa(dp9371
g2
S'We suggest that the efficacy of recombinant interferon alpha-C in a low-dose regime versus other types of interferon as first-line therapy for inoperable, metastatic, or locally recurrent renal cell carcinoma should be investigated in a prospective, controlled, randomized study.\n'
p9372
sg4
(lp9373
(dp9374
g7
I44
sg8
VP01566
p9375
sg10
I18
sg11
Vinterferon alpha-C
p9376
sg13
I2
sa(dp9377
g7
I44
sg8
VP01563
p9378
sg10
I10
sg11
Vinterferon
p9379
sg13
I1
sasg23
(lp9380
(dp9381
g7
I178
sg26
VC0278679
p9382
sg10
I30
sg11
Vrecurrent renal cell carcinoma
p9383
sg13
I4
sasa(dp9384
g2
S'Five out of 38 patients (13%) with metastatic renal cell carcinoma had mental deterioration 3 weeks to 13 months after the start of treatment with recombinant interferon alpha-C. Metastatic spread to the brain, paraneoplastic effect of the tumor on the central nervous system and other causes of dementia were excluded.\n'
p9385
sg4
(lp9386
(dp9387
g7
I159
sg8
VP01566
p9388
sg10
I18
sg11
Vinterferon alpha-C
p9389
sg13
I2
sasg23
(lp9390
(dp9391
g7
I261
sg26
VC0027769
p9392
sg10
I7
sg11
Vnervous
p9393
sg13
I1
sa(dp9394
g7
I296
sg26
VC0497327
p9395
sg10
I8
sg11
Vdementia
p9396
sg13
I1
sa(dp9397
g7
I35
sg26
VC0278678
p9398
sg10
I31
sg11
Vmetastatic renal cell carcinoma
p9399
sg13
I4
sa(dp9400
g7
I240
sg26
VC0027651
p9401
sg10
I5
sg11
Vtumor
p9402
sg13
I1
sa(dp9403
g7
I71
sg26
VC0234985
p9404
sg10
I20
sg11
Vmental deterioration
p9405
sg13
I2
sasa(dp9406
g2
S'The pharmacokinetics of rIFN alpha-C were studied in 11 patients with metastatic renal-cell carcinoma.\n'
p9407
sg4
(lp9408
sg23
(lp9409
(dp9410
g7
I92
sg26
VC0007097
p9411
sg10
I9
sg11
Vcarcinoma
p9412
sg13
I1
sasa(dp9413
g2
S'A 75-year-old patient with metastatic renal cell carcinoma was treated with recombinant interferon alpha-C and thereafter developed a neurologic syndrome of dementia, ataxia, confusional state, loss of concentration ability and cortical blindness.\n'
p9414
sg4
(lp9415
(dp9416
g7
I88
sg8
VP01566
p9417
sg10
I18
sg11
Vinterferon alpha-C
p9418
sg13
I2
sasg23
(lp9419
(dp9420
g7
I167
sg26
VC0004134
p9421
sg10
I6
sg11
Vataxia
p9422
sg13
I1
sa(dp9423
g7
I145
sg26
VC0039082
p9424
sg10
I8
sg11
Vsyndrome
p9425
sg13
I1
sa(dp9426
g7
I27
sg26
VC0278678
p9427
sg10
I31
sg11
Vmetastatic renal cell carcinoma
p9428
sg13
I4
sa(dp9429
g7
I175
sg26
VC0009676
p9430
sg10
I17
sg11
Vconfusional state
p9431
sg13
I2
sa(dp9432
g7
I228
sg26
VC0155320
p9433
sg10
I18
sg11
Vcortical blindness
p9434
sg13
I2
sa(dp9435
g7
I157
sg26
VC0497327
p9436
sg10
I8
sg11
Vdementia
p9437
sg13
I1
sasa(dp9438
g2
S'Taken together, these findings revealed the first evidence that Nur77 was an important modulator in microglia function that associated with microglia-mediated dopaminergic neurotoxicity, and thus modulation of Nur77 may represent a potential novel target for treatment for neurodegenerative disease.\n'
p9439
sg4
(lp9440
(dp9441
g7
I64
sg8
VP22736
p9442
sg10
I5
sg11
VNur77
p9443
sg13
I1
sa(dp9444
g7
I64
sg8
VP22736
p9445
sg10
I5
sg11
VNur77
p9446
sg13
I1
sasg23
(lp9447
(dp9448
g7
I273
sg26
VC0524851
p9449
sg10
I25
sg11
Vneurodegenerative disease
p9450
sg13
I2
sasa(dp9451
g2
S'Chromatography of 4-S-CAP on an affinity column (both CH- and CNBr-activated Sepharose 4B) identified a 58 kD protein in melanoma cells, which was present at very low levels in HeLa cells; this 58 kD protein was retained by both 4-S- and 2-S-CAP affinity columns, but not by columns of a phenolic thioether (cysteinylphenol: CP) or a phenolic thioether amide (N-acetyl-4-S-CAP), and could be retrieved by either 4-S or 2-S-CAP but not by CP and N-acetyl-4-S-CAP.\n'
p9452
sg4
(lp9453
sg23
(lp9454
(dp9455
g7
I22
sg26
VC1855179
p9456
sg10
I3
sg11
VCAP
p9457
sg13
I1
sa(dp9458
g7
I22
sg26
VC1855179
p9459
sg10
I3
sg11
VCAP
p9460
sg13
I1
sa(dp9461
g7
I22
sg26
VC1855179
p9462
sg10
I3
sg11
VCAP
p9463
sg13
I1
sa(dp9464
g7
I121
sg26
VC0025202
p9465
sg10
I8
sg11
Vmelanoma
p9466
sg13
I1
sa(dp9467
g7
I22
sg26
VC1855179
p9468
sg10
I3
sg11
VCAP
p9469
sg13
I1
sa(dp9470
g7
I22
sg26
VC1855179
p9471
sg10
I3
sg11
VCAP
p9472
sg13
I1
sasa(dp9473
g2
S'SOX3 and TDGF-1 were up-regulated in human glioma tissues and GSCs.\n'
p9474
sg4
(lp9475
(dp9476
g7
I0
sg8
VP41225
p9477
sg10
I4
sg11
VSOX3
p9478
sg13
I1
sasg23
(lp9479
(dp9480
g7
I43
sg26
VC0017638
p9481
sg10
I6
sg11
Vglioma
p9482
sg13
I1
sasa(dp9483
g2
S'This study is the first to demonstrate that the SOX2OT-miR-194-5p/miR-122-SOX3-TDGF-1 pathway forms a positive feedback loop and regulates the biological behaviors of GSCs, and these findings might provide a novel strategy for glioma treatment.\n'
p9484
sg4
(lp9485
(dp9486
g7
I66
sg8
g15
sg10
I19
sg11
VmiR-122-SOX3-TDGF-1
p9487
sg13
I1
sa(dp9488
g7
I48
sg8
g15
sg10
I17
sg11
VSOX2OT-miR-194-5p
p9489
sg13
I1
sasg23
(lp9490
(dp9491
g7
I227
sg26
VC0017638
p9492
sg10
I6
sg11
Vglioma
p9493
sg13
I1
sasa(dp9494
g2
S'Self-renewal factor Sox3 induces epithelial-mesenchymal transition at gastrulation and is also involved epithelial-mesenchymal transition in several cancers.\n'
p9495
sg4
(lp9496
(dp9497
g7
I20
sg8
VP41225
p9498
sg10
I4
sg11
VSox3
p9499
sg13
I1
sasg23
(lp9500
(dp9501
g7
I56
sg26
VC0599156
p9502
sg10
I10
sg11
Vtransition
p9503
sg13
I1
sa(dp9504
g7
I149
sg26
VC0006826
p9505
sg10
I7
sg11
Vcancers
p9506
sg13
I1
sa(dp9507
g7
I56
sg26
VC0599156
p9508
sg10
I10
sg11
Vtransition
p9509
sg13
I1
sasa(dp9510
g2
S'We intended to determine the roles of Sox3 in inducing epithelial-mesenchymal transition in endometrial cancer stem cells and the possible role of microRNA-194 in controlling Sox3 expression.\n'
p9511
sg4
(lp9512
(dp9513
g7
I38
sg8
VP41225
p9514
sg10
I4
sg11
VSox3
p9515
sg13
I1
sa(dp9516
g7
I38
sg8
VP41225
p9517
sg10
I4
sg11
VSox3
p9518
sg13
I1
sasg23
(lp9519
(dp9520
g7
I92
sg26
VC0476089
p9521
sg10
I18
sg11
Vendometrial cancer
p9522
sg13
I2
sa(dp9523
g7
I78
sg26
VC0599156
p9524
sg10
I10
sg11
Vtransition
p9525
sg13
I1
sasa(dp9526
g2
S'Firstly, we found that Sox3 and microRNA-194 expressions were associated with the status of endometrial cancer stem cells in a panel of endometrial carcinoma tissue, the CD133+ cell was higher in tumorsphere than in differentiated cells, and overexpression of microRNA-194 would decrease CD133+ cell expression.\n'
p9527
sg4
(lp9528
(dp9529
g7
I23
sg8
VP41225
p9530
sg10
I4
sg11
VSox3
p9531
sg13
I1
sasg23
(lp9532
(dp9533
g7
I92
sg26
VC0476089
p9534
sg10
I18
sg11
Vendometrial cancer
p9535
sg13
I2
sa(dp9536
g7
I136
sg26
VC0476089
p9537
sg10
I21
sg11
Vendometrial carcinoma
p9538
sg13
I2
sasa(dp9539
g2
S'Silencing of Sox3 in endometrial cancer stem cell upregulated the epithelial marker E-cadherin, downregulated the mesenchymal marker vimentin, and significantly reduced cell invasion in vitro; overexpression of Sox3 reversed these phenotypes.\n'
p9540
sg4
(lp9541
(dp9542
g7
I13
sg8
VP41225
p9543
sg10
I4
sg11
VSox3
p9544
sg13
I1
sa(dp9545
g7
I13
sg8
VP41225
p9546
sg10
I4
sg11
VSox3
p9547
sg13
I1
sa(dp9548
g7
I66
sg8
VP12830
p9549
sg10
I28
sg11
Vepithelial marker E-cadherin
p9550
sg13
I3
sasg23
(lp9551
(dp9552
g7
I169
sg26
VC2699153
p9553
sg10
I13
sg11
Vcell invasion
p9554
sg13
I2
sa(dp9555
g7
I21
sg26
VC0476089
p9556
sg10
I18
sg11
Vendometrial cancer
p9557
sg13
I2
sasa(dp9558
g2
S'These findings demonstrate the novel mechanism by which Sox3 contributes to endometrial cancer stem cell invasion and suggest that repression of Sox3 by microRNA-194 may have therapeutic potential to suppress endometrial carcinoma metastasis.\n'
p9559
sg4
(lp9560
(dp9561
g7
I56
sg8
VP41225
p9562
sg10
I4
sg11
VSox3
p9563
sg13
I1
sa(dp9564
g7
I56
sg8
VP41225
p9565
sg10
I4
sg11
VSox3
p9566
sg13
I1
sasg23
(lp9567
(dp9568
g7
I100
sg26
VC2699153
p9569
sg10
I13
sg11
Vcell invasion
p9570
sg13
I2
sa(dp9571
g7
I76
sg26
VC0476089
p9572
sg10
I18
sg11
Vendometrial cancer
p9573
sg13
I2
sa(dp9574
g7
I209
sg26
VC0476089
p9575
sg10
I21
sg11
Vendometrial carcinoma
p9576
sg13
I2
sa(dp9577
g7
I231
sg26
VC0027627
p9578
sg10
I10
sg11
Vmetastasis
p9579
sg13
I1
sasa(dp9580
g2
S'The transcription factor sex-determining region Y-box protein 3 (SOX3) plays important roles in various types of cancer.\n'
p9581
sg4
(lp9582
(dp9583
g7
I4
sg8
VP35398
p9584
sg10
I59
sg11
Vtranscription factor sex-determining region Y-box protein 3
p9585
sg13
I7
sa(dp9586
g7
I65
sg8
VP41225
p9587
sg10
I4
sg11
VSOX3
p9588
sg13
I1
sasg23
(lp9589
(dp9590
g7
I113
sg26
VC0006826
p9591
sg10
I6
sg11
Vcancer
p9592
sg13
I1
sasa(dp9593
g2
S'However, the clinical significance of SOX3 in human ovarian cancer remains elusive, and the identity of SOX3 in ovarian cancer initiation, progression, and the related underlying mechanism is unknown.\n'
p9594
sg4
(lp9595
(dp9596
g7
I38
sg8
VP41225
p9597
sg10
I4
sg11
VSOX3
p9598
sg13
I1
sa(dp9599
g7
I38
sg8
VP41225
p9600
sg10
I4
sg11
VSOX3
p9601
sg13
I1
sasg23
(lp9602
(dp9603
g7
I52
sg26
VC1140680
p9604
sg10
I14
sg11
Vovarian cancer
p9605
sg13
I2
sa(dp9606
g7
I52
sg26
VC1140680
p9607
sg10
I14
sg11
Vovarian cancer
p9608
sg13
I2
sasa(dp9609
g2
S'Subsequently, we found that overexpression of SOX3 in EOC cells promoted proliferation, migration, and invasion, while restrained apoptosis and adhesion of ovarian cancer cells.\n'
p9610
sg4
(lp9611
(dp9612
g7
I46
sg8
VP41225
p9613
sg10
I4
sg11
VSOX3
p9614
sg13
I1
sasg23
(lp9615
(dp9616
g7
I144
sg26
VC0001511
p9617
sg10
I8
sg11
Vadhesion
p9618
sg13
I1
sa(dp9619
g7
I156
sg26
VC1140680
p9620
sg10
I14
sg11
Vovarian cancer
p9621
sg13
I2
sa(dp9622
g7
I103
sg26
VC2699153
p9623
sg10
I8
sg11
Vinvasion
p9624
sg13
I1
sa(dp9625
g7
I73
sg26
VC0334094
p9626
sg10
I13
sg11
Vproliferation
p9627
sg13
I1
sasa(dp9628
g2
S'A liver targeting moiety is incorporated in GHDx so as to improve the therapeutic efficiency and decrease adverse effects of conventional cancer therapy.\n'
p9629
sg4
(lp9630
(dp9631
g7
I44
sg8
VP41225
p9632
sg10
I4
sg11
VGHDx
p9633
sg13
I1
sasg23
(lp9634
(dp9635
g7
I106
sg26
VC0879626
p9636
sg10
I15
sg11
Vadverse effects
p9637
sg13
I2
sa(dp9638
g7
I138
sg26
VC0006826
p9639
sg10
I6
sg11
Vcancer
p9640
sg13
I1
sasa(dp9641
g2
S'Since it was previously proposed that increased SOXB2 proteins level interfere with the activity of SOXB1 counteracting partners, we compared expression patterns of SOXB members during retinoic acid induction of embryonal carcinoma cells.\n'
p9642
sg4
(lp9643
(dp9644
g7
I48
sg8
VP02649
p9645
sg10
I14
sg11
VSOXB2 proteins
p9646
sg13
I2
sa(dp9647
g7
I165
sg8
VP41225
p9648
sg10
I12
sg11
VSOXB members
p9649
sg13
I2
sasg23
(lp9650
(dp9651
g7
I212
sg26
VC0206659
p9652
sg10
I19
sg11
Vembryonal carcinoma
p9653
sg13
I2
sasa(dp9654
g2
S'Data presented here provide an insight into SOX14 expression during in vitro neural differentiation of embryonal carcinoma cells and demonstrate the effect of its ectopic expression on protein levels of SOXB members in HeLa cells.\n'
p9655
sg4
(lp9656
(dp9657
g7
I203
sg8
VP41225
p9658
sg10
I12
sg11
VSOXB members
p9659
sg13
I2
sa(dp9660
g7
I44
sg8
g15
sg10
I5
sg11
VSOX14
p9661
sg13
I1
sasg23
(lp9662
(dp9663
g7
I103
sg26
VC0206659
p9664
sg10
I19
sg11
Vembryonal carcinoma
p9665
sg13
I2
sasa(dp9666
g2
S'This is a report of a very rare case of Schwartz Jampel syndrome, with few unusual findings, in a 13 years girl from Nepal, who concurrently also had superotemporal subluxation of the crystalline lens along with blepharophimosis syndrome.\n'
p9667
sg4
(lp9668
sg23
(lp9669
(dp9670
g7
I212
sg26
VC0265237
p9671
sg10
I25
sg11
Vblepharophimosis syndrome
p9672
sg13
I2
sa(dp9673
g7
I40
sg26
VC0036391
p9674
sg10
I24
sg11
VSchwartz Jampel syndrome
p9675
sg13
I3
sasa(dp9676
g2
S'The manifestations of SJS include short stature, blepharophimosis, and skeletal anomalies.\n'
p9677
sg4
(lp9678
sg23
(lp9679
(dp9680
g7
I22
sg26
VC0036391
p9681
sg10
I3
sg11
VSJS
p9682
sg13
I1
sa(dp9683
g7
I49
sg26
VC0005744
p9684
sg10
I16
sg11
Vblepharophimosis
p9685
sg13
I1
sa(dp9686
g7
I34
sg26
VC0013336
p9687
sg10
I13
sg11
Vshort stature
p9688
sg13
I2
sasa(dp9689
g2
S'Schwartz-Jampel syndrome (SJS) is a rare congenital disorder of continuous myotonia, causing visual and eyelid problems such as blepharospasm, acquired ptosis, and blepharophimosis.\n'
p9690
sg4
(lp9691
sg23
(lp9692
(dp9693
g7
I128
sg26
VC0005747
p9694
sg10
I13
sg11
Vblepharospasm
p9695
sg13
I1
sa(dp9696
g7
I41
sg26
VC0242354
p9697
sg10
I19
sg11
Vcongenital disorder
p9698
sg13
I2
sa(dp9699
g7
I0
sg26
VC0036391
p9700
sg10
I24
sg11
VSchwartz-Jampel syndrome
p9701
sg13
I2
sa(dp9702
g7
I26
sg26
VC0036391
p9703
sg10
I3
sg11
VSJS
p9704
sg13
I1
sa(dp9705
g7
I152
sg26
VC0005745
p9706
sg10
I6
sg11
Vptosis
p9707
sg13
I1
sa(dp9708
g7
I164
sg26
VC0005744
p9709
sg10
I16
sg11
Vblepharophimosis
p9710
sg13
I1
sasa(dp9711
g2
S'Schwartz Jampel syndrome is a usually recessive disorder that presents myotonia, skeletal (bone dysplasia) and facial (blepharophimosis) anomalies and low height, which is diagnosed in childhood.\n'
p9712
sg4
(lp9713
sg23
(lp9714
(dp9715
g7
I91
sg26
VC0005941
p9716
sg10
I14
sg11
Vbone dysplasia
p9717
sg13
I2
sa(dp9718
g7
I0
sg26
VC0036391
p9719
sg10
I24
sg11
VSchwartz Jampel syndrome
p9720
sg13
I3
sa(dp9721
g7
I119
sg26
VC0005744
p9722
sg10
I16
sg11
Vblepharophimosis
p9723
sg13
I1
sasa(dp9724
g2
S'Schwartz-Jampel syndrome is a disorder of continuous myotonia causing blepharospasm, acquired ptosis, and blepharophimosis.\n'
p9725
sg4
(lp9726
sg23
(lp9727
(dp9728
g7
I70
sg26
VC0005747
p9729
sg10
I13
sg11
Vblepharospasm
p9730
sg13
I1
sa(dp9731
g7
I0
sg26
VC0036391
p9732
sg10
I24
sg11
VSchwartz-Jampel syndrome
p9733
sg13
I2
sa(dp9734
g7
I94
sg26
VC0005745
p9735
sg10
I6
sg11
Vptosis
p9736
sg13
I1
sa(dp9737
g7
I106
sg26
VC0005744
p9738
sg10
I16
sg11
Vblepharophimosis
p9739
sg13
I1
sasa(dp9740
g2
S'Two patients with Schwartz-Jampel syndrome presented with blepharospasm, acquired ptosis, and blepharophimosis.\n'
p9741
sg4
(lp9742
sg23
(lp9743
(dp9744
g7
I18
sg26
VC0036391
p9745
sg10
I24
sg11
VSchwartz-Jampel syndrome
p9746
sg13
I2
sa(dp9747
g7
I58
sg26
VC0005747
p9748
sg10
I13
sg11
Vblepharospasm
p9749
sg13
I1
sa(dp9750
g7
I82
sg26
VC0005745
p9751
sg10
I6
sg11
Vptosis
p9752
sg13
I1
sa(dp9753
g7
I94
sg26
VC0005744
p9754
sg10
I16
sg11
Vblepharophimosis
p9755
sg13
I1
sasa(dp9756
g2
S'Macrophage polykaryons, but not osteoclasts, expressed CD14 and HLA-DR. CD51+/CD14-/HLA-DR-/CD163- giant cells were noted in all giant-cell lesions of bone, including giant cell tumour of bone, aneurysmal bone cyst, non-ossifying fibroma, chondroblastoma, telangiectatic osteosarcoma, chondromyxoid fibroma, Langerhans cell histiocytosis and brown tumour.\n'
p9757
sg4
(lp9758
(dp9759
g7
I92
sg8
g15
sg10
I5
sg11
VCD163
p9760
sg13
I1
sa(dp9761
g7
I64
sg8
VP30486
p9762
sg10
I6
sg11
VHLA-DR
p9763
sg13
I1
sa(dp9764
g7
I72
sg8
VP06756
p9765
sg10
I5
sg11
VCD51+
p9766
sg13
I1
sa(dp9767
g7
I55
sg8
VP08571
p9768
sg10
I4
sg11
VCD14
p9769
sg13
I1
sa(dp9770
g7
I64
sg8
VP30486
p9771
sg10
I3
sg11
VHLA
p9772
sg13
I1
sa(dp9773
g7
I55
sg8
VP08571
p9774
sg10
I4
sg11
VCD14
p9775
sg13
I1
sasg23
(lp9776
(dp9777
g7
I308
sg26
VC0019621
p9778
sg10
I29
sg11
VLangerhans cell histiocytosis
p9779
sg13
I3
sa(dp9780
g7
I194
sg26
VC0152244
p9781
sg10
I20
sg11
Vaneurysmal bone cyst
p9782
sg13
I3
sa(dp9783
g7
I216
sg26
VC0334067
p9784
sg10
I21
sg11
Vnon-ossifying fibroma
p9785
sg13
I2
sa(dp9786
g7
I239
sg26
VC0008441
p9787
sg10
I15
sg11
Vchondroblastoma
p9788
sg13
I1
sa(dp9789
g7
I256
sg26
VC0259782
p9790
sg10
I27
sg11
Vtelangiectatic osteosarcoma
p9791
sg13
I2
sa(dp9792
g7
I342
sg26
VC0029405
p9793
sg10
I12
sg11
Vbrown tumour
p9794
sg13
I2
sa(dp9795
g7
I285
sg26
VC0221290
p9796
sg10
I21
sg11
Vchondromyxoid fibroma
p9797
sg13
I2
sa(dp9798
g7
I99
sg26
VC0017547
p9799
sg10
I5
sg11
Vgiant
p9800
sg13
I1
sa(dp9801
g7
I99
sg26
VC0017547
p9802
sg10
I5
sg11
Vgiant
p9803
sg13
I1
sa(dp9804
g7
I167
sg26
VC0206638
p9805
sg10
I25
sg11
Vgiant cell tumour of bone
p9806
sg13
I5
sasa(dp9807
g2
S'3.81% of the GBL constituted for neoplastic lesions of which 75% were GBC.\n'
p9808
sg4
(lp9809
sg23
(lp9810
sa(dp9811
g2
S'Moreover, loss of critical ubiquitination residues in GBetaL, by either K305R/K313R mutations or a melanoma-associated GBetaL(DeltaW297) truncation, leads to elevated mTORC2 formation, which facilitates tumorigenesis, in part by activating AKT oncogenic signalling.\n'
p9812
sg4
(lp9813
(dp9814
g7
I99
sg8
g15
sg10
I26
sg11
Vmelanoma-associated GBetaL
p9815
sg13
I2
sa(dp9816
g7
I240
sg8
g15
sg10
I3
sg11
VAKT
p9817
sg13
I1
sasg23
(lp9818
(dp9819
g7
I137
sg26
VC1706395
p9820
sg10
I10
sg11
Vtruncation
p9821
sg13
I1
sa(dp9822
g7
I99
sg26
VC0025202
p9823
sg10
I8
sg11
Vmelanoma
p9824
sg13
I1
sa(dp9825
g7
I203
sg26
VC0007621
p9826
sg10
I13
sg11
Vtumorigenesis
p9827
sg13
I1
sasa(dp9828
g2
S'Other genes found to be differentially expressed at day 35 included v-akt murine thymoma viral oncogene homolog, eukaryotic translation elongation factor 2, eukaryotic translation initiation factor 4E binding protein 1, 3-phosphoinositide dependent protein kinase-1, ribosomal protein S6 kinase, 70 kDa, polypeptide 1 (RPS6KP1), avTOR associated protein, LST8 homolog, ghrelin, phosphoinositide-3-kinase (PI3K), forkhead box O1, and p53 E3 ubiquitin protein ligase homolog (MDM2).\n'
p9829
sg4
(lp9830
(dp9831
g7
I113
sg8
VP13639
p9832
sg10
I42
sg11
Veukaryotic translation elongation factor 2
p9833
sg13
I5
sa(dp9834
g7
I378
sg8
VP33981
p9835
sg10
I25
sg11
Vphosphoinositide-3-kinase
p9836
sg13
I1
sa(dp9837
g7
I440
sg8
VP62979
p9838
sg10
I32
sg11
Vubiquitin protein ligase homolog
p9839
sg13
I4
sa(dp9840
g7
I405
sg8
VP42336
p9841
sg10
I4
sg11
VPI3K
p9842
sg13
I1
sa(dp9843
g7
I267
sg8
VP62753
p9844
sg10
I27
sg11
Vribosomal protein S6 kinase
p9845
sg13
I4
sa(dp9846
g7
I157
sg8
VP06730
p9847
sg10
I108
sg11
Veukaryotic translation initiation factor 4E binding protein 1, 3-phosphoinositide dependent protein kinase-1
p9848
sg13
I12
sa(dp9849
g7
I369
sg8
g15
sg10
I7
sg11
Vghrelin
p9850
sg13
I1
sa(dp9851
g7
I433
sg8
VP42771
p9852
sg10
I6
sg11
Vp53 E3
p9853
sg13
I2
sa(dp9854
g7
I355
sg8
g15
sg10
I12
sg11
VLST8 homolog
p9855
sg13
I2
sa(dp9856
g7
I68
sg8
g15
sg10
I43
sg11
Vv-akt murine thymoma viral oncogene homolog
p9857
sg13
I6
sa(dp9858
g7
I296
sg8
VP23468
p9859
sg10
I21
sg11
V70 kDa, polypeptide 1
p9860
sg13
I4
sasg23
(lp9861
(dp9862
g7
I81
sg26
VC0040100
p9863
sg10
I7
sg11
Vthymoma
p9864
sg13
I1
sasa(dp9865
g2
S'Glioblastoma multiforme (GBL) is the most common and aggressive brain neoplasm.\n'
p9866
sg4
(lp9867
sg23
(lp9868
(dp9869
g7
I0
sg26
VC1621958
p9870
sg10
I23
sg11
VGlioblastoma multiforme
p9871
sg13
I2
sa(dp9872
g7
I64
sg26
VC0006118
p9873
sg10
I14
sg11
Vbrain neoplasm
p9874
sg13
I2
sa(dp9875
g7
I53
sg26
VC0001807
p9876
sg10
I10
sg11
Vaggressive
p9877
sg13
I1
sa(dp9878
g7
I25
sg26
VC1621958
p9879
sg10
I3
sg11
VGBL
p9880
sg13
I1
sasa(dp9881
g2
S'In this study, we found that the expression of mLST8, a required subunit of both mTOR complex 1 (mTORC1) and complex 2 (mTORC2), was upregulated in several human colon and prostate cancer cell lines and tissues.\n'
p9882
sg4
(lp9883
(dp9884
g7
I97
sg8
VP42345
p9885
sg10
I6
sg11
VmTORC1
p9886
sg13
I1
sa(dp9887
g7
I81
sg8
VP42345
p9888
sg10
I14
sg11
VmTOR complex 1
p9889
sg13
I3
sa(dp9890
g7
I47
sg8
g15
sg10
I5
sg11
VmLST8
p9891
sg13
I1
sasg23
(lp9892
(dp9893
g7
I172
sg26
VC0600139
p9894
sg10
I15
sg11
Vprostate cancer
p9895
sg13
I2
sasa(dp9896
g2
S'Knockdown of mLST8 significantly suppressed mTORC1 and mTORC2 complex formation, and it also inhibited tumor growth and invasiveness in human colon carcinoma (HCT116) and prostate cancer (LNCaP) cells.\n'
p9897
sg4
(lp9898
(dp9899
g7
I13
sg8
g15
sg10
I5
sg11
VmLST8
p9900
sg13
I1
sasg23
(lp9901
(dp9902
g7
I142
sg26
VC0699790
p9903
sg10
I15
sg11
Vcolon carcinoma
p9904
sg13
I2
sa(dp9905
g7
I103
sg26
VC0598934
p9906
sg10
I12
sg11
Vtumor growth
p9907
sg13
I2
sa(dp9908
g7
I171
sg26
VC0600139
p9909
sg10
I15
sg11
Vprostate cancer
p9910
sg13
I2
sasa(dp9911
g2
S'mLST8 knockdown reduced mTORC2-mediated phosphorylation of AKT in both cancer and normal cells, whereas it potently inhibited mTORC1-mediated phosphorylation of 4E-BP1 specifically in cancer cells.\n'
p9912
sg4
(lp9913
(dp9914
g7
I59
sg8
g15
sg10
I3
sg11
VAKT
p9915
sg13
I1
sa(dp9916
g7
I0
sg8
g15
sg10
I5
sg11
VmLST8
p9917
sg13
I1
sa(dp9918
g7
I161
sg8
g15
sg10
I6
sg11
V4E-BP1
p9919
sg13
I1
sasg23
(lp9920
(dp9921
g7
I71
sg26
VC0006826
p9922
sg10
I6
sg11
Vcancer
p9923
sg13
I1
sa(dp9924
g7
I71
sg26
VC0006826
p9925
sg10
I6
sg11
Vcancer
p9926
sg13
I1
sasa(dp9927
g2
S'These results suggest that mLST8 plays distinct roles in normal and cancer cells, depending upon its expression level, and that mLST8 upregulation may contribute to tumor progression by constitutively activating both the mTORC1 and mTORC2 pathways.\n'
p9928
sg4
(lp9929
(dp9930
g7
I27
sg8
g15
sg10
I5
sg11
VmLST8
p9931
sg13
I1
sa(dp9932
g7
I27
sg8
g15
sg10
I5
sg11
VmLST8
p9933
sg13
I1
sasg23
(lp9934
(dp9935
g7
I165
sg26
VC0178874
p9936
sg10
I17
sg11
Vtumor progression
p9937
sg13
I2
sa(dp9938
g7
I68
sg26
VC0006826
p9939
sg10
I6
sg11
Vcancer
p9940
sg13
I1
sasa(dp9941
g2
S'The DeltaatfA and DeltaatfB were shown to be avirulent and to have attenuated virulence, respectively, in both Galleria mellonella and a neutropenic murine model of invasive pulmonary aspergillosis.\n'
p9942
sg4
(lp9943
sg23
(lp9944
(dp9945
g7
I165
sg26
VC0276653
p9946
sg10
I32
sg11
Vinvasive pulmonary aspergillosis
p9947
sg13
I3
sasa(dp9948
g2
S'We observed genetic variation in RPS6KA1, RPS6KA2, and PRS6KB2 were associated with risk of developing colon cancer while only genetic variation in RPS6KA2 was associated with altering risk of rectal cancer.\n'
p9949
sg4
(lp9950
(dp9951
g7
I33
sg8
g15
sg10
I7
sg11
VRPS6KA1
p9952
sg13
I1
sa(dp9953
g7
I42
sg8
g15
sg10
I7
sg11
VRPS6KA2
p9954
sg13
I1
sa(dp9955
g7
I42
sg8
g15
sg10
I7
sg11
VRPS6KA2
p9956
sg13
I1
sasg23
(lp9957
(dp9958
g7
I193
sg26
VC0007113
p9959
sg10
I13
sg11
Vrectal cancer
p9960
sg13
I2
sa(dp9961
g7
I103
sg26
VC0699790
p9962
sg10
I12
sg11
Vcolon cancer
p9963
sg13
I2
sasa(dp9964
g2
S'These findings suggest that NO-cGMP-PKG signaling in the NTS can modify the acquisition of conditioned hypoglycemia, and suggests that this nucleus directly participates in this reflex.\n'
p9965
sg4
(lp9966
(dp9967
g7
I28
sg8
g15
sg10
I11
sg11
VNO-cGMP-PKG
p9968
sg13
I1
sasg23
(lp9969
(dp9970
g7
I103
sg26
VC0020615
p9971
sg10
I12
sg11
Vhypoglycemia
p9972
sg13
I1
sasa(dp9973
g2
S'Finally, genetic instability is investigated in CD34+ cells of a patient with acute myeloid leukemia by immunofluorescence microscopy of GammaH2AX and 53BP1.\n'
p9974
sg4
(lp9975
(dp9976
g7
I48
sg8
VP28906
p9977
sg10
I5
sg11
VCD34+
p9978
sg13
I1
sasg23
(lp9979
(dp9980
g7
I78
sg26
VC0023467
p9981
sg10
I22
sg11
Vacute myeloid leukemia
p9982
sg13
I3
sasa(dp9983
g2
S'The aims of this study were to determine whether BCCIP deficiency contributes to mammary tumorigenesis, especially for a subset of breast cancers with 53BP1 abnormality, and to reveal the mechanistic implications of BCCIP in breast cancer interventions.\n'
p9984
sg4
(lp9985
sg23
(lp9986
(dp9987
g7
I131
sg26
VC0006142
p9988
sg10
I13
sg11
Vbreast cancer
p9989
sg13
I2
sa(dp9990
g7
I131
sg26
VC0006142
p9991
sg10
I14
sg11
Vbreast cancers
p9992
sg13
I2
sa(dp9993
g7
I81
sg26
VC1512981
p9994
sg10
I21
sg11
Vmammary tumorigenesis
p9995
sg13
I2
sasa(dp9996
g2
S'We analyzed the BCCIP protein level in 470 cases of human breast cancer to determine the associations between BCCIP and 53BP1, p53, and subtypes of breast cancer.\n'
p9997
sg4
(lp9998
(dp9999
g7
I127
sg8
VP42771
p10000
sg10
I3
sg11
Vp53
p10001
sg13
I1
sa(dp10002
g7
I16
sg8
g15
sg10
I5
sg11
VBCCIP
p10003
sg13
I1
sa(dp10004
g7
I16
sg8
g15
sg10
I13
sg11
VBCCIP protein
p10005
sg13
I2
sasg23
(lp10006
(dp10007
g7
I58
sg26
VC0678222
p10008
sg10
I13
sg11
Vbreast cancer
p10009
sg13
I2
sa(dp10010
g7
I58
sg26
VC0678222
p10011
sg10
I13
sg11
Vbreast cancer
p10012
sg13
I2
sasa(dp10013
g2
S'The downregulation of BCCIP is mutually exclusive with p53 mutations but concurrent with 53BP1 loss in triple-negative breast cancer.\n'
p10014
sg4
(lp10015
(dp10016
g7
I22
sg8
g15
sg10
I5
sg11
VBCCIP
p10017
sg13
I1
sa(dp10018
g7
I55
sg8
VP42771
p10019
sg10
I13
sg11
Vp53 mutations
p10020
sg13
I2
sasg23
(lp10021
(dp10022
g7
I119
sg26
VC0678222
p10023
sg10
I13
sg11
Vbreast cancer
p10024
sg13
I2
sasa(dp10025
g2
S'Using secondary assays for detection of senescence biomarkers p21, 53BP1 and senescence associated beta-galactosidase (SABetaGal) in a panel of HCT116 cell lines carrying cancer-relevant mutations, we show that partial senescence phenotypes can be induced to varying degrees in a context dependent manner, even in the absence of p21 or p53 expression.\n'
p10026
sg4
(lp10027
(dp10028
g7
I62
sg8
VP42857
p10029
sg10
I3
sg11
Vp21
p10030
sg13
I1
sa(dp10031
g7
I62
sg8
VP42857
p10032
sg10
I3
sg11
Vp21
p10033
sg13
I1
sa(dp10034
g7
I336
sg8
VP42771
p10035
sg10
I3
sg11
Vp53
p10036
sg13
I1
sa(dp10037
g7
I67
sg8
VP16278
p10038
sg10
I50
sg11
V53BP1 and senescence associated beta-galactosidase
p10039
sg13
I5
sasg23
(lp10040
(dp10041
g7
I171
sg26
VC0006826
p10042
sg10
I6
sg11
Vcancer
p10043
sg13
I1
sasa(dp10044
g2
S'Our data exhibit that cancer-related genes ANK3, HACD4, TP53BP1, MFN1, LCMT2, RNMT, TRMT6, METTL8 and METTL16 harbor mutational ITH as well as the frameshift mutations in CRC with MSI-H. Also, the results suggest that frameshift mutations of these genes might play a role in tumorigenesis through their inactivation in CRC.\n'
p10045
sg4
(lp10046
(dp10047
g7
I91
sg8
g15
sg10
I6
sg11
VMETTL8
p10048
sg13
I1
sa(dp10049
g7
I43
sg8
g15
sg10
I4
sg11
VANK3
p10050
sg13
I1
sa(dp10051
g7
I71
sg8
g15
sg10
I5
sg11
VLCMT2
p10052
sg13
I1
sa(dp10053
g7
I84
sg8
g15
sg10
I5
sg11
VTRMT6
p10054
sg13
I1
sa(dp10055
g7
I56
sg8
g15
sg10
I7
sg11
VTP53BP1
p10056
sg13
I1
sa(dp10057
g7
I65
sg8
g15
sg10
I4
sg11
VMFN1
p10058
sg13
I1
sa(dp10059
g7
I171
sg8
VP31749
p10060
sg10
I3
sg11
VCRC
p10061
sg13
I1
sa(dp10062
g7
I78
sg8
g15
sg10
I4
sg11
VRNMT
p10063
sg13
I1
sa(dp10064
g7
I171
sg8
VP31749
p10065
sg10
I3
sg11
VCRC
p10066
sg13
I1
sasg23
(lp10067
(dp10068
g7
I180
sg26
VC0920269
p10069
sg10
I3
sg11
VMSI
p10070
sg13
I1
sa(dp10071
g7
I22
sg26
VC0006826
p10072
sg10
I6
sg11
Vcancer
p10073
sg13
I1
sa(dp10074
g7
I275
sg26
VC0007621
p10075
sg10
I13
sg11
Vtumorigenesis
p10076
sg13
I1
sa(dp10077
g7
I147
sg26
VC0079380
p10078
sg10
I20
sg11
Vframeshift mutations
p10079
sg13
I2
sa(dp10080
g7
I147
sg26
VC0079380
p10081
sg10
I20
sg11
Vframeshift mutations
p10082
sg13
I2
sa(dp10083
g7
I303
sg26
VC0544461
p10084
sg10
I12
sg11
Vinactivation
p10085
sg13
I1
sa(dp10086
g7
I171
sg26
VC1527249
p10087
sg10
I3
sg11
VCRC
p10088
sg13
I1
sa(dp10089
g7
I171
sg26
VC1527249
p10090
sg10
I3
sg11
VCRC
p10091
sg13
I1
sasa(dp10092
g2
S'This study was designed to compare the performance of eight patients (five males, three females, mean age +/- SD: 63.7+/-7.9 years) at early stage of unilateral thalamic lesions and eleven healthy controls (six males, five females, 49.6+/-12.2 years) in neurocognitive tests (CogState Battery: Groton Maze Learning Test, GML; Groton Maze Learning Test-Delayed Recall, GML-DR; Detection Task, DT; Identification Task, IT; One Card Learning Task, OCLT; One Back Task, OBT; Two Back Task, TBT; Set-Shifting Task, S-ST) and other well-known tests (Benton Visual Retention Test, BVRT; California Verbal Learning Test, CVLT; The Rey-Osterrieth Complex Figure Test, ROCF; Trail Making Test, TMT part A and B; Color - Word Stroop Task, CWST; Verbal Fluency Test, VFT), and social cognitive tasks (The Penn Emotion Recognition Test, ER40; Penn Emotion Discrimination Task, EmoDiff40; The Penn Emotional Acuity Test, PEAT40; Reading the Mind in the Eyes Test, revised version II; Toronto Alexithymia Scale, TAS-20).\n'
p10093
sg4
(lp10094
(dp10095
g7
I386
sg8
g15
sg10
I4
sg11
VTask
p10096
sg13
I1
sasg23
(lp10097
(dp10098
g7
I978
sg26
VC0002020
p10099
sg10
I11
sg11
VAlexithymia
p10100
sg13
I1
sa(dp10101
g7
I997
sg26
VC0559483
p10102
sg10
I3
sg11
VTAS
p10103
sg13
I1
sasa(dp10104
g2
S'RT-PCR (reverse transcription-PCR) analysis of spinal cord samples showed that both sst4 (somatostatin receptor 4) and sst2 receptor mRNA, but not myOR (my-opiate receptor) and NK1 (neurokinin-1) receptor mRNA, were down-regulated following BFP treatment, thus implicating somatostatin involvement in BFP-induced analgesia.\n'
p10105
sg4
(lp10106
(dp10107
g7
I90
sg8
VP61278
p10108
sg10
I23
sg11
Vsomatostatin receptor 4
p10109
sg13
I3
sa(dp10110
g7
I147
sg8
g15
sg10
I4
sg11
VmyOR
p10111
sg13
I1
sa(dp10112
g7
I241
sg8
g15
sg10
I3
sg11
VBFP
p10113
sg13
I1
sa(dp10114
g7
I119
sg8
VP30874
p10115
sg10
I18
sg11
Vsst2 receptor mRNA
p10116
sg13
I3
sa(dp10117
g7
I182
sg8
g15
sg10
I12
sg11
Vneurokinin-1
p10118
sg13
I1
sa(dp10119
g7
I90
sg8
VP61278
p10120
sg10
I12
sg11
Vsomatostatin
p10121
sg13
I1
sa(dp10122
g7
I153
sg8
g15
sg10
I18
sg11
Vmy-opiate receptor
p10123
sg13
I2
sa(dp10124
g7
I177
sg8
g15
sg10
I3
sg11
VNK1
p10125
sg13
I1
sasg23
(lp10126
(dp10127
g7
I313
sg26
VC0344307
p10128
sg10
I9
sg11
Vanalgesia
p10129
sg13
I1
sa(dp10130
g7
I54
sg26
VC0035334
p10131
sg10
I4
sg11
Vcord
p10132
sg13
I1
sasa(dp10133
g2
S'In addition, we identified the SSTR1 receptor as a novel pharmacologic target for somatostatin-mediated peripheral analgesia in inflammatory pain.\n'
p10134
sg4
(lp10135
(dp10136
g7
I31
sg8
VP30872
p10137
sg10
I14
sg11
VSSTR1 receptor
p10138
sg13
I2
sa(dp10139
g7
I82
sg8
VP61278
p10140
sg10
I12
sg11
Vsomatostatin
p10141
sg13
I1
sasg23
(lp10142
(dp10143
g7
I115
sg26
VC0344307
p10144
sg10
I9
sg11
Vanalgesia
p10145
sg13
I1
sa(dp10146
g7
I128
sg26
VC0234251
p10147
sg10
I17
sg11
Vinflammatory pain
p10148
sg13
I2
sasa(dp10149
g2
S'Overweight participants lost 1.1 kg less (p &lt; 0.01) than participants with class-I obesity and 1.5 kg less (p &lt; 0.01) than participants with class-II obesity.\n'
p10150
sg4
(lp10151
sg23
(lp10152
(dp10153
g7
I86
sg26
VC0028754
p10154
sg10
I7
sg11
Vobesity
p10155
sg13
I1
sa(dp10156
g7
I86
sg26
VC0028754
p10157
sg10
I7
sg11
Vobesity
p10158
sg13
I1
sa(dp10159
g7
I0
sg26
VC0497406
p10160
sg10
I10
sg11
VOverweight
p10161
sg13
I1
sasa(dp10162
g2
S'The present study investigated the relationship between the expression of miR-146a and miR-146b with the occurrence and prognosis of papillary thyroid carcinoma.\n'
p10163
sg4
(lp10164
(dp10165
g7
I87
sg8
g15
sg10
I8
sg11
VmiR-146b
p10166
sg13
I1
sa(dp10167
g7
I74
sg8
g15
sg10
I8
sg11
VmiR-146a
p10168
sg13
I1
sasg23
(lp10169
(dp10170
g7
I133
sg26
VC0238463
p10171
sg10
I27
sg11
Vpapillary thyroid carcinoma
p10172
sg13
I3
sasa(dp10173
g2
S'Carcinoma samples were obtained from each patient, and adjacent tissues were used as control samples to determine expression levels of miR-146a and miR146b by semi-quantitative RT-PCR.\n'
p10174
sg4
(lp10175
(dp10176
g7
I135
sg8
g15
sg10
I8
sg11
VmiR-146a
p10177
sg13
I1
sasg23
(lp10178
(dp10179
g7
I0
sg26
VC0007097
p10180
sg10
I9
sg11
VCarcinoma
p10181
sg13
I1
sasa(dp10182
g2
S'Our results showed that the expression levels of miR-146a and miR-146b in carcinoma tissues were significantly higher than the levels in cancer-free tissues (p&lt;0.01).\n'
p10183
sg4
(lp10184
(dp10185
g7
I49
sg8
g15
sg10
I8
sg11
VmiR-146a
p10186
sg13
I1
sa(dp10187
g7
I62
sg8
g15
sg10
I8
sg11
VmiR-146b
p10188
sg13
I1
sasg23
(lp10189
(dp10190
g7
I137
sg26
VC0006826
p10191
sg10
I6
sg11
Vcancer
p10192
sg13
I1
sa(dp10193
g7
I74
sg26
VC0007097
p10194
sg10
I9
sg11
Vcarcinoma
p10195
sg13
I1
sasa(dp10196
g2
S'Based on our findings, the expression of miR-146a and miR-146b correlates with the occurrence and prognosis of papillary thyroid carcinoma, and the expression levels of miR-146a and miR-146b seem to affect the cell proliferation and migration and regulate the expression of IRAK1 protein in cancer cells.\n'
p10197
sg4
(lp10198
(dp10199
g7
I54
sg8
g15
sg10
I8
sg11
VmiR-146b
p10200
sg13
I1
sa(dp10201
g7
I54
sg8
g15
sg10
I8
sg11
VmiR-146b
p10202
sg13
I1
sa(dp10203
g7
I274
sg8
VP51617
p10204
sg10
I13
sg11
VIRAK1 protein
p10205
sg13
I2
sa(dp10206
g7
I41
sg8
g15
sg10
I8
sg11
VmiR-146a
p10207
sg13
I1
sa(dp10208
g7
I41
sg8
g15
sg10
I8
sg11
VmiR-146a
p10209
sg13
I1
sasg23
(lp10210
(dp10211
g7
I291
sg26
VC0006826
p10212
sg10
I6
sg11
Vcancer
p10213
sg13
I1
sa(dp10214
g7
I111
sg26
VC0238463
p10215
sg10
I27
sg11
Vpapillary thyroid carcinoma
p10216
sg13
I3
sa(dp10217
g7
I215
sg26
VC0334094
p10218
sg10
I13
sg11
Vproliferation
p10219
sg13
I1
sasa(dp10220
g2
S'In this study, we evaluated the possible interaction between miR-146a and one of its putative targets ribonuclease L (RNASEL) in the risk of sporadic melanoma.\n'
p10221
sg4
(lp10222
(dp10223
g7
I94
sg8
g15
sg10
I22
sg11
Vtargets ribonuclease L
p10224
sg13
I3
sa(dp10225
g7
I118
sg8
g15
sg10
I6
sg11
VRNASEL
p10226
sg13
I1
sa(dp10227
g7
I61
sg8
g15
sg10
I8
sg11
VmiR-146a
p10228
sg13
I1
sasg23
(lp10229
(dp10230
g7
I150
sg26
VC0025202
p10231
sg10
I8
sg11
Vmelanoma
p10232
sg13
I1
sasa(dp10233
g2
S'Polymorphisms rs2910164 in miR-146a and rs486907 in the RNASEL gene have both independently been associated with the risk of different cancers, and an interaction between them has been observed in nonmelanoma skin cancer.\n'
p10234
sg4
(lp10235
(dp10236
g7
I56
sg8
g15
sg10
I11
sg11
VRNASEL gene
p10237
sg13
I2
sasg23
(lp10238
(dp10239
g7
I197
sg26
VC0699893
p10240
sg10
I23
sg11
Vnonmelanoma skin cancer
p10241
sg13
I3
sa(dp10242
g7
I135
sg26
VC0006826
p10243
sg10
I7
sg11
Vcancers
p10244
sg13
I1
sasa(dp10245
g2
S'The results reported in the present study suggest a sex-specific interaction between miR-146a and RNASEL genes in melanoma skin cancer susceptibility, and could account for possible discordant results in association studies when stratification according to sex is not performed.\n'
p10246
sg4
(lp10247
(dp10248
g7
I85
sg8
g15
sg10
I8
sg11
VmiR-146a
p10249
sg13
I1
sa(dp10250
g7
I114
sg8
g15
sg10
I35
sg11
Vmelanoma skin cancer susceptibility
p10251
sg13
I4
sasg23
(lp10252
(dp10253
g7
I114
sg26
VC0151779
p10254
sg10
I20
sg11
Vmelanoma skin cancer
p10255
sg13
I3
sasa(dp10256
g2
S'In the stratified analyses by sex, the associations between miR-499 rs3746444 and miR-146a rs2910164 polymorphisms with the susceptibility of oral squamous cell cancer were significant in males.\n'
p10257
sg4
(lp10258
(dp10259
g7
I82
sg8
g15
sg10
I8
sg11
VmiR-146a
p10260
sg13
I1
sa(dp10261
g7
I60
sg8
g15
sg10
I17
sg11
VmiR-499 rs3746444
p10262
sg13
I2
sasg23
(lp10263
(dp10264
g7
I147
sg26
VC0007137
p10265
sg10
I20
sg11
Vsquamous cell cancer
p10266
sg13
I3
sasa(dp10267
g2
S'These findings suggest that miR-499 rs3746444 and miR-146a rs2910164 polymorphisms may contribute to genetic susceptibility to oral squamous cell cancer.\n'
p10268
sg4
(lp10269
(dp10270
g7
I28
sg8
g15
sg10
I17
sg11
VmiR-499 rs3746444
p10271
sg13
I2
sa(dp10272
g7
I50
sg8
g15
sg10
I8
sg11
VmiR-146a
p10273
sg13
I1
sasg23
(lp10274
(dp10275
g7
I132
sg26
VC0007137
p10276
sg10
I20
sg11
Vsquamous cell cancer
p10277
sg13
I3
sasa(dp10278
g2
S'In the present study, we find that the expression of miR-146a was decreased in hepatocellular carcinoma (HCC) tissues compared with corresponding adjacent tissues, and the expression level in HCC cell lines was lower than in a normal liver cell.\n'
p10279
sg4
(lp10280
(dp10281
g7
I53
sg8
g15
sg10
I8
sg11
VmiR-146a
p10282
sg13
I1
sasg23
(lp10283
(dp10284
g7
I105
sg26
VC2239176
p10285
sg10
I3
sg11
VHCC
p10286
sg13
I1
sa(dp10287
g7
I105
sg26
VC2239176
p10288
sg10
I3
sg11
VHCC
p10289
sg13
I1
sa(dp10290
g7
I79
sg26
VC2239176
p10291
sg10
I24
sg11
Vhepatocellular carcinoma
p10292
sg13
I2
sasa(dp10293
g2
S'We also discovered that miR-146a may represent a novel potential candidate of the HCC carcinoma diagnostic marker in the long term.\n'
p10294
sg4
(lp10295
(dp10296
g7
I24
sg8
g15
sg10
I8
sg11
VmiR-146a
p10297
sg13
I1
sasg23
(lp10298
(dp10299
g7
I86
sg26
VC0007097
p10300
sg10
I9
sg11
Vcarcinoma
p10301
sg13
I1
sa(dp10302
g7
I82
sg26
VC2239176
p10303
sg10
I3
sg11
VHCC
p10304
sg13
I1
sasa(dp10305
g2
S'Our previous study found that dysregulated microRNA-146a-5p (miR-146a-5p) is involved in oesophageal squamous cell cancer (ESCC) proliferation.\n'
p10306
sg4
(lp10307
(dp10308
g7
I43
sg8
g15
sg10
I16
sg11
VmicroRNA-146a-5p
p10309
sg13
I1
sa(dp10310
g7
I61
sg8
g15
sg10
I11
sg11
VmiR-146a-5p
p10311
sg13
I1
sasg23
(lp10312
(dp10313
g7
I129
sg26
VC0334094
p10314
sg10
I13
sg11
Vproliferation
p10315
sg13
I1
sa(dp10316
g7
I101
sg26
VC0007137
p10317
sg10
I20
sg11
Vsquamous cell cancer
p10318
sg13
I3
sasa(dp10319
g2
S'Analysis of miR-146a expression in a series of 59 penile squamous cell carcinomas (PSCCs) showed that its levels were lower in high-risk HPV-positive than in HPV-negative PSCCs and inversely correlated with expression of epidermal growth factor receptor (EGFR), a known target for miR-146a.\n'
p10320
sg4
(lp10321
(dp10322
g7
I221
sg8
VP01133
p10323
sg10
I32
sg11
Vepidermal growth factor receptor
p10324
sg13
I4
sa(dp10325
g7
I12
sg8
g15
sg10
I8
sg11
VmiR-146a
p10326
sg13
I1
sa(dp10327
g7
I12
sg8
g15
sg10
I8
sg11
VmiR-146a
p10328
sg13
I1
sa(dp10329
g7
I255
sg8
VP01133
p10330
sg10
I4
sg11
VEGFR
p10331
sg13
I1
sasg23
(lp10332
(dp10333
g7
I57
sg26
VC0007137
p10334
sg10
I24
sg11
Vsquamous cell carcinomas
p10335
sg13
I3
sasa(dp10336
g2
S'Ectopic expression of miR-146a decreased expression of EGFR and inhibited proliferation of keratinocytes and cervical carcinoma cells.\n'
p10337
sg4
(lp10338
(dp10339
g7
I22
sg8
g15
sg10
I8
sg11
VmiR-146a
p10340
sg13
I1
sasg23
(lp10341
(dp10342
g7
I74
sg26
VC0334094
p10343
sg10
I13
sg11
Vproliferation
p10344
sg13
I1
sa(dp10345
g7
I109
sg26
VC0302592
p10346
sg10
I18
sg11
Vcervical carcinoma
p10347
sg13
I2
sasa(dp10348
g2
S'Using a melanoma progression model, miR-146a was identified as a key double-acting player in melanoma malignancy.\n'
p10349
sg4
(lp10350
(dp10351
g7
I36
sg8
g15
sg10
I8
sg11
VmiR-146a
p10352
sg13
I1
sasg23
(lp10353
(dp10354
g7
I102
sg26
VC0006826
p10355
sg10
I10
sg11
Vmalignancy
p10356
sg13
I1
sa(dp10357
g7
I8
sg26
VC0025202
p10358
sg10
I8
sg11
Vmelanoma
p10359
sg13
I1
sa(dp10360
g7
I8
sg26
VC0025202
p10361
sg10
I8
sg11
Vmelanoma
p10362
sg13
I1
sasa(dp10363
g2
S'It was determined that miR-146a coordinated melanoma cell growth by its direct targets lunatic fringe (LFNG) and NUMB, which operate on the NOTCH/PTEN/Akt pathway; while inhibition of metastasis formation was linked to decreased expression of ITGAV and ROCK1.\n'
p10364
sg4
(lp10365
(dp10366
g7
I23
sg8
g15
sg10
I8
sg11
VmiR-146a
p10367
sg13
I1
sa(dp10368
g7
I146
sg8
VP60484
p10369
sg10
I4
sg11
VPTEN
p10370
sg13
I1
sa(dp10371
g7
I243
sg8
VP06756
p10372
sg10
I5
sg11
VITGAV
p10373
sg13
I1
sa(dp10374
g7
I151
sg8
g15
sg10
I3
sg11
VAkt
p10375
sg13
I1
sa(dp10376
g7
I253
sg8
g15
sg10
I5
sg11
VROCK1
p10377
sg13
I1
sasg23
(lp10378
(dp10379
g7
I184
sg26
VC0027627
p10380
sg10
I10
sg11
Vmetastasis
p10381
sg13
I1
sa(dp10382
g7
I44
sg26
VC0025202
p10383
sg10
I8
sg11
Vmelanoma
p10384
sg13
I1
sasa(dp10385
g2
S'Relevantly, miR-146a expression correlated with melanoma recurrence and was enriched in both patient-derived melanoma and cutaneous metastasis specimens, while its direct targets were depleted.\n'
p10386
sg4
(lp10387
(dp10388
g7
I12
sg8
g15
sg10
I8
sg11
VmiR-146a
p10389
sg13
I1
sasg23
(lp10390
(dp10391
g7
I122
sg26
VC0153687
p10392
sg10
I20
sg11
Vcutaneous metastasis
p10393
sg13
I2
sa(dp10394
g7
I57
sg26
VC1458156
p10395
sg10
I10
sg11
Vrecurrence
p10396
sg13
I1
sa(dp10397
g7
I48
sg26
VC0025202
p10398
sg10
I8
sg11
Vmelanoma
p10399
sg13
I1
sa(dp10400
g7
I48
sg26
VC0025202
p10401
sg10
I8
sg11
Vmelanoma
p10402
sg13
I1
sasa(dp10403
g2
S'This study reconciles the contradictory biologic functions of miR-146a in melanoma progression and unravels distinct molecular mechanisms that need to be considered for therapeutic interventions.\n'
p10404
sg4
(lp10405
(dp10406
g7
I62
sg8
g15
sg10
I8
sg11
VmiR-146a
p10407
sg13
I1
sasg23
(lp10408
(dp10409
g7
I74
sg26
VC0025202
p10410
sg10
I8
sg11
Vmelanoma
p10411
sg13
I1
sasa(dp10412
g2
S'miR-146a controls melanoma progression in a dual way, promoting growth and inhibiting dissemination; however, it is poorly expressed in CTCs, resulting in overall tumor spreading and distant-site colonization.\n'
p10413
sg4
(lp10414
(dp10415
g7
I0
sg8
g15
sg10
I8
sg11
VmiR-146a
p10416
sg13
I1
sasg23
(lp10417
(dp10418
g7
I18
sg26
VC0025202
p10419
sg10
I8
sg11
Vmelanoma
p10420
sg13
I1
sa(dp10421
g7
I163
sg26
VC0027651
p10422
sg10
I5
sg11
Vtumor
p10423
sg13
I1
sasa(dp10424
g2
S'E2F3 is a transcription factor that has been shown to be overexpressed in hepatocellular carcinoma (HCC).\n'
p10425
sg4
(lp10426
(dp10427
g7
I0
sg8
g15
sg10
I4
sg11
VE2F3
p10428
sg13
I1
sasg23
(lp10429
(dp10430
g7
I100
sg26
VC2239176
p10431
sg10
I3
sg11
VHCC
p10432
sg13
I1
sa(dp10433
g7
I74
sg26
VC2239176
p10434
sg10
I24
sg11
Vhepatocellular carcinoma
p10435
sg13
I2
sasa(dp10436
g2
S'These results suggest that E2F3b functions as an important promoter for cell proliferation and plays important roles in transcriptional regulation in HepG2 liver cancer cells.\n'
p10437
sg4
(lp10438
sg23
(lp10439
(dp10440
g7
I77
sg26
VC0334094
p10441
sg10
I13
sg11
Vproliferation
p10442
sg13
I1
sa(dp10443
g7
I156
sg26
VC0345904
p10444
sg10
I12
sg11
Vliver cancer
p10445
sg13
I2
sasa(dp10446
g2
S'Expression of a panel of seven microRNAs (hsa-miR-34a, hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, hsa-miR-326, and hsa-miR-375) and seven target genes ( E2F3, PI3KCA, TOM34, WNT5A, PDCD4, DFFA, and EGFR) in 43 glioblastoma multiforme specimens were profiled compared to non-cancer tissues via quantitative reverse transcription-polymerase chain reaction.\n'
p10447
sg4
(lp10448
(dp10449
g7
I67
sg8
g15
sg10
I10
sg11
Vhsa-miR-17
p10450
sg13
I1
sa(dp10451
g7
I42
sg8
g15
sg10
I3
sg11
Vhsa
p10452
sg13
I1
sa(dp10453
g7
I194
sg8
g15
sg10
I14
sg11
VDFFA, and EGFR
p10454
sg13
I3
sa(dp10455
g7
I46
sg8
g15
sg10
I3
sg11
VmiR
p10456
sg13
I1
sa(dp10457
g7
I91
sg8
g15
sg10
I11
sg11
Vhsa-miR-221
p10458
sg13
I1
sa(dp10459
g7
I187
sg8
g15
sg10
I5
sg11
VPDCD4
p10460
sg13
I1
sa(dp10461
g7
I180
sg8
VP41221
p10462
sg10
I5
sg11
VWNT5A
p10463
sg13
I1
sa(dp10464
g7
I55
sg8
g15
sg10
I10
sg11
Vhsa-miR-16
p10465
sg13
I1
sa(dp10466
g7
I42
sg8
g15
sg10
I3
sg11
Vhsa
p10467
sg13
I1
sa(dp10468
g7
I104
sg8
g15
sg10
I11
sg11
Vhsa-miR-326
p10469
sg13
I1
sa(dp10470
g7
I42
sg8
g15
sg10
I3
sg11
Vhsa
p10471
sg13
I1
sa(dp10472
g7
I173
sg8
g15
sg10
I5
sg11
VTOM34
p10473
sg13
I1
sa(dp10474
g7
I159
sg8
g15
sg10
I4
sg11
VE2F3
p10475
sg13
I1
sasg23
(lp10476
(dp10477
g7
I42
sg26
VC0393754
p10478
sg10
I3
sg11
Vhsa
p10479
sg13
I1
sa(dp10480
g7
I280
sg26
VC0006826
p10481
sg10
I6
sg11
Vcancer
p10482
sg13
I1
sa(dp10483
g7
I42
sg26
VC0393754
p10484
sg10
I3
sg11
Vhsa
p10485
sg13
I1
sa(dp10486
g7
I216
sg26
VC1621958
p10487
sg10
I23
sg11
Vglioblastoma multiforme
p10488
sg13
I2
sa(dp10489
g7
I42
sg26
VC0393754
p10490
sg10
I3
sg11
Vhsa
p10491
sg13
I1
sa(dp10492
g7
I42
sg26
VC0393754
p10493
sg10
I3
sg11
Vhsa
p10494
sg13
I1
sa(dp10495
g7
I42
sg26
VC0393754
p10496
sg10
I3
sg11
Vhsa
p10497
sg13
I1
sa(dp10498
g7
I42
sg26
VC0393754
p10499
sg10
I3
sg11
Vhsa
p10500
sg13
I1
sa(dp10501
g7
I42
sg26
VC0393754
p10502
sg10
I3
sg11
Vhsa
p10503
sg13
I1
sasa(dp10504
g2
S'Our data demonstrated a significant upregulation of five microRNAs (hsa-miR-16, hsa-miR-17, hsa-miR-21, hsa-miR-221, and hsa-miR-375), three genes ( E2F3, PI3KCA, and Wnt5a), two proteins (VEGFA and BCL2), and downregulation of hsa-miR-34a and three other genes ( DFFA, PDCD4, and EGFR) in brain cancer tissues.\n'
p10505
sg4
(lp10506
(dp10507
g7
I68
sg8
g15
sg10
I10
sg11
Vhsa-miR-16
p10508
sg13
I1
sa(dp10509
g7
I149
sg8
g15
sg10
I4
sg11
VE2F3
p10510
sg13
I1
sa(dp10511
g7
I199
sg8
VP10415
p10512
sg10
I4
sg11
VBCL2
p10513
sg13
I1
sa(dp10514
g7
I228
sg8
g15
sg10
I11
sg11
Vhsa-miR-34a
p10515
sg13
I1
sa(dp10516
g7
I80
sg8
g15
sg10
I10
sg11
Vhsa-miR-17
p10517
sg13
I1
sa(dp10518
g7
I68
sg8
g15
sg10
I3
sg11
Vhsa
p10519
sg13
I1
sa(dp10520
g7
I264
sg8
g15
sg10
I4
sg11
VDFFA
p10521
sg13
I1
sa(dp10522
g7
I167
sg8
VP41221
p10523
sg10
I5
sg11
VWnt5a
p10524
sg13
I1
sa(dp10525
g7
I270
sg8
g15
sg10
I5
sg11
VPDCD4
p10526
sg13
I1
sasg23
(lp10527
(dp10528
g7
I68
sg26
VC0393754
p10529
sg10
I3
sg11
Vhsa
p10530
sg13
I1
sa(dp10531
g7
I290
sg26
VC0153633
p10532
sg10
I12
sg11
Vbrain cancer
p10533
sg13
I2
sa(dp10534
g7
I68
sg26
VC0393754
p10535
sg10
I3
sg11
Vhsa
p10536
sg13
I1
sa(dp10537
g7
I68
sg26
VC0393754
p10538
sg10
I3
sg11
Vhsa
p10539
sg13
I1
sa(dp10540
g7
I68
sg26
VC0393754
p10541
sg10
I3
sg11
Vhsa
p10542
sg13
I1
sa(dp10543
g7
I68
sg26
VC0393754
p10544
sg10
I3
sg11
Vhsa
p10545
sg13
I1
sa(dp10546
g7
I68
sg26
VC0393754
p10547
sg10
I3
sg11
Vhsa
p10548
sg13
I1
sasa(dp10549
g2
S'E2F3, as an oncogene, may promote NSCLC progression.\n'
p10550
sg4
(lp10551
(dp10552
g7
I0
sg8
g15
sg10
I4
sg11
VE2F3
p10553
sg13
I1
sasg23
(lp10554
(dp10555
g7
I34
sg26
VC0007131
p10556
sg10
I5
sg11
VNSCLC
p10557
sg13
I1
sasa(dp10558
g2
S'These results suggested that NEAT1 may promote the development of NSCLC through the miR-377-3p-E2F3 pathway.\n'
p10559
sg4
(lp10560
(dp10561
g7
I84
sg8
g15
sg10
I10
sg11
VmiR-377-3p
p10562
sg13
I1
sa(dp10563
g7
I95
sg8
g15
sg10
I4
sg11
VE2F3
p10564
sg13
I1
sasg23
(lp10565
(dp10566
g7
I66
sg26
VC0007131
p10567
sg10
I5
sg11
VNSCLC
p10568
sg13
I1
sasa(dp10569
g2
S'Alterations in E2F3 functions correspond with poor prognosis in various cancers, underscoring their status for the clinical cancer phenotype.\n'
p10570
sg4
(lp10571
(dp10572
g7
I15
sg8
g15
sg10
I4
sg11
VE2F3
p10573
sg13
I1
sasg23
(lp10574
(dp10575
g7
I72
sg26
VC0006826
p10576
sg10
I7
sg11
Vcancers
p10577
sg13
I1
sa(dp10578
g7
I72
sg26
VC0006826
p10579
sg10
I6
sg11
Vcancer
p10580
sg13
I1
sasa(dp10581
g2
S'Current understanding of the reciprocal link between E2F3 and miRNAs in human cancers were summarized, which could help to develop potential therapeutic strategies.\n'
p10582
sg4
(lp10583
(dp10584
g7
I53
sg8
g15
sg10
I15
sg11
VE2F3 and miRNAs
p10585
sg13
I3
sasg23
(lp10586
(dp10587
g7
I78
sg26
VC0006826
p10588
sg10
I7
sg11
Vcancers
p10589
sg13
I1
sasa(dp10590
g2
S'The E2F3 transcriptional regulatory pathway plays a major part in multiple-cancer progression, but the specific contributions of this pathway to tumor formation and the progression of clear cell renal cell carcinoma (ccRCC) are not fully understood.\n'
p10591
sg4
(lp10592
(dp10593
g7
I4
sg8
g15
sg10
I4
sg11
VE2F3
p10594
sg13
I1
sasg23
(lp10595
(dp10596
g7
I145
sg26
VC0027651
p10597
sg10
I5
sg11
Vtumor
p10598
sg13
I1
sa(dp10599
g7
I75
sg26
VC0178874
p10600
sg10
I18
sg11
Vcancer progression
p10601
sg13
I2
sa(dp10602
g7
I184
sg26
VC0279702
p10603
sg10
I31
sg11
Vclear cell renal cell carcinoma
p10604
sg13
I5
sa(dp10605
g7
I217
sg26
VC0279702
p10606
sg10
I5
sg11
VccRCC
p10607
sg13
I1
sasa(dp10608
g2
S'We evaluated the dehiscence and fenestration presence in maxillary and mandibular anterior teeth of patients affected by bilateral cleft lip and palate (BCLP) and compared the findings with a well-matched control group of noncleft patients using cone-beam computed tomography.\n'
p10609
sg4
(lp10610
sg23
(lp10611
(dp10612
g7
I32
sg26
VC0015826
p10613
sg10
I12
sg11
Vfenestration
p10614
sg13
I1
sa(dp10615
g7
I121
sg26
VC0392005
p10616
sg10
I19
sg11
Vbilateral cleft lip
p10617
sg13
I3
sa(dp10618
g7
I131
sg26
VC0158646
p10619
sg10
I20
sg11
Vcleft lip and palate
p10620
sg13
I4
sasa(dp10621
g2
S'Sample included 15 non-cleft (NC), 15 unilateral cleft lip and palate (UCLP) and 15 bilateral cleft lip and palate (BCLP) cases whose age were between 15 to 17.\n'
p10622
sg4
(lp10623
sg23
(lp10624
(dp10625
g7
I38
sg26
VC0392006
p10626
sg10
I20
sg11
Vunilateral cleft lip
p10627
sg13
I3
sa(dp10628
g7
I84
sg26
VC0392005
p10629
sg10
I19
sg11
Vbilateral cleft lip
p10630
sg13
I3
sa(dp10631
g7
I49
sg26
VC0158646
p10632
sg10
I20
sg11
Vcleft lip and palate
p10633
sg13
I4
sa(dp10634
g7
I49
sg26
VC0158646
p10635
sg10
I20
sg11
Vcleft lip and palate
p10636
sg13
I4
sasa(dp10637
g2
S'The aim of this study was to evaluate the facial profile esthetics of rehabilitated children with complete bilateral cleft lip and palate (BCLP), comparing the judgment of professionals related and not related to cleft rehabilitation and laypersons.\n'
p10638
sg4
(lp10639
sg23
(lp10640
(dp10641
g7
I117
sg26
VC0158646
p10642
sg10
I20
sg11
Vcleft lip and palate
p10643
sg13
I4
sa(dp10644
g7
I98
sg26
VC0158653
p10645
sg10
I28
sg11
Vcomplete bilateral cleft lip
p10646
sg13
I4
sasa(dp10647
g2
S'To evaluate the maxillary alveolar repositioning of the infants with bilateral cleft lip and palate (BCLP) undergoing computer-aided nasoalveolar molding (CAD-NAM).\n'
p10648
sg4
(lp10649
(dp10650
g7
I118
sg8
g15
sg10
I35
sg11
Vcomputer-aided nasoalveolar molding
p10651
sg13
I3
sa(dp10652
g7
I155
sg8
g15
sg10
I7
sg11
VCAD-NAM
p10653
sg13
I1
sasg23
(lp10654
(dp10655
g7
I69
sg26
VC0392005
p10656
sg10
I19
sg11
Vbilateral cleft lip
p10657
sg13
I3
sa(dp10658
g7
I79
sg26
VC0158646
p10659
sg10
I20
sg11
Vcleft lip and palate
p10660
sg13
I4
sa(dp10661
g7
I155
sg26
VC0010054
p10662
sg10
I3
sg11
VCAD
p10663
sg13
I1
sasa(dp10664
g2
S'Clefts were classified as right/left unilateral cleft lip and palate (UCLP), bilateral cleft lip and palate (BCLP) and cleft palate (CP).\n'
p10665
sg4
(lp10666
sg23
(lp10667
(dp10668
g7
I48
sg26
VC0158646
p10669
sg10
I20
sg11
Vcleft lip and palate
p10670
sg13
I4
sa(dp10671
g7
I77
sg26
VC0392005
p10672
sg10
I19
sg11
Vbilateral cleft lip
p10673
sg13
I3
sa(dp10674
g7
I119
sg26
VC0008925
p10675
sg10
I12
sg11
Vcleft palate
p10676
sg13
I2
sa(dp10677
g7
I133
sg26
VC0008925
p10678
sg10
I2
sg11
VCP
p10679
sg13
I1
sa(dp10680
g7
I37
sg26
VC0392006
p10681
sg10
I20
sg11
Vunilateral cleft lip
p10682
sg13
I3
sa(dp10683
g7
I48
sg26
VC0158646
p10684
sg10
I20
sg11
Vcleft lip and palate
p10685
sg13
I4
sasa(dp10686
g2
S"Four FEMs of unilateral cleft lip and palate (UCLP) or bilateral cleft lip and palate (BCLP) patients' cranio-maxillary complex with MA and TA were established.\n"
p10687
sg4
(lp10688
sg23
(lp10689
(dp10690
g7
I55
sg26
VC0392005
p10691
sg10
I19
sg11
Vbilateral cleft lip
p10692
sg13
I3
sa(dp10693
g7
I13
sg26
VC0392006
p10694
sg10
I20
sg11
Vunilateral cleft lip
p10695
sg13
I3
sa(dp10696
g7
I24
sg26
VC0158646
p10697
sg10
I20
sg11
Vcleft lip and palate
p10698
sg13
I4
sa(dp10699
g7
I24
sg26
VC0158646
p10700
sg10
I20
sg11
Vcleft lip and palate
p10701
sg13
I4
sasa(dp10702
g2
S'Blepharocheilodontic (BCD) syndrome is a rare condition characterized by bilateral cleft lip and palate (BCLP), eyelid abnormalities, and oligodontia.\n'
p10703
sg4
(lp10704
sg23
(lp10705
(dp10706
g7
I83
sg26
VC0158646
p10707
sg10
I20
sg11
Vcleft lip and palate
p10708
sg13
I4
sa(dp10709
g7
I46
sg26
VC0012634
p10710
sg10
I9
sg11
Vcondition
p10711
sg13
I1
sa(dp10712
g7
I0
sg26
VC1859486
p10713
sg10
I20
sg11
VBlepharocheilodontic
p10714
sg13
I1
sa(dp10715
g7
I27
sg26
VC0039082
p10716
sg10
I8
sg11
Vsyndrome
p10717
sg13
I1
sa(dp10718
g7
I73
sg26
VC0392005
p10719
sg10
I19
sg11
Vbilateral cleft lip
p10720
sg13
I3
sa(dp10721
g7
I22
sg26
VC1859486
p10722
sg10
I3
sg11
VBCD
p10723
sg13
I1
sa(dp10724
g7
I138
sg26
VC0020608
p10725
sg10
I11
sg11
Voligodontia
p10726
sg13
I1
sasa(dp10727
g2
S'To test the hypotheses that there are differences between orthodontists, individuals with cleft lip and palate (CLP) and laypersons in the visual perception of faces with unilateral (UCLP) and bilateral cleft lip and palate (BCLP), the faces with UCLP and BCLP are visually perceived differently and the hierarchy of visual attention changes when viewing individuals with CLP.\n'
p10728
sg4
(lp10729
sg23
(lp10730
(dp10731
g7
I112
sg26
VC0158646
p10732
sg10
I3
sg11
VCLP
p10733
sg13
I1
sa(dp10734
g7
I112
sg26
VC0158646
p10735
sg10
I3
sg11
VCLP
p10736
sg13
I1
sa(dp10737
g7
I193
sg26
VC0392005
p10738
sg10
I19
sg11
Vbilateral cleft lip
p10739
sg13
I3
sa(dp10740
g7
I90
sg26
VC0158646
p10741
sg10
I20
sg11
Vcleft lip and palate
p10742
sg13
I4
sa(dp10743
g7
I225
sg26
VC0158646
p10744
sg10
I4
sg11
VBCLP
p10745
sg13
I1
sa(dp10746
g7
I225
sg26
VC0158646
p10747
sg10
I4
sg11
VBCLP
p10748
sg13
I1
sa(dp10749
g7
I90
sg26
VC0158646
p10750
sg10
I20
sg11
Vcleft lip and palate
p10751
sg13
I4
sasa(dp10752
g2
S'The purpose of this "two-arm parallel" trial was to compare the orthopedic, dental, and alveolar bone plate changes of slow (SME) and rapid (RME) maxillary expansions in patients with complete bilateral cleft lip and palate (BCLP).\n'
p10753
sg4
(lp10754
sg23
(lp10755
(dp10756
g7
I184
sg26
VC0158653
p10757
sg10
I28
sg11
Vcomplete bilateral cleft lip
p10758
sg13
I4
sa(dp10759
g7
I203
sg26
VC0158646
p10760
sg10
I20
sg11
Vcleft lip and palate
p10761
sg13
I4
sasa(dp10762
g2
S"These included known adverse events: gastrointestinal discomfort, breast tenderness, reduced libido, dry skin (flutamide and finasteride); irregular bleeding (spironolactone); nausea, diarrhoea, bloating (metformin); hot flushes, decreased libido, vaginal dryness, headaches (gonadotropin-releasing hormone (GnRH) analogues)).Clinician's evaluation of hirsutism and change in androgen levels were addressed in most comparisons, change in body mass index (BMI) and improvement of other clinical signs of hyperandrogenism in one-third of studies.The quality of evidence was moderate to very low for most outcomes.There was low quality evidence for the effect of two oral contraceptive pills (OCPs) (ethinyl estradiol + cyproterone acetate versus ethinyl estradiol + desogestrel) on change from baseline of Ferriman-Gallwey scores.\n"
p10763
sg4
(lp10764
(dp10765
g7
I276
sg8
VP01148
p10766
sg10
I30
sg11
Vgonadotropin-releasing hormone
p10767
sg13
I2
sa(dp10768
g7
I308
sg8
VP01148
p10769
sg10
I4
sg11
VGnRH
p10770
sg13
I1
sasg23
(lp10771
(dp10772
g7
I85
sg26
VC0011124
p10773
sg10
I14
sg11
Vreduced libido
p10774
sg13
I2
sa(dp10775
g7
I37
sg26
VC1096250
p10776
sg10
I27
sg11
Vgastrointestinal discomfort
p10777
sg13
I2
sa(dp10778
g7
I265
sg26
VC0018681
p10779
sg10
I9
sg11
Vheadaches
p10780
sg13
I1
sa(dp10781
g7
I66
sg26
VC0262397
p10782
sg10
I17
sg11
Vbreast tenderness
p10783
sg13
I2
sa(dp10784
g7
I503
sg26
VC0206081
p10785
sg10
I16
sg11
Vhyperandrogenism
p10786
sg13
I1
sa(dp10787
g7
I139
sg26
VC0745411
p10788
sg10
I18
sg11
Virregular bleeding
p10789
sg13
I2
sa(dp10790
g7
I101
sg26
VC0151908
p10791
sg10
I8
sg11
Vdry skin
p10792
sg13
I2
sa(dp10793
g7
I195
sg26
VC1291077
p10794
sg10
I8
sg11
Vbloating
p10795
sg13
I1
sa(dp10796
g7
I230
sg26
VC0011124
p10797
sg10
I16
sg11
Vdecreased libido
p10798
sg13
I2
sa(dp10799
g7
I184
sg26
VC0011991
p10800
sg10
I9
sg11
Vdiarrhoea
p10801
sg13
I1
sa(dp10802
g7
I176
sg26
VC0027497
p10803
sg10
I6
sg11
Vnausea
p10804
sg13
I1
sa(dp10805
g7
I217
sg26
VC0600142
p10806
sg10
I11
sg11
Vhot flushes
p10807
sg13
I2
sasa(dp10808
g2
S'Plasma and sera from 3 patients suffering from either enteric dysmotility, irritable bowel syndrome (IBS) or gastroparesis were analysed for C-reactive protein (CRP), and for GnRH antibodies and soluble CD40 by ELISA methods.\n'
p10809
sg4
(lp10810
(dp10811
g7
I161
sg8
VP02741
p10812
sg10
I3
sg11
VCRP
p10813
sg13
I1
sa(dp10814
g7
I203
sg8
VP25942
p10815
sg10
I4
sg11
VCD40
p10816
sg13
I1
sa(dp10817
g7
I175
sg8
VP01148
p10818
sg10
I15
sg11
VGnRH antibodies
p10819
sg13
I2
sa(dp10820
g7
I141
sg8
VP02741
p10821
sg10
I18
sg11
VC-reactive protein
p10822
sg13
I2
sasg23
(lp10823
(dp10824
g7
I32
sg26
VC0683278
p10825
sg10
I9
sg11
Vsuffering
p10826
sg13
I1
sa(dp10827
g7
I101
sg26
VC0022104
p10828
sg10
I3
sg11
VIBS
p10829
sg13
I1
sa(dp10830
g7
I109
sg26
VC0152020
p10831
sg10
I13
sg11
Vgastroparesis
p10832
sg13
I1
sa(dp10833
g7
I62
sg26
VC0679316
p10834
sg10
I11
sg11
Vdysmotility
p10835
sg13
I1
sa(dp10836
g7
I75
sg26
VC0022104
p10837
sg10
I24
sg11
Virritable bowel syndrome
p10838
sg13
I3
sasa(dp10839
g2
S'We found statistically significant differences (P &lt; 0.01) between the healthy volunteers and patients with severe periodontitis in the following genes; gonadotropin-releasing hormone 1 (GNRH1), phosphatidylinositol 3-kinase regulatory 1 (PIK3R1), dipeptidylpeptidase 4 (DPP4), fibrinogen-like 2 (FGL2), and calcitonin receptor (CALCR).\n'
p10840
sg4
(lp10841
(dp10842
g7
I189
sg8
VP01148
p10843
sg10
I5
sg11
VGNRH1
p10844
sg13
I1
sa(dp10845
g7
I241
sg8
VP27986
p10846
sg10
I6
sg11
VPIK3R1
p10847
sg13
I1
sa(dp10848
g7
I197
sg8
VP42336
p10849
sg10
I42
sg11
Vphosphatidylinositol 3-kinase regulatory 1
p10850
sg13
I4
sa(dp10851
g7
I310
sg8
VP30988
p10852
sg10
I19
sg11
Vcalcitonin receptor
p10853
sg13
I2
sa(dp10854
g7
I299
sg8
g15
sg10
I4
sg11
VFGL2
p10855
sg13
I1
sa(dp10856
g7
I331
sg8
VP30988
p10857
sg10
I5
sg11
VCALCR
p10858
sg13
I1
sa(dp10859
g7
I273
sg8
VP27487
p10860
sg10
I4
sg11
VDPP4
p10861
sg13
I1
sa(dp10862
g7
I250
sg8
VP27487
p10863
sg10
I21
sg11
Vdipeptidylpeptidase 4
p10864
sg13
I2
sa(dp10865
g7
I155
sg8
VP01148
p10866
sg10
I32
sg11
Vgonadotropin-releasing hormone 1
p10867
sg13
I3
sa(dp10868
g7
I280
sg8
g15
sg10
I17
sg11
Vfibrinogen-like 2
p10869
sg13
I2
sasg23
(lp10870
(dp10871
g7
I117
sg26
VC0031099
p10872
sg10
I13
sg11
Vperiodontitis
p10873
sg13
I1
sasa(dp10874
g2
S'These results suggest that SNPs in the GNRH1, PIK3R1, DPP4, FGL2, and CALCR genes are genomic markers for severe periodontitis.\n'
p10875
sg4
(lp10876
(dp10877
g7
I54
sg8
VP27487
p10878
sg10
I4
sg11
VDPP4
p10879
sg13
I1
sa(dp10880
g7
I70
sg8
VP30988
p10881
sg10
I11
sg11
VCALCR genes
p10882
sg13
I2
sa(dp10883
g7
I60
sg8
g15
sg10
I4
sg11
VFGL2
p10884
sg13
I1
sa(dp10885
g7
I39
sg8
VP01148
p10886
sg10
I5
sg11
VGNRH1
p10887
sg13
I1
sa(dp10888
g7
I46
sg8
VP27986
p10889
sg10
I6
sg11
VPIK3R1
p10890
sg13
I1
sasg23
(lp10891
(dp10892
g7
I113
sg26
VC0031099
p10893
sg10
I13
sg11
Vperiodontitis
p10894
sg13
I1
sasa(dp10895
g2
S'Pharmacological inhibition of different signaling pathways and genetic knockdown of Notch-2 further revealed JNK as an upstream effector of Notch-2 in TGF-Beta1-mediated renal fibrosis.\n'
p10896
sg4
(lp10897
(dp10898
g7
I109
sg8
VP53779
p10899
sg10
I3
sg11
VJNK
p10900
sg13
I1
sa(dp10901
g7
I151
sg8
VP01137
p10902
sg10
I9
sg11
VTGF-Beta1
p10903
sg13
I1
sa(dp10904
g7
I84
sg8
g15
sg10
I7
sg11
VNotch-2
p10905
sg13
I1
sa(dp10906
g7
I84
sg8
g15
sg10
I7
sg11
VNotch-2
p10907
sg13
I1
sasg23
(lp10908
(dp10909
g7
I170
sg26
VC0151650
p10910
sg10
I14
sg11
Vrenal fibrosis
p10911
sg13
I2
sasa(dp10912
g2
S'Consistently, we also demonstrated that administration of TSA or a Gamma-secretase inhibitor RO4929097 in the mouse model of unilateral ureteral obstruction significantly ameliorated renal fibrosis through suppression of the JNK/Notch-2 signaling activation.\n'
p10913
sg4
(lp10914
(dp10915
g7
I229
sg8
g15
sg10
I7
sg11
VNotch-2
p10916
sg13
I1
sa(dp10917
g7
I225
sg8
VP53779
p10918
sg10
I3
sg11
VJNK
p10919
sg13
I1
sasg23
(lp10920
(dp10921
g7
I136
sg26
VC0041956
p10922
sg10
I20
sg11
Vureteral obstruction
p10923
sg13
I2
sa(dp10924
g7
I183
sg26
VC0151650
p10925
sg10
I14
sg11
Vrenal fibrosis
p10926
sg13
I2
sa(dp10927
g7
I206
sg26
VC0221103
p10928
sg10
I11
sg11
Vsuppression
p10929
sg13
I1
sasa(dp10930
g2
S'Although, renal abnormalities are considered an integral part of the HJCYS, published reports on ESRD are scarce.\n'
p10931
sg4
(lp10932
sg23
(lp10933
(dp10934
g7
I69
sg26
VC0917715
p10935
sg10
I5
sg11
VHJCYS
p10936
sg13
I1
sa(dp10937
g7
I97
sg26
VC0022661
p10938
sg10
I4
sg11
VESRD
p10939
sg13
I1
sasa(dp10940
g2
S'Here we show that Notch2 prevents podocyte loss and nephrosis.\n'
p10941
sg4
(lp10942
(dp10943
g7
I18
sg8
g15
sg10
I6
sg11
VNotch2
p10944
sg13
I1
sasg23
(lp10945
(dp10946
g7
I52
sg26
VC0027720
p10947
sg10
I9
sg11
Vnephrosis
p10948
sg13
I1
sasa(dp10949
g2
S'Administration of a Notch2 agonistic monoclonal antibody ameliorates proteinuria and glomerulosclerosis in a mouse model of nephrosis and focal segmental glomerulosclerosis.\n'
p10950
sg4
(lp10951
(dp10952
g7
I20
sg8
g15
sg10
I6
sg11
VNotch2
p10953
sg13
I1
sasg23
(lp10954
(dp10955
g7
I138
sg26
VC0017668
p10956
sg10
I34
sg11
Vfocal segmental glomerulosclerosis
p10957
sg13
I3
sa(dp10958
g7
I85
sg26
VC0178664
p10959
sg10
I18
sg11
Vglomerulosclerosis
p10960
sg13
I1
sa(dp10961
g7
I124
sg26
VC0027720
p10962
sg10
I9
sg11
Vnephrosis
p10963
sg13
I1
sasa(dp10964
g2
S'Hence, specific activation of Notch2 rescues damaged podocytes and activating Notch2 may represent a novel clinical strategy for the amelioration of nephrosis and glomerulosclerosis.\n'
p10965
sg4
(lp10966
(dp10967
g7
I30
sg8
g15
sg10
I6
sg11
VNotch2
p10968
sg13
I1
sa(dp10969
g7
I30
sg8
g15
sg10
I6
sg11
VNotch2
p10970
sg13
I1
sasg23
(lp10971
(dp10972
g7
I149
sg26
VC0027720
p10973
sg10
I9
sg11
Vnephrosis
p10974
sg13
I1
sa(dp10975
g7
I163
sg26
VC0178664
p10976
sg10
I18
sg11
Vglomerulosclerosis
p10977
sg13
I1
sasa(dp10978
g2
S'To investigate the effect of both fermented Cordyceps powder (CS) and prednisone on the Notch2/hes-1 signaling activation in the kidney tubules of rats with acute aristolochic acid nephropathy (AAAN).\n'
p10979
sg4
(lp10980
(dp10981
g7
I95
sg8
g15
sg10
I5
sg11
Vhes-1
p10982
sg13
I1
sa(dp10983
g7
I88
sg8
g15
sg10
I6
sg11
VNotch2
p10984
sg13
I1
sasg23
(lp10985
(dp10986
g7
I95
sg26
VC0206141
p10987
sg10
I3
sg11
Vhes
p10988
sg13
I1
sa(dp10989
g7
I181
sg26
VC0022658
p10990
sg10
I11
sg11
Vnephropathy
p10991
sg13
I1
sasa(dp10992
g2
S'The role of NOTCH2 and JAG1 in formation of proximal nephron structures and podocytes might explain the observed phenotypes of renal dysplasia and proteinuria in patients with Alagille syndrome, and renal tubular acidosis may be the result of JAG1 expression in the collecting ducts.\n'
p10993
sg4
(lp10994
(dp10995
g7
I12
sg8
g15
sg10
I6
sg11
VNOTCH2
p10996
sg13
I1
sa(dp10997
g7
I23
sg8
VP78504
p10998
sg10
I4
sg11
VJAG1
p10999
sg13
I1
sa(dp11000
g7
I23
sg8
VP78504
p11001
sg10
I4
sg11
VJAG1
p11002
sg13
I1
sasg23
(lp11003
(dp11004
g7
I127
sg26
VC0266313
p11005
sg10
I15
sg11
Vrenal dysplasia
p11006
sg13
I2
sa(dp11007
g7
I199
sg26
VC0001126
p11008
sg10
I22
sg11
Vrenal tubular acidosis
p11009
sg13
I3
sa(dp11010
g7
I176
sg26
VC0085280
p11011
sg10
I17
sg11
VAlagille syndrome
p11012
sg13
I2
sasa(dp11013
g2
S'We compared 25-hydroxyvitamin D and parathyroid hormone (PTH) levels between four groups of non-lactating women who gave birth within 12 months before the beginning of the study: hypothyroid women with post-partum thyroiditis (group A; n = 14), euthyroid females with post-partum thyroiditis (group B; n = 14), women with non-autoimmune hypothyroidism (group C; n = 16) and healthy euthyroid females without thyroid autoimmunity (group D; n = 15).\n'
p11014
sg4
(lp11015
(dp11016
g7
I36
sg8
VP01270
p11017
sg10
I19
sg11
Vparathyroid hormone
p11018
sg13
I2
sa(dp11019
g7
I57
sg8
VP01270
p11020
sg10
I3
sg11
VPTH
p11021
sg13
I1
sasg23
(lp11022
(dp11023
g7
I202
sg26
VC0271815
p11024
sg10
I23
sg11
Vpost-partum thyroiditis
p11025
sg13
I2
sa(dp11026
g7
I326
sg26
VC0342158
p11027
sg10
I25
sg11
Vautoimmune hypothyroidism
p11028
sg13
I2
sa(dp11029
g7
I293
sg26
VC0348801
p11030
sg10
I7
sg11
Vgroup B
p11031
sg13
I2
sa(dp11032
g7
I179
sg26
VC0020676
p11033
sg10
I11
sg11
Vhypothyroid
p11034
sg13
I1
sa(dp11035
g7
I416
sg26
VC0004368
p11036
sg10
I12
sg11
Vautoimmunity
p11037
sg13
I1
sa(dp11038
g7
I202
sg26
VC0271815
p11039
sg10
I23
sg11
Vpost-partum thyroiditis
p11040
sg13
I2
sasa(dp11041
g2
S'Serum levels of 25-hydroxyvitamin D were lower, while PTH higher in patients with post-partum thyroiditis than in patients without thyroid autoimmunity.\n'
p11042
sg4
(lp11043
(dp11044
g7
I54
sg8
VP01270
p11045
sg10
I3
sg11
VPTH
p11046
sg13
I1
sasg23
(lp11047
(dp11048
g7
I82
sg26
VC0271815
p11049
sg10
I23
sg11
Vpost-partum thyroiditis
p11050
sg13
I2
sa(dp11051
g7
I139
sg26
VC0004368
p11052
sg10
I12
sg11
Vautoimmunity
p11053
sg13
I1
sasa(dp11054
g2
S'They were also lower (25-hydroxyvitamin D) or higher (PTH) in group A than in group B, as well as in group C in comparison with group D. L-thyroxine treatment increased 25-hydroxyvitamin D and reduced PTH levels only in hypothyroid women with post-partum thyroiditis.\n'
p11055
sg4
(lp11056
(dp11057
g7
I54
sg8
VP01270
p11058
sg10
I3
sg11
VPTH
p11059
sg13
I1
sa(dp11060
g7
I54
sg8
VP01270
p11061
sg10
I3
sg11
VPTH
p11062
sg13
I1
sasg23
(lp11063
(dp11064
g7
I243
sg26
VC0271815
p11065
sg10
I23
sg11
Vpost-partum thyroiditis
p11066
sg13
I2
sa(dp11067
g7
I78
sg26
VC0348801
p11068
sg10
I7
sg11
Vgroup B
p11069
sg13
I2
sa(dp11070
g7
I220
sg26
VC0020676
p11071
sg10
I11
sg11
Vhypothyroid
p11072
sg13
I1
sasa(dp11073
g2
S'In comparing PTH deficient patients (group 1) with patients in group 2, there were no differences in age, gender, thyroid pathology, the incidence of thyroiditis, or other factors that would predict hypoparathyroidism.\n'
p11074
sg4
(lp11075
sg23
(lp11076
(dp11077
g7
I150
sg26
VC0040147
p11078
sg10
I11
sg11
Vthyroiditis
p11079
sg13
I1
sa(dp11080
g7
I199
sg26
VC0020626
p11081
sg10
I18
sg11
Vhypoparathyroidism
p11082
sg13
I1
sa(dp11083
g7
I122
sg26
VC0677042
p11084
sg10
I9
sg11
Vpathology
p11085
sg13
I1
sasa(dp11086
g2
S"This study was performed to investigate the levels of platelet activation marker SCUBE-1 and sCD40L which plays some role in the progression of atherosclerosis, in patients with hypothyroidism due to Hashimoto's thyroiditis.\n"
p11087
sg4
(lp11088
sg23
(lp11089
(dp11090
g7
I144
sg26
VC0004153
p11091
sg10
I15
sg11
Vatherosclerosis
p11092
sg13
I1
sa(dp11093
g7
I178
sg26
VC0342159
p11094
sg10
I45
sg11
Vhypothyroidism due to Hashimoto's thyroiditis
p11095
sg13
I5
sasa(dp11096
g2
S"Hypothyroidism due to Hashimoto's thyroiditis in comparison to the control group that includes healthy volunteers; SCUBE-1 and sCD40L, were increased.\n"
p11097
sg4
(lp11098
sg23
(lp11099
(dp11100
g7
I0
sg26
VC0342159
p11101
sg10
I45
sg11
VHypothyroidism due to Hashimoto's thyroiditis
p11102
sg13
I5
sasa(dp11103
g2
S"SCUBE-1 and sCD40L levels were increased in Hashimoto's hypothyroidism patients.\n"
p11104
sg4
(lp11105
sg23
(lp11106
(dp11107
g7
I56
sg26
VC0020676
p11108
sg10
I14
sg11
Vhypothyroidism
p11109
sg13
I1
sasa(dp11110
g2
S'There has been no study evaluating SCUBE1 levels in patients with overt hyperthyroidism (OHyper) and subclinical hyperthyroidism (SHyper), conditions which are known to show impairment of both endothelial and platelet function.\n'
p11111
sg4
(lp11112
sg23
(lp11113
(dp11114
g7
I101
sg26
VC1998045
p11115
sg10
I27
sg11
Vsubclinical hyperthyroidism
p11116
sg13
I2
sa(dp11117
g7
I174
sg26
VC0684336
p11118
sg10
I10
sg11
Vimpairment
p11119
sg13
I1
sa(dp11120
g7
I72
sg26
VC0020550
p11121
sg10
I15
sg11
Vhyperthyroidism
p11122
sg13
I1
sa(dp11123
g7
I130
sg26
VC1998045
p11124
sg10
I6
sg11
VSHyper
p11125
sg13
I1
sasa(dp11126
g2
S'SCUBE1 may be used as a reliable marker of endothelial damage in hyperthyroidism, especially in the subclinical period.\n'
p11127
sg4
(lp11128
(dp11129
g7
I0
sg8
g15
sg10
I6
sg11
VSCUBE1
p11130
sg13
I1
sasg23
(lp11131
(dp11132
g7
I65
sg26
VC0020550
p11133
sg10
I15
sg11
Vhyperthyroidism
p11134
sg13
I1
sasa(dp11135
g2
S'We report a new case for consanguineous parents with homozygous novel mutation in GLIS3 gene who presented with neonatal diabetes mellitus, severe resistant congenital hypothyroidism, cholestatic liver disease, bilateral congenital glaucoma and facial dysmorphism.\n'
p11136
sg4
(lp11137
(dp11138
g7
I82
sg8
g15
sg10
I10
sg11
VGLIS3 gene
p11139
sg13
I2
sasg23
(lp11140
(dp11141
g7
I245
sg26
VC0266617
p11142
sg10
I18
sg11
Vfacial dysmorphism
p11143
sg13
I2
sa(dp11144
g7
I112
sg26
VC0158981
p11145
sg10
I26
sg11
Vneonatal diabetes mellitus
p11146
sg13
I3
sa(dp11147
g7
I64
sg26
VC2985438
p11148
sg10
I14
sg11
Vnovel mutation
p11149
sg13
I2
sa(dp11150
g7
I184
sg26
VC0860204
p11151
sg10
I25
sg11
Vcholestatic liver disease
p11152
sg13
I3
sa(dp11153
g7
I157
sg26
VC0342200
p11154
sg10
I25
sg11
Vcongenital hypothyroidism
p11155
sg13
I2
sa(dp11156
g7
I221
sg26
VC0020302
p11157
sg10
I19
sg11
Vcongenital glaucoma
p11158
sg13
I2
sasa(dp11159
g2
S'A total of 4687 patients without preexisting diabetes (age 2-20 years, 2004-2010) surviving with a functioning transplant for longer than 1 year with at least one follow-up report were identified from the OPTN/UNOS database as of September 2014.\n'
p11160
sg4
(lp11161
sg23
(lp11162
(dp11163
g7
I45
sg26
VC0011849
p11164
sg10
I8
sg11
Vdiabetes
p11165
sg13
I1
sasa(dp11166
g2
S'Microcephaly with simplified gyration, epilepsy and permanent neonatal diabetes syndrome (MEDS) is a recently described, autosomal recessive-inherited syndrome.\n'
p11167
sg4
(lp11168
sg23
(lp11169
(dp11170
g7
I80
sg26
VC0039082
p11171
sg10
I8
sg11
Vsyndrome
p11172
sg13
I1
sa(dp11173
g7
I80
sg26
VC0039082
p11174
sg10
I8
sg11
Vsyndrome
p11175
sg13
I1
sa(dp11176
g7
I90
sg26
VC3280240
p11177
sg10
I4
sg11
VMEDS
p11178
sg13
I1
sa(dp11179
g7
I62
sg26
VC0158981
p11180
sg10
I17
sg11
Vneonatal diabetes
p11181
sg13
I2
sa(dp11182
g7
I39
sg26
VC0014544
p11183
sg10
I8
sg11
Vepilepsy
p11184
sg13
I1
sa(dp11185
g7
I0
sg26
VC0025958
p11186
sg10
I12
sg11
VMicrocephaly
p11187
sg13
I1
sasa(dp11188
g2
S"Motor improvement was evaluated using Unified Parkinson's Disease Rating Scale (UPDRS) III scores in stim ON/meds OFF in comparison with preoperative scores.\n"
p11189
sg4
(lp11190
sg23
(lp11191
(dp11192
g7
I109
sg26
VC3280240
p11193
sg10
I4
sg11
Vmeds
p11194
sg13
I1
sa(dp11195
g7
I46
sg26
VC0030567
p11196
sg10
I19
sg11
VParkinson's Disease
p11197
sg13
I2
sasa(dp11198
g2
S'Minimally efficacious doses (MEDs) in epilepsy were compared to doses in the POP trials that produced 50-100% response (ED50-100).\n'
p11199
sg4
(lp11200
sg23
(lp11201
(dp11202
g7
I38
sg26
VC0014544
p11203
sg10
I8
sg11
Vepilepsy
p11204
sg13
I1
sa(dp11205
g7
I0
sg26
VC3280240
p11206
sg10
I27
sg11
VMinimally efficacious doses
p11207
sg13
I3
sa(dp11208
g7
I29
sg26
VC3280240
p11209
sg10
I4
sg11
VMEDs
p11210
sg13
I1
sasa(dp11211
g2
S'A syndrome of permanent neonatal diabetes along with primary microcephaly with simplified gyral pattern associated with severe infantile epileptic encephalopathy was recently described in two independent reports in which disease-causing homozygous mutations were identified in the immediate early response-3 interacting protein-1 (IER3IP1) gene.\n'
p11212
sg4
(lp11213
(dp11214
g7
I331
sg8
g15
sg10
I7
sg11
VIER3IP1
p11215
sg13
I1
sa(dp11216
g7
I281
sg8
g15
sg10
I48
sg11
Vimmediate early response-3 interacting protein-1
p11217
sg13
I5
sasg23
(lp11218
(dp11219
g7
I2
sg26
VC0039082
p11220
sg10
I8
sg11
Vsyndrome
p11221
sg13
I1
sa(dp11222
g7
I137
sg26
VC0543888
p11223
sg10
I24
sg11
Vepileptic encephalopathy
p11224
sg13
I2
sa(dp11225
g7
I24
sg26
VC0158981
p11226
sg10
I17
sg11
Vneonatal diabetes
p11227
sg13
I2
sa(dp11228
g7
I53
sg26
VC0431350
p11229
sg10
I20
sg11
Vprimary microcephaly
p11230
sg13
I2
sa(dp11231
g7
I61
sg26
VC1863516
p11232
sg10
I42
sg11
Vmicrocephaly with simplified gyral pattern
p11233
sg13
I5
sasa(dp11234
g2
S'Although association between gene polymorphisms in EPHX1 and TNF-a genes and chronic obstructive pulmonary disease (COPD) have been found but till date no genetic association studies have been done in the COPD affected Kazakhstan population.\n'
p11235
sg4
(lp11236
(dp11237
g7
I61
sg8
VP01375
p11238
sg10
I3
sg11
VTNF
p11239
sg13
I1
sasg23
(lp11240
(dp11241
g7
I116
sg26
VC0024117
p11242
sg10
I4
sg11
VCOPD
p11243
sg13
I1
sa(dp11244
g7
I116
sg26
VC0024117
p11245
sg10
I4
sg11
VCOPD
p11246
sg13
I1
sa(dp11247
g7
I77
sg26
VC0024117
p11248
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p11249
sg13
I4
sasa(dp11250
g2
S"To explore whether the tagging single nucleotide polymorphisms (SNPs) within EPHX1 gene were involved in the genetic susceptibility to coal worker's pneumoconiosis (CWP) by case-control study.\n"
p11251
sg4
(lp11252
sg23
(lp11253
(dp11254
g7
I165
sg26
VC0003165
p11255
sg10
I3
sg11
VCWP
p11256
sg13
I1
sa(dp11257
g7
I135
sg26
VC0003165
p11258
sg10
I28
sg11
Vcoal worker's pneumoconiosis
p11259
sg13
I3
sasa(dp11260
g2
S'Microsomal epoxide hydrolase (EPHX1) is an enzyme involved in the detoxification the products of smoking and is proposed to be a genetic factor for the development of chronic obstructive pulmonary disease (COPD).\n'
p11261
sg4
(lp11262
(dp11263
g7
I0
sg8
VP00167
p11264
sg10
I28
sg11
VMicrosomal epoxide hydrolase
p11265
sg13
I3
sasg23
(lp11266
(dp11267
g7
I206
sg26
VC0024117
p11268
sg10
I4
sg11
VCOPD
p11269
sg13
I1
sa(dp11270
g7
I167
sg26
VC0024117
p11271
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p11272
sg13
I4
sasa(dp11273
g2
S'We found that rats with diabetes had significantly higher abundance of the Protein disulfide isomerase associated 3, Aspartoacylase-3,3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase, Lactamase beta 2 and Agmat protein.\n'
p11274
sg4
(lp11275
(dp11276
g7
I206
sg8
g15
sg10
I13
sg11
VAgmat protein
p11277
sg13
I2
sa(dp11278
g7
I185
sg8
VP68371
p11279
sg10
I16
sg11
VLactamase beta 2
p11280
sg13
I3
sa(dp11281
g7
I75
sg8
VP07237
p11282
sg10
I40
sg11
VProtein disulfide isomerase associated 3
p11283
sg13
I5
sa(dp11284
g7
I117
sg8
VP45381
p11285
sg10
I66
sg11
VAspartoacylase-3,3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase
p11286
sg13
I3
sasg23
(lp11287
(dp11288
g7
I24
sg26
VC0011849
p11289
sg10
I8
sg11
Vdiabetes
p11290
sg13
I1
sasa(dp11291
g2
S'The aim of this study was to evaluate the association between the noggin rs227731 polymorphism on chromosome 17q22 and risk of nonsyndromic cleft lip with or without palate (NSCL/P).\n'
p11292
sg4
(lp11293
(dp11294
g7
I66
sg8
g15
sg10
I15
sg11
Vnoggin rs227731
p11295
sg13
I2
sasg23
(lp11296
(dp11297
g7
I140
sg26
VC0008924
p11298
sg10
I9
sg11
Vcleft lip
p11299
sg13
I2
sasa(dp11300
g2
S'Our findings demonstrate multiple roles of Noggin in different domains for craniofacial skeletogenesis, and suggest an indirect mechanism for secondary cleft palate in Nog mutants that may be relevant to human cleft palate as well.\n'
p11301
sg4
(lp11302
(dp11303
g7
I43
sg8
g15
sg10
I6
sg11
VNoggin
p11304
sg13
I1
sasg23
(lp11305
(dp11306
g7
I142
sg26
VC0008925
p11307
sg10
I22
sg11
Vsecondary cleft palate
p11308
sg13
I3
sa(dp11309
g7
I152
sg26
VC0008925
p11310
sg10
I12
sg11
Vcleft palate
p11311
sg13
I2
sasa(dp11312
g2
S'In turn, four variables were found to be associated with decreased mortality rates: treatment of benign prostatic hypertrophy, treatment of dyslipidemia, IGF-1 and being female.\n'
p11313
sg4
(lp11314
(dp11315
g7
I154
sg8
VP01343
p11316
sg10
I5
sg11
VIGF-1
p11317
sg13
I1
sasg23
(lp11318
(dp11319
g7
I140
sg26
VC0242339
p11320
sg10
I12
sg11
Vdyslipidemia
p11321
sg13
I1
sa(dp11322
g7
I97
sg26
VC0005001
p11323
sg10
I28
sg11
Vbenign prostatic hypertrophy
p11324
sg13
I3
sasa(dp11325
g2
S'Several other T2DM-related pathophysiological changes, e.g., osteoblast insulin resistance, impaired productions of osteogenic growth factors (particularly insulin-like growth factor 1 and bone morphogenetic proteins), overproduction of pro-inflammatory cytokines, hyperglycemia, and dyslipidemia, also aggravate diabetic osteopathy.\n'
p11326
sg4
(lp11327
(dp11328
g7
I72
sg8
VP01308
p11329
sg10
I7
sg11
Vinsulin
p11330
sg13
I1
sa(dp11331
g7
I156
sg8
VP01308
p11332
sg10
I28
sg11
Vinsulin-like growth factor 1
p11333
sg13
I4
sa(dp11334
g7
I189
sg8
VP02649
p11335
sg10
I27
sg11
Vbone morphogenetic proteins
p11336
sg13
I3
sasg23
(lp11337
(dp11338
g7
I72
sg26
VC0021655
p11339
sg10
I18
sg11
Vinsulin resistance
p11340
sg13
I2
sa(dp11341
g7
I284
sg26
VC0242339
p11342
sg10
I12
sg11
Vdyslipidemia
p11343
sg13
I1
sa(dp11344
g7
I265
sg26
VC0020456
p11345
sg10
I13
sg11
Vhyperglycemia
p11346
sg13
I1
sa(dp11347
g7
I92
sg26
VC0684336
p11348
sg10
I8
sg11
Vimpaired
p11349
sg13
I1
sa(dp11350
g7
I322
sg26
VC0005940
p11351
sg10
I10
sg11
Vosteopathy
p11352
sg13
I1
sasa(dp11353
g2
S"In synaptosomes, amyloid-Beta (ABeta) oligomers, the causative agent in Alzheimer's disease, bind to cellular prion proteins (PrPC) resulting in increased cholesterol concentrations, translocation of cytoplasmic phospholipase A2 (cPLA2, also known as PLA2G4A) to lipid rafts, and activation of cPLA2 The formation of ABeta-PrPC complexes is controlled by the cholesterol ester cycle.\n"
p11354
sg4
(lp11355
(dp11356
g7
I200
sg8
VP04054
p11357
sg10
I28
sg11
Vcytoplasmic phospholipase A2
p11358
sg13
I3
sa(dp11359
g7
I230
sg8
VP47712
p11360
sg10
I5
sg11
VcPLA2
p11361
sg13
I1
sa(dp11362
g7
I31
sg8
g15
sg10
I5
sg11
VABeta
p11363
sg13
I1
sa(dp11364
g7
I230
sg8
VP47712
p11365
sg10
I5
sg11
VcPLA2
p11366
sg13
I1
sa(dp11367
g7
I31
sg8
g15
sg10
I5
sg11
VABeta
p11368
sg13
I1
sa(dp11369
g7
I126
sg8
VP48637
p11370
sg10
I4
sg11
VPrPC
p11371
sg13
I1
sa(dp11372
g7
I17
sg8
g15
sg10
I12
sg11
Vamyloid-Beta
p11373
sg13
I1
sa(dp11374
g7
I126
sg8
VP48637
p11375
sg10
I4
sg11
VPrPC
p11376
sg13
I1
sa(dp11377
g7
I251
sg8
VP47712
p11378
sg10
I7
sg11
VPLA2G4A
p11379
sg13
I1
sasg23
(lp11380
(dp11381
g7
I17
sg26
VC0011560
p11382
sg10
I7
sg11
Vamyloid
p11383
sg13
I1
sa(dp11384
g7
I183
sg26
VC0040715
p11385
sg10
I13
sg11
Vtranslocation
p11386
sg13
I1
sa(dp11387
g7
I72
sg26
VC1521724
p11388
sg10
I19
sg11
VAlzheimer's disease
p11389
sg13
I2
sasa(dp11390
g2
S"To investigate the effect of lithium on cytosolic phospholipase A2 (PLA2) activity, a key player on membrane phospholipid turnover which has been found to be reduced in blood and brain tissue of patients with Alzheimer's disease (AD).\n"
p11391
sg4
(lp11392
(dp11393
g7
I68
sg8
VP04054
p11394
sg10
I4
sg11
VPLA2
p11395
sg13
I1
sa(dp11396
g7
I40
sg8
VP47712
p11397
sg10
I26
sg11
Vcytosolic phospholipase A2
p11398
sg13
I3
sasg23
(lp11399
(dp11400
g7
I209
sg26
VC1521724
p11401
sg10
I19
sg11
VAlzheimer's disease
p11402
sg13
I2
sa(dp11403
g7
I230
sg26
VC1521724
p11404
sg10
I2
sg11
VAD
p11405
sg13
I1
sasa(dp11406
g2
S"We covered an introduction to sphingomyelinases and its enzymatic product ceramide, in membrane domains or lipid rafts and the nucleus; followed by crosstalk between sphingomyelinase and cytosolic phospholipase A2 (cPLA2) catalysed products including arachidonic acid, functions of acid sphingomyelinase (aSMase) and neutral sphingomyelinase (N-SMase) in neurons, neuronal progenitor cells, glial cells, and brain endothelial cells; alterations in acid and N-SMases in Niemann Pick Disease Type A, major depression, Alzheimer's disease, cerebral ischemia, and pain; and recent developments in identification of inhibitors to sphingomyelinases.\n"
p11407
sg4
(lp11408
(dp11409
g7
I469
sg8
g15
sg10
I27
sg11
VNiemann Pick Disease Type A
p11410
sg13
I5
sa(dp11411
g7
I317
sg8
g15
sg10
I24
sg11
Vneutral sphingomyelinase
p11412
sg13
I2
sa(dp11413
g7
I457
sg8
g15
sg10
I8
sg11
VN-SMases
p11414
sg13
I1
sa(dp11415
g7
I282
sg8
VP17405
p11416
sg10
I21
sg11
Vacid sphingomyelinase
p11417
sg13
I2
sa(dp11418
g7
I343
sg8
g15
sg10
I7
sg11
VN-SMase
p11419
sg13
I1
sa(dp11420
g7
I187
sg8
VP47712
p11421
sg10
I26
sg11
Vcytosolic phospholipase A2
p11422
sg13
I3
sa(dp11423
g7
I305
sg8
VP17405
p11424
sg10
I6
sg11
VaSMase
p11425
sg13
I1
sa(dp11426
g7
I215
sg8
VP47712
p11427
sg10
I5
sg11
VcPLA2
p11428
sg13
I1
sasg23
(lp11429
(dp11430
g7
I469
sg26
VC0028064
p11431
sg10
I20
sg11
VNiemann Pick Disease
p11432
sg13
I3
sa(dp11433
g7
I516
sg26
VC1521724
p11434
sg10
I19
sg11
VAlzheimer's disease
p11435
sg13
I2
sa(dp11436
g7
I498
sg26
VC1269683
p11437
sg10
I16
sg11
Vmajor depression
p11438
sg13
I2
sa(dp11439
g7
I537
sg26
VC0917798
p11440
sg10
I17
sg11
Vcerebral ischemia
p11441
sg13
I2
sasa(dp11442
g2
S"Healthy brain aging does not show upregulation of PLA2G4 or PTGS2 expression, which was found in Alzheimer's disease.\n"
p11443
sg4
(lp11444
(dp11445
g7
I60
sg8
VP35354
p11446
sg10
I5
sg11
VPTGS2
p11447
sg13
I1
sa(dp11448
g7
I50
sg8
VP47712
p11449
sg10
I6
sg11
VPLA2G4
p11450
sg13
I1
sasg23
(lp11451
(dp11452
g7
I97
sg26
VC1521724
p11453
sg10
I19
sg11
VAlzheimer's disease
p11454
sg13
I2
sasa(dp11455
g2
S'In the present study, circulating proportions of CD8(+) T (Tc) cell subsets, including IL-17 (Tc17) and IL-10 (Tc10) producing cells, were assessed in relapsing-remitting MS (RRMS) patients and a possible effect of beta interferon (IFN-Beta), glatiramer acetate (GA), and vitamin D (VitD) on these cell subsets was investigated.\n'
p11456
sg4
(lp11457
(dp11458
g7
I49
sg8
VP01732
p11459
sg10
I3
sg11
VCD8
p11460
sg13
I1
sa(dp11461
g7
I215
sg8
VP01563
p11462
sg10
I15
sg11
Vbeta interferon
p11463
sg13
I2
sa(dp11464
g7
I232
sg8
VP01574
p11465
sg10
I8
sg11
VIFN-Beta
p11466
sg13
I1
sa(dp11467
g7
I111
sg8
VP17081
p11468
sg10
I4
sg11
VTc10
p11469
sg13
I1
sasg23
(lp11470
sa(dp11471
g2
S'We show that both Tc17 and Tc10 cell fractions are elevated in the circulation of RRMS patients in remission compared to healthy subjects and that these Tc subsets remain unaffected by current immune modulating regimens.\n'
p11472
sg4
(lp11473
(dp11474
g7
I27
sg8
VP17081
p11475
sg10
I4
sg11
VTc10
p11476
sg13
I1
sasg23
(lp11477
(dp11478
g7
I99
sg26
VC0687702
p11479
sg10
I9
sg11
Vremission
p11480
sg13
I1
sasa(dp11481
g2
S'Several lines of evidence implicate cytosolic phospholipase A(2)Alfa (cPLA(2)Alfa) as a critical enzyme in inflammatory disorders, including rheumatoid arthritis.\n'
p11482
sg4
(lp11483
(dp11484
g7
I70
sg8
VP0C870
p11485
sg10
I11
sg11
VcPLA(2)Alfa
p11486
sg13
I1
sa(dp11487
g7
I36
sg8
VP0C870
p11488
sg10
I32
sg11
Vcytosolic phospholipase A(2)Alfa
p11489
sg13
I3
sasg23
(lp11490
(dp11491
g7
I141
sg26
VC0003873
p11492
sg10
I20
sg11
Vrheumatoid arthritis
p11493
sg13
I2
sasa(dp11494
g2
S'Human group IIA-secreted phospholipase A(2) (sPLA(2)-IIA) is an important regulator of cytokine-mediated inflammatory responses in both in vitro and in vivo models of rheumatoid arthritis (RA).\n'
p11495
sg4
(lp11496
sg23
(lp11497
(dp11498
g7
I167
sg26
VC0003873
p11499
sg10
I20
sg11
Vrheumatoid arthritis
p11500
sg13
I2
sa(dp11501
g7
I105
sg26
VC1155266
p11502
sg10
I22
sg11
Vinflammatory responses
p11503
sg13
I2
sa(dp11504
g7
I189
sg26
VC0003873
p11505
sg10
I2
sg11
VRA
p11506
sg13
I1
sasa(dp11507
g2
S"We have therefore been unable to confirm a potential role for lysosomal cathepsins in the characteristic neurodegeneration associated with Alzheimer's disease; however the finding of significant increases in activity of dipeptidyl aminopeptidase II, cathepsin H and cathepsin D specifically in cases with Huntington's disease is of particular note.\n"
p11508
sg4
(lp11509
(dp11510
g7
I220
sg8
g15
sg10
I28
sg11
Vdipeptidyl aminopeptidase II
p11511
sg13
I3
sa(dp11512
g7
I62
sg8
VP25774
p11513
sg10
I20
sg11
Vlysosomal cathepsins
p11514
sg13
I2
sa(dp11515
g7
I266
sg8
VP07339
p11516
sg10
I11
sg11
Vcathepsin D
p11517
sg13
I2
sa(dp11518
g7
I250
sg8
VP09668
p11519
sg10
I11
sg11
Vcathepsin H
p11520
sg13
I2
sasg23
(lp11521
(dp11522
g7
I305
sg26
VC0020179
p11523
sg10
I20
sg11
VHuntington's disease
p11524
sg13
I2
sa(dp11525
g7
I139
sg26
VC1521724
p11526
sg10
I19
sg11
VAlzheimer's disease
p11527
sg13
I2
sa(dp11528
g7
I105
sg26
VC0027746
p11529
sg10
I17
sg11
Vneurodegeneration
p11530
sg13
I1
sasa(dp11531
g2
S'Moreover, in vitro cell culture experiments revealed the expression alternations of Mapk10, Jun, Vegfb, Pik3r5, Pld1, Tek, Itga6 exposed to TPF treatment by qRT-PCR, whilst providing an insight into the mechanism underlying TPF chemotherapeutic response in LSCC.\n'
p11532
sg4
(lp11533
(dp11534
g7
I112
sg8
VP14314
p11535
sg10
I4
sg11
VPld1
p11536
sg13
I1
sa(dp11537
g7
I92
sg8
VP05412
p11538
sg10
I3
sg11
VJun
p11539
sg13
I1
sa(dp11540
g7
I84
sg8
VP53779
p11541
sg10
I6
sg11
VMapk10
p11542
sg13
I1
sa(dp11543
g7
I104
sg8
g15
sg10
I6
sg11
VPik3r5
p11544
sg13
I1
sa(dp11545
g7
I97
sg8
VP49765
p11546
sg10
I5
sg11
VVegfb
p11547
sg13
I1
sa(dp11548
g7
I118
sg8
g15
sg10
I3
sg11
VTek
p11549
sg13
I1
sasg23
(lp11550
sa(dp11551
g2
S'Patients with refractory hyperaldosteronism (n = 41, 38%, with plasma concentration &gt;180 ng/l, URL, median 283 ng/l, interquartile range 218-433), when compared with those without (106 ng/l, 74-144; P &lt; 0.001), were not different either for treatment or LVEF, while presented with different AGT M235T genotype distribution (P = 0.047).\n'
p11552
sg4
(lp11553
(dp11554
g7
I297
sg8
VP21549
p11555
sg10
I18
sg11
VAGT M235T genotype
p11556
sg13
I3
sasg23
(lp11557
(dp11558
g7
I25
sg26
VC0020428
p11559
sg10
I18
sg11
Vhyperaldosteronism
p11560
sg13
I1
sasa(dp11561
g2
S'Among polymorphisms, only AGT M235T (P = 0.038) was associated with refractory hyperaldosteronism, after adjustment for nongenetic variables.\n'
p11562
sg4
(lp11563
sg23
(lp11564
(dp11565
g7
I79
sg26
VC0020428
p11566
sg10
I18
sg11
Vhyperaldosteronism
p11567
sg13
I1
sasa(dp11568
g2
S'In conclusion, refractory hyperaldosteronism in heart failure may be influenced by AGT M235T polymorphism, among RAAS candidate genes, and by PRA, which may represent, respectively, a constitutive (genotype dependent) and a nongenetic (phenotype-dependent) trigger for aldosterone elevation.\n'
p11569
sg4
(lp11570
(dp11571
g7
I83
sg8
VP21549
p11572
sg10
I9
sg11
VAGT M235T
p11573
sg13
I2
sasg23
(lp11574
(dp11575
g7
I26
sg26
VC0020428
p11576
sg10
I18
sg11
Vhyperaldosteronism
p11577
sg13
I1
sa(dp11578
g7
I48
sg26
VC0018802
p11579
sg10
I13
sg11
Vheart failure
p11580
sg13
I2
sasa(dp11581
g2
S'The BrGR-expressing yeast strain induced the activation of metabolic enzymes (Hxt, G6PDH, GAPDH and Ald), antioxidant systems (Gpx, Trx2, Trx3, Trr1, Tsa1 and porin) and molecular chaperones (Hsp104, Hsp90, Hsp70, Hsp42, Hsp26, Grp, Sti1 and Zpr1), which led to lower oxidative protein damage after a reduction in the level of cellular ROS in the BrGR-expressing yeast strain exposed to H(2)O(2) than in the wild-type yeast strain.\n'
p11582
sg4
(lp11583
(dp11584
g7
I100
sg8
VP33897
p11585
sg10
I3
sg11
VAld
p11586
sg13
I1
sa(dp11587
g7
I127
sg8
g15
sg10
I3
sg11
VGpx
p11588
sg13
I1
sa(dp11589
g7
I228
sg8
VP07492
p11590
sg10
I3
sg11
VGrp
p11591
sg13
I1
sa(dp11592
g7
I90
sg8
VP04406
p11593
sg10
I5
sg11
VGAPDH
p11594
sg13
I1
sa(dp11595
g7
I159
sg8
VP21796
p11596
sg10
I5
sg11
Vporin
p11597
sg13
I1
sa(dp11598
g7
I132
sg8
g15
sg10
I4
sg11
VTrx2
p11599
sg13
I1
sa(dp11600
g7
I150
sg8
g15
sg10
I4
sg11
VTsa1
p11601
sg13
I1
sa(dp11602
g7
I207
sg8
VP34932
p11603
sg10
I5
sg11
VHsp70
p11604
sg13
I1
sa(dp11605
g7
I242
sg8
g15
sg10
I4
sg11
VZpr1
p11606
sg13
I1
sa(dp11607
g7
I83
sg8
VP11413
p11608
sg10
I5
sg11
VG6PDH
p11609
sg13
I1
sa(dp11610
g7
I200
sg8
VP07900
p11611
sg10
I5
sg11
VHsp90
p11612
sg13
I1
sa(dp11613
g7
I78
sg8
g15
sg10
I3
sg11
VHxt
p11614
sg13
I1
sa(dp11615
g7
I233
sg8
VP31948
p11616
sg10
I4
sg11
VSti1
p11617
sg13
I1
sasg23
(lp11618
(dp11619
g7
I100
sg26
VC0162309
p11620
sg10
I3
sg11
VAld
p11621
sg13
I1
sasa(dp11622
g2
S'In this investigation, we explored the role of cancer-associated fibroblasts (CAFs) in the regulation of the tumor microenvironment in head and neck squamous cell carcinoma (HNSCC) though a complex intercellular BDNF-TrkB signaling system.\n'
p11623
sg4
(lp11624
(dp11625
g7
I212
sg8
g15
sg10
I9
sg11
VBDNF-TrkB
p11626
sg13
I1
sasg23
(lp11627
(dp11628
g7
I109
sg26
VC0027651
p11629
sg10
I5
sg11
Vtumor
p11630
sg13
I1
sa(dp11631
g7
I78
sg26
VC0795907
p11632
sg10
I4
sg11
VCAFs
p11633
sg13
I1
sa(dp11634
g7
I174
sg26
VC1168401
p11635
sg10
I5
sg11
VHNSCC
p11636
sg13
I1
sa(dp11637
g7
I47
sg26
VC0795907
p11638
sg10
I29
sg11
Vcancer-associated fibroblasts
p11639
sg13
I2
sa(dp11640
g7
I135
sg26
VC1168401
p11641
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p11642
sg13
I6
sasa(dp11643
g2
S'The aims of this study were to review the literature concerning the role of BDNF/TrkB activation in head and neck squamous cell carcinoma and malignant salivary gland tumors and to discuss future perspectives of BDNF/TrkB-target therapy.\n'
p11644
sg4
(lp11645
(dp11646
g7
I81
sg8
g15
sg10
I4
sg11
VTrkB
p11647
sg13
I1
sa(dp11648
g7
I81
sg8
g15
sg10
I4
sg11
VTrkB
p11649
sg13
I1
sasg23
(lp11650
(dp11651
g7
I167
sg26
VC0027651
p11652
sg10
I6
sg11
Vtumors
p11653
sg13
I1
sa(dp11654
g7
I100
sg26
VC1168401
p11655
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p11656
sg13
I6
sasa(dp11657
g2
S'More recently, TrkB was found to be overexpressed in head and neck squamous cell carcinoma (SCC) and to be involved in multistep tumour progression.\n'
p11658
sg4
(lp11659
(dp11660
g7
I15
sg8
g15
sg10
I4
sg11
VTrkB
p11661
sg13
I1
sasg23
(lp11662
(dp11663
g7
I53
sg26
VC1168401
p11664
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p11665
sg13
I6
sa(dp11666
g7
I129
sg26
VC0178874
p11667
sg10
I18
sg11
Vtumour progression
p11668
sg13
I2
sasa(dp11669
g2
S'Further studies should investigate possible inhibitors of TrkB and their suitability for the treatment of head and neck cancer.\n'
p11670
sg4
(lp11671
(dp11672
g7
I58
sg8
g15
sg10
I4
sg11
VTrkB
p11673
sg13
I1
sasg23
(lp11674
(dp11675
g7
I106
sg26
VC0278996
p11676
sg10
I20
sg11
Vhead and neck cancer
p11677
sg13
I4
sasa(dp11678
g2
S'The current study evaluates long-term quality of life (QOL) and sexual function of patients with endometrial cancer who received adjuvant pelvic external beam radiotherapy (EBRT) and/or vaginal brachytherapy (BRT).\n'
p11679
sg4
(lp11680
sg23
(lp11681
(dp11682
g7
I97
sg26
VC0476089
p11683
sg10
I18
sg11
Vendometrial cancer
p11684
sg13
I2
sasa(dp11685
g2
S'To investigate dosimetric effects of bladder distention on organs at risk (OARs) during treatment of endometrial cancer using 3D image-based planning of postoperative vaginal vault brachytherapy (BRT).\n'
p11686
sg4
(lp11687
sg23
(lp11688
(dp11689
g7
I101
sg26
VC0476089
p11690
sg10
I18
sg11
Vendometrial cancer
p11691
sg13
I2
sa(dp11692
g7
I37
sg26
VC0005687
p11693
sg10
I18
sg11
Vbladder distention
p11694
sg13
I2
sasa(dp11695
g2
S'Fifteen patients with early-stage endometrial cancer were studied, each undergoing adjuvant BRT of vaginal vault via 3.5 cm diameter cylinder.\n'
p11696
sg4
(lp11697
sg23
(lp11698
(dp11699
g7
I34
sg26
VC0476089
p11700
sg10
I18
sg11
Vendometrial cancer
p11701
sg13
I2
sasa(dp11702
g2
S'We investigated 174 patients with endometrial carcinoma treated with external radiotherapy (RT) and brachytherapy (BRT) (101 patients, 58%) or BRT alone (73 patients, 42%).\n'
p11703
sg4
(lp11704
sg23
(lp11705
(dp11706
g7
I34
sg26
VC0476089
p11707
sg10
I21
sg11
Vendometrial carcinoma
p11708
sg13
I2
sasa(dp11709
g2
S'To correlate comorbidity and acute radiation toxicity in elderly patients treated with adjuvant external beam radiotherapy (EBRT) plus brachytherapy-high dose rate (HDR-BRT) for endometrial cancer (EC).\n'
p11710
sg4
(lp11711
sg23
(lp11712
(dp11713
g7
I198
sg26
VC0476089
p11714
sg10
I2
sg11
VEC
p11715
sg13
I1
sa(dp11716
g7
I29
sg26
VC2363882
p11717
sg10
I24
sg11
Vacute radiation toxicity
p11718
sg13
I3
sa(dp11719
g7
I178
sg26
VC0476089
p11720
sg10
I18
sg11
Vendometrial cancer
p11721
sg13
I2
sa(dp11722
g7
I165
sg26
VC1840333
p11723
sg10
I3
sg11
VHDR
p11724
sg13
I1
sasa(dp11725
g2
S'The aim of our study was to present the experience of our department in the treatment of endometrial cancer with postoperative external beam radiotherapy (EBRT) without intracavitary brachytherapy (BRT) and to evaluate the efficacy of such a method.\n'
p11726
sg4
(lp11727
sg23
(lp11728
(dp11729
g7
I89
sg26
VC0476089
p11730
sg10
I18
sg11
Vendometrial cancer
p11731
sg13
I2
sasa(dp11732
g2
S'We retrospectively retrieved the medical records of all patients with endometrial cancer treated with surgery and EBRT alone (median dose 50.0 Gy).\n'
p11733
sg4
(lp11734
sg23
(lp11735
(dp11736
g7
I70
sg26
VC0476089
p11737
sg10
I18
sg11
Vendometrial cancer
p11738
sg13
I2
sasa(dp11739
g2
S'EBRT without BRT achieved an excellent local control in women with endometrial cancer although some of them were candidates for supplementary BRT.\n'
p11740
sg4
(lp11741
sg23
(lp11742
(dp11743
g7
I67
sg26
VC0476089
p11744
sg10
I18
sg11
Vendometrial cancer
p11745
sg13
I2
sasa(dp11746
g2
S'MiR-744 is aberrantly expressed in different types of human cancer.\n'
p11747
sg4
(lp11748
(dp11749
g7
I0
sg8
g15
sg10
I3
sg11
VMiR
p11750
sg13
I1
sasg23
(lp11751
(dp11752
g7
I60
sg26
VC0006826
p11753
sg10
I6
sg11
Vcancer
p11754
sg13
I1
sasa(dp11755
g2
S'However, the expression pattern and biological roles of miR-744 in gastric cancer remain unknown.\n'
p11756
sg4
(lp11757
(dp11758
g7
I56
sg8
g15
sg10
I7
sg11
VmiR-744
p11759
sg13
I1
sasg23
(lp11760
(dp11761
g7
I67
sg26
VC0024623
p11762
sg10
I14
sg11
Vgastric cancer
p11763
sg13
I2
sasa(dp11764
g2
S'The present study demonstrated that miR-744 expression was low in gastric cancer tissues and cell lines.\n'
p11765
sg4
(lp11766
sg23
(lp11767
(dp11768
g7
I66
sg26
VC0024623
p11769
sg10
I14
sg11
Vgastric cancer
p11770
sg13
I2
sasa(dp11771
g2
S'Low expression levels of miR-744 was significantly correlated with lymph node metastasis, invasive depth and TNM staging in gastric cancer patients.\n'
p11772
sg4
(lp11773
sg23
(lp11774
(dp11775
g7
I67
sg26
VC0686619
p11776
sg10
I21
sg11
Vlymph node metastasis
p11777
sg13
I3
sa(dp11778
g7
I124
sg26
VC0024623
p11779
sg10
I14
sg11
Vgastric cancer
p11780
sg13
I2
sasa(dp11781
g2
S'Bioinformatic prediction, luciferase reporter assay, reverse transcription-quantitative polymerase chain reaction and western blot analysis verified that brain-derived neurotrophic factor (BDNF) is a direct target of miR-744 in gastric cancer cells.\n'
p11782
sg4
(lp11783
(dp11784
g7
I189
sg8
g15
sg10
I4
sg11
VBDNF
p11785
sg13
I1
sa(dp11786
g7
I154
sg8
g15
sg10
I33
sg11
Vbrain-derived neurotrophic factor
p11787
sg13
I3
sa(dp11788
g7
I217
sg8
g15
sg10
I7
sg11
VmiR-744
p11789
sg13
I1
sasg23
(lp11790
(dp11791
g7
I228
sg26
VC0024623
p11792
sg10
I14
sg11
Vgastric cancer
p11793
sg13
I2
sasa(dp11794
g2
S'Furthermore, BDNF was upregulated in gastric cancer tissues and inversely correlated with miR-744 expression.\n'
p11795
sg4
(lp11796
sg23
(lp11797
(dp11798
g7
I37
sg26
VC0024623
p11799
sg10
I14
sg11
Vgastric cancer
p11800
sg13
I2
sasa(dp11801
g2
S'Furthermore, enforced BDNF expression reversed the tumor-suppressing effects of miR-744 on the proliferation and invasion of gastric cancer cells, indicating that BDNF is a functional mediator of miR-744 in gastric cancer.\n'
p11802
sg4
(lp11803
sg23
(lp11804
(dp11805
g7
I113
sg26
VC2699153
p11806
sg10
I8
sg11
Vinvasion
p11807
sg13
I1
sa(dp11808
g7
I125
sg26
VC0024623
p11809
sg10
I14
sg11
Vgastric cancer
p11810
sg13
I2
sa(dp11811
g7
I125
sg26
VC0024623
p11812
sg10
I14
sg11
Vgastric cancer
p11813
sg13
I2
sa(dp11814
g7
I95
sg26
VC0334094
p11815
sg10
I13
sg11
Vproliferation
p11816
sg13
I1
sa(dp11817
g7
I51
sg26
VC0027651
p11818
sg10
I5
sg11
Vtumor
p11819
sg13
I1
sasa(dp11820
g2
S'The present study suggests that miR-744 is a potential prognostic biomarker and treatment target in gastric cancer patients.\n'
p11821
sg4
(lp11822
sg23
(lp11823
(dp11824
g7
I100
sg26
VC0024623
p11825
sg10
I14
sg11
Vgastric cancer
p11826
sg13
I2
sasa(dp11827
g2
S'Results: Expressions of hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all up regulated in high invasion capable cell lines (SNU423, SNU449) and vascular invasion patients with hepatocellular carcinoma (logFC&gt;1, P&lt;0.05).\n'
p11828
sg4
(lp11829
(dp11830
g7
I24
sg8
g15
sg10
I3
sg11
Vhsa
p11831
sg13
I1
sa(dp11832
g7
I38
sg8
g15
sg10
I11
sg11
Vhsa-mir-149
p11833
sg13
I1
sa(dp11834
g7
I51
sg8
g15
sg10
I11
sg11
Vhsa-mir-744
p11835
sg13
I1
sa(dp11836
g7
I24
sg8
g15
sg10
I12
sg11
Vhsa-mir-1180
p11837
sg13
I1
sasg23
(lp11838
(dp11839
g7
I24
sg26
VC0393754
p11840
sg10
I3
sg11
Vhsa
p11841
sg13
I1
sa(dp11842
g7
I24
sg26
VC0393754
p11843
sg10
I3
sg11
Vhsa
p11844
sg13
I1
sa(dp11845
g7
I24
sg26
VC0393754
p11846
sg10
I3
sg11
Vhsa
p11847
sg13
I1
sa(dp11848
g7
I24
sg26
VC0393754
p11849
sg10
I3
sg11
Vhsa
p11850
sg13
I1
sa(dp11851
g7
I109
sg26
VC2699153
p11852
sg10
I8
sg11
Vinvasion
p11853
sg13
I1
sa(dp11854
g7
I190
sg26
VC1512411
p11855
sg10
I24
sg11
Vhepatocellular carcinoma
p11856
sg13
I2
sa(dp11857
g7
I109
sg26
VC2699153
p11858
sg10
I8
sg11
Vinvasion
p11859
sg13
I1
sasa(dp11860
g2
S'Conclusion: With TCGA and GEO data mining, we found that hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all highly related to the prognosis of hepatocellular carcinoma, that enabled it to be used to further study the biomarkers related to the prognosis of hepatocellular carcinoma.\n'
p11861
sg4
(lp11862
(dp11863
g7
I57
sg8
g15
sg10
I12
sg11
Vhsa-mir-1180
p11864
sg13
I1
sa(dp11865
g7
I71
sg8
g15
sg10
I11
sg11
Vhsa-mir-149
p11866
sg13
I1
sa(dp11867
g7
I84
sg8
g15
sg10
I11
sg11
Vhsa-mir-744
p11868
sg13
I1
sa(dp11869
g7
I57
sg8
g15
sg10
I3
sg11
Vhsa
p11870
sg13
I1
sasg23
(lp11871
(dp11872
g7
I57
sg26
VC0393754
p11873
sg10
I3
sg11
Vhsa
p11874
sg13
I1
sa(dp11875
g7
I156
sg26
VC1512411
p11876
sg10
I24
sg11
Vhepatocellular carcinoma
p11877
sg13
I2
sa(dp11878
g7
I156
sg26
VC1512411
p11879
sg10
I24
sg11
Vhepatocellular carcinoma
p11880
sg13
I2
sa(dp11881
g7
I57
sg26
VC0393754
p11882
sg10
I3
sg11
Vhsa
p11883
sg13
I1
sa(dp11884
g7
I57
sg26
VC0393754
p11885
sg10
I3
sg11
Vhsa
p11886
sg13
I1
sa(dp11887
g7
I57
sg26
VC0393754
p11888
sg10
I3
sg11
Vhsa
p11889
sg13
I1
sasa(dp11890
g2
S'### ###GEO (Gene Expression Omnibus) #TCGA (The Cancer Genome Atlas) #####, ###########microRNA, ############ ### ##GEO###########microRNA#### (GSE67140) , #5########### (SNU423#SNU449#HepG2#Hep3B#SNU398) #########, ##81############91#######################TCGA####362############, ##microRNA########GO#KEGG### ### hsa-mir-1180#hsa-mir-149#hsa-mir-744#hsa-mir-940########################### (logFC&gt;1, P&lt;0.05) #######, hsa-mir-1180 (HR=1.623, 95%CI#1.114~2.365, P=0.012) #hsa-mir-149 (HR=2.400, 95% CI#1.639~3.514, P&lt;0.001) #hsa-mir-744 (HR=1.679, 95%CI#1.161~2.427, P=0.006) #hsa-mir-940 (HR=1.704, 95%CI#1.188~2.443, P=0.004) #############, ############### (P&lt;0.05) #GO#KEGG############################## ### ###TCGA#GEO######, ####hsa-mir-1180#hsa-mir-149#hsa-mir-744#hsa-mir-940#########, ##############.\n'
p11891
sg4
(lp11892
(dp11893
g7
I315
sg8
g15
sg10
I3
sg11
Vhsa
p11894
sg13
I1
sa(dp11895
g7
I315
sg8
g15
sg10
I3
sg11
Vhsa
p11896
sg13
I1
sa(dp11897
g7
I315
sg8
g15
sg10
I3
sg11
Vhsa
p11898
sg13
I1
sasg23
(lp11899
(dp11900
g7
I315
sg26
VC0393754
p11901
sg10
I3
sg11
Vhsa
p11902
sg13
I1
sa(dp11903
g7
I315
sg26
VC0393754
p11904
sg10
I3
sg11
Vhsa
p11905
sg13
I1
sa(dp11906
g7
I315
sg26
VC0393754
p11907
sg10
I3
sg11
Vhsa
p11908
sg13
I1
sa(dp11909
g7
I315
sg26
VC0393754
p11910
sg10
I3
sg11
Vhsa
p11911
sg13
I1
sa(dp11912
g7
I315
sg26
VC0393754
p11913
sg10
I3
sg11
Vhsa
p11914
sg13
I1
sa(dp11915
g7
I315
sg26
VC0393754
p11916
sg10
I3
sg11
Vhsa
p11917
sg13
I1
sa(dp11918
g7
I315
sg26
VC0393754
p11919
sg10
I3
sg11
Vhsa
p11920
sg13
I1
sa(dp11921
g7
I48
sg26
VC0006826
p11922
sg10
I6
sg11
VCancer
p11923
sg13
I1
sa(dp11924
g7
I315
sg26
VC0393754
p11925
sg10
I3
sg11
Vhsa
p11926
sg13
I1
sa(dp11927
g7
I315
sg26
VC0393754
p11928
sg10
I3
sg11
Vhsa
p11929
sg13
I1
sa(dp11930
g7
I315
sg26
VC0393754
p11931
sg10
I3
sg11
Vhsa
p11932
sg13
I1
sa(dp11933
g7
I315
sg26
VC0393754
p11934
sg10
I3
sg11
Vhsa
p11935
sg13
I1
sa(dp11936
g7
I315
sg26
VC0393754
p11937
sg10
I3
sg11
Vhsa
p11938
sg13
I1
sasa(dp11939
g2
S'However, little is known about how miR-744 impacts on the tumorigenesis of human prostate cancer.\n'
p11940
sg4
(lp11941
sg23
(lp11942
(dp11943
g7
I81
sg26
VC0600139
p11944
sg10
I15
sg11
Vprostate cancer
p11945
sg13
I2
sa(dp11946
g7
I58
sg26
VC0007621
p11947
sg10
I13
sg11
Vtumorigenesis
p11948
sg13
I1
sasa(dp11949
g2
S'The aim of this study was to investigate the role of miR-222, miR-29a, miR-34a, miR-130a, miR-90b, miR-200b, miR-452, miR-197, miR-138, miR-210, miR-423, miR-4298, miR-4644, miR-139, miR-1246, miR-1268a, miR-140, miR-149, miR-3178, miR-3613, miR-4258, miR-574, miR-671, miR-6780b, miR-7107, miR-744 and miR-7847 linked to drug resistance in breast cancer formalin-fixed paraffin-embedded tissues and the association of prognosis with miRNAs, thus providing effective targets in chemotherapy, as well as potential biomarkers for guiding effective treatments of breast cancer.\n'
p11950
sg4
(lp11951
(dp11952
g7
I174
sg8
g15
sg10
I7
sg11
VmiR-139
p11953
sg13
I1
sa(dp11954
g7
I222
sg8
g15
sg10
I8
sg11
VmiR-3178
p11955
sg13
I1
sa(dp11956
g7
I242
sg8
g15
sg10
I8
sg11
VmiR-4258
p11957
sg13
I1
sa(dp11958
g7
I270
sg8
g15
sg10
I9
sg11
VmiR-6780b
p11959
sg13
I1
sa(dp11960
g7
I118
sg8
g15
sg10
I7
sg11
VmiR-197
p11961
sg13
I1
sa(dp11962
g7
I154
sg8
g15
sg10
I8
sg11
VmiR-4298
p11963
sg13
I1
sa(dp11964
g7
I261
sg8
g15
sg10
I7
sg11
VmiR-671
p11965
sg13
I1
sa(dp11966
g7
I183
sg8
g15
sg10
I8
sg11
VmiR-1246
p11967
sg13
I1
sa(dp11968
g7
I193
sg8
g15
sg10
I9
sg11
VmiR-1268a
p11969
sg13
I1
sa(dp11970
g7
I99
sg8
g15
sg10
I8
sg11
VmiR-200b
p11971
sg13
I1
sa(dp11972
g7
I53
sg8
g15
sg10
I7
sg11
VmiR-222
p11973
sg13
I1
sa(dp11974
g7
I281
sg8
g15
sg10
I8
sg11
VmiR-7107
p11975
sg13
I1
sa(dp11976
g7
I62
sg8
g15
sg10
I7
sg11
VmiR-29a
p11977
sg13
I1
sa(dp11978
g7
I145
sg8
g15
sg10
I7
sg11
VmiR-423
p11979
sg13
I1
sa(dp11980
g7
I213
sg8
g15
sg10
I7
sg11
VmiR-149
p11981
sg13
I1
sa(dp11982
g7
I204
sg8
g15
sg10
I7
sg11
VmiR-140
p11983
sg13
I1
sa(dp11984
g7
I80
sg8
g15
sg10
I8
sg11
VmiR-130a
p11985
sg13
I1
sa(dp11986
g7
I127
sg8
g15
sg10
I7
sg11
VmiR-138
p11987
sg13
I1
sa(dp11988
g7
I109
sg8
g15
sg10
I7
sg11
VmiR-452
p11989
sg13
I1
sa(dp11990
g7
I232
sg8
g15
sg10
I8
sg11
VmiR-3613
p11991
sg13
I1
sa(dp11992
g7
I291
sg8
g15
sg10
I7
sg11
VmiR-744
p11993
sg13
I1
sa(dp11994
g7
I71
sg8
g15
sg10
I7
sg11
VmiR-34a
p11995
sg13
I1
sa(dp11996
g7
I252
sg8
g15
sg10
I7
sg11
VmiR-574
p11997
sg13
I1
sa(dp11998
g7
I164
sg8
g15
sg10
I8
sg11
VmiR-4644
p11999
sg13
I1
sa(dp12000
g7
I90
sg8
g15
sg10
I7
sg11
VmiR-90b
p12001
sg13
I1
sa(dp12002
g7
I136
sg8
g15
sg10
I7
sg11
VmiR-210
p12003
sg13
I1
sa(dp12004
g7
I303
sg8
g15
sg10
I8
sg11
VmiR-7847
p12005
sg13
I1
sasg23
(lp12006
(dp12007
g7
I341
sg26
VC0678222
p12008
sg10
I13
sg11
Vbreast cancer
p12009
sg13
I2
sa(dp12010
g7
I341
sg26
VC0678222
p12011
sg10
I13
sg11
Vbreast cancer
p12012
sg13
I2
sasa(dp12013
g2
S'Upregulation of miR-744 is associated with poor prognosis in many types of cancer patients, but it is still unclear how miR-744 becomes elevated in these tumors.\n'
p12014
sg4
(lp12015
(dp12016
g7
I16
sg8
g15
sg10
I7
sg11
VmiR-744
p12017
sg13
I1
sasg23
(lp12018
(dp12019
g7
I154
sg26
VC0027651
p12020
sg10
I6
sg11
Vtumors
p12021
sg13
I1
sa(dp12022
g7
I75
sg26
VC0006826
p12023
sg10
I6
sg11
Vcancer
p12024
sg13
I1
sasa(dp12025
g2
S'C-Jun-induced miR-744 upregulation could significantly promote migration and invasion of nasopharyngeal carcinoma cells and non-small cell lung cancer (NSCLC) cells, hence ectopic c-Jun was sufficient to rescue the migratory and invasive ability of these cells when miR-744 was knockdown.\n'
p12026
sg4
(lp12027
(dp12028
g7
I2
sg8
VP05412
p12029
sg10
I3
sg11
VJun
p12030
sg13
I1
sa(dp12031
g7
I180
sg8
VP05412
p12032
sg10
I5
sg11
Vc-Jun
p12033
sg13
I1
sasg23
(lp12034
(dp12035
g7
I124
sg26
VC0007131
p12036
sg10
I26
sg11
Vnon-small cell lung cancer
p12037
sg13
I4
sa(dp12038
g7
I77
sg26
VC2699153
p12039
sg10
I8
sg11
Vinvasion
p12040
sg13
I1
sa(dp12041
g7
I152
sg26
VC0007131
p12042
sg10
I5
sg11
VNSCLC
p12043
sg13
I1
sa(dp12044
g7
I89
sg26
VC2931822
p12045
sg10
I24
sg11
Vnasopharyngeal carcinoma
p12046
sg13
I2
sasa(dp12047
g2
S'Additionally, a positive correlation between the expression levels of miR-744 and c-Jun was revealed in NSCLC samples with high (top 10%) level of miR-744 expression from the TCGA dataset.\n'
p12048
sg4
(lp12049
(dp12050
g7
I70
sg8
g15
sg10
I7
sg11
VmiR-744
p12051
sg13
I1
sa(dp12052
g7
I70
sg8
g15
sg10
I7
sg11
VmiR-744
p12053
sg13
I1
sa(dp12054
g7
I82
sg8
VP05412
p12055
sg10
I5
sg11
Vc-Jun
p12056
sg13
I1
sasg23
(lp12057
(dp12058
g7
I104
sg26
VC0007131
p12059
sg10
I5
sg11
VNSCLC
p12060
sg13
I1
sasa(dp12061
g2
S'Taken together, our results demonstrated for the first time the regulatory mechanism of miR-744 transcription by c-Jun, providing a potential mechanism underlying the upregulation of miR-744 in cancers.\n'
p12062
sg4
(lp12063
(dp12064
g7
I113
sg8
VP05412
p12065
sg10
I5
sg11
Vc-Jun
p12066
sg13
I1
sa(dp12067
g7
I88
sg8
g15
sg10
I7
sg11
VmiR-744
p12068
sg13
I1
sasg23
(lp12069
(dp12070
g7
I194
sg26
VC0006826
p12071
sg10
I7
sg11
Vcancers
p12072
sg13
I1
sasa(dp12073
g2
S'Aberrant miR-744 expression has been indicated in many growth of tumor, the mechanism of miR-744 inhibits both the proliferation and metastatic ability for cervical cancer remains unclear.\n'
p12074
sg4
(lp12075
(dp12076
g7
I9
sg8
g15
sg10
I7
sg11
VmiR-744
p12077
sg13
I1
sasg23
(lp12078
(dp12079
g7
I65
sg26
VC0027651
p12080
sg10
I5
sg11
Vtumor
p12081
sg13
I1
sa(dp12082
g7
I115
sg26
VC0334094
p12083
sg10
I13
sg11
Vproliferation
p12084
sg13
I1
sa(dp12085
g7
I156
sg26
VC0302592
p12086
sg10
I15
sg11
Vcervical cancer
p12087
sg13
I2
sasa(dp12088
g2
S'The goal of this study was to identify miR-744 that could inhibit the growth, migration, invasion, proliferation and metastasis of gastric cancer through targeting Bcl-2 expression.\n'
p12089
sg4
(lp12090
(dp12091
g7
I164
sg8
VP10415
p12092
sg10
I5
sg11
VBcl-2
p12093
sg13
I1
sasg23
(lp12094
(dp12095
g7
I99
sg26
VC0334094
p12096
sg10
I13
sg11
Vproliferation
p12097
sg13
I1
sa(dp12098
g7
I117
sg26
VC0027627
p12099
sg10
I10
sg11
Vmetastasis
p12100
sg13
I1
sa(dp12101
g7
I131
sg26
VC0024623
p12102
sg10
I14
sg11
Vgastric cancer
p12103
sg13
I2
sa(dp12104
g7
I89
sg26
VC2699153
p12105
sg10
I8
sg11
Vinvasion
p12106
sg13
I1
sasa(dp12107
g2
S'Our study indicated that miR-744 targeted on Bcl-2, which leads to the inactivation of apoptosis signaling and the cell proliferation of cervical cancer cells, ameliorating cervical cancer growth and progression.\n'
p12108
sg4
(lp12109
(dp12110
g7
I25
sg8
g15
sg10
I7
sg11
VmiR-744
p12111
sg13
I1
sa(dp12112
g7
I45
sg8
VP10415
p12113
sg10
I5
sg11
VBcl-2
p12114
sg13
I1
sasg23
(lp12115
(dp12116
g7
I120
sg26
VC0334094
p12117
sg10
I13
sg11
Vproliferation
p12118
sg13
I1
sa(dp12119
g7
I137
sg26
VC0302592
p12120
sg10
I15
sg11
Vcervical cancer
p12121
sg13
I2
sa(dp12122
g7
I71
sg26
VC0544461
p12123
sg10
I12
sg11
Vinactivation
p12124
sg13
I1
sa(dp12125
g7
I137
sg26
VC0302592
p12126
sg10
I15
sg11
Vcervical cancer
p12127
sg13
I2
sasa(dp12128
g2
S'In addition, both up-regulation of miR-744 and down-regulation of Bcl-2 could stimulate Caspase-3 expression, promoting apoptosis of cervical cancer cells.\n'
p12129
sg4
(lp12130
(dp12131
g7
I35
sg8
g15
sg10
I7
sg11
VmiR-744
p12132
sg13
I1
sa(dp12133
g7
I66
sg8
VP10415
p12134
sg10
I5
sg11
VBcl-2
p12135
sg13
I1
sa(dp12136
g7
I88
sg8
VP42574
p12137
sg10
I9
sg11
VCaspase-3
p12138
sg13
I1
sasg23
(lp12139
(dp12140
g7
I133
sg26
VC0302592
p12141
sg10
I15
sg11
Vcervical cancer
p12142
sg13
I2
sasa(dp12143
g2
S'Therefore, our research revealed the mechanistic links between miR-744 and Bcl-2 in the pathogenesis of cervical cancer through modulation of Caspase-3, leading to the inhibition of cervical cancer cell growth.\n'
p12144
sg4
(lp12145
(dp12146
g7
I75
sg8
VP10415
p12147
sg10
I5
sg11
VBcl-2
p12148
sg13
I1
sa(dp12149
g7
I142
sg8
VP42574
p12150
sg10
I9
sg11
VCaspase-3
p12151
sg13
I1
sa(dp12152
g7
I63
sg8
g15
sg10
I7
sg11
VmiR-744
p12153
sg13
I1
sasg23
(lp12154
(dp12155
g7
I191
sg26
VC1516170
p12156
sg10
I18
sg11
Vcancer cell growth
p12157
sg13
I3
sa(dp12158
g7
I104
sg26
VC0302592
p12159
sg10
I15
sg11
Vcervical cancer
p12160
sg13
I2
sa(dp12161
g7
I88
sg26
VC0699748
p12162
sg10
I12
sg11
Vpathogenesis
p12163
sg13
I1
sasa(dp12164
g2
S'And targeting miR-744 could be served as a novel strategy for future cervical cancer therapy clinically.\n'
p12165
sg4
(lp12166
(dp12167
g7
I14
sg8
g15
sg10
I7
sg11
VmiR-744
p12168
sg13
I1
sasg23
(lp12169
(dp12170
g7
I69
sg26
VC0302592
p12171
sg10
I15
sg11
Vcervical cancer
p12172
sg13
I2
sasa(dp12173
g2
S'Dysregulation of miR-744 is common in a number of cancers, indicating miR-774 might be closely correlated with the tumorigenesis process.\n'
p12174
sg4
(lp12175
(dp12176
g7
I17
sg8
g15
sg10
I7
sg11
VmiR-744
p12177
sg13
I1
sa(dp12178
g7
I70
sg8
g15
sg10
I7
sg11
VmiR-774
p12179
sg13
I1
sasg23
(lp12180
(dp12181
g7
I115
sg26
VC0007621
p12182
sg10
I13
sg11
Vtumorigenesis
p12183
sg13
I1
sa(dp12184
g7
I50
sg26
VC0006826
p12185
sg10
I7
sg11
Vcancers
p12186
sg13
I1
sasa(dp12187
g2
S'Functionally validated SNPs support identification of an SNP in SYNGR1 which may expose to the risk of rheumatoid arthritis and primary biliary cirrhosis, as well as an SNP in the last intron of COG6 exposing to the risk of psoriasis.\n'
p12188
sg4
(lp12189
(dp12190
g7
I64
sg8
g15
sg10
I6
sg11
VSYNGR1
p12191
sg13
I1
sa(dp12192
g7
I195
sg8
g15
sg10
I4
sg11
VCOG6
p12193
sg13
I1
sasg23
(lp12194
(dp12195
g7
I103
sg26
VC0003873
p12196
sg10
I20
sg11
Vrheumatoid arthritis
p12197
sg13
I2
sa(dp12198
g7
I224
sg26
VC0033860
p12199
sg10
I9
sg11
Vpsoriasis
p12200
sg13
I1
sa(dp12201
g7
I128
sg26
VC0008312
p12202
sg10
I25
sg11
Vprimary biliary cirrhosis
p12203
sg13
I3
sasa(dp12204
g2
S'The aim of this study was to test the hypothesis about the protective role of high stefin A and stefin B concentrations in operable carcinoma of the head and neck.\n'
p12205
sg4
(lp12206
(dp12207
g7
I83
sg8
VP01040
p12208
sg10
I8
sg11
Vstefin A
p12209
sg13
I2
sa(dp12210
g7
I96
sg8
VP04080
p12211
sg10
I8
sg11
Vstefin B
p12212
sg13
I2
sasg23
(lp12213
(dp12214
g7
I132
sg26
VC1168401
p12215
sg10
I30
sg11
Vcarcinoma of the head and neck
p12216
sg13
I6
sasa(dp12217
g2
S'Stefin A was recognized as a promising candidate marker for prognosis in patients with operable carcinoma of the head and neck.\n'
p12218
sg4
(lp12219
(dp12220
g7
I0
sg8
VP01040
p12221
sg10
I8
sg11
VStefin A
p12222
sg13
I2
sasg23
(lp12223
(dp12224
g7
I96
sg26
VC1168401
p12225
sg10
I30
sg11
Vcarcinoma of the head and neck
p12226
sg13
I6
sasa(dp12227
g2
S'Here we report that mouse embryos homozygous for a gene trap insertion in the fibulin-1 (Fbln1) gene are deficient in Fbln1 and exhibit cardiac ventricular wall thinning and ventricular septal defects with double outlet right ventricle or overriding aorta.\n'
p12228
sg4
(lp12229
sg23
(lp12230
(dp12231
g7
I239
sg26
VC0265886
p12232
sg10
I16
sg11
Voverriding aorta
p12233
sg13
I2
sa(dp12234
g7
I206
sg26
VC0013069
p12235
sg10
I29
sg11
Vdouble outlet right ventricle
p12236
sg13
I4
sa(dp12237
g7
I174
sg26
VC0018818
p12238
sg10
I26
sg11
Vventricular septal defects
p12239
sg13
I3
sasa(dp12240
g2
S'Three cases with deletion of the whole sodium channel gene cluster (SCN3A, SCN2A, SCN1A, SCN9A, and SCN7A) exhibited a complex epilepsy phenotype that was atypical for Dravet syndrome and suggestive of migrating partial seizures of infancy: early seizure onset (before 2 months of age), severe developmental delay from seizure onset, multifocal interictal spikes, polymorphous focal seizures, and acquired microcephaly.\n'
p12241
sg4
(lp12242
(dp12243
g7
I82
sg8
VP35498
p12244
sg10
I5
sg11
VSCN1A
p12245
sg13
I1
sa(dp12246
g7
I75
sg8
g15
sg10
I5
sg11
VSCN2A
p12247
sg13
I1
sa(dp12248
g7
I100
sg8
g15
sg10
I5
sg11
VSCN7A
p12249
sg13
I1
sasg23
(lp12250
(dp12251
g7
I406
sg26
VC0025958
p12252
sg10
I12
sg11
Vmicrocephaly
p12253
sg13
I1
sa(dp12254
g7
I377
sg26
VC0751495
p12255
sg10
I14
sg11
Vfocal seizures
p12256
sg13
I2
sa(dp12257
g7
I212
sg26
VC0751495
p12258
sg10
I16
sg11
Vpartial seizures
p12259
sg13
I2
sa(dp12260
g7
I294
sg26
VC0424605
p12261
sg10
I19
sg11
Vdevelopmental delay
p12262
sg13
I2
sa(dp12263
g7
I127
sg26
VC0014544
p12264
sg10
I8
sg11
Vepilepsy
p12265
sg13
I1
sa(dp12266
g7
I220
sg26
VC0036572
p12267
sg10
I7
sg11
Vseizure
p12268
sg13
I1
sa(dp12269
g7
I168
sg26
VC0751122
p12270
sg10
I15
sg11
VDravet syndrome
p12271
sg13
I2
sa(dp12272
g7
I220
sg26
VC0036572
p12273
sg10
I7
sg11
Vseizure
p12274
sg13
I1
sasa(dp12275
g2
S'A literature review of cases with chromosome 2q24.3 deletion revealed that, in most Dravet syndrome cases, it does not involve SCN2A and SCN3A, whereas a complex epilepsy phenotype that is shared with migrating partial seizures of infancy was associated with cases of deletion of the whole sodium channel gene cluster.\n'
p12276
sg4
(lp12277
(dp12278
g7
I127
sg8
g15
sg10
I5
sg11
VSCN2A
p12279
sg13
I1
sasg23
(lp12280
(dp12281
g7
I84
sg26
VC0751122
p12282
sg10
I15
sg11
VDravet syndrome
p12283
sg13
I2
sa(dp12284
g7
I162
sg26
VC0014544
p12285
sg10
I8
sg11
Vepilepsy
p12286
sg13
I1
sa(dp12287
g7
I211
sg26
VC0751495
p12288
sg10
I16
sg11
Vpartial seizures
p12289
sg13
I2
sasa(dp12290
g2
S'In contrast to known forms of retinal dystrophy, including those caused by mutations in the tubby-like protein TULP-1, loss of function of TUB in the proband and two affected family members was associated with early-onset obesity, consistent with an additional role for TUB in energy homeostasis.\n'
p12291
sg4
(lp12292
(dp12293
g7
I92
sg8
VP50607
p12294
sg10
I18
sg11
Vtubby-like protein
p12295
sg13
I2
sa(dp12296
g7
I139
sg8
VP50607
p12297
sg10
I3
sg11
VTUB
p12298
sg13
I1
sa(dp12299
g7
I139
sg8
VP50607
p12300
sg10
I3
sg11
VTUB
p12301
sg13
I1
sasg23
(lp12302
(dp12303
g7
I222
sg26
VC0028754
p12304
sg10
I7
sg11
Vobesity
p12305
sg13
I1
sa(dp12306
g7
I30
sg26
VC0854723
p12307
sg10
I17
sg11
Vretinal dystrophy
p12308
sg13
I2
sasa(dp12309
g2
S'TULP1 (the gene encoding tubby-like protein 1) is a candidate target for the disease mutation because it maps to the RP14 minimum genetic region and because a mutation in the highly homologous mouse tub gene leads to obesity, deafness and early progressive retinal degeneration.\n'
p12310
sg4
(lp12311
(dp12312
g7
I193
sg8
VP50607
p12313
sg10
I14
sg11
Vmouse tub gene
p12314
sg13
I3
sa(dp12315
g7
I25
sg8
VP14222
p12316
sg10
I20
sg11
Vtubby-like protein 1
p12317
sg13
I3
sa(dp12318
g7
I117
sg8
g15
sg10
I4
sg11
VRP14
p12319
sg13
I1
sa(dp12320
g7
I0
sg8
g15
sg10
I5
sg11
VTULP1
p12321
sg13
I1
sasg23
(lp12322
(dp12323
g7
I217
sg26
VC0028754
p12324
sg10
I7
sg11
Vobesity
p12325
sg13
I1
sa(dp12326
g7
I117
sg26
VC1838603
p12327
sg10
I4
sg11
VRP14
p12328
sg13
I1
sa(dp12329
g7
I257
sg26
VC0035304
p12330
sg10
I20
sg11
Vretinal degeneration
p12331
sg13
I2
sa(dp12332
g7
I226
sg26
VC0011053
p12333
sg10
I8
sg11
Vdeafness
p12334
sg13
I1
sasa(dp12335
g2
S'The association of diabetes and cigarette smoke in DSPP group caused altered glycemia at term, reduced number of implantation and live fetuses, decreased litter and maternal weight, increased pre and postimplantation loss rates, reduced triglyceride and VLDL-c concentrations, increased levels of thiol groups and MDA.\n'
p12336
sg4
(lp12337
(dp12338
g7
I51
sg8
g15
sg10
I4
sg11
VDSPP
p12339
sg13
I1
sasg23
(lp12340
(dp12341
g7
I19
sg26
VC0011849
p12342
sg10
I8
sg11
Vdiabetes
p12343
sg13
I1
sasa(dp12344
g2
S'According to the duration of diabetes or observation (1, 3, 6 months), each group was randomly subdivided into DM1, DM3, DM6; DMP1, DMP3, DMP6; and C1, C3, C6 groups.\n'
p12345
sg4
(lp12346
(dp12347
g7
I132
sg8
g15
sg10
I4
sg11
VDMP3
p12348
sg13
I1
sa(dp12349
g7
I126
sg8
g15
sg10
I4
sg11
VDMP1
p12350
sg13
I1
sa(dp12351
g7
I111
sg8
g15
sg10
I3
sg11
VDM1
p12352
sg13
I1
sasg23
(lp12353
(dp12354
g7
I29
sg26
VC0011849
p12355
sg10
I8
sg11
Vdiabetes
p12356
sg13
I1
sa(dp12357
g7
I111
sg26
VC2931688
p12358
sg10
I3
sg11
VDM1
p12359
sg13
I1
sasa(dp12360
g2
S'The gene pathogenicity analysis revealed five key genes in psoriasis: PPARD, GATA3, TIMP3, WNT5A and PTTG1.\n'
p12361
sg4
(lp12362
(dp12363
g7
I101
sg8
g15
sg10
I5
sg11
VPTTG1
p12364
sg13
I1
sa(dp12365
g7
I84
sg8
VP35625
p12366
sg10
I5
sg11
VTIMP3
p12367
sg13
I1
sa(dp12368
g7
I70
sg8
g15
sg10
I5
sg11
VPPARD
p12369
sg13
I1
sa(dp12370
g7
I77
sg8
VP23771
p12371
sg10
I5
sg11
VGATA3
p12372
sg13
I1
sa(dp12373
g7
I91
sg8
VP41221
p12374
sg10
I5
sg11
VWNT5A
p12375
sg13
I1
sasg23
(lp12376
(dp12377
g7
I59
sg26
VC0033860
p12378
sg10
I9
sg11
Vpsoriasis
p12379
sg13
I1
sasa(dp12380
g2
S'Peroxisome proliferator-activated receptor Beta/Delta is a member of the nuclear hormone receptor superfamily suggested to contribute to psoriasis pathogenesis.\n'
p12381
sg4
(lp12382
(dp12383
g7
I0
sg8
g15
sg10
I53
sg11
VPeroxisome proliferator-activated receptor Beta/Delta
p12384
sg13
I4
sa(dp12385
g7
I73
sg8
VP51843
p12386
sg10
I36
sg11
Vnuclear hormone receptor superfamily
p12387
sg13
I4
sasg23
(lp12388
(dp12389
g7
I147
sg26
VC0699748
p12390
sg10
I12
sg11
Vpathogenesis
p12391
sg13
I1
sa(dp12392
g7
I137
sg26
VC0033860
p12393
sg10
I9
sg11
Vpsoriasis
p12394
sg13
I1
sasa(dp12395
g2
S'RAB24 has also been connected to several diseases including ataxia, cancer and tuberculosis.\n'
p12396
sg4
(lp12397
(dp12398
g7
I0
sg8
g15
sg10
I5
sg11
VRAB24
p12399
sg13
I1
sasg23
(lp12400
(dp12401
g7
I60
sg26
VC0004134
p12402
sg10
I6
sg11
Vataxia
p12403
sg13
I1
sa(dp12404
g7
I79
sg26
VC0041296
p12405
sg10
I12
sg11
Vtuberculosis
p12406
sg13
I1
sa(dp12407
g7
I68
sg26
VC0006826
p12408
sg10
I6
sg11
Vcancer
p12409
sg13
I1
sasa(dp12410
g2
S'We identified 12 biomarkers consistently associated with either clinical groups "upstream" towards culture-positive TB on the TB disease spectrum (CD14, FCGR1A, FPR1, MMP9, RAB24, SEC14L1, and TIMP2) or "downstream" towards a decreased likelihood of TB disease (BLR1, CD3E, CD8A, IL7R, and TGFBR2), suggesting a correlation with MTB-related pathology and high relevance to a future POC test for pediatric TB.\n'
p12411
sg4
(lp12412
(dp12413
g7
I147
sg8
VP08571
p12414
sg10
I4
sg11
VCD14
p12415
sg13
I1
sa(dp12416
g7
I173
sg8
g15
sg10
I5
sg11
VRAB24
p12417
sg13
I1
sa(dp12418
g7
I153
sg8
VP12314
p12419
sg10
I6
sg11
VFCGR1A
p12420
sg13
I1
sa(dp12421
g7
I268
sg8
VP07766
p12422
sg10
I4
sg11
VCD3E
p12423
sg13
I1
sa(dp12424
g7
I274
sg8
VP01732
p12425
sg10
I4
sg11
VCD8A
p12426
sg13
I1
sa(dp12427
g7
I262
sg8
VP32302
p12428
sg10
I4
sg11
VBLR1
p12429
sg13
I1
sa(dp12430
g7
I180
sg8
g15
sg10
I7
sg11
VSEC14L1
p12431
sg13
I1
sa(dp12432
g7
I167
sg8
VP14780
p12433
sg10
I4
sg11
VMMP9
p12434
sg13
I1
sa(dp12435
g7
I193
sg8
VP16035
p12436
sg10
I5
sg11
VTIMP2
p12437
sg13
I1
sa(dp12438
g7
I161
sg8
VP21462
p12439
sg10
I4
sg11
VFPR1
p12440
sg13
I1
sa(dp12441
g7
I290
sg8
VP37173
p12442
sg10
I6
sg11
VTGFBR2
p12443
sg13
I1
sasg23
(lp12444
(dp12445
g7
I341
sg26
VC0677042
p12446
sg10
I9
sg11
Vpathology
p12447
sg13
I1
sasa(dp12448
g2
S'Taken together, our results suggest that a defect in RAB24, a gene associated with autophagy, is highly associated with and may contribute to canine hereditary ataxia in Old English Sheepdogs and Gordon Setters.\n'
p12449
sg4
(lp12450
(dp12451
g7
I53
sg8
g15
sg10
I5
sg11
VRAB24
p12452
sg13
I1
sasg23
(lp12453
(dp12454
g7
I149
sg26
VC0004138
p12455
sg10
I17
sg11
Vhereditary ataxia
p12456
sg13
I2
sasa(dp12457
g2
S'Since 2013, 3 female patients; 2 of them with Binder syndrome and 1 cleft lip/palate patient (average 18 years) with previous rhinoplasty (3-6 procedures) are subjected to secondary rhinoplasty using GPFF turning it over the osteochondral nasal framework.\n'
p12458
sg4
(lp12459
sg23
(lp12460
(dp12461
g7
I68
sg26
VC0158646
p12462
sg10
I16
sg11
Vcleft lip/palate
p12463
sg13
I2
sa(dp12464
g7
I46
sg26
VC0220692
p12465
sg10
I15
sg11
VBinder syndrome
p12466
sg13
I2
sasa(dp12467
g2
S'In the remaining ten cases who could be followed up (31.2%), seven patients (21.8%) showed partial resolution with no further surgery required, two patients (6.2%) required additional excision of redundant mucosa as second procedure, one patient (3%) with associated cleft lip/palate and tracheomalacia had to undergo a tracheostomy.\n'
p12468
sg4
(lp12469
sg23
(lp12470
(dp12471
g7
I267
sg26
VC0158646
p12472
sg10
I16
sg11
Vcleft lip/palate
p12473
sg13
I2
sa(dp12474
g7
I288
sg26
VC0948187
p12475
sg10
I14
sg11
Vtracheomalacia
p12476
sg13
I1
sa(dp12477
g7
I196
sg26
VC1265575
p12478
sg10
I16
sg11
Vredundant mucosa
p12479
sg13
I2
sasa(dp12480
g2
S'This review focuses on the effects of oxidative stress and the role of a particular antioxidant system-the Keap1-Nrf2-ARE pathway-on ocular diseases, specifically age-related macular degeneration, cataracts, diabetic retinopathy, and glaucoma.\n'
p12481
sg4
(lp12482
(dp12483
g7
I113
sg8
g15
sg10
I4
sg11
VNrf2
p12484
sg13
I1
sa(dp12485
g7
I107
sg8
g15
sg10
I5
sg11
VKeap1
p12486
sg13
I1
sasg23
(lp12487
(dp12488
g7
I197
sg26
VC0521707
p12489
sg10
I9
sg11
Vcataracts
p12490
sg13
I1
sa(dp12491
g7
I163
sg26
VC0242383
p12492
sg10
I32
sg11
Vage-related macular degeneration
p12493
sg13
I3
sa(dp12494
g7
I234
sg26
VC0017601
p12495
sg10
I8
sg11
Vglaucoma
p12496
sg13
I1
sa(dp12497
g7
I208
sg26
VC0011884
p12498
sg10
I20
sg11
Vdiabetic retinopathy
p12499
sg13
I2
sa(dp12500
g7
I38
sg26
VC0242606
p12501
sg10
I16
sg11
Voxidative stress
p12502
sg13
I2
sasa(dp12503
g2
S'Tim9 and Tim10 are translocase components of the intermembrane space, related to deafness-dystonia peptide 1 (DDP1).\n'
p12504
sg4
(lp12505
(dp12506
g7
I81
sg8
g15
sg10
I27
sg11
Vdeafness-dystonia peptide 1
p12507
sg13
I3
sa(dp12508
g7
I110
sg8
g15
sg10
I4
sg11
VDDP1
p12509
sg13
I1
sa(dp12510
g7
I0
sg8
g15
sg10
I4
sg11
VTim9
p12511
sg13
I1
sa(dp12512
g7
I9
sg8
VP62072
p12513
sg10
I5
sg11
VTim10
p12514
sg13
I1
sasg23
(lp12515
(dp12516
g7
I81
sg26
VC0011053
p12517
sg10
I8
sg11
Vdeafness
p12518
sg13
I1
sa(dp12519
g7
I90
sg26
VC0393593
p12520
sg10
I8
sg11
Vdystonia
p12521
sg13
I1
sasa(dp12522
g2
S'This is the first report of analysis of human serum proteome alterations in leptospirosis patients, which revealed several differentially expressed proteins, including Alfa-1-antitrypsin, vitronectin, ceruloplasmin, G-protein signaling regulator, apolipoprotein A-IV, which have not been reported in context of leptospirosis previously.\n'
p12523
sg4
(lp12524
(dp12525
g7
I201
sg8
VP00450
p12526
sg10
I13
sg11
Vceruloplasmin
p12527
sg13
I1
sa(dp12528
g7
I216
sg8
g15
sg10
I9
sg11
VG-protein
p12529
sg13
I1
sa(dp12530
g7
I168
sg8
g15
sg10
I18
sg11
VAlfa-1-antitrypsin
p12531
sg13
I1
sa(dp12532
g7
I247
sg8
VP08519
p12533
sg10
I19
sg11
Vapolipoprotein A-IV
p12534
sg13
I2
sa(dp12535
g7
I188
sg8
VP04004
p12536
sg10
I11
sg11
Vvitronectin
p12537
sg13
I1
sasg23
(lp12538
(dp12539
g7
I76
sg26
VC0023364
p12540
sg10
I13
sg11
Vleptospirosis
p12541
sg13
I1
sa(dp12542
g7
I76
sg26
VC0023364
p12543
sg10
I13
sg11
Vleptospirosis
p12544
sg13
I1
sasa(dp12545
g2
S'MED15 is part of the multiprotein Mediator complex which presents an integrative hub for transcriptional regulation and is known to be deregulated in several malignancies, such as prostate cancer and bladder cancer role, whereas the role of the Mediator complex in TGCT has not been investigated so far.\n'
p12546
sg4
(lp12547
(dp12548
g7
I0
sg8
g15
sg10
I5
sg11
VMED15
p12549
sg13
I1
sasg23
(lp12550
(dp12551
g7
I265
sg26
VC1336708
p12552
sg10
I4
sg11
VTGCT
p12553
sg13
I1
sa(dp12554
g7
I180
sg26
VC0600139
p12555
sg10
I15
sg11
Vprostate cancer
p12556
sg13
I2
sa(dp12557
g7
I158
sg26
VC0006826
p12558
sg10
I12
sg11
Vmalignancies
p12559
sg13
I1
sa(dp12560
g7
I200
sg26
VC0699885
p12561
sg10
I14
sg11
Vbladder cancer
p12562
sg13
I2
sasa(dp12563
g2
S'The mediator subunit MED15 is essential for transforming growth factor (TGF)-Beta signaling and involved in breast and prostate cancers.\n'
p12564
sg4
(lp12565
(dp12566
g7
I4
sg8
g15
sg10
I22
sg11
Vmediator subunit MED15
p12567
sg13
I3
sa(dp12568
g7
I44
sg8
g15
sg10
I37
sg11
Vtransforming growth factor (TGF)-Beta
p12569
sg13
I4
sasg23
(lp12570
(dp12571
g7
I119
sg26
VC0376358
p12572
sg10
I16
sg11
Vprostate cancers
p12573
sg13
I2
sasa(dp12574
g2
S'In this study, we investigated whether the mediator subunit MED15 is implicated in castration-resistant prostate cancer (CRPC).\n'
p12575
sg4
(lp12576
(dp12577
g7
I43
sg8
g15
sg10
I22
sg11
Vmediator subunit MED15
p12578
sg13
I3
sasg23
(lp12579
(dp12580
g7
I104
sg26
VC0600139
p12581
sg10
I15
sg11
Vprostate cancer
p12582
sg13
I2
sasa(dp12583
g2
S'MED15 expression and copy number/rearrangement status were assessed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively on 718 prostate cancer (PCa) specimens and sequenced by Sanger on a subset.\n'
p12584
sg4
(lp12585
(dp12586
g7
I0
sg8
g15
sg10
I5
sg11
VMED15
p12587
sg13
I1
sasg23
(lp12588
(dp12589
g7
I182
sg26
VC0268398
p12590
sg10
I3
sg11
VPCa
p12591
sg13
I1
sa(dp12592
g7
I165
sg26
VC0600139
p12593
sg10
I15
sg11
Vprostate cancer
p12594
sg13
I2
sasa(dp12595
g2
S'CD56 (NCAM), a neural adhesion molecule, is normally expressed on natural killer cells and subsets of T cells and is commonly seen on hematolymphoid neoplasms such as plasma cell myeloma and acute myelogenous leukemia.\n'
p12596
sg4
(lp12597
(dp12598
g7
I15
sg8
g15
sg10
I24
sg11
Vneural adhesion molecule
p12599
sg13
I3
sa(dp12600
g7
I6
sg8
g15
sg10
I4
sg11
VNCAM
p12601
sg13
I1
sasg23
(lp12602
(dp12603
g7
I167
sg26
VC0026764
p12604
sg10
I19
sg11
Vplasma cell myeloma
p12605
sg13
I3
sa(dp12606
g7
I22
sg26
VC0001511
p12607
sg10
I8
sg11
Vadhesion
p12608
sg13
I1
sa(dp12609
g7
I191
sg26
VC0023467
p12610
sg10
I26
sg11
Vacute myelogenous leukemia
p12611
sg13
I3
sa(dp12612
g7
I149
sg26
VC0027651
p12613
sg10
I9
sg11
Vneoplasms
p12614
sg13
I1
sasa(dp12615
g2
S'CD56 is a neural adhesion molecule and expressed in 70-80% cases of multiple myeloma (MM).\n'
p12616
sg4
(lp12617
(dp12618
g7
I10
sg8
g15
sg10
I24
sg11
Vneural adhesion molecule
p12619
sg13
I3
sasg23
(lp12620
(dp12621
g7
I17
sg26
VC0001511
p12622
sg10
I8
sg11
Vadhesion
p12623
sg13
I1
sa(dp12624
g7
I68
sg26
VC0026764
p12625
sg10
I16
sg11
Vmultiple myeloma
p12626
sg13
I2
sasa(dp12627
g2
S'While DC-STAMP gene expression is upregulated in the gingival tissue with periodontitis, its pathophysiological roles in periodontitis remain unclear.\n'
p12628
sg4
(lp12629
(dp12630
g7
I6
sg8
g15
sg10
I13
sg11
VDC-STAMP gene
p12631
sg13
I2
sasg23
(lp12632
(dp12633
g7
I74
sg26
VC0031099
p12634
sg10
I13
sg11
Vperiodontitis
p12635
sg13
I1
sa(dp12636
g7
I74
sg26
VC0031099
p12637
sg10
I13
sg11
Vperiodontitis
p12638
sg13
I1
sasa(dp12639
g2
S'To evaluate the effects of DC-STAMP in periodontitis, anti-DC-STAMP-monoclonal antibody (mAb) was tested in a mouse model of ligature-induced periodontitis ( n = 6-7/group) where Pasteurella pneumotropica ( Pp)-reactive immune response activated T cells to produce receptor activator of nuclear factor kappa-B ligand (RANKL), which, in turn, promotes the periodontal bone loss via upregulation of osteoclastogenesis.\n'
p12640
sg4
(lp12641
(dp12642
g7
I265
sg8
g15
sg10
I51
sg11
Vreceptor activator of nuclear factor kappa-B ligand
p12643
sg13
I7
sa(dp12644
g7
I179
sg8
g15
sg10
I47
sg11
VPasteurella pneumotropica ( Pp)-reactive immune
p12645
sg13
I5
sa(dp12646
g7
I318
sg8
g15
sg10
I5
sg11
VRANKL
p12647
sg13
I1
sa(dp12648
g7
I54
sg8
g15
sg10
I39
sg11
Vanti-DC-STAMP-monoclonal antibody (mAb)
p12649
sg13
I3
sasg23
(lp12650
(dp12651
g7
I39
sg26
VC0031099
p12652
sg10
I13
sg11
Vperiodontitis
p12653
sg13
I1
sa(dp12654
g7
I355
sg26
VC0002382
p12655
sg10
I21
sg11
Vperiodontal bone loss
p12656
sg13
I3
sa(dp12657
g7
I39
sg26
VC0031099
p12658
sg10
I13
sg11
Vperiodontitis
p12659
sg13
I1
sasa(dp12660
g2
S'At dose level 3 (60 mg/m(2) docetaxel, 1,000 mg/m(2) capecitabine, 100 mg/m(2) oxaliplatin), 1 diarrhea (DLT) was found among 6 patients while at dose level 4 (60 mg/m(2) docetaxel, 800 mg/m(2) capecitabine, 130 mg/m(2) oxaliplatin), 2 DLTs (febrile neutropenia and diarrhea) were observed among 3 patients.\n'
p12661
sg4
(lp12662
sg23
(lp12663
(dp12664
g7
I95
sg26
VC0011991
p12665
sg10
I8
sg11
Vdiarrhea
p12666
sg13
I1
sa(dp12667
g7
I95
sg26
VC0011991
p12668
sg10
I8
sg11
Vdiarrhea
p12669
sg13
I1
sa(dp12670
g7
I242
sg26
VC0746883
p12671
sg10
I19
sg11
Vfebrile neutropenia
p12672
sg13
I2
sasa(dp12673
g2
S'The potential roles of Ski2w and Dom3z on the clearance of degraded nuclear and cytoplasmic RNA raised their possibilities as susceptibility genes of systemic lupus erythematosus that is a disease with flawed processes in the removal of apoptotic materials.\n'
p12674
sg4
(lp12675
(dp12676
g7
I23
sg8
g15
sg10
I5
sg11
VSki2w
p12677
sg13
I1
sasg23
(lp12678
(dp12679
g7
I150
sg26
VC0024141
p12680
sg10
I28
sg11
Vsystemic lupus erythematosus
p12681
sg13
I3
sasa(dp12682
g2
S'Copolymers of 1,5-dioxepan-2-one (DXO) and L- or D,L-dilactide have been synthesized and characterized.\n'
p12683
sg4
(lp12684
sg23
(lp12685
sa(dp12686
g2
S'The molar ratio of the two monomers was around 20/80 of DXO and L- or D,L-lactide respectively.\n'
p12687
sg4
(lp12688
sg23
(lp12689
sa(dp12690
g2
S'The PG response to IL-1 alpha was suppressed to about 50% by simultaneous addition of CRF in endothelial cells (75.6 +/- 6.2 vs. 159.7 +/- 14.9 ng 6-keto-PGF1 alpha/mg protein) and fibroblasts (115.5 +/- 23 vs. 233.6 +/- 42 ng PGE2/mg protein).\n'
p12691
sg4
(lp12692
(dp12693
g7
I86
sg8
VP06850
p12694
sg10
I3
sg11
VCRF
p12695
sg13
I1
sa(dp12696
g7
I19
sg8
VP01583
p12697
sg10
I10
sg11
VIL-1 alpha
p12698
sg13
I2
sasg23
(lp12699
(dp12700
g7
I86
sg26
VC0022661
p12701
sg10
I3
sg11
VCRF
p12702
sg13
I1
sasa(dp12703
g2
S'ACEi protected from lymphangiogenesis and associated inflammation, preserved glomerular podoplanin protein expression, and reduced glomerulosclerosis, proteinuria, tubulointerstitial fibrosis, and blood capillary rarefaction at 32 wk.\n'
p12704
sg4
(lp12705
(dp12706
g7
I88
sg8
g15
sg10
I18
sg11
Vpodoplanin protein
p12707
sg13
I2
sasg23
(lp12708
(dp12709
g7
I131
sg26
VC0178664
p12710
sg10
I18
sg11
Vglomerulosclerosis
p12711
sg13
I1
sa(dp12712
g7
I53
sg26
VC0021368
p12713
sg10
I12
sg11
Vinflammation
p12714
sg13
I1
sa(dp12715
g7
I183
sg26
VC0016059
p12716
sg10
I8
sg11
Vfibrosis
p12717
sg13
I1
sasa(dp12718
g2
S'Prevention of glomerular podoplanin loss and proteinuria could be attributed to the known intraglomerular pressure-lowering effects of ACEi.\n'
p12719
sg4
(lp12720
sg23
(lp12721
sa(dp12722
g2
S'The rising incidence of renal cell carcinoma, its more frequent early detection (stage T1a) and the increasing prevalence of chronic renal failure with higher morbidity and shorter life expectancy underscore the need for multimodal focal nephron-sparing therapy.\n'
p12723
sg4
(lp12724
sg23
(lp12725
(dp12726
g7
I24
sg26
VC0007134
p12727
sg10
I20
sg11
Vrenal cell carcinoma
p12728
sg13
I3
sa(dp12729
g7
I125
sg26
VC0022661
p12730
sg10
I21
sg11
Vchronic renal failure
p12731
sg13
I3
sasa(dp12732
g2
S'Decrease of podoplanin (PDPN) in podocytes and podocyte loss has been associated with the development of proteinuria.\n'
p12733
sg4
(lp12734
(dp12735
g7
I12
sg8
g15
sg10
I10
sg11
Vpodoplanin
p12736
sg13
I1
sa(dp12737
g7
I24
sg8
g15
sg10
I4
sg11
VPDPN
p12738
sg13
I1
sasg23
(lp12739
sa(dp12740
g2
S'Compared with radical nephrectomy, partial nephrectomy can prevent chronic kidney disease and still achieve an excellent oncological outcome for T1 renal tumours, in particular T1a tumours and tumours with a low R.E.N.A.L.\n'
p12741
sg4
(lp12742
(dp12743
g7
I177
sg8
g15
sg10
I3
sg11
VT1a
p12744
sg13
I1
sasg23
(lp12745
(dp12746
g7
I154
sg26
VC0027651
p12747
sg10
I7
sg11
Vtumours
p12748
sg13
I1
sa(dp12749
g7
I67
sg26
VC1561643
p12750
sg10
I22
sg11
Vchronic kidney disease
p12751
sg13
I3
sa(dp12752
g7
I154
sg26
VC0027651
p12753
sg10
I7
sg11
Vtumours
p12754
sg13
I1
sa(dp12755
g7
I148
sg26
VC0022665
p12756
sg10
I13
sg11
Vrenal tumours
p12757
sg13
I2
sasa(dp12758
g2
S'The recent identification of the novel uPAR ligand SRPX2 (Sushi repeat protein, X-linked 2) and the regulation of both the SRPX2 and PLAUR genes by transcription factor FOXP2 has shed novel and exciting insights into the role of uPAR-related molecular networks in rolandic epilepsy, in developmental verbal dyspraxia, in perisylvian polymicrogyria, and generally in disorders of the speech areas and circuits.\n'
p12759
sg4
(lp12760
(dp12761
g7
I51
sg8
g15
sg10
I5
sg11
VSRPX2
p12762
sg13
I1
sa(dp12763
g7
I148
sg8
VP35398
p12764
sg10
I26
sg11
Vtranscription factor FOXP2
p12765
sg13
I3
sa(dp12766
g7
I133
sg8
VP01893
p12767
sg10
I11
sg11
VPLAUR genes
p12768
sg13
I2
sa(dp12769
g7
I51
sg8
g15
sg10
I5
sg11
VSRPX2
p12770
sg13
I1
sasg23
(lp12771
(dp12772
g7
I264
sg26
VC0376532
p12773
sg10
I17
sg11
Vrolandic epilepsy
p12774
sg13
I2
sa(dp12775
g7
I286
sg26
VC0750927
p12776
sg10
I30
sg11
Vdevelopmental verbal dyspraxia
p12777
sg13
I3
sa(dp12778
g7
I333
sg26
VC0266464
p12779
sg10
I14
sg11
Vpolymicrogyria
p12780
sg13
I1
sasa(dp12781
g2
S'Mutations in SRPX2 (Sushi-Repeat Protein, X-linked 2) cause rolandic epilepsy with speech impairment (RESDX syndrome) or with altered development of the speech cortex (bilateral perisylvian polymicrogyria).\n'
p12782
sg4
(lp12783
(dp12784
g7
I13
sg8
g15
sg10
I5
sg11
VSRPX2
p12785
sg13
I1
sasg23
(lp12786
(dp12787
g7
I102
sg26
VC1845070
p12788
sg10
I5
sg11
VRESDX
p12789
sg13
I1
sa(dp12790
g7
I108
sg26
VC0039082
p12791
sg10
I8
sg11
Vsyndrome
p12792
sg13
I1
sa(dp12793
g7
I60
sg26
VC0376532
p12794
sg10
I17
sg11
Vrolandic epilepsy
p12795
sg13
I2
sa(dp12796
g7
I190
sg26
VC0266464
p12797
sg10
I14
sg11
Vpolymicrogyria
p12798
sg13
I1
sa(dp12799
g7
I83
sg26
VC0233715
p12800
sg10
I17
sg11
Vspeech impairment
p12801
sg13
I2
sasa(dp12802
g2
S'SPR analysis indicated that the p.Y72S mutation associated with rolandic epilepsy and perisylvian polymicrogyria, led to a 5.8-fold gain-of-affinity of SRPX2 with uPAR.\n'
p12803
sg4
(lp12804
(dp12805
g7
I152
sg8
g15
sg10
I5
sg11
VSRPX2
p12806
sg13
I1
sasg23
(lp12807
(dp12808
g7
I64
sg26
VC0376532
p12809
sg10
I17
sg11
Vrolandic epilepsy
p12810
sg13
I2
sa(dp12811
g7
I98
sg26
VC0266464
p12812
sg10
I14
sg11
Vpolymicrogyria
p12813
sg13
I1
sasa(dp12814
g2
S'Morphine dependence can induce testis cell apoptosis, an increase in testis NOS positive cells, a decrease in CaM content and the activity of SOD and GSHPx in the testis.\n'
p12815
sg4
(lp12816
(dp12817
g7
I150
sg8
VP07203
p12818
sg10
I5
sg11
VGSHPx
p12819
sg13
I1
sa(dp12820
g7
I142
sg8
VP00441
p12821
sg10
I3
sg11
VSOD
p12822
sg13
I1
sa(dp12823
g7
I110
sg8
VP01768
p12824
sg10
I3
sg11
VCaM
p12825
sg13
I1
sasg23
(lp12826
(dp12827
g7
I0
sg26
VC0026552
p12828
sg10
I19
sg11
VMorphine dependence
p12829
sg13
I2
sa(dp12830
g7
I110
sg26
VC1861821
p12831
sg10
I3
sg11
VCaM
p12832
sg13
I1
sasa(dp12833
g2
S'Given the long postulated role of BDNF in epileptogenesis, TRPC3 channels may be a critical component in the underlying pathophysiology of seizure and epilepsy.\n'
p12834
sg4
(lp12835
(dp12836
g7
I59
sg8
g15
sg10
I14
sg11
VTRPC3 channels
p12837
sg13
I2
sasg23
(lp12838
(dp12839
g7
I151
sg26
VC0014544
p12840
sg10
I8
sg11
Vepilepsy
p12841
sg13
I1
sa(dp12842
g7
I139
sg26
VC0036572
p12843
sg10
I7
sg11
Vseizure
p12844
sg13
I1
sasa(dp12845
g2
S'In this study, we investigated the precise role of TRPC3 channels in pilocarpine-induced status epilepticus (SE).\n'
p12846
sg4
(lp12847
(dp12848
g7
I51
sg8
g15
sg10
I14
sg11
VTRPC3 channels
p12849
sg13
I2
sasg23
(lp12850
(dp12851
g7
I89
sg26
VC0038220
p12852
sg10
I18
sg11
Vstatus epilepticus
p12853
sg13
I2
sa(dp12854
g7
I109
sg26
VC0038220
p12855
sg10
I2
sg11
VSE
p12856
sg13
I1
sasa(dp12857
g2
S'Following status epilepticus (SE), up-regulated transient receptor potential canonical channel-3 (TRPC3), a Ca2+-permeable cation channels in endothelial cells, is relevant to vasogenic edema formation in the rat piriform cortex.\n'
p12858
sg4
(lp12859
(dp12860
g7
I48
sg8
g15
sg10
I48
sg11
Vtransient receptor potential canonical channel-3
p12861
sg13
I5
sa(dp12862
g7
I98
sg8
g15
sg10
I5
sg11
VTRPC3
p12863
sg13
I1
sasg23
(lp12864
(dp12865
g7
I186
sg26
VC0013604
p12866
sg10
I5
sg11
Vedema
p12867
sg13
I1
sa(dp12868
g7
I30
sg26
VC0038220
p12869
sg10
I2
sg11
VSE
p12870
sg13
I1
sa(dp12871
g7
I10
sg26
VC0038220
p12872
sg10
I18
sg11
Vstatus epilepticus
p12873
sg13
I2
sasa(dp12874
g2
S'Therefore, BDNF and TRPC3 should be involved in the occurrence and development of epilepsy.\n'
p12875
sg4
(lp12876
(dp12877
g7
I20
sg8
g15
sg10
I5
sg11
VTRPC3
p12878
sg13
I1
sasg23
(lp12879
(dp12880
g7
I82
sg26
VC0014544
p12881
sg10
I8
sg11
Vepilepsy
p12882
sg13
I1
sasa(dp12883
g2
S'Studies using mouse models as well as recent genetic and transcriptomic human findings point to an important role for TRPC3 signaling in cerebellar ataxia.\n'
p12884
sg4
(lp12885
(dp12886
g7
I118
sg8
g15
sg10
I5
sg11
VTRPC3
p12887
sg13
I1
sasg23
(lp12888
(dp12889
g7
I137
sg26
VC0007758
p12890
sg10
I17
sg11
Vcerebellar ataxia
p12891
sg13
I2
sasa(dp12892
g2
S'We measured the expression of two subtypes of TRPC channels, TRPC3 and TRPC6, in temporal lobe epileptic foci excised from patients with intractable epilepsy and in hippocampus of mice with pilocarpine-induced status epilepticus (SE), an animal model of TLE.\n'
p12893
sg4
(lp12894
(dp12895
g7
I61
sg8
g15
sg10
I5
sg11
VTRPC3
p12896
sg13
I1
sa(dp12897
g7
I71
sg8
g15
sg10
I5
sg11
VTRPC6
p12898
sg13
I1
sasg23
(lp12899
(dp12900
g7
I230
sg26
VC0038220
p12901
sg10
I2
sg11
VSE
p12902
sg13
I1
sa(dp12903
g7
I95
sg26
VC0014544
p12904
sg10
I9
sg11
Vepileptic
p12905
sg13
I1
sa(dp12906
g7
I254
sg26
VC0014556
p12907
sg10
I3
sg11
VTLE
p12908
sg13
I1
sa(dp12909
g7
I210
sg26
VC0038220
p12910
sg10
I18
sg11
Vstatus epilepticus
p12911
sg13
I2
sa(dp12912
g7
I137
sg26
VC1096063
p12913
sg10
I20
sg11
Vintractable epilepsy
p12914
sg13
I2
sasa(dp12915
g2
S'The aim of the present study is to explore the expression pattern of Pin1 in patients with refractory epilepsy and in a chronic pilocarpine-induced epileptic mouse model.\n'
p12916
sg4
(lp12917
(dp12918
g7
I69
sg8
g15
sg10
I4
sg11
VPin1
p12919
sg13
I1
sasg23
(lp12920
(dp12921
g7
I148
sg26
VC0014544
p12922
sg10
I9
sg11
Vepileptic
p12923
sg13
I1
sa(dp12924
g7
I91
sg26
VC1096063
p12925
sg10
I19
sg11
Vrefractory epilepsy
p12926
sg13
I2
sasa(dp12927
g2
S'Our results are the first to indicate that the expression of Pin1 in epileptic brain tissue could play important roles in epilepsy.\n'
p12928
sg4
(lp12929
(dp12930
g7
I61
sg8
g15
sg10
I4
sg11
VPin1
p12931
sg13
I1
sasg23
(lp12932
(dp12933
g7
I69
sg26
VC0014544
p12934
sg10
I9
sg11
Vepileptic
p12935
sg13
I1
sa(dp12936
g7
I122
sg26
VC0014544
p12937
sg10
I8
sg11
Vepilepsy
p12938
sg13
I1
sasa(dp12939
g2
S'There is evidence that with longer duration of migraine disease (DOD) amplitudes and habituation of CNV become progressively abnormal.\n'
p12940
sg4
(lp12941
sg23
(lp12942
(dp12943
g7
I47
sg26
VC0149931
p12944
sg10
I8
sg11
Vmigraine
p12945
sg13
I1
sa(dp12946
g7
I85
sg26
VC0013170
p12947
sg10
I11
sg11
Vhabituation
p12948
sg13
I1
sasa(dp12949
g2
S'According to DOD, the total sample of migraine patients was divided into two groups (group a: DOD &lt;121 months, n = 17 subjects, group b: DOD &gt;120 months, n = 15 subjects).\n'
p12950
sg4
(lp12951
sg23
(lp12952
(dp12953
g7
I131
sg26
VC0348801
p12954
sg10
I7
sg11
Vgroup b
p12955
sg13
I2
sa(dp12956
g7
I38
sg26
VC0149931
p12957
sg10
I8
sg11
Vmigraine
p12958
sg13
I1
sasa(dp12959
g2
S"Near-complete fragmentation of proteins up to 29 kDa is achieved with UVPD including the unambiguous localization of a single residue mutation and several protein modifications on Pin1 (Q13526), a protein implicated in the development of Alzheimer's disease and in cancer pathogenesis.\n"
p12960
sg4
(lp12961
(dp12962
g7
I180
sg8
g15
sg10
I4
sg11
VPin1
p12963
sg13
I1
sasg23
(lp12964
(dp12965
g7
I238
sg26
VC1521724
p12966
sg10
I19
sg11
VAlzheimer's disease
p12967
sg13
I2
sa(dp12968
g7
I14
sg26
VC0332472
p12969
sg10
I13
sg11
Vfragmentation
p12970
sg13
I1
sa(dp12971
g7
I265
sg26
VC0006826
p12972
sg10
I6
sg11
Vcancer
p12973
sg13
I1
sa(dp12974
g7
I272
sg26
VC0699748
p12975
sg10
I12
sg11
Vpathogenesis
p12976
sg13
I1
sasa(dp12977
g2
S"In the present study, we analysed the potential involvement of Pin1 in selective vulnerability of hippocampal neurons to neurofibrillary degeneration in Alzheimer's disease.\n"
p12978
sg4
(lp12979
(dp12980
g7
I63
sg8
g15
sg10
I4
sg11
VPin1
p12981
sg13
I1
sasg23
(lp12982
(dp12983
g7
I153
sg26
VC1521724
p12984
sg10
I19
sg11
VAlzheimer's disease
p12985
sg13
I2
sa(dp12986
g7
I121
sg26
VC0085400
p12987
sg10
I28
sg11
Vneurofibrillary degeneration
p12988
sg13
I2
sasa(dp12989
g2
S"Since the main markers of granulovacuolar degeneration do not co-label Pin1-immunoreactive granules, we propose that these granules may represent a new lesion in Alzheimer's disease.\n"
p12990
sg4
(lp12991
(dp12992
g7
I71
sg8
g15
sg10
I4
sg11
VPin1
p12993
sg13
I1
sasg23
(lp12994
(dp12995
g7
I26
sg26
VC0333454
p12996
sg10
I28
sg11
Vgranulovacuolar degeneration
p12997
sg13
I2
sa(dp12998
g7
I162
sg26
VC1521724
p12999
sg10
I19
sg11
VAlzheimer's disease
p13000
sg13
I2
sasa(dp13001
g2
S"In this context, Pin1 becomes depleted from the nucleus in Alzheimer's disease (AD) neurons when it is redirected to the large amounts of hyperphosphorylated tau associated with the neurofibrillary tangles.\n"
p13002
sg4
(lp13003
(dp13004
g7
I17
sg8
g15
sg10
I4
sg11
VPin1
p13005
sg13
I1
sasg23
(lp13006
(dp13007
g7
I59
sg26
VC1521724
p13008
sg10
I19
sg11
VAlzheimer's disease
p13009
sg13
I2
sa(dp13010
g7
I80
sg26
VC1521724
p13011
sg10
I2
sg11
VAD
p13012
sg13
I1
sa(dp13013
g7
I182
sg26
VC0085400
p13014
sg10
I23
sg11
Vneurofibrillary tangles
p13015
sg13
I2
sasa(dp13016
g2
S'Women (N = 40) with incident bacterial vaginosis (Nugent 7-10) had significantly lower concentrations of lactobacilli and higher concentrations of Gardnerella vaginalis, Atopobium vaginae, and Prevotella bivia, at the incident visit and when concentrations of proinflammatory cytokines (IL-1Beta, IL-12p70) were increased and IP-10 and elafin were decreased.\n'
p13017
sg4
(lp13018
(dp13019
g7
I287
sg8
VP01584
p13020
sg10
I8
sg11
VIL-1Beta
p13021
sg13
I1
sasg23
(lp13022
(dp13023
g7
I147
sg26
VC0085166
p13024
sg10
I11
sg11
VGardnerella
p13025
sg13
I1
sa(dp13026
g7
I159
sg26
VC0750103
p13027
sg10
I9
sg11
Vvaginalis
p13028
sg13
I1
sa(dp13029
g7
I29
sg26
VC0085166
p13030
sg10
I19
sg11
Vbacterial vaginosis
p13031
sg13
I2
sasa(dp13032
g2
S'Using a multiplex biochip array method (Randox, United Kingdom), the interleukins (ILs) IL-1Alfa, IL-1Beta, IL-2, IL-4, IL-6, IL-8, and IL-10; vascular endothelial growth factor; interferon Gamma, tumor necrosis factor Alfa ; monocyte chemotactic protein 1 (MCP-1); and epidermal growth factor were measured in citrated plasma samples drawn from the arms and legs of 24 patients with varicose veins and 24 controls.\n'
p13033
sg4
(lp13034
(dp13035
g7
I179
sg8
VP01579
p13036
sg10
I16
sg11
Vinterferon Gamma
p13037
sg13
I2
sa(dp13038
g7
I270
sg8
VP01133
p13039
sg10
I23
sg11
Vepidermal growth factor
p13040
sg13
I3
sa(dp13041
g7
I197
sg8
VP01375
p13042
sg10
I59
sg11
Vtumor necrosis factor Alfa ; monocyte chemotactic protein 1
p13043
sg13
I9
sa(dp13044
g7
I98
sg8
VP01584
p13045
sg10
I8
sg11
VIL-1Beta
p13046
sg13
I1
sa(dp13047
g7
I108
sg8
VP60568
p13048
sg10
I4
sg11
VIL-2
p13049
sg13
I1
sa(dp13050
g7
I69
sg8
VP05231
p13051
sg10
I27
sg11
Vinterleukins (ILs) IL-1Alfa
p13052
sg13
I3
sa(dp13053
g7
I114
sg8
VP05112
p13054
sg10
I4
sg11
VIL-4
p13055
sg13
I1
sa(dp13056
g7
I143
sg8
g15
sg10
I34
sg11
Vvascular endothelial growth factor
p13057
sg13
I4
sa(dp13058
g7
I120
sg8
VP05231
p13059
sg10
I4
sg11
VIL-6
p13060
sg13
I1
sa(dp13061
g7
I258
sg8
VP41597
p13062
sg10
I5
sg11
VMCP-1
p13063
sg13
I1
sasg23
(lp13064
(dp13065
g7
I197
sg26
VC0333516
p13066
sg10
I14
sg11
Vtumor necrosis
p13067
sg13
I2
sa(dp13068
g7
I83
sg26
VC1843916
p13069
sg10
I3
sg11
VILs
p13070
sg13
I1
sa(dp13071
g7
I350
sg26
VC0206655
p13072
sg10
I4
sg11
Varms
p13073
sg13
I1
sa(dp13074
g7
I384
sg26
VC0042345
p13075
sg10
I14
sg11
Vvaricose veins
p13076
sg13
I2
sa(dp13077
g7
I69
sg26
VC1843916
p13078
sg10
I12
sg11
Vinterleukins
p13079
sg13
I1
sasa(dp13080
g2
S'Recently, germline fumarate hydratase (FH) mutations have been identified in a subset of PGL/PCC, and patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC) may have an increased risk of developing PGL/PCC.\n'
p13081
sg4
(lp13082
(dp13083
g7
I10
sg8
VP07954
p13084
sg10
I27
sg11
Vgermline fumarate hydratase
p13085
sg13
I3
sasg23
(lp13086
(dp13087
g7
I168
sg26
VC1708350
p13088
sg10
I5
sg11
VHLRCC
p13089
sg13
I1
sa(dp13090
g7
I93
sg26
VC1832526
p13091
sg10
I3
sg11
VPCC
p13092
sg13
I1
sa(dp13093
g7
I93
sg26
VC1832526
p13094
sg10
I3
sg11
VPCC
p13095
sg13
I1
sa(dp13096
g7
I116
sg26
VC1708350
p13097
sg10
I50
sg11
Vhereditary leiomyomatosis and renal cell carcinoma
p13098
sg13
I6
sa(dp13099
g7
I89
sg26
VC0030421
p13100
sg10
I3
sg11
VPGL
p13101
sg13
I1
sa(dp13102
g7
I89
sg26
VC0030421
p13103
sg10
I3
sg11
VPGL
p13104
sg13
I1
sasa(dp13105
g2
S'In addition, heterozygous mutations of the FH gene are responsible for hereditary leiomyomatosis and renal cell cancer (HLRCC).\n'
p13106
sg4
(lp13107
sg23
(lp13108
(dp13109
g7
I71
sg26
VC1708350
p13110
sg10
I47
sg11
Vhereditary leiomyomatosis and renal cell cancer
p13111
sg13
I6
sa(dp13112
g7
I120
sg26
VC1708350
p13113
sg10
I5
sg11
VHLRCC
p13114
sg13
I1
sasa(dp13115
g2
S'Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare and aggressive tumor affecting mostly younger patients.\n'
p13116
sg4
(lp13117
sg23
(lp13118
(dp13119
g7
I29
sg26
VC0007134
p13120
sg10
I20
sg11
Vrenal cell carcinoma
p13121
sg13
I3
sa(dp13122
g7
I84
sg26
VC0027651
p13123
sg10
I5
sg11
Vtumor
p13124
sg13
I1
sa(dp13125
g7
I54
sg26
VC0007134
p13126
sg10
I3
sg11
VRCC
p13127
sg13
I1
sa(dp13128
g7
I73
sg26
VC0001807
p13129
sg10
I10
sg11
Vaggressive
p13130
sg13
I1
sasa(dp13131
g2
S'Progression Free Survival (PFS) of RSCC was significantly lower than that of LRCC and rectal cancer.\n'
p13132
sg4
(lp13133
(dp13134
g7
I77
sg8
VP07954
p13135
sg10
I4
sg11
VLRCC
p13136
sg13
I1
sasg23
(lp13137
(dp13138
g7
I77
sg26
VC1708350
p13139
sg10
I4
sg11
VLRCC
p13140
sg13
I1
sa(dp13141
g7
I86
sg26
VC0007113
p13142
sg10
I13
sg11
Vrectal cancer
p13143
sg13
I2
sasa(dp13144
g2
S'A CpG island methylator phenotype was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase.\n'
p13145
sg4
(lp13146
(dp13147
g7
I186
sg8
VP07954
p13148
sg10
I18
sg11
Vfumarate hydratase
p13149
sg13
I2
sasg23
(lp13150
(dp13151
g7
I101
sg26
VC0007097
p13152
sg10
I10
sg11
Vcarcinomas
p13153
sg13
I1
sasa(dp13154
g2
S'Heterozygous germline mutations in the FH gene predispose to an aggressive autosomal dominant inherited early-onset kidney cancer syndrome: hereditary leiomyomatosis and renal cell cancer (HLRCC).\n'
p13155
sg4
(lp13156
sg23
(lp13157
(dp13158
g7
I140
sg26
VC1708350
p13159
sg10
I47
sg11
Vhereditary leiomyomatosis and renal cell cancer
p13160
sg13
I6
sa(dp13161
g7
I130
sg26
VC0039082
p13162
sg10
I8
sg11
Vsyndrome
p13163
sg13
I1
sa(dp13164
g7
I189
sg26
VC1708350
p13165
sg10
I5
sg11
VHLRCC
p13166
sg13
I1
sa(dp13167
g7
I116
sg26
VC0740457
p13168
sg10
I13
sg11
Vkidney cancer
p13169
sg13
I2
sa(dp13170
g7
I64
sg26
VC0001807
p13171
sg10
I10
sg11
Vaggressive
p13172
sg13
I1
sasa(dp13173
g2
S'While the theoretical risk of kidney cancer in parents of children with recessive fumarate hydratase deficiency is well recognized, to our knowledge this is the first report of a kidney tumour being detected in a parent by screening performed for this indication.\n'
p13174
sg4
(lp13175
(dp13176
g7
I82
sg8
VP07954
p13177
sg10
I18
sg11
Vfumarate hydratase
p13178
sg13
I2
sasg23
(lp13179
(dp13180
g7
I179
sg26
VC0022665
p13181
sg10
I13
sg11
Vkidney tumour
p13182
sg13
I2
sa(dp13183
g7
I30
sg26
VC0740457
p13184
sg10
I13
sg11
Vkidney cancer
p13185
sg13
I2
sasa(dp13186
g2
S'Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is a recognized distinct phenotypic variant of multiple cutaneous and uterine leiomyomatosis.\n'
p13187
sg4
(lp13188
sg23
(lp13189
(dp13190
g7
I52
sg26
VC1708350
p13191
sg10
I5
sg11
VHLRCC
p13192
sg13
I1
sa(dp13193
g7
I115
sg26
VC1835485
p13194
sg10
I45
sg11
Vmultiple cutaneous and uterine leiomyomatosis
p13195
sg13
I5
sa(dp13196
g7
I59
sg26
VC0039082
p13197
sg10
I8
sg11
Vsyndrome
p13198
sg13
I1
sa(dp13199
g7
I0
sg26
VC1708350
p13200
sg10
I50
sg11
VHereditary leiomyomatosis and renal cell carcinoma
p13201
sg13
I6
sasa(dp13202
g2
S'The present case reports an extremely rare case of HLRCC syndrome combined with adrenocortical carcinoma.\n'
p13203
sg4
(lp13204
sg23
(lp13205
(dp13206
g7
I57
sg26
VC0039082
p13207
sg10
I8
sg11
Vsyndrome
p13208
sg13
I1
sa(dp13209
g7
I51
sg26
VC1708350
p13210
sg10
I5
sg11
VHLRCC
p13211
sg13
I1
sa(dp13212
g7
I80
sg26
VC0206686
p13213
sg10
I24
sg11
Vadrenocortical carcinoma
p13214
sg13
I2
sasa(dp13215
g2
S'The case suggests that HLRCC should be considered in any young patient with bulky uterine leiomyomas and renal cell cancer, and F-FDG PET/CT can help detect unexpected additional primary malignancy in a patient with known cancer.\n'
p13216
sg4
(lp13217
(dp13218
g7
I23
sg8
VP07954
p13219
sg10
I5
sg11
VHLRCC
p13220
sg13
I1
sasg23
(lp13221
(dp13222
g7
I116
sg26
VC0006826
p13223
sg10
I6
sg11
Vcancer
p13224
sg13
I1
sa(dp13225
g7
I23
sg26
VC1708350
p13226
sg10
I5
sg11
VHLRCC
p13227
sg13
I1
sa(dp13228
g7
I90
sg26
VC0023267
p13229
sg10
I10
sg11
Vleiomyomas
p13230
sg13
I1
sa(dp13231
g7
I187
sg26
VC0006826
p13232
sg10
I10
sg11
Vmalignancy
p13233
sg13
I1
sa(dp13234
g7
I105
sg26
VC0007134
p13235
sg10
I17
sg11
Vrenal cell cancer
p13236
sg13
I3
sasa(dp13237
g2
S'We report a case of congenital hypertrichosis and FOXN1 duplication.\n'
p13238
sg4
(lp13239
(dp13240
g7
I50
sg8
g15
sg10
I5
sg11
VFOXN1
p13241
sg13
I1
sasg23
(lp13242
(dp13243
g7
I56
sg26
VC1705960
p13244
sg10
I11
sg11
Vduplication
p13245
sg13
I1
sa(dp13246
g7
I20
sg26
VC2936812
p13247
sg10
I25
sg11
Vcongenital hypertrichosis
p13248
sg13
I2
sasa(dp13249
g2
S'As far as we are aware, this is the first case of FOXN1 duplication associated with congenital hypertrichosis to be reported in the literature.\n'
p13250
sg4
(lp13251
(dp13252
g7
I50
sg8
g15
sg10
I5
sg11
VFOXN1
p13253
sg13
I1
sasg23
(lp13254
(dp13255
g7
I56
sg26
VC1705960
p13256
sg10
I11
sg11
Vduplication
p13257
sg13
I1
sa(dp13258
g7
I84
sg26
VC2936812
p13259
sg10
I25
sg11
Vcongenital hypertrichosis
p13260
sg13
I2
sasa(dp13261
g2
S"AIRE: autoimmune regulator; cAMP: cyclic adenosine 3',5'-cyclic monophosphate; CEA: carcinoembryonic antigen; CML: chronic myeloid leukemia; CREB: cyclicamp response element binding; CSCs: cancer stem cells; CTAs: cancer/testis antigens; CTL: cytotoxic T lymphocyte; DCs: dendritic cells; EMT: epithelial-mesenchymal transition; ERK: extracellular signal-regulated kinase; ESCC: esophageal squamous cell carcinoma; ETS: E26 transformation-specific; His: histidine; HLA: human leukocyte antigen; HNSCC: head and neck squamous cell carcinoma; IFN-Gamma: interferon-Gamma; IHC: Immunohistochemistry; IL-7: Interleukin7; MHC: major histocompatibility complex; MMP2: matrix metalloproteinase 2; mTECs: medullary thymus epithelial cells; MUC1: mucin 1; NSCLC: non-small cell lung cancer; PRAME: preferentially expressed antigen in melanoma; RDA: representational difference analysis; SEREX: serological analysis of cDNA expression; SSX: synovial sarcoma X chromosome; TAAs: tumor-associated antigens; TCR: T-cell receptor; TCGA: The Cancer Genome Atlas; TGF-Beta: transforming growth factor-Beta.\n"
p13262
sg4
(lp13263
(dp13264
g7
I662
sg8
VP08253
p13265
sg10
I26
sg11
Vmatrix metalloproteinase 2
p13266
sg13
I3
sa(dp13267
g7
I738
sg8
g15
sg10
I7
sg11
Vmucin 1
p13268
sg13
I2
sa(dp13269
g7
I84
sg8
VP40198
p13270
sg10
I24
sg11
Vcarcinoembryonic antigen
p13271
sg13
I2
sa(dp13272
g7
I1058
sg8
VP18075
p13273
sg10
I31
sg11
Vtransforming growth factor-Beta
p13274
sg13
I3
sa(dp13275
g7
I334
sg8
VP53779
p13276
sg10
I37
sg11
Vextracellular signal-regulated kinase
p13277
sg13
I3
sa(dp13278
g7
I329
sg8
VP29323
p13279
sg10
I3
sg11
VERK
p13280
sg13
I1
sa(dp13281
g7
I1048
sg8
VP18075
p13282
sg10
I8
sg11
VTGF-Beta
p13283
sg13
I1
sa(dp13284
g7
I465
sg8
VP30486
p13285
sg10
I3
sg11
VHLA
p13286
sg13
I1
sa(dp13287
g7
I570
sg8
VP13232
p13288
sg10
I31
sg11
VIHC: Immunohistochemistry; IL-7
p13289
sg13
I3
sa(dp13290
g7
I552
sg8
VP01579
p13291
sg10
I16
sg11
Vinterferon-Gamma
p13292
sg13
I1
sa(dp13293
g7
I141
sg8
VP16220
p13294
sg10
I4
sg11
VCREB
p13295
sg13
I1
sa(dp13296
g7
I415
sg8
VP20908
p13297
sg10
I3
sg11
VETS
p13298
sg13
I1
sa(dp13299
g7
I541
sg8
VP01579
p13300
sg10
I9
sg11
VIFN-Gamma
p13301
sg13
I1
sa(dp13302
g7
I603
sg8
VP13747
p13303
sg10
I51
sg11
VInterleukin7; MHC: major histocompatibility complex
p13304
sg13
I5
sa(dp13305
g7
I79
sg8
VP40198
p13306
sg10
I3
sg11
VCEA
p13307
sg13
I1
sa(dp13308
g7
I926
sg8
g15
sg10
I3
sg11
VSSX
p13309
sg13
I1
sa(dp13310
g7
I1000
sg8
g15
sg10
I15
sg11
VT-cell receptor
p13311
sg13
I2
sa(dp13312
g7
I968
sg8
VP51572
p13313
sg10
I25
sg11
Vtumor-associated antigens
p13314
sg13
I2
sa(dp13315
g7
I656
sg8
VP08253
p13316
sg10
I4
sg11
VMMP2
p13317
sg13
I1
sasg23
(lp13318
(dp13319
g7
I931
sg26
VC0039101
p13320
sg10
I16
sg11
Vsynovial sarcoma
p13321
sg13
I2
sa(dp13322
g7
I968
sg26
VC0027651
p13323
sg10
I5
sg11
Vtumor
p13324
sg13
I1
sa(dp13325
g7
I495
sg26
VC1168401
p13326
sg10
I5
sg11
VHNSCC
p13327
sg13
I1
sa(dp13328
g7
I747
sg26
VC0007131
p13329
sg10
I5
sg11
VNSCLC
p13330
sg13
I1
sa(dp13331
g7
I317
sg26
VC0599156
p13332
sg10
I10
sg11
Vtransition
p13333
sg13
I1
sa(dp13334
g7
I502
sg26
VC1168401
p13335
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p13336
sg13
I6
sa(dp13337
g7
I835
sg26
VC0267244
p13338
sg10
I3
sg11
VRDA
p13339
sg13
I1
sa(dp13340
g7
I110
sg26
VC0023473
p13341
sg10
I3
sg11
VCML
p13342
sg13
I1
sa(dp13343
g7
I115
sg26
VC0023473
p13344
sg10
I24
sg11
Vchronic myeloid leukemia
p13345
sg13
I3
sa(dp13346
g7
I1027
sg26
VC0006826
p13347
sg10
I6
sg11
VCancer
p13348
sg13
I1
sa(dp13349
g7
I267
sg26
VC0268238
p13350
sg10
I3
sg11
VDCs
p13351
sg13
I1
sa(dp13352
g7
I754
sg26
VC0007131
p13353
sg10
I26
sg11
Vnon-small cell lung cancer
p13354
sg13
I4
sa(dp13355
g7
I189
sg26
VC0006826
p13356
sg10
I6
sg11
Vcancer
p13357
sg13
I1
sa(dp13358
g7
I189
sg26
VC0006826
p13359
sg10
I6
sg11
Vcancer
p13360
sg13
I1
sa(dp13361
g7
I6
sg26
VC0443146
p13362
sg10
I10
sg11
Vautoimmune
p13363
sg13
I1
sa(dp13364
g7
I424
sg26
VC1510411
p13365
sg10
I14
sg11
Vtransformation
p13366
sg13
I1
sa(dp13367
g7
I379
sg26
VC0279626
p13368
sg10
I34
sg11
Vesophageal squamous cell carcinoma
p13369
sg13
I4
sa(dp13370
g7
I825
sg26
VC0025202
p13371
sg10
I8
sg11
Vmelanoma
p13372
sg13
I1
sasa(dp13373
g2
S'Consistent with our results, a clinical database showed that high expression of CREB correlates with favorable prognosis in B-cell lymphoma patients, which is totally different from the function of CREB in other cancers such as colorectal cancer, acute myeloid leukemia, and some endocrine cancers.\n'
p13374
sg4
(lp13375
(dp13376
g7
I80
sg8
VP16220
p13377
sg10
I4
sg11
VCREB
p13378
sg13
I1
sa(dp13379
g7
I80
sg8
VP16220
p13380
sg10
I4
sg11
VCREB
p13381
sg13
I1
sasg23
(lp13382
(dp13383
g7
I228
sg26
VC1527249
p13384
sg10
I17
sg11
Vcolorectal cancer
p13385
sg13
I2
sa(dp13386
g7
I124
sg26
VC0079731
p13387
sg10
I15
sg11
VB-cell lymphoma
p13388
sg13
I2
sa(dp13389
g7
I212
sg26
VC0006826
p13390
sg10
I7
sg11
Vcancers
p13391
sg13
I1
sa(dp13392
g7
I247
sg26
VC0023467
p13393
sg10
I22
sg11
Vacute myeloid leukemia
p13394
sg13
I3
sa(dp13395
g7
I280
sg26
VC1704374
p13396
sg10
I17
sg11
Vendocrine cancers
p13397
sg13
I2
sasa(dp13398
g2
S'The transcription factor CREB (cAMP Response-Element Binding Protein) is overexpressed in the majority of acute myeloid leukemia (AML) patients, and this is associated with a worse prognosis.\n'
p13399
sg4
(lp13400
(dp13401
g7
I4
sg8
VP35398
p13402
sg10
I25
sg11
Vtranscription factor CREB
p13403
sg13
I3
sa(dp13404
g7
I31
sg8
VP49913
p13405
sg10
I37
sg11
VcAMP Response-Element Binding Protein
p13406
sg13
I4
sasg23
(lp13407
(dp13408
g7
I130
sg26
VC0023467
p13409
sg10
I3
sg11
VAML
p13410
sg13
I1
sa(dp13411
g7
I106
sg26
VC0023467
p13412
sg10
I22
sg11
Vacute myeloid leukemia
p13413
sg13
I3
sasa(dp13414
g2
S'cAMP response element binding protein (CREB) is frequently overexpressed in acute myeloid leukemia (AML) and acts as a proto-oncogene; however, it is still debated whether such overactivation alone is able to induce leukemia as its pathogenetic downstream signaling is still unclear.\n'
p13415
sg4
(lp13416
(dp13417
g7
I0
sg8
VP16220
p13418
sg10
I37
sg11
VcAMP response element binding protein
p13419
sg13
I5
sa(dp13420
g7
I39
sg8
VP16220
p13421
sg10
I4
sg11
VCREB
p13422
sg13
I1
sasg23
(lp13423
(dp13424
g7
I76
sg26
VC0023467
p13425
sg10
I22
sg11
Vacute myeloid leukemia
p13426
sg13
I3
sa(dp13427
g7
I100
sg26
VC0023467
p13428
sg10
I3
sg11
VAML
p13429
sg13
I1
sa(dp13430
g7
I90
sg26
VC0023418
p13431
sg10
I8
sg11
Vleukemia
p13432
sg13
I1
sasa(dp13433
g2
S'We generated a zebrafish model overexpressing CREB in the myeloid lineage, which showed an aberrant regulation of primitive hematopoiesis, and in 79% of adult CREB-zebrafish a block of myeloid differentiation, triggering to a monocytic leukemia akin the human counterpart.\n'
p13434
sg4
(lp13435
(dp13436
g7
I159
sg8
VP16220
p13437
sg10
I14
sg11
VCREB-zebrafish
p13438
sg13
I1
sa(dp13439
g7
I46
sg8
VP16220
p13440
sg10
I4
sg11
VCREB
p13441
sg13
I1
sasg23
(lp13442
(dp13443
g7
I226
sg26
VC0598894
p13444
sg10
I18
sg11
Vmonocytic leukemia
p13445
sg13
I2
sasa(dp13446
g2
S'The transcription factor CREB (cAMP Response Element Binding Protein) is an important determinant in the growth of Acute Myeloid Leukemia (AML) cells.\n'
p13447
sg4
(lp13448
(dp13449
g7
I31
sg8
VP16220
p13450
sg10
I37
sg11
VcAMP Response Element Binding Protein
p13451
sg13
I5
sa(dp13452
g7
I4
sg8
VP35398
p13453
sg10
I25
sg11
Vtranscription factor CREB
p13454
sg13
I3
sasg23
(lp13455
(dp13456
g7
I139
sg26
VC0023467
p13457
sg10
I3
sg11
VAML
p13458
sg13
I1
sa(dp13459
g7
I115
sg26
VC0023467
p13460
sg10
I22
sg11
VAcute Myeloid Leukemia
p13461
sg13
I3
sasa(dp13462
g2
S'We aimed to analyze the expression of JAK/STAT family members in a set of prevalent ISDs: psoriasis, lichen planus (LP), cutaneous lupus erythematosus (CLE), atopic dermatitis (AD), pyoderma gangrenosum (PG) and alopecia areata (AA) versus healthy controls for (p)JAK1, (p)JAK2, (p)JAK3, (p)TYK2, pSTAT1, pSTAT2 and pSTAT3.\n'
p13463
sg4
(lp13464
(dp13465
g7
I291
sg8
VP29597
p13466
sg10
I4
sg11
VTYK2
p13467
sg13
I1
sa(dp13468
g7
I264
sg8
VP23458
p13469
sg10
I4
sg11
VJAK1
p13470
sg13
I1
sa(dp13471
g7
I273
sg8
g15
sg10
I4
sg11
VJAK2
p13472
sg13
I1
sa(dp13473
g7
I282
sg8
VP52333
p13474
sg10
I4
sg11
VJAK3
p13475
sg13
I1
sa(dp13476
g7
I42
sg8
g15
sg10
I4
sg11
VSTAT
p13477
sg13
I1
sasg23
(lp13478
(dp13479
g7
I158
sg26
VC0011615
p13480
sg10
I17
sg11
Vatopic dermatitis
p13481
sg13
I2
sa(dp13482
g7
I121
sg26
VC0024137
p13483
sg10
I29
sg11
Vcutaneous lupus erythematosus
p13484
sg13
I3
sa(dp13485
g7
I152
sg26
VC2931489
p13486
sg10
I3
sg11
VCLE
p13487
sg13
I1
sa(dp13488
g7
I177
sg26
VC0011615
p13489
sg10
I2
sg11
VAD
p13490
sg13
I1
sa(dp13491
g7
I204
sg26
VC0085652
p13492
sg10
I2
sg11
VPG
p13493
sg13
I1
sa(dp13494
g7
I116
sg26
VC0023646
p13495
sg10
I2
sg11
VLP
p13496
sg13
I1
sa(dp13497
g7
I90
sg26
VC0033860
p13498
sg10
I9
sg11
Vpsoriasis
p13499
sg13
I1
sa(dp13500
g7
I212
sg26
VC0002171
p13501
sg10
I15
sg11
Valopecia areata
p13502
sg13
I2
sa(dp13503
g7
I101
sg26
VC0023646
p13504
sg10
I13
sg11
Vlichen planus
p13505
sg13
I2
sa(dp13506
g7
I182
sg26
VC0085652
p13507
sg10
I20
sg11
Vpyoderma gangrenosum
p13508
sg13
I2
sasa(dp13509
g2
S'The purpose of this case-control study was to investigate whether polymorphisms and gene-gene interactions of the two type I interferon (IFN) genes (IRF5 and TYK2) are the susceptible factors of systemic Lupus erythematosus (SLE) in the Han Chinese population.\n'
p13510
sg4
(lp13511
(dp13512
g7
I118
sg8
VP05000
p13513
sg10
I17
sg11
Vtype I interferon
p13514
sg13
I3
sa(dp13515
g7
I158
sg8
VP29597
p13516
sg10
I4
sg11
VTYK2
p13517
sg13
I1
sa(dp13518
g7
I137
sg8
VP01562
p13519
sg10
I3
sg11
VIFN
p13520
sg13
I1
sa(dp13521
g7
I149
sg8
g15
sg10
I4
sg11
VIRF5
p13522
sg13
I1
sasg23
(lp13523
(dp13524
g7
I225
sg26
VC0024141
p13525
sg10
I3
sg11
VSLE
p13526
sg13
I1
sa(dp13527
g7
I195
sg26
VC0024141
p13528
sg10
I28
sg11
Vsystemic Lupus erythematosus
p13529
sg13
I3
sasa(dp13530
g2
S'Second, we show that the same three TYK2 variants protect against systemic lupus erythematosus (SLE, Pomnibus = 6 x 10(-18)), and provide suggestive evidence that two of the TYK2 variants (P1104A and A928V) may also protect against inflammatory bowel disease (IBD; P(omnibus) = 0.005).\n'
p13531
sg4
(lp13532
(dp13533
g7
I36
sg8
VP29597
p13534
sg10
I13
sg11
VTYK2 variants
p13535
sg13
I2
sa(dp13536
g7
I36
sg8
VP29597
p13537
sg10
I13
sg11
VTYK2 variants
p13538
sg13
I2
sasg23
(lp13539
(dp13540
g7
I260
sg26
VC0021390
p13541
sg10
I3
sg11
VIBD
p13542
sg13
I1
sa(dp13543
g7
I66
sg26
VC0024141
p13544
sg10
I28
sg11
Vsystemic lupus erythematosus
p13545
sg13
I3
sa(dp13546
g7
I96
sg26
VC0024141
p13547
sg10
I3
sg11
VSLE
p13548
sg13
I1
sa(dp13549
g7
I232
sg26
VC0021390
p13550
sg10
I26
sg11
Vinflammatory bowel disease
p13551
sg13
I3
sasa(dp13552
g2
S'In addition, Tyk2-mediated signaling promoted the production of autoimmune-associated components, which is implicated in the pathogenesis of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis.\n'
p13553
sg4
(lp13554
(dp13555
g7
I13
sg8
VP29597
p13556
sg10
I4
sg11
VTyk2
p13557
sg13
I1
sasg23
(lp13558
(dp13559
g7
I141
sg26
VC0004364
p13560
sg10
I19
sg11
Vautoimmune diseases
p13561
sg13
I2
sa(dp13562
g7
I64
sg26
VC0443146
p13563
sg10
I10
sg11
Vautoimmune
p13564
sg13
I1
sa(dp13565
g7
I125
sg26
VC0699748
p13566
sg10
I12
sg11
Vpathogenesis
p13567
sg13
I1
sa(dp13568
g7
I192
sg26
VC0024141
p13569
sg10
I28
sg11
Vsystemic lupus erythematosus
p13570
sg13
I3
sa(dp13571
g7
I170
sg26
VC0003873
p13572
sg10
I20
sg11
Vrheumatoid arthritis
p13573
sg13
I2
sa(dp13574
g7
I222
sg26
VC0026769
p13575
sg10
I18
sg11
Vmultiple sclerosis
p13576
sg13
I2
sasa(dp13577
g2
S'However, OVX rats receiving 1,25(OH)2D3 alone or in combination with 1,24,25(OH)3D3 exhibited hypercalcemia, hyperphosphatemia, hypercalciuria, and impaired bone mineralization.\n'
p13578
sg4
(lp13579
sg23
(lp13580
(dp13581
g7
I94
sg26
VC0020437
p13582
sg10
I13
sg11
Vhypercalcemia
p13583
sg13
I1
sa(dp13584
g7
I148
sg26
VC0684336
p13585
sg10
I8
sg11
Vimpaired
p13586
sg13
I1
sa(dp13587
g7
I128
sg26
VC0020438
p13588
sg10
I14
sg11
Vhypercalciuria
p13589
sg13
I1
sa(dp13590
g7
I109
sg26
VC0085681
p13591
sg10
I17
sg11
Vhyperphosphatemia
p13592
sg13
I1
sasa(dp13593
g2
S'We performed a fixed effects meta-analysis of genome-wide association results of myopia and hyperopia from 9 studies of European-derived populations: AREDS, KORA, FES, OGP-Talana, MESA, RSI, RSII, RSIII and ERF.\n'
p13594
sg4
(lp13595
(dp13596
g7
I163
sg8
VP07332
p13597
sg10
I3
sg11
VFES
p13598
sg13
I1
sa(dp13599
g7
I168
sg8
g15
sg10
I10
sg11
VOGP-Talana
p13600
sg13
I1
sa(dp13601
g7
I207
sg8
VP50548
p13602
sg10
I3
sg11
VERF
p13603
sg13
I1
sasg23
(lp13604
(dp13605
g7
I186
sg26
VC0035127
p13606
sg10
I3
sg11
VRSI
p13607
sg13
I1
sa(dp13608
g7
I81
sg26
VC0027092
p13609
sg10
I6
sg11
Vmyopia
p13610
sg13
I1
sa(dp13611
g7
I92
sg26
VC0020490
p13612
sg10
I9
sg11
Vhyperopia
p13613
sg13
I1
sasa(dp13614
g2
S'Napsin A was negative in all thyroid carcinomas.\n'
p13615
sg4
(lp13616
(dp13617
g7
I0
sg8
g15
sg10
I8
sg11
VNapsin A
p13618
sg13
I2
sasg23
(lp13619
(dp13620
g7
I37
sg26
VC0007097
p13621
sg10
I10
sg11
Vcarcinomas
p13622
sg13
I1
sasa(dp13623
g2
S'However, studies have shown that napsin A is also positive in approximately 5% of papillary thyroid carcinomas.\n'
p13624
sg4
(lp13625
(dp13626
g7
I33
sg8
g15
sg10
I8
sg11
Vnapsin A
p13627
sg13
I2
sasg23
(lp13628
(dp13629
g7
I100
sg26
VC0007097
p13630
sg10
I10
sg11
Vcarcinomas
p13631
sg13
I1
sasa(dp13632
g2
S'The prevalence of napsin A in more aggressive types of thyroid carcinoma is unknown.\n'
p13633
sg4
(lp13634
(dp13635
g7
I18
sg8
g15
sg10
I8
sg11
Vnapsin A
p13636
sg13
I2
sasg23
(lp13637
(dp13638
g7
I55
sg26
VC0549473
p13639
sg10
I17
sg11
Vthyroid carcinoma
p13640
sg13
I2
sa(dp13641
g7
I35
sg26
VC0001807
p13642
sg10
I10
sg11
Vaggressive
p13643
sg13
I1
sasa(dp13644
g2
S'Napsin A positivity in metastatic thyroid carcinoma, especially in conjunction with thyroid transcription factor-1 (TTF-1), could be misdiagnosed as lung adenocarcinoma.\n'
p13645
sg4
(lp13646
(dp13647
g7
I116
sg8
VP43699
p13648
sg10
I5
sg11
VTTF-1
p13649
sg13
I1
sa(dp13650
g7
I84
sg8
VP43699
p13651
sg10
I30
sg11
Vthyroid transcription factor-1
p13652
sg13
I3
sasg23
(lp13653
(dp13654
g7
I149
sg26
VC0152013
p13655
sg10
I19
sg11
Vlung adenocarcinoma
p13656
sg13
I2
sa(dp13657
g7
I34
sg26
VC0549473
p13658
sg10
I17
sg11
Vthyroid carcinoma
p13659
sg13
I2
sasa(dp13660
g2
S'We investigated napsin A, TTF-1, and PAX8 expression in 26 anaplastic, 16 poorly differentiated, and 2 micropapillary pattern thyroid carcinomas.\n'
p13661
sg4
(lp13662
(dp13663
g7
I26
sg8
VP43699
p13664
sg10
I5
sg11
VTTF-1
p13665
sg13
I1
sa(dp13666
g7
I37
sg8
g15
sg10
I4
sg11
VPAX8
p13667
sg13
I1
sa(dp13668
g7
I16
sg8
g15
sg10
I8
sg11
Vnapsin A
p13669
sg13
I2
sasg23
(lp13670
(dp13671
g7
I134
sg26
VC0007097
p13672
sg10
I10
sg11
Vcarcinomas
p13673
sg13
I1
sasa(dp13674
g2
S'Four of 26 (15%) anaplastic, 2/16 (13%) poorly differentiated, and 2/2 (100%) micropapillary pattern thyroid carcinomas were napsin A positive.\n'
p13675
sg4
(lp13676
(dp13677
g7
I125
sg8
g15
sg10
I8
sg11
Vnapsin A
p13678
sg13
I2
sasg23
(lp13679
(dp13680
g7
I109
sg26
VC0007097
p13681
sg10
I10
sg11
Vcarcinomas
p13682
sg13
I1
sasa(dp13683
g2
S'In summary, a minority of anaplastic and poorly differentiated thyroid carcinomas are napsin A positive.\n'
p13684
sg4
(lp13685
(dp13686
g7
I86
sg8
g15
sg10
I8
sg11
Vnapsin A
p13687
sg13
I2
sasg23
(lp13688
(dp13689
g7
I71
sg26
VC0007097
p13690
sg10
I10
sg11
Vcarcinomas
p13691
sg13
I1
sasa(dp13692
g2
S'PAX8 may be diagnostically useful to distinguish these napsin A-positive thyroid carcinomas from lung adenocarcinomas, which are PAX8 negative.\n'
p13693
sg4
(lp13694
(dp13695
g7
I55
sg8
g15
sg10
I8
sg11
Vnapsin A
p13696
sg13
I2
sa(dp13697
g7
I0
sg8
g15
sg10
I4
sg11
VPAX8
p13698
sg13
I1
sa(dp13699
g7
I0
sg8
g15
sg10
I4
sg11
VPAX8
p13700
sg13
I1
sasg23
(lp13701
(dp13702
g7
I102
sg26
VC0001418
p13703
sg10
I15
sg11
Vadenocarcinomas
p13704
sg13
I1
sa(dp13705
g7
I81
sg26
VC0007097
p13706
sg10
I10
sg11
Vcarcinomas
p13707
sg13
I1
sasa(dp13708
g2
S'The morphology and immunohistochemistry (Napsin-A, Thyroglobulin) are very important in differential diagnosis of lung primary adenocarcinoma and metastatic papillary thyroid carcinoma.\n'
p13709
sg4
(lp13710
(dp13711
g7
I51
sg8
g15
sg10
I13
sg11
VThyroglobulin
p13712
sg13
I1
sa(dp13713
g7
I41
sg8
g15
sg10
I8
sg11
VNapsin-A
p13714
sg13
I1
sasg23
(lp13715
(dp13716
g7
I127
sg26
VC0001418
p13717
sg10
I14
sg11
Vadenocarcinoma
p13718
sg13
I1
sa(dp13719
g7
I157
sg26
VC0238463
p13720
sg10
I27
sg11
Vpapillary thyroid carcinoma
p13721
sg13
I3
sasa(dp13722
g2
S'The Napsin-A immunohistochemical evaluation was carried out using surgical specimens from 18 cases of adenocarcinoma, 19 cases of squamous cell carcinoma, 2 cases of large cell carcinoma, 1 case of bronchoalveolar carcinoma of lung, as well as 33 cases of renal cell carcinoma, 30 cases of thyroid neoplasm, 31 cases of colonic carcinoma, 31 cases of breast carcinoma, and 30 cases of endometrial adenocarcinoma.\n'
p13723
sg4
(lp13724
sg23
(lp13725
(dp13726
g7
I320
sg26
VC0699790
p13727
sg10
I17
sg11
Vcolonic carcinoma
p13728
sg13
I2
sa(dp13729
g7
I102
sg26
VC0001418
p13730
sg10
I14
sg11
Vadenocarcinoma
p13731
sg13
I1
sa(dp13732
g7
I214
sg26
VC0684249
p13733
sg10
I17
sg11
Vcarcinoma of lung
p13734
sg13
I3
sa(dp13735
g7
I385
sg26
VC1153706
p13736
sg10
I26
sg11
Vendometrial adenocarcinoma
p13737
sg13
I2
sa(dp13738
g7
I351
sg26
VC0678222
p13739
sg10
I16
sg11
Vbreast carcinoma
p13740
sg13
I2
sa(dp13741
g7
I290
sg26
VC0040136
p13742
sg10
I16
sg11
Vthyroid neoplasm
p13743
sg13
I2
sa(dp13744
g7
I130
sg26
VC0007137
p13745
sg10
I23
sg11
Vsquamous cell carcinoma
p13746
sg13
I3
sa(dp13747
g7
I256
sg26
VC0007134
p13748
sg10
I20
sg11
Vrenal cell carcinoma
p13749
sg13
I3
sa(dp13750
g7
I166
sg26
VC0206704
p13751
sg10
I20
sg11
Vlarge cell carcinoma
p13752
sg13
I3
sasa(dp13753
g2
S'Nap-A is superior to TTF-1 in distinguishing primary lung ACA from other carcinomas (except kidney), particularly primary lung small cell carcinoma, and primary thyroid carcinoma.\n'
p13754
sg4
(lp13755
(dp13756
g7
I0
sg8
VP42830
p13757
sg10
I5
sg11
VNap-A
p13758
sg13
I1
sa(dp13759
g7
I21
sg8
VP43699
p13760
sg10
I5
sg11
VTTF-1
p13761
sg13
I1
sasg23
(lp13762
(dp13763
g7
I127
sg26
VC0262584
p13764
sg10
I20
sg11
Vsmall cell carcinoma
p13765
sg13
I3
sa(dp13766
g7
I73
sg26
VC0007097
p13767
sg10
I10
sg11
Vcarcinomas
p13768
sg13
I1
sa(dp13769
g7
I161
sg26
VC0549473
p13770
sg10
I17
sg11
Vthyroid carcinoma
p13771
sg13
I2
sasa(dp13772
g2
S'In the thyroid, only 2 cases of papillary thyroid carcinoma (5%), both with tall cell morphology, were positive for napsin A, whereas all other papillary and follicular carcinomas were negative.\n'
p13773
sg4
(lp13774
(dp13775
g7
I116
sg8
g15
sg10
I8
sg11
Vnapsin A
p13776
sg13
I2
sasg23
(lp13777
(dp13778
g7
I169
sg26
VC0007097
p13779
sg10
I10
sg11
Vcarcinomas
p13780
sg13
I1
sa(dp13781
g7
I32
sg26
VC0238463
p13782
sg10
I27
sg11
Vpapillary thyroid carcinoma
p13783
sg13
I3
sasa(dp13784
g2
S'Napsin A is a sensitive marker for pulmonary adenocarcinoma and is also expressed in a subset of renal cell carcinomas, particularly of the papillary type, as well as in rare cases of papillary thyroid carcinomas.\n'
p13785
sg4
(lp13786
(dp13787
g7
I0
sg8
g15
sg10
I8
sg11
VNapsin A
p13788
sg13
I2
sasg23
(lp13789
(dp13790
g7
I97
sg26
VC0007134
p13791
sg10
I21
sg11
Vrenal cell carcinomas
p13792
sg13
I3
sa(dp13793
g7
I45
sg26
VC0001418
p13794
sg10
I14
sg11
Vadenocarcinoma
p13795
sg13
I1
sa(dp13796
g7
I108
sg26
VC0007097
p13797
sg10
I10
sg11
Vcarcinomas
p13798
sg13
I1
sasa(dp13799
g2
S'On the other hand, the association between vestibular schwannoma and enlarged vestibular aqueduct with variants in NF2 and SLC26A4, respectively, seems increasingly clear.\n'
p13800
sg4
(lp13801
(dp13802
g7
I123
sg8
g15
sg10
I7
sg11
VSLC26A4
p13803
sg13
I1
sasg23
(lp13804
(dp13805
g7
I115
sg26
VC0027832
p13806
sg10
I3
sg11
VNF2
p13807
sg13
I1
sa(dp13808
g7
I43
sg26
VC0027859
p13809
sg10
I21
sg11
Vvestibular schwannoma
p13810
sg13
I2
sa(dp13811
g7
I69
sg26
VC1863752
p13812
sg10
I28
sg11
Venlarged vestibular aqueduct
p13813
sg13
I3
sasa(dp13814
g2
S'Cochlear implants and auditory brainstem implant have made hearing rehabilitation possible in NF2 patients who had bilateral sensorineural hearing loss.\n'
p13815
sg4
(lp13816
sg23
(lp13817
(dp13818
g7
I125
sg26
VC0018784
p13819
sg10
I26
sg11
Vsensorineural hearing loss
p13820
sg13
I3
sa(dp13821
g7
I94
sg26
VC0027832
p13822
sg10
I3
sg11
VNF2
p13823
sg13
I1
sasa(dp13824
g2
S'The population comprised 23 NF2, 3 postmeningitis bilateral ossified cochleas, 3 solitary vestibular schwannomas on the only hearing ear, 1 inner ear malformation, and 1 bilateral cochlear destruction by otosclerosis.\n'
p13825
sg4
(lp13826
sg23
(lp13827
(dp13828
g7
I146
sg26
VC0266589
p13829
sg10
I16
sg11
Vear malformation
p13830
sg13
I2
sa(dp13831
g7
I90
sg26
VC0027859
p13832
sg10
I22
sg11
Vvestibular schwannomas
p13833
sg13
I2
sa(dp13834
g7
I28
sg26
VC0027832
p13835
sg10
I3
sg11
VNF2
p13836
sg13
I1
sa(dp13837
g7
I204
sg26
VC0029899
p13838
sg10
I12
sg11
Votosclerosis
p13839
sg13
I1
sasa(dp13840
g2
S'Clinical evaluation showed hemotympanum on right with moderately severe conductive hearing loss, grade III LMN facial palsy and BPPV.\n'
p13841
sg4
(lp13842
sg23
(lp13843
(dp13844
g7
I72
sg26
VC0018777
p13845
sg10
I23
sg11
Vconductive hearing loss
p13846
sg13
I3
sa(dp13847
g7
I111
sg26
VC0015469
p13848
sg10
I12
sg11
Vfacial palsy
p13849
sg13
I2
sa(dp13850
g7
I27
sg26
VC0019125
p13851
sg10
I12
sg11
Vhemotympanum
p13852
sg13
I1
sa(dp13853
g7
I128
sg26
VC0155502
p13854
sg10
I4
sg11
VBPPV
p13855
sg13
I1
sasa(dp13856
g2
S'Studies on the immunopathogenesis of autoimmune arthritis in the rat adjuvant arthritis (AA) model of human rheumatoid arthritis (RA) as well as observations in patients with RA and juvenile idiopathic arthritis (JIA) have unraveled immunoregulatory attributes of self-Hsp65-directed immunity.\n'
p13857
sg4
(lp13858
(dp13859
g7
I269
sg8
VP10809
p13860
sg10
I5
sg11
VHsp65
p13861
sg13
I1
sasg23
(lp13862
(dp13863
g7
I130
sg26
VC0003873
p13864
sg10
I2
sg11
VRA
p13865
sg13
I1
sa(dp13866
g7
I108
sg26
VC0003873
p13867
sg10
I20
sg11
Vrheumatoid arthritis
p13868
sg13
I2
sa(dp13869
g7
I37
sg26
VC3160909
p13870
sg10
I20
sg11
Vautoimmune arthritis
p13871
sg13
I2
sa(dp13872
g7
I213
sg26
VC0553662
p13873
sg10
I3
sg11
VJIA
p13874
sg13
I1
sa(dp13875
g7
I130
sg26
VC0003873
p13876
sg10
I2
sg11
VRA
p13877
sg13
I1
sa(dp13878
g7
I182
sg26
VC0553662
p13879
sg10
I29
sg11
Vjuvenile idiopathic arthritis
p13880
sg13
I3
sa(dp13881
g7
I48
sg26
VC0003864
p13882
sg10
I9
sg11
Varthritis
p13883
sg13
I1
sasa(dp13884
g2
S'We believe that these insights into Hsp65 immunity would not only advance our understanding of the disease process in RA/JIA, but also lead to the development of novel therapeutic approaches for autoimmune arthritis.\n'
p13885
sg4
(lp13886
sg23
(lp13887
(dp13888
g7
I195
sg26
VC3160909
p13889
sg10
I20
sg11
Vautoimmune arthritis
p13890
sg13
I2
sasa(dp13891
g2
S'HSP60 deficiency is relevant to the existence of end-stage knee osteoarthritis.\n'
p13892
sg4
(lp13893
(dp13894
g7
I0
sg8
VP10809
p13895
sg10
I5
sg11
VHSP60
p13896
sg13
I1
sasg23
(lp13897
(dp13898
g7
I59
sg26
VC0409959
p13899
sg10
I19
sg11
Vknee osteoarthritis
p13900
sg13
I2
sasa(dp13901
g2
S'HSP60 transgenic mice showed mild articular injury during knee osteoarthritis.\n'
p13902
sg4
(lp13903
(dp13904
g7
I0
sg8
VP10809
p13905
sg10
I5
sg11
VHSP60
p13906
sg13
I1
sasg23
(lp13907
(dp13908
g7
I58
sg26
VC0409959
p13909
sg10
I19
sg11
Vknee osteoarthritis
p13910
sg13
I2
sasa(dp13911
g2
S'Control of cartilage-anabolic regulator HSP60 ameliorates knee osteoarthritis.\n'
p13912
sg4
(lp13913
(dp13914
g7
I40
sg8
VP10809
p13915
sg10
I5
sg11
VHSP60
p13916
sg13
I1
sasg23
(lp13917
(dp13918
g7
I58
sg26
VC0409959
p13919
sg10
I19
sg11
Vknee osteoarthritis
p13920
sg13
I2
sasa(dp13921
g2
S'Prozumab was shown to bind to HSP60, the highly conserved mammalian homolog of the bacterial protein, and it was found to be effective in protecting and suppressing autoimmune arthritis in the models of adjuvant arthritis and collagen-induced arthritis in rats and mice, respectively, as well as in acute hapten-mediated colitis and chronic, spontaneous colitis models.\n'
p13922
sg4
(lp13923
(dp13924
g7
I30
sg8
VP10809
p13925
sg10
I5
sg11
VHSP60
p13926
sg13
I1
sasg23
(lp13927
(dp13928
g7
I176
sg26
VC0003864
p13929
sg10
I9
sg11
Varthritis
p13930
sg13
I1
sa(dp13931
g7
I165
sg26
VC3160909
p13932
sg10
I20
sg11
Vautoimmune arthritis
p13933
sg13
I2
sa(dp13934
g7
I321
sg26
VC0009319
p13935
sg10
I7
sg11
Vcolitis
p13936
sg13
I1
sa(dp13937
g7
I321
sg26
VC0009319
p13938
sg10
I7
sg11
Vcolitis
p13939
sg13
I1
sa(dp13940
g7
I176
sg26
VC0003864
p13941
sg10
I9
sg11
Varthritis
p13942
sg13
I1
sasa(dp13943
g2
S'There was no significance difference in single CD4+, CD8+, CD22+, CD14+ and CD68+ staining between sarcoidosis and tuberculosis sections.\n'
p13944
sg4
(lp13945
(dp13946
g7
I53
sg8
VP01732
p13947
sg10
I4
sg11
VCD8+
p13948
sg13
I1
sa(dp13949
g7
I76
sg8
VP34810
p13950
sg10
I5
sg11
VCD68+
p13951
sg13
I1
sa(dp13952
g7
I47
sg8
VP01730
p13953
sg10
I4
sg11
VCD4+
p13954
sg13
I1
sa(dp13955
g7
I66
sg8
VP08571
p13956
sg10
I5
sg11
VCD14+
p13957
sg13
I1
sasg23
(lp13958
(dp13959
g7
I115
sg26
VC0041296
p13960
sg10
I12
sg11
Vtuberculosis
p13961
sg13
I1
sa(dp13962
g7
I99
sg26
VC0036202
p13963
sg10
I11
sg11
Vsarcoidosis
p13964
sg13
I1
sasa(dp13965
g2
S'The novel bispecific ligand-directed toxin (BLT) DT2219 consists of a recombinant fusion between the catalytic and translocation enhancing domain of diphtheria toxin (DT) and bispecific single-chain variable fragments (scFV) of antibodies targeting human CD19 and CD22.\n'
p13966
sg4
(lp13967
(dp13968
g7
I49
sg8
g15
sg10
I2
sg11
VDT
p13969
sg13
I1
sa(dp13970
g7
I255
sg8
VP15391
p13971
sg10
I4
sg11
VCD19
p13972
sg13
I1
sa(dp13973
g7
I149
sg8
g15
sg10
I16
sg11
Vdiphtheria toxin
p13974
sg13
I2
sasg23
(lp13975
(dp13976
g7
I149
sg26
VC0012546
p13977
sg10
I10
sg11
Vdiphtheria
p13978
sg13
I1
sa(dp13979
g7
I115
sg26
VC0040715
p13980
sg10
I13
sg11
Vtranslocation
p13981
sg13
I1
sasa(dp13982
g2
S'This study unravels an anti-metastatic role of AKT1 in the NSCLC cells with KRAS or EGFR mutations, and establishes an AKT1-MARCKS-LAMC2 feedback loop in this regulation.\n'
p13983
sg4
(lp13984
(dp13985
g7
I124
sg8
VP29966
p13986
sg10
I6
sg11
VMARCKS
p13987
sg13
I1
sa(dp13988
g7
I76
sg8
VP01116
p13989
sg10
I4
sg11
VKRAS
p13990
sg13
I1
sa(dp13991
g7
I47
sg8
VP31749
p13992
sg10
I4
sg11
VAKT1
p13993
sg13
I1
sa(dp13994
g7
I131
sg8
g15
sg10
I5
sg11
VLAMC2
p13995
sg13
I1
sa(dp13996
g7
I47
sg8
VP31749
p13997
sg10
I4
sg11
VAKT1
p13998
sg13
I1
sasg23
(lp13999
(dp14000
g7
I59
sg26
VC0007131
p14001
sg10
I5
sg11
VNSCLC
p14002
sg13
I1
sasa(dp14003
g2
S'In Africa, anemia in pregnancy contributes to non-attainment of the MDG goals 4 and 5.\n'
p14004
sg4
(lp14005
sg23
(lp14006
(dp14007
g7
I11
sg26
VC0271930
p14008
sg10
I19
sg11
Vanemia in pregnancy
p14009
sg13
I3
sasa(dp14010
g2
S'With OxMdG, grade 3-4 toxicity was rare (neutropenia 2.8% cycles; vomiting or diarrhoea &lt;1% cycles), but despite this there were two infection-associated deaths.\n'
p14011
sg4
(lp14012
sg23
(lp14013
(dp14014
g7
I78
sg26
VC0011991
p14015
sg10
I9
sg11
Vdiarrhoea
p14016
sg13
I1
sa(dp14017
g7
I136
sg26
VC0009450
p14018
sg10
I9
sg11
Vinfection
p14019
sg13
I1
sa(dp14020
g7
I66
sg26
VC0042963
p14021
sg10
I8
sg11
Vvomiting
p14022
sg13
I1
sasa(dp14023
g2
S'For validation, we tested the candidates for association with healthy thinness in additional pedigree members while accounting for effects of obesity-associated genes: NPFFR2, NPY2R, FTO, and MC4R.\n'
p14024
sg4
(lp14025
(dp14026
g7
I183
sg8
g15
sg10
I3
sg11
VFTO
p14027
sg13
I1
sa(dp14028
g7
I168
sg8
g15
sg10
I6
sg11
VNPFFR2
p14029
sg13
I1
sa(dp14030
g7
I176
sg8
VP49146
p14031
sg10
I5
sg11
VNPY2R
p14032
sg13
I1
sa(dp14033
g7
I192
sg8
VP32245
p14034
sg10
I4
sg11
VMC4R
p14035
sg13
I1
sasg23
(lp14036
(dp14037
g7
I142
sg26
VC0028754
p14038
sg10
I7
sg11
Vobesity
p14039
sg13
I1
sasa(dp14040
g2
S'We conclude that haplotypes containing the rs17376826 SNP in intron 1 of NPY2R have strong associations with BMI, some NPFFR2 haplotypes are strongly protective against or increase risk of obesity, and both NPY2R and NPFFR2 play important roles in obesity predisposition independent of FTO and MC4R.\n'
p14041
sg4
(lp14042
(dp14043
g7
I294
sg8
VP32245
p14044
sg10
I4
sg11
VMC4R
p14045
sg13
I1
sa(dp14046
g7
I73
sg8
VP49146
p14047
sg10
I5
sg11
VNPY2R
p14048
sg13
I1
sa(dp14049
g7
I286
sg8
g15
sg10
I3
sg11
VFTO
p14050
sg13
I1
sa(dp14051
g7
I119
sg8
g15
sg10
I17
sg11
VNPFFR2 haplotypes
p14052
sg13
I2
sa(dp14053
g7
I119
sg8
g15
sg10
I6
sg11
VNPFFR2
p14054
sg13
I1
sa(dp14055
g7
I73
sg8
VP49146
p14056
sg10
I5
sg11
VNPY2R
p14057
sg13
I1
sasg23
(lp14058
(dp14059
g7
I189
sg26
VC0028754
p14060
sg10
I7
sg11
Vobesity
p14061
sg13
I1
sa(dp14062
g7
I189
sg26
VC0028754
p14063
sg10
I7
sg11
Vobesity
p14064
sg13
I1
sasa(dp14065
g2
S'We report a haplotype in the GPR74 gene, ATAG, with allele frequency ~4% in Scandinavian cohorts, which was associated with protection against obesity in two samples selected for obese and lean phenotypes (odds ratio for obesity 0.48 and 0.62; nominal P=.0014 and .014; n=1,013 and 1,423, respectively).\n'
p14066
sg4
(lp14067
(dp14068
g7
I29
sg8
g15
sg10
I10
sg11
VGPR74 gene
p14069
sg13
I2
sasg23
(lp14070
(dp14071
g7
I179
sg26
VC0028754
p14072
sg10
I5
sg11
Vobese
p14073
sg13
I1
sa(dp14074
g7
I143
sg26
VC0028754
p14075
sg10
I7
sg11
Vobesity
p14076
sg13
I1
sa(dp14077
g7
I143
sg26
VC0028754
p14078
sg10
I7
sg11
Vobesity
p14079
sg13
I1
sasa(dp14080
g2
S'These findings suggest that a common haplotype in the GPR74 gene protects against obesity, which, at least in part, is caused by a relief of inhibition of lipid mobilization from adipose tissue.\n'
p14081
sg4
(lp14082
(dp14083
g7
I54
sg8
g15
sg10
I10
sg11
VGPR74 gene
p14084
sg13
I2
sasg23
(lp14085
(dp14086
g7
I82
sg26
VC0028754
p14087
sg10
I7
sg11
Vobesity
p14088
sg13
I1
sasa(dp14089
g2
S'We separately reviewed interventions implemented as part of selected broader PSPs by way of example: hand hygiene, ventilator-associated pneumonia, rapid response systems and care transitions.\n'
p14090
sg4
(lp14091
sg23
(lp14092
(dp14093
g7
I115
sg26
VC1701940
p14094
sg10
I31
sg11
Vventilator-associated pneumonia
p14095
sg13
I2
sasa(dp14096
g2
S'Since tachykinins appear to be involved in the pathogenesis of allergic asthma, we investigated a possible association between 28 single nucleotide polymorphisms of the tachykinin genes TAC1, TAC3 and TAC4, and asthma susceptibility.\n'
p14097
sg4
(lp14098
(dp14099
g7
I169
sg8
VP29401
p14100
sg10
I21
sg11
Vtachykinin genes TAC1
p14101
sg13
I3
sa(dp14102
g7
I201
sg8
g15
sg10
I4
sg11
VTAC4
p14103
sg13
I1
sa(dp14104
g7
I6
sg8
VP29401
p14105
sg10
I11
sg11
Vtachykinins
p14106
sg13
I1
sa(dp14107
g7
I192
sg8
g15
sg10
I4
sg11
VTAC3
p14108
sg13
I1
sasg23
(lp14109
(dp14110
g7
I72
sg26
VC0004096
p14111
sg10
I6
sg11
Vasthma
p14112
sg13
I1
sa(dp14113
g7
I63
sg26
VC0155877
p14114
sg10
I15
sg11
Vallergic asthma
p14115
sg13
I2
sa(dp14116
g7
I47
sg26
VC0699748
p14117
sg10
I12
sg11
Vpathogenesis
p14118
sg13
I1
sasa(dp14119
g2
S'Next to CD34 hypermethylation, miR-665 was predicted and experimentally confirmed to target CD34 mRNA in GIST-T1 cells.\n'
p14120
sg4
(lp14121
(dp14122
g7
I8
sg8
VP28906
p14123
sg10
I4
sg11
VCD34
p14124
sg13
I1
sa(dp14125
g7
I92
sg8
VP28906
p14126
sg10
I9
sg11
VCD34 mRNA
p14127
sg13
I2
sasg23
(lp14128
(dp14129
g7
I105
sg26
VC1847319
p14130
sg10
I4
sg11
VGIST
p14131
sg13
I1
sasa(dp14132
g2
S'Our results suggest that CD34 expression in GISTs may undergo a complex control by DNA methylation and miR-665.\n'
p14133
sg4
(lp14134
(dp14135
g7
I25
sg8
VP28906
p14136
sg10
I4
sg11
VCD34
p14137
sg13
I1
sa(dp14138
g7
I44
sg8
VP10721
p14139
sg10
I5
sg11
VGISTs
p14140
sg13
I1
sasg23
(lp14141
(dp14142
g7
I44
sg26
VC0238198
p14143
sg10
I5
sg11
VGISTs
p14144
sg13
I1
sasa(dp14145
g2
S'Bioinformatics analysis identified rs1836724 to be a polymorphism in the seed region of four miRNA binding sites (hsa-miR335-5p, hsa-miR-28-5p, has-miR-708-5p and has-miR-665), which may participate in the development of breast cancer.\n'
p14146
sg4
(lp14147
(dp14148
g7
I129
sg8
g15
sg10
I13
sg11
Vhsa-miR-28-5p
p14149
sg13
I1
sa(dp14150
g7
I114
sg8
g15
sg10
I13
sg11
Vhsa-miR335-5p
p14151
sg13
I1
sasg23
(lp14152
(dp14153
g7
I114
sg26
VC0393754
p14154
sg10
I3
sg11
Vhsa
p14155
sg13
I1
sa(dp14156
g7
I221
sg26
VC0678222
p14157
sg10
I13
sg11
Vbreast cancer
p14158
sg13
I2
sa(dp14159
g7
I114
sg26
VC0393754
p14160
sg10
I3
sg11
Vhsa
p14161
sg13
I1
sasa(dp14162
g2
S'Samples of GSRCC were compared to that of intestinal gastric adenocarcinoma using Agilent microarray technique, and two differentially expressed miRNAs were identified, hsa-miR-665 and hsa-miR-95.\n'
p14163
sg4
(lp14164
(dp14165
g7
I169
sg8
g15
sg10
I11
sg11
Vhsa-miR-665
p14166
sg13
I1
sa(dp14167
g7
I185
sg8
g15
sg10
I10
sg11
Vhsa-miR-95
p14168
sg13
I1
sasg23
(lp14169
(dp14170
g7
I42
sg26
VC0279633
p14171
sg10
I33
sg11
Vintestinal gastric adenocarcinoma
p14172
sg13
I3
sa(dp14173
g7
I169
sg26
VC0393754
p14174
sg10
I3
sg11
Vhsa
p14175
sg13
I1
sa(dp14176
g7
I169
sg26
VC0393754
p14177
sg10
I3
sg11
Vhsa
p14178
sg13
I1
sasa(dp14179
g2
S'It was concluded that hsa-miR-665 and hsa-miR-95 were downregulated in GSRCC but upregulated in intestinal gastric adenocarcinoma, and the relatively differential expression of the miRNAs negatively controlling their target genes could be closely related to the high invasive metastasis and chemoresistance of GSRCC.\n'
p14180
sg4
(lp14181
(dp14182
g7
I22
sg8
g15
sg10
I11
sg11
Vhsa-miR-665
p14183
sg13
I1
sa(dp14184
g7
I38
sg8
g15
sg10
I10
sg11
Vhsa-miR-95
p14185
sg13
I1
sasg23
(lp14186
(dp14187
g7
I96
sg26
VC0279633
p14188
sg10
I33
sg11
Vintestinal gastric adenocarcinoma
p14189
sg13
I3
sa(dp14190
g7
I22
sg26
VC0393754
p14191
sg10
I3
sg11
Vhsa
p14192
sg13
I1
sa(dp14193
g7
I276
sg26
VC0027627
p14194
sg10
I10
sg11
Vmetastasis
p14195
sg13
I1
sa(dp14196
g7
I22
sg26
VC0393754
p14197
sg10
I3
sg11
Vhsa
p14198
sg13
I1
sasa(dp14199
g2
S'The purpose of the study was to assess urinary excretion of alpha-glutathione S-transferase (alpha-GST), pi-glutathione S-transferase (pi-GST), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and serum NGAL level in children with idiopathic nephrotic syndrome (INS).\n'
p14200
sg4
(lp14201
(dp14202
g7
I221
sg8
g15
sg10
I5
sg11
VKIM-1
p14203
sg13
I1
sa(dp14204
g7
I66
sg8
VP09488
p14205
sg10
I25
sg11
Vglutathione S-transferase
p14206
sg13
I2
sa(dp14207
g7
I233
sg8
VP80188
p14208
sg10
I10
sg11
Vserum NGAL
p14209
sg13
I2
sa(dp14210
g7
I60
sg8
VP09488
p14211
sg10
I31
sg11
Valpha-glutathione S-transferase
p14212
sg13
I2
sa(dp14213
g7
I93
sg8
g15
sg10
I9
sg11
Valpha-GST
p14214
sg13
I1
sa(dp14215
g7
I195
sg8
g15
sg10
I24
sg11
Vkidney injury molecule-1
p14216
sg13
I3
sasg23
(lp14217
(dp14218
g7
I298
sg26
VC1533172
p14219
sg10
I3
sg11
VINS
p14220
sg13
I1
sa(dp14221
g7
I267
sg26
VC1704321
p14222
sg10
I29
sg11
Vidiopathic nephrotic syndrome
p14223
sg13
I3
sasa(dp14224
g2
S'Our results revealed that neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 levels were significantly increased in the urine of patients with minimal change nephrotic syndrome (MCNS) and the culture supernatant of HK-2 cells treated by urinary proteins extracted from MCNS patients.\n'
p14225
sg4
(lp14226
(dp14227
g7
I26
sg8
VP08253
p14228
sg10
I21
sg11
Vneutrophil gelatinase
p14229
sg13
I2
sasg23
(lp14230
(dp14231
g7
I164
sg26
VC1704321
p14232
sg10
I33
sg11
Vminimal change nephrotic syndrome
p14233
sg13
I4
sa(dp14234
g7
I199
sg26
VC1704321
p14235
sg10
I4
sg11
VMCNS
p14236
sg13
I1
sa(dp14237
g7
I199
sg26
VC1704321
p14238
sg10
I4
sg11
VMCNS
p14239
sg13
I1
sasa(dp14240
g2
S'To study serum levels of serum amyloid P component (SAP) and SAP-DNA complexes in a population-based cohort of patients with systemic lupus erythematosus (SLE).\n'
p14241
sg4
(lp14242
(dp14243
g7
I25
sg8
VP02743
p14244
sg10
I25
sg11
Vserum amyloid P component
p14245
sg13
I4
sa(dp14246
g7
I61
sg8
VP02743
p14247
sg10
I17
sg11
VSAP-DNA complexes
p14248
sg13
I2
sa(dp14249
g7
I52
sg8
VP02743
p14250
sg10
I3
sg11
VSAP
p14251
sg13
I1
sasg23
(lp14252
(dp14253
g7
I125
sg26
VC0024141
p14254
sg10
I28
sg11
Vsystemic lupus erythematosus
p14255
sg13
I3
sa(dp14256
g7
I31
sg26
VC0011560
p14257
sg10
I7
sg11
Vamyloid
p14258
sg13
I1
sa(dp14259
g7
I155
sg26
VC0024141
p14260
sg10
I3
sg11
VSLE
p14261
sg13
I1
sasa(dp14262
g2
S'To determine the presence of raised titres of anti-serum amyloid P component (SAP) antibodies in patients with systemic lupus erythematosus (SLE) and to evaluate their correlation with clinical disease by the SLEDAI and clinical manifestations.\n'
p14263
sg4
(lp14264
(dp14265
g7
I46
sg8
VP02743
p14266
sg10
I30
sg11
Vanti-serum amyloid P component
p14267
sg13
I4
sa(dp14268
g7
I78
sg8
VP02743
p14269
sg10
I3
sg11
VSAP
p14270
sg13
I1
sasg23
(lp14271
(dp14272
g7
I111
sg26
VC0024141
p14273
sg10
I28
sg11
Vsystemic lupus erythematosus
p14274
sg13
I3
sa(dp14275
g7
I141
sg26
VC0024141
p14276
sg10
I3
sg11
VSLE
p14277
sg13
I1
sa(dp14278
g7
I57
sg26
VC0011560
p14279
sg10
I7
sg11
Vamyloid
p14280
sg13
I1
sasa(dp14281
g2
S'The C-reactive protein (CRP) response is defective in patients with acute flares of disease, and mice with targeted deletions of the serum amyloid P component gene (Sap) develop a lupus-like illness.\n'
p14282
sg4
(lp14283
(dp14284
g7
I133
sg8
VP02743
p14285
sg10
I30
sg11
Vserum amyloid P component gene
p14286
sg13
I5
sa(dp14287
g7
I4
sg8
VP02741
p14288
sg10
I18
sg11
VC-reactive protein
p14289
sg13
I2
sa(dp14290
g7
I165
sg8
VP02743
p14291
sg10
I3
sg11
VSap
p14292
sg13
I1
sa(dp14293
g7
I24
sg8
VP02741
p14294
sg10
I3
sg11
VCRP
p14295
sg13
I1
sasg23
(lp14296
(dp14297
g7
I180
sg26
VC0024131
p14298
sg10
I5
sg11
Vlupus
p14299
sg13
I1
sa(dp14300
g7
I139
sg26
VC0011560
p14301
sg10
I7
sg11
Vamyloid
p14302
sg13
I1
sasa(dp14303
g2
S'Aortae from lupus mice showed reduced endothelium-dependent vasodilator responses to acetylcholine and increased nicotinamide adenine dinucleotide phosphate oxidase-driven vascular reactive oxygen species production, which were normalized by GW0742 treatment.\n'
p14304
sg4
(lp14305
(dp14306
g7
I113
sg8
g15
sg10
I51
sg11
Vnicotinamide adenine dinucleotide phosphate oxidase
p14307
sg13
I5
sasg23
(lp14308
(dp14309
g7
I12
sg26
VC0024131
p14310
sg10
I5
sg11
Vlupus
p14311
sg13
I1
sasa(dp14312
g2
S"The expression and cell localization of caveolin-1 (Cav-1), thyroperoxidase (TPO), and dual oxidase (DUOX), involved in extracellular iodination, is modulated by Th1 cytokines in human normal thyroid cells and in Hashimoto's thyroiditis (HT).\n"
p14313
sg4
(lp14314
(dp14315
g7
I40
sg8
g15
sg10
I10
sg11
Vcaveolin-1
p14316
sg13
I1
sa(dp14317
g7
I101
sg8
g15
sg10
I4
sg11
VDUOX
p14318
sg13
I1
sa(dp14319
g7
I77
sg8
VP40225
p14320
sg10
I3
sg11
VTPO
p14321
sg13
I1
sa(dp14322
g7
I87
sg8
g15
sg10
I12
sg11
Vdual oxidase
p14323
sg13
I2
sa(dp14324
g7
I52
sg8
VP35218
p14325
sg10
I5
sg11
VCav-1
p14326
sg13
I1
sa(dp14327
g7
I162
sg8
VP01374
p14328
sg10
I13
sg11
VTh1 cytokines
p14329
sg13
I2
sa(dp14330
g7
I60
sg8
VP40225
p14331
sg10
I15
sg11
Vthyroperoxidase
p14332
sg13
I1
sasg23
(lp14333
(dp14334
g7
I238
sg26
VC0920350
p14335
sg10
I2
sg11
VHT
p14336
sg13
I1
sa(dp14337
g7
I213
sg26
VC0920350
p14338
sg10
I23
sg11
VHashimoto's thyroiditis
p14339
sg13
I2
sasa(dp14340
g2
S'Vascular reactive oxygen species content and mRNA levels of nicotinamide adenine dinucleotide phosphate oxidase subunits NOX-1 and p47(phox) were increased in lupus mice and reduced by hydroxychloroquine or antioxidants.\n'
p14341
sg4
(lp14342
(dp14343
g7
I135
sg8
VP19878
p14344
sg10
I4
sg11
Vphox
p14345
sg13
I1
sa(dp14346
g7
I131
sg8
VP08567
p14347
sg10
I3
sg11
Vp47
p14348
sg13
I1
sa(dp14349
g7
I60
sg8
g15
sg10
I66
sg11
Vnicotinamide adenine dinucleotide phosphate oxidase subunits NOX-1
p14350
sg13
I7
sasg23
(lp14351
(dp14352
g7
I159
sg26
VC0024131
p14353
sg10
I5
sg11
Vlupus
p14354
sg13
I1
sasa(dp14355
g2
S"These findings led us to investigate the effects of the main cytokines involved in Hashimoto thyroiditis (IFN-Gamma) and Graves' diseases (IL-4/IL-13) on the transcriptional regulation of DUOX and their corresponding DUOXA genes in thyroid cells.\n"
p14356
sg4
(lp14357
(dp14358
g7
I139
sg8
VP05112
p14359
sg10
I10
sg11
VIL-4/IL-13
p14360
sg13
I1
sa(dp14361
g7
I106
sg8
VP01579
p14362
sg10
I9
sg11
VIFN-Gamma
p14363
sg13
I1
sasg23
(lp14364
(dp14365
g7
I83
sg26
VC0920350
p14366
sg10
I21
sg11
VHashimoto thyroiditis
p14367
sg13
I2
sasa(dp14368
g2
S'The present data open new perspectives for a better understanding of the pathophysiology of thyroid autoimmune diseases considering DUOX2-mediated oxidative damages.\n'
p14369
sg4
(lp14370
sg23
(lp14371
(dp14372
g7
I100
sg26
VC0004364
p14373
sg10
I19
sg11
Vautoimmune diseases
p14374
sg13
I2
sasa(dp14375
g2
S'Real-time PCR of human FECD endothelium revealed a 10.4-fold upregulation of DRAM1 (P &lt; 0.0001) compared to autopsy controls.\n'
p14376
sg4
(lp14377
sg23
(lp14378
sa(dp14379
g2
S"The rs17070145-T variant of the WWC1 gene, coding for the KIBRA protein, has been associated with both increased episodic memory performance and lowered risk for late onset Alzheimer's disease, although the mechanism behind this protective effect has not been completely elucidated.\n"
p14380
sg4
(lp14381
(dp14382
g7
I32
sg8
g15
sg10
I9
sg11
VWWC1 gene
p14383
sg13
I2
sa(dp14384
g7
I58
sg8
g15
sg10
I13
sg11
VKIBRA protein
p14385
sg13
I2
sa(dp14386
g7
I4
sg8
VP26640
p14387
sg10
I20
sg11
Vrs17070145-T variant
p14388
sg13
I2
sasg23
(lp14389
(dp14390
g7
I173
sg26
VC1521724
p14391
sg10
I19
sg11
VAlzheimer's disease
p14392
sg13
I2
sasa(dp14393
g2
S"In conclusion, our results suggest that the effect of the WWC1 rs17070145 polymorphism on memory performance and Alzheimer's disease might be due to a differential regulation of the MAPK signaling, a key pathway involved in memory and learning processes.\n"
p14394
sg4
(lp14395
(dp14396
g7
I182
sg8
VP53779
p14397
sg10
I4
sg11
VMAPK
p14398
sg13
I1
sa(dp14399
g7
I58
sg8
g15
sg10
I15
sg11
VWWC1 rs17070145
p14400
sg13
I2
sasg23
(lp14401
(dp14402
g7
I113
sg26
VC1521724
p14403
sg10
I19
sg11
VAlzheimer's disease
p14404
sg13
I2
sasa(dp14405
g2
S"Genetic variations of APOE and KIBRA have been associated with human memory and Alzheimer's disease.\n"
p14406
sg4
(lp14407
(dp14408
g7
I22
sg8
VP02649
p14409
sg10
I4
sg11
VAPOE
p14410
sg13
I1
sa(dp14411
g7
I31
sg8
g15
sg10
I5
sg11
VKIBRA
p14412
sg13
I1
sasg23
(lp14413
(dp14414
g7
I80
sg26
VC1521724
p14415
sg10
I19
sg11
VAlzheimer's disease
p14416
sg13
I2
sasa(dp14417
g2
S"Functional studies suggest that KIBRA is a potential candidate gene for memory and Alzheimer's disease (AD) risk.\n"
p14418
sg4
(lp14419
(dp14420
g7
I32
sg8
g15
sg10
I5
sg11
VKIBRA
p14421
sg13
I1
sasg23
(lp14422
(dp14423
g7
I104
sg26
VC1521724
p14424
sg10
I2
sg11
VAD
p14425
sg13
I1
sa(dp14426
g7
I83
sg26
VC1521724
p14427
sg10
I19
sg11
VAlzheimer's disease
p14428
sg13
I2
sasa(dp14429
g2
S"The human KIBRA gene has been linked to human cognition through a lead intronic single-nucleotide polymorphism (SNP; rs17070145) that is associated with episodic memory performance and the risk to develop Alzheimer's disease.\n"
p14430
sg4
(lp14431
(dp14432
g7
I4
sg8
g15
sg10
I16
sg11
Vhuman KIBRA gene
p14433
sg13
I3
sasg23
(lp14434
(dp14435
g7
I205
sg26
VC1521724
p14436
sg10
I19
sg11
VAlzheimer's disease
p14437
sg13
I2
sasa(dp14438
g2
S"Genetic variation at the KIBRA rs17070145 polymorphism has been linked to episodic memory, executive function, and Alzheimer's disease (AD), which are related to the structural and functional integrity of the default-mode network (DMN) and executive control network (ECN).\n"
p14439
sg4
(lp14440
(dp14441
g7
I25
sg8
g15
sg10
I16
sg11
VKIBRA rs17070145
p14442
sg13
I2
sasg23
(lp14443
(dp14444
g7
I115
sg26
VC1521724
p14445
sg10
I19
sg11
VAlzheimer's disease
p14446
sg13
I2
sa(dp14447
g7
I136
sg26
VC1521724
p14448
sg10
I2
sg11
VAD
p14449
sg13
I1
sasa(dp14450
g2
S"This allele was associated with reduced Alzheimer's disease (AD) risk in 1 study, which also found overexpression of KIBRA in memory-related brain regions of AD.\n"
p14451
sg4
(lp14452
(dp14453
g7
I117
sg8
g15
sg10
I5
sg11
VKIBRA
p14454
sg13
I1
sasg23
(lp14455
(dp14456
g7
I40
sg26
VC1521724
p14457
sg10
I19
sg11
VAlzheimer's disease
p14458
sg13
I2
sa(dp14459
g7
I61
sg26
VC1521724
p14460
sg10
I2
sg11
VAD
p14461
sg13
I1
sa(dp14462
g7
I61
sg26
VC1521724
p14463
sg10
I2
sg11
VAD
p14464
sg13
I1
sasa(dp14465
g2
S'We present prenatal diagnosis of mosaicism for a small supernumerary marker chromosome (sSMC) derived from chromosome 22 associated with cat eye syndrome (CES) using cultured amniocytes in a pregnancy with fetal microcephaly, intrauterine growth restriction, left renal hypoplasia, total anomalous pulmonary venous return with dominant right heart and right ear deformity.\n'
p14466
sg4
(lp14467
sg23
(lp14468
(dp14469
g7
I155
sg26
VC0265493
p14470
sg10
I3
sg11
VCES
p14471
sg13
I1
sa(dp14472
g7
I362
sg26
VC0302142
p14473
sg10
I9
sg11
Vdeformity
p14474
sg13
I1
sa(dp14475
g7
I33
sg26
VC0392053
p14476
sg10
I9
sg11
Vmosaicism
p14477
sg13
I1
sa(dp14478
g7
I282
sg26
VC0036400
p14479
sg10
I39
sg11
Vtotal anomalous pulmonary venous return
p14480
sg13
I5
sa(dp14481
g7
I69
sg26
VC2919537
p14482
sg10
I17
sg11
Vmarker chromosome
p14483
sg13
I2
sa(dp14484
g7
I206
sg26
VC2315667
p14485
sg10
I18
sg11
Vfetal microcephaly
p14486
sg13
I2
sa(dp14487
g7
I226
sg26
VC0015934
p14488
sg10
I31
sg11
Vintrauterine growth restriction
p14489
sg13
I3
sa(dp14490
g7
I137
sg26
VC0265493
p14491
sg10
I16
sg11
Vcat eye syndrome
p14492
sg13
I3
sa(dp14493
g7
I264
sg26
VC0266295
p14494
sg10
I16
sg11
Vrenal hypoplasia
p14495
sg13
I2
sasa(dp14496
g2
S'The cat eye syndrome is a congenital malformation usually associated with anal atresia, ocular coloboma, downward slanting eyes, microphthalmia, hypertelorism, strabismus, preauricular tags or fistulas, congenital heart defect particularly septal defect, urinary tract abnormalities, skeletal anomalies and frequently mental and physical retardation.\n'
p14497
sg4
(lp14498
sg23
(lp14499
(dp14500
g7
I240
sg26
VC0018816
p14501
sg10
I13
sg11
Vseptal defect
p14502
sg13
I2
sa(dp14503
g7
I160
sg26
VC0038379
p14504
sg10
I10
sg11
Vstrabismus
p14505
sg13
I1
sa(dp14506
g7
I88
sg26
VC0009363
p14507
sg10
I15
sg11
Vocular coloboma
p14508
sg13
I2
sa(dp14509
g7
I193
sg26
VC0016169
p14510
sg10
I8
sg11
Vfistulas
p14511
sg13
I1
sa(dp14512
g7
I172
sg26
VC0266609
p14513
sg10
I17
sg11
Vpreauricular tags
p14514
sg13
I2
sa(dp14515
g7
I4
sg26
VC0265493
p14516
sg10
I16
sg11
Vcat eye syndrome
p14517
sg13
I3
sa(dp14518
g7
I26
sg26
VC1705254
p14519
sg10
I23
sg11
Vcongenital malformation
p14520
sg13
I2
sa(dp14521
g7
I129
sg26
VC0026010
p14522
sg10
I14
sg11
Vmicrophthalmia
p14523
sg13
I1
sa(dp14524
g7
I203
sg26
VC0018798
p14525
sg10
I23
sg11
Vcongenital heart defect
p14526
sg13
I3
sa(dp14527
g7
I145
sg26
VC0020534
p14528
sg10
I13
sg11
Vhypertelorism
p14529
sg13
I1
sa(dp14530
g7
I74
sg26
VC0003466
p14531
sg10
I12
sg11
Vanal atresia
p14532
sg13
I2
sasa(dp14533
g2
S'However, the physiological relevance of these findings is unclear as no overt differences in the development of lung disease were observed in the Nlrp12(-/-) mice.\n'
p14534
sg4
(lp14535
(dp14536
g7
I146
sg8
VP59046
p14537
sg10
I6
sg11
VNlrp12
p14538
sg13
I1
sasg23
(lp14539
(dp14540
g7
I112
sg26
VC0024115
p14541
sg10
I12
sg11
Vlung disease
p14542
sg13
I2
sasa(dp14543
g2
S'The return-to-forward peak current ratio, ipr/ipf, was found to increase towards unity with increasing DMF content of the medium, indicating the extended lifetime of RNO2(-.'
p14544
sg4
(lp14545
(dp14546
g7
I42
sg8
g15
sg10
I3
sg11
Vipr
p14547
sg13
I1
sa(dp14548
g7
I46
sg8
g15
sg10
I3
sg11
Vipf
p14549
sg13
I1
sasg23
(lp14550
sa(dp14551
g2
S').\n'
p14552
sg4
(lp14553
sg23
(lp14554
sa(dp14555
g2
S'All target molecules, except adenosine and guanine, resulted in interaction with RNO2.-, as measured by the decrease in the ipr/ipf ratio in the following order of increasing reactivity: adenine, guanosine, thymine, uracil, uridine, and thymidine (at a metronidazole:target ratio of 1:1).\n'
p14556
sg4
(lp14557
(dp14558
g7
I81
sg8
VP59046
p14559
sg10
I4
sg11
VRNO2
p14560
sg13
I1
sasg23
(lp14561
sa(dp14562
g2
S"Moreover, the simultaneous inhibition of IL-4 and IL-13 has shown significant clinical activity in diseases that are often co-morbid with asthma - atopic dermatitis and chronic sinusitis with nasal polyps - supporting the hypothesis that targeting a central 'driver pathway' could benefit multiple allergic diseases.\n"
p14563
sg4
(lp14564
(dp14565
g7
I41
sg8
VP05112
p14566
sg10
I4
sg11
VIL-4
p14567
sg13
I1
sa(dp14568
g7
I50
sg8
VP35225
p14569
sg10
I5
sg11
VIL-13
p14570
sg13
I1
sasg23
(lp14571
(dp14572
g7
I138
sg26
VC0004096
p14573
sg10
I6
sg11
Vasthma
p14574
sg13
I1
sa(dp14575
g7
I147
sg26
VC0011615
p14576
sg10
I17
sg11
Vatopic dermatitis
p14577
sg13
I2
sa(dp14578
g7
I169
sg26
VC0149516
p14579
sg10
I17
sg11
Vchronic sinusitis
p14580
sg13
I2
sa(dp14581
g7
I192
sg26
VC0027430
p14582
sg10
I12
sg11
Vnasal polyps
p14583
sg13
I2
sasa(dp14584
g2
S'In addition to the characteristic OPMD symptoms including ptosis and dysphagia, other symptoms such as limb girdle and axial weakness, and external ophthalmoplegia were frequently observed.\n'
p14585
sg4
(lp14586
sg23
(lp14587
(dp14588
g7
I58
sg26
VC0005745
p14589
sg10
I6
sg11
Vptosis
p14590
sg13
I1
sa(dp14591
g7
I139
sg26
VC0162292
p14592
sg10
I24
sg11
Vexternal ophthalmoplegia
p14593
sg13
I2
sa(dp14594
g7
I125
sg26
VC1883552
p14595
sg10
I8
sg11
Vweakness
p14596
sg13
I1
sa(dp14597
g7
I34
sg26
VC0270952
p14598
sg10
I4
sg11
VOPMD
p14599
sg13
I1
sa(dp14600
g7
I69
sg26
VC0011168
p14601
sg10
I9
sg11
Vdysphagia
p14602
sg13
I1
sasa(dp14603
g2
S'Oculopharyngeal muscular dystrophy (OPMD) is a hereditary neuromuscular disease with autosomal dominant and rarely with autosomal recessive inheritance types.\n'
p14604
sg4
(lp14605
sg23
(lp14606
(dp14607
g7
I58
sg26
VC0027868
p14608
sg10
I21
sg11
Vneuromuscular disease
p14609
sg13
I2
sa(dp14610
g7
I0
sg26
VC0270952
p14611
sg10
I34
sg11
VOculopharyngeal muscular dystrophy
p14612
sg13
I3
sa(dp14613
g7
I36
sg26
VC0270952
p14614
sg10
I4
sg11
VOPMD
p14615
sg13
I1
sasa(dp14616
g2
S'Oculopharyngeal muscular dystrophy (OPMD) is an inherited neuromuscular disease associated with a short trinucleotide repeat expansion in Exon 1 of the PABPN1 gene.\n'
p14617
sg4
(lp14618
(dp14619
g7
I152
sg8
g15
sg10
I11
sg11
VPABPN1 gene
p14620
sg13
I2
sasg23
(lp14621
(dp14622
g7
I58
sg26
VC0027868
p14623
sg10
I21
sg11
Vneuromuscular disease
p14624
sg13
I2
sa(dp14625
g7
I0
sg26
VC0270952
p14626
sg10
I34
sg11
VOculopharyngeal muscular dystrophy
p14627
sg13
I3
sa(dp14628
g7
I36
sg26
VC0270952
p14629
sg10
I4
sg11
VOPMD
p14630
sg13
I1
sasa(dp14631
g2
S'To describe the clinical and electrophysiologic features of an unselected population of patients diagnosed clinically or genetically with oculopharyngeal muscular dystrophy (OPMD), and to discern any association with a peripheral neuropathy.\n'
p14632
sg4
(lp14633
sg23
(lp14634
(dp14635
g7
I219
sg26
VC0031117
p14636
sg10
I21
sg11
Vperipheral neuropathy
p14637
sg13
I2
sa(dp14638
g7
I174
sg26
VC0270952
p14639
sg10
I4
sg11
VOPMD
p14640
sg13
I1
sa(dp14641
g7
I138
sg26
VC0270952
p14642
sg10
I34
sg11
Voculopharyngeal muscular dystrophy
p14643
sg13
I3
sasa(dp14644
g2
S'These findings argue against an association between OPMD and peripheral neuropathy.\n'
p14645
sg4
(lp14646
sg23
(lp14647
(dp14648
g7
I61
sg26
VC0031117
p14649
sg10
I21
sg11
Vperipheral neuropathy
p14650
sg13
I2
sa(dp14651
g7
I52
sg26
VC0270952
p14652
sg10
I4
sg11
VOPMD
p14653
sg13
I1
sasa(dp14654
g2
S'OPMD may not be associated with a peripheral neuropathy, as has been previously suggested.\n'
p14655
sg4
(lp14656
sg23
(lp14657
(dp14658
g7
I0
sg26
VC0270952
p14659
sg10
I4
sg11
VOPMD
p14660
sg13
I1
sa(dp14661
g7
I34
sg26
VC0031117
p14662
sg10
I21
sg11
Vperipheral neuropathy
p14663
sg13
I2
sasa(dp14664
g2
S'In this report a patient with both recessive OPMD and HNPP is described.\n'
p14665
sg4
(lp14666
(dp14667
g7
I45
sg8
g15
sg10
I4
sg11
VOPMD
p14668
sg13
I1
sa(dp14669
g7
I54
sg8
VP08034
p14670
sg10
I4
sg11
VHNPP
p14671
sg13
I1
sasg23
(lp14672
(dp14673
g7
I45
sg26
VC0270952
p14674
sg10
I4
sg11
VOPMD
p14675
sg13
I1
sa(dp14676
g7
I54
sg26
VC0393814
p14677
sg10
I4
sg11
VHNPP
p14678
sg13
I1
sasa(dp14679
g2
S'Although an elevated hemoglobin A1c (HbAc1) level is an independent predictor of worse survival in patients with both digestive cancer and diabetes mellitus, its relationship to short-term prognosis in these patients has not been addressed.\n'
p14680
sg4
(lp14681
(dp14682
g7
I37
sg8
VP40145
p14683
sg10
I5
sg11
VHbAc1
p14684
sg13
I1
sa(dp14685
g7
I21
sg8
g15
sg10
I14
sg11
Vhemoglobin A1c
p14686
sg13
I2
sasg23
(lp14687
(dp14688
g7
I139
sg26
VC0011849
p14689
sg10
I17
sg11
Vdiabetes mellitus
p14690
sg13
I2
sa(dp14691
g7
I118
sg26
VC0685938
p14692
sg10
I16
sg11
Vdigestive cancer
p14693
sg13
I2
sasa(dp14694
g2
S'We identified novel driver mutations that developed during adenoma and cancer evolution, particularly in OR1B1 (GPCR signaling pathway) for adenoma evolution, and LAMA1 (PI3K-Akt signaling pathway) and ADCY3 (FGFR signaling pathway) for CRC evolution.\n'
p14695
sg4
(lp14696
(dp14697
g7
I163
sg8
VP25391
p14698
sg10
I5
sg11
VLAMA1
p14699
sg13
I1
sa(dp14700
g7
I175
sg8
g15
sg10
I3
sg11
VAkt
p14701
sg13
I1
sa(dp14702
g7
I112
sg8
g15
sg10
I4
sg11
VGPCR
p14703
sg13
I1
sa(dp14704
g7
I170
sg8
VP42336
p14705
sg10
I4
sg11
VPI3K
p14706
sg13
I1
sa(dp14707
g7
I105
sg8
g15
sg10
I5
sg11
VOR1B1
p14708
sg13
I1
sa(dp14709
g7
I237
sg8
VP31749
p14710
sg10
I3
sg11
VCRC
p14711
sg13
I1
sa(dp14712
g7
I202
sg8
VP40145
p14713
sg10
I5
sg11
VADCY3
p14714
sg13
I1
sasg23
(lp14715
(dp14716
g7
I59
sg26
VC0001430
p14717
sg10
I7
sg11
Vadenoma
p14718
sg13
I1
sa(dp14719
g7
I237
sg26
VC1527249
p14720
sg10
I3
sg11
VCRC
p14721
sg13
I1
sa(dp14722
g7
I59
sg26
VC0001430
p14723
sg10
I7
sg11
Vadenoma
p14724
sg13
I1
sa(dp14725
g7
I71
sg26
VC0006826
p14726
sg10
I6
sg11
Vcancer
p14727
sg13
I1
sasa(dp14728
g2
S'Recently, we provided human validation for a cooperating oncogenic role for cAMP in brain tumorigenesis when we found that SNPs in ADCY8 were correlated with glioma (brain tumor) risk in individuals with Neurofibromatosis type 1 (NF1).\n'
p14729
sg4
(lp14730
(dp14731
g7
I230
sg8
VP21359
p14732
sg10
I3
sg11
VNF1
p14733
sg13
I1
sa(dp14734
g7
I131
sg8
VP40145
p14735
sg10
I5
sg11
VADCY8
p14736
sg13
I1
sa(dp14737
g7
I204
sg8
VP21359
p14738
sg10
I24
sg11
VNeurofibromatosis type 1
p14739
sg13
I3
sasg23
(lp14740
(dp14741
g7
I230
sg26
VC0027831
p14742
sg10
I3
sg11
VNF1
p14743
sg13
I1
sa(dp14744
g7
I84
sg26
VC0006118
p14745
sg10
I11
sg11
Vbrain tumor
p14746
sg13
I2
sa(dp14747
g7
I204
sg26
VC0027831
p14748
sg10
I24
sg11
VNeurofibromatosis type 1
p14749
sg13
I3
sa(dp14750
g7
I84
sg26
VC0006118
p14751
sg10
I80
sg11
Vbrain tumorigenesis when we found that SNPs in ADCY8 were correlated with glioma
p14752
sg13
I13
sasa(dp14753
g2
S'However, the cAMP pathway is well-known to be sexually dimorphic, and SNPs in ADCY8 affected glioma risk in a sex-specific fashion, elevating the risk for females while protecting males.\n'
p14754
sg4
(lp14755
(dp14756
g7
I78
sg8
VP40145
p14757
sg10
I5
sg11
VADCY8
p14758
sg13
I1
sasg23
(lp14759
(dp14760
g7
I93
sg26
VC0017638
p14761
sg10
I6
sg11
Vglioma
p14762
sg13
I1
sasa(dp14763
g2
S'Here, we report genetic polymorphisms in the human adenylate cyclase gene adenylate cyclase 8 (ADCY8) that correlate with glioma risk in NF1 in a sex-specific manner, elevating risk in females while reducing risk in males.\n'
p14764
sg4
(lp14765
(dp14766
g7
I95
sg8
VP40145
p14767
sg10
I5
sg11
VADCY8
p14768
sg13
I1
sa(dp14769
g7
I45
sg8
g15
sg10
I48
sg11
Vhuman adenylate cyclase gene adenylate cyclase 8
p14770
sg13
I7
sa(dp14771
g7
I137
sg8
VP21359
p14772
sg10
I3
sg11
VNF1
p14773
sg13
I1
sasg23
(lp14774
(dp14775
g7
I122
sg26
VC0017638
p14776
sg10
I6
sg11
Vglioma
p14777
sg13
I1
sa(dp14778
g7
I137
sg26
VC0027831
p14779
sg10
I3
sg11
VNF1
p14780
sg13
I1
sasa(dp14781
g2
S'Overall, our results establish a sex-specific role for cAMP regulation in human gliomagenesis, specifically identifying ADCY8 as a modifier of glioma risk in NF1.\n'
p14782
sg4
(lp14783
(dp14784
g7
I158
sg8
VP21359
p14785
sg10
I3
sg11
VNF1
p14786
sg13
I1
sa(dp14787
g7
I120
sg8
VP40145
p14788
sg10
I5
sg11
VADCY8
p14789
sg13
I1
sasg23
(lp14790
(dp14791
g7
I158
sg26
VC0027831
p14792
sg10
I3
sg11
VNF1
p14793
sg13
I1
sa(dp14794
g7
I80
sg26
VC0017638
p14795
sg10
I6
sg11
Vglioma
p14796
sg13
I1
sasa(dp14797
g2
S'Some of the other CpG site annotated genes appear to be critical to the development of cancers and cardiovascular diseases (i.e., WNT16, C18orf8, ANGPTL2, SAPCD2, ADCY3, PRR16, ERBB2, DOK2, PLAC1).\n'
p14798
sg4
(lp14799
(dp14800
g7
I130
sg8
g15
sg10
I5
sg11
VWNT16
p14801
sg13
I1
sa(dp14802
g7
I170
sg8
g15
sg10
I5
sg11
VPRR16
p14803
sg13
I1
sa(dp14804
g7
I137
sg8
g15
sg10
I7
sg11
VC18orf8
p14805
sg13
I1
sa(dp14806
g7
I177
sg8
VP04626
p14807
sg10
I5
sg11
VERBB2
p14808
sg13
I1
sa(dp14809
g7
I146
sg8
g15
sg10
I7
sg11
VANGPTL2
p14810
sg13
I1
sa(dp14811
g7
I190
sg8
g15
sg10
I5
sg11
VPLAC1
p14812
sg13
I1
sa(dp14813
g7
I163
sg8
VP40145
p14814
sg10
I5
sg11
VADCY3
p14815
sg13
I1
sa(dp14816
g7
I184
sg8
g15
sg10
I4
sg11
VDOK2
p14817
sg13
I1
sasg23
(lp14818
(dp14819
g7
I87
sg26
VC0006826
p14820
sg10
I7
sg11
Vcancers
p14821
sg13
I1
sa(dp14822
g7
I99
sg26
VC0007222
p14823
sg10
I23
sg11
Vcardiovascular diseases
p14824
sg13
I2
sasa(dp14825
g2
S'The prominent CD-68 and lysozyme staining along with the histological features, the clinical presentation of erythematous nodules with diffuse erythematous plaques, and absence of bone marrow findings, led to the diagnosis of malignant histiocytosis confined to the skin.\n'
p14826
sg4
(lp14827
(dp14828
g7
I24
sg8
VP61626
p14829
sg10
I8
sg11
Vlysozyme
p14830
sg13
I1
sasg23
(lp14831
(dp14832
g7
I156
sg26
VC0333463
p14833
sg10
I7
sg11
Vplaques
p14834
sg13
I1
sa(dp14835
g7
I226
sg26
VC0019623
p14836
sg10
I23
sg11
Vmalignant histiocytosis
p14837
sg13
I2
sa(dp14838
g7
I122
sg26
VC0028259
p14839
sg10
I7
sg11
Vnodules
p14840
sg13
I1
sasa(dp14841
g2
S'The atypical histiocytes were positive for CD68 and lysozyme and negative for lymphoid markers, and the diagnosis of true malignant histiocytosis associated with mediastinal germ cell tumor was made.\n'
p14842
sg4
(lp14843
(dp14844
g7
I52
sg8
VP61626
p14845
sg10
I8
sg11
Vlysozyme
p14846
sg13
I1
sa(dp14847
g7
I43
sg8
VP34810
p14848
sg10
I4
sg11
VCD68
p14849
sg13
I1
sasg23
(lp14850
(dp14851
g7
I117
sg26
VC0334663
p14852
sg10
I28
sg11
Vtrue malignant histiocytosis
p14853
sg13
I3
sa(dp14854
g7
I162
sg26
VC1334655
p14855
sg10
I27
sg11
Vmediastinal germ cell tumor
p14856
sg13
I4
sasa(dp14857
g2
S'Several histiocytic markers, including lysozyme, alpha1-antitrypsin and lectin RCA-1, revealed histiocytic origin of both inflammatory and neoplastic cells, however, those were not determinative for the discrimination between GME and malignant histiocytosis.\n'
p14858
sg4
(lp14859
(dp14860
g7
I72
sg8
g15
sg10
I12
sg11
Vlectin RCA-1
p14861
sg13
I2
sa(dp14862
g7
I39
sg8
VP61626
p14863
sg10
I8
sg11
Vlysozyme
p14864
sg13
I1
sa(dp14865
g7
I49
sg8
VP25100
p14866
sg10
I18
sg11
Valpha1-antitrypsin
p14867
sg13
I1
sasg23
(lp14868
(dp14869
g7
I234
sg26
VC0019623
p14870
sg10
I23
sg11
Vmalignant histiocytosis
p14871
sg13
I2
sasa(dp14872
g2
S'We used fMRI to evaluate verum and sham acupuncture stimulation at acupoint LI-4 in Carpal Tunnel Syndrome (CTS) patients and healthy controls (HC).\n'
p14873
sg4
(lp14874
sg23
(lp14875
(dp14876
g7
I84
sg26
VC0007286
p14877
sg10
I22
sg11
VCarpal Tunnel Syndrome
p14878
sg13
I3
sa(dp14879
g7
I108
sg26
VC0007286
p14880
sg10
I3
sg11
VCTS
p14881
sg13
I1
sasa(dp14882
g2
S'Our results indicate that the stimulatory effect of PTL on the differentiation of osteoblasts in inflammatory environments may involve the activation of the Wnt/Beta-catenin signaling pathway, and PTL may be a promising component for bone regeneration in periodontitis treatment.\n'
p14883
sg4
(lp14884
(dp14885
g7
I52
sg8
VP16233
p14886
sg10
I3
sg11
VPTL
p14887
sg13
I1
sasg23
(lp14888
(dp14889
g7
I255
sg26
VC0031099
p14890
sg10
I13
sg11
Vperiodontitis
p14891
sg13
I1
sasa(dp14892
g2
S'Our findings indicated that baicalein enhanced the osteogenic differentiation of hPDLCs via the activation of the Wnt/Beta-catenin signaling pathway, which may represent a potential candidate for periodontitis therapy.\n'
p14893
sg4
(lp14894
sg23
(lp14895
(dp14896
g7
I196
sg26
VC0031099
p14897
sg10
I13
sg11
Vperiodontitis
p14898
sg13
I1
sasa(dp14899
g2
S'We used the Fluidigm (San Francisco, CA) C1 single-cell Autoprep System for single-cell complementary DNA (cDNA) generation and an enzyme-based tagmentation system (Nextera XT; Illumina, San Diego, CA) with a nanoliter liquid handler (mosquito HTS; TTP Labtech, Royston, UK) for library preparation, reducing the reaction volume down to 2 myL and using as little as 20 pg of input cDNA.\n'
p14900
sg4
(lp14901
(dp14902
g7
I339
sg8
VP29590
p14903
sg10
I3
sg11
VmyL
p14904
sg13
I1
sasg23
(lp14905
(dp14906
g7
I249
sg26
VC1268935
p14907
sg10
I3
sg11
VTTP
p14908
sg13
I1
sa(dp14909
g7
I244
sg26
VC1854310
p14910
sg10
I3
sg11
VHTS
p14911
sg13
I1
sasa(dp14912
g2
S'The authors sought to analyze the safety and efficacy of the thulium 2-mym laser applied through navigated, robot-assisted endoscopy in disconnection surgery for HHs.\n'
p14913
sg4
(lp14914
sg23
(lp14915
(dp14916
g7
I162
sg26
VC0265354
p14917
sg10
I3
sg11
VHHs
p14918
sg13
I1
sasa(dp14919
g2
S'The Insulin-like growth factor (IGF)/IGF-receptor pathway with its scaffolding proteins Insulin Receptor Substrate (IRS)1 and IRS2 are crucial regulators of metabolism and progression in metastatic colorectal cancer (mCRC).\n'
p14920
sg4
(lp14921
(dp14922
g7
I37
sg8
g15
sg10
I12
sg11
VIGF-receptor
p14923
sg13
I1
sa(dp14924
g7
I32
sg8
VP01344
p14925
sg10
I3
sg11
VIGF
p14926
sg13
I1
sa(dp14927
g7
I4
sg8
VP01308
p14928
sg10
I26
sg11
VInsulin-like growth factor
p14929
sg13
I3
sa(dp14930
g7
I88
sg8
VP01308
p14931
sg10
I33
sg11
VInsulin Receptor Substrate (IRS)1
p14932
sg13
I4
sa(dp14933
g7
I126
sg8
g15
sg10
I4
sg11
VIRS2
p14934
sg13
I1
sasg23
(lp14935
(dp14936
g7
I217
sg26
VC0948380
p14937
sg10
I4
sg11
VmCRC
p14938
sg13
I1
sa(dp14939
g7
I187
sg26
VC0948380
p14940
sg10
I28
sg11
Vmetastatic colorectal cancer
p14941
sg13
I3
sasa(dp14942
g2
S'Recent studies explored the association between insulin receptor substrate-2 (IRS-2) gene rs1805097 polymorphism and colorectal cancer (CRC) with contradictory findings.\n'
p14943
sg4
(lp14944
(dp14945
g7
I48
sg8
VP01308
p14946
sg10
I28
sg11
Vinsulin receptor substrate-2
p14947
sg13
I3
sa(dp14948
g7
I78
sg8
g15
sg10
I5
sg11
VIRS-2
p14949
sg13
I1
sa(dp14950
g7
I85
sg8
VP31749
p14951
sg10
I55
sg11
Vgene rs1805097 polymorphism and colorectal cancer (CRC)
p14952
sg13
I7
sasg23
(lp14953
(dp14954
g7
I136
sg26
VC1527249
p14955
sg10
I3
sg11
VCRC
p14956
sg13
I1
sa(dp14957
g7
I117
sg26
VC1527249
p14958
sg10
I17
sg11
Vcolorectal cancer
p14959
sg13
I2
sasa(dp14960
g2
S'Taken together, our study provides the first evidence that miR-30a suppressed colon cancer cell growth through inhibition of IRS2.\n'
p14961
sg4
(lp14962
(dp14963
g7
I125
sg8
g15
sg10
I4
sg11
VIRS2
p14964
sg13
I1
sa(dp14965
g7
I59
sg8
g15
sg10
I7
sg11
VmiR-30a
p14966
sg13
I1
sasg23
(lp14967
(dp14968
g7
I84
sg26
VC1516170
p14969
sg10
I18
sg11
Vcancer cell growth
p14970
sg13
I3
sasa(dp14971
g2
S'Given the role of insulin resistance in colorectal cancer (CRC), we explored whether genetic variants in insulin (INS), insulin receptor (INSR), insulin receptor substrate 1 (IRS1), insulin receptor substrate 2 (IRS2), insulin-like growth factor 1 (IGF1), and insulin-like growth factor binding protein 3 (IGFBP3) genes were associated with CRC risk.\n'
p14972
sg4
(lp14973
(dp14974
g7
I18
sg8
VP01308
p14975
sg10
I45
sg11
Vinsulin resistance in colorectal cancer (CRC)
p14976
sg13
I6
sa(dp14977
g7
I138
sg8
VP06213
p14978
sg10
I4
sg11
VINSR
p14979
sg13
I1
sa(dp14980
g7
I18
sg8
VP01308
p14981
sg10
I7
sg11
Vinsulin
p14982
sg13
I1
sa(dp14983
g7
I175
sg8
VP35568
p14984
sg10
I4
sg11
VIRS1
p14985
sg13
I1
sa(dp14986
g7
I212
sg8
g15
sg10
I4
sg11
VIRS2
p14987
sg13
I1
sa(dp14988
g7
I120
sg8
VP01308
p14989
sg10
I16
sg11
Vinsulin receptor
p14990
sg13
I2
sa(dp14991
g7
I145
sg8
VP35568
p14992
sg10
I28
sg11
Vinsulin receptor substrate 1
p14993
sg13
I4
sa(dp14994
g7
I306
sg8
VP17936
p14995
sg10
I6
sg11
VIGFBP3
p14996
sg13
I1
sa(dp14997
g7
I219
sg8
VP01308
p14998
sg10
I28
sg11
Vinsulin-like growth factor 1
p14999
sg13
I4
sa(dp15000
g7
I260
sg8
VP01308
p15001
sg10
I44
sg11
Vinsulin-like growth factor binding protein 3
p15002
sg13
I6
sa(dp15003
g7
I182
sg8
VP01308
p15004
sg10
I28
sg11
Vinsulin receptor substrate 2
p15005
sg13
I4
sa(dp15006
g7
I249
sg8
VP01343
p15007
sg10
I4
sg11
VIGF1
p15008
sg13
I1
sa(dp15009
g7
I114
sg8
VP01308
p15010
sg10
I3
sg11
VINS
p15011
sg13
I1
sasg23
(lp15012
(dp15013
g7
I18
sg26
VC1533172
p15014
sg10
I7
sg11
Vinsulin
p15015
sg13
I1
sa(dp15016
g7
I18
sg26
VC1533172
p15017
sg10
I7
sg11
Vinsulin
p15018
sg13
I1
sa(dp15019
g7
I18
sg26
VC0021655
p15020
sg10
I18
sg11
Vinsulin resistance
p15021
sg13
I2
sa(dp15022
g7
I18
sg26
VC1533172
p15023
sg10
I7
sg11
Vinsulin
p15024
sg13
I1
sa(dp15025
g7
I18
sg26
VC1533172
p15026
sg10
I7
sg11
Vinsulin
p15027
sg13
I1
sa(dp15028
g7
I18
sg26
VC1533172
p15029
sg10
I7
sg11
Vinsulin
p15030
sg13
I1
sa(dp15031
g7
I18
sg26
VC1533172
p15032
sg10
I7
sg11
Vinsulin
p15033
sg13
I1
sa(dp15034
g7
I40
sg26
VC1527249
p15035
sg10
I17
sg11
Vcolorectal cancer
p15036
sg13
I2
sa(dp15037
g7
I59
sg26
VC1527249
p15038
sg10
I3
sg11
VCRC
p15039
sg13
I1
sa(dp15040
g7
I114
sg26
VC1533172
p15041
sg10
I3
sg11
VINS
p15042
sg13
I1
sa(dp15043
g7
I59
sg26
VC1527249
p15044
sg10
I3
sg11
VCRC
p15045
sg13
I1
sasa(dp15046
g2
S'The prevalence of IRS2 CNG in colorectal cancer tumors as measured by qPCR-CNV is approximately 35%.\n'
p15047
sg4
(lp15048
(dp15049
g7
I18
sg8
g15
sg10
I8
sg11
VIRS2 CNG
p15050
sg13
I2
sasg23
(lp15051
(dp15052
g7
I30
sg26
VC1527249
p15053
sg10
I17
sg11
Vcolorectal cancer
p15054
sg13
I2
sa(dp15055
g7
I48
sg26
VC0027651
p15056
sg10
I6
sg11
Vtumors
p15057
sg13
I1
sasa(dp15058
g2
S'To determine the risk of colon cancer by analysing the IRS-2 gene polymorphism in Turkish patients.\n'
p15059
sg4
(lp15060
(dp15061
g7
I55
sg8
g15
sg10
I10
sg11
VIRS-2 gene
p15062
sg13
I2
sasg23
(lp15063
(dp15064
g7
I25
sg26
VC0699790
p15065
sg10
I12
sg11
Vcolon cancer
p15066
sg13
I2
sasa(dp15067
g2
S'Our results demonstrated that IRS-2 G1057D polymorphism is not associated with colorectal cancer in the Turkish population.\n'
p15068
sg4
(lp15069
(dp15070
g7
I30
sg8
g15
sg10
I12
sg11
VIRS-2 G1057D
p15071
sg13
I2
sasg23
(lp15072
(dp15073
g7
I79
sg26
VC1527249
p15074
sg10
I17
sg11
Vcolorectal cancer
p15075
sg13
I2
sasa(dp15076
g2
S"Historeactivities to Congo red, PAS, Oil Red O, alcian blue, and Masson's trichrome were not detected, but immunoreactivities to CD29, CD34, and TG-2 were detected in the pingueculae with AF.\n"
p15077
sg4
(lp15078
(dp15079
g7
I135
sg8
VP28906
p15080
sg10
I4
sg11
VCD34
p15081
sg13
I1
sasg23
(lp15082
sa(dp15083
g2
S'However, CD29, CD34, and TG-2 were not detected in the pingueculae without AF.\n'
p15084
sg4
(lp15085
(dp15086
g7
I15
sg8
VP28906
p15087
sg10
I4
sg11
VCD34
p15088
sg13
I1
sasg23
(lp15089
sa(dp15090
g2
S'The AF of pingueculae may be related to CD29, CD34, and TG-2.\n'
p15091
sg4
(lp15092
(dp15093
g7
I46
sg8
VP28906
p15094
sg10
I4
sg11
VCD34
p15095
sg13
I1
sasg23
(lp15096
sa(dp15097
g2
S'Disease-causing gene mutations were found in 10 patients from 7 families: DNAH5 in 4 families, and DNAI1, CCDC40, and RSPH4A in 1 family each.\n'
p15098
sg4
(lp15099
(dp15100
g7
I106
sg8
g15
sg10
I6
sg11
VCCDC40
p15101
sg13
I1
sa(dp15102
g7
I99
sg8
g15
sg10
I5
sg11
VDNAI1
p15103
sg13
I1
sa(dp15104
g7
I118
sg8
g15
sg10
I6
sg11
VRSPH4A
p15105
sg13
I1
sasg23
(lp15106
sa(dp15107
g2
S'Approximately 2.7% (n=10) and 16.4% (n=60) patients with scrub typhus had overt DIC, as defined by the International Society on Thrombosis and Hemostasis DIC score (DIC1) and the DIC-scoring template with a fibrinogen/C-reactive protein-ratio (DIC2), respectively.\n'
p15108
sg4
(lp15109
(dp15110
g7
I207
sg8
VP22087
p15111
sg10
I10
sg11
Vfibrinogen
p15112
sg13
I1
sa(dp15113
g7
I218
sg8
VP02741
p15114
sg10
I18
sg11
VC-reactive protein
p15115
sg13
I2
sasg23
(lp15116
(dp15117
g7
I80
sg26
VC0012739
p15118
sg10
I3
sg11
VDIC
p15119
sg13
I1
sa(dp15120
g7
I80
sg26
VC0012739
p15121
sg10
I3
sg11
VDIC
p15122
sg13
I1
sa(dp15123
g7
I57
sg26
VC0036472
p15124
sg10
I12
sg11
Vscrub typhus
p15125
sg13
I2
sa(dp15126
g7
I80
sg26
VC0012739
p15127
sg10
I3
sg11
VDIC
p15128
sg13
I1
sa(dp15129
g7
I128
sg26
VC0040053
p15130
sg10
I10
sg11
VThrombosis
p15131
sg13
I1
sasa(dp15132
g2
S'A key enzyme for SA biosynthesis is isochorismate synthase (ICS), which converts chorismate into isochorismate, and for which there are two genes in Arabidopsis thaliana One (AtICS1) has been shown to be required for increased SA biosynthesis in response to pathogens and its expression can be stimulated throughout the leaf by virus infection and exogenous SA.\n'
p15133
sg4
(lp15134
(dp15135
g7
I36
sg8
VP06241
p15136
sg10
I22
sg11
Visochorismate synthase
p15137
sg13
I2
sa(dp15138
g7
I60
sg8
g15
sg10
I3
sg11
VICS
p15139
sg13
I1
sasg23
(lp15140
(dp15141
g7
I36
sg26
VC0022521
p15142
sg10
I22
sg11
Visochorismate synthase
p15143
sg13
I2
sa(dp15144
g7
I60
sg26
VC0022521
p15145
sg10
I3
sg11
VICS
p15146
sg13
I1
sa(dp15147
g7
I328
sg26
VC0042769
p15148
sg10
I15
sg11
Vvirus infection
p15149
sg13
I2
sasa(dp15150
g2
S'The gene encoding myopodin, an actin binding protein, is commonly deleted in invasive, but not in indolent, prostate cancers.\n'
p15151
sg4
(lp15152
(dp15153
g7
I4
sg8
g15
sg10
I22
sg11
Vgene encoding myopodin
p15154
sg13
I3
sa(dp15155
g7
I31
sg8
VP31146
p15156
sg10
I21
sg11
Vactin binding protein
p15157
sg13
I3
sasg23
(lp15158
(dp15159
g7
I108
sg26
VC0376358
p15160
sg10
I16
sg11
Vprostate cancers
p15161
sg13
I2
sasa(dp15162
g2
S'There are conflicting reports on the effects of myopodin expression on prostate cancer cell migration and invasion.\n'
p15163
sg4
(lp15164
(dp15165
g7
I48
sg8
g15
sg10
I8
sg11
Vmyopodin
p15166
sg13
I1
sasg23
(lp15167
(dp15168
g7
I106
sg26
VC2699153
p15169
sg10
I8
sg11
Vinvasion
p15170
sg13
I1
sa(dp15171
g7
I71
sg26
VC0600139
p15172
sg10
I15
sg11
Vprostate cancer
p15173
sg13
I2
sasa(dp15174
g2
S'The recent recognition that myopodin is expressed as four different isoforms further complicates our understanding of how this potentially important invasive prostate cancer biomarker affects tumor cell migration and invasion.\n'
p15175
sg4
(lp15176
(dp15177
g7
I28
sg8
g15
sg10
I8
sg11
Vmyopodin
p15178
sg13
I1
sasg23
(lp15179
(dp15180
g7
I158
sg26
VC0600139
p15181
sg10
I15
sg11
Vprostate cancer
p15182
sg13
I2
sa(dp15183
g7
I192
sg26
VC0027627
p15184
sg10
I20
sg11
Vtumor cell migration
p15185
sg13
I3
sa(dp15186
g7
I217
sg26
VC2699153
p15187
sg10
I8
sg11
Vinvasion
p15188
sg13
I1
sasa(dp15189
g2
S'We now show that myopodin affects the chemokinetic, rather than the chemotactic, properties of PC3 prostate cancer cells.\n'
p15190
sg4
(lp15191
(dp15192
g7
I95
sg8
VP42025
p15193
sg10
I3
sg11
VPC3
p15194
sg13
I1
sa(dp15195
g7
I17
sg8
g15
sg10
I8
sg11
Vmyopodin
p15196
sg13
I1
sasg23
(lp15197
(dp15198
g7
I99
sg26
VC0600139
p15199
sg10
I15
sg11
Vprostate cancer
p15200
sg13
I2
sasa(dp15201
g2
S'The correlation between loss of myopodin expression and invasive prostate cancer therefore reflects complex myopodin interactions with pathways that regulate the cellular migration response to diverse signals that may be present in a tumor microenvironment.\n'
p15202
sg4
(lp15203
(dp15204
g7
I32
sg8
g15
sg10
I8
sg11
Vmyopodin
p15205
sg13
I1
sasg23
(lp15206
(dp15207
g7
I234
sg26
VC0027651
p15208
sg10
I5
sg11
Vtumor
p15209
sg13
I1
sa(dp15210
g7
I65
sg26
VC0600139
p15211
sg10
I15
sg11
Vprostate cancer
p15212
sg13
I2
sasa(dp15213
g2
S'Myopodin has recently been characterized as a tumor suppressor gene whose encoded product inhibits prostate cancer growth and metastasis both in vitro and in animal models.\n'
p15214
sg4
(lp15215
(dp15216
g7
I0
sg8
g15
sg10
I8
sg11
VMyopodin
p15217
sg13
I1
sasg23
(lp15218
(dp15219
g7
I99
sg26
VC0600139
p15220
sg10
I15
sg11
Vprostate cancer
p15221
sg13
I2
sa(dp15222
g7
I46
sg26
VC0027651
p15223
sg10
I5
sg11
Vtumor
p15224
sg13
I1
sa(dp15225
g7
I126
sg26
VC0027627
p15226
sg10
I10
sg11
Vmetastasis
p15227
sg13
I1
sasa(dp15228
g2
S'In this study, we conducted a large-scale analysis of myopodin expression in prostate cancer samples to examine the relationship between myopodin expression and prostate cancer grade and stage and the probability of clinical relapse.\n'
p15229
sg4
(lp15230
(dp15231
g7
I54
sg8
g15
sg10
I8
sg11
Vmyopodin
p15232
sg13
I1
sa(dp15233
g7
I54
sg8
g15
sg10
I8
sg11
Vmyopodin
p15234
sg13
I1
sasg23
(lp15235
(dp15236
g7
I77
sg26
VC0600139
p15237
sg10
I15
sg11
Vprostate cancer
p15238
sg13
I2
sa(dp15239
g7
I225
sg26
VC0277556
p15240
sg10
I7
sg11
Vrelapse
p15241
sg13
I1
sa(dp15242
g7
I77
sg26
VC0600139
p15243
sg10
I15
sg11
Vprostate cancer
p15244
sg13
I2
sasa(dp15245
g2
S'The myopodin expression levels were examined in relation to prostate cancer grade and stage, preoperative prostate-specific antigen level, surgical margin involvement, tumor volume, and clinical relapse.\n'
p15246
sg4
(lp15247
(dp15248
g7
I4
sg8
g15
sg10
I8
sg11
Vmyopodin
p15249
sg13
I1
sa(dp15250
g7
I106
sg8
VP07288
p15251
sg10
I25
sg11
Vprostate-specific antigen
p15252
sg13
I2
sasg23
(lp15253
(dp15254
g7
I60
sg26
VC0600139
p15255
sg10
I15
sg11
Vprostate cancer
p15256
sg13
I2
sa(dp15257
g7
I195
sg26
VC0277556
p15258
sg10
I7
sg11
Vrelapse
p15259
sg13
I1
sa(dp15260
g7
I168
sg26
VC0027651
p15261
sg10
I5
sg11
Vtumor
p15262
sg13
I1
sasa(dp15263
g2
S'The mean myopodin expression score (range 0 to 3) was 2.1 and 0.88 for benign prostatic tissue and prostate cancer, respectively.\n'
p15264
sg4
(lp15265
(dp15266
g7
I9
sg8
g15
sg10
I8
sg11
Vmyopodin
p15267
sg13
I1
sasg23
(lp15268
(dp15269
g7
I99
sg26
VC0600139
p15270
sg10
I15
sg11
Vprostate cancer
p15271
sg13
I2
sasa(dp15272
g2
S'Minimal variation in myopodin expression was observed among the various grades, stages, tumor volumes, and preoperative prostate-specific antigen levels of prostate cancer.\n'
p15273
sg4
(lp15274
(dp15275
g7
I120
sg8
VP07288
p15276
sg10
I25
sg11
Vprostate-specific antigen
p15277
sg13
I2
sa(dp15278
g7
I21
sg8
g15
sg10
I8
sg11
Vmyopodin
p15279
sg13
I1
sasg23
(lp15280
(dp15281
g7
I88
sg26
VC0027651
p15282
sg10
I5
sg11
Vtumor
p15283
sg13
I1
sa(dp15284
g7
I156
sg26
VC0600139
p15285
sg10
I15
sg11
Vprostate cancer
p15286
sg13
I2
sasa(dp15287
g2
S'Our results suggest that myopodin is an important predictor of prostate cancer metastasis, independent of Gleason score, preoperative prostate-specific antigen level, and tumor stage.\n'
p15288
sg4
(lp15289
(dp15290
g7
I25
sg8
g15
sg10
I8
sg11
Vmyopodin
p15291
sg13
I1
sa(dp15292
g7
I134
sg8
VP07288
p15293
sg10
I25
sg11
Vprostate-specific antigen
p15294
sg13
I2
sasg23
(lp15295
(dp15296
g7
I79
sg26
VC0027627
p15297
sg10
I10
sg11
Vmetastasis
p15298
sg13
I1
sa(dp15299
g7
I63
sg26
VC0600139
p15300
sg10
I15
sg11
Vprostate cancer
p15301
sg13
I2
sa(dp15302
g7
I171
sg26
VC0027651
p15303
sg10
I5
sg11
Vtumor
p15304
sg13
I1
sasa(dp15305
g2
S'Myopodin was identified as a tumor suppressor gene that is frequently deleted in aggressive prostate cancer.\n'
p15306
sg4
(lp15307
(dp15308
g7
I0
sg8
g15
sg10
I8
sg11
VMyopodin
p15309
sg13
I1
sasg23
(lp15310
(dp15311
g7
I29
sg26
VC0027651
p15312
sg10
I5
sg11
Vtumor
p15313
sg13
I1
sa(dp15314
g7
I81
sg26
VC0001807
p15315
sg10
I10
sg11
Vaggressive
p15316
sg13
I1
sa(dp15317
g7
I92
sg26
VC0600139
p15318
sg10
I15
sg11
Vprostate cancer
p15319
sg13
I2
sasa(dp15320
g2
S'Myopodin was previously reported as a gene that was frequently deleted in prostate cancer.\n'
p15321
sg4
(lp15322
(dp15323
g7
I0
sg8
g15
sg10
I8
sg11
VMyopodin
p15324
sg13
I1
sasg23
(lp15325
(dp15326
g7
I74
sg26
VC0600139
p15327
sg10
I15
sg11
Vprostate cancer
p15328
sg13
I2
sasa(dp15329
g2
S'To clarify the functional role of myopodin in prostate cancer, several assays were performed to evaluate the tumor suppression activity of myopodin.\n'
p15330
sg4
(lp15331
(dp15332
g7
I34
sg8
g15
sg10
I8
sg11
Vmyopodin
p15333
sg13
I1
sa(dp15334
g7
I34
sg8
g15
sg10
I8
sg11
Vmyopodin
p15335
sg13
I1
sasg23
(lp15336
(dp15337
g7
I46
sg26
VC0600139
p15338
sg10
I15
sg11
Vprostate cancer
p15339
sg13
I2
sa(dp15340
g7
I109
sg26
VC0027651
p15341
sg10
I5
sg11
Vtumor
p15342
sg13
I1
sa(dp15343
g7
I115
sg26
VC0221103
p15344
sg10
I11
sg11
Vsuppression
p15345
sg13
I1
sasa(dp15346
g2
S'To further evaluate the role of myopodin in suppressing the invasiveness of prostate cancer, an expression analysis of myopodin protein was performed in prostate tissues.\n'
p15347
sg4
(lp15348
(dp15349
g7
I119
sg8
g15
sg10
I16
sg11
Vmyopodin protein
p15350
sg13
I2
sa(dp15351
g7
I32
sg8
g15
sg10
I8
sg11
Vmyopodin
p15352
sg13
I1
sasg23
(lp15353
(dp15354
g7
I76
sg26
VC0600139
p15355
sg10
I15
sg11
Vprostate cancer
p15356
sg13
I2
sasa(dp15357
g2
S'The results indicate that down-regulation of myopodin expression occurs mostly in invasive stages of prostate cancer, implying a potential invasion suppression role for myopodin in prostate cancer.\n'
p15358
sg4
(lp15359
(dp15360
g7
I45
sg8
g15
sg10
I8
sg11
Vmyopodin
p15361
sg13
I1
sa(dp15362
g7
I45
sg8
g15
sg10
I8
sg11
Vmyopodin
p15363
sg13
I1
sasg23
(lp15364
(dp15365
g7
I139
sg26
VC2699153
p15366
sg10
I8
sg11
Vinvasion
p15367
sg13
I1
sa(dp15368
g7
I101
sg26
VC0600139
p15369
sg10
I15
sg11
Vprostate cancer
p15370
sg13
I2
sa(dp15371
g7
I101
sg26
VC0600139
p15372
sg10
I15
sg11
Vprostate cancer
p15373
sg13
I2
sa(dp15374
g7
I148
sg26
VC0221103
p15375
sg10
I11
sg11
Vsuppression
p15376
sg13
I1
sasa(dp15377
g2
S'In addition, hemizygous deletion and down-regulation of myopodin expression occur in three aggressive prostate cancer cell lines.\n'
p15378
sg4
(lp15379
(dp15380
g7
I56
sg8
g15
sg10
I8
sg11
Vmyopodin
p15381
sg13
I1
sasg23
(lp15382
(dp15383
g7
I102
sg26
VC0600139
p15384
sg10
I15
sg11
Vprostate cancer
p15385
sg13
I2
sa(dp15386
g7
I91
sg26
VC0001807
p15387
sg10
I10
sg11
Vaggressive
p15388
sg13
I1
sasa(dp15389
g2
S'Further study shows that frequent complete or partial deletions of the myopodin gene occurred among invasive prostate cancer cases (25 of 31 cases, or 80%).\n'
p15390
sg4
(lp15391
(dp15392
g7
I71
sg8
g15
sg10
I13
sg11
Vmyopodin gene
p15393
sg13
I2
sasg23
(lp15394
(dp15395
g7
I109
sg26
VC0600139
p15396
sg10
I15
sg11
Vprostate cancer
p15397
sg13
I2
sasa(dp15398
g2
S'Statistical analysis indicates that deletion of myopodin is highly correlated with the invasiveness of prostate cancers, and thus may hold promise as an important prognostic marker for prostate cancers.\n'
p15399
sg4
(lp15400
(dp15401
g7
I48
sg8
g15
sg10
I8
sg11
Vmyopodin
p15402
sg13
I1
sasg23
(lp15403
(dp15404
g7
I103
sg26
VC0376358
p15405
sg10
I16
sg11
Vprostate cancers
p15406
sg13
I2
sa(dp15407
g7
I103
sg26
VC0376358
p15408
sg10
I16
sg11
Vprostate cancers
p15409
sg13
I2
sasa(dp15410
g2
S"We examined immunostaining of TGFB1 and BMPs (BMP2/BMP4/BMP6/BMP7/BMP9) in a total of 19 post-mortem human brain samples as follows: 7 SVD patients (4 males, 76-90 years old); 6 Alzheimer's disease (AD) patients (2 males, 67-93 years old) and 6 age-matched disease controls (3 males, 68-78 years old).\n"
p15411
sg4
(lp15412
(dp15413
g7
I66
sg8
VP43026
p15414
sg10
I4
sg11
VBMP9
p15415
sg13
I1
sa(dp15416
g7
I61
sg8
VP18075
p15417
sg10
I4
sg11
VBMP7
p15418
sg13
I1
sa(dp15419
g7
I46
sg8
VP12643
p15420
sg10
I4
sg11
VBMP2
p15421
sg13
I1
sa(dp15422
g7
I30
sg8
VP01137
p15423
sg10
I5
sg11
VTGFB1
p15424
sg13
I1
sa(dp15425
g7
I56
sg8
VP22004
p15426
sg10
I4
sg11
VBMP6
p15427
sg13
I1
sa(dp15428
g7
I51
sg8
VP12644
p15429
sg10
I4
sg11
VBMP4
p15430
sg13
I1
sasg23
(lp15431
(dp15432
g7
I178
sg26
VC1521724
p15433
sg10
I19
sg11
VAlzheimer's disease
p15434
sg13
I2
sa(dp15435
g7
I199
sg26
VC1521724
p15436
sg10
I2
sg11
VAD
p15437
sg13
I1
sa(dp15438
g7
I135
sg26
VC0039010
p15439
sg10
I3
sg11
VSVD
p15440
sg13
I1
sasa(dp15441
g2
S'Liver sections were labeled to detect antigens associated with liver epithelial cells [E-cadherin (E-cad)], EMT [fibroblast-specific protein-1 (FSP-1), vimentin], myofibroblasts [Alfa-smooth muscle actin (Alfa-SMA)], and intracellular signal-transduction mediated by forming liver fibrosis undergo EMT, resulting in the formation of invasive fibroblasts; this process may be driven or impeded by a response to local TGF-Beta1 or BMP-7.\n'
p15442
sg4
(lp15443
(dp15444
g7
I87
sg8
g15
sg10
I5
sg11
VE-cad
p15445
sg13
I1
sa(dp15446
g7
I144
sg8
VP09341
p15447
sg10
I5
sg11
VFSP-1
p15448
sg13
I1
sa(dp15449
g7
I205
sg8
g15
sg10
I8
sg11
VAlfa-SMA
p15450
sg13
I1
sa(dp15451
g7
I86
sg8
g15
sg10
I11
sg11
V[E-cadherin
p15452
sg13
I1
sa(dp15453
g7
I429
sg8
VP18075
p15454
sg10
I5
sg11
VBMP-7
p15455
sg13
I1
sa(dp15456
g7
I416
sg8
VP01137
p15457
sg10
I9
sg11
VTGF-Beta1
p15458
sg13
I1
sa(dp15459
g7
I178
sg8
g15
sg10
I25
sg11
V[Alfa-smooth muscle actin
p15460
sg13
I3
sa(dp15461
g7
I112
sg8
VP09341
p15462
sg10
I30
sg11
V[fibroblast-specific protein-1
p15463
sg13
I2
sasg23
(lp15464
(dp15465
g7
I210
sg26
VC0026847
p15466
sg10
I3
sg11
VSMA
p15467
sg13
I1
sa(dp15468
g7
I275
sg26
VC0239946
p15469
sg10
I14
sg11
Vliver fibrosis
p15470
sg13
I2
sa(dp15471
g7
I89
sg26
VC0010054
p15472
sg10
I3
sg11
Vcad
p15473
sg13
I1
sasa(dp15474
g2
S'The RPPA investigation and its validation, identified 3 series of proteins: 1) molecules whose expression levels reached statistically significant differences in CLL vs. healthy controls (HSP70, Smac/DIABLO, cleaved PARP, and cleaved caspase-6); 2) proteins with a positive trend of difference in CLL vs. healthy controls (HS1, Gamma-tubulin, PKC Alfa/Beta-II Thr-638/641, p38 MAPK Thr-180/Tyr-182, NF-KB Ser-536, Bcl2 Ser-70 and Src Tyr-527); and 3) molecules differentially expressed in patients with IGHV mutations vs. those without mutations (ZAP70, PKC-ZetaLambda, Thr-410/403, and CD45).\n'
p15475
sg4
(lp15476
(dp15477
g7
I414
sg8
VP10415
p15478
sg10
I11
sg11
VBcl2 Ser-70
p15479
sg13
I2
sa(dp15480
g7
I195
sg8
g15
sg10
I4
sg11
VSmac
p15481
sg13
I1
sa(dp15482
g7
I554
sg8
VP17252
p15483
sg10
I14
sg11
VPKC-ZetaLambda
p15484
sg13
I1
sa(dp15485
g7
I430
sg8
VP14679
p15486
sg10
I11
sg11
VSrc Tyr-527
p15487
sg13
I2
sa(dp15488
g7
I234
sg8
VP55212
p15489
sg10
I9
sg11
Vcaspase-6
p15490
sg13
I1
sa(dp15491
g7
I343
sg8
VP17252
p15492
sg10
I16
sg11
VPKC Alfa/Beta-II
p15493
sg13
I2
sa(dp15494
g7
I547
sg8
VP43403
p15495
sg10
I5
sg11
VZAP70
p15496
sg13
I1
sa(dp15497
g7
I216
sg8
VP09874
p15498
sg10
I4
sg11
VPARP
p15499
sg13
I1
sa(dp15500
g7
I200
sg8
g15
sg10
I6
sg11
VDIABLO
p15501
sg13
I1
sa(dp15502
g7
I323
sg8
VP27348
p15503
sg10
I3
sg11
VHS1
p15504
sg13
I1
sa(dp15505
g7
I587
sg8
VP08575
p15506
sg10
I4
sg11
VCD45
p15507
sg13
I1
sa(dp15508
g7
I328
sg8
VP23258
p15509
sg10
I13
sg11
VGamma-tubulin
p15510
sg13
I1
sa(dp15511
g7
I399
sg8
g15
sg10
I13
sg11
VNF-KB Ser-536
p15512
sg13
I2
sa(dp15513
g7
I188
sg8
VP34932
p15514
sg10
I5
sg11
VHSP70
p15515
sg13
I1
sa(dp15516
g7
I373
sg8
VP46108
p15517
sg10
I3
sg11
Vp38
p15518
sg13
I1
sa(dp15519
g7
I382
sg8
VP14679
p15520
sg10
I15
sg11
VThr-180/Tyr-182
p15521
sg13
I1
sasg23
(lp15522
(dp15523
g7
I162
sg26
VC0023434
p15524
sg10
I3
sg11
VCLL
p15525
sg13
I1
sa(dp15526
g7
I162
sg26
VC0023434
p15527
sg10
I3
sg11
VCLL
p15528
sg13
I1
sa(dp15529
g7
I343
sg26
VC1868682
p15530
sg10
I3
sg11
VPKC
p15531
sg13
I1
sa(dp15532
g7
I343
sg26
VC1868682
p15533
sg10
I3
sg11
VPKC
p15534
sg13
I1
sa(dp15535
g7
I323
sg26
VC2674218
p15536
sg10
I3
sg11
VHS1
p15537
sg13
I1
sasa(dp15538
g2
S'A study was conducted to find whether a deficiency in prostacyclin (prostaglandin I2; PGI2) is implicated in the pathogenesis of thrombotic thrombocytopenic purpura.\n'
p15539
sg4
(lp15540
sg23
(lp15541
(dp15542
g7
I129
sg26
VC0034155
p15543
sg10
I35
sg11
Vthrombotic thrombocytopenic purpura
p15544
sg13
I3
sa(dp15545
g7
I113
sg26
VC0699748
p15546
sg10
I12
sg11
Vpathogenesis
p15547
sg13
I1
sasa(dp15548
g2
S'IgM levels were measured with the Luminex assay and compared to levels measured using the microarray for 126 healthy individuals and 77 prostate cancer patients.\n'
p15549
sg4
(lp15550
(dp15551
g7
I0
sg8
VP29965
p15552
sg10
I3
sg11
VIgM
p15553
sg13
I1
sasg23
(lp15554
(dp15555
g7
I136
sg26
VC0600139
p15556
sg10
I15
sg11
Vprostate cancer
p15557
sg13
I2
sasa(dp15558
g2
S'Elevated blood glucose and increased activities of secreted phospholipase A2 (sPLA2) are strongly linked to coronary heart disease.\n'
p15559
sg4
(lp15560
(dp15561
g7
I51
sg8
VP14555
p15562
sg10
I25
sg11
Vsecreted phospholipase A2
p15563
sg13
I3
sa(dp15564
g7
I78
sg8
VP14555
p15565
sg10
I5
sg11
VsPLA2
p15566
sg13
I1
sasg23
(lp15567
(dp15568
g7
I108
sg26
VC0010054
p15569
sg10
I22
sg11
Vcoronary heart disease
p15570
sg13
I3
sasa(dp15571
g2
S'Secretory phospholipases (sPLA2) are a group of pro-inflammatory molecules associated with diseases such as atherosclerosis, which increase the risk of reperfusion injury.\n'
p15572
sg4
(lp15573
(dp15574
g7
I0
sg8
VP04054
p15575
sg10
I24
sg11
VSecretory phospholipases
p15576
sg13
I2
sa(dp15577
g7
I26
sg8
VP14555
p15578
sg10
I5
sg11
VsPLA2
p15579
sg13
I1
sasg23
(lp15580
(dp15581
g7
I108
sg26
VC0004153
p15582
sg10
I15
sg11
Vatherosclerosis
p15583
sg13
I1
sasa(dp15584
g2
S'A critical association between type II secretory phospholipase A2 (sPLA2-IIa) and established atherosclerotic cardiovascular disease has been demonstrated.\n'
p15585
sg4
(lp15586
(dp15587
g7
I31
sg8
VP04054
p15588
sg10
I34
sg11
Vtype II secretory phospholipase A2
p15589
sg13
I5
sa(dp15590
g7
I67
sg8
VP14555
p15591
sg10
I9
sg11
VsPLA2-IIa
p15592
sg13
I1
sasg23
(lp15593
(dp15594
g7
I94
sg26
VC0004153
p15595
sg10
I38
sg11
Vatherosclerotic cardiovascular disease
p15596
sg13
I3
sasa(dp15597
g2
S'However, the contribution of sPLA2-IIa to early atherosclerosis remains unknown.\n'
p15598
sg4
(lp15599
(dp15600
g7
I29
sg8
VP14555
p15601
sg10
I9
sg11
VsPLA2-IIa
p15602
sg13
I1
sasg23
(lp15603
(dp15604
g7
I48
sg26
VC0004153
p15605
sg10
I15
sg11
Vatherosclerosis
p15606
sg13
I1
sasa(dp15607
g2
S'This study investigated the association between early-stage atherosclerosis and sPLA2-IIa in metabolic syndrome (MetS) patients.\n'
p15608
sg4
(lp15609
(dp15610
g7
I80
sg8
VP14555
p15611
sg10
I9
sg11
VsPLA2-IIa
p15612
sg13
I1
sasg23
(lp15613
(dp15614
g7
I60
sg26
VC0004153
p15615
sg10
I15
sg11
Vatherosclerosis
p15616
sg13
I1
sa(dp15617
g7
I93
sg26
VC0524620
p15618
sg10
I18
sg11
Vmetabolic syndrome
p15619
sg13
I2
sa(dp15620
g7
I113
sg26
VC0524620
p15621
sg10
I4
sg11
VMetS
p15622
sg13
I1
sasa(dp15623
g2
S'Moreover, multivariate analysis showed that high sPLA2-IIa protein and activity levels were independent risk factors of early atherosclerosis in MetS patients.\n'
p15624
sg4
(lp15625
(dp15626
g7
I49
sg8
VP14555
p15627
sg10
I17
sg11
VsPLA2-IIa protein
p15628
sg13
I2
sa(dp15629
g7
I145
sg8
VP41162
p15630
sg10
I4
sg11
VMetS
p15631
sg13
I1
sasg23
(lp15632
(dp15633
g7
I126
sg26
VC0004153
p15634
sg10
I15
sg11
Vatherosclerosis
p15635
sg13
I1
sasa(dp15636
g2
S'This study demonstrates an independent association between early-stage atherosclerosis and increased levels of sPLA2-IIa, implying that increased sPLA2-IIa may predict early-stage atherosclerosis in MetS patients.\n'
p15637
sg4
(lp15638
(dp15639
g7
I111
sg8
VP14555
p15640
sg10
I9
sg11
VsPLA2-IIa
p15641
sg13
I1
sa(dp15642
g7
I199
sg8
VP41162
p15643
sg10
I4
sg11
VMetS
p15644
sg13
I1
sa(dp15645
g7
I111
sg8
VP14555
p15646
sg10
I9
sg11
VsPLA2-IIa
p15647
sg13
I1
sasg23
(lp15648
(dp15649
g7
I71
sg26
VC0004153
p15650
sg10
I15
sg11
Vatherosclerosis
p15651
sg13
I1
sa(dp15652
g7
I71
sg26
VC0004153
p15653
sg10
I15
sg11
Vatherosclerosis
p15654
sg13
I1
sasa(dp15655
g2
S'This study is the first to report on the molecular interaction between maslinic acid and inflammatory target hGIIA-sPLA2 as well as its effect towards hGIIA-sPLA2-induced THP-1 monocyte adhesive and migratory capabilities, an important immune-inflammation process in atherosclerosis.\n'
p15656
sg4
(lp15657
(dp15658
g7
I109
sg8
VP14555
p15659
sg10
I11
sg11
VhGIIA-sPLA2
p15660
sg13
I1
sa(dp15661
g7
I109
sg8
VP14555
p15662
sg10
I11
sg11
VhGIIA-sPLA2
p15663
sg13
I1
sasg23
(lp15664
(dp15665
g7
I243
sg26
VC1155266
p15666
sg10
I20
sg11
Vinflammation process
p15667
sg13
I2
sa(dp15668
g7
I267
sg26
VC0004153
p15669
sg10
I15
sg11
Vatherosclerosis
p15670
sg13
I1
sasa(dp15671
g2
S'Group IIA secretory phospholipase A2 (sPLA2-IIA) has an important role in atherosclerosis.\n'
p15672
sg4
(lp15673
(dp15674
g7
I20
sg8
VP04054
p15675
sg10
I16
sg11
Vphospholipase A2
p15676
sg13
I2
sa(dp15677
g7
I38
sg8
VP14555
p15678
sg10
I9
sg11
VsPLA2-IIA
p15679
sg13
I1
sasg23
(lp15680
(dp15681
g7
I74
sg26
VC0004153
p15682
sg10
I15
sg11
Vatherosclerosis
p15683
sg13
I1
sasa(dp15684
g2
S'In this study, we explored whether sPLA2-IIA overexpression could promote atherosclerosis in normal environment alone or with other inflammatory factors.\n'
p15685
sg4
(lp15686
(dp15687
g7
I35
sg8
VP14555
p15688
sg10
I9
sg11
VsPLA2-IIA
p15689
sg13
I1
sasg23
(lp15690
(dp15691
g7
I74
sg26
VC0004153
p15692
sg10
I15
sg11
Vatherosclerosis
p15693
sg13
I1
sasa(dp15694
g2
S'Observational studies report that secretory phospholipase A2 (sPLA2) activity is a marker for coronary heart disease (CHD) risk, and activity measures are thought to represent the composite activity of sPLA2-IIA, -V, and -X.\n'
p15695
sg4
(lp15696
(dp15697
g7
I34
sg8
VP14555
p15698
sg10
I26
sg11
Vsecretory phospholipase A2
p15699
sg13
I3
sa(dp15700
g7
I62
sg8
VP14555
p15701
sg10
I5
sg11
VsPLA2
p15702
sg13
I1
sa(dp15703
g7
I202
sg8
VP14555
p15704
sg10
I9
sg11
VsPLA2-IIA
p15705
sg13
I1
sasg23
(lp15706
(dp15707
g7
I94
sg26
VC0010054
p15708
sg10
I22
sg11
Vcoronary heart disease
p15709
sg13
I3
sa(dp15710
g7
I118
sg26
VC0010054
p15711
sg10
I3
sg11
VCHD
p15712
sg13
I1
sasa(dp15713
g2
S'The aim of this study was to use genetic variants of PLA2G10, encoding sPLA2-X, to investigate the contribution of sPLA2-X to the measure of sPLA2 activity and coronary heart disease (CHD) risk traits and outcome.\n'
p15714
sg4
(lp15715
(dp15716
g7
I71
sg8
g15
sg10
I7
sg11
VsPLA2-X
p15717
sg13
I1
sa(dp15718
g7
I71
sg8
VP14555
p15719
sg10
I5
sg11
VsPLA2
p15720
sg13
I1
sa(dp15721
g7
I71
sg8
g15
sg10
I7
sg11
VsPLA2-X
p15722
sg13
I1
sa(dp15723
g7
I53
sg8
g15
sg10
I7
sg11
VPLA2G10
p15724
sg13
I1
sasg23
(lp15725
(dp15726
g7
I184
sg26
VC0010054
p15727
sg10
I3
sg11
VCHD
p15728
sg13
I1
sa(dp15729
g7
I160
sg26
VC0010054
p15730
sg10
I22
sg11
Vcoronary heart disease
p15731
sg13
I3
sasa(dp15732
g2
S'Given that high-density lipoprotein (HDL) is the major substrate for sPLA2 in plasma, we investigated the effects of sPLA2-mediated modification of HDL (sPLA2-HDL) on neutrophil function, an essential arm of the innate immune response and atherosclerosis.\n'
p15733
sg4
(lp15734
(dp15735
g7
I37
sg8
VP28845
p15736
sg10
I3
sg11
VHDL
p15737
sg13
I1
sa(dp15738
g7
I37
sg8
VP28845
p15739
sg10
I3
sg11
VHDL
p15740
sg13
I1
sa(dp15741
g7
I69
sg8
VP14555
p15742
sg10
I5
sg11
VsPLA2
p15743
sg13
I1
sa(dp15744
g7
I11
sg8
VP28845
p15745
sg10
I24
sg11
Vhigh-density lipoprotein
p15746
sg13
I2
sa(dp15747
g7
I69
sg8
VP14555
p15748
sg10
I5
sg11
VsPLA2
p15749
sg13
I1
sa(dp15750
g7
I37
sg8
VP28845
p15751
sg10
I3
sg11
VHDL
p15752
sg13
I1
sa(dp15753
g7
I69
sg8
VP14555
p15754
sg10
I5
sg11
VsPLA2
p15755
sg13
I1
sasg23
(lp15756
(dp15757
g7
I239
sg26
VC0004153
p15758
sg10
I15
sg11
Vatherosclerosis
p15759
sg13
I1
sa(dp15760
g7
I212
sg26
VC1155265
p15761
sg10
I22
sg11
Vinnate immune response
p15762
sg13
I3
sasa(dp15763
g2
S'For immunohistochemistry, 95 thyroid tumors (follicular adenoma, papillary TC, follicular TC, PDTC, and anaplastic TC [ATC]) were investigated for GLUT1 expression and proliferation (Ki-67 index).\n'
p15764
sg4
(lp15765
(dp15766
g7
I147
sg8
VP11166
p15767
sg10
I5
sg11
VGLUT1
p15768
sg13
I1
sasg23
(lp15769
(dp15770
g7
I56
sg26
VC0205650
p15771
sg10
I18
sg11
Vadenoma, papillary
p15772
sg13
I2
sa(dp15773
g7
I168
sg26
VC0334094
p15774
sg10
I13
sg11
Vproliferation
p15775
sg13
I1
sa(dp15776
g7
I29
sg26
VC0040136
p15777
sg10
I14
sg11
Vthyroid tumors
p15778
sg13
I2
sasa(dp15779
g2
S'Glucose transporter-1 (GLUT-1) expression was immunohistochemically analysed in a total of 268 cases of thyroid gland disease, including 129 cases of papillary carcinoma (PC), 60 cases of follicular carcinoma (FC), 57 cases of follicular adenoma, and 22 cases of adenomatous goitre.\n'
p15780
sg4
(lp15781
(dp15782
g7
I0
sg8
VP11166
p15783
sg10
I21
sg11
VGlucose transporter-1
p15784
sg13
I2
sa(dp15785
g7
I23
sg8
VP11166
p15786
sg10
I6
sg11
VGLUT-1
p15787
sg13
I1
sasg23
(lp15788
(dp15789
g7
I104
sg26
VC0040128
p15790
sg10
I21
sg11
Vthyroid gland disease
p15791
sg13
I3
sa(dp15792
g7
I227
sg26
VC0205647
p15793
sg10
I18
sg11
Vfollicular adenoma
p15794
sg13
I2
sa(dp15795
g7
I150
sg26
VC0007133
p15796
sg10
I19
sg11
Vpapillary carcinoma
p15797
sg13
I2
sa(dp15798
g7
I188
sg26
VC0206682
p15799
sg10
I20
sg11
Vfollicular carcinoma
p15800
sg13
I2
sa(dp15801
g7
I171
sg26
VC0007133
p15802
sg10
I2
sg11
VPC
p15803
sg13
I1
sa(dp15804
g7
I210
sg26
VC0206682
p15805
sg10
I2
sg11
VFC
p15806
sg13
I1
sa(dp15807
g7
I263
sg26
VC0311361
p15808
sg10
I18
sg11
Vadenomatous goitre
p15809
sg13
I2
sasa(dp15810
g2
S'GLUT-1 expression was observed in 5% (3/60) of FC cases, but all follicular adenomas and adenomatous goitres were negative for GLUT-1 (PC vs. FC, p&lt;0.0001).\n'
p15811
sg4
(lp15812
(dp15813
g7
I0
sg8
VP11166
p15814
sg10
I6
sg11
VGLUT-1
p15815
sg13
I1
sa(dp15816
g7
I0
sg8
VP11166
p15817
sg10
I6
sg11
VGLUT-1
p15818
sg13
I1
sasg23
(lp15819
(dp15820
g7
I65
sg26
VC0205647
p15821
sg10
I19
sg11
Vfollicular adenomas
p15822
sg13
I2
sa(dp15823
g7
I101
sg26
VC0018021
p15824
sg10
I7
sg11
Vgoitres
p15825
sg13
I1
sasa(dp15826
g2
S'Semi-quantitative analysis of glut-1 mRNA by RT-PCR showed a tendency toward higher expression in PCs compared to FCs, follicular adenomas and adenomatous goitres, and the mRNA expression in PCs with a membrane-like pattern was higher than those showing cytoplasm-predominance.\n'
p15827
sg4
(lp15828
(dp15829
g7
I30
sg8
VP11166
p15830
sg10
I11
sg11
Vglut-1 mRNA
p15831
sg13
I2
sasg23
(lp15832
(dp15833
g7
I98
sg26
VC1864389
p15834
sg10
I3
sg11
VPCs
p15835
sg13
I1
sa(dp15836
g7
I98
sg26
VC1864389
p15837
sg10
I3
sg11
VPCs
p15838
sg13
I1
sa(dp15839
g7
I155
sg26
VC0018021
p15840
sg10
I7
sg11
Vgoitres
p15841
sg13
I1
sa(dp15842
g7
I119
sg26
VC0205647
p15843
sg10
I19
sg11
Vfollicular adenomas
p15844
sg13
I2
sasa(dp15845
g2
S'Tropomyosin-related kinase B (TrkB), Her2, and downstream targets were analyzed in primary breast cancer, breast-to-brain metastasis (BBM) tissues, and tumor-derived cell lines using quantitative real-time PCR, western blot, and immunohistochemical assessment.\n'
p15846
sg4
(lp15847
(dp15848
g7
I0
sg8
VP07951
p15849
sg10
I28
sg11
VTropomyosin-related kinase B
p15850
sg13
I3
sa(dp15851
g7
I30
sg8
g15
sg10
I4
sg11
VTrkB
p15852
sg13
I1
sa(dp15853
g7
I37
sg8
VP04626
p15854
sg10
I4
sg11
VHer2
p15855
sg13
I1
sasg23
(lp15856
(dp15857
g7
I152
sg26
VC0027651
p15858
sg10
I5
sg11
Vtumor
p15859
sg13
I1
sa(dp15860
g7
I116
sg26
VC0220650
p15861
sg10
I16
sg11
Vbrain metastasis
p15862
sg13
I2
sa(dp15863
g7
I98
sg26
VC0006142
p15864
sg10
I14
sg11
Vcancer, breast
p15865
sg13
I2
sasa(dp15866
g2
S'TrkB knockdown in breast cancer cells led to decreased frequency and growth of brain metastasis in animal models, suggesting that circulating breast cancer cells entering the brain may take advantage of paracrine BDNF-TrkB signaling for colonization.\n'
p15867
sg4
(lp15868
(dp15869
g7
I0
sg8
g15
sg10
I4
sg11
VTrkB
p15870
sg13
I1
sa(dp15871
g7
I0
sg8
g15
sg10
I4
sg11
VTrkB
p15872
sg13
I1
sasg23
(lp15873
(dp15874
g7
I79
sg26
VC0220650
p15875
sg10
I16
sg11
Vbrain metastasis
p15876
sg13
I2
sa(dp15877
g7
I18
sg26
VC0678222
p15878
sg10
I13
sg11
Vbreast cancer
p15879
sg13
I2
sa(dp15880
g7
I18
sg26
VC0678222
p15881
sg10
I13
sg11
Vbreast cancer
p15882
sg13
I2
sasa(dp15883
g2
S'In addition, we investigated a possible interaction between TrkB and Her2 receptors on brain metastatic breast cancer cells, and found that BDNF phosphorylated both its cognate TrkB receptor and the Her2 receptor in brain metastatic breast cancer cells.\n'
p15884
sg4
(lp15885
(dp15886
g7
I177
sg8
g15
sg10
I13
sg11
VTrkB receptor
p15887
sg13
I2
sa(dp15888
g7
I69
sg8
VP04626
p15889
sg10
I14
sg11
VHer2 receptors
p15890
sg13
I2
sa(dp15891
g7
I69
sg8
VP04626
p15892
sg10
I13
sg11
VHer2 receptor
p15893
sg13
I2
sa(dp15894
g7
I60
sg8
g15
sg10
I4
sg11
VTrkB
p15895
sg13
I1
sasg23
(lp15896
(dp15897
g7
I93
sg26
VC0278488
p15898
sg10
I24
sg11
Vmetastatic breast cancer
p15899
sg13
I3
sa(dp15900
g7
I93
sg26
VC0278488
p15901
sg10
I24
sg11
Vmetastatic breast cancer
p15902
sg13
I3
sasa(dp15903
g2
S'Collectively, our findings suggest that heterodimerization of Her2 and TrkB receptors gives breast cancer cells a survival advantage in the brain and that dual inhibition of these receptors may hold therapeutic potential.\n'
p15904
sg4
(lp15905
(dp15906
g7
I62
sg8
VP04626
p15907
sg10
I4
sg11
VHer2
p15908
sg13
I1
sa(dp15909
g7
I71
sg8
g15
sg10
I14
sg11
VTrkB receptors
p15910
sg13
I2
sasg23
(lp15911
(dp15912
g7
I92
sg26
VC0678222
p15913
sg10
I13
sg11
Vbreast cancer
p15914
sg13
I2
sasa(dp15915
g2
S'Brain-derived neurotrophic factor (BDNF) is a potent neurotrophic factor that has been shown to stimulate breast cancer cell growth and metastasis via tyrosine kinase receptors TrkA, TrkB, and the p75NTR death receptor.\n'
p15916
sg4
(lp15917
(dp15918
g7
I0
sg8
g15
sg10
I40
sg11
VBrain-derived neurotrophic factor (BDNF)
p15919
sg13
I4
sa(dp15920
g7
I177
sg8
VP06753
p15921
sg10
I4
sg11
VTrkA
p15922
sg13
I1
sa(dp15923
g7
I151
sg8
VP29401
p15924
sg10
I25
sg11
Vtyrosine kinase receptors
p15925
sg13
I3
sa(dp15926
g7
I197
sg8
VP08138
p15927
sg10
I21
sg11
Vp75NTR death receptor
p15928
sg13
I3
sa(dp15929
g7
I183
sg8
g15
sg10
I4
sg11
VTrkB
p15930
sg13
I1
sasg23
(lp15931
(dp15932
g7
I113
sg26
VC1516170
p15933
sg10
I18
sg11
Vcancer cell growth
p15934
sg13
I3
sa(dp15935
g7
I136
sg26
VC0027627
p15936
sg10
I10
sg11
Vmetastasis
p15937
sg13
I1
sasa(dp15938
g2
S'The aim of the current review was to provide an overview of the role of BDNF/TrkB pathways in the pathogenesis of breast cancer and its value as a potential therapeutic target.\n'
p15939
sg4
(lp15940
(dp15941
g7
I77
sg8
g15
sg10
I4
sg11
VTrkB
p15942
sg13
I1
sasg23
(lp15943
(dp15944
g7
I98
sg26
VC0699748
p15945
sg10
I12
sg11
Vpathogenesis
p15946
sg13
I1
sa(dp15947
g7
I114
sg26
VC0678222
p15948
sg10
I13
sg11
Vbreast cancer
p15949
sg13
I2
sasa(dp15950
g2
S'The purpose of the present study was to examine the relationships between genetic polymorphisms within Neurotrophic tyrosine kinase receptor 1 (NTRK1), Neurotrophic tyrosine kinase receptor 2 (NTRK2), and catechol-O-methyltransferase ( COMT) and patient symptom burden of QOL, pain, fatigue, anxiety, depression, and sleep disturbance before, during, and after treatment for breast cancer in a subset of participants ( N = 51) in a randomized clinical trial of a novel symptom-management modality for women with breast cancer undergoing chemotherapy.\n'
p15951
sg4
(lp15952
(dp15953
g7
I236
sg8
VP21964
p15954
sg10
I4
sg11
VCOMT
p15955
sg13
I1
sa(dp15956
g7
I205
sg8
VP21964
p15957
sg10
I28
sg11
Vcatechol-O-methyltransferase
p15958
sg13
I1
sa(dp15959
g7
I152
sg8
VP29401
p15960
sg10
I39
sg11
VNeurotrophic tyrosine kinase receptor 2
p15961
sg13
I5
sa(dp15962
g7
I144
sg8
VP29401
p15963
sg10
I5
sg11
VNTRK1
p15964
sg13
I1
sa(dp15965
g7
I103
sg8
VP29401
p15966
sg10
I39
sg11
VNeurotrophic tyrosine kinase receptor 1
p15967
sg13
I5
sa(dp15968
g7
I193
sg8
g15
sg10
I5
sg11
VNTRK2
p15969
sg13
I1
sasg23
(lp15970
(dp15971
g7
I375
sg26
VC0678222
p15972
sg10
I13
sg11
Vbreast cancer
p15973
sg13
I2
sa(dp15974
g7
I301
sg26
VC0011581
p15975
sg10
I10
sg11
Vdepression
p15976
sg13
I1
sa(dp15977
g7
I375
sg26
VC0678222
p15978
sg10
I13
sg11
Vbreast cancer
p15979
sg13
I2
sa(dp15980
g7
I317
sg26
VC0700201
p15981
sg10
I17
sg11
Vsleep disturbance
p15982
sg13
I2
sa(dp15983
g7
I283
sg26
VC0015672
p15984
sg10
I7
sg11
Vfatigue
p15985
sg13
I1
sa(dp15986
g7
I254
sg26
VC1457887
p15987
sg10
I7
sg11
Vsymptom
p15988
sg13
I1
sa(dp15989
g7
I254
sg26
VC1457887
p15990
sg10
I7
sg11
Vsymptom
p15991
sg13
I1
sasa(dp15992
g2
S'These findings, while exploratory, indicate that the genotypes of NTRK2 and COMT may contribute to relative risk for symptom burden during and shortly after the period of chemotherapy in women with early stage breast cancer.\n'
p15993
sg4
(lp15994
(dp15995
g7
I66
sg8
g15
sg10
I5
sg11
VNTRK2
p15996
sg13
I1
sa(dp15997
g7
I76
sg8
VP21964
p15998
sg10
I4
sg11
VCOMT
p15999
sg13
I1
sasg23
(lp16000
(dp16001
g7
I204
sg26
VC2216702
p16002
sg10
I19
sg11
Vstage breast cancer
p16003
sg13
I3
sa(dp16004
g7
I117
sg26
VC1457887
p16005
sg10
I7
sg11
Vsymptom
p16006
sg13
I1
sasa(dp16007
g2
S'9/34 down-regulated genes (FIGF, RELN, PROM1, SFRP1, MMP7, NTRK2, LAMB3, SPRY2, KIT) had changes larger than CDH1, a hallmark of ILC.\n'
p16008
sg4
(lp16009
(dp16010
g7
I66
sg8
g15
sg10
I5
sg11
VLAMB3
p16011
sg13
I1
sa(dp16012
g7
I46
sg8
g15
sg10
I5
sg11
VSFRP1
p16013
sg13
I1
sa(dp16014
g7
I39
sg8
g15
sg10
I5
sg11
VPROM1
p16015
sg13
I1
sa(dp16016
g7
I80
sg8
VP10721
p16017
sg10
I3
sg11
VKIT
p16018
sg13
I1
sa(dp16019
g7
I53
sg8
VP09237
p16020
sg10
I4
sg11
VMMP7
p16021
sg13
I1
sa(dp16022
g7
I33
sg8
VP78509
p16023
sg10
I4
sg11
VRELN
p16024
sg13
I1
sa(dp16025
g7
I109
sg8
VP12830
p16026
sg10
I4
sg11
VCDH1
p16027
sg13
I1
sa(dp16028
g7
I27
sg8
g15
sg10
I4
sg11
VFIGF
p16029
sg13
I1
sa(dp16030
g7
I59
sg8
g15
sg10
I5
sg11
VNTRK2
p16031
sg13
I1
sa(dp16032
g7
I73
sg8
g15
sg10
I5
sg11
VSPRY2
p16033
sg13
I1
sasg23
(lp16034
sa(dp16035
g2
S'While screening for the key regulators of cancer metastasis, we observed that neurotrophin receptor TrkB is frequently overexpressed in breast cancer patients and breast cancer cell lines.\n'
p16036
sg4
(lp16037
(dp16038
g7
I78
sg8
g15
sg10
I26
sg11
Vneurotrophin receptor TrkB
p16039
sg13
I3
sasg23
(lp16040
(dp16041
g7
I136
sg26
VC0678222
p16042
sg10
I13
sg11
Vbreast cancer
p16043
sg13
I2
sa(dp16044
g7
I42
sg26
VC0006826
p16045
sg10
I6
sg11
Vcancer
p16046
sg13
I1
sa(dp16047
g7
I136
sg26
VC0678222
p16048
sg10
I13
sg11
Vbreast cancer
p16049
sg13
I2
sa(dp16050
g7
I49
sg26
VC0027627
p16051
sg10
I10
sg11
Vmetastasis
p16052
sg13
I1
sasa(dp16053
g2
S'Additionally, we demonstrate that TrkB expression and clinical breast tumor pathological phenotypes show significant correlation.\n'
p16054
sg4
(lp16055
(dp16056
g7
I34
sg8
g15
sg10
I4
sg11
VTrkB
p16057
sg13
I1
sasg23
(lp16058
(dp16059
g7
I63
sg26
VC1458155
p16060
sg10
I12
sg11
Vbreast tumor
p16061
sg13
I2
sasa(dp16062
g2
S'Moreover, TrkB expression was significantly upregulated in basal-like, claudin-low, and metaplastic breast cancers from a published microarray database and in patients with triple-negative breast cancer, which is associated with a higher risk of invasive recurrence.\n'
p16063
sg4
(lp16064
(dp16065
g7
I10
sg8
g15
sg10
I4
sg11
VTrkB
p16066
sg13
I1
sasg23
(lp16067
(dp16068
g7
I255
sg26
VC1458156
p16069
sg10
I10
sg11
Vrecurrence
p16070
sg13
I1
sa(dp16071
g7
I100
sg26
VC0006142
p16072
sg10
I13
sg11
Vbreast cancer
p16073
sg13
I2
sa(dp16074
g7
I100
sg26
VC0006142
p16075
sg10
I14
sg11
Vbreast cancers
p16076
sg13
I2
sasa(dp16077
g2
S'Interestingly, we identified a new TrkB-regulated functional network that is important for the tumorigenicity and metastasis of breast cancer.\n'
p16078
sg4
(lp16079
(dp16080
g7
I35
sg8
g15
sg10
I4
sg11
VTrkB
p16081
sg13
I1
sasg23
(lp16082
(dp16083
g7
I114
sg26
VC0027627
p16084
sg10
I10
sg11
Vmetastasis
p16085
sg13
I1
sa(dp16086
g7
I128
sg26
VC0678222
p16087
sg10
I13
sg11
Vbreast cancer
p16088
sg13
I2
sa(dp16089
g7
I95
sg26
VC1519697
p16090
sg10
I14
sg11
Vtumorigenicity
p16091
sg13
I1
sasa(dp16092
g2
S'These observations suggest that TrkB plays a key role in tumorigenicity and metastasis of breast cancer cells through suppression of Runx3 or Keap1 and that it is a promising target for future intervention strategies for preventing tumor metastasis and cancer chemoprevention.\n'
p16093
sg4
(lp16094
(dp16095
g7
I133
sg8
g15
sg10
I5
sg11
VRunx3
p16096
sg13
I1
sa(dp16097
g7
I142
sg8
g15
sg10
I5
sg11
VKeap1
p16098
sg13
I1
sa(dp16099
g7
I32
sg8
g15
sg10
I4
sg11
VTrkB
p16100
sg13
I1
sasg23
(lp16101
(dp16102
g7
I232
sg26
VC0027627
p16103
sg10
I16
sg11
Vtumor metastasis
p16104
sg13
I2
sa(dp16105
g7
I76
sg26
VC0027627
p16106
sg10
I10
sg11
Vmetastasis
p16107
sg13
I1
sa(dp16108
g7
I97
sg26
VC0006826
p16109
sg10
I6
sg11
Vcancer
p16110
sg13
I1
sa(dp16111
g7
I57
sg26
VC1519697
p16112
sg10
I14
sg11
Vtumorigenicity
p16113
sg13
I1
sa(dp16114
g7
I118
sg26
VC0221103
p16115
sg10
I11
sg11
Vsuppression
p16116
sg13
I1
sa(dp16117
g7
I90
sg26
VC0678222
p16118
sg10
I13
sg11
Vbreast cancer
p16119
sg13
I2
sasa(dp16120
g2
S'Analysis of a pediatric medulloblastoma showed that clusters of NRBP2 positive tumor cells co-expressed neurofilament, but not GFAP.\n'
p16121
sg4
(lp16122
(dp16123
g7
I64
sg8
g15
sg10
I5
sg11
VNRBP2
p16124
sg13
I1
sasg23
(lp16125
(dp16126
g7
I79
sg26
VC0027651
p16127
sg10
I5
sg11
Vtumor
p16128
sg13
I1
sa(dp16129
g7
I14
sg26
VC0278510
p16130
sg10
I25
sg11
Vpediatric medulloblastoma
p16131
sg13
I2
sasa(dp16132
g2
S'Recently, we reported a high prevalence of immunoglobulin G and/or immunoglobulin M anticardiolipin antibodies (aCL) in patients with autoimmune liver diseases, namely, autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), which were independent of the respective isotypes of antibodies against beta2-glycoprotein I (anti-b2GPI).\n'
p16133
sg4
(lp16134
(dp16135
g7
I325
sg8
VP02749
p16136
sg10
I39
sg11
Vantibodies against beta2-glycoprotein I
p16137
sg13
I4
sa(dp16138
g7
I112
sg8
VP53396
p16139
sg10
I3
sg11
VaCL
p16140
sg13
I1
sa(dp16141
g7
I67
sg8
VP01871
p16142
sg10
I43
sg11
Vimmunoglobulin M anticardiolipin antibodies
p16143
sg13
I4
sa(dp16144
g7
I366
sg8
VP02749
p16145
sg10
I10
sg11
Vanti-b2GPI
p16146
sg13
I1
sa(dp16147
g7
I43
sg8
g15
sg10
I16
sg11
Vimmunoglobulin G
p16148
sg13
I2
sasg23
(lp16149
(dp16150
g7
I197
sg26
VC0008312
p16151
sg10
I25
sg11
Vprimary biliary cirrhosis
p16152
sg13
I3
sa(dp16153
g7
I145
sg26
VC0023895
p16154
sg10
I14
sg11
Vliver diseases
p16155
sg13
I2
sa(dp16156
g7
I266
sg26
VC0566602
p16157
sg10
I3
sg11
VPSC
p16158
sg13
I1
sa(dp16159
g7
I134
sg26
VC0443146
p16160
sg10
I10
sg11
Vautoimmune
p16161
sg13
I1
sa(dp16162
g7
I224
sg26
VC0008312
p16163
sg10
I3
sg11
VPBC
p16164
sg13
I1
sa(dp16165
g7
I234
sg26
VC0566602
p16166
sg10
I30
sg11
Vprimary sclerosing cholangitis
p16167
sg13
I3
sa(dp16168
g7
I191
sg26
VC0241910
p16169
sg10
I3
sg11
VAIH
p16170
sg13
I1
sa(dp16171
g7
I169
sg26
VC0241910
p16172
sg10
I20
sg11
Vautoimmune hepatitis
p16173
sg13
I2
sasa(dp16174
g2
S'In addition to thrombocytopenia (50 Gpt/l) and leukocytopenia (1,51 10 (9)/l) we diagnosed a hyperchromic and macrocytic anemia (Hb 3,6 mmol/l [5,8 g/dl], Hk 0,17, MCH 2.52 fmol, 116,8 fl).\n'
p16175
sg4
(lp16176
sg23
(lp16177
(dp16178
g7
I47
sg26
VC0023530
p16179
sg10
I14
sg11
Vleukocytopenia
p16180
sg13
I1
sa(dp16181
g7
I110
sg26
VC0002886
p16182
sg10
I17
sg11
Vmacrocytic anemia
p16183
sg13
I2
sasa(dp16184
g2
S'We also examined secretion of a series of other chemokines and cytokines: MCO-1, IL-6, IL-1Beta, IL-8, GM-CFS, and others.\n'
p16185
sg4
(lp16186
(dp16187
g7
I81
sg8
VP05231
p16188
sg10
I4
sg11
VIL-6
p16189
sg13
I1
sa(dp16190
g7
I87
sg8
VP01584
p16191
sg10
I8
sg11
VIL-1Beta
p16192
sg13
I1
sa(dp16193
g7
I103
sg8
VP04141
p16194
sg10
I6
sg11
VGM-CFS
p16195
sg13
I1
sasg23
(lp16196
(dp16197
g7
I106
sg26
VC0015674
p16198
sg10
I3
sg11
VCFS
p16199
sg13
I1
sasa(dp16200
g2
S'In addition, IMD1-53 decreased the production of inflammatory factors such as tumor necrosis factor-Alfa, monocyte chemotactic protein-1, interleukin-6 (IL-6), and IL-1Beta in the mouse myocardium and rat CFs treated with Hcy.\n'
p16201
sg4
(lp16202
(dp16203
g7
I78
sg8
VP01375
p16204
sg10
I58
sg11
Vtumor necrosis factor-Alfa, monocyte chemotactic protein-1
p16205
sg13
I6
sa(dp16206
g7
I164
sg8
VP01584
p16207
sg10
I8
sg11
VIL-1Beta
p16208
sg13
I1
sa(dp16209
g7
I138
sg8
VP05231
p16210
sg10
I13
sg11
Vinterleukin-6
p16211
sg13
I1
sa(dp16212
g7
I153
sg8
VP05231
p16213
sg10
I4
sg11
VIL-6
p16214
sg13
I1
sasg23
(lp16215
(dp16216
g7
I205
sg26
VC0015674
p16217
sg10
I3
sg11
VCFs
p16218
sg13
I1
sa(dp16219
g7
I13
sg26
VC0221026
p16220
sg10
I4
sg11
VIMD1
p16221
sg13
I1
sa(dp16222
g7
I78
sg26
VC0333516
p16223
sg10
I14
sg11
Vtumor necrosis
p16224
sg13
I2
sasa(dp16225
g2
S'GC sensitivity differed significantly between CFS patients and healthy controls, with CFS patients showing a greater sensitivity towards GCs (TNF-Alfa: F 1/39 = 7.32, P = 0.01; IL-6: F 1/39 = 9.73, P = 0.004).\n'
p16226
sg4
(lp16227
(dp16228
g7
I142
sg8
VP01375
p16229
sg10
I8
sg11
VTNF-Alfa
p16230
sg13
I1
sa(dp16231
g7
I137
sg8
VP48506
p16232
sg10
I3
sg11
VGCs
p16233
sg13
I1
sa(dp16234
g7
I177
sg8
VP05231
p16235
sg10
I4
sg11
VIL-6
p16236
sg13
I1
sasg23
(lp16237
(dp16238
g7
I46
sg26
VC0015674
p16239
sg10
I3
sg11
VCFS
p16240
sg13
I1
sa(dp16241
g7
I46
sg26
VC0015674
p16242
sg10
I3
sg11
VCFS
p16243
sg13
I1
sasa(dp16244
g2
S'Treatment with IL-6 significantly promoted the proliferation and collagen production of cultured cardiac fibroblasts (CFs).\n'
p16245
sg4
(lp16246
(dp16247
g7
I15
sg8
VP05231
p16248
sg10
I4
sg11
VIL-6
p16249
sg13
I1
sasg23
(lp16250
(dp16251
g7
I97
sg26
VC0015674
p16252
sg10
I19
sg11
Vcardiac fibroblasts
p16253
sg13
I2
sa(dp16254
g7
I47
sg26
VC0334094
p16255
sg10
I13
sg11
Vproliferation
p16256
sg13
I1
sa(dp16257
g7
I118
sg26
VC0015674
p16258
sg10
I3
sg11
VCFs
p16259
sg13
I1
sasa(dp16260
g2
S'High glucose treatment increased collagen production, which were mitigated in CFs from IL-6 KO mice.\n'
p16261
sg4
(lp16262
(dp16263
g7
I87
sg8
VP05231
p16264
sg10
I4
sg11
VIL-6
p16265
sg13
I1
sasg23
(lp16266
(dp16267
g7
I78
sg26
VC0015674
p16268
sg10
I3
sg11
VCFs
p16269
sg13
I1
sasa(dp16270
g2
S'Moreover, IL-6 knockout alleviated the up-regulation of TGFBeta1 in diabetic hearts of mice and cultured CFs treated with high glucose or IL-6.\n'
p16271
sg4
(lp16272
(dp16273
g7
I56
sg8
VP01137
p16274
sg10
I8
sg11
VTGFBeta1
p16275
sg13
I1
sa(dp16276
g7
I10
sg8
VP05231
p16277
sg10
I4
sg11
VIL-6
p16278
sg13
I1
sa(dp16279
g7
I10
sg8
VP05231
p16280
sg10
I4
sg11
VIL-6
p16281
sg13
I1
sasg23
(lp16282
(dp16283
g7
I105
sg26
VC0015674
p16284
sg10
I3
sg11
VCFs
p16285
sg13
I1
sasa(dp16286
g2
S'Overexpression of miR-29 blocked the pro-fibrotic effects of IL-6 on cultured CFs.\n'
p16287
sg4
(lp16288
(dp16289
g7
I18
sg8
g15
sg10
I6
sg11
VmiR-29
p16290
sg13
I1
sa(dp16291
g7
I61
sg8
VP05231
p16292
sg10
I4
sg11
VIL-6
p16293
sg13
I1
sasg23
(lp16294
(dp16295
g7
I78
sg26
VC0015674
p16296
sg10
I3
sg11
VCFs
p16297
sg13
I1
sasa(dp16298
g2
S'By contrast, incubation of the co-culture with CFS increased IL-1Beta, IL-6, TGF-Beta2 and IP-10 production only when Salmonella was present.\n'
p16299
sg4
(lp16300
(dp16301
g7
I61
sg8
VP01584
p16302
sg10
I8
sg11
VIL-1Beta
p16303
sg13
I1
sa(dp16304
g7
I77
sg8
VP61812
p16305
sg10
I9
sg11
VTGF-Beta2
p16306
sg13
I1
sa(dp16307
g7
I91
sg8
VP02778
p16308
sg10
I5
sg11
VIP-10
p16309
sg13
I1
sa(dp16310
g7
I71
sg8
VP05231
p16311
sg10
I4
sg11
VIL-6
p16312
sg13
I1
sasg23
(lp16313
(dp16314
g7
I47
sg26
VC0015674
p16315
sg10
I3
sg11
VCFS
p16316
sg13
I1
sa(dp16317
g7
I118
sg26
VC0036117
p16318
sg10
I10
sg11
VSalmonella
p16319
sg13
I1
sasa(dp16320
g2
S'Quantitative RT-PCR showed that HS6ST2, COL1A1, F2RL1, LEPREL1, PDZK1, and PDZK1IP1 are overexpressed in thyroid carcinoma samples compared with normal thyroids.\n'
p16321
sg4
(lp16322
(dp16323
g7
I75
sg8
g15
sg10
I8
sg11
VPDZK1IP1
p16324
sg13
I1
sa(dp16325
g7
I64
sg8
g15
sg10
I5
sg11
VPDZK1
p16326
sg13
I1
sa(dp16327
g7
I48
sg8
VP55085
p16328
sg10
I5
sg11
VF2RL1
p16329
sg13
I1
sa(dp16330
g7
I55
sg8
g15
sg10
I7
sg11
VLEPREL1
p16331
sg13
I1
sasg23
(lp16332
(dp16333
g7
I105
sg26
VC0549473
p16334
sg10
I17
sg11
Vthyroid carcinoma
p16335
sg13
I2
sasa(dp16336
g2
S'Among these, antisense noncoding RNA in the INK4 locus (ANRIL), hypoxia inducible factor 1alpha antisense RNA-2 (HIF1A-AS2), and urothelial carcinoma-associated 1 (UCA1) were markedly upregulated in plasma of patients with TNBC compared with patients with NTNBC (P &lt; 0.01).\n'
p16337
sg4
(lp16338
(dp16339
g7
I64
sg8
g15
sg10
I47
sg11
Vhypoxia inducible factor 1alpha antisense RNA-2
p16340
sg13
I6
sa(dp16341
g7
I113
sg8
g15
sg10
I9
sg11
VHIF1A-AS2
p16342
sg13
I1
sa(dp16343
g7
I44
sg8
VP42771
p16344
sg10
I10
sg11
VINK4 locus
p16345
sg13
I2
sasg23
(lp16346
(dp16347
g7
I129
sg26
VC0007138
p16348
sg10
I20
sg11
Vurothelial carcinoma
p16349
sg13
I2
sa(dp16350
g7
I64
sg26
VC0242184
p16351
sg10
I7
sg11
Vhypoxia
p16352
sg13
I1
sasa(dp16353
g2
S'Among regulatory mechanisms for HIF expression is a natural occurring antisense named aHIF, which has been shown to be overexpressed in breast cancer and influence the level of the HIF-1Alfa transcript.\n'
p16354
sg4
(lp16355
sg23
(lp16356
(dp16357
g7
I136
sg26
VC0678222
p16358
sg10
I13
sg11
Vbreast cancer
p16359
sg13
I2
sasa(dp16360
g2
S'In the present study, we analyzed the expression of HIF-1Alfa and aHIF in breast cancer tissues versus adjacent noncancer tissues (ANCTs) in relation with the clinical and biological behavior of the tumors.\n'
p16361
sg4
(lp16362
sg23
(lp16363
(dp16364
g7
I74
sg26
VC0678222
p16365
sg10
I13
sg11
Vbreast cancer
p16366
sg13
I2
sa(dp16367
g7
I199
sg26
VC0027651
p16368
sg10
I6
sg11
Vtumors
p16369
sg13
I1
sasa(dp16370
g2
S'aHIF has been shown to be expressed in 67.4% of invasive ductal carcinoma samples, while none of ANCTs showed its expression.\n'
p16371
sg4
(lp16372
sg23
(lp16373
(dp16374
g7
I48
sg26
VC1134719
p16375
sg10
I25
sg11
Vinvasive ductal carcinoma
p16376
sg13
I3
sasa(dp16377
g2
S'Collectively, these data suggest that aHIF overexpression can be used as a potential biomarker in breast cancer.\n'
p16378
sg4
(lp16379
sg23
(lp16380
(dp16381
g7
I98
sg26
VC0678222
p16382
sg10
I13
sg11
Vbreast cancer
p16383
sg13
I2
sasa(dp16384
g2
S'LncRNA hypoxia inducible factor 1alpha antisense RNA-2 (HIF1A-AS2) is upregulated in gastric carcinomas and knockdown of HIF1A-AS2 expression by siRNA could inhibit cell proliferation in vitro and tumorigenesis in vivo.\n'
p16385
sg4
(lp16386
(dp16387
g7
I56
sg8
g15
sg10
I5
sg11
VHIF1A
p16388
sg13
I1
sa(dp16389
g7
I0
sg8
g15
sg10
I38
sg11
VLncRNA hypoxia inducible factor 1alpha
p16390
sg13
I5
sa(dp16391
g7
I56
sg8
g15
sg10
I5
sg11
VHIF1A
p16392
sg13
I1
sasg23
(lp16393
(dp16394
g7
I197
sg26
VC0007621
p16395
sg10
I13
sg11
Vtumorigenesis
p16396
sg13
I1
sa(dp16397
g7
I170
sg26
VC0334094
p16398
sg10
I13
sg11
Vproliferation
p16399
sg13
I1
sa(dp16400
g7
I93
sg26
VC0007097
p16401
sg10
I10
sg11
Vcarcinomas
p16402
sg13
I1
sa(dp16403
g7
I7
sg26
VC0242184
p16404
sg10
I7
sg11
Vhypoxia
p16405
sg13
I1
sasa(dp16406
g2
S'Inspired by these observations, we hypothesized that HIF1A-AS2 possibly plays the analogous roles in bladder cancer.\n'
p16407
sg4
(lp16408
(dp16409
g7
I53
sg8
g15
sg10
I5
sg11
VHIF1A
p16410
sg13
I1
sasg23
(lp16411
(dp16412
g7
I101
sg26
VC0699885
p16413
sg10
I14
sg11
Vbladder cancer
p16414
sg13
I2
sasa(dp16415
g2
S'In our study, we first reported that HIF1A-AS2 was up-regulated in bladder cancer tissues and cells, and HIF1A-AS2 expression level in bladder cancer tissues is positively associated with advanced clinical pathologic grade and TNM phase.\n'
p16416
sg4
(lp16417
(dp16418
g7
I37
sg8
g15
sg10
I5
sg11
VHIF1A
p16419
sg13
I1
sa(dp16420
g7
I37
sg8
g15
sg10
I5
sg11
VHIF1A
p16421
sg13
I1
sasg23
(lp16422
(dp16423
g7
I67
sg26
VC0699885
p16424
sg10
I14
sg11
Vbladder cancer
p16425
sg13
I2
sa(dp16426
g7
I67
sg26
VC0699885
p16427
sg10
I14
sg11
Vbladder cancer
p16428
sg13
I2
sasa(dp16429
g2
S'Cell proliferation inhibition, cell migration suppression and apoptosis induction were observed by silencing HIF1A-AS2 in bladder cancer T24 and 5637 cells.\n'
p16430
sg4
(lp16431
(dp16432
g7
I109
sg8
g15
sg10
I9
sg11
VHIF1A-AS2
p16433
sg13
I1
sasg23
(lp16434
(dp16435
g7
I5
sg26
VC0334094
p16436
sg10
I13
sg11
Vproliferation
p16437
sg13
I1
sa(dp16438
g7
I122
sg26
VC0699885
p16439
sg10
I14
sg11
Vbladder cancer
p16440
sg13
I2
sa(dp16441
g7
I46
sg26
VC0221103
p16442
sg10
I11
sg11
Vsuppression
p16443
sg13
I1
sasa(dp16444
g2
S'Besides, we utilized the emerging technology of medical synthetic biology to design tetracycline-inducible small hairpin RNA (shRNA) vector which specifically silenced HIF1A-AS2 in a dosage-dependent manner to inhibit the progression of human bladder cancer.\n'
p16445
sg4
(lp16446
(dp16447
g7
I168
sg8
g15
sg10
I9
sg11
VHIF1A-AS2
p16448
sg13
I1
sasg23
(lp16449
(dp16450
g7
I243
sg26
VC0699885
p16451
sg10
I14
sg11
Vbladder cancer
p16452
sg13
I2
sasa(dp16453
g2
S'In conclusion, our data suggested that HIF1A-AS2 plays oncogenic roles and can be used as a therapeutic target for treating human bladder cancer.\n'
p16454
sg4
(lp16455
(dp16456
g7
I39
sg8
g15
sg10
I5
sg11
VHIF1A
p16457
sg13
I1
sasg23
(lp16458
(dp16459
g7
I130
sg26
VC0699885
p16460
sg10
I14
sg11
Vbladder cancer
p16461
sg13
I2
sasa(dp16462
g2
S'Synthetic "tetracycline-on" switch system that quantitatively controlled the expression of HIF1A-AS2 in bladder cancer can inhibit the progression of bladder cancer cells in a dosage-dependent manner.\n'
p16463
sg4
(lp16464
(dp16465
g7
I91
sg8
g15
sg10
I9
sg11
VHIF1A-AS2
p16466
sg13
I1
sasg23
(lp16467
(dp16468
g7
I104
sg26
VC0699885
p16469
sg10
I14
sg11
Vbladder cancer
p16470
sg13
I2
sa(dp16471
g7
I104
sg26
VC0699885
p16472
sg10
I14
sg11
Vbladder cancer
p16473
sg13
I2
sasa(dp16474
g2
S'Our findings provide new insights into the role of the lncRNA HIF1A-AS2 in the bladder cancer.\n'
p16475
sg4
(lp16476
(dp16477
g7
I55
sg8
g15
sg10
I16
sg11
VlncRNA HIF1A-AS2
p16478
sg13
I2
sasg23
(lp16479
(dp16480
g7
I79
sg26
VC0699885
p16481
sg10
I14
sg11
Vbladder cancer
p16482
sg13
I2
sasa(dp16483
g2
S'LncRNA hypoxia-inducible factor 1alpha antisense RNA-2 (HIF1A-AS2) is overexpressed in nonpapillary clear-cell renal carcinomas and involved in cancer progression.\n'
p16484
sg4
(lp16485
(dp16486
g7
I0
sg8
g15
sg10
I38
sg11
VLncRNA hypoxia-inducible factor 1alpha
p16487
sg13
I4
sasg23
(lp16488
(dp16489
g7
I144
sg26
VC0178874
p16490
sg10
I18
sg11
Vcancer progression
p16491
sg13
I2
sa(dp16492
g7
I7
sg26
VC0242184
p16493
sg10
I7
sg11
Vhypoxia
p16494
sg13
I1
sa(dp16495
g7
I117
sg26
VC0007097
p16496
sg10
I10
sg11
Vcarcinomas
p16497
sg13
I1
sasa(dp16498
g2
S'This study was to evaluate the expression of HIF1A-AS2 in gastric cancer (GC) and further explore its biological function in GC cells.\n'
p16499
sg4
(lp16500
(dp16501
g7
I45
sg8
g15
sg10
I9
sg11
VHIF1A-AS2
p16502
sg13
I1
sasg23
(lp16503
(dp16504
g7
I74
sg26
VC0024623
p16505
sg10
I2
sg11
VGC
p16506
sg13
I1
sa(dp16507
g7
I58
sg26
VC0024623
p16508
sg10
I14
sg11
Vgastric cancer
p16509
sg13
I2
sa(dp16510
g7
I74
sg26
VC0024623
p16511
sg10
I2
sg11
VGC
p16512
sg13
I1
sasa(dp16513
g2
S'With a semiquantitative multiplex reverse transcriptase-PCR (RT-PCR) assay, we assessed transcript concentrations of HIF-1alpha, sHIF-1alpha and aHIF in 110 patients with invasive breast carcinoma.\n'
p16514
sg4
(lp16515
(dp16516
g7
I34
sg8
VP63136
p16517
sg10
I21
sg11
Vreverse transcriptase
p16518
sg13
I2
sa(dp16519
g7
I117
sg8
g15
sg10
I10
sg11
VHIF-1alpha
p16520
sg13
I1
sasg23
(lp16521
(dp16522
g7
I171
sg26
VC0853879
p16523
sg10
I25
sg11
Vinvasive breast carcinoma
p16524
sg13
I3
sasa(dp16525
g2
S'aHIF transcript expression was associated with poor disease-free survival in univariate (P = 0.0038) and multivariate (P = 0.0016) analyses in this series of high-risk primary breast carcinomas.\n'
p16526
sg4
(lp16527
sg23
(lp16528
(dp16529
g7
I176
sg26
VC0678222
p16530
sg10
I17
sg11
Vbreast carcinomas
p16531
sg13
I2
sasa(dp16532
g2
S'In our series of breast cancer patients, aHIF, and not HIF-1alpha transcript, is a marker of poor prognosis.\n'
p16533
sg4
(lp16534
(dp16535
g7
I55
sg8
g15
sg10
I21
sg11
VHIF-1alpha transcript
p16536
sg13
I2
sasg23
(lp16537
(dp16538
g7
I17
sg26
VC0678222
p16539
sg10
I13
sg11
Vbreast cancer
p16540
sg13
I2
sasa(dp16541
g2
S'Recently, mutations of the CSMD3 gene were identified in schizophrenia and autism patients.\n'
p16542
sg4
(lp16543
(dp16544
g7
I27
sg8
g15
sg10
I10
sg11
VCSMD3 gene
p16545
sg13
I2
sasg23
(lp16546
(dp16547
g7
I75
sg26
VC0004352
p16548
sg10
I6
sg11
Vautism
p16549
sg13
I1
sa(dp16550
g7
I57
sg26
VC0036341
p16551
sg10
I13
sg11
Vschizophrenia
p16552
sg13
I1
sasa(dp16553
g2
S'To investigate the expression of MMP-2, TIMP-1, E-cadherin and beta-catenin in endometrial serous carcinoma (ESC), low-grade endometrial endometrioid carcinoma (EEC), and proliferative endometrium.\n'
p16554
sg4
(lp16555
(dp16556
g7
I63
sg8
VP35222
p16557
sg10
I12
sg11
Vbeta-catenin
p16558
sg13
I1
sa(dp16559
g7
I33
sg8
VP08253
p16560
sg10
I5
sg11
VMMP-2
p16561
sg13
I1
sa(dp16562
g7
I40
sg8
VP01033
p16563
sg10
I6
sg11
VTIMP-1
p16564
sg13
I1
sa(dp16565
g7
I48
sg8
VP12830
p16566
sg10
I10
sg11
VE-cadherin
p16567
sg13
I1
sasg23
(lp16568
(dp16569
g7
I91
sg26
VC0206701
p16570
sg10
I16
sg11
Vserous carcinoma
p16571
sg13
I2
sa(dp16572
g7
I171
sg26
VC0334094
p16573
sg10
I13
sg11
Vproliferative
p16574
sg13
I1
sa(dp16575
g7
I161
sg26
VC1851841
p16576
sg10
I3
sg11
VEEC
p16577
sg13
I1
sa(dp16578
g7
I137
sg26
VC0206687
p16579
sg10
I22
sg11
Vendometrioid carcinoma
p16580
sg13
I2
sasa(dp16581
g2
S'This study attempts to assess the prognostic importance of stromal MMP-2 in patients with ovarian endometrioid and serous adenocarcinoma.\n'
p16582
sg4
(lp16583
(dp16584
g7
I67
sg8
VP08253
p16585
sg10
I5
sg11
VMMP-2
p16586
sg13
I1
sasg23
(lp16587
(dp16588
g7
I115
sg26
VC0206701
p16589
sg10
I21
sg11
Vserous adenocarcinoma
p16590
sg13
I2
sasa(dp16591
g2
S'MMP-2, MMP-2 activator, MT1-MMP, and its inhibitor (TIMP-2) were immunostained in 84 primary epithelial ovarian carcinomas (EOCs) (35 endometrioid adenocarcinomas [ECs] and 49 serous adenocarcinomas [SCs]).\n'
p16592
sg4
(lp16593
(dp16594
g7
I7
sg8
VP08253
p16595
sg10
I15
sg11
VMMP-2 activator
p16596
sg13
I2
sa(dp16597
g7
I24
sg8
VP50281
p16598
sg10
I7
sg11
VMT1-MMP
p16599
sg13
I1
sa(dp16600
g7
I0
sg8
VP08253
p16601
sg10
I5
sg11
VMMP-2
p16602
sg13
I1
sasg23
(lp16603
(dp16604
g7
I147
sg26
VC0001418
p16605
sg10
I15
sg11
Vadenocarcinomas
p16606
sg13
I1
sa(dp16607
g7
I200
sg26
VC0175699
p16608
sg10
I3
sg11
VSCs
p16609
sg13
I1
sa(dp16610
g7
I134
sg26
VC1569637
p16611
sg10
I28
sg11
Vendometrioid adenocarcinomas
p16612
sg13
I2
sa(dp16613
g7
I104
sg26
VC0029925
p16614
sg10
I18
sg11
Vovarian carcinomas
p16615
sg13
I2
sasa(dp16616
g2
S'Concentrations of MMP-9 and MMP-2 were statistically higher in serous adenocarcinomas than in serous adenomas (p &lt; 0.01, p &lt; 0.05, respectively), while the concentrations of TIMP-1 and TIMP-2 showed no significant difference between adenocarcinomas and adenomas.\n'
p16617
sg4
(lp16618
(dp16619
g7
I180
sg8
VP01033
p16620
sg10
I6
sg11
VTIMP-1
p16621
sg13
I1
sa(dp16622
g7
I18
sg8
VP14780
p16623
sg10
I5
sg11
VMMP-9
p16624
sg13
I1
sa(dp16625
g7
I28
sg8
VP08253
p16626
sg10
I5
sg11
VMMP-2
p16627
sg13
I1
sa(dp16628
g7
I191
sg8
VP16035
p16629
sg10
I6
sg11
VTIMP-2
p16630
sg13
I1
sasg23
(lp16631
(dp16632
g7
I70
sg26
VC0001418
p16633
sg10
I15
sg11
Vadenocarcinomas
p16634
sg13
I1
sa(dp16635
g7
I101
sg26
VC0001430
p16636
sg10
I8
sg11
Vadenomas
p16637
sg13
I1
sa(dp16638
g7
I70
sg26
VC0001418
p16639
sg10
I15
sg11
Vadenocarcinomas
p16640
sg13
I1
sa(dp16641
g7
I101
sg26
VC0001430
p16642
sg10
I8
sg11
Vadenomas
p16643
sg13
I1
sasa(dp16644
g2
S'These observations indicate that matriolytic enzymes such as MMP-2, MMP-7 and MMP-9 are secreted into cyst fluid from serous adenocarcinoma tissues.\n'
p16645
sg4
(lp16646
(dp16647
g7
I68
sg8
VP09237
p16648
sg10
I5
sg11
VMMP-7
p16649
sg13
I1
sa(dp16650
g7
I78
sg8
VP14780
p16651
sg10
I5
sg11
VMMP-9
p16652
sg13
I1
sa(dp16653
g7
I61
sg8
VP08253
p16654
sg10
I5
sg11
VMMP-2
p16655
sg13
I1
sasg23
(lp16656
(dp16657
g7
I102
sg26
VC0010709
p16658
sg10
I4
sg11
Vcyst
p16659
sg13
I1
sa(dp16660
g7
I118
sg26
VC0206701
p16661
sg10
I21
sg11
Vserous adenocarcinoma
p16662
sg13
I2
sasa(dp16663
g2
S'Genome wide association studies suggest that polymorphisms within human elmo1 act as a potential contributing factor for the development of diabetic nephropathy.\n'
p16664
sg4
(lp16665
sg23
(lp16666
(dp16667
g7
I140
sg26
VC0011881
p16668
sg10
I20
sg11
Vdiabetic nephropathy
p16669
sg13
I2
sasa(dp16670
g2
S'Thus, this study aimed to identify the role played by ELMO1 in renal development in zebrafish, under hyperglycaemic conditions, and in diabetic nephropathy patients.\n'
p16671
sg4
(lp16672
(dp16673
g7
I54
sg8
g15
sg10
I5
sg11
VELMO1
p16674
sg13
I1
sasg23
(lp16675
(dp16676
g7
I135
sg26
VC0011881
p16677
sg10
I20
sg11
Vdiabetic nephropathy
p16678
sg13
I2
sasa(dp16679
g2
S'This is the first study to report a significant association of the SLC12A3 rs11643718 and ELMO1 rs741301 (Single nucleotide Polymorphism) SNPs with diabetic nephropathy in south Indians.\n'
p16680
sg4
(lp16681
(dp16682
g7
I67
sg8
VP55017
p16683
sg10
I18
sg11
VSLC12A3 rs11643718
p16684
sg13
I2
sa(dp16685
g7
I90
sg8
g15
sg10
I14
sg11
VELMO1 rs741301
p16686
sg13
I2
sasg23
(lp16687
(dp16688
g7
I148
sg26
VC0011881
p16689
sg10
I20
sg11
Vdiabetic nephropathy
p16690
sg13
I2
sasa(dp16691
g2
S'Human genome-wide association studies have demonstrated that polymorphisms in the engulfment and cell motility protein 1 gene (ELMO1) are strongly associated with susceptibility to diabetic nephropathy.\n'
p16692
sg4
(lp16693
(dp16694
g7
I127
sg8
g15
sg10
I5
sg11
VELMO1
p16695
sg13
I1
sa(dp16696
g7
I82
sg8
g15
sg10
I43
sg11
Vengulfment and cell motility protein 1 gene
p16697
sg13
I7
sasg23
(lp16698
(dp16699
g7
I181
sg26
VC0011881
p16700
sg10
I20
sg11
Vdiabetic nephropathy
p16701
sg13
I2
sasa(dp16702
g2
S'Remarkably, the reduced Elmo1 expression in the 30% hypomorphs almost abolishes the pathological features of diabetic nephropathy, although it does not affect the hyperglycemia caused by the Akita mutation.\n'
p16703
sg4
(lp16704
(dp16705
g7
I24
sg8
g15
sg10
I5
sg11
VElmo1
p16706
sg13
I1
sasg23
(lp16707
(dp16708
g7
I163
sg26
VC0020456
p16709
sg10
I13
sg11
Vhyperglycemia
p16710
sg13
I1
sa(dp16711
g7
I109
sg26
VC0011881
p16712
sg10
I20
sg11
Vdiabetic nephropathy
p16713
sg13
I2
sasa(dp16714
g2
S'Thus, ELMO1 plays an important role in the development of type 1 diabetic nephropathy, and its inhibition could be a promising option for slowing or preventing progression of the condition to end-stage renal disease.\n'
p16715
sg4
(lp16716
(dp16717
g7
I6
sg8
g15
sg10
I5
sg11
VELMO1
p16718
sg13
I1
sasg23
(lp16719
(dp16720
g7
I65
sg26
VC0011881
p16721
sg10
I20
sg11
Vdiabetic nephropathy
p16722
sg13
I2
sa(dp16723
g7
I192
sg26
VC0022661
p16724
sg10
I23
sg11
Vend-stage renal disease
p16725
sg13
I3
sa(dp16726
g7
I179
sg26
VC0012634
p16727
sg10
I9
sg11
Vcondition
p16728
sg13
I1
sasa(dp16729
g2
S'However, until now only a handful number of genetic variants were reported to be associated with either nephropathy (ACE, ELMO1, FRMD3, and AKR1B1) or retinopathy (VEGF, AKR1B1, and EPO), and only a few studies were carried out for genetic susceptibility to cardiovascular diseases (ADIPOQ, GLUL) in patients with diabetes.\n'
p16730
sg4
(lp16731
(dp16732
g7
I122
sg8
g15
sg10
I5
sg11
VELMO1
p16733
sg13
I1
sa(dp16734
g7
I182
sg8
VP01588
p16735
sg10
I3
sg11
VEPO
p16736
sg13
I1
sa(dp16737
g7
I117
sg8
VP12821
p16738
sg10
I3
sg11
VACE
p16739
sg13
I1
sa(dp16740
g7
I140
sg8
VP15121
p16741
sg10
I6
sg11
VAKR1B1
p16742
sg13
I1
sa(dp16743
g7
I140
sg8
VP15121
p16744
sg10
I6
sg11
VAKR1B1
p16745
sg13
I1
sa(dp16746
g7
I81
sg8
VP12821
p16747
sg10
I34
sg11
Vassociated with either nephropathy
p16748
sg13
I4
sasg23
(lp16749
(dp16750
g7
I258
sg26
VC0007222
p16751
sg10
I23
sg11
Vcardiovascular diseases
p16752
sg13
I2
sa(dp16753
g7
I104
sg26
VC0022658
p16754
sg10
I11
sg11
Vnephropathy
p16755
sg13
I1
sa(dp16756
g7
I151
sg26
VC0035309
p16757
sg10
I11
sg11
Vretinopathy
p16758
sg13
I1
sa(dp16759
g7
I314
sg26
VC0011849
p16760
sg10
I8
sg11
Vdiabetes
p16761
sg13
I1
sasa(dp16762
g2
S'Four genes (HFE, ELMO1, SLC12A3, and CCR5) were selected on the basis of reported association with type 2 diabetes and nephropathy.\n'
p16763
sg4
(lp16764
(dp16765
g7
I17
sg8
g15
sg10
I5
sg11
VELMO1
p16766
sg13
I1
sa(dp16767
g7
I37
sg8
VP32302
p16768
sg10
I4
sg11
VCCR5
p16769
sg13
I1
sa(dp16770
g7
I24
sg8
VP55017
p16771
sg10
I7
sg11
VSLC12A3
p16772
sg13
I1
sasg23
(lp16773
(dp16774
g7
I119
sg26
VC0022658
p16775
sg10
I11
sg11
Vnephropathy
p16776
sg13
I1
sa(dp16777
g7
I99
sg26
VC0011860
p16778
sg10
I15
sg11
Vtype 2 diabetes
p16779
sg13
I3
sasa(dp16780
g2
S'In all, 417 diabetic subjects (215 without kidney disease [DM] and 202 with DN) and 197 healthy controls (HC) were evaluated for variations in HFE (845 G&gt;A and 187G&gt;C), SLC12A3 (g.34372G&gt;A), CCR5 (59029A&gt;G), and ELMO1 (+9170 G&gt;A).\n'
p16781
sg4
(lp16782
(dp16783
g7
I224
sg8
g15
sg10
I5
sg11
VELMO1
p16784
sg13
I1
sa(dp16785
g7
I175
sg8
VP55017
p16786
sg10
I7
sg11
VSLC12A3
p16787
sg13
I1
sa(dp16788
g7
I200
sg8
VP32302
p16789
sg10
I4
sg11
VCCR5
p16790
sg13
I1
sasg23
(lp16791
(dp16792
g7
I43
sg26
VC0022658
p16793
sg10
I14
sg11
Vkidney disease
p16794
sg13
I2
sasa(dp16795
g2
S'Strong biological candidates for CKD that showed statistically significant differential methylation include CUX1, ELMO1, FKBP5, INHBA-AS1, PTPRN2, and PRKAG2 genes; several genes are differentially methylated in kidney tissue and RNA-seq supports a functional role for differential methylation in ELMO1 and PRKAG2 genes.\n'
p16796
sg4
(lp16797
(dp16798
g7
I128
sg8
VP08476
p16799
sg10
I9
sg11
VINHBA-AS1
p16800
sg13
I1
sa(dp16801
g7
I114
sg8
g15
sg10
I5
sg11
VELMO1
p16802
sg13
I1
sa(dp16803
g7
I151
sg8
g15
sg10
I12
sg11
VPRKAG2 genes
p16804
sg13
I2
sa(dp16805
g7
I151
sg8
g15
sg10
I12
sg11
VPRKAG2 genes
p16806
sg13
I2
sa(dp16807
g7
I139
sg8
g15
sg10
I6
sg11
VPTPRN2
p16808
sg13
I1
sa(dp16809
g7
I108
sg8
VP39880
p16810
sg10
I4
sg11
VCUX1
p16811
sg13
I1
sa(dp16812
g7
I121
sg8
g15
sg10
I5
sg11
VFKBP5
p16813
sg13
I1
sa(dp16814
g7
I114
sg8
g15
sg10
I5
sg11
VELMO1
p16815
sg13
I1
sasg23
(lp16816
(dp16817
g7
I134
sg26
VC1846534
p16818
sg10
I3
sg11
VAS1
p16819
sg13
I1
sasa(dp16820
g2
S'AKR1B1, APOE, ENPP1, ELMO1 and IGFBP1 are the genes that have been identified as an important target for type II diabetic nephropathy through experimental studies.\n'
p16821
sg4
(lp16822
(dp16823
g7
I0
sg8
VP15121
p16824
sg10
I6
sg11
VAKR1B1
p16825
sg13
I1
sa(dp16826
g7
I14
sg8
VP22413
p16827
sg10
I5
sg11
VENPP1
p16828
sg13
I1
sa(dp16829
g7
I21
sg8
g15
sg10
I5
sg11
VELMO1
p16830
sg13
I1
sa(dp16831
g7
I8
sg8
VP02649
p16832
sg10
I4
sg11
VAPOE
p16833
sg13
I1
sa(dp16834
g7
I31
sg8
VP01343
p16835
sg10
I6
sg11
VIGFBP1
p16836
sg13
I1
sasg23
(lp16837
(dp16838
g7
I113
sg26
VC0011881
p16839
sg10
I20
sg11
Vdiabetic nephropathy
p16840
sg13
I2
sasa(dp16841
g2
S'A total of 1635 patients without symptoms and signs relevant to diabetic polyneuropathy (1275 with T2DM and 360 with LADA) were included and were further categorized into 3 groups according to diabetes duration: &lt;5years, 5-14 years and &gt;=15years.\n'
p16842
sg4
(lp16843
(dp16844
g7
I117
sg8
g15
sg10
I4
sg11
VLADA
p16845
sg13
I1
sasg23
(lp16846
(dp16847
g7
I33
sg26
VC0037088
p16848
sg10
I18
sg11
Vsymptoms and signs
p16849
sg13
I3
sa(dp16850
g7
I64
sg26
VC0271680
p16851
sg10
I23
sg11
Vdiabetic polyneuropathy
p16852
sg13
I2
sa(dp16853
g7
I193
sg26
VC0011849
p16854
sg10
I8
sg11
Vdiabetes
p16855
sg13
I1
sasa(dp16856
g2
S'The expressions of TRIP11, HIF-1Beta, THRA, THRB, FURIN, VEGFA, and GLUT1 were disturbed in renal cancer.\n'
p16857
sg4
(lp16858
(dp16859
g7
I27
sg8
VP27540
p16860
sg10
I9
sg11
VHIF-1Beta
p16861
sg13
I1
sa(dp16862
g7
I68
sg8
VP11166
p16863
sg10
I5
sg11
VGLUT1
p16864
sg13
I1
sa(dp16865
g7
I19
sg8
g15
sg10
I6
sg11
VTRIP11
p16866
sg13
I1
sa(dp16867
g7
I50
sg8
VP09958
p16868
sg10
I5
sg11
VFURIN
p16869
sg13
I1
sa(dp16870
g7
I38
sg8
VP10827
p16871
sg10
I4
sg11
VTHRA
p16872
sg13
I1
sa(dp16873
g7
I44
sg8
VP10828
p16874
sg10
I4
sg11
VTHRB
p16875
sg13
I1
sasg23
(lp16876
(dp16877
g7
I92
sg26
VC0740457
p16878
sg10
I12
sg11
Vrenal cancer
p16879
sg13
I2
sasa.